Clustering O 0 6.987139386183117e-06
of O 0 9.48067313544243e-09
missense O 0 1.0583179573586676e-05
mutations O 0 1.0211572316620732e-06
in O 0 4.971543621223873e-09
the O 0 6.204300007084385e-08
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
gene O 0 2.9300972528290004e-05
in O 0 6.533961371957275e-09
a O 0 5.232470456917326e-09
sporadic B-Disease 0 2.7440639314590953e-05
T I-Disease 1 0.9996980428695679
- I-Disease 0 0.4169248044490814
cell I-Disease 0 0.002527874894440174
leukaemia I-Disease 0 0.16601164638996124
. O 0 2.89671049813478e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.5907793045043945
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.5432469746556876e-09
is O 0 3.560847797179356e-11
a O 0 1.4138547277386948e-10
recessive B-Disease 0 2.2935313609195873e-05
multi I-Disease 1 0.9974570870399475
- I-Disease 1 0.9999449253082275
system I-Disease 0 0.00310115166939795
disorder I-Disease 0 0.23120224475860596
caused O 0 1.2991798747918892e-09
by O 0 4.303706002684038e-11
mutations O 0 1.3783094665598128e-08
in O 0 7.734866913633454e-11
the O 0 6.428288457094311e-11
ATM O 0 4.496148875432482e-08
gene O 0 5.08045197022966e-08
at O 0 3.3907443519609615e-09
11q22 O 0 8.746134767534386e-07
- O 0 6.200448865456565e-07
q23 O 0 2.914597700964805e-07
( O 0 2.427579803843116e-10
ref O 0 1.039345818298898e-07
. O 0 3.353471111910977e-10
3 O 0 6.997997181734661e-10
) O 0 1.4974732565065096e-09
. O 0 1.8334702645006473e-08

The O 0 1.872283483805859e-08
risk O 0 1.9560367547910573e-07
of O 0 1.201065497058451e-10
cancer B-Disease 0 1.0323223165187301e-07
, O 0 1.2476676636286044e-10
especially O 0 6.739581115411397e-10
lymphoid B-Disease 0 9.296009295667318e-08
neoplasias I-Disease 0 5.012181645724922e-06
, O 0 3.965911765657637e-10
is O 0 1.3817247346281647e-10
substantially O 0 3.2044682463094887e-09
elevated O 0 1.3619425587307887e-08
in O 0 1.9314178700824414e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.8136786062968895e-05
and O 0 1.3620060634877973e-10
has O 0 1.6648797618312727e-10
long O 0 1.025726614756195e-09
been O 0 5.805727565366681e-10
associated O 0 4.236931250289899e-09
with O 0 2.556990708058038e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 1.55343548158271e-06

By O 0 9.427877500911563e-08
analysing O 0 4.0650434129929636e-06
tumour B-Disease 1 0.9999990463256836
DNA O 0 3.034544988622656e-07
from O 0 5.016949633507295e-10
patients O 0 4.994248570255877e-09
with O 0 1.364049567742498e-10
sporadic B-Disease 0 1.7389785398336244e-06
T I-Disease 1 0.9668058753013611
- I-Disease 0 0.0031454497948288918
cell I-Disease 0 0.0003551373374648392
prolymphocytic I-Disease 0 0.04926024377346039
leukaemia I-Disease 0 0.03844738379120827
( O 0 4.236470285690075e-09
T B-Disease 0 2.5634910798544297e-06
- I-Disease 0 1.5050541435357445e-07
PLL I-Disease 0 6.677872192994982e-07
) O 0 1.072240560229254e-10
, O 0 8.931942858947384e-12
a O 0 3.5738301207288714e-11
rare O 0 1.5904834116398092e-09
clonal B-Disease 0 1.1038484615255584e-07
malignancy I-Disease 0 1.3111241514707217e-06
with O 0 3.9166041937432894e-11
similarities O 0 2.2306840818941964e-09
to O 0 3.5433697642694995e-10
a O 0 9.054595961899281e-10
mature B-Disease 0 1.3361038497805566e-07
T I-Disease 0 6.777855560358148e-06
- I-Disease 0 3.564591395388561e-07
cell I-Disease 0 6.23091182205826e-07
leukaemia I-Disease 0 2.397354728600476e-05
seen O 0 5.08879267613338e-08
in O 0 4.813395459990488e-09
A B-Disease 1 1.0
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
, O 0 5.470844333110847e-10
we O 0 4.864428651552011e-11
demonstrate O 0 9.552360985543018e-11
a O 0 1.492894523280608e-11
high O 0 2.544819632799289e-10
frequency O 0 2.6530024843651745e-09
of O 0 1.2583697972523566e-10
ATM O 0 4.2225732954648265e-07
mutations O 0 4.6254473318185774e-07
in O 0 1.4286026583931744e-08
T B-Disease 0 9.551969560561702e-05
- I-Disease 0 4.811176950170193e-06
PLL I-Disease 0 0.00010427465895190835
. O 0 2.58615074244517e-07

In O 0 9.741591533440896e-09
marked O 0 6.448607425824093e-09
contrast O 0 5.892165866328014e-09
to O 0 3.8607711472238293e-10
the O 0 1.9764075098738232e-10
ATM O 0 1.8192997686128365e-07
mutation O 0 3.4112314750700534e-08
pattern O 0 6.312649958317706e-08
in O 0 1.664613904495127e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 1.0450813131557268e-10
the O 0 4.209617463640791e-12
most O 0 4.190839082013342e-12
frequent O 0 1.7141842112433636e-10
nucleotide O 0 4.673514464315076e-09
changes O 0 5.664157476381604e-10
in O 0 7.853228484178132e-11
this O 0 1.0938689953832181e-09
leukaemia B-Disease 0 3.4109662010450847e-06
were O 0 6.903160709725853e-09
missense O 0 5.820640581077896e-06
mutations O 0 2.5920469397533452e-06
. O 0 1.2873753973963176e-07

These O 0 1.077374900404493e-08
clustered O 0 4.76604782306822e-08
in O 0 8.597231815343775e-10
the O 0 1.9407991880271425e-10
region O 0 1.6345889086721854e-09
corresponding O 0 3.0304132536684847e-09
to O 0 1.6973733529823676e-10
the O 0 2.236872319316685e-11
kinase O 0 4.505469330950973e-09
domain O 0 1.149535244771016e-09
, O 0 6.727454010535538e-11
which O 0 8.102654658337372e-11
is O 0 2.8355352788000943e-11
highly O 0 9.843411502563626e-11
conserved O 0 4.246419049724892e-10
in O 0 1.6892569287829673e-10
ATM O 0 1.7895915505050652e-07
- O 0 1.6432018412615434e-08
related O 0 1.645584557508073e-09
proteins O 0 3.366204259780403e-10
in O 0 6.392390783371837e-11
mouse O 0 1.1095832697094465e-08
, O 0 6.548942499406962e-10
yeast O 0 8.118477268226343e-08
and O 0 3.2427300844517504e-09
Drosophila O 0 4.0627455177855154e-08
. O 0 4.0050871064067906e-08

The O 0 2.3611612220975076e-08
resulting O 0 3.137949633469361e-08
amino O 0 1.8162675985422538e-07
- O 0 1.0659534410706328e-07
acid O 0 8.869059264782209e-09
substitutions O 0 1.0916616499656584e-09
are O 0 2.5098461503558767e-11
predicted O 0 4.642195239323854e-10
to O 0 2.4008850463275166e-11
interfere O 0 2.3507751301110602e-09
with O 0 1.8297546811041343e-10
ATP O 0 7.675915014715429e-08
binding O 0 5.544224990217117e-08
or O 0 5.490887300396707e-09
substrate O 0 6.199804261086683e-07
recognition O 0 2.1362384927670064e-07
. O 0 3.347499557548872e-07

Two O 0 6.850314981932115e-09
of O 0 7.570046256510921e-10
seventeen O 0 3.734675857458569e-08
mutated O 0 5.426173856903915e-07
T B-Disease 0 2.783247964543989e-06
- I-Disease 0 3.372106505139527e-08
PLL I-Disease 0 2.4287734845529485e-07
samples O 0 2.6080182458088075e-09
had O 0 1.1084272388828253e-10
a O 0 1.9609286416866212e-11
previously O 0 6.171215982675449e-09
reported O 0 1.035393097481574e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
allele O 0 4.00877688662149e-05
. O 0 2.910322791649378e-07

In O 0 4.494217442641002e-09
contrast O 0 8.70473471081823e-09
, O 0 2.2395074683601024e-10
no O 0 3.97841259935916e-10
mutations O 0 9.85371606532226e-09
were O 0 1.6309412154136282e-10
detected O 0 5.912328404633627e-09
in O 0 6.666092677853896e-11
the O 0 3.113074034666319e-11
p53 O 0 3.2793463500269127e-09
gene O 0 1.9976089671303043e-09
, O 0 2.4607097609541384e-11
suggesting O 0 4.990703961205156e-10
that O 0 4.7631960875538226e-11
this O 0 5.103718003773849e-10
tumour B-Disease 1 1.0
suppressor O 0 1.8255565237268456e-07
is O 0 5.407055914119496e-10
not O 0 1.6598700192105298e-10
frequently O 0 1.1319486459271388e-09
altered O 0 1.0797159610831386e-08
in O 0 1.0189330490462112e-09
this O 0 4.5550843097430516e-09
leukaemia B-Disease 0 2.3150380002334714e-05
. O 0 8.074988500084146e-08

Occasional O 0 3.782773273997009e-05
missense O 0 0.0001584677811479196
mutations O 0 6.482377102656756e-06
in O 0 2.896575646005317e-09
ATM O 0 1.4144650606340292e-07
were O 0 2.5489741428685875e-09
also O 0 4.987002477641056e-10
found O 0 1.4622152377796738e-09
in O 0 4.379729912074026e-09
tumour B-Disease 1 1.0
DNA O 0 2.6543736453277234e-07
from O 0 1.7062934398737184e-10
patients O 0 1.4375345358530467e-09
with O 0 8.809989543445695e-11
B B-Disease 0 3.903830929630203e-07
- I-Disease 0 1.9255257655004243e-07
cell I-Disease 0 0.00010313535312889144
non I-Disease 1 0.7479789853096008
- I-Disease 1 0.9756067395210266
Hodgkins I-Disease 1 0.9998929500579834
lymphomas I-Disease 0 0.00019364399486221373
( O 0 7.405017155015514e-10
B B-Disease 0 4.076508020034453e-08
- I-Disease 0 8.535296025513617e-09
NHL I-Disease 0 2.263203180419282e-09
) O 0 3.250609850735664e-11
and O 0 2.3814379288000787e-11
a O 0 3.299383821708801e-10
B B-Disease 0 1.6941834246608778e-07
- I-Disease 0 8.881640667368629e-08
NHL I-Disease 0 8.353481462108903e-08
cell O 0 1.5059198688049946e-07
line O 0 3.134373116608913e-07
. O 0 7.722098160911628e-08

The O 0 1.1776848385380845e-09
evidence O 0 2.1228410140849974e-09
of O 0 9.84998020647776e-12
a O 0 5.1627140063015275e-11
significant O 0 6.681536435237945e-10
proportion O 0 1.1099219321408782e-08
of O 0 3.9371037680036025e-11
loss O 0 9.907313192059064e-09
- O 0 1.7422566500613357e-08
of O 0 2.3931823189826673e-10
- O 0 6.371742244937195e-08
function O 0 4.996830949011155e-09
mutations O 0 1.8539823898322538e-08
and O 0 1.5036633049803072e-10
a O 0 5.0717697402946627e-11
complete O 0 2.603712800919311e-10
absence O 0 3.7823222331923034e-10
of O 0 2.808245606542026e-12
the O 0 1.631372988086799e-11
normal O 0 1.8507442800519414e-10
copy O 0 2.479094485252631e-09
of O 0 8.287050733135626e-12
ATM O 0 4.614539861336198e-09
in O 0 7.068124557862987e-11
the O 0 1.2464759779895473e-10
majority O 0 1.2277611816102763e-08
of O 0 1.4647331125772212e-09
mutated O 0 9.607702668290585e-05
tumours B-Disease 1 1.0
establishes O 0 1.9766382308716857e-07
somatic O 0 1.9203652357191459e-07
inactivation O 0 6.350667831611645e-07
of O 0 2.131114902603759e-11
this O 0 1.0764058047674219e-11
gene O 0 1.3666335840767374e-09
in O 0 3.338490942028649e-11
the O 0 3.615295215975145e-11
pathogenesis O 0 8.868483725166243e-09
of O 0 1.939404192796701e-10
sporadic B-Disease 0 5.471128133649472e-06
T I-Disease 1 0.7440648078918457
- I-Disease 0 5.215890269028023e-06
PLL I-Disease 0 2.836056182786706e-06
and O 0 3.0137073392388913e-10
suggests O 0 5.91353188639232e-10
that O 0 2.0080893545215694e-11
ATM O 0 5.104207279060802e-09
acts O 0 8.103293591688043e-10
as O 0 6.966859866786024e-10
a O 0 1.63565943012145e-08
tumour B-Disease 1 0.9999998807907104
suppressor O 0 2.6523253836785443e-05
. O 0 8.717115065337566e-07

As O 0 7.640315047297008e-09
constitutional O 0 2.610925031731881e-09
DNA O 0 1.8506755239400263e-08
was O 0 3.256972747056608e-10
not O 0 7.491497873435282e-12
available O 0 6.809052627287926e-11
, O 0 2.2184533723934585e-11
a O 0 3.309884866187218e-10
putative O 0 2.1500600269064307e-06
hereditary O 0 5.264760329737328e-05
predisposition O 0 3.1471918191527948e-06
to O 0 1.631213564223799e-08
T B-Disease 0 0.0013131328159943223
- I-Disease 0 1.3713232647205587e-06
PLL I-Disease 0 3.1265710731531726e-06
will O 0 2.560589795752577e-10
require O 0 2.85408280342736e-10
further O 0 2.1717977416457757e-10
investigation O 0 4.086423643911985e-09
. O 0 1.4506785772638864e-09
. O 0 1.889236855845411e-08

Myotonic B-Disease 1 0.9999966621398926
dystrophy I-Disease 1 0.999974250793457
protein O 0 1.2953972145623993e-05
kinase O 0 9.959510862245224e-06
is O 0 2.4736908077471753e-09
involved O 0 7.556428816002381e-10
in O 0 3.7554064025169254e-11
the O 0 2.4456152381002738e-11
modulation O 0 3.974872431200538e-09
of O 0 5.3577146191807756e-11
the O 0 1.9212798019196953e-09
Ca2 O 0 2.9955322133901063e-06
+ O 0 5.772221811639611e-07
homeostasis O 0 1.252905576620833e-06
in O 0 7.1967951598139734e-09
skeletal O 0 4.70102622784907e-06
muscle O 0 5.491766842169454e-06
cells O 0 1.4347338037623558e-06
. O 0 7.86673197694654e-08

Myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999998807907104
( O 0 2.8406036562955705e-06
DM B-Disease 1 1.0
) O 0 4.679285403597078e-09
, O 0 1.3226640269148326e-11
the O 0 6.896437847875303e-12
most O 0 2.78836703726526e-10
prevalent O 0 9.987712701331475e-07
muscular B-Disease 0 1.6209032764891163e-06
disorder I-Disease 0 4.45785881311167e-05
in O 0 8.17846124157029e-10
adults O 0 7.295130188822441e-08
, O 0 2.7552768400163075e-10
is O 0 3.321825592372818e-10
caused O 0 8.545651963842715e-10
by O 0 1.1399255150923437e-10
( O 0 1.7109666461401218e-10
CTG O 0 9.937445355490127e-08
) O 0 2.0629931096749488e-10
n O 0 4.391258556779576e-08
- O 0 4.5601375120440935e-08
repeat O 0 7.951920366622289e-08
expansion O 0 8.156542663506627e-10
in O 0 3.9637848558982114e-11
a O 0 4.210960746764414e-11
gene O 0 3.482360622086844e-09
encoding O 0 3.610433951806158e-09
a O 0 9.95314275442638e-10
protein O 0 6.965431254002397e-08
kinase O 0 2.0427501112862956e-06
( O 0 1.065684607226558e-08
DM B-Disease 1 0.9999990463256836
protein O 0 8.993415434588314e-08
kinase O 0 2.5179517137985385e-07
; O 0 1.0236470560087696e-09
DMPK O 0 1.84372467515459e-07
) O 0 1.4559167760275216e-10
and O 0 1.5401841260698212e-11
involves O 0 2.2794739706899492e-10
changes O 0 1.1088676643566941e-09
in O 0 1.7747651959165722e-10
cytoarchitecture O 0 3.857084323044546e-07
and O 0 3.2480227396547434e-09
ion O 0 5.963750595583406e-07
homeostasis O 0 2.1345174900488928e-05
. O 0 2.763103736924677e-07

To O 0 2.813890231934124e-09
obtain O 0 3.4865208498047195e-09
clues O 0 1.2661112158696142e-08
to O 0 1.1560562229728788e-10
the O 0 3.118375002664209e-11
normal O 0 7.259686740646032e-10
biological O 0 6.01959637691607e-09
role O 0 2.91667778817839e-09
of O 0 4.683611137812349e-11
DMPK O 0 1.1074757111373401e-07
in O 0 2.2265682353417304e-10
cellular O 0 1.7438093635746554e-08
ion O 0 1.5198232006241597e-08
homeostasis O 0 6.955912112971419e-08
, O 0 3.984221563779755e-10
we O 0 2.2710246183610394e-10
have O 0 5.876604064480873e-11
compared O 0 1.7825545206573423e-10
the O 0 9.396913802639517e-11
resting O 0 1.7786369710393046e-08
[ O 0 6.933774887585287e-09
Ca2 O 0 8.994324929290087e-08
+ O 0 1.7504440563698154e-08
] O 0 8.971927201173457e-09
i O 0 2.823551614739017e-09
, O 0 3.635838375162792e-12
the O 0 2.576017957972576e-12
amplitude O 0 1.6952897419209023e-10
and O 0 8.495559811194653e-11
shape O 0 6.243769945513122e-09
of O 0 3.267313641863723e-10
depolarization O 0 1.8836171022940107e-07
- O 0 1.780524598871125e-06
induced O 0 8.018445214474923e-07
Ca2 O 0 3.720825816344586e-07
+ O 0 2.530867071470766e-08
transients O 0 1.0691073271118512e-07
, O 0 9.658032706916231e-11
and O 0 2.466696465142082e-11
the O 0 5.870248731554284e-12
content O 0 2.4580090740577987e-10
of O 0 1.888740379374365e-11
ATP O 0 2.3954822125915598e-08
- O 0 2.0387624033446627e-08
driven O 0 2.158967582488458e-08
ion O 0 3.4684951799590635e-08
pumps O 0 6.960225107377482e-08
in O 0 7.26004645290601e-10
cultured O 0 1.3619339256365492e-07
skeletal O 0 5.587420446317992e-07
muscle O 0 1.0290509777632906e-07
cells O 0 8.300905740554754e-09
of O 0 1.7262673929208106e-11
wild O 0 1.92927762654449e-09
- O 0 6.001291126267461e-07
type O 0 4.449275934348407e-07
and O 0 3.006211279910076e-09
DMPK O 0 4.067828740517143e-07
[ O 0 1.007973526867545e-08
- O 0 7.452235450955413e-08
/ O 0 1.2503411994657654e-07
- O 0 1.7036730071140482e-07
] O 0 7.609515506601383e-08
knockout O 0 1.8642268742041779e-06
mice O 0 1.2908720918858307e-06
. O 0 7.432588944311647e-08

In O 0 1.9061805289766198e-07
vitro O 0 2.1618996470351703e-05
- O 0 4.046284630021546e-06
differentiated O 0 1.4004601780470693e-06
DMPK O 0 1.91306594388152e-06
[ O 0 3.313779117775084e-08
- O 0 1.43989154821611e-07
/ O 0 2.4920791474869475e-07
- O 0 8.568052578539209e-08
] O 0 8.242294846638742e-09
myotubes O 0 3.5752400151523034e-08
exhibit O 0 1.486863077104772e-09
a O 0 5.402324143588544e-10
higher O 0 4.949007426091612e-09
resting O 0 2.190424908121713e-08
[ O 0 1.6043962602907413e-08
Ca2 O 0 8.78952590710469e-08
+ O 0 2.79683352033544e-08
] O 0 3.968963380174273e-09
i O 0 9.754043128751277e-10
than O 0 1.2167139691598994e-11
do O 0 1.0900445129857772e-10
wild O 0 8.203344253887579e-11
- O 0 5.6791646940723695e-09
type O 0 2.3689457062658903e-09
myotubes O 0 8.158743725061868e-08
because O 0 4.6125137043162567e-10
of O 0 1.9120972166719596e-12
an O 0 5.954474760483386e-12
altered O 0 7.383738953592456e-09
open O 0 6.060818069641982e-09
probability O 0 4.1991646271277716e-10
of O 0 2.6285508492041032e-11
voltage O 0 1.384882182264846e-07
- O 0 2.389453129580943e-06
dependent O 0 9.540977771393955e-06
l O 0 1.2218050869705621e-05
- O 0 4.1706022102516727e-07
type O 0 4.7428875404875726e-07
Ca2 O 0 1.532213104837865e-06
+ O 0 1.8152616121369647e-07
and O 0 1.0777901238157028e-08
Na O 0 8.326977081196674e-07
+ O 0 1.0144602669015512e-07
channels O 0 2.6457428248249926e-07
. O 0 7.247158606560333e-08

The O 0 1.6753041620631848e-08
mutant O 0 3.1659141086493037e-07
myotubes O 0 2.6229989202875004e-07
exhibit O 0 4.158319466540661e-09
smaller O 0 1.0322430021858509e-08
and O 0 3.32305649664022e-09
slower O 0 1.3158449974071118e-07
Ca2 O 0 9.12527866603341e-07
+ O 0 7.044984329240833e-08
responses O 0 5.138581560260036e-09
upon O 0 3.200667231251231e-10
triggering O 0 3.5116618501973562e-09
by O 0 7.806558177669842e-11
acetylcholine O 0 1.4492390221221285e-07
or O 0 5.891758405596192e-07
high O 0 9.242789928975981e-07
external O 0 5.393671017372981e-05
K O 0 3.602739070629468e-06
+ O 0 1.0087505870615132e-06
. O 0 1.3303643697781808e-07

In O 0 5.497478916538512e-09
addition O 0 3.8337839569635435e-09
, O 0 2.3745586053003365e-10
we O 0 2.0360596542090548e-10
observed O 0 2.1105626968331848e-10
that O 0 3.15383379134726e-11
these O 0 3.236839407616543e-10
Ca2 O 0 1.3856390523869777e-07
+ O 0 3.2260135895967323e-08
transients O 0 4.705179037500784e-07
partially O 0 1.628898047556504e-07
result O 0 8.440084742211695e-10
from O 0 3.413028887289116e-11
an O 0 1.6612785799785534e-11
influx O 0 1.0410317941023095e-08
of O 0 2.2999432913728413e-10
extracellular O 0 1.8000697821207723e-08
Ca2 O 0 1.3975713386571442e-07
+ O 0 9.248662280469944e-09
through O 0 1.6285725545905905e-10
the O 0 3.9575695498506036e-10
l O 0 6.683874289592495e-07
- O 0 1.55906647592019e-07
type O 0 3.342045147292083e-07
Ca2 O 0 1.679020101619244e-06
+ O 0 3.41114457569347e-07
channel O 0 1.111190726987843e-06
. O 0 1.6756149534558062e-07

Neither O 0 8.980403549685434e-07
the O 0 8.274850804568246e-10
content O 0 4.183689394920975e-09
nor O 0 4.685965837580852e-09
the O 0 5.754657861345436e-11
activity O 0 3.5391702901677036e-09
of O 0 2.848035696167983e-10
Na O 0 9.14790689421352e-07
+ O 0 3.2696618745831074e-07
/ O 0 2.0563018665598065e-07
K O 0 3.869976694659272e-07
+ O 0 2.926543629655498e-07
ATPase O 0 4.716401690529892e-06
and O 0 2.5883162280138095e-08
sarcoplasmic O 0 1.1832109521492384e-05
reticulum O 0 1.5000107850937638e-05
Ca2 O 0 3.5912431485485286e-05
+ O 0 8.376922778552398e-06
- O 0 4.004009497293737e-06
ATPase O 0 2.5591294615878724e-05
are O 0 2.9887050612131816e-09
affected O 0 3.149815297476266e-09
by O 0 9.481789797760598e-10
DMPK O 0 5.81199356020079e-06
absence O 0 3.37482930490296e-07
. O 0 1.31665842673101e-07

In O 0 2.6948852038799487e-08
conclusion O 0 1.2949080918644995e-08
, O 0 3.580805096881079e-10
our O 0 1.9960159913789965e-10
data O 0 4.1705097708621963e-10
suggest O 0 7.805593948972955e-10
that O 0 1.696433792053309e-11
DMPK O 0 4.353488236574776e-08
is O 0 2.554846612046191e-11
involved O 0 4.953006407792948e-11
in O 0 2.023221347402515e-11
modulating O 0 3.838847018045044e-09
the O 0 3.664055864271987e-11
initial O 0 5.35790134481573e-10
events O 0 2.35642561019489e-10
of O 0 3.089448835646991e-11
excitation O 0 1.293933422630289e-07
- O 0 5.65643949812511e-06
contraction O 0 6.10875304118963e-07
coupling O 0 5.15660083522107e-08
in O 0 7.094573817312266e-10
skeletal O 0 4.3497081492205325e-07
muscle O 0 7.803381549820188e-07
. O 0 4.310192203149654e-09
. O 0 2.6443446543567006e-08

Constitutional O 0 1.1055926734115928e-05
RB1 O 0 0.0009116512956097722
- O 0 2.3168202460510656e-05
gene O 0 1.929111249410198e-06
mutations O 0 1.3096008615320898e-06
in O 0 1.5989759516443769e-09
patients O 0 1.8861333828112947e-08
with O 0 9.214198848361832e-10
isolated O 0 1.40877864396316e-06
unilateral B-Disease 0 0.0002727902610786259
retinoblastoma I-Disease 0 0.000492587685585022
. O 0 1.947563532667118e-06

In O 0 9.136763345907184e-09
most O 0 1.0070660971805978e-09
patients O 0 2.8794662210174238e-09
with O 0 2.7741432415129275e-11
isolated O 0 2.6694189969589388e-08
unilateral B-Disease 0 3.2865668799786363e-06
retinoblastoma I-Disease 0 9.53513790591387e-06
, O 0 2.79921219537016e-09
tumor B-Disease 0 1.387126502550018e-07
development O 0 2.899398499067729e-10
is O 0 6.038657074380893e-11
initiated O 0 3.3655173092839163e-10
by O 0 5.7189648849931274e-11
somatic O 0 2.243507069010775e-08
inactivation O 0 1.9417608143612597e-07
of O 0 2.614465588468562e-11
both O 0 2.6634658367719055e-10
alleles O 0 1.2680156480371352e-08
of O 0 2.6662308472147345e-10
the O 0 6.015739906217732e-09
RB1 O 0 2.200225935666822e-05
gene O 0 2.0670916001108708e-06
. O 0 2.738326827511628e-07

However O 0 1.223399248573287e-08
, O 0 7.351971115232558e-11
some O 0 4.745112289206155e-12
of O 0 1.1104872446945913e-12
these O 0 1.199369215054702e-10
patients O 0 1.6613468378778862e-09
can O 0 2.2333095095472544e-10
transmit O 0 2.5241948975462947e-08
retinoblastoma B-Disease 0 6.06840899308736e-07
predisposition O 0 2.8033099397362093e-07
to O 0 2.2815673794696067e-09
their O 0 7.96842147821053e-09
offspring O 0 6.043874236638658e-07
. O 0 1.534325946295212e-07

To O 0 6.2513962895138775e-09
determine O 0 2.040500213240648e-09
the O 0 1.0737974745489431e-11
frequency O 0 2.6726068025340055e-09
and O 0 1.0156631785607217e-10
nature O 0 1.4089686362073195e-10
of O 0 5.604682690174556e-11
constitutional O 0 3.149360239262933e-08
RB1 O 0 1.9414108464843594e-05
- O 0 1.0161974017819375e-07
gene O 0 6.647513117741255e-08
mutations O 0 1.1283444223408878e-07
in O 0 3.2003008576531045e-10
patients O 0 2.453059977369776e-09
with O 0 3.863494593692174e-11
isolated O 0 6.525967677362132e-08
unilateral B-Disease 0 1.6764921610956662e-06
retinoblastoma I-Disease 0 2.7497837891132804e-06
, O 0 1.0854971366214272e-09
we O 0 1.4854677210518474e-10
analyzed O 0 8.854636468491606e-10
DNA O 0 3.501114953508022e-09
from O 0 7.730605044997674e-11
peripheral O 0 1.7868895696437903e-08
blood O 0 4.064497360900532e-08
and O 0 1.0743415046476912e-09
from O 0 2.4722239810870406e-09
tumor B-Disease 0 4.2196852518827654e-06
tissue O 0 6.938798378541833e-06
. O 0 4.005752316516009e-07

The O 0 2.6733919522570204e-09
analysis O 0 1.2946538063829394e-08
of O 0 3.8943184788031715e-10
tumors B-Disease 1 1.0
from O 0 3.700212636292832e-10
54 O 0 2.4494177797151906e-09
( O 0 1.3020816369557764e-10
71 O 0 3.864825348642853e-09
% O 0 1.5669898711934138e-10
) O 0 8.300263948379794e-11
of O 0 2.5522603128158572e-11
76 O 0 3.3660776388444447e-09
informative O 0 1.9281603869103492e-08
patients O 0 6.633391080868023e-08
showed O 0 2.7747242725695287e-08
loss O 0 6.0005560520437484e-09
of O 0 2.2810048294630292e-10
constitutional O 0 1.507605560391312e-07
heterozygosity O 0 0.0003277992072980851
( O 0 2.140630783742381e-08
LOH O 1 0.9999850988388062
) O 0 8.959051278623065e-09
at O 0 7.474082686087513e-09
intragenic O 0 1.7233820699402713e-06
loci O 0 1.209888750963728e-06
. O 0 1.3510053520349175e-07

Three O 0 2.919050068328488e-08
of O 0 1.0383225390597772e-09
13 O 0 1.3583235869418786e-08
uninformative O 0 5.582415724347811e-06
patients O 0 4.636616210973443e-07
had O 0 3.3718543512861743e-09
constitutional O 0 5.40607096866097e-08
deletions O 0 2.2482763597508892e-06
. O 0 1.9287602981421514e-07

For O 0 5.8979341410747566e-09
39 O 0 1.555930317920229e-08
randomly O 0 2.561930934064094e-08
selected O 0 1.2854283681917877e-07
tumors B-Disease 1 1.0
, O 0 8.714170718349123e-09
SSCP O 0 8.059007086558267e-06
, O 0 4.664946651189439e-09
hetero O 0 4.756161797558889e-05
- O 0 1.7836894983247475e-07
duplex O 0 3.758719913093955e-07
analysis O 0 2.8038396049367975e-09
, O 0 1.3301399912069023e-11
sequencing O 0 2.772568286069088e-10
, O 0 2.907099734550389e-11
and O 0 1.0759589746944798e-10
Southern O 0 1.87335791324017e-09
blot O 0 3.552760574621061e-07
analysis O 0 2.3541717464325984e-09
were O 0 6.146880920931963e-11
used O 0 4.641053374943027e-10
to O 0 5.167849481679809e-10
identify O 0 1.83920789709191e-07
mutations O 0 1.0166932042920962e-06
. O 0 7.377013133691435e-08

Mutations O 0 1.4896584616508335e-05
were O 0 1.1849542680408831e-08
detected O 0 2.616659422471912e-08
in O 0 5.118604429199536e-10
21 O 0 4.431270073101956e-10
( O 0 5.1203492834606124e-11
91 O 0 1.0788446802578733e-09
% O 0 2.0713875059641396e-10
) O 0 3.7201544622611493e-10
of O 0 4.051219637535297e-10
23 O 0 0.00025568835553713143
tumors B-Disease 1 1.0
with O 0 1.2007641316813533e-06
LOH O 1 1.0
. O 0 1.2852351574110799e-06

In O 0 3.3877853411468095e-08
6 O 0 5.167112515636063e-09
( O 0 1.3454194702777755e-10
38 O 0 1.1266907407048166e-09
% O 0 1.2350974409880422e-10
) O 0 9.923964428004695e-11
of O 0 9.487682167685918e-11
16 O 0 8.142409569700249e-06
tumors B-Disease 1 1.0
without O 0 4.139221800869564e-06
LOH O 1 0.9999998807907104
, O 0 3.3232705476393676e-10
one O 0 1.4049539309723968e-10
mutation O 0 3.732636866260464e-09
was O 0 4.456018887211144e-10
detected O 0 2.5677022730263843e-09
, O 0 3.0909934334300004e-11
and O 0 4.9461434947772887e-11
in O 0 3.408871795951285e-11
9 O 0 1.28797292275884e-10
( O 0 1.2777784906548018e-11
56 O 0 2.1101682901036867e-10
% O 0 2.6161265861968097e-11
) O 0 4.523090235686311e-11
of O 0 2.6094187574599026e-11
the O 0 7.268213266797829e-07
tumors B-Disease 1 1.0
without O 0 2.546152245486155e-05
LOH O 1 0.9999998807907104
, O 0 2.3877930188653806e-10
both O 0 2.048258923581514e-10
mutations O 0 1.3853201252800318e-08
were O 0 5.614304021683836e-10
found O 0 2.1701382912908684e-09
. O 0 3.2117760895289393e-08

Thus O 0 3.550409033437063e-08
, O 0 3.316861785229719e-10
a O 0 6.444321465348679e-11
total O 0 5.174514289274512e-11
of O 0 2.6323287299900855e-11
45 O 0 5.441901929081894e-10
mutations O 0 1.7370771487890124e-08
were O 0 3.6004743630968505e-10
identified O 0 2.9660705891387806e-08
in O 0 3.003885495900249e-08
tumors B-Disease 1 1.0
of O 0 9.10127639919267e-10
36 O 0 1.0195871880114282e-07
patients O 0 1.0865504407320259e-07
. O 0 7.110593003289978e-08

Thirty O 0 2.0012423647131072e-06
- O 0 2.6744548904389376e-06
nine O 0 3.936611925325906e-09
of O 0 2.053413515612501e-11
the O 0 3.2025954804781875e-11
mutations O 0 1.6136153746515447e-08
- O 0 4.330975578170637e-09
including O 0 1.5112019968732682e-10
34 O 0 5.243377398933546e-10
small O 0 7.855254224864439e-10
mutations O 0 6.46963940198475e-08
, O 0 2.627248973929852e-10
2 O 0 1.9459107936103948e-10
large O 0 7.755094344474855e-10
structural O 0 1.0826482821357786e-06
alterations O 0 1.2773459445725166e-07
, O 0 2.4044560786862235e-10
and O 0 1.6699269744790968e-10
hypermethylation O 0 5.264507763058646e-07
in O 0 4.223489113996948e-09
3 O 0 1.0541013750753336e-07
tumors O 1 1.0
- O 0 0.00051687570521608
were O 0 2.235394758187681e-09
not O 0 2.592033809811767e-10
detected O 0 1.3060121872854324e-09
in O 0 2.608393709357948e-11
the O 0 3.317290192539346e-11
corresponding O 0 3.136274528969807e-08
peripheral O 0 3.590479593640339e-07
blood O 0 1.546106318528473e-07
DNA O 0 1.427321990377095e-06
. O 0 1.4001247450323717e-07

In O 0 4.387265306604604e-08
6 O 0 9.819719259951398e-09
( O 0 2.2068023797228165e-10
17 O 0 2.2211896211210558e-10
% O 0 1.824380230219802e-11
) O 0 5.291799116957652e-12
of O 0 1.5286815866974446e-12
the O 0 8.210138124908894e-11
36 O 0 3.4573439666729655e-09
patients O 0 2.3576136598535413e-09
, O 0 8.30675372237577e-12
a O 0 8.550212621249997e-11
mutation O 0 1.9598211054017156e-08
was O 0 1.4473950926685575e-09
detected O 0 3.396453562842794e-09
in O 0 3.61838545237525e-11
constitutional O 0 1.4107461032697444e-10
DNA O 0 4.778743623035098e-09
, O 0 2.8960974243763538e-11
and O 0 2.766850810964616e-11
1 O 0 2.766697808354035e-11
of O 0 1.5696025208733477e-12
these O 0 1.6437831651394674e-10
mutations O 0 4.470671832734752e-09
is O 0 2.2953363168487506e-11
known O 0 1.1920324449743447e-10
to O 0 7.388211570313885e-11
be O 0 2.4359891881431395e-10
associated O 0 1.7106542848921436e-09
with O 0 5.912855205458811e-10
reduced O 0 1.7661163553839287e-07
expressivity O 0 3.09084243781399e-05
. O 0 2.3067602228366013e-07

The O 0 1.2755395628616384e-09
presence O 0 2.4914283969224016e-09
of O 0 8.908633379600683e-12
a O 0 7.749116626154517e-11
constitutional O 0 1.881325095709485e-09
mutation O 0 1.2795364767725914e-08
was O 0 9.68517377408773e-10
not O 0 2.7652047318582618e-11
associated O 0 5.828737492663549e-11
with O 0 4.581365235095669e-12
an O 0 1.2016262984637649e-11
early O 0 1.0674138017918722e-08
age O 0 6.062575330645359e-09
at O 0 1.3937766496496806e-09
treatment O 0 2.84031926867101e-08
. O 0 2.546511801426732e-08

In O 0 3.573801521383757e-08
1 O 0 1.9939442097438587e-08
patient O 0 3.410021776062422e-08
, O 0 4.4106190921766597e-10
somatic O 0 2.5397073954991356e-07
mosaicism O 0 1.5503806935157627e-05
was O 0 1.2449660857782874e-08
demonstrated O 0 1.8119323819121291e-09
by O 0 2.6472475253558336e-11
molecular O 0 3.491438915759204e-09
analysis O 0 3.745874277427674e-09
of O 0 5.210416126333328e-11
DNA O 0 9.903688891199636e-08
and O 0 1.3675983678851367e-09
RNA O 0 1.7113928052481242e-08
from O 0 1.2636883761629747e-09
peripheral O 0 6.131451186774939e-07
blood O 0 1.0579522040643496e-06
. O 0 1.6679778980233095e-07

In O 0 3.587816266303889e-08
2 O 0 1.457407439175995e-08
patients O 0 1.2828989426338921e-08
without O 0 7.498510146142223e-10
a O 0 5.020261983901264e-10
detectable O 0 1.5389435930046602e-06
mutation O 0 1.837044720787162e-07
in O 0 1.0203820011156495e-09
peripheral O 0 1.4022400307567295e-07
blood O 0 9.373297871206887e-08
, O 0 2.410052990509115e-10
mosaicism O 0 3.2132933824868815e-07
was O 0 1.8603718565657346e-09
suggested O 0 2.3002120208559518e-09
because O 0 4.53107967812727e-10
1 O 0 5.7534071257192565e-11
of O 0 3.3741783238977474e-12
the O 0 3.9846700938817037e-10
patients O 0 3.4724465081126255e-08
showed O 0 5.422284132805544e-08
multifocal O 0 0.16245168447494507
tumors B-Disease 1 1.0
and O 0 3.719013985659103e-09
the O 0 3.440742829541321e-11
other O 0 2.233710022503388e-10
later O 0 7.044255845300995e-09
developed O 0 3.179283680765366e-08
bilateral B-Disease 0 2.419668874154013e-07
retinoblastoma I-Disease 0 9.179313565255143e-06
. O 0 3.234041798805265e-07

In O 0 2.6497570360106693e-08
conclusion O 0 1.5834137556680616e-08
, O 0 6.942584840352595e-10
our O 0 3.794309311189181e-10
results O 0 4.300237665955109e-10
emphasize O 0 1.1785478148951256e-09
that O 0 2.6926922497283456e-11
the O 0 1.864181205235571e-11
manifestation O 0 2.090970285806293e-09
and O 0 2.675359656034715e-10
transmissibility O 0 2.558415168607553e-08
of O 0 9.553831684105951e-12
retinoblastoma B-Disease 0 4.707016554306165e-09
depend O 0 8.518686311909107e-10
on O 0 6.765064897162887e-11
the O 0 7.392197097499942e-12
nature O 0 7.348859021316656e-11
of O 0 1.345574693334406e-12
the O 0 3.997371010588946e-12
first O 0 1.6942489078353162e-10
mutation O 0 3.003699233783408e-10
, O 0 2.496857538433761e-12
its O 0 3.263990640267611e-12
time O 0 1.4277404258855597e-10
in O 0 1.3038406292131821e-11
development O 0 8.966712788938125e-12
, O 0 5.635884987864603e-12
and O 0 1.0573091013821312e-11
the O 0 1.981591757002632e-12
number O 0 5.626564839045223e-11
and O 0 5.0062131523587183e-11
types O 0 2.6247296003312215e-10
of O 0 3.3091177367716718e-12
cells O 0 1.0060312582993447e-09
that O 0 5.882189180184128e-11
are O 0 1.1105519281962017e-10
affected O 0 8.700548059792368e-10
. O 0 1.1293586066329908e-09
. O 0 3.63660177526981e-08

Hereditary B-Disease 1 0.9999935626983643
deficiency I-Disease 1 0.9999839067459106
of I-Disease 0 6.825830456413939e-10
the I-Disease 0 2.0474269502024356e-10
fifth I-Disease 0 3.318761931936365e-09
component I-Disease 0 6.841762267839613e-09
of I-Disease 0 2.645581670401853e-11
complement I-Disease 0 3.2052751564037862e-09
in O 0 9.167394621201197e-10
man O 0 1.783781442554755e-07
. O 0 9.081499285912287e-08

I O 0 0.00017001906235236675
. O 0 1.5023724699858576e-06

Clinical O 0 4.353824624558911e-05
, O 0 9.829838276687042e-09
immunochemical O 0 1.0709427442634478e-06
, O 0 1.94610105808124e-09
and O 0 1.286034279068815e-09
family O 0 2.7760423293443637e-08
studies O 0 4.6086097427178174e-07
. O 0 1.6198558228097681e-07

The O 0 6.154817988601735e-09
first O 0 2.7707407479482526e-09
recognized O 0 7.161604198557825e-09
human O 0 1.2319336661903435e-09
kindred O 0 2.9700908044105745e-07
with O 0 2.665627274467397e-09
hereditary B-Disease 1 0.9979670643806458
deficiency I-Disease 1 0.931358814239502
of I-Disease 0 1.7091390802637108e-11
the I-Disease 0 1.0887769852363505e-10
fifth I-Disease 0 3.241783952390165e-09
component I-Disease 0 2.1917202275290038e-08
of I-Disease 0 8.347433161359774e-11
complement I-Disease 0 4.4437754809223406e-08
( O 0 8.069207524386002e-10
C5 O 0 5.748896469981446e-08
) O 0 5.419466542200269e-10
is O 0 3.9765310488881767e-10
described O 0 2.34355521655516e-08
. O 0 7.446750771578081e-08

The O 0 4.574020273651058e-09
proband O 0 6.346114673760894e-07
, O 0 2.4221177841177166e-10
a O 0 9.11591704899628e-11
20 O 0 1.7814667796489658e-10
- O 0 7.2056685063159875e-09
year O 0 3.442091722760665e-09
- O 0 3.0129690742342063e-08
old O 0 9.606127093775285e-08
black O 0 1.0539301875667206e-08
female O 0 2.2512486097525652e-08
with O 0 4.639993278487964e-09
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9766244292259216
erythematosus I-Disease 1 1.0
since O 0 9.004003231893876e-07
age O 0 4.825587041068502e-08
11 O 0 1.0883332013378322e-09
, O 0 2.6013696752258397e-10
lacked O 0 1.243720646471047e-07
serum O 0 4.884672648586275e-07
hemolytic O 0 8.582402415413526e-07
complement O 0 3.427312433856855e-09
activity O 0 8.414339447426755e-09
, O 0 1.849184555480221e-10
even O 0 9.069114903503817e-10
during O 0 1.0475590173086857e-08
remission O 0 4.732351044367533e-07
. O 0 3.868750653168718e-08

C5 O 0 0.00015667460684198886
was O 0 3.4511367630329914e-07
undetectable O 0 4.7169325512186333e-07
in O 0 2.4910282170331755e-10
her O 0 2.0803883060693806e-09
serum O 0 4.0034584536385864e-09
by O 0 3.721962321678873e-11
both O 0 8.663074702042195e-10
immunodiffusion O 0 1.1736332226064405e-06
and O 0 1.2329661736032449e-08
hemolytic O 0 1.580562093295157e-05
assays O 0 1.6538377167307772e-05
. O 0 2.6484516979508044e-07

Other O 0 2.092486406368721e-09
complement O 0 4.7224930632694395e-09
components O 0 4.3176138220246685e-09
were O 0 2.0195792260757628e-10
normal O 0 1.0767909897069217e-09
during O 0 1.1682415035352278e-09
remission O 0 3.058642406017498e-08
of O 0 8.341560775448897e-11
lupus O 0 1.9494141270115506e-06
, O 0 2.762818029911074e-10
but O 0 3.870033182806765e-09
C1 O 0 5.972316330371541e-07
, O 0 2.700748513717599e-10
C4 O 0 5.956372817195188e-08
, O 0 3.1151781154648006e-10
C2 O 0 7.616456798587024e-08
, O 0 3.623062960755874e-10
and O 0 2.2489856643659323e-09
C3 O 0 7.467843943231856e-07
levels O 0 2.35913972801427e-08
fell O 0 2.4285463950945996e-07
during O 0 1.1654950071715575e-07
exacerbations O 0 0.00012337198131717741
. O 0 2.492181465640897e-07

A O 0 3.4168056828320914e-08
younger O 0 2.6951987308621028e-08
half O 0 2.390870612600793e-09
- O 0 1.2463107879057134e-08
sister O 0 1.69145426553996e-08
, O 0 1.524112364093e-10
who O 0 6.6924572550419725e-09
had O 0 5.830121718730652e-09
no O 0 1.8145297486782397e-09
underlying O 0 4.317161256039981e-06
disease O 0 2.9168685244940207e-08
, O 0 6.954681275317398e-11
was O 0 7.58675966494593e-09
also O 0 5.814571046869332e-10
found O 0 5.254049417757756e-10
to O 0 1.2953100814172558e-09
lack O 0 4.547317544734142e-08
immunochemically O 0 2.514016341592651e-05
detectable O 0 4.280629218555987e-05
C5 O 0 1.072178656613687e-05
. O 0 1.2936274629282707e-07

By O 0 1.9007819673788617e-07
hemolytic O 0 4.8619069275446236e-05
assay O 0 1.958343455044087e-05
, O 0 6.167756527730717e-09
she O 0 1.9089016589646235e-08
exhibited O 0 5.3047624071211885e-09
1 O 0 1.327773890835715e-09
- O 0 9.640631404295164e-09
2 O 0 3.1804939237822794e-10
% O 0 6.482550607422866e-11
of O 0 7.2231881934059494e-12
the O 0 3.4516756119984393e-10
normal O 0 2.995669490246655e-08
serum O 0 2.3889077738203923e-07
C5 O 0 6.426458298847137e-08
level O 0 1.6130021762705837e-09
and O 0 1.497429680252793e-10
normal O 0 2.664807263741409e-10
concentrations O 0 2.6763204985513767e-09
of O 0 5.0513482285907685e-12
other O 0 8.248247224118543e-11
complement O 0 3.869471854045514e-09
components O 0 5.148178416902738e-08
. O 0 3.18883692784766e-08

C5 O 0 1.4883135918353219e-05
levels O 0 6.129316432179621e-08
of O 0 8.209115678892154e-12
other O 0 2.8892284398285284e-11
family O 0 9.761297325994178e-11
members O 0 1.527335896644999e-11
were O 0 7.613874808409804e-11
either O 0 1.642654762212814e-10
normal O 0 2.2802218446749123e-10
or O 0 5.72575389878871e-11
approximately O 0 5.839954214659215e-11
half O 0 1.0576616915614068e-08
- O 0 8.005509357644769e-07
normal O 0 3.1469267192107964e-09
, O 0 4.1478192408517245e-11
consistent O 0 9.019432978263353e-10
with O 0 1.3470936865989103e-10
autosomal O 0 3.971654223278165e-07
codominant O 0 1.1599584581745148e-07
inheritance O 0 1.8287167335984122e-08
of O 0 4.46196135595045e-11
the O 0 6.832421295399627e-10
gene O 0 4.6537652451661415e-06
determining O 0 0.002534553175792098
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 6.74051875648729e-07

Normal O 0 7.350878877332434e-05
hemolytic O 0 0.0016432005213573575
titers O 0 0.00020504424173850566
were O 0 1.3137980481303657e-08
restored O 0 1.9555866259679533e-08
to O 0 8.041398102953679e-10
both O 0 8.70734151448005e-09
homozygous O 0 0.22871795296669006
C5 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
( O 0 2.041712043876487e-08
C5D B-Disease 1 1.0
) O 0 1.4730455744071946e-09
sera O 0 1.1055948156979412e-08
by O 0 2.811666524604739e-11
addition O 0 5.597196595097387e-10
of O 0 2.0126840472034502e-10
highly O 0 2.053330483420268e-08
purified O 0 2.3278917637981067e-07
human O 0 3.78485900398573e-08
C5 O 0 2.4326359380211215e-06
. O 0 5.761388521818844e-08

In O 0 6.970109467374641e-08
specific O 0 7.072125640661397e-08
C5 O 0 9.360547892356408e-07
titrations O 0 4.587562671076739e-06
, O 0 6.311380307266745e-10
however O 0 2.288587652721219e-10
, O 0 3.7198261831905555e-11
it O 0 1.1391930454518473e-10
was O 0 6.287602660748348e-10
noted O 0 1.4607288989498812e-10
that O 0 2.2962513834823284e-11
when O 0 9.993771088456782e-11
limited O 0 4.7091403693189093e-11
amounts O 0 4.669974407178756e-10
of O 0 3.095925946161593e-11
C5 O 0 4.905691852741256e-09
were O 0 4.200828920830624e-11
assayed O 0 5.336058706006952e-09
in O 0 4.0874720275141385e-11
the O 0 1.4919154453507666e-11
presence O 0 2.701742995991907e-10
of O 0 1.4564826775198547e-11
low O 0 4.0616434660023515e-09
dilutions O 0 4.14204720300404e-07
of O 0 7.264863016720469e-11
either O 0 2.998842063561824e-08
C5D B-Disease 1 1.0
serum O 0 1.1996523596735642e-07
, O 0 2.600634117777556e-11
curving O 0 1.0230069014127707e-09
rather O 0 2.063107323868607e-10
than O 0 4.16595230534611e-11
linear O 0 1.4178143104004448e-09
dose O 0 1.9335820411470195e-07
- O 0 1.2326158760345152e-08
response O 0 4.856440249945138e-10
plots O 0 5.688618465171658e-09
were O 0 4.3835055030250203e-10
consistently O 0 2.5281250426445467e-09
obtained O 0 3.280752336465298e-10
, O 0 1.7100458202246038e-11
suggesting O 0 6.169447175352616e-10
some O 0 4.017353116836375e-11
inhibitory O 0 2.639290741512923e-08
effect O 0 9.794656818939984e-08
. O 0 5.738467123705959e-08

Further O 0 6.12658155318968e-08
studies O 0 2.7638014543640566e-08
suggested O 0 4.722574331594842e-09
that O 0 2.667970566694322e-10
low O 0 9.19077169925231e-09
dilutions O 0 4.340142368164379e-06
of O 0 1.3656668018668938e-09
C5D B-Disease 1 1.0
serum O 0 9.926400679205472e-08
contain O 0 8.724810318661014e-10
a O 0 1.037290670025115e-10
factor O 0 7.329167828196148e-10
( O 0 1.0090145732832845e-11
or O 0 8.059097833523765e-11
factors O 0 8.504805193432219e-10
) O 0 2.5429892566708467e-11
interfering O 0 6.37717156859452e-10
at O 0 6.582212552785904e-11
some O 0 3.879487009417204e-12
step O 0 9.768789110964349e-10
in O 0 1.2761716683407087e-10
the O 0 6.838810073794832e-10
hemolytic O 0 1.2740201782435179e-06
assay O 0 4.814012868337159e-07
of O 0 1.5625369054195204e-10
C5 O 0 1.748898981190905e-08
, O 0 1.8835275353290548e-11
rather O 0 4.4937758375551695e-11
than O 0 8.917580562872729e-11
a O 0 6.881019642968056e-10
true O 0 5.744895759107749e-08
C5 O 0 5.879751370230224e-07
inhibitor O 0 6.492099657862127e-08
or O 0 4.062727931852805e-09
inactivator O 0 2.4326359380211215e-06
. O 0 1.673098353194291e-07

Of O 0 6.274068375944353e-09
clinical O 0 6.688516691610857e-07
interest O 0 4.86107643027367e-09
are O 0 9.62590424036236e-11
( O 0 2.0049512397535274e-11
a O 0 3.990592925551262e-11
) O 0 6.129974305935093e-11
the O 0 3.3154118339595584e-11
documentation O 0 8.6833766843597e-09
of O 0 6.552978160101475e-10
membranous O 1 0.9643041491508484
glomerulonephritis B-Disease 1 1.0
, O 0 3.9315574440479395e-07
vasculitis B-Disease 1 1.0
, O 0 8.722717659281898e-09
and O 0 2.1832364893725753e-07
arthritis B-Disease 1 1.0
in O 0 6.411430830688403e-10
an O 0 2.534593646075223e-10
individual O 0 1.4778811951998705e-08
lacking O 0 1.1040864222877644e-07
C5 O 0 1.359770607223254e-07
( O 0 7.210280289493554e-11
and O 0 2.0383160437287273e-11
its O 0 3.010396792957337e-11
biologic O 0 3.956877048238994e-09
functions O 0 8.401918050182644e-11
) O 0 3.4346712973754023e-11
, O 0 1.736729857149122e-11
and O 0 7.709651667076045e-11
( O 0 3.8847390582130714e-11
b O 0 1.3410290655713197e-09
) O 0 8.367833335964914e-12
a O 0 1.6381547160437826e-11
remarkable O 0 1.2630522183698645e-09
propensity O 0 3.643356905058681e-08
to O 0 1.1171261249387499e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 9.636907938315176e-11
the O 0 1.47608453238135e-11
proband O 0 2.0043463777597026e-08
, O 0 7.447560797235742e-12
even O 0 4.390255520236863e-11
during O 0 2.8306395422061925e-11
periods O 0 1.6093422150476044e-09
of O 0 1.281048444407018e-11
low O 0 1.2384766989725904e-08
- O 0 1.3683765232030964e-08
dose O 0 2.6239463934984997e-08
or O 0 1.1573314528945389e-10
alternate O 0 2.070610571891507e-09
- O 0 2.8524857142997462e-08
day O 0 6.535357144343834e-09
corticosteroid O 0 3.239507122998475e-06
therapy O 0 3.6755341170646716e-07
. O 0 1.9962692832109497e-08

Other O 0 3.786763347335409e-09
observations O 0 6.522082873772206e-09
indicate O 0 2.148159428116969e-09
that O 0 3.242881657650187e-11
the O 0 1.064501195524592e-10
C5D B-Disease 1 1.0
state O 0 9.434362180371636e-10
is O 0 4.030677180910658e-11
compatible O 0 8.283488339699829e-10
with O 0 7.413266528422113e-11
normal O 0 2.7811606351235696e-09
coagulation O 0 7.188646566902435e-09
function O 0 4.6195836045370697e-10
and O 0 6.509524169695524e-11
the O 0 1.1290064369506858e-11
capacity O 0 9.350215046666221e-11
to O 0 4.603616793330545e-11
mount O 0 2.2465002302851644e-08
a O 0 1.463932264300638e-08
neutrophilic O 0 0.0003589117550291121
leukocytosis O 0 0.00011084938159910962
during O 0 3.930747425329173e-07
pyogenic B-Disease 0 0.00599021976813674
infection I-Disease 0 9.654799941927195e-05
. O 0 1.0315738485644488e-08
. O 0 5.836878358422837e-08

Susceptibility O 0 0.00011268868547631428
to O 0 1.4752727111044805e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 1.394964073142546e-07
twins O 0 1.3456343594953069e-07
: O 0 1.3922907271535223e-10
the O 0 5.871245763872102e-12
role O 0 9.593685845743494e-10
of O 0 4.931050793383074e-12
genes O 0 6.935583218847796e-10
, O 0 8.768983456031165e-11
HLA O 0 8.181086030845108e-09
, O 0 1.3234420503938082e-10
and O 0 2.519632280595374e-10
the O 0 6.634068294708584e-10
environment O 0 5.661884117103e-08
. O 0 4.079673487922264e-08

OBJECTIVE O 0 8.059299716478563e-07
To O 0 5.69189306798279e-10
determine O 0 5.340617392768365e-10
the O 0 1.4623226241017306e-11
relative O 0 5.278538162123425e-10
effects O 0 4.2943217870572425e-09
of O 0 5.3585295922697895e-12
genetic O 0 1.0924037674442388e-08
and O 0 1.0539069617010455e-10
environmental O 0 3.200422982185813e-10
factors O 0 2.6236837702420246e-10
in O 0 8.300549136919244e-11
susceptibility O 0 1.516823715519422e-07
to O 0 1.4880077969792183e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 8.069274031186069e-07
AS B-Disease 1 0.999997615814209
) O 0 1.2843997865275014e-08
. O 0 5.0544908702931934e-08

METHODS O 0 3.9835120446696237e-07
Twins O 0 5.894236920767071e-08
with O 0 2.008856692103933e-10
AS B-Disease 1 0.9966679215431213
were O 0 5.42083843091401e-11
identified O 0 2.423855283151255e-10
from O 0 1.7333544322095662e-11
the O 0 1.0483294787810848e-10
Royal O 0 1.4907405443409516e-07
National O 0 2.1050396981081576e-09
Hospital O 0 1.93143989690725e-08
for O 0 4.402678666082238e-09
Rheumatic B-Disease 0 9.018452692544088e-05
Diseases I-Disease 0 1.5575446923321579e-06
database O 0 6.581292382179527e-07
. O 0 2.0032213399190368e-07

Clinical O 0 2.117349322361406e-05
and O 0 9.00245655799381e-09
radiographic O 0 1.1727275705197826e-05
examinations O 0 2.2777079777824838e-07
were O 0 2.812568788979064e-10
performed O 0 4.572971445959695e-10
to O 0 2.1282715173542854e-11
establish O 0 2.538828702824958e-09
diagnoses O 0 3.3579788123461185e-06
, O 0 3.6011404969116256e-10
and O 0 5.937721869742063e-09
disease O 0 4.887631277483706e-08
severity O 0 6.253974760284109e-08
was O 0 7.561012926871058e-10
assessed O 0 3.84618170645723e-10
using O 0 1.2578010855079924e-10
a O 0 4.113861334920088e-11
combination O 0 2.2212798267418066e-09
of O 0 2.879485191953357e-11
validated O 0 2.46375204682181e-08
scoring O 0 8.438028942236997e-09
systems O 0 5.114705814435183e-08
. O 0 3.950582083689369e-08

HLA O 0 8.169878128683195e-05
typing O 0 6.860981102363439e-06
for O 0 1.3714127611308413e-08
HLA O 0 2.2240017187868943e-06
- O 0 7.263584507199994e-07
B27 O 0 6.414708764168608e-07
, O 0 7.865478823809724e-10
HLA O 0 7.349921560262374e-08
- O 0 3.5469572168267405e-08
B60 O 0 1.1402327260157108e-07
, O 0 2.614412020207624e-10
and O 0 6.223281334705177e-10
HLA O 0 2.0835193481616443e-07
- O 0 5.870518293704663e-07
DR1 O 0 0.00012756722571793944
was O 0 3.2458180587724428e-09
performed O 0 4.0953870850124474e-10
by O 0 4.010202586668399e-11
polymerase O 0 4.901669736767644e-09
chain O 0 3.9337844981446324e-08
reaction O 0 1.0176357534419367e-09
with O 0 1.218688084475561e-11
sequence O 0 1.352980727453712e-09
- O 0 6.531394980413552e-09
specific O 0 4.781229856476443e-10
primers O 0 6.10940418255268e-08
, O 0 6.611403785550252e-11
and O 0 1.0268575573180172e-10
zygosity O 0 3.803254244871823e-08
was O 0 3.056563058212447e-10
assessed O 0 3.8171914518159156e-09
using O 0 5.40685229921678e-09
microsatellite O 0 4.5380479605228174e-06
markers O 0 1.6165546412594267e-06
. O 0 2.6814370812644484e-07

Genetic O 0 1.2963092558493372e-05
and O 0 6.8446985856951414e-09
environmental O 0 2.7324709162002137e-09
variance O 0 9.849934201611177e-10
components O 0 5.793706403522947e-09
were O 0 2.4739302273424357e-10
assessed O 0 1.6478617359538816e-09
with O 0 2.368225060500606e-11
the O 0 3.033550494135895e-11
program O 0 1.4529242253757957e-09
Mx O 0 2.5512603141208956e-09
, O 0 9.83379393540429e-13
using O 0 6.5682758711160805e-12
data O 0 6.294210985746673e-11
from O 0 3.758636197420673e-12
this O 0 6.737941801726599e-12
and O 0 8.423885894393024e-11
previous O 0 2.146639976885467e-09
studies O 0 1.1791728704579896e-09
of O 0 3.3032214116768266e-12
twins O 0 4.9610004992928225e-09
with O 0 3.6371181066918723e-10
AS B-Disease 1 0.9999991655349731
. O 0 1.237880837834382e-07

RESULTS O 0 2.106970441673184e-06
Six O 0 1.2412388450400158e-08
of O 0 5.696672022992288e-10
8 O 0 1.2139665273025457e-08
monozygotic O 0 2.1552518774115015e-06
( O 0 7.83596920683749e-09
MZ O 0 0.002498641610145569
) O 0 2.8610334101841772e-09
twin O 0 2.438211765820597e-07
pairs O 0 4.029053712883979e-08
were O 0 1.4321657637594853e-08
disease O 0 1.2967940499208908e-08
concordant O 0 2.6989026125079363e-08
, O 0 7.029109239109488e-11
compared O 0 1.863833670734394e-10
with O 0 1.5167311850916576e-11
4 O 0 2.5607169162888965e-10
of O 0 5.257214455434145e-11
15 O 0 2.467602344680131e-09
B27 O 0 5.157742180017522e-07
- O 0 2.4799854259072163e-07
positive O 0 1.4331303255232797e-08
dizygotic O 0 1.479417619520973e-07
( O 0 2.7119087531168873e-10
DZ O 0 2.367759464050323e-07
) O 0 2.0959042834611807e-10
twin O 0 9.456220695369666e-09
pairs O 0 2.5142998794080995e-09
( O 0 1.564743751236719e-10
27 O 0 7.446943062205946e-10
% O 0 4.211579349155947e-11
) O 0 2.151322696375413e-11
and O 0 6.221046594534485e-11
4 O 0 1.6457532558966648e-10
of O 0 1.1110328629326816e-10
32 O 0 1.771239865888674e-08
DZ O 0 2.5472936613368802e-05
twin O 0 4.77415028399264e-07
pairs O 0 1.7504206084595353e-08
overall O 0 7.538293544939734e-09
( O 0 8.95656465660366e-11
12 O 0 2.1072964206947375e-10
. O 0 8.89108578427944e-11
5 O 0 5.489617649345746e-10
% O 0 1.811433919529648e-10
) O 0 5.641859757155032e-10
. O 0 1.818039940815197e-08

Nonsignificant O 0 2.0845316612394527e-05
increases O 0 6.582460088111475e-08
in O 0 8.215808589007167e-11
similarity O 0 7.052425310405397e-10
with O 0 5.966821654823651e-12
regard O 0 1.7299170429474486e-10
to O 0 8.968821518795522e-11
age O 0 1.6113139711393387e-09
at O 0 6.135404961860047e-10
disease O 0 2.6497051219820378e-09
onset O 0 3.0504085923865887e-09
and O 0 4.757348681661e-11
all O 0 3.851764827228488e-12
of O 0 2.9534079175330685e-12
the O 0 1.0042099374274471e-09
disease O 0 4.9882348918117714e-08
severity O 0 3.889259758693697e-08
scores O 0 7.015454883685379e-09
assessed O 0 2.156106626571841e-09
were O 0 1.1402431082663256e-10
noted O 0 8.059993783504638e-10
in O 0 1.1077810890824935e-09
disease O 0 3.2548808803767315e-07
- O 0 4.028753210150171e-06
concordant O 0 0.00011447376891737804
MZ O 0 0.014391620643436909
twins O 0 4.136678342092637e-07
compared O 0 1.3500685014378178e-08
with O 0 1.8460843964618334e-09
concordant O 0 1.4390721844392829e-05
DZ O 0 0.0007261310238391161
twins O 0 8.191243068722542e-06
. O 0 2.7280623271508375e-07

HLA O 0 0.0006372853531502187
- O 0 6.831569044152275e-05
B27 O 0 2.046802364930045e-06
and O 0 9.898355468607178e-10
B60 O 0 2.1808533645639727e-08
were O 0 3.4977007401515436e-11
associated O 0 6.696958265717257e-11
with O 0 2.350364694536644e-11
the O 0 2.8171645571895e-10
disease O 0 4.7488502019632506e-09
in O 0 2.431058479523962e-11
probands O 0 6.078463599124007e-08
, O 0 3.250064453674817e-11
and O 0 3.6726063162850764e-11
the O 0 4.752143470398984e-11
rate O 0 3.5824465616229872e-09
of O 0 4.821273935640136e-11
disease O 0 8.202648338340168e-09
concordance O 0 5.26868371153455e-09
was O 0 1.562501905638669e-09
significantly O 0 6.054474699368484e-09
increased O 0 8.856883004781935e-10
among O 0 7.510032040691783e-10
DZ O 0 7.819965617272828e-07
twin O 0 6.510899197564868e-08
pairs O 0 2.7069488872655256e-09
in O 0 1.379396874501282e-10
which O 0 1.7618542735853282e-10
the O 0 8.950980234789796e-11
co O 0 9.952746768249199e-05
- O 0 2.204831872631985e-07
twin O 0 8.258401066996157e-06
was O 0 1.5404912900862655e-09
positive O 0 1.4871091857937557e-10
for O 0 1.2899241570718534e-11
both O 0 5.167041239317882e-10
B27 O 0 5.076161642136867e-07
and O 0 2.1616376244537605e-08
DR1 O 0 3.016488153662067e-05
. O 0 1.1227552221271253e-07

Additive O 0 1.4259084082368645e-06
genetic O 0 5.193001584302692e-07
effects O 0 6.748488345920123e-08
were O 0 2.0092551233918954e-10
estimated O 0 6.123371948385525e-11
to O 0 7.608270957693009e-11
contribute O 0 2.2199952987023153e-10
97 O 0 3.34084926389977e-10
% O 0 3.6664050268031545e-11
of O 0 5.154702185927729e-12
the O 0 2.1169326014369716e-10
population O 0 2.8849580502310346e-09
variance O 0 5.0727830824826015e-08
. O 0 7.478021757378883e-08

CONCLUSION O 0 2.45890333872012e-07
Susceptibility O 0 1.7727327872307796e-07
to O 0 4.032426836886316e-09
AS B-Disease 1 0.9999959468841553
is O 0 2.2423669865379026e-10
largely O 0 9.255292088283795e-10
genetically O 0 1.483237532795556e-09
determined O 0 2.318097935827268e-09
, O 0 2.2107107811031312e-11
and O 0 2.5778672599341412e-11
the O 0 1.3879257985960347e-11
environmental O 0 6.786159412186521e-10
trigger O 0 3.4000444681936415e-09
for O 0 4.566118663729135e-11
the O 0 6.292257270779089e-10
disease O 0 2.6502473104983437e-08
is O 0 5.567999949995794e-10
probably O 0 1.0688581575379885e-08
ubiquitous O 0 5.231495379121043e-07
. O 0 1.4964895456159866e-07

HLA O 0 0.00039028434548527
- O 0 5.870860150025692e-06
B27 O 0 3.317102823530149e-07
accounts O 0 2.6420292620343844e-09
for O 0 3.3383889402882616e-11
a O 0 5.096274097171616e-11
minority O 0 1.5184383528321632e-08
of O 0 9.562893012182716e-12
the O 0 1.022218421020682e-10
overall O 0 6.8138406028595e-09
genetic O 0 5.8936748814630846e-08
susceptibility O 0 6.566045840372681e-08
to O 0 1.1237510477712931e-08
AS B-Disease 1 0.9999678134918213
. O 0 1.143686105820052e-07

Cell O 0 0.00017495806969236583
cycle O 0 6.526094512082636e-05
- O 0 8.897832231014036e-06
dependent O 0 6.458801635744749e-07
colocalization O 0 7.14180657723773e-07
of O 0 7.448704431034514e-10
BARD1 O 0 1.7094846498366678e-06
and O 0 3.443516805035074e-09
BRCA1 O 0 9.893286545548108e-08
proteins O 0 7.036852767150492e-10
in O 0 1.0009604950456108e-10
discrete O 0 6.449679545994513e-08
nuclear O 0 1.6442337482658331e-06
domains O 0 4.847459535994858e-07
. O 0 1.029286522680195e-07

Germ O 0 0.006326673086732626
- O 0 0.0006058703875169158
line O 0 4.797733481609612e-07
mutations O 0 2.463705754962575e-07
of O 0 8.948129737174071e-11
the O 0 3.798320824532908e-10
BRCA1 O 0 3.5833579659083625e-07
gene O 0 8.355951308658405e-08
predispose O 0 2.680667421373073e-07
women O 0 1.2340430899371313e-09
to O 0 3.926282562960459e-11
early O 0 1.5004388842498884e-08
- O 0 0.00018526724306866527
onset O 0 0.06478478759527206
breast B-Disease 1 0.9999994039535522
and I-Disease 1 0.9999934434890747
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 2.3948765193182453e-10
compromising O 0 1.1069583649714332e-07
the O 0 1.7977279387348943e-10
genes O 0 1.779841696247786e-08
presumptive O 0 7.908145676083222e-07
function O 0 8.370448334460434e-09
as O 0 8.44828318413704e-10
a O 0 3.415669969086821e-09
tumor B-Disease 0 5.0245339480170514e-06
suppressor O 0 3.1696457881480455e-05
. O 0 1.1583217656152556e-06

Although O 0 7.100928911540905e-08
the O 0 3.535336190463312e-10
biochemical O 0 2.3618365929678475e-08
properties O 0 9.934864486638162e-09
of O 0 1.1451535553153036e-10
BRCA1 O 0 1.3150545896678523e-07
polypeptides O 0 4.2834198410446334e-08
are O 0 4.0995057348780506e-10
not O 0 3.15556830665642e-10
understood O 0 2.391394859913021e-09
, O 0 4.397815098200475e-11
their O 0 1.2153925088576045e-10
expression O 0 2.7436468652553003e-09
pattern O 0 8.95821656854423e-08
and O 0 1.7604040447594116e-09
subcellular O 0 4.020119206415984e-07
localization O 0 2.1857506027345153e-08
suggest O 0 4.014117038764198e-09
a O 0 7.235340104827515e-11
role O 0 3.762192335443615e-09
in O 0 3.5815497789748463e-10
cell O 0 7.573872267130355e-07
- O 0 2.782845331239514e-05
cycle O 0 1.630288807064062e-06
regulation O 0 2.3142300165091e-07
. O 0 1.0387156379465523e-07

When O 0 2.055099457720644e-06
resting O 0 4.4139821397948253e-07
cells O 0 1.0469202749163742e-07
are O 0 7.441206539837708e-10
induced O 0 8.554022379314574e-09
to O 0 1.2444661967592197e-10
proliferate O 0 3.7724120716120524e-08
, O 0 3.2030964686180496e-11
the O 0 1.3491964490075503e-11
steady O 0 4.293822186696161e-09
- O 0 2.1671860750416272e-08
state O 0 1.6067811525743991e-09
levels O 0 1.5437622291614161e-09
of O 0 1.0805301965677305e-11
BRCA1 O 0 1.6013574466455793e-08
increase O 0 2.7760288512368447e-10
in O 0 2.6433522037905277e-11
late O 0 6.198912494426168e-10
G1 O 0 1.9202987644462155e-08
and O 0 8.295563541649287e-11
reach O 0 5.013236353823558e-11
a O 0 3.659041472592328e-11
maximum O 0 3.920103408550091e-10
during O 0 4.5409449533906354e-09
S O 0 5.424750497695641e-07
phase O 0 1.0097673452946765e-07
. O 0 6.194497359501838e-08

Moreover O 0 1.344882889497967e-06
, O 0 4.276535570113538e-09
in O 0 2.280201361060108e-09
S O 0 1.4521888260787819e-06
phase O 0 8.344292723450053e-08
cells O 0 7.320847572600542e-08
, O 0 8.803073270335915e-10
BRCA1 O 0 2.608871056963835e-07
polypeptides O 0 8.295432962768245e-08
are O 0 3.8405295610388634e-10
hyperphosphorylated O 0 4.413813314840809e-08
and O 0 4.775351780672565e-10
accumulate O 0 1.1558876522599348e-08
into O 0 6.644477745787469e-10
discrete O 0 2.397964919964579e-07
subnuclear O 0 2.477879934303928e-05
foci O 0 1.069331574399257e-05
termed O 0 1.3699614100914914e-06
" O 0 9.798506539482332e-08
BRCA1 O 0 1.0689849659684114e-05
nuclear O 0 1.4883613630445325e-06
dots O 0 6.314676738838898e-06
. O 0 4.48008080411455e-07

" O 0 6.202489544193668e-07
BRCA1 O 0 7.1229842433240265e-06
associates O 0 7.135311648198694e-07
in O 0 8.340053647692969e-10
vivo O 0 1.6851256532390835e-06
with O 0 5.45389344797087e-10
a O 0 3.4956435523980645e-09
structurally O 0 4.043207866288867e-07
related O 0 9.214804919110975e-08
protein O 0 2.6332651259508566e-07
termed O 0 6.906204816914396e-07
BARD1 O 0 3.701281821122393e-05
. O 0 1.3908805840401328e-07

Here O 0 9.062862460496035e-08
we O 0 1.7793486684070103e-09
show O 0 3.65335983687487e-10
that O 0 4.749205369247722e-12
the O 0 6.033277610145715e-12
steady O 0 3.3478484429139144e-09
- O 0 1.2584093767031845e-08
state O 0 8.41785086080904e-10
levels O 0 5.664708147001818e-10
of O 0 3.3378076778195487e-12
BARD1 O 0 9.57296286685505e-09
, O 0 6.036281717525238e-12
unlike O 0 4.4059925846662296e-11
those O 0 2.8179533359540265e-11
of O 0 7.843703117571543e-12
BRCA1 O 0 5.727259377863447e-08
, O 0 2.084315359196509e-10
remain O 0 6.212737546640312e-10
relatively O 0 2.1027274366147708e-10
constant O 0 4.516869989146244e-09
during O 0 1.1664140764366948e-08
cell O 0 1.0787916835397482e-06
cycle O 0 1.8774528598441975e-06
progression O 0 4.0476635376762715e-07
. O 0 7.738567120441076e-08

However O 0 2.0146282508903823e-07
, O 0 5.076187914454522e-09
immunostaining O 0 6.207839078342658e-07
revealed O 0 7.3646276632644e-08
that O 0 2.1405111017003264e-09
BARD1 O 0 9.412746067027911e-07
resides O 0 4.388504137864402e-08
within O 0 1.0333063293899158e-09
BRCA1 O 0 2.786360937534482e-07
nuclear O 0 2.5526734503955595e-08
dots O 0 5.2209987444484796e-08
during O 0 4.465294800581887e-09
S O 0 7.417803260523215e-08
phase O 0 1.9761974279219885e-09
of O 0 4.963368691740522e-12
the O 0 2.918194158540999e-11
cell O 0 1.631331869589303e-08
cycle O 0 7.843251381700611e-09
, O 0 2.0160218980325162e-11
but O 0 7.943905255825001e-11
not O 0 4.518235785511138e-11
during O 0 1.517136971607158e-10
the O 0 3.180693763926712e-10
G1 O 0 1.0113321877724957e-06
phase O 0 1.558184976602206e-07
. O 0 3.796021630364521e-08

Nevertheless O 0 3.1471979582420317e-06
, O 0 6.378306327547989e-09
BARD1 O 0 2.724302987644478e-07
polypeptides O 0 6.73943247875286e-08
are O 0 9.038440829112204e-11
found O 0 4.5455243735670336e-11
exclusively O 0 2.1071436262509735e-10
in O 0 6.024483689692772e-11
the O 0 1.7255826975648425e-11
nuclear O 0 1.992023435093415e-09
fractions O 0 1.622142836721352e-10
of O 0 5.352033052852256e-12
both O 0 2.051958047921687e-10
G1 O 0 2.2808816879660299e-07
- O 0 5.0127084705309244e-08
and O 0 2.4422894817632823e-09
S O 0 8.167882015186478e-07
- O 0 1.2242330171829963e-07
phase O 0 1.4256117708555394e-07
cells O 0 2.2142742750475009e-07
. O 0 4.032144218513167e-08

Therefore O 0 1.1482839568088821e-07
, O 0 1.2881061772773705e-09
progression O 0 1.0475091016814986e-08
to O 0 1.3349144012408942e-09
S O 0 1.0122256526301499e-06
phase O 0 4.83723194832919e-09
is O 0 4.427525013284139e-11
accompanied O 0 3.885294516670079e-11
by O 0 6.384089871330767e-12
the O 0 2.8898621343143027e-11
aggregation O 0 2.5961763849835506e-09
of O 0 1.9111984217445865e-10
nuclear O 0 2.1608322242627764e-07
BARD1 O 0 5.784301038147532e-07
polypeptides O 0 1.806857170549847e-07
into O 0 9.974356451891708e-09
BRCA1 O 0 3.781911573241814e-06
nuclear O 0 5.345474392015603e-07
dots O 0 1.8362317177889054e-06
. O 0 2.0220910812440707e-07

This O 0 3.314727692327324e-08
cell O 0 1.6561137954340666e-06
cycle O 0 1.7224637076651561e-06
- O 0 7.847622214285366e-07
dependent O 0 9.7141530375211e-08
colocalization O 0 4.0985605664900504e-07
of O 0 1.253643161502893e-10
BARD1 O 0 3.881715997522406e-07
and O 0 5.933326052698362e-10
BRCA1 O 0 7.269101587326077e-08
indicates O 0 9.536127443254827e-10
a O 0 5.1570844816772876e-11
role O 0 9.466050165940487e-10
for O 0 2.0776036446790158e-10
BARD1 O 0 3.396157808310818e-07
in O 0 4.147934440368317e-09
BRCA1 O 0 1.2911435078422073e-05
- O 0 4.751538654090837e-06
mediated O 0 7.404511961794924e-06
tumor B-Disease 0 3.6382571124704555e-06
suppression O 0 6.500444555967988e-07
. O 0 1.9272563633876416e-07

Ethnic O 0 1.20700424304232e-05
differences O 0 3.233972392990836e-06
in O 0 1.656187365028927e-08
the O 0 1.747605082869086e-08
HFE O 0 0.00016984695685096085
codon O 0 1.3116045920469332e-05
282 O 0 5.556112796512025e-07
( O 0 2.173370461377999e-08
Cys O 0 0.008946756832301617
/ O 0 3.7487247936951462e-06
Tyr O 0 4.811048256669892e-06
) O 0 9.353328778161085e-09
polymorphism O 0 1.5614590438417508e-06
. O 0 1.6501985555805732e-07

Recent O 0 1.2377380187444942e-07
studies O 0 3.4136334647882904e-08
have O 0 1.2431999873996347e-09
shown O 0 1.5552773291460653e-08
that O 0 7.175484029176005e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 1.5399200492538512e-07
HH B-Disease 0 0.0040911538526415825
) O 0 2.1581925135905067e-09
is O 0 1.3380950514285672e-10
likely O 0 5.744177355992974e-10
to O 0 5.269290906384505e-11
be O 0 2.1752677437092416e-10
caused O 0 4.669339914720183e-11
by O 0 5.136006637346258e-12
homozygosity O 0 9.924675303807362e-09
for O 0 2.7219190443239505e-11
a O 0 2.793328068850798e-10
Cys282Tyr O 0 1.7724606493629835e-07
mutation O 0 4.1655212612567993e-08
in O 0 7.589650019568239e-10
the O 0 4.521065466445151e-10
HFE O 0 4.681136033468647e-06
gene O 0 5.796671587177116e-08
located O 0 1.4699786277105886e-08
4 O 0 5.031933980603753e-08
. O 0 1.0385372917198765e-07

5 O 0 2.297877244927804e-06
Mb O 0 6.82723702993826e-06
telomeric O 0 5.958753899903968e-05
to O 0 4.820968868557429e-08
HLA O 0 6.042247605364537e-06
- O 0 5.2725949899468105e-06
A O 0 6.714311240330062e-08
. O 0 1.1677836653234408e-07

Population O 0 1.268686276034714e-07
studies O 0 5.007672143619857e-08
of O 0 2.025936189642419e-11
this O 0 1.8167337426100438e-11
polymorphism O 0 2.0676317546985956e-08
are O 0 3.055250150096889e-11
facilitated O 0 1.4758796962333065e-10
by O 0 6.2785119984976046e-12
the O 0 5.423369652673982e-12
fact O 0 1.1425616008864381e-10
that O 0 2.2245675787568864e-11
the O 0 6.411512987192225e-11
Cys282Tyr O 0 3.0604869039052573e-07
mutation O 0 3.217631672214338e-08
creates O 0 1.9098074233170337e-09
a O 0 3.793687031183879e-10
Rsal O 0 8.187146249838406e-08
restriction O 0 5.810327774469215e-09
site O 0 2.565715995217488e-08
. O 0 3.221776978534763e-08

We O 0 7.644297994602312e-08
have O 0 5.963027849276159e-10
studied O 0 7.345265284897096e-09
the O 0 1.0215212009612173e-09
codon O 0 6.327718438114971e-07
282 O 0 5.0335177803617626e-08
( O 0 3.26504800973737e-09
Cys O 0 0.0009283263934776187
/ O 0 5.20812875492993e-07
Tyr O 0 4.56927949699093e-07
) O 0 3.342308929621396e-10
polymorphism O 0 8.080994540193842e-09
in O 0 5.340889883131972e-11
different O 0 3.392159331205846e-10
ethnic O 0 1.995732468174083e-08
groups O 0 2.8971349763651233e-08
. O 0 4.6051514601685994e-08

In O 0 4.283981169805884e-09
agreement O 0 1.044980213471547e-09
with O 0 4.507037798529012e-11
previous O 0 2.0385861887461942e-09
observations O 0 4.1374961234907914e-09
the O 0 2.5467278286228634e-10
Tyr O 0 1.719356959029028e-07
allele O 0 3.822577454570819e-08
appeared O 0 2.3957731354329326e-09
to O 0 5.7272832310051314e-11
be O 0 2.5101381043168836e-11
rare O 0 7.643674582169524e-11
or O 0 3.896487854593289e-10
absent O 0 4.255834795685587e-09
in O 0 4.0397457601315523e-10
Asiatic O 0 8.400468765046298e-09
( O 0 7.649668398723719e-11
Indian O 0 8.885681634929199e-10
, O 0 4.2728952320825186e-11
Chinese O 0 8.99815638666368e-11
) O 0 4.5873504994631276e-10
populations O 0 1.3070446946983338e-08
. O 0 2.8648409866605107e-08

The O 0 3.931339165319514e-08
highest O 0 6.471071145597307e-08
allele O 0 1.4085125599194726e-07
frequency O 0 4.142994569633629e-08
( O 0 4.0006548074345005e-10
7 O 0 2.253884440195364e-10
. O 0 6.348588321714033e-11
5 O 0 8.651329652664685e-11
% O 0 3.083491448285791e-11
) O 0 3.091901387697327e-11
was O 0 4.789728058618437e-10
found O 0 1.9691237529428918e-09
in O 0 3.18602633164744e-09
Swedes O 0 1.916039218485821e-05
. O 0 1.1460848980959781e-07

Saamis O 0 4.454174268175848e-05
( O 0 2.8175922039963552e-08
2 O 0 6.511306160916774e-09
% O 0 5.637997846363874e-10
) O 0 1.6516966960811175e-10
and O 0 2.780596863871665e-10
Mordvinians O 0 2.93063155965001e-08
( O 0 2.518429909059705e-11
1 O 0 4.575437945186778e-11
. O 0 4.301482434132531e-11
8 O 0 1.5425723198791985e-10
% O 0 2.1558657636866485e-11
) O 0 5.998158220110739e-11
had O 0 8.433085341152946e-10
significantly O 0 5.53420365090318e-10
lower O 0 3.207401844118607e-10
frequencies O 0 2.22208473843466e-09
of O 0 5.7442842149590945e-11
the O 0 2.639148233285482e-09
Tyr O 0 2.954129058707622e-06
allele O 0 1.0172062729907339e-06
. O 0 8.575311483127734e-08

Comparisons O 0 6.806075703025272e-08
with O 0 1.456222920026562e-09
allele O 0 7.541604674088376e-08
frequencies O 0 1.4591820196585559e-08
based O 0 8.436467524575164e-09
on O 0 2.4019042310641225e-09
prevalence O 0 2.1868018507120723e-07
estimates O 0 1.0522328786066737e-08
of O 0 1.8621813813179955e-10
HH B-Disease 0 0.002843981608748436
showed O 0 1.3343143479005448e-08
some O 0 2.963741752015636e-11
disagreements O 0 8.460123268605457e-09
with O 0 1.2010602581935537e-11
the O 0 1.9246557472762937e-11
RFLP O 0 1.540424499069104e-08
data O 0 4.0006245538570795e-10
, O 0 1.2762293825907545e-11
particularly O 0 1.475964211961056e-10
in O 0 6.274388231197747e-10
Finns O 0 9.551752100378508e-07
. O 0 5.123072810420126e-08

The O 0 4.997681557483702e-08
newly O 0 1.1903528474022096e-07
described O 0 1.3045291957780591e-08
HFE O 0 1.882006131381786e-06
marker O 0 3.9608430313364806e-08
provides O 0 3.4910976887125855e-10
a O 0 5.582619089228302e-11
new O 0 1.693841594763157e-10
approach O 0 5.977945916058047e-10
to O 0 2.6296138877501818e-11
the O 0 7.40994071657397e-12
screening O 0 1.3541838761454983e-09
of O 0 6.82457432579775e-12
HH B-Disease 0 1.224559866841446e-07
as O 0 9.958987107205886e-11
well O 0 7.26019522279131e-11
as O 0 4.123830790736527e-11
studies O 0 2.843996982360153e-10
of O 0 1.3777179267218664e-12
the O 0 1.0628289047465156e-11
relationship O 0 1.5519872054170492e-09
between O 0 1.303348956538386e-10
the O 0 8.08391908968531e-10
HFE O 0 1.2924703696626239e-05
Tyr O 0 3.636858991740155e-07
allele O 0 7.73091102246326e-08
and O 0 6.718954836948399e-10
different O 0 6.8932397567778025e-09
disorders O 0 2.5434403596591437e-06
including O 0 9.616099561071678e-08
cancer B-Disease 0 6.469292566180229e-05

Autosomal B-Disease 1 0.9995957016944885
dominant I-Disease 1 0.9984613656997681
neurohypophyseal I-Disease 1 0.9998944997787476
diabetes I-Disease 1 0.9999946355819702
insipidus I-Disease 1 0.9437187314033508
associated O 0 7.358112270594575e-07
with O 0 5.2359947488866965e-09
a O 0 1.6680218095643795e-08
missense O 0 1.773449002939742e-05
mutation O 0 6.487519499387417e-07
encoding O 0 3.6974196859773656e-07
Gly23 O 0 1.6213969502132386e-05
- O 0 1.8986465875059366e-05
- O 0 1.1265599823673256e-05
> O 0 9.484399470238714e-07
Val O 0 3.0101200536591932e-05
in O 0 1.5990194057735607e-08
neurophysin O 0 8.522165444446728e-06
II O 0 1.030877569974109e-06
. O 0 1.2859311482316116e-07

Autosomal B-Disease 1 0.9997642636299133
dominant I-Disease 1 0.9992808699607849
neurohypophyseal I-Disease 1 0.9999499320983887
diabetes I-Disease 1 0.9999959468841553
insipidus I-Disease 1 0.9985975623130798
( O 0 6.844206268397102e-08
ADNDI B-Disease 0 7.394061412924202e-06
) O 0 2.431357781773613e-09
is O 0 8.619380764685047e-10
an O 0 1.0940844674678374e-08
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 6.482757441972353e-08
by O 0 6.263268792494614e-10
progressive O 0 1.5151118759604287e-07
degeneration O 0 6.252925004446297e-07
of O 0 1.3148170052712516e-10
the O 0 3.6315311868762024e-10
magnocellular O 0 6.119154818406969e-07
neurons O 0 2.5457396191086445e-08
of O 0 2.2524006965118915e-11
the O 0 4.124255104098751e-11
hypothalamus O 0 7.782660738087088e-09
leading O 0 1.9416706020791707e-09
to O 0 1.287216444545436e-10
decreased O 0 1.3375575091956193e-09
ability O 0 1.2377061597845795e-09
to O 0 1.7113616079811322e-10
produce O 0 2.2018087353359306e-09
the O 0 2.314060498775916e-09
hormone O 0 3.103279766492051e-07
arginine O 0 7.283215808229215e-08
vasopressin O 0 2.4040144808168407e-07
( O 0 8.055721090194368e-10
AVP O 0 4.4895506334796664e-07
) O 0 4.1389562888127784e-09
. O 0 1.6308060679648406e-08

Affected O 0 1.1263114885196046e-07
individuals O 0 5.961526827746866e-10
are O 0 4.6696604916185436e-11
not O 0 1.0386111415350285e-10
symptomatic O 0 9.508013265602244e-10
at O 0 1.0572531738972657e-10
birth O 0 7.077085029116859e-10
, O 0 8.345665825082449e-11
but O 0 2.9309261684318244e-09
usually O 0 3.660764491542068e-08
develop O 0 6.243474217626499e-07
diabetes B-Disease 0 1.7952657799469307e-05
insipidus I-Disease 0 8.70876647240948e-06
at O 0 4.753036630944507e-09
1 O 0 1.1037701419525092e-08
- O 0 2.6672564672480803e-06
6 O 0 5.2325532351460424e-08
yr O 0 3.749683401110815e-06
of O 0 3.6622832544352946e-10
age O 0 3.2889698076132845e-08
. O 0 3.317422070381326e-08

The O 0 2.0971940628555785e-08
genetic O 0 3.6665963421000924e-07
locus O 0 2.463952455400431e-07
of O 0 2.322150388645028e-10
the O 0 1.3465677461965697e-09
disease O 0 5.6266273418259516e-08
is O 0 1.6050435980297095e-10
the O 0 2.252638076072344e-10
AVP O 0 1.0521051081013866e-05
- O 0 1.1181663239767659e-06
neurophysin O 0 7.293262569874059e-06
II O 0 4.3937806282201564e-08
( O 0 1.856808179434566e-10
NPII O 0 2.4113798957614563e-08
) O 0 3.5289882127642613e-11
gene O 0 3.0102145776034206e-10
, O 0 2.4015582925085432e-11
and O 0 8.26022861222242e-11
mutations O 0 1.3045913682674382e-08
that O 0 2.9032776183157694e-10
cause O 0 6.235412186583744e-10
ADNDI B-Disease 0 5.711135599995032e-07
have O 0 1.0278142781317001e-09
been O 0 3.566736350713029e-10
found O 0 1.2817162609035648e-10
in O 0 3.318543356778392e-11
both O 0 7.136942425933768e-11
the O 0 5.31712555928987e-11
signal O 0 1.2368660540218457e-09
peptide O 0 1.1103321595484772e-09
of O 0 6.293715115041065e-12
the O 0 1.2958506490079458e-10
prepro O 0 1.3930219893154572e-06
- O 0 4.1233420233766083e-07
AVP O 0 5.442334895633394e-06
- O 0 1.0479411116648407e-07
NPII O 0 4.493444407671632e-07
precursor O 0 2.5367144829147037e-08
and O 0 7.936609147662921e-10
within O 0 1.837463736720224e-09
NPII O 0 2.488477093720576e-06
itself O 0 1.685683486130074e-07
. O 0 1.1371020747219518e-07

An O 0 9.571027526078524e-09
affected O 0 1.9646078541768475e-08
girl O 0 3.2053446830104804e-07
who O 0 1.6097044808205396e-09
presented O 0 2.814946331586299e-10
at O 0 1.282430411864155e-10
9 O 0 1.197801025032419e-10
months O 0 4.793200836239464e-10
of O 0 5.178846500947243e-12
age O 0 1.2992492637309283e-09
and O 0 2.183365016561467e-10
her O 0 1.833801444028893e-09
similarly O 0 4.249978147186084e-09
affected O 0 3.658387481841885e-10
younger O 0 4.262226127593749e-10
brother O 0 2.830576051326972e-10
and O 0 6.986976969214354e-11
father O 0 4.118652641160736e-10
were O 0 5.934115698824627e-11
all O 0 3.513586123438106e-12
found O 0 6.286279830014507e-11
to O 0 3.74836481298324e-11
have O 0 1.1920869846804294e-10
a O 0 1.6904722066612976e-10
novel O 0 4.595070279833635e-08
missense O 0 2.8857248253189027e-06
mutation O 0 1.4921971569492598e-07
( O 0 6.6211747196121e-10
G1758 O 0 2.769860429907567e-07
- O 0 7.54043185224873e-07
- O 0 6.089581461310445e-07
> O 0 3.6997580110664785e-08
T O 0 1.4140724147182482e-07
) O 0 5.375371328608658e-11
encoding O 0 5.001748459854127e-10
the O 0 9.594285088621035e-11
amino O 0 3.540176374272619e-09
acid O 0 2.507838825493991e-09
substitution O 0 1.2983647490472094e-09
Gly23 O 0 1.9472906842565862e-07
- O 0 2.522453144138126e-07
- O 0 5.101387614558917e-07
> O 0 1.0989935361749303e-07
Val O 0 3.0744281502848025e-06
within O 0 1.9869927925242337e-08
NPII O 0 1.2492482710513286e-05
. O 0 8.106809445962426e-08

The O 0 4.7731347763146914e-08
mutation O 0 9.333645039077965e-07
was O 0 1.5493439420311006e-08
confirmed O 0 2.5222828270443642e-09
by O 0 2.108172802994801e-10
restriction O 0 2.6995410351560167e-08
endonuclease O 0 2.121040779456962e-06
analysis O 0 4.2995449689442466e-07
. O 0 1.3641086127336166e-07

A O 0 4.0791530864225933e-07
T1 O 0 2.899023274949286e-05
- O 0 4.431659021975065e-07
weighted O 0 2.4886087857112216e-08
magnetic O 0 5.906534816801923e-09
resonance O 0 3.633384793033656e-08
imaging O 0 1.1743700270017143e-06
of O 0 3.0936841977080576e-10
the O 0 1.578055019990643e-09
fathers O 0 8.643398246022116e-07
pituitary O 0 2.7834682896354934e-06
gland O 0 7.989591495061177e-07
demonstrates O 0 4.005171305720978e-08
an O 0 8.452764599375939e-10
attenuated O 0 2.0214886262692744e-06
posterior O 0 2.2033107597962953e-05
pituitary O 0 0.00027815080829896033
bright O 0 2.661298367456766e-06
spot O 0 3.919580194633454e-06
. O 0 2.7576993488764856e-07

This O 0 1.0823201002096994e-08
mutation O 0 7.757054731882818e-08
may O 0 9.204977335919295e-10
be O 0 2.3422364308495203e-12
valuable O 0 3.3053157433293734e-11
for O 0 3.2425457718171513e-12
developing O 0 2.2207913286109715e-10
models O 0 8.287047492672173e-09
of O 0 1.3801416953729273e-10
dominantly B-Disease 0 3.715834463946521e-05
inherited I-Disease 0 0.11352495104074478
neurodegeneration I-Disease 1 1.0
, O 0 1.2460837917060985e-10
as O 0 6.7822193174083e-12
the O 0 2.0321775946047227e-12
early O 0 1.0149102669387844e-09
age O 0 3.509122437073131e-10
of O 0 1.2347152814062845e-11
onset O 0 3.081449762021293e-08
of O 0 1.8569709658855515e-10
symptoms O 0 1.883354272536053e-08
suggests O 0 3.696699613087162e-10
that O 0 9.685809446158267e-12
this O 0 1.623714704357404e-11
mutation O 0 3.435021822539852e-09
may O 0 1.2691424577937482e-09
be O 0 4.079418747249264e-11
particularly O 0 2.2134798161044245e-10
deleterious O 0 1.918614778162464e-08
to O 0 2.683454569663013e-10
the O 0 5.380410561528493e-10
magnocellular O 0 9.444847250961175e-07
neuron O 0 5.0253639471975475e-08
. O 0 5.630714561277728e-09
. O 0 4.852463675319996e-08

Frequent O 0 4.525738040683791e-05
inactivation O 0 0.0001161090622190386
of O 0 2.62324082456189e-08
PTEN O 0 9.634447633288801e-05
/ O 0 4.789276772498852e-06
MMAC1 O 0 1.1365699720045086e-05
in O 0 6.716398814887725e-08
primary O 1 0.9996095299720764
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.3441725741358823e-06

Sporadic B-Disease 1 0.7477466464042664
prostate I-Disease 1 0.9999685287475586
carcinoma I-Disease 1 1.0
is O 0 6.949321829097244e-08
the O 0 3.0792729477369107e-10
most O 0 4.278426224413323e-10
common O 0 3.613954691061849e-09
male B-Disease 0 3.104564072486937e-08
cancer I-Disease 0 1.5293379007630392e-08
in O 0 1.342250702945913e-11
the O 0 9.436620755642888e-12
Western O 0 1.066019494899706e-09
world O 0 5.63612712056738e-10
, O 0 7.456656819782026e-12
yet O 0 2.639432596096558e-11
many O 0 5.819668965484359e-12
of O 0 2.768368488007683e-13
the O 0 4.754298951054059e-12
major O 0 1.0200525840664554e-10
genetic O 0 5.913001754898062e-10
events O 0 5.248978335314902e-11
involved O 0 8.431022546773193e-11
in O 0 6.901912201484617e-12
the O 0 6.7748623551466824e-12
progression O 0 1.773810959226907e-10
of O 0 1.6163752194348069e-12
this O 0 4.074247536567377e-11
often O 0 2.6668243435779004e-07
fatal O 0 0.0002543797018006444
cancer B-Disease 0 3.0499149943352677e-06
remain O 0 1.2086589507021017e-09
to O 0 1.4386995761395127e-10
be O 0 1.1849852210588097e-09
elucidated O 0 1.4791636431255029e-06
. O 0 4.3510976155403114e-08

Numerous O 0 2.8579651711879706e-07
cytogenetic O 0 7.375594577752054e-05
and O 0 2.1635186087110014e-08
allelotype O 0 6.966652676965168e-07
studies O 0 2.208661520342048e-08
have O 0 3.1447894288660905e-10
reported O 0 1.479316003027975e-09
frequent O 0 2.5514173884744196e-08
loss O 0 1.2352352918298948e-08
of O 0 5.098568442440943e-11
heterozygosity O 0 7.301663117686985e-06
on O 0 1.4225717492877266e-08
chromosomal O 0 0.00149873411282897
arm O 0 2.7915344617213123e-05
10q O 0 2.34111257668701e-06
in O 0 2.8916529615230502e-08
sporadic B-Disease 1 0.8509440422058105
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.33399600044504e-07

Deletion O 0 5.744616373704048e-06
mapping O 0 1.0260714589094277e-06
studies O 0 2.9787369726363977e-07
have O 0 8.654816308073521e-10
unambiguously O 0 2.2983055458780655e-08
identified O 0 9.445801474328164e-09
a O 0 3.104483892180099e-10
region O 0 2.945227395301231e-09
of O 0 2.6778648742897815e-11
chromosome O 0 2.9256442601877097e-08
10q23 O 0 6.267349306199321e-08
to O 0 1.6117926437964059e-10
be O 0 4.067639627902686e-11
the O 0 8.388383737623073e-12
minimal O 0 1.0889311674588953e-09
area O 0 2.7244564382300496e-09
of O 0 5.548567161284268e-10
loss O 0 3.3052612025130657e-07
. O 0 1.0385154780578887e-07

A O 0 3.113453601599758e-07
new O 0 7.772960941565543e-08
tumor B-Disease 0 7.966795578795427e-07
suppressor O 0 6.571238486685615e-07
gene O 0 5.452764639812813e-07
, O 0 7.312945360382628e-09
PTEN O 0 1.0895656487264205e-05
/ O 0 7.70502992963884e-07
MMAC1 O 0 4.694709332397906e-06
, O 0 1.2318467357275154e-09
was O 0 1.2062868481876876e-09
isolated O 0 1.1826421619787197e-08
recently O 0 3.7186580925663293e-07
at O 0 7.254247202936881e-10
this O 0 5.182880860599148e-11
region O 0 1.9250909755186285e-09
of O 0 4.3636406987790366e-11
chromosome O 0 4.403991127333029e-08
10q23 O 0 7.128055301564018e-08
and O 0 7.319217454337945e-11
found O 0 5.653544646322395e-11
to O 0 1.0956259337280283e-11
be O 0 1.3100477300187485e-11
inactivated O 0 6.750142667044656e-10
by O 0 2.381960427511043e-11
mutation O 0 4.1238270576116065e-09
in O 0 8.180769950349998e-10
three O 0 1.181598122457217e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
cell O 0 2.171598680433817e-06
lines O 0 2.915019194915658e-06
. O 0 3.5230624462201376e-07

We O 0 7.265767294484249e-07
screened O 0 1.9909305137844058e-06
80 O 0 2.0017795065996324e-07
prostate B-Disease 0 0.007290744688361883
tumors I-Disease 1 1.0
by O 0 9.394052202793546e-10
microsatellite O 0 1.65876770097384e-06
analysis O 0 3.24129096895831e-08
and O 0 7.239415733550914e-10
found O 0 1.18602083709618e-09
chromosome O 0 9.084999419428641e-08
10q23 O 0 8.503240422896852e-08
to O 0 1.180468361949849e-10
be O 0 4.655511046114391e-11
deleted O 0 6.665755947210528e-09
in O 0 3.3936800591938265e-10
23 O 0 1.4855874308494776e-09
cases O 0 2.366633555794806e-09
. O 0 4.0323978822698336e-08

We O 0 2.7668320967677573e-07
then O 0 2.6130571040283712e-09
proceeded O 0 1.4429296646412126e-09
with O 0 1.7163130291986128e-11
sequence O 0 3.419481642286115e-10
analysis O 0 6.030856369854121e-10
of O 0 8.608758671202477e-12
the O 0 1.4580926743779088e-10
entire O 0 2.4924851516061608e-08
PTEN O 0 1.6473541109007783e-05
/ O 0 1.7900950410876248e-07
MMAC1 O 0 5.764949264630559e-07
coding O 0 4.999121756554814e-07
region O 0 5.707159189682898e-09
and O 0 3.2221975088120303e-10
tested O 0 2.4014188415577564e-09
for O 0 1.0479871311031008e-11
homozygous O 0 3.003219450903316e-09
deletion O 0 2.624365613712598e-09
with O 0 2.909873557388476e-11
new O 0 4.3500478219549166e-10
intragenic O 0 1.9406162010682237e-08
markers O 0 1.0332457556216923e-08
in O 0 5.995184904072914e-11
these O 0 4.652342400213172e-11
23 O 0 1.1884342121515346e-10
cases O 0 4.569586375957613e-11
with O 0 6.404570623841366e-11
10q23 O 0 2.615782079828932e-07
loss O 0 1.6971128502518695e-08
of O 0 1.054410225798108e-09
heterozygosity O 0 2.416500501567498e-05
. O 0 3.2109497283272503e-07

The O 0 1.0988688847746175e-09
identification O 0 2.1150690088234114e-09
of O 0 1.496977715398362e-11
the O 0 2.8310064362213616e-11
second O 0 7.054954953567005e-10
mutational O 0 1.944471961223826e-07
event O 0 3.9919902938834184e-09
in O 0 1.0103130138050531e-10
10 O 0 1.0393741423087022e-10
( O 0 5.741589148566817e-11
43 O 0 4.1352952173667745e-09
% O 0 3.39015593375791e-09
) O 0 9.075871787445067e-08
tumors B-Disease 1 1.0
establishes O 0 1.422744844603585e-06
PTEN O 0 1.2335080100456253e-05
/ O 0 1.4925416280675563e-07
MMAC1 O 0 2.220677686182171e-07
as O 0 1.8109122534859523e-10
a O 0 6.910557542871842e-11
main O 0 3.0975473297445433e-09
inactivation O 0 1.9556804886633472e-07
target O 0 7.258028844603359e-09
of O 0 1.961953689788576e-11
10q O 0 9.882686669016039e-08
loss O 0 1.405880389881986e-08
in O 0 3.597860676052278e-09
sporadic B-Disease 1 0.993778645992279
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.9855114885558578e-08
. O 0 6.355357129450567e-08

Risk O 0 1.69740233104676e-05
reversals O 0 6.078174124013458e-07
in O 0 1.294628404480136e-09
predictive O 0 1.5603559688770474e-07
testing O 0 7.888052522275757e-08
for O 0 7.809886959364576e-09
Huntington B-Disease 1 0.9999992847442627
disease I-Disease 1 0.9999985694885254
. O 0 3.639575538727513e-07

The O 0 1.8625446740472285e-09
first O 0 8.801596118601651e-10
predictive O 0 8.42793141941911e-08
testing O 0 3.335339116006253e-08
for O 0 6.895146231755689e-09
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999983310699463
( O 0 8.394729911209708e-10
HD B-Disease 0 2.290106522195856e-06
) O 0 1.0611650447245324e-09
was O 0 3.509791624001224e-10
based O 0 2.28630572807198e-10
on O 0 5.5544836091714345e-11
analysis O 0 8.943032425712261e-10
of O 0 3.075421167730852e-11
linked O 0 5.781654621728194e-08
polymorphic O 0 2.5544412807221306e-08
DNA O 0 1.1751387418712511e-08
markers O 0 3.248518343212936e-09
to O 0 4.6922216112577075e-11
estimate O 0 7.869350726608104e-10
the O 0 2.3104327478984388e-11
likelihood O 0 3.0383189297822355e-09
of O 0 2.427967722706814e-11
inheriting O 0 9.882965557039824e-09
the O 0 2.616656891163416e-10
mutation O 0 1.789840098354034e-08
for O 0 9.099644926457984e-10
HD B-Disease 0 1.9840670120174764e-06
. O 0 1.0292080787621671e-07

Limits O 0 9.500443809429271e-08
to O 0 8.429579811952692e-10
accuracy O 0 4.019671706601002e-09
included O 0 2.1154110407817228e-10
recombination O 0 1.3477523541638448e-09
between O 0 1.0368000902261088e-10
the O 0 1.741161034796157e-11
DNA O 0 4.010114462715819e-09
markers O 0 7.605623686401941e-09
and O 0 2.941391852306907e-10
the O 0 9.609889273232142e-11
mutation O 0 2.1522124526995867e-08
, O 0 1.833968393816221e-10
pedigree O 0 4.4251340369783065e-08
structure O 0 7.426421699818775e-09
, O 0 2.3338461718758197e-10
and O 0 7.051077083319868e-11
whether O 0 2.900975015762697e-10
DNA O 0 2.537623000620215e-09
samples O 0 6.251166806414687e-10
were O 0 5.890002374719927e-11
available O 0 1.747243322247627e-10
from O 0 5.7217692389643915e-11
family O 0 2.5441704298856394e-09
members O 0 4.421478738692031e-09
. O 0 5.875996578197373e-08

With O 0 3.0376701154466446e-09
direct O 0 1.2974396668141708e-08
tests O 0 1.1930504584256596e-08
for O 0 3.203242879279422e-11
the O 0 3.0831739938896874e-11
HD B-Disease 0 6.695447751781103e-08
mutation O 0 5.395993429857526e-09
, O 0 3.297092113219158e-11
we O 0 2.92972174298356e-11
have O 0 8.052870870134399e-12
assessed O 0 4.758837421348083e-11
the O 0 2.272981065518098e-12
accuracy O 0 1.4029811756799404e-09
of O 0 7.570644632026724e-12
results O 0 3.5775010731597945e-10
obtained O 0 2.9276897572927396e-10
by O 0 1.2575509210355218e-11
linkage O 0 2.040398960900802e-09
approaches O 0 4.049282686935385e-09
when O 0 2.232031920401667e-10
requested O 0 1.3161945144890552e-10
to O 0 3.81085857315e-11
do O 0 2.419642819440071e-10
so O 0 7.159994819261328e-12
by O 0 1.0672798582411769e-11
the O 0 8.516114896606197e-11
test O 0 8.699688969215913e-09
individuals O 0 1.2596815812671025e-09
. O 0 1.421427153758259e-08

For O 0 1.7711916378004844e-09
six O 0 6.874037450366188e-11
such O 0 6.035752193184196e-12
individuals O 0 2.2533416105252613e-11
, O 0 1.3049054024827367e-11
there O 0 3.900025094538684e-11
was O 0 5.566683225488589e-10
significant O 0 1.3120369235508633e-09
disparity O 0 1.0286149709770598e-08
between O 0 2.545596233805014e-10
the O 0 7.219807529601496e-10
tests O 0 1.1739798111420896e-07
. O 0 2.07964347964662e-08

Three O 0 6.839752764165041e-09
went O 0 4.687369159483978e-09
from O 0 3.801051487450913e-11
a O 0 1.1570532726379312e-10
decreased O 0 1.9622710567546164e-08
risk O 0 8.141299190356222e-09
to O 0 3.648017651847191e-11
an O 0 1.8044879826484284e-11
increased O 0 7.862899220612007e-10
risk O 0 8.376180637981179e-09
, O 0 6.90404504399833e-12
while O 0 1.9053666630575172e-11
in O 0 5.176525874617255e-12
another O 0 1.7020993989258493e-11
three O 0 9.822931357206244e-11
the O 0 4.740549064408128e-10
risk O 0 4.486216482746386e-07
was O 0 1.6736466434963404e-08
decreased O 0 8.251170413586806e-08
. O 0 7.35724228206891e-08

Knowledge O 0 6.72909266086208e-08
of O 0 4.747885418154851e-11
the O 0 2.8534934831681014e-11
potential O 0 2.677922328331306e-10
reasons O 0 1.325371895566363e-10
for O 0 1.1563307819942303e-12
these O 0 2.841554248844691e-12
changes O 0 9.226135827544724e-11
in O 0 2.453895073251111e-11
results O 0 3.527235392652983e-09
and O 0 3.479205257228557e-10
impact O 0 5.675415137851303e-10
of O 0 3.40297798620548e-12
these O 0 7.593440459752188e-11
risk O 0 1.1762324447772698e-09
reversals O 0 2.778043350915027e-09
on O 0 6.211312714166084e-11
both O 0 1.147889214236919e-10
patients O 0 7.929164547171297e-10
and O 0 1.2301431574768262e-11
the O 0 6.2875598824674306e-12
counseling O 0 8.955561847656668e-10
team O 0 1.3698995063315955e-11
can O 0 5.489612237008501e-12
assist O 0 3.1517757154153614e-12
in O 0 4.872402828426381e-12
the O 0 3.1056116879535356e-12
development O 0 6.2230134240115476e-12
of O 0 4.2176201767163413e-13
strategies O 0 1.3617722227632356e-10
for O 0 2.1204262304341803e-12
the O 0 3.945559157170209e-12
prevention O 0 2.629127471287518e-11
and O 0 6.800016712910084e-12
, O 0 2.4300466153204248e-12
where O 0 1.2064029462910408e-11
necessary O 0 2.0049598092874987e-10
, O 0 2.119113044762866e-11
management O 0 2.2782819034117274e-11
of O 0 1.0510834824034587e-12
a O 0 1.5340165249178028e-10
risk O 0 4.274334219900311e-09
reversal O 0 3.078640231635177e-09
in O 0 5.2917715348543837e-11
any O 0 1.7748735814393513e-10
predictive O 0 6.748128100753092e-08
testing O 0 6.640300309612712e-09
program O 0 2.196816728528006e-09
. O 0 5.20942455839446e-10
. O 0 7.163270865362392e-09

A O 0 1.2780563451997295e-07
novel O 0 2.387677966453339e-07
common O 0 1.3728762837672548e-07
missense O 0 1.4323005416372325e-05
mutation O 0 1.7472489162173588e-06
G301C O 0 8.911418944990146e-07
in O 0 1.1078423733934528e-09
the O 0 3.5923250485403457e-10
N O 0 9.709519872558303e-07
- O 0 5.89171861520299e-07
acetylgalactosamine O 0 5.7459001254756004e-05
- O 0 8.267504654213553e-07
6 O 0 5.359306953778287e-08
- O 0 3.568176225599018e-07
sulfate O 0 1.6321587281709071e-06
sulfatase O 0 5.257556495052995e-06
gene O 0 1.4348881904879818e-07
in O 0 1.0087428670146892e-08
mucopolysaccharidosis B-Disease 0 7.210330295492895e-06
IVA I-Disease 0 5.568638880504295e-05
. O 0 2.6637283667696465e-07

Mucopolysaccharidosis B-Disease 0 0.03864143788814545
IVA I-Disease 0 0.015580728650093079
( O 0 1.6923066823437694e-06
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 8.326482614506858e-09
is O 0 8.762183201227458e-10
an O 0 4.661548924644876e-09
autosomal B-Disease 1 0.9999172687530518
recessive I-Disease 1 0.9996534585952759
lysosomal I-Disease 1 0.9986125230789185
storage I-Disease 1 0.9712874889373779
disorder I-Disease 1 0.9999979734420776
caused O 0 2.4869413550732133e-07
by O 0 1.6045668127517843e-09
a O 0 1.6881128317436378e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.4501259748556095e-08
N O 0 3.758605453185737e-05
- O 0 4.924758286506403e-06
acetylgalactosamine O 0 0.002885072259232402
- O 0 5.934343789704144e-06
6 O 0 1.6060931784522836e-07
- O 0 1.3898943507228978e-06
sulfate O 0 6.305349415924866e-06
sulfatase O 0 8.731926754990127e-06
( O 0 1.1192562432427167e-09
GALNS O 0 6.62649881633115e-07
) O 0 3.848215968105251e-09
. O 0 1.8143541780091255e-08

In O 0 7.185740003023966e-09
previous O 0 5.826119586771483e-09
studies O 0 8.7371043733242e-09
, O 0 1.9451240618195698e-10
we O 0 1.2926981707295226e-10
have O 0 3.0709077641910554e-11
found O 0 3.270585538506232e-11
two O 0 2.7139252650743018e-11
common O 0 3.424514005700985e-10
mutations O 0 7.74667174852084e-09
in O 0 6.752483294736322e-11
Caucasians O 0 2.993487413505136e-08
and O 0 3.4925359826409874e-10
Japanese O 0 4.094529604259378e-09
, O 0 2.8116139971778864e-10
respectively O 0 2.092874318293525e-08
. O 0 5.484609744144109e-08

To O 0 2.444499713760706e-08
characterize O 0 2.2076913808177778e-07
the O 0 4.3782830139171836e-10
mutational O 0 2.718476252994151e-07
spectrum O 0 4.559970179229822e-09
in O 0 4.6758815569480916e-11
various O 0 4.985592494399782e-11
ethnic O 0 3.5972638201542395e-09
groups O 0 2.8299782517393623e-09
, O 0 2.6959878773880064e-10
mutations O 0 1.0428919949845294e-08
in O 0 8.930550743357912e-11
the O 0 1.196483467857945e-10
GALNS O 0 9.998436922842302e-08
gene O 0 1.4385391544635695e-08
in O 0 1.959674422735702e-09
Colombian O 0 1.744974156281387e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 9.849491533486798e-08
were O 0 6.499425303507778e-11
investigated O 0 3.902380640852243e-09
, O 0 7.594250922560164e-11
and O 0 1.5850255830063276e-10
genetic O 0 5.8004840930436785e-09
backgrounds O 0 1.0356647095477456e-08
were O 0 6.25357265970905e-11
extensively O 0 3.4007299754001963e-10
analyzed O 0 1.6304041450254658e-09
to O 0 3.439856732789792e-11
identify O 0 2.5931969904746666e-09
racial O 0 1.446649910974429e-09
origin O 0 6.458881762760882e-10
, O 0 2.3015042996399337e-11
based O 0 3.5932981590214297e-10
on O 0 2.853070557584658e-10
mitochondrial O 0 2.2852356451608102e-08
DNA O 0 1.756699390398353e-07
( O 0 1.1187588633276846e-09
mtDNA O 0 1.6342521291790035e-07
) O 0 5.6753317601021536e-09
lineages O 0 1.8960420788971533e-07
. O 0 1.3405914955910703e-07

Three O 0 1.4745917553682375e-07
novel O 0 7.852952421671944e-07
missense O 0 1.6375175619032234e-05
mutations O 0 1.6361780126317171e-06
never O 0 1.9167352149906947e-07
identified O 0 1.0032341180021831e-08
previously O 0 4.757789717757532e-09
in O 0 3.49469342353359e-11
other O 0 3.990387534291706e-11
populations O 0 8.847208521345351e-10
and O 0 2.0716681148336136e-10
found O 0 1.804832949758861e-10
in O 0 2.5940553524672616e-11
16 O 0 4.263898956136103e-11
out O 0 1.4086534889934388e-11
of O 0 3.71238387253392e-11
19 O 0 5.701131122748393e-09
Colombian O 0 5.880082198927994e-07
MPS B-Disease 1 0.9999992847442627
IVA I-Disease 1 0.9999877214431763
unrelated O 0 1.300026468697979e-07
alleles O 0 4.5019756811370826e-08
account O 0 9.743338580392447e-09
for O 0 1.1742531391689681e-09
84 O 0 5.55754411379894e-08
. O 0 5.371956390831656e-08

2 O 0 1.958461410822565e-07
% O 0 4.3982555375521315e-09
of O 0 1.687591212606865e-11
the O 0 8.4775110542612e-11
alleles O 0 5.767190724981219e-09
in O 0 2.002250309995901e-10
this O 0 1.7809097252463602e-10
study O 0 9.891414798346432e-09
. O 0 2.216308203628614e-08

The O 0 1.8862197137536896e-08
G301C O 0 4.970788154423644e-07
and O 0 2.4414417154616785e-09
S162F O 0 1.8013153635365597e-07
mutations O 0 5.582126760828032e-08
account O 0 3.7014287190828554e-09
for O 0 8.761180669836222e-10
68 O 0 8.384576943853972e-08
. O 0 6.962230258977797e-08

4 O 0 6.522545845655259e-07
% O 0 2.3204748345051485e-08
and O 0 7.068346796756941e-09
10 O 0 1.014214134897884e-08
. O 0 5.086133825216166e-08

5 O 0 1.034269487831807e-07
% O 0 2.313574887224945e-09
of O 0 1.909980333614225e-11
mutations O 0 1.0216307799737478e-08
, O 0 1.3202072768336848e-10
respectively O 0 1.6235057742619574e-09
, O 0 5.051312146342468e-11
whereas O 0 7.11993741742134e-10
the O 0 3.612690008258923e-11
remaining O 0 3.521098523862065e-09
F69V O 0 5.990740191919031e-06
is O 0 8.298316894750357e-11
limited O 0 6.048189726826081e-11
to O 0 3.386416841388851e-11
a O 0 2.397344545101987e-10
single O 0 4.837004397018063e-08
allele O 0 3.420677330723265e-06
. O 0 4.2778350461958325e-07

The O 0 2.7153481241271038e-08
skewed O 0 7.075815346979653e-07
prevalence O 0 6.956834113225341e-07
of O 0 7.80925393795151e-11
G301C O 0 2.1757927015642053e-08
in O 0 7.055974554637245e-11
only O 0 1.2093062662366094e-10
Colombian O 0 1.9170784071320668e-08
patients O 0 4.3744452504768105e-09
and O 0 2.0991490490285258e-10
haplotype O 0 4.9319446304707526e-08
analysis O 0 1.262445259442302e-09
by O 0 8.528518169459431e-11
restriction O 0 1.1552699907824149e-09
fragment O 0 9.884304041918313e-09
length O 0 2.3145634298060713e-09
polymorphisms O 0 2.3158878548201756e-07
in O 0 3.702478601486092e-10
the O 0 1.335020705095502e-10
GALNS O 0 6.375389460799852e-08
gene O 0 6.231669846812338e-09
suggest O 0 1.5221375271323723e-09
that O 0 4.165181394233386e-11
G301C O 0 6.574364164180224e-09
originated O 0 1.0729059862768509e-09
from O 0 5.7486900656433804e-11
a O 0 2.0278548285013187e-10
common O 0 1.966098839289998e-09
ancestor O 0 1.1341172267975708e-07
. O 0 2.1895355928336357e-07

Investigation O 0 6.430038723692633e-08
of O 0 1.41885780902129e-10
the O 0 8.132102630176163e-11
genetic O 0 8.027962294931967e-09
background O 0 7.873152796378236e-09
by O 0 5.029892127805802e-11
means O 0 8.359450909267707e-10
of O 0 1.812870686901391e-11
mtDNA O 0 2.009513977441202e-08
lineages O 0 1.1432881308337528e-09
indicate O 0 1.1441716463167495e-09
that O 0 3.499649181559761e-11
all O 0 2.25657600244622e-11
our O 0 9.25511126070866e-11
patients O 0 1.1560429696855223e-10
are O 0 1.7709693303849527e-12
probably O 0 5.390381890846285e-11
of O 0 1.2994883814843039e-11
native O 0 8.34392288595609e-09
American O 0 6.096955189605069e-07
descent O 0 3.920071685570292e-05

Low O 0 5.496000085258856e-06
frequency O 0 8.685465218150057e-07
of O 0 7.563699000456836e-09
BRCA1 O 0 1.1283103958703578e-05
germline O 0 4.021613221993903e-06
mutations O 0 3.182985608418676e-07
in O 0 3.1294369318146664e-09
45 O 0 4.927600727455683e-08
German O 1 0.9900054335594177
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.068778369197389e-07
. O 0 1.7276772723562317e-07

In O 0 4.861484104168312e-09
this O 0 8.020897834803975e-11
study O 0 4.779871498605814e-10
we O 0 2.6945534692401907e-10
investigated O 0 5.084240140007523e-09
45 O 0 4.836051559209409e-09
German O 0 0.07629255205392838
breast B-Disease 1 0.9999982118606567
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.1153036716393672e-08
for O 0 4.460704028375062e-10
germline O 0 1.2715912589555955e-06
mutations O 0 3.881464465393947e-07
in O 0 7.442995109130379e-10
the O 0 2.4477364579666983e-09
BRCA1 O 0 3.0808794235781534e-06
gene O 0 1.8183072825195268e-06
. O 0 1.7664413576312654e-07

We O 0 7.003905722058335e-08
identified O 0 1.3982587532268553e-08
four O 0 1.429517726414531e-09
germline O 0 4.206760593206127e-07
mutations O 0 1.2375562619126868e-07
in O 0 5.44597200669017e-10
three O 0 4.3702335084105925e-09
breast B-Disease 0 0.006233402993530035
cancer I-Disease 0 2.8280051083129365e-06
families O 0 1.422819917440421e-10
and O 0 4.927649260855205e-11
in O 0 5.477265307973767e-10
one O 0 0.00021696566545870155
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.909974844949147e-09
. O 0 2.3135814444796843e-11
among O 0 9.824649774281546e-12
these O 0 1.0689626267490482e-11
were O 0 1.0699259533897276e-10
one O 0 7.440397742364269e-10
frameshift O 0 1.5976634131220635e-06
mutation O 0 8.380339977520634e-08
, O 0 2.6304178279978885e-10
one O 0 1.8457604333832478e-09
nonsense O 0 3.173050799887278e-07
mutation O 0 1.6355821230717993e-07
, O 0 3.088554689778533e-10
one O 0 1.6395809709912612e-10
novel O 0 1.0239424419467014e-08
splice O 0 9.065955168807704e-07
site O 0 6.97502997581978e-08
mutation O 0 1.3650794983277592e-07
, O 0 5.190362029061646e-10
and O 0 6.548729891697747e-10
one O 0 8.654903460580954e-09
missense O 0 4.266812902642414e-05
mutation O 0 1.3627224689116701e-05
. O 0 6.032092869645567e-07

The O 0 6.940618391126918e-08
missense O 0 1.6628095181658864e-05
mutation O 0 2.884260993596399e-06
was O 0 6.270529695484583e-08
also O 0 1.235701208024409e-09
found O 0 1.1498992869007907e-09
in O 0 8.396299211455016e-10
2 O 0 1.0321367760468547e-08
. O 0 5.350329246311958e-08

8 O 0 1.2921799452669802e-07
% O 0 2.20151474827901e-09
of O 0 5.601805044136432e-12
the O 0 1.4138567053234574e-11
general O 0 5.711835518451558e-11
population O 0 1.627554063743375e-10
, O 0 1.6647964257154868e-11
suggesting O 0 9.139478063246997e-10
that O 0 1.9567516010288166e-11
it O 0 8.541525126082306e-11
is O 0 3.079143606754542e-10
not O 0 3.574488260937869e-09
disease O 0 9.432155501087891e-09
associated O 0 2.2584654146839966e-08
. O 0 7.814166735897743e-08

The O 0 5.823364013224364e-09
average O 0 3.645984492095522e-08
age O 0 6.016727116531229e-09
of O 0 1.0237773823140728e-10
disease O 0 3.9046305744250276e-08
onset O 0 5.400474734074123e-08
in O 0 2.1972013097837362e-10
those O 0 1.2218034362021513e-09
families O 0 4.366342398753886e-09
harbouring O 0 2.870929392884136e-06
causative O 0 1.0528849998081569e-05
mutations O 0 1.2241633839948918e-06
was O 0 7.265910095810568e-09
between O 0 2.665408560531546e-09
32 O 0 7.455334838368799e-08
. O 0 1.0036229980414646e-07

3 O 0 1.2195594081276795e-06
and O 0 7.885104480465088e-08
37 O 0 4.7436108729925763e-07
. O 0 2.116226767157059e-07

4 O 0 9.172526915790513e-08
years O 0 6.453036771603138e-09
, O 0 7.530669837718662e-11
whereas O 0 2.582735969536287e-10
the O 0 4.5784938340620585e-11
family O 0 9.62827706452174e-10
harbouring O 0 1.945870593544896e-07
the O 0 2.2070632821336034e-10
missense O 0 3.6806099501518474e-07
mutation O 0 2.187389469554546e-08
had O 0 3.9378492133756993e-10
an O 0 1.1500560052890574e-11
average O 0 1.843452501759657e-09
age O 0 2.3043618124773957e-09
of O 0 7.383168382224525e-11
onset O 0 1.0233806335691042e-07
of O 0 1.1239047470468222e-09
51 O 0 4.1579849607842334e-07
. O 0 2.4356506855838234e-07

2 O 0 9.481985330239695e-07
years O 0 3.1323889970735763e-07
. O 0 9.310080173463575e-08

These O 0 1.9364195580351407e-08
findings O 0 1.3791720654410256e-08
show O 0 9.628006836237546e-09
that O 0 3.641262291687042e-10
BRCA1 O 0 8.097074299939777e-08
is O 0 8.809317164626407e-11
implicated O 0 1.69512237579994e-09
in O 0 9.60002910499469e-12
a O 0 9.606585492372144e-12
small O 0 3.524093239448689e-10
fraction O 0 2.208779470436184e-08
of O 0 1.1982408842925452e-08
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5504783013042811e-09
suggesting O 0 3.972962403508973e-09
the O 0 3.169392179258601e-11
involvement O 0 2.667259746402806e-09
of O 0 1.740662995686204e-11
another O 0 6.635612614935837e-10
susceptibility O 0 6.757555581771157e-08
gene O 0 2.2640772101567563e-07
( O 0 1.3231253426226885e-08
s O 0 8.097589670796879e-06
) O 0 3.214896366898756e-07

Paternal O 0 0.00014359042688738555
transmission O 0 0.00022590109438169748
of O 0 1.0310859579476528e-06
congenital B-Disease 1 0.9999895095825195
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
. O 0 2.535111161705572e-05

We O 0 3.0685180263390066e-07
report O 0 3.9294332232486795e-09
a O 0 5.256813387366499e-11
rare O 0 1.752553518974409e-10
case O 0 1.4242786949836272e-09
of O 0 7.75494668481258e-10
paternally O 0 0.00025044046924449503
transmitted O 0 0.004763484932482243
congenital B-Disease 1 0.9999970197677612
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 6.336502792692045e-06
DM B-Disease 1 1.0
) O 0 3.279855604887416e-07
. O 0 2.3557007011731912e-07

The O 0 3.6077836274017727e-09
proband O 0 4.817554213332187e-07
is O 0 1.4553835914199453e-10
a O 0 3.9029869614015666e-11
23 O 0 2.543494859175155e-10
year O 0 1.2895977341553788e-10
old O 0 1.335255461754059e-07
, O 0 1.6480031783672189e-09
mentally B-Disease 1 1.0
retarded I-Disease 1 0.999998927116394
male O 0 3.945389835280366e-06
who O 0 1.7873267665891035e-07
suffers O 0 0.00311059458181262
severe O 0 3.0608411179855466e-05
muscular B-Disease 0 0.00033531623193994164
weakness I-Disease 0 0.014169342815876007
. O 0 5.874903195035586e-07

He O 0 4.993251323526238e-08
presented O 0 3.1309412840130335e-09
with O 0 5.790687374052084e-10
respiratory O 0 1.988081379522555e-07
and O 0 1.5895949001532017e-09
feeding O 0 3.3310158187305206e-08
difficulties O 0 6.796553861931898e-07
at O 0 7.66859464818026e-09
birth O 0 1.6280843340155116e-07
. O 0 7.478777774849732e-08

His O 0 7.724896988747787e-08
two O 0 3.1114879561755515e-08
sibs O 0 0.026594193652272224
suffer O 0 1.2469486136978958e-05
from O 0 1.6151673776221287e-08
childhood O 0 0.00010392057447461411
onset O 1 0.654189944267273
DM B-Disease 1 1.0
. O 0 3.505137556203408e-06

Their O 0 1.3886799266060734e-08
late O 0 1.6851876338819238e-08
father O 0 1.3483212768505837e-08
had O 0 4.751692928017803e-10
the O 0 1.4183971705494791e-11
adult O 0 2.3787347647186152e-09
type O 0 7.145503744254711e-09
of O 0 3.5945729726094555e-10
DM B-Disease 1 1.0
, O 0 1.6747211950551844e-10
with O 0 3.7770214039722916e-11
onset O 0 1.895755730174642e-08
around O 0 6.676555419637964e-10
30 O 0 2.6886921578039846e-09
years O 0 1.4447892660029993e-08
. O 0 3.531707548631857e-08

Only O 0 4.1711483156348095e-09
six O 0 1.9784064664296608e-10
other O 0 1.1015874844255702e-11
cases O 0 8.119703520659272e-11
of O 0 1.5970905153928072e-11
paternal O 0 2.4253267838503234e-07
transmission O 0 5.3264404414221644e-05
of O 0 1.0691294960452069e-08
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
have O 0 2.7189350930711953e-06
been O 0 2.515524322177498e-08
reported O 0 3.2254355630811915e-08
recently O 0 1.5357400684479217e-07
. O 0 3.540185034012211e-08

We O 0 6.66080168798544e-08
review O 0 4.4625956263644184e-09
the O 0 2.8080220440540593e-11
sex O 0 8.606600432337075e-10
related O 0 2.983122360245005e-10
effects O 0 5.820188331284726e-09
on O 0 5.822828330614982e-10
transmission O 0 2.8264202001082595e-07
of O 0 2.299498014224355e-08
congenital B-Disease 1 0.9999949932098389
DM I-Disease 1 1.0
. O 0 2.45439355239796e-06

Decreased O 0 2.44353623202187e-06
fertility O 0 1.041863015416311e-06
of O 0 2.5745422460587974e-10
males O 0 1.3050020619687075e-08
with O 0 9.794275390717644e-10
adult O 0 2.9595165074169927e-07
onset O 0 2.0196666810079478e-05
DM B-Disease 1 1.0
and O 0 1.9797286032741113e-09
contraction O 0 3.919447877365201e-09
of O 0 5.0328738572524845e-12
the O 0 2.1834513364016317e-11
repeat O 0 1.1833483526402233e-08
upon O 0 9.650280574646786e-11
male O 0 1.696946916318609e-09
transmission O 0 8.124944606002771e-10
contribute O 0 1.8869076440219956e-11
to O 0 2.2557487561886136e-12
the O 0 2.7031885844325254e-12
almost O 0 4.08394949802382e-11
absent O 0 3.95552657295184e-09
occurrence O 0 1.3146051358603472e-08
of O 0 1.7508529348564394e-10
paternal O 0 2.511098102786491e-07
transmission O 0 3.203967708031996e-06
of O 0 4.144930798588575e-08
congenital B-Disease 1 0.9999966621398926
DM I-Disease 1 1.0
. O 0 3.2612397262710147e-06

Also O 0 1.7746417668718095e-08
the O 0 1.1920234244122696e-10
fathers O 0 2.9022881875562234e-09
of O 0 7.534171203582574e-12
the O 0 9.114056731540643e-11
reported O 0 1.9106936477442105e-08
congenitally O 0 3.1345643947133794e-07
affected O 0 3.7654013240739914e-09
children O 0 5.249321533007389e-10
showed O 0 9.905984921232402e-10
, O 0 4.297969966038373e-12
on O 0 2.7579360670215713e-11
average O 0 6.477028913209892e-10
, O 0 7.031254745104576e-11
shorter O 0 4.042555090677524e-08
CTG O 0 3.754445856429811e-07
repeat O 0 2.1597500676762138e-08
lengths O 0 3.434139017599591e-08
and O 0 1.9910273429957215e-10
hence O 0 1.5031077493787848e-09
less O 0 9.151094881865163e-10
severe O 0 2.772471248135844e-07
clinical O 0 1.0566756145635736e-06
symptoms O 0 2.858776682046482e-08
than O 0 3.9157375258946914e-11
the O 0 5.7004297115970104e-11
mothers O 0 5.47595213618024e-09
of O 0 1.836085103401608e-11
children O 0 4.335852121784001e-09
with O 0 1.1172966551953323e-08
congenital B-Disease 1 0.99996018409729
DM I-Disease 1 1.0
. O 0 3.3099245229095686e-06

We O 0 1.517985737109484e-07
conclude O 0 1.6150041304285878e-08
that O 0 1.0368159802931487e-10
paternal O 0 1.8498779397191356e-08
transmission O 0 1.25495603242598e-07
of O 0 1.1982334013893592e-09
congenital B-Disease 1 0.9999973773956299
DM I-Disease 1 1.0
is O 0 7.110183108949286e-09
rare O 0 1.6549961401324254e-09
and O 0 1.357747109187457e-10
preferentially O 0 4.4974499679995006e-09
occurs O 0 3.783555968528418e-10
with O 0 4.8458802942574764e-11
onset O 0 8.848698662689003e-09
of O 0 2.258876558025591e-10
DM B-Disease 1 1.0
past O 0 4.6704244027750974e-08
30 O 0 9.70649671749868e-10
years O 0 1.132343774301603e-09
in O 0 3.887918806344537e-11
the O 0 7.79584452548221e-11
father O 0 6.626547310872866e-09
. O 0 2.563884882178513e-09
. O 0 4.9027381265887016e-08

The O 0 2.4203612269957375e-07
RB1 O 0 6.648464477621019e-05
gene O 0 8.127747719299805e-07
mutation O 0 1.2541232763396692e-07
in O 0 6.554015663517987e-10
a O 0 2.1755344192797565e-09
child O 0 6.51557002129266e-07
with O 0 3.408923419101484e-07
ectopic B-Disease 1 0.9999949932098389
intracranial I-Disease 1 0.9999306201934814
retinoblastoma I-Disease 1 0.892807126045227
. O 0 1.6337831766577438e-05

The O 0 3.3961254075620673e-07
RB1 O 0 0.00010115018085343763
gene O 0 1.910597347887233e-06
mutation O 0 1.3209739790909225e-06
was O 0 3.990034080914029e-09
investigated O 0 2.436804713568108e-08
in O 0 1.776709335210569e-10
a O 0 1.2041238006688104e-09
child O 0 5.328723204911512e-07
with O 0 4.7368754252374856e-08
ectopic B-Disease 1 0.999738872051239
intracranial I-Disease 0 0.21051287651062012
retinoblastoma I-Disease 0 1.4526417544402648e-06
using O 0 7.167507476424362e-09
DNA O 0 1.6969735838756606e-08
obtained O 0 1.5023338129083186e-09
from O 0 1.2163194063052885e-11
both O 0 2.1186280160789828e-11
the O 0 1.594333970400541e-10
pineal B-Disease 0 6.409602519852342e-07
and I-Disease 0 5.624084309374666e-08
retinal I-Disease 0 0.0011684434721246362
tumours I-Disease 1 1.0
of O 0 4.570268330450489e-10
the O 0 3.5891150051980958e-09
patient O 0 5.098167434880452e-07
. O 0 6.45184528025311e-08

A O 0 3.759856497254077e-07
nonsense O 0 3.076991788475425e-06
mutation O 0 6.137178161225165e-07
in O 0 2.872653004359904e-09
exon O 0 3.8637739407931804e-07
17 O 0 1.1545193245865448e-08
( O 0 2.90590385088052e-10
codon O 0 4.2318774262639636e-08
556 O 0 3.6794811641982506e-09
) O 0 1.1491904650107188e-10
of O 0 8.085483671482763e-12
the O 0 5.2790289500892484e-11
RB1 O 0 1.801640081566802e-07
gene O 0 9.362181252470236e-09
was O 0 8.54291415386399e-10
found O 0 3.810931084591296e-11
to O 0 1.1764309144901564e-11
be O 0 1.1010014080992114e-11
present O 0 2.1858556631393355e-11
homozygously O 0 9.308319448564362e-09
in O 0 2.117165817661082e-11
both O 0 7.157745923747072e-11
the O 0 7.52656270641694e-11
retinal B-Disease 0 1.0042012377198262e-07
and I-Disease 0 3.1031828218175406e-09
the I-Disease 0 5.905577360465486e-09
pineal I-Disease 0 0.0005702407215721905
tumours I-Disease 1 1.0
. O 0 6.184994276736688e-07

The O 0 4.695870359228138e-09
same O 0 3.3461888815367047e-09
mutation O 0 2.510400598509932e-08
was O 0 5.800702140845715e-10
present O 0 1.7794327122899745e-10
heterozygously O 0 5.0299284737320704e-08
in O 0 6.262715346316838e-11
the O 0 2.5740645726024525e-11
DNA O 0 7.458773154667142e-09
from O 0 3.6986653323412e-11
the O 0 1.0486369585172017e-11
constitutional O 0 7.777595789626446e-10
cells O 0 7.929104595127967e-10
of O 0 1.3824507944654174e-12
the O 0 1.6490767085208802e-11
patient O 0 8.791512517980493e-10
, O 0 6.452878596047151e-12
proving O 0 4.062338798682674e-10
it O 0 2.1309280728853963e-11
to O 0 1.646430561330625e-11
be O 0 6.039751337949539e-11
of O 0 5.6819108446015676e-11
germline O 0 5.114929990668315e-07
origin O 0 1.118738595096147e-07
. O 0 1.1813755662615222e-07

The O 0 1.2559300266445916e-08
initial O 0 2.6110010153956864e-08
mutation O 0 5.9174080746515756e-08
was O 0 5.526145097078938e-10
shown O 0 4.645933082692011e-10
to O 0 1.1450792397615928e-10
have O 0 3.4444677665668166e-10
occurred O 0 2.356939310388384e-09
in O 0 1.8384442579399973e-10
the O 0 1.7581893718698893e-09
paternally O 0 3.2567390917392913e-06
derived O 0 1.0267791594742448e-06
RB1 O 0 9.515096462564543e-05
allele O 0 1.0205429134657606e-05
. O 0 4.3716116238101677e-07

The O 0 6.865828794389017e-09
mutation O 0 5.1698364700314414e-08
is O 0 2.0757102980883957e-10
in O 0 6.990710094134656e-11
an O 0 1.3754553052081064e-11
area O 0 6.168929811423141e-10
of O 0 2.360590195538137e-11
the O 0 6.611176189830203e-11
gene O 0 6.869535607023636e-09
that O 0 7.413747393769654e-11
encodes O 0 7.621157038784077e-10
the O 0 4.062258862624901e-11
protein O 0 4.251632379492776e-09
- O 0 2.454741476753952e-08
binding O 0 1.1094944518674765e-08
region O 0 1.300111907021062e-09
known O 0 7.576517191409948e-10
as O 0 6.968770699389282e-11
the O 0 2.689894661178638e-11
pocket O 0 7.813905540388077e-06
region O 0 1.4599621067645785e-07
and O 0 1.3140686760948483e-08
has O 0 2.5775945822203994e-09
been O 0 4.882212967238786e-10
detected O 0 4.083219595774068e-10
in O 0 6.177895868486605e-12
other O 0 1.9166513862134416e-11
cases O 0 2.7647528710872393e-10
of O 0 6.680972441941435e-11
retinoblastoma B-Disease 0 9.525302147039838e-08
. O 0 5.10664133201999e-09
. O 0 6.097890548062423e-08

Low O 0 0.0010705133900046349
levels O 0 4.3463950305522303e-07
of O 0 1.4113947510718816e-10
beta O 0 5.9559268628106565e-09
hexosaminidase O 0 6.957822762387877e-08
A O 0 1.761766843522139e-10
in O 0 1.5799486718925948e-10
healthy O 0 6.005625441396489e-10
individuals O 0 8.66751601047433e-11
with O 0 2.1105546477162562e-10
apparent O 0 1.1152386605317588e-06
deficiency O 0 1.1382110642443877e-05
of O 0 3.363866477035238e-11
this O 0 4.981403067816359e-10
enzyme O 0 2.6616663717504707e-07
. O 0 2.036694546347917e-08

Appreciable O 0 2.527080687286798e-05
beta O 0 2.5840772650553845e-06
hexosaminidase O 0 9.221324035024736e-06
A O 0 8.884144087062396e-09
( O 0 4.395385444500022e-10
hex O 0 1.4646771262505354e-07
A O 0 3.902795586707697e-10
) O 0 9.957486918343861e-11
activity O 0 1.5477865655810774e-09
has O 0 4.90759821669684e-10
been O 0 3.877641541194521e-10
detected O 0 4.339177905876568e-09
in O 0 1.2520301462259908e-10
cultured O 0 1.1784139530846005e-07
skin O 0 3.1318901960730727e-07
fibroblasts O 0 8.367338466541696e-08
and O 0 1.3407073673477043e-08
melanoma B-Disease 0 1.6572179447393864e-05
tissue O 0 1.2002652205467257e-08
from O 0 9.15180639604607e-11
healthy O 0 1.923779607837517e-10
individuals O 0 1.1759104974473633e-11
previously O 0 1.2398706505933887e-09
reported O 0 3.477435450705002e-09
as O 0 7.305525073775243e-10
having O 0 1.5746530834803707e-06
deficiency B-Disease 0 1.921674993354827e-06
of I-Disease 0 1.2973907538571527e-11
hex I-Disease 0 3.325534692066867e-07
A I-Disease 0 1.9821305707878878e-10
activity O 0 4.299630651516395e-10
indistinguishable O 0 4.1112904747286905e-10
from O 0 8.971109445587988e-12
that O 0 3.541123123895762e-12
of O 0 2.43933410797037e-12
patients O 0 1.5675705178352928e-09
with O 0 1.4875418230531068e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.00047865824308246374
( O 0 4.377908702224431e-09
TSD B-Disease 0 1.6013662389013916e-05
) O 0 1.7826241816010224e-08
. O 0 5.276188375091806e-08

Identification O 0 6.986306857470481e-07
and O 0 9.573985160216125e-09
quantitation O 0 1.8938820858238614e-06
of O 0 2.6389354590428127e-10
hex O 0 5.167889867152553e-07
A O 0 6.37272123960031e-10
, O 0 7.798893475463586e-11
amounting O 0 1.6290891968750998e-09
to O 0 1.49058565490634e-09
3 O 0 1.310044694946555e-08
. O 0 7.426127268672644e-08

5 O 0 1.1136921784782317e-06
% O 0 1.7553362852140708e-07
- O 0 9.912030691339169e-06
6 O 0 2.4541756715734664e-07
. O 0 1.2921995562464872e-07

9 O 0 2.0372198150653276e-07
% O 0 2.876995752743028e-09
of O 0 3.019597766273918e-11
total O 0 1.4634896072784898e-10
beta O 0 1.5450826396090633e-08
hexosaminidase O 0 9.273501433426645e-08
activity O 0 2.8472659785450105e-09
, O 0 7.03227406861906e-11
has O 0 1.3856438219050915e-10
been O 0 6.363171795031874e-11
obtained O 0 9.438970716146855e-10
by O 0 6.309442412977262e-10
cellulose O 0 1.3015240938329953e-06
acetate O 0 3.877738663504715e-07
gel O 0 1.3097121154714841e-05
electrophoresis O 0 9.709241339805885e-07
, O 0 1.4845281670616828e-09
DEAE O 0 8.613995987616363e-07
- O 0 7.682813674136924e-08
cellulose O 0 6.407365731320169e-07
ion O 0 5.100589461903837e-08
- O 0 2.5175499018814662e-08
exchange O 0 5.337880804034967e-09
chromatography O 0 3.935900849683094e-08
, O 0 8.990401478836674e-11
radial O 0 2.761351147739788e-08
immunodiffusion O 0 2.412148489838728e-07
, O 0 5.444424910905354e-10
and O 0 2.348986782862994e-09
radioimmunoassay O 0 4.224404165142914e-06
. O 0 1.0548938433885269e-07

Previous O 0 5.073644615549711e-07
family O 0 1.7136954966190387e-08
studies O 0 8.943343843270668e-09
suggested O 0 1.4211742893621704e-09
that O 0 6.155641968375036e-12
these O 0 1.12642100508209e-11
individuals O 0 1.8830607212416695e-11
may O 0 2.6587759771601327e-10
be O 0 1.6206515296435242e-11
compound O 0 3.422268024522168e-10
heterozygotes O 0 1.0231245184399995e-08
for O 0 1.5772711262074246e-11
the O 0 8.308358168118701e-11
common O 0 2.8626327974734522e-09
mutant O 0 1.097476953759724e-07
TSD B-Disease 0 7.042497713882767e-07
gene O 0 1.664871795981071e-08
and O 0 7.228542764359247e-10
a O 0 4.1421846508349347e-10
rare O 0 4.329373304301498e-09
( O 0 2.054826087061201e-09
allelic O 0 4.2692113311204594e-07
) O 0 4.886929527714301e-09
mutant O 0 2.6301250954929856e-07
gene O 0 1.9087194687017472e-06
. O 0 1.5187170276931283e-07

Thus O 0 1.5494553906592046e-07
, O 0 9.41561384415479e-10
the O 0 9.061364159013152e-11
postulated O 0 1.6000324620790707e-08
rate O 0 3.845471940877587e-09
mutant O 0 7.819843439449414e-09
gene O 0 9.028628511487113e-09
appears O 0 1.0731577848588358e-09
to O 0 7.386403988451917e-12
code O 0 2.183563746482875e-11
for O 0 2.7318830791295268e-12
the O 0 4.833332952619562e-12
expression O 0 1.2980101715687198e-10
of O 0 5.690313237965983e-12
low O 0 1.0974299247124009e-09
amounts O 0 1.1784938580561288e-09
of O 0 1.4617544674688787e-10
hex O 0 1.8174820297645056e-06
A O 0 2.637720619702577e-08
. O 0 8.559297270949173e-08

Heterozygotes O 0 6.21747130935546e-06
for O 0 1.0386413951124496e-09
the O 0 6.634052335252605e-11
rare O 0 4.3520398396168503e-10
mutant O 0 4.9043283212313327e-08
may O 0 2.80888201587004e-09
be O 0 2.927933936969218e-11
indistinguishable O 0 6.619734760349161e-10
from O 0 2.4015262001242377e-11
heterozygotes O 0 7.352778386149339e-09
for O 0 4.1710249837345614e-11
the O 0 4.3849351927249813e-10
common O 0 3.31017844246162e-08
TSD B-Disease 0 2.668325942067895e-05
mutant O 0 3.3548294595675543e-06
. O 0 2.1200163757839618e-07

However O 0 4.25138324544605e-08
, O 0 4.982504964168299e-10
direct O 0 5.550609971649578e-10
visualization O 0 3.886249189122282e-08
and O 0 8.438716947445357e-10
quantitation O 0 1.095923380489694e-06
of O 0 1.347723460609629e-10
hex O 0 4.7404543579432357e-07
A O 0 1.0355451218746481e-10
by O 0 1.1653004949874202e-11
the O 0 7.097841845521424e-12
methods O 0 6.463161561498509e-09
described O 0 5.008625070246353e-09
may O 0 3.2710381070444328e-09
prevent O 0 1.864016052621764e-09
false O 0 6.107328420767999e-09
- O 0 3.581478225100909e-08
positive O 0 7.210260388745837e-09
prenatal O 0 6.216589554242091e-07
diagnosis O 0 7.844496963116399e-08
of O 0 5.7031487171732564e-11
TSD B-Disease 0 7.859260904297116e-07
in O 0 6.056261603326618e-10
fetuses O 0 1.0705153385970334e-07
having O 0 1.6674484015766211e-09
the O 0 8.518665634005274e-11
incomplete O 0 3.0192266464723616e-09
hex B-Disease 0 1.621842420718167e-05
A I-Disease 0 1.1267128563474671e-08
deficiency I-Disease 0 4.484531075377163e-07
of O 0 3.809708191276906e-12
the O 0 3.9768400378337176e-11
type O 0 9.316898363920245e-09
described O 0 1.8235888354922736e-09
in O 0 3.1921562615444543e-10
the O 0 3.331838693831912e-10
four O 0 9.531986755462185e-09
healthy O 0 1.2849075403664756e-07
individuals O 0 9.201369266520487e-08

The O 0 1.5646057249796286e-07
tumor B-Disease 0 4.485186764213722e-06
suppressor O 0 2.352338242417318e-06
gene O 0 1.1517763596202713e-06
Smad4 O 0 3.7488107409444638e-06
/ O 0 5.23091671311704e-07
Dpc4 O 0 5.216245995143254e-07
is O 0 2.129787318727594e-10
required O 0 1.0615652801249098e-10
for O 0 7.999230618171982e-12
gastrulation O 0 3.6305427553173786e-09
and O 0 1.210942873752785e-10
later O 0 1.1273570965641966e-09
for O 0 1.2126323556405083e-10
anterior O 0 1.2783623049017478e-07
development O 0 3.7750283454762723e-10
of O 0 3.754797861521553e-11
the O 0 4.0733250106228525e-10
mouse O 0 3.051563055578299e-07
embryo O 0 2.0372986000438686e-06
. O 0 1.7571417743056372e-07

Mutations O 0 2.195855813624803e-05
in O 0 1.910431279839031e-08
the O 0 8.09012412616994e-09
SMAD4 O 0 3.8915819459361956e-05
/ O 0 1.2654131751332898e-06
DPC4 O 0 4.1057337512029335e-06
tumor B-Disease 0 2.6437882638674637e-07
suppressor O 0 1.0163756769543397e-07
gene O 0 7.153197145726153e-08
, O 0 5.126156721324548e-10
a O 0 2.2193474835674465e-10
key O 0 1.2611558908304232e-08
signal O 0 2.73868661082588e-08
transducer O 0 1.197274883679711e-07
in O 0 2.2271245958549457e-10
most O 0 3.972051021428058e-10
TGFbeta O 0 8.782886879998841e-07
- O 0 4.926454266751534e-08
related O 0 1.8795818235162187e-09
pathways O 0 7.89575183013369e-10
, O 0 3.2100851924538043e-12
are O 0 1.943516311428417e-12
involved O 0 3.7434635252742154e-11
in O 0 3.3580586228376674e-11
50 O 0 4.266186848234099e-10
% O 0 5.128386049157996e-10
of O 0 1.7392641771252215e-09
pancreatic B-Disease 1 0.9962664246559143
cancers I-Disease 1 0.9998689889907837
. O 0 4.414563079535583e-07

Homozygous O 0 0.0006621595239266753
Smad4 O 0 0.00014257276779972017
mutant O 0 3.158656181767583e-05
mice O 0 6.070718518458307e-05
die O 0 0.000121611803479027
before O 0 6.45736051296808e-08
day O 0 1.5202262559910196e-08
7 O 0 1.7594448564750564e-08
. O 0 2.5314463414360944e-08

5 O 0 2.063716237898916e-07
of O 0 3.3774092411675838e-09
embryogenesis O 0 2.79263872471347e-06
. O 0 6.622454975513392e-07

Mutant O 0 3.886393187713111e-06
embryos O 0 6.795270337534021e-07
have O 0 9.481468943306481e-09
reduced O 0 4.726151470180184e-09
size O 0 8.037706500374497e-09
, O 0 2.184682434958063e-09
fail O 0 1.5715116319370281e-07
to O 0 1.3875506299498852e-10
gastrulate O 0 9.868710293403637e-08
or O 0 2.617731365006648e-09
express O 0 1.0822328588844243e-09
a O 0 7.537337420870927e-11
mesodermal O 0 8.118631456000003e-08
marker O 0 5.4207326627420116e-08
, O 0 4.4000825205614547e-10
and O 0 9.720724225559252e-10
show O 0 2.0278689305541775e-07
abnormal O 0 3.2961168017209275e-07
visceral O 0 4.4383207864484575e-07
endoderm O 0 3.2251518859993666e-05
development O 0 1.0599623578855244e-07
. O 0 2.201249742483924e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 0.9999995231628418
of O 0 4.1689510177356226e-10
the O 0 7.887517861071558e-10
Smad4 O 0 1.5154822904150933e-05
- O 0 1.7199062085637706e-06
deficient O 0 3.075162169352552e-07
embryos O 0 2.4468649328923675e-08
results O 0 1.1421089629592984e-09
from O 0 4.85337256495022e-11
reduced O 0 1.5337422443195692e-09
cell O 0 2.8641961691278084e-08
proliferation O 0 7.953601333099414e-09
rather O 0 1.6681186987277385e-10
than O 0 1.081157455229409e-10
increased O 0 1.2982559471907962e-09
apoptosis O 0 2.7025599536045775e-08
. O 0 3.974548334895189e-08

Aggregation O 0 2.729318794081337e-06
of O 0 8.395343087386209e-09
mutant O 0 1.7849977211881196e-06
Smad4 O 0 1.5030624126666225e-05
ES O 0 2.095429323389908e-07
cells O 0 5.893042498428258e-09
with O 0 1.1212962502948898e-10
wild O 0 7.89369281051222e-09
- O 0 3.069933654842316e-06
type O 0 1.182114260700473e-06
tetraploid O 0 8.815816727292258e-06
morulae O 0 7.6110482041258365e-06
rescues O 0 7.527190177825105e-07
the O 0 9.427640890180555e-09
gastrulation B-Disease 0 4.291935056244256e-06
defect I-Disease 0 4.67218069388764e-06
. O 0 1.2412890271207289e-07

These O 0 2.420370037725661e-08
results O 0 9.807832768160551e-09
indicate O 0 2.7886979392377498e-09
that O 0 7.831329335017401e-11
Smad4 O 0 3.0093850966750324e-08
is O 0 4.772035197553315e-11
initially O 0 3.4112868085856007e-10
required O 0 4.9448983102662325e-11
for O 0 4.34621175854355e-12
the O 0 4.471867754568537e-12
differentiation O 0 2.2597385074263343e-10
of O 0 4.278014140851605e-12
the O 0 3.8014792702600886e-11
visceral O 0 5.357801757810421e-09
endoderm O 0 3.3329229154333007e-07
and O 0 1.9376183990615914e-10
that O 0 2.4272082607690315e-11
the O 0 3.675443976947079e-11
gastrulation B-Disease 0 2.342527238852199e-08
defect I-Disease 0 1.581632780300879e-08
in O 0 3.995970221382095e-11
the O 0 6.209287251035533e-11
epiblast O 0 5.093055506222299e-07
is O 0 6.965345522580435e-10
secondary O 0 7.201285789903977e-09
and O 0 1.3427130518550712e-09
non O 0 2.6036317990474345e-07
- O 0 3.7416458553707344e-07
cell O 0 3.588549191135826e-07
autonomous O 0 1.3678956634066708e-07
. O 0 2.0739639694511425e-07

Rescued O 0 8.987361070467159e-06
embryos O 0 3.401496996957576e-06
show O 0 1.903489874166553e-06
severe O 0 3.2172010833164677e-06
anterior O 0 1.4689841009385418e-05
truncations O 0 2.703846803342458e-06
, O 0 2.83509482557065e-09
indicating O 0 7.25935800360844e-09
a O 0 1.6599524532701082e-10
second O 0 1.723060999436754e-10
important O 0 1.5184484225549966e-10
role O 0 2.1449126919037553e-09
for O 0 2.090012052313739e-10
Smad4 O 0 2.248286250505771e-07
in O 0 3.3179516911729934e-09
anterior O 0 2.8503293378889794e-06
patterning O 0 1.1936674127355218e-05
during O 0 1.6513793354988593e-07
embryogenesis O 0 3.08456606035179e-06
. O 0 4.244350861881685e-07

Prevalence O 0 0.0006623520166613162
of O 0 1.6126676882777247e-08
p16 O 0 2.283198000441189e-06
and O 0 2.0069972350711396e-08
CDK4 O 0 6.291521913226461e-06
germline O 0 5.8277723837818485e-06
mutations O 0 4.948585683450801e-07
in O 0 1.5921377549688032e-09
48 O 0 1.1049164072574058e-07
melanoma B-Disease 1 0.9995688796043396
- O 0 0.3606793284416199
prone O 0 0.00031077515450306237
families O 0 1.619106093642131e-08
in O 0 7.3899806274368984e-09
France O 0 6.477970600826666e-06
. O 0 5.867272179216343e-08

The O 0 3.486812829578412e-07
French O 0 1.4865418961562682e-05
Familial B-Disease 0 0.0029903727117925882
Melanoma I-Disease 1 0.6773578524589539
Study O 0 5.075053195469081e-07
Group O 0 4.096665122688137e-07
. O 0 1.3833614787017723e-07

Germline O 0 0.00034457872970961034
mutations O 0 1.2021701877529267e-05
in O 0 3.7136556052530523e-09
the O 0 3.0500926784249316e-10
p16 O 0 7.270390511848746e-08
and O 0 5.60679169758771e-10
CDK4 O 0 7.053306916304791e-08
genes O 0 3.7075758019256e-09
have O 0 2.6719276791098423e-10
been O 0 2.1242131664767072e-10
reported O 0 3.149188965156924e-10
in O 0 1.2297936106964169e-11
a O 0 2.1915831996399682e-11
subset O 0 2.3476429689139877e-09
of O 0 1.5684847864960716e-10
melanoma B-Disease 0 4.364431788417278e-06
pedigrees O 0 1.399264988322102e-07
, O 0 5.470364161652697e-10
but O 0 9.139163870131028e-10
their O 0 7.387144229653586e-10
prevalence O 0 3.5614348803392204e-07
is O 0 2.9312771654410597e-10
not O 0 2.2321554327131565e-10
well O 0 3.482146238020789e-10
known O 0 7.978092853022645e-09
. O 0 5.5190298553497996e-08

We O 0 1.2042667307810007e-08
searched O 0 7.452786832118363e-09
for O 0 5.601647271036292e-11
such O 0 7.942450863662742e-11
germline O 0 2.3331281795435643e-07
mutations O 0 1.1006297739868387e-07
in O 0 8.436238374542882e-10
48 O 0 6.614843783836477e-08
French O 0 9.680851690063719e-06
melanoma B-Disease 1 0.9999220371246338
- O 0 0.0074523151852190495
prone O 0 6.319463068393816e-07
families O 0 5.540265468617633e-10
selected O 0 1.9641104714862578e-11
according O 0 7.424102131670107e-12
to O 0 4.2155072835226015e-12
two O 0 7.733078934146764e-12
major O 0 3.511747281859101e-10
criteria O 0 3.2023541596259975e-09
families O 0 1.5213698356664196e-11
with O 0 1.315074026238261e-12
at O 0 4.204668557772351e-11
least O 0 2.5624011593117224e-11
three O 0 1.3753431726826193e-10
affected O 0 5.180294526674345e-10
members O 0 5.279260362200944e-11
( O 0 2.295900969340181e-11
n O 0 5.196208796576229e-09
= O 0 8.033629761428074e-09
20 O 0 6.503964034010323e-11
) O 0 1.0947486840662268e-11
or O 0 4.0799242456701634e-11
families O 0 8.263233847172202e-12
with O 0 2.1151062672142285e-12
two O 0 5.199783312259676e-11
affected O 0 1.8459707373796874e-10
members O 0 1.9278703633496264e-11
, O 0 2.3754756842131464e-12
one O 0 3.5865433886672626e-12
of O 0 2.328760285736503e-13
them O 0 8.666420879543946e-12
affected O 0 3.2240217440193675e-11
before O 0 5.7010604570528756e-11
the O 0 4.827095754361688e-12
age O 0 1.2820194905671656e-10
of O 0 2.2217763653159528e-12
50 O 0 6.269587626839268e-11
( O 0 3.6867623537384375e-11
n O 0 1.5967398070415584e-08
= O 0 3.045840557547308e-08
28 O 0 1.1560039592239946e-09
) O 0 2.535888513066631e-11
, O 0 7.505915160244125e-12
and O 0 2.397206044779665e-11
one O 0 5.4913320418625844e-11
additional O 0 6.519902950863354e-10
minor O 0 2.5916161661143633e-08
criterion O 0 2.3051812547691952e-07
. O 0 8.461724121389125e-08

Sixteen O 0 3.7062068258819636e-07
different O 0 2.0856099069987977e-08
p16 O 0 1.8865507627197076e-06
germline O 0 3.906511665263679e-06
mutations O 0 2.3485046085625072e-07
were O 0 6.75550115847301e-10
found O 0 3.0428004560434374e-10
in O 0 1.1833201085664768e-10
21 O 0 5.916340750644622e-10
families O 0 9.56546994390628e-11
, O 0 2.906162810401014e-11
while O 0 4.701227185321954e-10
one O 0 8.010841989758433e-10
germline O 0 4.384663725431892e-07
mutation O 0 5.978453287980301e-08
, O 0 1.4719887808656296e-10
Arg24His O 0 4.880141801777427e-08
, O 0 1.7283241504628677e-10
was O 0 1.255519910259295e-09
detected O 0 8.468486356605354e-09
in O 0 2.537457188811487e-10
the O 0 1.4117534918867136e-09
CDK4 O 0 2.34955132327741e-06
gene O 0 3.721152097568847e-07
. O 0 1.1500340946213328e-07

The O 0 1.1889455642233315e-08
frequency O 0 5.502296573922649e-08
of O 0 2.3530663528781304e-10
p16 O 0 1.4810930792918953e-07
gene O 0 4.767839456576439e-08
mutation O 0 2.5944849824099947e-08
in O 0 1.369482305335623e-10
our O 0 2.6975258138328684e-10
sample O 0 7.250470224207106e-10
( O 0 3.275829954518805e-11
44 O 0 8.675504065136508e-11
% O 0 3.0448484011902366e-11
) O 0 2.291158929246251e-11
is O 0 1.8778886431980446e-11
among O 0 3.891376110232159e-11
the O 0 3.275548582371002e-11
highest O 0 1.7351895920114657e-08
rates O 0 5.3164647795256315e-08
yet O 0 3.0174935883309217e-09
reported O 0 1.2505917412752865e-09
and O 0 3.3333752424979934e-11
the O 0 2.0340631956550226e-11
CDK4 O 0 1.4647650914412225e-07
mutation O 0 9.65593716095725e-10
is O 0 1.2935904084021566e-11
the O 0 1.929014413482033e-11
second O 0 8.539329798828987e-10
mutation O 0 1.0363542912728008e-08
detected O 0 2.0164701020064513e-09
in O 0 5.7607862924413666e-11
this O 0 5.886262310905721e-11
gene O 0 3.7321193246953044e-08
worldwide O 0 6.755803383384773e-08
. O 0 5.7988170709677433e-08

In O 0 9.008194190585073e-09
summary O 0 1.1772431030010466e-08
, O 0 5.16158449315185e-10
our O 0 1.6980468420246808e-10
results O 0 3.6961708693716844e-10
show O 0 1.81031567514367e-09
frequent O 0 4.260781505394107e-09
involvement O 0 5.014599402386466e-09
of O 0 1.778797074913907e-11
the O 0 8.624738423446132e-11
p16 O 0 3.4336345322572015e-08
gene O 0 2.4059266579001815e-08
in O 0 1.4077256027533736e-09
familial B-Disease 0 1.0514350833545905e-05
melanoma I-Disease 1 0.6232455372810364
and O 0 2.1653669968202394e-09
confirm O 0 1.3213271365941637e-08
the O 0 2.5145132503956447e-11
role O 0 3.031910500439494e-09
of O 0 1.2948642158505663e-11
the O 0 6.93699542253512e-11
CDK4 O 0 7.65659891044379e-08
gene O 0 7.05549707546993e-09
as O 0 6.956131226587559e-10
a O 0 4.7400181557577525e-09
melanoma B-Disease 0 0.09120474010705948
- O 0 2.7813562155643012e-06
predisposing O 0 3.7745792269561207e-06
gene O 0 2.683181890006381e-07
. O 0 1.2328862375454719e-08
. O 0 6.574642696932642e-08

Progression O 0 1.6188121662708e-05
of O 0 3.804901638204683e-08
somatic O 0 1.0970476978400256e-05
CTG O 0 4.763796823681332e-05
repeat O 0 1.4517540876113344e-06
length O 0 2.139087840191678e-08
heterogeneity O 0 3.911026738023793e-07
in O 0 9.84766157507977e-10
the O 0 3.2187086329571457e-10
blood O 0 1.6901706700878094e-08
cells O 0 4.106662743197376e-08
of O 0 8.63524896033141e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00020992793724872172
. O 0 2.7999354301755375e-07

The O 0 6.817402642411707e-09
genetic O 0 1.3677470178663498e-07
basis O 0 1.324759058007885e-08
of O 0 9.750532825592018e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.075701246440076e-07
DM B-Disease 1 1.0
) O 0 5.548792092469057e-09
is O 0 4.7593276542023943e-11
the O 0 1.0034411669634924e-11
expansion O 0 7.142106905888568e-10
of O 0 1.7185797923646717e-11
an O 0 1.3191601977435852e-10
unstable O 0 1.9536673789843917e-07
CTG O 0 3.346337678067357e-07
repeat O 0 7.876175089904791e-08
in O 0 9.36406507889842e-11
the O 0 7.304726962198416e-11
34 O 0 1.1124646759341772e-09
UTR O 0 5.8504205924236885e-08
of O 0 1.5386640572767618e-10
the O 0 3.744053067578079e-09
DM B-Disease 1 0.9999980926513672
protein O 0 6.696788545923482e-08
kinase O 0 1.3366570783546194e-07
gene O 0 5.095280286582238e-08
on O 0 4.259278263418764e-09
chromosome O 0 2.6878813059738604e-06
19 O 0 2.5008813508975436e-07
. O 0 1.5173026213233243e-07

One O 0 2.94778050857758e-08
of O 0 9.949949891785437e-11
the O 0 2.806394526488898e-11
principal O 0 1.2756588008144831e-09
features O 0 6.028992860507287e-10
of O 0 7.209675911834523e-11
the O 0 4.084351079569615e-09
DM B-Disease 1 1.0
mutation O 0 9.270721079701616e-07
is O 0 3.405585258242638e-10
an O 0 1.6474734770843824e-11
extraordinarily O 0 1.0748790302272937e-08
high O 0 7.28450411102699e-09
level O 0 9.074616613702347e-10
of O 0 1.2058462735275999e-11
somatic O 0 1.3422578604149749e-08
mosaicism O 0 3.085982314132707e-07
, O 0 6.283151082753236e-11
due O 0 1.2567627494242117e-10
to O 0 3.983421925646269e-11
an O 0 1.467203442073739e-11
extremely O 0 6.322296575156372e-10
high O 0 1.6457195606278674e-09
degree O 0 9.499009578917139e-09
of O 0 3.1738806027803435e-11
somatic O 0 6.671137953162543e-08
instability O 0 3.844300522359845e-08
both O 0 2.1526332105725743e-10
within O 0 5.240455291932733e-11
and O 0 9.138914625062e-11
between O 0 1.9809476281551497e-10
different O 0 2.1114012760392598e-09
tissues O 0 2.0428441871445102e-07
. O 0 5.6305133000478236e-08

This O 0 6.482559911091812e-08
instability O 0 1.4897685218784318e-07
appears O 0 8.461640277346305e-09
to O 0 1.8247289790274124e-10
be O 0 5.309636411099383e-11
biased O 0 2.346425276300579e-09
towards O 0 5.2549690293668405e-11
further O 0 1.9396251965675404e-11
expansion O 0 7.403164192787415e-11
and O 0 5.345669740197678e-11
continuous O 0 1.4972012518654765e-10
throughout O 0 9.489944940987982e-11
the O 0 1.929415481549679e-11
life O 0 5.76100556148873e-11
of O 0 1.44680773438155e-12
an O 0 1.3550912779033975e-12
individual O 0 2.11061793042866e-11
, O 0 2.57404362581648e-12
features O 0 2.1637681923980523e-10
that O 0 1.9365062331466731e-10
could O 0 9.458836380815683e-09
be O 0 3.131117587429344e-11
associated O 0 3.594886541224973e-11
with O 0 3.240690918740463e-12
the O 0 6.445612099614806e-11
progressive O 0 2.165338131021599e-09
nature O 0 1.3506756824099853e-09
of O 0 5.0484710162335134e-11
the O 0 4.207914017229086e-09
disease O 0 1.3970222312309488e-07
. O 0 2.265687903957314e-08

Although O 0 9.256077504460336e-08
increasing O 0 7.590029937887266e-09
measured O 0 2.5620972010642618e-08
allele O 0 8.22729901983621e-08
size O 0 1.2546538918911665e-08
between O 0 3.675987736428965e-09
patients O 0 3.412103311006831e-08
clearly O 0 3.559240402406516e-10
correlates O 0 2.9804891887863505e-10
with O 0 9.573478294833127e-12
an O 0 1.1179878203759763e-11
increased O 0 6.305424515851143e-10
severity O 0 6.007590513945615e-08
of O 0 1.0433983538282732e-10
symptoms O 0 3.5678350940315795e-08
and O 0 4.8329024809889987e-11
an O 0 6.000078038581602e-12
earlier O 0 3.1418829760099243e-09
age O 0 1.1533897170679097e-09
of O 0 7.331635298868378e-12
onset O 0 1.107591529603269e-08
, O 0 1.316146150398545e-11
this O 0 4.464087086097912e-12
correlation O 0 9.721002891538433e-10
is O 0 4.499187480910827e-11
not O 0 2.5148393784091283e-11
precise O 0 1.2536724991463188e-09
and O 0 1.5091108918063867e-10
measured O 0 1.4647666413125648e-09
allele O 0 7.045330541188832e-09
length O 0 2.471248095048395e-09
cannot O 0 7.232545673474533e-09
be O 0 9.561543397318406e-12
used O 0 3.4883200494828515e-11
as O 0 4.436686695113989e-12
an O 0 2.5978121563630108e-12
accurate O 0 4.235606088087707e-09
predictor O 0 4.260605237504933e-07
of O 0 3.4329615539174796e-11
age O 0 5.89469539846732e-09
of O 0 1.2522888281907285e-09
onset O 0 3.399136176085449e-06
. O 0 2.1935379379556252e-07

In O 0 7.028955639754031e-09
order O 0 3.0734170763935253e-10
to O 0 2.8631597093209393e-11
further O 0 5.6364898859406765e-11
characterize O 0 7.149157266184147e-09
the O 0 3.112493873747013e-10
dynamics O 0 5.6506213041984665e-08
of O 0 2.5418860349901706e-09
DM B-Disease 1 1.0
CTG O 0 8.790866559138522e-06
repeat O 0 2.2166595670114475e-07
somatic O 0 9.026910419152046e-08
instability O 0 2.074327021261979e-08
, O 0 5.626296650795837e-11
we O 0 3.441156387617994e-11
have O 0 1.0277269486824725e-11
studied O 0 4.97577201663546e-10
repeat O 0 1.0374772152488276e-09
length O 0 1.0428889696267873e-10
changes O 0 1.4403937764750907e-10
over O 0 1.1525967680281468e-11
time O 0 1.49853254804988e-10
in O 0 2.1653204229643563e-10
111 O 0 7.259540524273689e-08
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999967813491821
patients O 0 2.837520582943398e-07
with O 0 1.1038953778852445e-10
varying O 0 6.610048508548516e-09
clinical O 0 8.86266889210674e-07
severity O 0 8.361306527149281e-07
and O 0 4.317087132221786e-09
CTG O 0 3.532610719503282e-07
repeat O 0 2.4712681678806803e-08
size O 0 4.911934192719514e-10
over O 0 9.509876219837565e-11
time O 0 2.8356231251969177e-10
intervals O 0 1.349377942716501e-09
of O 0 9.655154280252543e-12
1 O 0 2.279997080023577e-09
- O 0 1.6041430228597164e-07
7 O 0 3.2350881973286505e-09
years O 0 1.0840162545378007e-08
. O 0 1.6120218049309187e-08

We O 0 1.4598172981550306e-07
have O 0 6.995354850936053e-10
found O 0 6.068168884043601e-11
a O 0 2.21193410809839e-11
direct O 0 5.339864106446157e-10
progression O 0 4.146589738240891e-09
of O 0 1.2566901512467421e-11
the O 0 5.098111169332675e-11
size O 0 8.559795094953415e-10
heterogeneity O 0 1.9203135082079825e-08
over O 0 3.464933895358513e-10
time O 0 1.657250725539683e-10
related O 0 2.965094836326898e-10
to O 0 1.1866742311017475e-10
initial O 0 1.5491865568151297e-09
CTG O 0 8.766237158397416e-08
repeat O 0 1.9366190429082053e-08
size O 0 4.78238837420264e-10
and O 0 3.690195718442091e-11
the O 0 5.07755469614235e-12
time O 0 2.244754798708115e-10
interval O 0 6.066377955527003e-10
and O 0 8.458468647720707e-11
always O 0 8.885530089486338e-10
biased O 0 8.43881764467369e-09
towards O 0 5.263046110037806e-10
further O 0 6.607145941472936e-10
expansion O 0 4.683001719740787e-08
. O 0 4.050535906685582e-08

Attempts O 0 2.677757322544494e-07
to O 0 2.2281367861864965e-09
mathematically O 0 1.4117461866192116e-08
model O 0 1.0446578713185772e-08
the O 0 8.534342677002371e-11
dynamics O 0 1.0791436189094838e-08
have O 0 6.743747227311303e-10
proved O 0 1.1345446804256198e-09
only O 0 3.265349796111039e-11
partially O 0 3.988443353364346e-09
successful O 0 1.0818346218854913e-09
suggesting O 0 1.0443027553819206e-09
that O 0 1.4251224332573198e-11
individual O 0 1.0206671445522897e-11
specific O 0 4.0534898354538385e-11
genetic O 0 1.4657475233548212e-09
and O 0 1.1124854509825255e-10
/ O 0 1.6494088317386968e-09
or O 0 2.392707976195396e-10
environmental O 0 3.2518268633374703e-10
factors O 0 4.0449424365540665e-10
also O 0 1.2954873285231372e-10
play O 0 3.049778762864719e-10
a O 0 9.581246213086203e-11
role O 0 7.72353825340133e-09
in O 0 2.239423091410231e-09
somatic O 0 5.966287517367164e-07
mosaicism O 0 5.532907380256802e-06
. O 0 1.63898850047417e-08
. O 0 1.2428574791556457e-07

Aspartylglucosaminuria B-Disease 1 0.9999948740005493
among O 0 3.3939768400159664e-06
Palestinian O 0 0.00020185073663014919
Arabs O 0 0.0002200401941081509
. O 0 1.4132866681393352e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 1.6651758869556943e-06
AGU B-Disease 1 0.9999997615814209
) O 0 4.451688351281291e-09
is O 0 7.745009494852795e-11
a O 0 2.940544474583362e-10
rare O 0 2.273306520805818e-08
disorder B-Disease 0 3.289603773737326e-05
of I-Disease 0 9.916187315717195e-11
glycoprotein I-Disease 0 1.211028120451374e-06
metabolism I-Disease 0 2.861231678252807e-06
caused O 0 1.1037490033061204e-08
by O 0 2.2605403660058698e-10
the O 0 4.208708936914718e-09
deficiency B-Disease 0 1.963665636139922e-05
of I-Disease 0 4.897170169382292e-11
the I-Disease 0 8.266363149544986e-10
lysosomal I-Disease 0 1.2900210094812792e-05
enzyme I-Disease 0 2.260222800032352e-06
aspartylglucosaminidase I-Disease 0 1.1307029126328416e-06
( O 0 1.5451703250235482e-09
AGA O 0 1.764624641964474e-07
) O 0 9.596198502492825e-09
. O 0 4.82091344622404e-08

AGU B-Disease 1 0.9999996423721313
is O 0 1.1285500534086168e-07
inherited O 0 6.57604743992124e-07
as O 0 1.673384097955477e-09
an O 0 1.2815654093500939e-09
autosomal O 0 0.0039021254051476717
recessive O 0 0.00033355053164996207
trait O 0 0.00020120243425481021
and O 0 6.2005236500795036e-09
occurs O 0 2.0824051372159147e-09
with O 0 5.1963624375650497e-11
a O 0 3.2847097264365743e-10
high O 0 3.1515758891487167e-09
frequency O 0 3.287057026568618e-08
in O 0 3.7137475317194912e-09
Finland O 0 1.481479102949379e-06
because O 0 2.6926025853413194e-09
of O 0 1.4697156686116486e-11
a O 0 2.2839043156697159e-10
founder O 0 3.037231266489471e-08
effect O 0 9.397267319855018e-08
. O 0 3.3548879230238526e-08

While O 0 1.7238639316019544e-07
very O 0 9.231508890650275e-10
few O 0 4.278257303980126e-09
patients O 0 8.924089023309989e-09
with O 0 2.228892348465905e-10
AGU B-Disease 1 1.0
have O 0 1.2958858430778264e-09
been O 0 1.6395809709912612e-10
reported O 0 5.228018573610882e-10
from O 0 9.4760359281576e-11
non O 0 5.46382068478124e-07
- O 0 1.8261135892316815e-07
Finnish O 0 1.7190151524459907e-08
origin O 0 1.4057078834284198e-09
, O 0 2.852994229751715e-10
we O 0 3.098433509762799e-09
diagnosed O 0 1.5395792729577806e-07
the O 0 1.350103223662913e-10
disorder O 0 1.6609396880085114e-07
in O 0 8.741946749823981e-11
8 O 0 3.7218650383863405e-10
patients O 0 2.4468438386548996e-10
originating O 0 1.2457107567698245e-10
from O 0 1.3936823049787161e-11
3 O 0 2.2565027971155338e-11
unrelated O 0 5.970767213980821e-10
families O 0 8.2133799761408e-11
, O 0 8.780912628958415e-12
all O 0 3.107710963567989e-11
Palestinian O 0 4.1564547359485005e-07
Arabs O 0 3.9207137092489575e-07
from O 0 8.466555928565711e-11
the O 0 8.357916442269797e-11
region O 0 7.751490116447712e-09
of O 0 5.934729929713001e-10
Jerusalem O 0 7.905333768576384e-05
. O 0 2.2545880540292274e-07

The O 0 2.7734598617712436e-08
clinical O 0 1.4679552577945287e-06
diagnosis O 0 1.0119832040800247e-05
of O 0 1.058811593956932e-09
AGU B-Disease 1 1.0
is O 0 2.399829890364913e-09
often O 0 3.061214837174475e-09
difficult O 0 9.80052128340958e-09
, O 0 1.6417957271475103e-11
in O 0 4.55483437425408e-12
particular O 0 3.496559985993741e-11
early O 0 4.3084147360872294e-10
in O 0 2.767922349655727e-11
the O 0 3.5207926851743565e-11
course O 0 2.4289578348657415e-08
of O 0 5.662866443129078e-12
the O 0 8.896344771969211e-11
disease O 0 9.16840825482268e-10
, O 0 1.7399783870664098e-12
and O 0 2.5149147087760726e-12
most O 0 3.914316787367866e-12
of O 0 1.1333706325875048e-12
the O 0 4.0431043929478605e-11
patients O 0 1.1487198969817314e-09
are O 0 4.986952517604948e-11
diagnosed O 0 1.465798593613954e-08
after O 0 7.62269414256167e-11
the O 0 2.383273786654705e-11
age O 0 5.081134957229949e-10
of O 0 5.44592539467037e-12
5 O 0 3.957018324118877e-10
years O 0 5.789475565620705e-09
. O 0 1.747231692661444e-08

However O 0 4.3159609219856065e-08
, O 0 5.769035804625844e-10
since O 0 7.928075973495652e-10
these O 0 2.93499599623992e-11
patients O 0 2.2499671570308521e-10
excrete O 0 4.644471474080092e-10
early O 0 5.488033985590057e-11
large O 0 1.7230369908638465e-11
amounts O 0 1.5211500115075438e-10
of O 0 6.727103683129565e-12
aspartylglucosamine O 0 4.673748321692983e-08
in O 0 1.6363817245679257e-10
urine O 0 9.862698435725292e-10
, O 0 1.652899692117238e-11
biochemical O 0 2.9692275305137628e-09
screening O 0 2.79730150154478e-09
is O 0 7.046291328194343e-11
easy O 0 1.582485920081922e-09
by O 0 2.989353486970714e-10
urine O 0 2.06440837757782e-08
chromatography O 0 1.1038779490490924e-07
. O 0 3.4823737227185347e-09
. O 0 2.8876682378609075e-08

Detection O 0 9.087725629797205e-07
of O 0 9.862849426056641e-10
heterozygous O 0 7.925361700245048e-08
carriers O 0 1.267512583780217e-08
of O 0 2.0552992641142964e-10
the O 0 4.966807054529454e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 5.11491080601445e-08
ATM O 0 2.4035674073275004e-07
) O 0 8.591281575043297e-10
gene O 0 1.3404184429077759e-08
by O 0 1.6813215264477321e-09
G2 O 0 5.388276917983603e-07
phase O 0 1.1021927548426902e-07
chromosomal O 0 1.3221562767284922e-05
radiosensitivity O 0 4.590752268995857e-06
of O 0 3.444876606195635e-09
peripheral O 0 6.958035100979032e-06
blood O 0 1.5485216863453388e-05
lymphocytes O 0 0.00012802296259906143
. O 0 1.1950851330766454e-06

In O 0 5.2356058404257055e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.20707668364048004
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4310844953513424e-08
patients O 0 7.687692260560652e-09
, O 0 1.3742857546406029e-11
mutations O 0 1.91146187766833e-09
in O 0 2.6353880883123182e-11
a O 0 2.051151089255132e-11
single O 0 2.4784976848657436e-10
gene O 0 1.7863129864181815e-09
, O 0 3.7185209772472305e-11
ATM O 0 7.253240674742756e-09
, O 0 3.487288929848731e-11
result O 0 3.7723293933034086e-10
in O 0 1.6435519611945892e-09
an O 0 0.000481863011373207
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.213570022251531e-09
embraces O 0 7.94055043940034e-09
a O 0 1.211005185020042e-10
variety O 0 2.5090288180429354e-10
of O 0 2.2476924835257428e-11
clinical O 0 1.3803061804651406e-08
features O 0 5.188909746323134e-09
and O 0 1.6171978201029447e-09
manifests O 0 8.778313187463027e-09
extreme O 0 7.374970412143966e-09
radiosensitivity O 0 3.3779269870137796e-07
and O 0 3.027361417107244e-10
a O 0 1.3385520469810785e-10
strong O 0 5.6215716526253345e-09
pre O 0 1.1039574019378051e-05
- O 0 5.835108254359511e-07
disposition O 0 2.9422596981021343e-07
to O 0 2.0382064036539305e-08
malignancy B-Disease 0 2.7462159778224304e-05
. O 0 9.183135318835411e-08

Heterozygotes O 0 9.415661224920768e-06
for O 0 1.0925239601888848e-09
the O 0 1.1366970559256728e-10
ATM O 0 2.2340360672501447e-08
gene O 0 1.066937471705387e-08
have O 0 4.2054809634706203e-10
no O 0 1.0377260162286461e-10
clinical O 0 2.4369011253355666e-09
expression O 0 3.710630136488646e-10
of O 0 7.526649442590738e-11
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 9.145955459644028e-08
may O 0 6.093005655571915e-09
be O 0 2.565899437367847e-10
cancer B-Disease 0 1.1712764091953431e-08
prone O 0 1.953606165727706e-09
with O 0 1.5503468300814838e-11
a O 0 3.2545943717821046e-10
moderate O 0 8.042127319640713e-08
increase O 0 3.771396084317757e-09
in O 0 6.097734539523003e-10
in O 0 1.6870329577756138e-09
vitro O 0 3.015840775333345e-06
radiosensitivity O 0 4.912154508929234e-06
. O 0 6.257769058493068e-08

We O 0 1.804190077336898e-07
performed O 0 5.950161963141909e-08
a O 0 2.7194775320538156e-09
blind O 0 1.0082681001222227e-07
chromosomal O 0 1.1101421932835365e-06
analysis O 0 2.0022257629648266e-08
on O 0 1.9227239800301277e-09
G2 O 0 5.832815759276855e-07
- O 0 2.6688800858210016e-07
phase O 0 4.8100389449245995e-08
lymphocytes O 0 3.417170546526904e-08
from O 0 8.065848683402876e-11
7 O 0 3.724712482888748e-10
unrelated O 0 3.050864094689132e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 1.3408332222297759e-07
, O 0 2.972953480617768e-11
13 O 0 4.92582918898421e-10
obligate O 0 7.45439621141486e-08
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.99998939037323
T I-Disease 1 1.0
heterozygotes O 0 1.123369429478771e-06
( O 0 6.9727987273005e-11
parents O 0 2.7340385511109844e-10
of O 0 1.7142608946946192e-12
the O 0 2.226129523774656e-11
patients O 0 3.2262378879543974e-10
) O 0 7.582032224284774e-12
, O 0 8.452610139597638e-12
and O 0 3.405208615081534e-10
14 O 0 3.4694175310434616e-10
normal O 0 7.747879560149329e-10
controls O 0 4.994420432780089e-09
following O 0 4.662222830020823e-10
X O 0 5.7206538173204535e-08
- O 0 5.910129718955659e-09
irradiation O 0 1.1188618920243698e-08
with O 0 7.827880010857768e-11
1 O 0 4.676579679063764e-10
Gy O 0 1.70768771567964e-07
in O 0 2.529425106867489e-11
order O 0 3.6160401062357295e-11
to O 0 1.1418007164754052e-11
evaluate O 0 6.071412816943678e-10
this O 0 4.8859067833251224e-12
cytogenetic O 0 8.306511922739901e-09
method O 0 6.173803135389733e-10
as O 0 4.568575032171118e-11
a O 0 1.3470159015982475e-11
tool O 0 7.053680306512433e-09
for O 0 7.042474936547194e-11
detection O 0 3.458465069883232e-09
of O 0 2.2707301317037576e-10
ATM O 0 8.966736118054541e-07
carriers O 0 5.465973345053499e-07
. O 0 9.735874328953287e-08

Both O 0 2.7563366984395543e-06
A B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999874830245972
T I-Disease 1 0.9999998807907104
homozygotes O 0 1.1175681720487773e-05
and O 0 1.4307262041768354e-09
heterozygotes O 0 2.0339041384431766e-07
showed O 0 4.193532188168092e-09
significantly O 0 1.634052781973594e-09
increased O 0 4.731993685780367e-10
levels O 0 5.910780753737299e-10
of O 0 2.6639317488030834e-11
radiation O 0 1.687325379862159e-06
- O 0 1.998103243749938e-06
induced O 0 8.03804482529813e-07
chromatid O 0 5.682493792846799e-05
damage O 0 5.2719332899187066e-08
relative O 0 1.2332735943587636e-09
to O 0 2.9022853564875106e-11
that O 0 1.647916525460147e-11
of O 0 1.5006055426036724e-11
normal O 0 5.996471763580757e-09
controls O 0 1.1971645790254115e-06
. O 0 2.6541280817582447e-07

These O 0 1.4209040166690556e-08
results O 0 8.611185542406474e-09
show O 0 2.8670041896106113e-09
that O 0 8.833950237985277e-11
the O 0 3.063169717876235e-10
G2 O 0 4.948188916387153e-07
- O 0 1.9717693078291632e-07
phase O 0 5.755127929774062e-08
chromosomal O 0 9.946563750418136e-07
radiosensitivity O 0 2.3108248115022434e-07
assay O 0 1.0056311339212698e-07
can O 0 1.0897970720291639e-10
be O 0 2.2637135221881266e-12
used O 0 1.7540944391436497e-11
for O 0 2.929390454167735e-12
the O 0 6.147076771212401e-12
detection O 0 2.5754911536779446e-09
of O 0 4.003097298088676e-10
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
heterozygotes O 0 0.0002121663565048948
. O 0 2.2790399611949397e-07

In O 0 3.015884075807662e-08
combination O 0 6.299455890257377e-08
with O 0 5.62193347430906e-10
molecular O 0 1.9709096577003038e-08
genetic O 0 6.622190795724237e-08
analyses O 0 4.8042895883781966e-08
, O 0 3.546649085528486e-10
this O 0 7.609185503909544e-11
test O 0 1.005941552278955e-08
may O 0 2.0228521635523578e-10
be O 0 1.9881490117418243e-12
of O 0 1.905895282089745e-13
value O 0 3.1718773441102854e-11
in O 0 2.7916809489103578e-11
studies O 0 9.999572281316205e-10
of O 0 6.902373204248358e-12
familial B-Disease 0 1.5253824869887467e-07
and I-Disease 0 8.546014562682558e-09
sporadic I-Disease 0 9.391921594215091e-06
cancers I-Disease 1 0.999290943145752
aimed O 0 8.892624947520744e-08
at O 0 4.3900230672910823e-10
determination O 0 2.5801510927792037e-10
of O 0 1.4985224432856326e-12
the O 0 1.2720470510263482e-11
potential O 0 7.789026645887986e-10
involvement O 0 1.4790760838323536e-09
of O 0 2.2522329487517645e-11
ATM O 0 1.4407858373033378e-07
mutations O 0 1.1461056459438623e-07
in O 0 2.1293740104511016e-09
tumor B-Disease 0 2.005462647503009e-06
risk O 0 6.548580131493509e-07
or O 0 2.240572394285323e-09
development O 0 1.1709140324001055e-09
. O 0 2.8695041898174622e-09
. O 0 6.811530539607702e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.0981700171441844e-07
identification O 0 1.9785440841246782e-08
and O 0 4.966053679389404e-10
detection O 0 2.7997781870681138e-09
of O 0 2.081557148869706e-11
founder O 0 4.906667072646087e-08
- O 0 2.5278864086430985e-06
effect O 0 1.3732848458403168e-07
mutations O 0 1.4106479540032524e-08
in O 0 7.025409420879924e-11
the O 0 1.7573895463862677e-11
ATM O 0 1.0891310964211698e-08
gene O 0 1.0855680798727008e-08
in O 0 9.418236190938956e-10
ethnic O 0 1.1176274483659654e-07
populations O 0 8.091861900538788e-07
. O 0 1.4968522066283185e-07

To O 0 1.850265052283362e-09
facilitate O 0 4.359350380678251e-10
the O 0 5.2348108486865996e-11
evaluation O 0 3.140006310520249e-10
of O 0 6.018738025331816e-12
ATM O 0 7.070747098936181e-09
heterozygotes O 0 2.879533589350558e-08
for O 0 2.3239703564326142e-11
susceptibility O 0 2.1253732107595624e-09
to O 0 6.967786764233708e-11
other O 0 2.1648124959305903e-10
diseases O 0 8.22130274968913e-09
, O 0 2.1217166478598726e-12
such O 0 9.12628219523759e-12
as O 0 1.4122167879548897e-09
breast B-Disease 0 2.76367541118816e-06
cancer I-Disease 0 1.0312423910363577e-06
, O 0 3.464839873346115e-11
we O 0 4.0692227365468625e-11
have O 0 1.0281485732233087e-11
attempted O 0 2.262110360140568e-10
to O 0 6.183577955232167e-12
define O 0 3.518559055226689e-10
the O 0 4.317253152197331e-12
most O 0 1.8224465339611307e-11
common O 0 1.4516630952865484e-10
mutations O 0 1.5735346359235791e-09
and O 0 1.6481900913523084e-11
their O 0 1.9414869018019587e-11
frequencies O 0 1.5431682598432417e-08
in O 0 1.0313618048485296e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00019900297047570348
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.775463553954637e-09
homozygotes O 0 8.009459406821406e-08
from O 0 7.522946154914223e-11
10 O 0 2.8070060165141797e-10
ethnic O 0 1.1881815531467055e-08
populations O 0 3.4990949870916666e-07
. O 0 8.361260483980004e-08

Both O 0 7.785365596646443e-08
genomic O 0 1.4315384078145144e-06
mutations O 0 1.1059322559958673e-06
and O 0 2.5240203260779026e-09
their O 0 5.56023116438098e-10
effects O 0 3.6903067268667655e-08
on O 0 2.507737073553784e-10
cDNA O 0 4.151672072794099e-08
were O 0 3.693628514156444e-09
characterized O 0 1.4915086410383083e-07
. O 0 2.587951826171775e-07

Protein O 0 6.486649908765685e-06
- O 0 2.485535787855042e-06
truncation O 0 4.968953817297006e-07
testing O 0 3.945115523151799e-08
of O 0 2.981681568314798e-11
the O 0 6.149636355701205e-11
entire O 0 1.6343364439563857e-09
ATM O 0 3.7359512816692586e-08
cDNA O 0 3.566726292092426e-08
detected O 0 2.753126082666313e-08
92 O 0 3.7059000312922308e-09
( O 0 1.4861847863478772e-10
66 O 0 3.0510718396214997e-09
% O 0 2.6178251233410776e-10
) O 0 3.307455143097826e-10
truncating O 0 2.0503469499999483e-07
mutations O 0 1.9613511881289014e-07
in O 0 3.280833937857608e-10
140 O 0 4.768000216870405e-09
mutant O 0 6.333635269584192e-07
alleles O 0 1.1458481594672776e-06
screened O 0 3.085781372647034e-06
. O 0 2.116022983500443e-07

The O 0 6.106384731197068e-09
haplotyping O 0 5.977849468763452e-07
of O 0 1.532063365061731e-10
patients O 0 7.369556520586684e-09
with O 0 2.1689774976074716e-11
identical O 0 8.868500600556217e-09
mutations O 0 1.6236000988101296e-07
indicates O 0 6.637261407149708e-09
that O 0 1.3016416069988601e-11
almost O 0 1.4618374219455e-11
all O 0 4.827123509937303e-12
of O 0 8.633863480926596e-13
these O 0 9.20956887140445e-12
represent O 0 9.157585800778634e-11
common O 0 4.979835432905588e-10
ancestry O 0 3.741391907396974e-08
and O 0 1.8086340758394215e-10
that O 0 2.6842415443151246e-11
very O 0 2.14366427386814e-10
few O 0 6.13978645702673e-09
spontaneously O 0 4.897355054822583e-08
recurring O 0 1.2287413255762658e-06
ATM O 0 4.030812760902336e-06
mutations O 0 2.5750193799467525e-06
exist O 0 8.732058063287695e-07
. O 0 1.3210126326157479e-07

Assays O 0 8.974821867013816e-06
requiring O 0 8.994994260547173e-08
minimal O 0 2.5948212467596932e-08
amounts O 0 3.149160487936342e-09
of O 0 3.229893782985549e-11
genomic O 0 1.5797182228993734e-08
DNA O 0 2.5852326501762946e-08
were O 0 8.469349527251424e-11
designed O 0 3.526897385253136e-10
to O 0 7.201755251179387e-12
allow O 0 7.045578703790412e-11
rapid O 0 1.025086543426923e-10
screening O 0 6.234627258905334e-10
for O 0 3.76420561387647e-11
common O 0 2.7179789530151766e-09
ethnic O 0 3.7397978758235695e-07
mutations O 0 1.1696304682118353e-05
. O 0 2.5938200565178704e-07

These O 0 3.6214292009617566e-08
rapid O 0 7.312948469007097e-08
assays O 0 5.791073931504798e-07
detected O 0 7.132883439453508e-08
mutations O 0 4.2571684844006086e-08
in O 0 2.905765350558198e-10
76 O 0 4.524742802658466e-09
% O 0 3.0236566028740697e-10
of O 0 4.202848485901356e-11
Costa O 0 1.0162031571780972e-07
Rican O 0 4.762276972769541e-08
patients O 0 6.228235704952567e-09
( O 0 5.5973511416118615e-12
3 O 0 1.009033741977694e-11
) O 0 6.742364479228602e-12
, O 0 1.0252933051180246e-11
50 O 0 4.9968831156155247e-11
% O 0 6.073391095595682e-11
of O 0 4.645585305329547e-11
Norwegian O 1 0.9465469121932983
patients O 0 3.32075806852572e-08
( O 0 7.481188411817552e-12
1 O 0 1.857221494649952e-11
) O 0 1.2969651394523218e-11
, O 0 1.1306334340988045e-11
25 O 0 3.52879982179477e-11
% O 0 3.498654838063331e-11
of O 0 1.4722688346235913e-11
Polish O 0 0.0001348124205833301
patients O 0 7.279462366227563e-09
( O 0 7.013022541163538e-12
4 O 0 8.860456639225855e-12
) O 0 7.249799285208303e-12
, O 0 6.6639402329649045e-12
and O 0 8.785943500511095e-11
14 O 0 1.6560625093475778e-10
% O 0 2.7810623595692086e-11
of O 0 1.3392382688937055e-11
Italian O 0 3.053482578252442e-05
patients O 0 4.628387895166952e-09
( O 0 8.2147700100621e-12
1 O 0 3.737050252583529e-11
) O 0 2.23386222714117e-11
, O 0 4.2357046689533995e-12
as O 0 6.511979757511943e-12
well O 0 2.4574125720433493e-11
as O 0 3.139549384356677e-11
in O 0 1.0038436054626843e-10
patients O 0 2.117511277432982e-09
of O 0 2.62444302401299e-11
Amish O 0 1.4843766393823898e-07
/ O 0 6.37001704717477e-08
Mennonite O 0 9.596677585932412e-08
and O 0 7.272523472323655e-09
Irish O 0 1.7240989791389438e-07
English O 0 3.5095407469043494e-08
backgrounds O 0 3.6508563994175347e-07
. O 0 1.2134762528148713e-07

Additional O 0 1.4620465549342043e-07
mutations O 0 2.708334818635194e-07
were O 0 1.002489535828488e-09
observed O 0 1.685485973013101e-09
in O 0 1.7824387799070252e-10
Japanese O 0 2.057814585398887e-09
, O 0 2.2043779995817303e-11
Utah O 0 6.183183409724791e-10
Mormon O 0 2.0814638901356375e-09
, O 0 8.115554755994125e-11
and O 0 2.361748574486455e-10
African O 0 1.2950580607906659e-09
American O 0 9.595246375226907e-09
patients O 0 3.887539179459054e-08
. O 0 1.7105147520624087e-08

These O 0 3.633826572979615e-09
assays O 0 1.2911242208701879e-07
should O 0 2.9856325745036827e-10
facilitate O 0 2.2085203110755458e-10
screening O 0 6.858760670525044e-09
for O 0 1.036452590419401e-09
A B-Disease 1 0.9999959468841553
- I-Disease 1 0.9999818801879883
T I-Disease 1 1.0
heterozygotes O 0 1.070734356289904e-06
in O 0 3.9956751796133005e-10
the O 0 9.48688627655514e-11
populations O 0 3.933759984420249e-09
studied O 0 1.2358291279213063e-08
. O 0 1.5305803291454367e-09
. O 0 2.4243018259539895e-08

The O 0 9.58873442868935e-07
von B-Disease 1 0.9989495873451233
Hippel I-Disease 1 0.9996675252914429
- I-Disease 1 0.9997045397758484
Lindau I-Disease 1 0.9997945427894592
tumor I-Disease 0 2.6236288249492645e-05
suppressor O 0 1.3000328635826008e-06
gene O 0 3.217751896045229e-07
is O 0 1.0847851505957351e-09
required O 0 4.78873274367686e-10
for O 0 8.960443498295945e-11
cell O 0 8.271402407444839e-08
cycle O 0 8.968184062041473e-08
exit O 0 4.0454477101548036e-08
upon O 0 3.5320355529222525e-09
serum O 0 7.298372679542808e-07
withdrawal O 0 1.742767267387535e-06
. O 0 1.2112609226733184e-07

The O 0 1.3393833597774574e-08
inactivation O 0 1.026386598823592e-06
of O 0 1.7279351560706147e-10
the O 0 5.187039686660455e-09
von B-Disease 1 0.9998812675476074
Hippel I-Disease 1 0.9999898672103882
- I-Disease 1 0.9999890327453613
Lindau I-Disease 1 0.999996542930603
( I-Disease 0 1.751376572656227e-07
VHL I-Disease 0 0.0001221289421664551
) I-Disease 0 1.4765175748721049e-08
tumor I-Disease 0 3.1003804679130553e-07
suppressor O 0 8.165233680301753e-07
gene O 0 6.995514354457555e-07
predisposes O 0 7.556736250080576e-07
affected O 0 4.073016590666612e-09
individuals O 0 1.0567430958063895e-10
to O 0 7.350359210178681e-11
the O 0 5.704358652103281e-10
human O 0 1.6319269491305022e-07
VHL B-Disease 1 0.9999856948852539
cancer I-Disease 1 0.9999967813491821
syndrome I-Disease 1 0.9998791217803955
and O 0 1.9278273422074221e-10
is O 0 5.425234220202135e-11
associated O 0 3.804776493865347e-09
with O 0 5.251667545280725e-09
sporadic B-Disease 1 0.9989537000656128
renal I-Disease 1 0.999997615814209
cell I-Disease 1 0.9999996423721313
carcinomas I-Disease 1 1.0
( O 0 2.364303327340167e-06
RCC B-Disease 1 0.6666064858436584
) O 0 8.164129638998929e-08
and O 0 2.309484514739779e-08
brain B-Disease 0 1.3300882528710645e-05
hemangioblastomas I-Disease 0 8.190784137696028e-05
. O 0 3.285408922693023e-07

VHL O 0 0.046026501804590225
- O 0 0.1189287081360817
negative O 0 7.528343849116936e-05
786 O 0 2.2718126274412498e-05
- O 0 3.577989264158532e-05
0 O 0 2.845867470568919e-07
RCC B-Disease 0 2.8170334189780988e-06
cells O 0 5.1400252942812585e-08
are O 0 2.590546110958769e-10
tumorigenic O 0 1.8878974117342295e-07
in O 0 6.671616037401407e-10
nude O 0 5.256026724964613e-06
mice O 0 2.544090023093304e-07
which O 0 2.7449750805708106e-10
is O 0 1.8824788949878268e-11
suppressed O 0 1.8656939881900314e-10
by O 0 8.976141878391797e-12
the O 0 3.033446410727336e-11
reintroduction O 0 9.287126623291897e-09
of O 0 9.399285794131629e-10
VHL B-Disease 0 1.2061091183568351e-05
. O 0 3.5489058802795626e-08

Remarkably O 0 1.1956653906963766e-06
, O 0 2.2991109016601285e-09
this O 0 4.15645157181288e-11
occurs O 0 2.6078228465564735e-10
without O 0 1.670044796897585e-10
affecting O 0 7.0707434352002e-10
the O 0 5.963286114907262e-11
growth O 0 3.876992948903535e-09
rate O 0 4.314132162619444e-09
and O 0 4.1932421424029087e-10
cell O 0 1.8002655366444742e-08
cycle O 0 1.4320947983037513e-08
profile O 0 3.194449504917429e-08
of O 0 5.979536310540823e-12
these O 0 4.8013693715320827e-11
cells O 0 1.896854451288732e-09
in O 0 2.2969315338627894e-10
culture O 0 2.73116960158859e-08
. O 0 3.184570118719421e-08

The O 0 8.642963678084925e-08
786 O 0 1.995935917875613e-06
- O 0 1.51334143083659e-06
0 O 0 7.418678116266619e-09
cell O 0 1.976424357508222e-08
line O 0 6.4600067517517346e-09
, O 0 2.9662695910648296e-11
like O 0 1.213203842942434e-10
many O 0 1.715849129446667e-10
cancer B-Disease 0 6.322842249772975e-09
cells O 0 1.2183454245473513e-09
, O 0 7.776761179467684e-11
fails O 0 1.5142791909283915e-08
to O 0 6.305578281740054e-11
exit O 0 3.872720810704777e-09
the O 0 1.1944654987328107e-10
cell O 0 7.325205331198958e-08
cycle O 0 2.7939650593111764e-08
upon O 0 2.8422848519227273e-09
serum O 0 3.794975782511756e-07
withdrawal O 0 7.657313858544512e-07
. O 0 7.756728592767104e-08

Here O 0 3.2602514465907007e-08
, O 0 3.4971020523855145e-10
it O 0 4.7161875099677175e-11
is O 0 6.5968511035741084e-12
shown O 0 3.1328200450486676e-11
that O 0 4.174262064476908e-12
reintroduction O 0 2.2263514642961724e-10
of O 0 2.949343460428855e-12
the O 0 3.973208567709108e-11
wild O 0 6.1702745135505666e-09
- O 0 8.911248983167752e-07
type O 0 1.6440378658444388e-07
VHL B-Disease 0 1.5609126648996607e-06
gene O 0 3.17079980050039e-08
restores O 0 2.4856865010747242e-08
the O 0 4.84007937895381e-11
ability O 0 2.3608941468467037e-09
of O 0 4.5543785409662974e-10
VHL O 0 5.909871106268838e-05
- O 0 3.87507607229054e-05
negative O 0 1.7047721485141665e-05
RCC B-Disease 0 4.484922828851268e-05
cancer I-Disease 0 5.064923698228085e-07
cells O 0 4.273486009509497e-09
to O 0 8.967829950856654e-11
exit O 0 4.618361693076167e-09
the O 0 2.52065146533198e-10
cell O 0 1.1486672946148246e-07
cycle O 0 2.0384655385896622e-07
and O 0 5.098252486845922e-09
enter O 0 1.0952060591762347e-07
G0 O 0 1.0105886758537963e-05
/ O 0 1.6276030123663077e-07
quiescence O 0 2.734939243964618e-06
in O 0 1.7776839555949664e-08
low O 0 7.662163739041716e-07
serum O 0 3.8581770240853075e-06
. O 0 1.2404677818267373e-07

Both O 0 4.55381012898215e-07
VHL O 0 0.00019827907090075314
- O 0 3.3595351851545274e-05
positive O 0 1.67830975783545e-07
and O 0 1.1868270810566628e-08
VHL O 0 3.6140107113169506e-05
- O 0 1.4417838428926188e-05
negative O 0 2.9219049793027807e-06
RCC B-Disease 0 6.787668098695576e-06
cells O 0 1.9418015995142923e-07
exit O 0 8.961789177419632e-08
the O 0 6.875562341690511e-10
cell O 0 2.24545559035505e-07
cycle O 0 5.3463200089254315e-08
by O 0 5.709682171506358e-10
contact O 0 2.4065354864433175e-07
inhibition O 0 7.738699423498474e-07
. O 0 1.524781794159935e-07

The O 0 5.057282805864816e-07
cyclin O 0 0.0021788491867482662
- O 0 2.3102586055756547e-05
dependent O 0 2.352585170228849e-06
kinase O 0 3.333709400976659e-06
inhibitor O 0 3.503796506265644e-07
, O 0 6.752048919977938e-10
p27 O 0 2.1194563259996357e-07
, O 0 7.474459939871281e-11
accumulates O 0 1.5438269551637518e-09
upon O 0 1.3840034673862078e-10
serum O 0 1.1066665805969933e-08
withdrawal O 0 8.776304127877665e-09
, O 0 3.2582575526518553e-11
only O 0 1.4414730693801392e-11
in O 0 1.915905628591119e-11
the O 0 3.154387515080792e-11
presence O 0 7.702144477761408e-10
of O 0 1.4163424773283584e-11
VHL B-Disease 0 1.4807429238317127e-07
, O 0 2.7863504906133763e-11
as O 0 2.3451299929755365e-11
a O 0 1.9608988044428344e-11
result O 0 1.395739218645886e-10
of O 0 4.211416805566248e-12
the O 0 4.518330501412926e-11
stabilization O 0 4.663310182451141e-09
of O 0 4.9834247839442014e-11
the O 0 8.864302070143992e-10
protein O 0 6.950806152872246e-08
. O 0 2.48523139845247e-08

We O 0 1.804972526997517e-08
propose O 0 4.919728180396987e-09
that O 0 9.917999581332548e-12
the O 0 4.4222394843251855e-12
loss O 0 7.875443353011491e-11
of O 0 2.73296186029115e-12
wild O 0 3.042517793261368e-09
- O 0 4.7179587454593275e-06
type O 0 9.621491017242079e-07
VHL B-Disease 0 2.385472953392309e-06
gene O 0 6.219655546146896e-08
results O 0 2.9505744514324306e-09
in O 0 2.15008809367756e-11
a O 0 5.633469732369001e-11
specific O 0 1.723268971964842e-09
cellular O 0 1.4794726155287208e-07
defect O 0 1.6983068462650408e-07
in O 0 3.357996103403593e-10
serum O 0 1.7290355458499107e-07
- O 0 3.590500341488223e-07
dependent O 0 9.9662952379731e-07
growth O 0 1.255822290602282e-08
control O 0 5.649217094116921e-09
, O 0 1.0193679927938959e-10
which O 0 5.824016824362843e-10
may O 0 2.4898560990749274e-09
initiate O 0 6.793661633253123e-09
tumor B-Disease 0 8.964386921661571e-08
formation O 0 2.3662240167254822e-08
. O 0 5.056091723076861e-08

This O 0 9.478648088645514e-09
is O 0 6.066898650125552e-10
corrected O 0 6.202427904611341e-09
by O 0 7.473572975758014e-12
the O 0 5.586557258463465e-12
reintroduction O 0 1.0229405100758981e-09
of O 0 2.0650866433546966e-11
wild O 0 6.474364599995397e-09
- O 0 2.344111453567166e-05
type O 0 1.9759756469284184e-05
VHL B-Disease 0 2.771047547867056e-05
, O 0 1.77933512368611e-09
implicating O 0 1.3259402464882442e-07
VHL B-Disease 0 5.821512445436383e-07
as O 0 1.3859187408815643e-10
the O 0 2.395332196480915e-11
first O 0 2.739399540541143e-10
tumor B-Disease 0 3.4594942466270595e-09
suppressor O 0 7.053963191339108e-09
involved O 0 1.759249301791499e-09
in O 0 1.034445584746635e-10
the O 0 3.2149151396598796e-11
regulation O 0 8.486882863145695e-10
of O 0 1.0520266949254342e-11
cell O 0 1.2852502173643643e-08
cycle O 0 1.5237070272178244e-08
exit O 0 2.4016399535753408e-08
, O 0 2.0158960611915688e-10
which O 0 4.92949459030001e-10
is O 0 2.6888238857658564e-10
consistent O 0 1.120292081324692e-09
with O 0 2.0401867695252207e-11
its O 0 1.8621636177496015e-10
gatekeeper O 0 3.1632129804393117e-08
function O 0 1.2059072629355683e-09
in O 0 6.474484282037452e-10
the O 0 1.5508954120946328e-09
kidney O 0 2.090423549816478e-07
. O 0 7.150834591129751e-09
. O 0 6.513333516977582e-08

Piebaldism B-Disease 1 1.0
with O 0 4.31726330134552e-05
deafness B-Disease 1 1.0
: O 0 3.75788244966202e-09
molecular O 0 5.616469955782577e-09
evidence O 0 1.4095956624160522e-09
for O 0 3.659271843869938e-11
an O 0 4.3800535420857045e-10
expanded O 0 0.00011434732732595876
syndrome O 1 0.997058629989624
. O 0 1.2998080478610063e-07

In O 0 6.018150422448798e-09
a O 0 1.6069803265850169e-09
South O 0 8.523679539962359e-09
African O 0 1.9574217802187377e-09
girl O 0 1.440400687613419e-08
of O 0 3.742599632983179e-11
Xhosa O 0 1.5518259033342474e-07
stock O 0 2.9255492250968018e-08
with O 0 3.3547697952940325e-10
severe O 0 1.2903991830626182e-07
piebaldism B-Disease 0 1.6475880784128094e-06
and O 0 6.657369766571719e-09
profound O 0 3.167396869230288e-07
congenital O 1 0.9998341798782349
sensorineural B-Disease 1 0.999956488609314
deafness I-Disease 1 1.0
we O 0 1.0536346053413581e-06
identified O 0 2.472503624062483e-08
a O 0 2.9168320536676617e-10
novel O 0 6.817272524273221e-09
missense O 0 3.149123699586198e-07
substitution O 0 1.1628199736435363e-08
at O 0 2.130779774844882e-09
a O 0 3.5941344345147286e-10
highly O 0 1.470830568450765e-09
conserved O 0 6.875250591065196e-09
residue O 0 7.880382923985962e-08
in O 0 4.4192760562111744e-10
the O 0 3.3211414174338927e-10
intracellular O 0 2.773295726399283e-08
kinase O 0 1.8521586042652416e-08
domain O 0 2.2763426699157208e-09
of O 0 2.343135928339901e-11
the O 0 2.992388281608527e-10
KIT O 0 7.154281433940923e-07
proto O 0 3.462755330474465e-06
- O 0 4.2449093484719924e-07
oncogene O 0 2.4293092337757116e-06
, O 0 3.0472102618972485e-09
R796G O 0 7.224703608699201e-07
. O 0 7.447659555737118e-08

Though O 0 6.571702897417708e-07
auditory B-Disease 0 2.005097258006572e-06
anomalies I-Disease 0 1.396126208419446e-06
have O 0 2.644837682197476e-09
been O 0 4.386240259890428e-10
observed O 0 1.244910841080582e-09
in O 0 1.5803404418424094e-10
mice O 0 9.335505701812963e-09
with O 0 2.7223512333307553e-10
dominant O 0 4.708959295385284e-06
white O 0 2.973582695631194e-07
spotting O 0 8.340755812241696e-06
( O 0 1.1258721732687604e-09
W O 0 1.2432607036316767e-05
) O 0 3.2489130830093416e-10
due O 0 3.34346328401125e-10
to O 0 2.766245565943848e-10
KIT O 0 2.3909005903988145e-06
mutations O 0 2.276979103044141e-06
, O 0 6.450476597308352e-09
deafness B-Disease 1 1.0
is O 0 4.502883399482016e-09
not O 0 8.209389834590297e-10
typical O 0 3.411490201443712e-09
in O 0 9.364605757511413e-10
human O 0 8.194157352647835e-09
piebaldism B-Disease 0 8.556710781704169e-06
. O 0 8.869282908108289e-08

Thus O 0 2.4438378432023455e-08
, O 0 2.4751339866568856e-10
the O 0 5.5553520117435085e-11
occurrence O 0 1.4097334855023291e-08
of O 0 3.108536483775737e-10
sensorineural B-Disease 1 0.9338279366493225
deafness I-Disease 1 1.0
in O 0 8.654936323182483e-09
this O 0 2.590595515883365e-10
patient O 0 4.584125523621196e-09
extends O 0 2.080126293435569e-09
considerably O 0 1.3227234862966952e-09
the O 0 2.270287083327993e-11
phenotypic O 0 1.4401479120351723e-08
range O 0 1.5269587816391095e-09
of O 0 3.4283811900515104e-11
piebaldism B-Disease 0 1.6992514417779603e-07
due O 0 2.28200258689526e-09
to O 0 4.315166557411487e-10
KIT O 0 6.271510244459932e-08
gene O 0 2.8933524021113044e-08
mutation O 0 7.622412034891113e-09
in O 0 3.115200458703171e-11
humans O 0 2.1968325769616825e-10
and O 0 2.3520521641451353e-10
tightens O 0 2.981157649628585e-07
the O 0 8.191070738350348e-11
clinical O 0 4.338913228707497e-09
similarity O 0 1.6387876611290153e-09
between O 0 5.356999219219283e-11
piebaldism B-Disease 0 2.6553223619885102e-08
and O 0 3.617937199829058e-11
the O 0 3.3366176575150286e-12
various O 0 3.5335952913717605e-11
forms O 0 8.361559444836075e-09
of O 0 1.9551951169205495e-08
Waardenburg B-Disease 1 0.9999645948410034
syndrome I-Disease 1 0.9860100746154785
. O 0 8.566185982772367e-09
. O 0 4.3986435827036985e-08

Cycloheximide O 0 1.8609798644320108e-05
facilitates O 0 2.1962905805139599e-07
the O 0 8.228562276002549e-10
identification O 0 1.1941683197846942e-08
of O 0 1.9800559802884976e-10
aberrant O 0 3.264177905748511e-08
transcripts O 0 9.200421402510983e-08
resulting O 0 3.329311715205563e-09
from O 0 2.891810124694416e-10
a O 0 1.7523363315952167e-10
novel O 0 1.5470908110160053e-08
splice O 0 1.0602029760775622e-05
- O 0 5.350533456294215e-07
site O 0 3.032536710634304e-08
mutation O 0 3.885552501969869e-08
in O 0 2.2989346537549693e-10
COL17A1 O 0 9.976301384995168e-08
in O 0 6.314520434314019e-11
a O 0 3.6610400822034705e-10
patient O 0 1.463828969150427e-08
with O 0 2.722690295442476e-09
generalized O 0 1.32948580358061e-05
atrophic B-Disease 1 0.9959927797317505
benign I-Disease 1 0.9891908168792725
epidermolysis I-Disease 1 0.988822340965271
bullosa I-Disease 1 0.9600785970687866
. O 0 1.5512592653976753e-05

Patients O 0 3.7978708860464394e-05
with O 0 2.1829742991030798e-07
generalized O 0 5.779542698292062e-05
atrophic B-Disease 1 0.995662271976471
benign I-Disease 1 0.8348945379257202
epidermolysis I-Disease 1 0.8697656393051147
bullosa I-Disease 0 0.06109470874071121
often O 0 7.992731525519048e-07
show O 0 2.1142176365174237e-07
decreased O 0 4.996347513497312e-08
expression O 0 1.5369701955592063e-08
of O 0 8.624594372008687e-10
type O 0 6.831540986240725e-07
XVII O 0 1.472207259212155e-06
collagen O 0 3.3660830922599416e-07
, O 0 1.60180246844277e-09
a O 0 4.7047725715287925e-09
transmembrane O 0 1.0407974286863464e-06
hemidesmosomal O 0 5.031420755585714e-07
protein O 0 1.3293430356497993e-08
encoded O 0 8.015324404198054e-09
by O 0 2.7823756632017194e-09
COL17A1 O 0 8.96182973519899e-06
. O 0 1.1830012880409413e-07

This O 0 2.0894960428563536e-08
report O 0 6.383551909294738e-09
documents O 0 2.663284259796228e-09
a O 0 1.5210978310253864e-10
novel O 0 4.070670467370974e-09
splice O 0 8.53650453791488e-06
- O 0 5.462418926072132e-07
site O 0 2.591596448553446e-08
mutation O 0 2.0777404685645706e-08
in O 0 9.326401456677402e-11
COL17A1 O 0 6.814051545234179e-08
in O 0 3.8326463530635735e-11
a O 0 8.135003781717387e-11
patient O 0 9.441820658651068e-09
with O 0 1.2840439822525695e-09
generalized O 0 2.8015697353112046e-06
atrophic B-Disease 1 0.9780540466308594
benign I-Disease 0 0.0034538842737674713
epidermolysis I-Disease 0 0.0050116111524403095
bullosa I-Disease 0 0.04186946526169777
, O 0 8.519860372757648e-09
and O 0 2.2612862971005399e-10
applies O 0 2.134212806481628e-09
a O 0 5.410044287557092e-11
new O 0 2.5775540035688493e-10
methodology O 0 1.729370313618972e-09
to O 0 3.367281453670046e-11
define O 0 3.8338492380773914e-09
and O 0 1.6314484485580039e-10
characterize O 0 2.1621819001893527e-08
the O 0 8.565234077551054e-10
resulting O 0 2.48291449622684e-08
mRNA O 0 1.2113289926674042e-07
splice O 0 4.063562300871126e-06
variants O 0 8.402713547184248e-07
. O 0 1.6899539900805394e-07

Mutational O 0 0.000421464181272313
analysis O 0 1.4889860722178128e-06
of O 0 3.3242040231584724e-09
COL17A1 O 0 3.628610556916101e-06
identified O 0 1.2021821760299645e-07
a O 0 8.18673662195124e-09
maternally O 0 2.7969620077783475e-06
inherited O 0 9.26315635751962e-07
G O 0 1.5542311757599236e-06
- O 0 4.012336205505562e-07
to O 0 8.266415107982539e-09
- O 0 2.9285175173754396e-07
T O 0 1.9694932973379764e-07
transversion O 0 3.4131190318476e-08
at O 0 1.5991245827517986e-10
the O 0 3.289818070739692e-11
- O 0 1.0373984338230002e-08
1 O 0 5.589131379934997e-10
position O 0 3.6527625368876215e-09
of O 0 9.623847552209241e-11
exon O 0 2.0395368949266413e-07
32 O 0 1.194177912111627e-07
. O 0 7.091225029398629e-08

This O 0 4.979261092330489e-08
acceptor O 0 5.344699047782342e-07
splice O 0 7.149130397010595e-06
- O 0 8.426145541307051e-07
site O 0 1.9034807507978257e-08
mutation O 0 2.8033387167170076e-08
led O 0 4.847851564626637e-10
to O 0 5.4702575802423326e-11
the O 0 2.2578116459781583e-11
formation O 0 1.1484192069532995e-10
of O 0 4.802695133948598e-12
aberrant O 0 8.962721675942475e-10
transcripts O 0 1.7691962339583256e-09
present O 0 1.62426669336746e-10
at O 0 7.170279370249943e-10
extremely O 0 7.639396670811038e-09
low O 0 9.407002039552026e-07
levels O 0 5.578778541348584e-07
. O 0 9.919284593706834e-08

Based O 0 8.634593484657671e-08
on O 0 1.7524943718427721e-09
our O 0 3.410798588010522e-10
recent O 0 1.0308790487911779e-09
finding O 0 2.363917728231968e-09
that O 0 4.785454255085142e-10
cycloheximide O 0 5.729410759158782e-07
stabilized O 0 1.7947614878721652e-06
mutant O 0 2.489152848283993e-07
COL17A1 O 0 2.842994888396788e-07
transcripts O 0 1.3853941993602348e-08
in O 0 2.3110026392547667e-10
keratinocytes O 0 4.889514926276206e-08
homozygous O 0 4.1712137743843414e-08
for O 0 1.169560837066541e-10
a O 0 3.795510850057582e-10
frameshift O 0 1.7090364963223692e-06
mutation O 0 8.370307824634438e-08
, O 0 2.234170071169217e-10
the O 0 5.61198865156598e-11
effects O 0 8.027996756254652e-08
of O 0 1.7231356966296296e-11
the O 0 6.801861851535307e-11
splice O 0 6.987097003730014e-05
- O 0 1.981721027277672e-07
site O 0 1.1491346540992708e-08
mutation O 0 4.405173559263176e-09
on O 0 7.627130871323828e-11
splicing O 0 1.676301408792824e-08
of O 0 3.2994072751701964e-11
COL17A1 O 0 3.110805479877854e-08
transcripts O 0 5.138101499824188e-09
were O 0 5.4906308666335946e-11
determined O 0 4.360098670996848e-10
using O 0 1.0140743800235441e-09
reverse O 0 5.961828009048986e-08
transcriptase O 0 3.6654392943091807e-07
polymerase O 0 3.643051371682304e-08
chain O 0 7.146583413941698e-08
reaction O 0 7.095389165101551e-09
of O 0 1.0838167169291424e-10
total O 0 2.3935889381654363e-10
RNA O 0 1.053307219223143e-08
from O 0 3.356279976163279e-10
keratinocytes O 0 1.0393795690788465e-07
incubated O 0 4.0100097464801365e-08
for O 0 4.794609154146201e-10
2 O 0 2.7782287581601395e-09
. O 0 2.242274987906967e-08

5 O 0 1.3819703781337012e-07
h O 0 1.7584426359462668e-07
in O 0 3.3075497896106754e-10
the O 0 3.521262795236346e-11
presence O 0 1.0681953099833663e-09
or O 0 2.130999154914548e-09
absence O 0 1.6135099922820473e-09
of O 0 5.961694332645706e-11
10 O 0 7.57501505965763e-10
microg O 0 3.9127988316067785e-07
cycloheximide O 0 8.980351253740082e-07
per O 0 3.909116585987249e-08
ml O 0 3.2934599403233733e-06
. O 0 9.204880058177878e-08

Using O 0 2.6530441843419794e-08
this O 0 4.908890516297504e-10
approach O 0 2.084782657618689e-08
, O 0 1.0912785119998603e-09
an O 0 3.47498724240225e-10
abnormally O 0 8.091532066600848e-08
spliced O 0 1.3916092029830907e-06
transcript O 0 1.612978735465731e-06
was O 0 9.242014264998488e-09
identified O 0 3.383302082937689e-09
that O 0 4.89911063106252e-12
contains O 0 2.6367948623151616e-12
an O 0 7.224248976811509e-12
extra O 0 1.4626970468167855e-10
264 O 0 2.9110738819504434e-10
bases O 0 3.1392097255000806e-10
upstream O 0 3.9057890255378425e-10
from O 0 3.71483468986078e-11
exon O 0 1.289424389483429e-08
32 O 0 2.6364013194779545e-09
, O 0 4.520399332630376e-11
resulting O 0 6.68089916722181e-10
in O 0 3.8655825762567986e-10
a O 0 5.962030424910836e-09
premature O 0 2.1259445759369555e-07
termination O 0 2.695577450140263e-07
codon O 0 6.319938847809681e-07
27 O 0 1.2314972153149029e-08
bp O 0 7.234687871005008e-08
downstream O 0 3.7495198057513335e-09
from O 0 1.1092160523418215e-10
the O 0 1.2832647444671608e-10
cryptic O 0 7.539274804457818e-08
splice O 0 3.3807382351369597e-06
site O 0 2.991789642692311e-07
. O 0 1.0308819753390708e-07

Three O 0 4.611970361168005e-09
other O 0 2.9013455526971654e-10
splice O 0 1.0362084168491492e-07
variants O 0 9.668843503618518e-09
, O 0 3.129314515848414e-11
including O 0 1.2937310077398845e-11
one O 0 1.758459176881555e-11
derived O 0 1.5790418972372322e-10
from O 0 4.190143891580345e-12
the O 0 4.591390202063339e-12
skipping O 0 1.8277569457936238e-09
of O 0 6.9794218147956055e-12
exon O 0 2.9927211819824606e-09
32 O 0 1.9804915485366337e-09
, O 0 5.4197115545440155e-11
were O 0 4.953727428258503e-10
also O 0 2.0940993383788964e-09
identified O 0 8.020145259024503e-08
. O 0 5.6180379459647156e-08

These O 0 2.7780657774201245e-08
results O 0 9.862101357782649e-09
indicate O 0 1.9002148743396674e-09
the O 0 2.173906193947417e-11
usefulness O 0 1.2228805745806426e-09
of O 0 6.302652844070167e-12
cycloheximide O 0 1.5256349072956255e-08
treatment O 0 2.1556583185144973e-09
in O 0 2.407437964258019e-11
evaluating O 0 3.187898833800773e-09
the O 0 6.167491517494739e-11
abnormal O 0 2.194936454813501e-09
processing O 0 9.916722998326577e-10
of O 0 1.9436471529465926e-11
mRNA O 0 1.3239703777756517e-09
due O 0 7.029930526591954e-10
to O 0 1.564194745951042e-10
splice O 0 1.7411027783964528e-06
- O 0 6.840355837312018e-08
site O 0 5.7186220203675475e-09
mutations O 0 1.5045140244751565e-08
, O 0 5.6202365678048594e-11
because O 0 2.440481428056529e-10
( O 0 2.414984878740256e-11
i O 0 4.0635786402454244e-10
) O 0 2.6968455246745293e-11
aberrant O 0 8.985623911605956e-10
splicing O 0 2.5981840678923618e-08
often O 0 2.1512798209499806e-09
generates O 0 4.599934655402649e-09
a O 0 1.3724771319445495e-09
premature O 0 7.828636938711497e-08
termination O 0 4.489575999855333e-08
codon O 0 1.7687895592644054e-07
, O 0 2.0226052777072567e-10
( O 0 4.066964473525836e-11
ii O 0 6.503768634757989e-10
) O 0 2.1258982421668016e-11
transcripts O 0 2.3313915242795247e-09
with O 0 1.0649479215141255e-10
premature O 0 8.389868355607177e-09
termination O 0 2.8829834075594363e-09
codons O 0 1.780646563531718e-08
can O 0 6.38966324295609e-10
occur O 0 5.544948944447015e-10
at O 0 5.574481987125068e-10
low O 0 2.141635313535062e-08
or O 0 2.561207956830458e-08
undetectable O 0 4.240124781063059e-06
levels O 0 1.029040852529306e-08
due O 0 8.914217697331139e-10
to O 0 4.0159758851743277e-10
nonsense O 0 1.33589111328547e-07
- O 0 2.9674682267000208e-08
mediated O 0 3.8640237676190736e-08
mRNA O 0 1.5610779335872849e-09
decay O 0 7.918736777412505e-10
, O 0 1.3529123134292664e-11
and O 0 1.2553317760288785e-11
( O 0 3.770081469234299e-12
iii O 0 2.7315419370843586e-10
) O 0 5.284176568531862e-11
the O 0 5.846953476940087e-11
levels O 0 6.514308537042268e-10
of O 0 4.608988429626037e-13
these O 0 2.4355127289932277e-12
transcripts O 0 6.423683251988166e-10
can O 0 8.270790302633557e-11
be O 0 1.911026024925544e-11
increased O 0 6.324717832795201e-11
by O 0 6.357642745591363e-10
cycloheximide O 0 2.0335194221843267e-06
. O 0 4.8610047542752e-08

A O 0 1.2409836358528992e-07
deletion O 0 1.5801242625457235e-06
mutation O 0 2.397768525952415e-07
in O 0 6.550354147982773e-10
COL17A1 O 0 2.511277443772997e-07
in O 0 3.421066763209524e-10
five O 0 1.0112138904005974e-09
Austrian O 0 2.380043753191785e-07
families O 0 6.269439190020876e-09
with O 0 3.5911007500999403e-09
generalized O 0 2.6000388970714994e-05
atrophic B-Disease 1 0.9987175464630127
benign I-Disease 1 0.9766407608985901
epidermolysis I-Disease 1 0.9610921144485474
bullosa I-Disease 0 0.04462382197380066
represents O 0 2.0646925236178504e-07
propagation O 0 7.03169362736844e-08
of O 0 5.708070682786115e-10
an O 0 8.87824536111026e-10
ancestral O 0 9.855012876869296e-07
allele O 0 3.729505988303572e-05
. O 0 5.349349976313533e-07

Patients O 0 3.2606476452201605e-05
with O 0 2.364755857797718e-07
generalized O 0 6.861417932668701e-05
atrophic B-Disease 1 0.999474823474884
benign I-Disease 1 0.9719957113265991
epidermolysis I-Disease 1 0.9951777458190918
bullosa I-Disease 1 0.9143520593643188
, O 0 1.3487817085433562e-08
a O 0 8.637863757599007e-10
usually O 0 3.107275325930914e-09
nonlethal O 0 1.7230551918601122e-07
form O 0 3.025211370299985e-08
of O 0 8.191813449798246e-09
junctional B-Disease 0 0.020748231559991837
epidermolysis I-Disease 0 0.41954487562179565
bullosa I-Disease 0 0.010036162100732327
, O 0 1.4885230825711915e-09
have O 0 1.258528281589122e-10
generalized O 0 4.7707295891541435e-09
blistering B-Disease 0 6.603422519901869e-08
, O 0 1.792298975900053e-09
nail B-Disease 1 0.9707911014556885
dystrophy I-Disease 0 1.2783986676367931e-05
, O 0 6.192274248917329e-09
patchy B-Disease 0 3.279320662841201e-05
alopecia I-Disease 1 0.9998791217803955
, O 0 3.340776189020289e-08
and O 0 2.5357962840644177e-07
dental B-Disease 1 0.999572217464447
abnormalities I-Disease 1 0.9984173774719238
. O 0 1.022861056299007e-06

Skin B-Disease 1 0.960219144821167
fragility I-Disease 0 1.3717229194298852e-05
in O 0 4.08443473487452e-10
most O 0 8.381351168651463e-11
cases O 0 7.223374676179617e-10
is O 0 1.1136127436861543e-10
due O 0 5.603573716150834e-10
to O 0 1.247027758832786e-10
mutations O 0 5.524208646079387e-09
in O 0 2.4215620827994222e-11
the O 0 4.4869240267697563e-11
gene O 0 1.9832519626561407e-08
encoding O 0 6.975987787427584e-08
type O 0 1.7840445707406616e-06
XVII O 0 2.6149889436055673e-06
collagen O 0 8.453656619167305e-07
( O 0 2.9276745472373022e-09
COL17A1 O 0 1.894405841085245e-06
) O 0 8.868044076848491e-09
. O 0 3.480595722749058e-08

Recently O 0 1.4389172520168358e-06
, O 0 1.0364803459950167e-09
we O 0 6.26556251326349e-10
reported O 0 8.589692290783546e-10
five O 0 1.3348780414368377e-10
Austrian O 0 8.134255580216632e-08
families O 0 1.0611508338698172e-09
with O 0 1.1826550849747264e-09
generalized O 0 6.396061053237645e-06
atrophic B-Disease 1 0.9956320524215698
benign I-Disease 0 0.037051599472761154
epidermolysis I-Disease 0 0.012487318366765976
bullosa I-Disease 0 0.030971737578511238
who O 0 5.854706728314341e-07
share O 0 3.172360152348119e-08
the O 0 7.441419147546924e-10
same O 0 1.3708216783925309e-08
COL17A1 O 0 2.7811312975245528e-05
mutation O 0 4.8258816605084576e-06
. O 0 2.3897669620964734e-07

Affected O 0 2.1978179631787498e-07
individuals O 0 1.7703608579111574e-09
in O 0 7.771200349893093e-11
three O 0 5.6972777190411605e-11
families O 0 5.0768795417655e-11
are O 0 6.427500892636218e-12
homozygous O 0 7.422693570902084e-10
for O 0 1.2935114784839996e-11
4003delTC O 0 7.891570064089137e-09
, O 0 2.3686498942798728e-11
whereas O 0 6.980344080531609e-11
those O 0 1.5397259855998158e-11
in O 0 2.101563541245799e-11
two O 0 7.35156518993918e-11
others O 0 6.178644818000123e-10
are O 0 2.4709406742928763e-10
compound O 0 6.95221160640358e-08
heterozygotes O 0 5.383112693380099e-06
. O 0 2.192611390228194e-07

To O 0 9.08678021716014e-09
determine O 0 5.260991198241527e-09
if O 0 7.582213190637788e-10
the O 0 1.41967739647475e-11
occurrence O 0 1.213287692536369e-09
of O 0 9.40923120668069e-12
4003delTC O 0 1.7299418786365095e-08
in O 0 3.211066829100773e-11
these O 0 4.308322101853612e-11
unrelated O 0 2.4719550850704763e-09
families O 0 2.0558990621033502e-10
signifies O 0 1.2962066142652162e-10
propagation O 0 2.1917975767671294e-10
of O 0 6.698001962096578e-12
an O 0 1.5690346591434867e-11
ancestral O 0 1.2155188855444976e-08
allele O 0 2.206990359354677e-07
or O 0 4.603445624695723e-09
a O 0 1.3820179445289682e-09
mutational O 0 1.7074464722099947e-06
hot O 0 2.009782917866687e-07
spot O 0 1.6153281023889576e-07
, O 0 7.892017594990364e-10
haplotypes O 0 8.129524786681941e-08
were O 0 1.4933859704413521e-09
determined O 0 3.733633846536577e-09
for O 0 1.8772126908483955e-10
polymorphisms O 0 1.3066537007944135e-07
both O 0 1.4555037175512098e-09
within O 0 9.408056556026168e-10
and O 0 8.719840849380489e-09
flanking O 0 5.331083684723126e-06
COL17A1 O 0 0.0001151935284724459
. O 0 3.3169573043778655e-07

Five O 0 6.593077728211938e-08
intragenic O 0 5.691588853551366e-07
polymorphisms O 0 9.64296759775607e-07
were O 0 2.299426649088332e-09
chosen O 0 1.884417066833066e-09
based O 0 1.1451191106459646e-09
on O 0 3.877700660570582e-10
their O 0 2.7683002556955216e-09
informativeness O 0 3.1238917017617496e-06
. O 0 7.11595191660308e-08

One O 0 9.77531833257217e-09
of O 0 1.6828854282335826e-11
these O 0 2.7330205806808117e-11
, O 0 1.78757546959174e-11
not O 0 6.904720545319876e-11
previously O 0 4.272451281650547e-09
reported O 0 2.30583041549437e-09
, O 0 3.391724054391254e-11
was O 0 1.0406402406459847e-09
2988 O 0 2.362715179060615e-08
A O 0 3.4856281749817697e-10
or O 0 1.571773933228826e-09
C O 0 4.005505260806785e-09
that O 0 8.531083825480401e-12
introduces O 0 2.445924296434754e-10
a O 0 6.182579448399395e-11
new O 0 1.9629203817927987e-10
restriction O 0 2.056891323931609e-10
site O 0 6.173638267270576e-10
for O 0 1.6913655198624866e-10
Eco0109 O 0 2.9847819860151503e-07
I O 0 1.1608127437057192e-07
. O 0 3.336191412017797e-08

All O 0 9.28427557056466e-09
the O 0 7.757624542747976e-10
4003delTC O 0 1.2489623202327493e-07
alleles O 0 2.728649484140533e-08
showed O 0 2.3256843117991366e-09
the O 0 5.438513788619259e-12
same O 0 8.840220916406238e-11
haplotype O 0 1.4326575481504733e-08
for O 0 3.7059175173048686e-11
these O 0 1.5681349274654366e-10
five O 0 1.2309988584036091e-09
polymorphic O 0 2.077491529917097e-07
markers O 0 8.853731401359255e-07
. O 0 1.8093884079917189e-07

Fourteen O 0 1.0750245564850047e-06
microsatellite O 0 4.363416337582748e-06
polymorphisms O 0 1.5840953437873395e-06
were O 0 1.4137071513431465e-09
selected O 0 2.381975450216345e-10
based O 0 5.554666726581559e-10
on O 0 1.3275730514905604e-10
their O 0 2.5808205572630527e-10
high O 0 4.803637043693243e-09
heterozygosity O 0 2.6273423259226547e-07
and O 0 3.049999697246619e-10
their O 0 7.423553438634656e-11
location O 0 4.3133336902201336e-09
within O 0 9.389359290068455e-10
10q23 O 0 1.5833703628231888e-06
- O 0 1.1162698001498939e-06
q25 O 0 2.2794949927629204e-06
near O 0 7.388207734493335e-08
COL17A1 O 0 8.20664718048647e-06
. O 0 1.246282863576198e-07

Three O 0 1.8418882063997444e-07
families O 0 5.821479476253444e-08
shared O 0 1.9414381213778142e-08
microsatellite O 0 9.274541525883251e-07
polymorphisms O 0 1.2044743016303983e-06
covering O 0 5.4230493873319574e-08
at O 0 1.5826095989268651e-09
most O 0 3.297188355677605e-10
19 O 0 5.786712220512413e-10
cM O 0 1.3697546430435636e-09
, O 0 9.696202868392234e-11
whereas O 0 6.75501155011915e-10
the O 0 4.3490995527140086e-11
others O 0 4.756326443811076e-10
shared O 0 1.4971583695011503e-10
smaller O 0 1.8103087917609173e-09
regions O 0 3.575122420329535e-09
consistent O 0 2.9268705237228687e-09
with O 0 2.004568906699422e-11
cross O 0 5.772032185547005e-09
- O 0 1.3268631526841546e-08
over O 0 8.457049643917358e-11
events O 0 1.1321143328357763e-10
during O 0 4.391344232690386e-11
passage O 0 6.893653703432534e-11
of O 0 3.5545895653993353e-12
this O 0 2.5736520553598652e-11
mutation O 0 5.401716296482562e-10
through O 0 2.447864654031573e-11
several O 0 4.268205511248624e-10
generations O 0 4.164282074725634e-08
. O 0 2.5432646211243082e-08

These O 0 1.660663251357164e-08
results O 0 1.3353353089939901e-08
indicate O 0 5.854659423931707e-09
that O 0 1.0743695516568508e-10
4003delTC O 0 2.1367798197502452e-08
occurs O 0 2.347489702625438e-10
on O 0 3.507842280536799e-11
a O 0 6.950212627643282e-11
single O 0 2.076740779344277e-09
ancestral O 0 6.36825561173282e-08
allele O 0 4.200591092740069e-07
. O 0 7.035085403117591e-09
. O 0 4.505823980593959e-08

The O 0 1.6200581853809126e-07
haptoglobin O 0 7.219544932013378e-05
- O 0 1.3971383623356814e-06
gene O 0 5.89546743867686e-07
deletion O 0 4.0208860241364164e-07
responsible O 0 2.0492887387035807e-08
for O 0 2.7304181138276817e-09
anhaptoglobinemia B-Disease 0 3.1069921533344314e-06
. O 0 9.702913672526847e-08

We O 0 7.771834731329363e-08
have O 0 7.738280016766907e-10
found O 0 2.389921038847831e-10
an O 0 4.0472476064978835e-11
allelic O 0 2.922927677673215e-08
deletion O 0 4.7395413815820575e-08
of O 0 1.2707672414347115e-10
the O 0 9.127909539330403e-10
haptoglobin O 0 7.131746997401933e-07
( O 0 2.077298610903e-10
Hp O 0 1.7910823935096687e-09
) O 0 2.5735635844625904e-11
gene O 0 7.645238886411221e-10
from O 0 3.794568131931797e-11
an O 0 2.7902328017526123e-11
individual O 0 2.595671233507346e-09
with O 0 3.871088782858578e-09
anhaptoglobinemia B-Disease 0 1.598408016434405e-05
. O 0 1.340339679245517e-07

The O 0 2.912404362120924e-08
Hp O 0 1.5445323242602171e-07
gene O 0 8.247865679322786e-08
cluster O 0 2.8874424629066198e-08
consists O 0 4.1323597321785144e-10
of O 0 5.5881799188028936e-11
coding O 0 1.287219788537186e-06
regions O 0 1.8883794083990324e-08
of O 0 8.726802613878704e-11
the O 0 2.569386370332438e-10
alpha O 0 1.6678300962524872e-09
chain O 0 7.414069358446795e-08
and O 0 4.720869806185135e-10
beta O 0 3.745981747016458e-09
chain O 0 1.1818709566568941e-08
of O 0 3.0218678254145814e-11
the O 0 1.7377313477062728e-10
haptoglobin O 0 1.2274665550648933e-07
gene O 0 5.284101156632914e-09
( O 0 3.547181645635611e-11
Hp O 0 7.990378914080054e-10
) O 0 3.3633529988863486e-11
and O 0 4.357353020068011e-11
of O 0 6.019519084576874e-12
the O 0 9.447558013686574e-11
alpha O 0 1.259986781576572e-09
chain O 0 7.052970119048041e-08
and O 0 3.669484993640282e-10
beta O 0 1.408515193368487e-09
chain O 0 3.7177660949794245e-09
of O 0 1.3261830002220254e-11
the O 0 1.0354957169500523e-10
haptoglobin O 0 9.740496125232312e-07
- O 0 2.112046715296856e-08
related O 0 6.395251439528238e-09
gene O 0 1.7249963235599353e-08
( O 0 1.1944745192948858e-10
Hpr O 0 2.6153422538754967e-08
) O 0 1.0970442609892217e-10
, O 0 1.484481287894468e-11
in O 0 1.3727401160235075e-11
tandem O 0 2.6272353181866492e-09
from O 0 1.4555169569607784e-10
the O 0 4.4337977733732714e-10
5 O 0 7.973529392302225e-09
side O 0 1.12568649512923e-07
. O 0 6.690213893989494e-08

Southern O 0 4.1305424929305445e-06
blot O 0 2.747242797340732e-05
and O 0 6.392446127989615e-09
PCR O 0 1.8843161342374515e-07
analyses O 0 2.8540094731965837e-08
have O 0 2.720908220954499e-10
indicated O 0 4.202321546298293e-10
that O 0 9.674842524343141e-12
the O 0 3.381877677205436e-12
individual O 0 6.037332439534637e-11
with O 0 3.884005270182733e-11
anhaptoglobinemia B-Disease 0 9.353545493695492e-08
was O 0 4.950024834471378e-10
homozygous O 0 5.033976346879854e-09
for O 0 1.3764395005722019e-11
the O 0 1.0771307457080326e-11
gene O 0 1.0574351394510018e-09
deletion O 0 1.6629391197398036e-08
and O 0 2.2553722778262397e-10
that O 0 8.76978177577481e-12
the O 0 4.80531586743993e-12
gene O 0 7.937607793273571e-10
deletion O 0 7.738298890558326e-09
was O 0 2.445961766461835e-10
included O 0 3.227381209502944e-11
at O 0 5.0915226895709154e-11
least O 0 6.470095726546221e-12
from O 0 1.0428088947911363e-11
the O 0 2.962628406488754e-11
promoter O 0 5.1712369497636246e-08
region O 0 7.002848079196156e-09
of O 0 5.1543016382771256e-11
Hp O 0 1.20066125930407e-08
to O 0 3.0338875856017467e-10
Hpr O 0 9.665749445275651e-08
alpha O 0 1.2611551802876875e-09
but O 0 3.828104222503015e-10
not O 0 3.685322880198072e-10
to O 0 4.297449895940275e-10
Hpr O 0 6.881464855723607e-07
beta O 0 4.272885334444254e-08
( O 0 8.345972801748758e-10
Hpdel O 0 2.548235045196634e-07
) O 0 7.92224508217032e-09
. O 0 2.7391671153509378e-08

In O 0 8.84139339518697e-09
addition O 0 1.923949222160104e-09
, O 0 2.785437991370543e-10
we O 0 1.6486122189629526e-10
found O 0 2.279507485547505e-11
seven O 0 1.3844489790693082e-11
individuals O 0 3.4753350371119485e-12
with O 0 3.2482161491792505e-12
hypohaptoglobinemia B-Disease 0 2.1569055874692822e-08
in O 0 5.039543088392051e-11
three O 0 4.112072488071661e-11
families O 0 5.0303622378677915e-11
, O 0 1.508125915816727e-11
and O 0 2.204613575029768e-11
the O 0 1.5362469976687443e-11
genotypes O 0 3.3432987489590005e-09
of O 0 2.081222564079277e-12
six O 0 6.58767554395645e-11
of O 0 1.1085467396462767e-12
the O 0 9.419016781808676e-12
seven O 0 5.6382426505408034e-11
individuals O 0 1.1851263893858377e-11
were O 0 1.860526142871688e-11
found O 0 3.199957659960617e-11
to O 0 1.0615936602009768e-10
be O 0 1.9989352395555215e-09
Hp2 O 0 1.2945928347107838e-06
/ O 0 2.1708561348532385e-07
Hpdel O 0 2.530122173993732e-06
. O 0 7.902629306499875e-08

The O 0 1.4650747282018983e-08
phenotypes O 0 2.8333292334536964e-07
and O 0 1.5545884579637459e-09
genotypes O 0 4.495008099070219e-08
in O 0 5.5665951015360093e-11
one O 0 5.45247597072418e-11
of O 0 1.2101172928297155e-12
these O 0 2.395898757168169e-11
three O 0 5.6749792365362595e-11
families O 0 9.086285196469035e-11
showed O 0 9.092185337955527e-10
the O 0 1.1508240541080461e-11
father O 0 3.4373531798692625e-10
to O 0 9.195882250123688e-11
be O 0 1.846463815180499e-10
hypohaptoglobinemic B-Disease 0 4.3833843221818825e-08
( O 0 9.909494752546877e-11
Hp2 O 0 1.5991657775771273e-08
) O 0 1.1594082638399783e-10
and O 0 7.620078179559897e-11
Hp2 O 0 8.657829653202498e-08
/ O 0 1.1642359076802222e-08
Hpdel O 0 6.45170956659058e-08
, O 0 6.038599481561491e-11
the O 0 1.2554300481137926e-11
mother O 0 9.493733577059515e-10
to O 0 2.516437058730503e-11
be O 0 9.957049768027915e-11
Hp2 O 0 3.113761692929984e-08
- O 0 1.0580571974116992e-08
1 O 0 1.662880388941801e-10
and O 0 7.816242791891526e-11
Hp1 O 0 1.3870651294212166e-08
/ O 0 1.280233918876661e-09
Hp2 O 0 6.154712295369791e-09
, O 0 9.709633271015594e-12
one O 0 3.839698090729593e-12
of O 0 3.079609050410381e-13
the O 0 2.8838368325290187e-12
two O 0 2.5771496048321296e-11
children O 0 8.425396491595905e-11
to O 0 1.4594303196502345e-11
be O 0 7.12057218743567e-11
hypohaptoglobinemic B-Disease 0 1.2546395922186093e-08
( O 0 2.86259713849768e-11
Hp2 O 0 7.933979695451399e-09
) O 0 3.8954457715068e-11
and O 0 5.896881594136261e-11
Hp2 O 0 4.460946811946087e-08
/ O 0 3.849243590536844e-09
Hpdel O 0 2.9512403187936798e-08
, O 0 1.8672450738388413e-11
and O 0 1.0377532166927494e-11
the O 0 1.7435496406023598e-12
other O 0 1.2432984329568963e-11
child O 0 1.7572833466150684e-10
to O 0 1.3332030791846083e-11
be O 0 6.244073313954601e-11
Hp1 O 0 1.2984052055742268e-08
and O 0 2.0236316788935227e-10
Hp1 O 0 6.440767208459874e-08
/ O 0 4.020553667771765e-09
Hpdel O 0 1.6684925441268206e-08
, O 0 2.6805885636194127e-11
showing O 0 1.357851386885045e-09
an O 0 2.1103563341284826e-11
anomalous O 0 8.50208525804419e-09
inheritance O 0 6.766661897472659e-08
of O 0 1.9239849990970725e-10
Hp O 0 3.2485942824678204e-08
phenotypes O 0 2.6028166288938337e-08
in O 0 1.4291080818740198e-10
the O 0 2.3560570161507144e-10
child O 0 1.3188319769597001e-08
with O 0 1.008172989536149e-09
Hp1 O 0 5.008999323763419e-06
. O 0 1.2491743461851001e-07

The O 0 2.0335738426524586e-08
Hp2 O 0 3.022304554178845e-06
/ O 0 1.6999614160795318e-07
Hpdel O 0 1.0247654103068271e-07
individuals O 0 8.740717039046331e-10
had O 0 5.356044052717834e-09
an O 0 7.508711014070357e-11
extremely O 0 6.642187688754575e-09
low O 0 1.750809929035313e-06
level O 0 6.134623919962223e-09
of O 0 3.554184377363434e-11
Hp O 0 7.108989397153209e-09
( O 0 6.11505013292657e-11
mean O 0 1.8002269674965987e-09
+ O 0 4.113019969054221e-08
/ O 0 1.1753745354781131e-07
- O 0 5.025225391364074e-07
SD O 0 6.87937199472799e-06
= O 0 1.852139916991291e-07
0 O 0 3.0616993385024216e-09
. O 0 4.2211434347905197e-10
049 O 0 2.822902160914964e-07
+ O 0 4.79013486653912e-08
/ O 0 7.612970875925384e-08
- O 0 1.2254430714619957e-07
0 O 0 7.111891964228789e-09
. O 0 9.324111482911235e-10
043 O 0 7.138156661312678e-07
mg O 0 1.0652785675802079e-07
/ O 0 2.8226212478443813e-08
ml O 0 6.022596465982133e-08
; O 0 5.377496781200364e-10
n O 0 1.4141905424480683e-08
= O 0 8.821247732271331e-09
6 O 0 1.8174139970739134e-10
) O 0 2.1737318542380812e-11
, O 0 3.697880543440668e-12
compared O 0 9.214967677806385e-11
with O 0 1.1902573544830819e-11
the O 0 2.850171487711606e-10
level O 0 2.036161461660413e-09
( O 0 2.5228432190549377e-11
1 O 0 8.171066601114774e-11
. O 0 8.67449514996288e-11
64 O 0 2.7549199033138905e-10
+ O 0 6.019619913644192e-09
/ O 0 1.18582246244614e-08
- O 0 2.3258051484731368e-08
1 O 0 1.4018229910206514e-09
. O 0 6.717186806781683e-10
07 O 0 2.250943786918924e-08
mg O 0 2.4013832700120474e-08
/ O 0 2.2929449450259654e-09
ml O 0 4.166218481316264e-09
) O 0 1.0220230044211132e-11
obtained O 0 1.3666327791650446e-10
from O 0 1.2657140613381301e-10
52 O 0 3.152718308641056e-09
healthy O 0 2.247321884141229e-09
volunteers O 0 1.094110912980284e-09
having O 0 6.333258806279218e-09
phenotype O 0 4.482610904688045e-08
Hp2 O 0 1.6578252370891278e-07
, O 0 3.4756700295623943e-10
whereas O 0 2.469947579797349e-09
the O 0 1.302757346444139e-10
serum O 0 1.8944184887459414e-08
Hp O 0 7.883821595555673e-09
level O 0 2.111665980963906e-10
of O 0 1.9357252346169362e-12
an O 0 1.0885500834056927e-11
individual O 0 1.727038789756108e-10
with O 0 2.918223163117517e-10
Hp1 O 0 1.5936840327412938e-06
/ O 0 8.653851324424977e-08
Hpdel O 0 7.842601803531579e-07
was O 0 1.2298517759745664e-08
0 O 0 1.4879958598612575e-08
. O 0 2.4483727045776504e-08

50 O 0 4.919655793855782e-07
mg O 0 7.601224183417798e-07
/ O 0 3.093823579547461e-07
ml O 0 5.406096192928089e-07
, O 0 2.3177167129961873e-10
which O 0 1.0812935269388646e-10
was O 0 1.5022928734342855e-10
approximately O 0 5.0674471563372236e-11
half O 0 2.025930534443887e-09
the O 0 1.8378903954285875e-10
level O 0 8.630863801428745e-10
of O 0 5.132021110160201e-12
Hp O 0 1.887136225064978e-09
in O 0 7.463533957530188e-11
control O 0 4.271709652670097e-09
sera O 0 2.5634806277707867e-08
from O 0 2.229558725141967e-11
the O 0 1.4390948155362793e-10
Hp1 O 0 4.445810759534652e-07
phenotype O 0 5.609343389778587e-08
( O 0 4.685692805983521e-11
1 O 0 1.0401673966597969e-10
. O 0 1.0510484149683919e-10
26 O 0 3.373872570211489e-10
+ O 0 2.518240282967099e-09
/ O 0 6.334128332952105e-09
- O 0 1.777829794491481e-08
0 O 0 1.1414862388647862e-09
. O 0 1.670850957591341e-10
33 O 0 1.1552038214901472e-09
mg O 0 2.2105496100266464e-08
/ O 0 6.991303536096893e-09
ml O 0 2.486886430119739e-08
; O 0 2.6605159741954765e-10
n O 0 2.573351842727334e-08
= O 0 1.9922296701224695e-08
9 O 0 8.005756058082625e-10
) O 0 3.850003302274807e-11
, O 0 1.723566254996367e-11
showing O 0 2.739756199687804e-09
a O 0 1.7318649292441535e-10
gene O 0 1.0111048709404713e-07
- O 0 8.978912546808715e-07
dosage O 0 5.855041763425106e-06
effect O 0 3.568754891603021e-07
. O 0 6.477640823732145e-08

The O 0 2.0470802830629964e-09
other O 0 5.324953256113929e-10
allele O 0 4.8109747297075955e-08
( O 0 1.3411612098668257e-10
Hp2 O 0 1.4417694593760189e-08
) O 0 4.534319447691004e-11
of O 0 2.2030864545857787e-12
individuals O 0 3.092178596508788e-11
with O 0 5.341857858831567e-11
Hp2 O 0 2.2715040870480152e-07
/ O 0 2.2988272618817973e-08
Hpdel O 0 9.252652688473972e-08
was O 0 3.3344388361555843e-10
found O 0 2.3609142418834494e-11
to O 0 8.684390012669851e-12
have O 0 4.620806168253999e-11
, O 0 3.1214915634930618e-12
in O 0 9.80914741793848e-12
all O 0 1.0731976071709504e-11
exons O 0 1.2091322609819599e-08
, O 0 1.621734552204046e-10
no O 0 2.604547133522317e-10
mutation O 0 2.484670913460718e-09
, O 0 1.6543063793839075e-11
by O 0 4.42905365161117e-11
DNA O 0 3.257069280948599e-08
sequencing O 0 2.2880973915562208e-07
. O 0 7.576928595653953e-08

On O 0 2.998800541220703e-09
the O 0 1.4897997765994653e-11
basis O 0 8.307628890369401e-11
of O 0 4.032874294929156e-12
the O 0 3.151909636067707e-11
present O 0 1.1427272322839244e-10
study O 0 7.792173156717652e-11
, O 0 6.846686412265157e-12
the O 0 5.216837378752004e-12
mechanism O 0 6.41145192492587e-11
of O 0 2.7654410879318636e-12
anhaptoglobinemia B-Disease 0 3.122141123412803e-08
and O 0 4.185553292845867e-11
the O 0 5.278704123118372e-12
mechanism O 0 1.7983248223885084e-10
of O 0 9.062586618646673e-12
anomalous O 0 5.057400276342605e-09
inheritance O 0 4.912810425139469e-08
of O 0 2.6575286415919663e-10
Hp O 0 4.272942533134483e-08
phenotypes O 0 5.8538358160831194e-08
were O 0 1.1215193218561126e-09
well O 0 3.038510332231681e-09
explained O 0 1.225673287308382e-07
. O 0 4.5374410007070765e-08

However O 0 1.1279968958888276e-07
, O 0 5.939531089182992e-10
the O 0 8.616319463472522e-11
mechanism O 0 2.6692088539448378e-09
of O 0 8.658432304464725e-10
hypohaptoglobinemia B-Disease 0 4.600573902280303e-06
remains O 0 3.966120516452065e-07
unknown O 0 3.1963472792995162e-06

ATM O 0 4.8023804993135855e-05
mutations O 0 1.6905720258364454e-05
and O 0 4.418732757471844e-08
phenotypes O 0 6.0781326283176895e-06
in O 0 2.5476055043327506e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 2.8373790428304346e-06
in O 0 3.8655256773267865e-09
the O 0 1.2467168408747398e-09
British O 0 0.0003251511661801487
Isles O 0 4.1174235576590945e-08
: O 0 2.436117974013996e-11
expression O 0 1.9836196921141358e-11
of O 0 4.563310449998137e-13
mutant O 0 2.2697514701075505e-10
ATM O 0 1.8430376114153546e-09
and O 0 2.529482873159239e-11
the O 0 2.6043670692255105e-11
risk O 0 1.976311381213236e-08
of O 0 2.1925877780049063e-10
leukemia B-Disease 1 0.6184093356132507
, O 0 3.3210628203050874e-07
lymphoma B-Disease 1 1.0
, O 0 2.1239721093024855e-08
and O 0 7.896841225374374e-07
breast B-Disease 1 0.9315719604492188
cancer I-Disease 0 0.00029561136034317315
. O 0 1.5465973035588831e-07

We O 0 2.2911390828994627e-07
report O 0 6.887391545973287e-09
the O 0 3.749351523696376e-11
spectrum O 0 1.3245260443994766e-09
of O 0 1.1387542991903032e-10
59 O 0 1.9156454200697226e-08
ATM O 0 4.735664731470024e-07
mutations O 0 3.6487193710854626e-07
observed O 0 2.3676263083416416e-07
in O 0 1.8802107604187768e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.3831649720668793
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.212448694891236e-09
patients O 0 3.2568192587234535e-09
in O 0 6.101081445608614e-11
the O 0 8.667916939764098e-10
British O 0 7.809658200130798e-06
Isles O 0 1.9122396679449594e-06
. O 0 1.2810569671728445e-07

Of O 0 3.817426375007926e-08
51 O 0 4.2703641156549565e-07
ATM O 0 1.2481281146392575e-06
mutations O 0 2.7640709276965936e-07
identified O 0 1.7591897716329186e-08
in O 0 1.1829161261633914e-10
families O 0 9.613831258858951e-11
native O 0 4.457251234768478e-10
to O 0 1.4248703605890256e-10
the O 0 1.840226582228155e-10
British O 0 1.4928234577382682e-06
Isles O 0 2.703266233083923e-08
, O 0 7.985163918977634e-11
11 O 0 1.1488048012875396e-10
were O 0 2.849740582400173e-11
founder O 0 8.31527458000636e-10
mutations O 0 3.4779399360473917e-09
, O 0 1.6215173301303842e-11
and O 0 2.2001608868116307e-11
2 O 0 1.771311396170372e-11
of O 0 5.877719101363144e-13
these O 0 3.298211703750553e-11
11 O 0 6.932061868969441e-11
conferred O 0 3.0284991181517285e-10
a O 0 5.765567884230549e-11
milder O 0 5.120689294813019e-08
clinical O 0 1.0206476019902766e-07
phenotype O 0 2.0526568889067676e-08
with O 0 2.6144903950142684e-11
respect O 0 1.672971483568375e-10
to O 0 2.1152939122526249e-10
both O 0 4.584833845910907e-09
cerebellar B-Disease 0 4.140568307775538e-06
degeneration I-Disease 0 3.680690952023724e-06
and O 0 7.508231369968144e-09
cellular O 0 1.4243954638004652e-07
features O 0 3.970484101500915e-07
. O 0 3.7080417314427905e-07

We O 0 4.564941207263473e-07
report O 0 5.7397993025176675e-09
, O 0 6.802172713982202e-11
in O 0 2.9756763025856614e-11
two O 0 6.209541769663929e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 6.157366172487855e-09
, O 0 4.70770332439141e-11
an O 0 7.178951877406803e-11
ATM O 0 2.574579696101864e-07
mutation O 0 4.954365095954927e-08
( O 0 1.8688281477885482e-10
7271T O 0 8.226922432186257e-08
- O 0 5.560831084494566e-08
- O 0 3.1987053006332644e-08
> O 0 2.00526284466207e-09
G O 0 9.294481628785434e-09
) O 0 3.2712346720309426e-11
that O 0 9.643282700144695e-12
may O 0 3.217665300869754e-10
be O 0 3.6502012350225765e-12
associated O 0 9.296364893163211e-12
with O 0 1.027383473434229e-12
an O 0 1.8087056158355708e-11
increased O 0 7.345559271954016e-09
risk O 0 1.5156089716583665e-07
of O 0 2.1481419421043313e-10
breast B-Disease 0 3.438483690842986e-05
cancer I-Disease 0 4.738172094675974e-07
in O 0 6.898626114804074e-11
both O 0 9.03005392682843e-10
homozygotes O 0 7.014627385615313e-07
and O 0 4.764171279703078e-10
heterozygotes O 0 1.1138287447920447e-07
( O 0 8.54440893038877e-11
relative O 0 9.724884009187917e-09
risk O 0 1.7696602583328058e-07
12 O 0 3.2564076435370737e-10
. O 0 8.672840917656188e-11
7 O 0 4.6051470969921127e-10
; O 0 8.91862250718134e-10
P O 0 2.055326831396087e-06
= O 0 1.174742081389013e-08
. O 0 1.6744047814931662e-10
0025 O 0 3.123189529219417e-08
) O 0 2.5999051869729506e-11
, O 0 1.4057862946642574e-12
although O 0 1.4256960195746515e-11
there O 0 3.0240861897956606e-12
is O 0 4.4463269871508615e-12
a O 0 1.8895366174498385e-11
less O 0 1.1405612010406685e-09
severe O 0 0.003835330018773675
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.1781357898144051e-06
in O 0 4.833547798122062e-11
terms O 0 1.7426304843581875e-10
of O 0 8.617757115553237e-13
the O 0 1.0323518082056005e-11
degree O 0 7.077979535807799e-09
of O 0 8.750041802230157e-10
cerebellar B-Disease 0 1.7056861906894483e-05
degeneration I-Disease 0 3.2779076718725264e-05
. O 0 3.753268060791015e-07

This O 0 4.7886459242363344e-08
mutation O 0 2.7089447485195706e-07
( O 0 1.4977274975791488e-09
7271T O 0 3.114207629550947e-07
- O 0 3.3825045875346405e-07
- O 0 2.075216229968646e-07
> O 0 2.3858060416159788e-08
G O 0 4.2807982936210465e-08
) O 0 1.5292635213715045e-10
also O 0 3.497694148202335e-11
allows O 0 4.667469535868385e-11
expression O 0 9.897235808686844e-11
of O 0 5.1953294097351055e-12
full O 0 5.618546183860929e-10
- O 0 6.660138662795134e-09
length O 0 2.2250155051750653e-09
ATM O 0 1.5264644659396254e-08
protein O 0 1.178206088248146e-09
at O 0 2.1774552994013874e-10
a O 0 2.6304215750005966e-11
level O 0 9.498691416753857e-11
comparable O 0 7.472610863423768e-10
with O 0 9.03243972671941e-12
that O 0 2.134251282648325e-11
in O 0 2.2469821836512693e-10
unaffected O 0 8.5587096521067e-08
individuals O 0 5.739055009001959e-09
. O 0 4.0250441202260845e-08

In O 0 3.5923819474703578e-09
addition O 0 1.1247861531060721e-09
, O 0 1.0707731229464557e-10
we O 0 4.3007770955671987e-11
have O 0 1.3719993023630916e-11
studied O 0 1.522707471224294e-08
18 O 0 1.1413320955000472e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.287582532289889e-07
, O 0 9.516930646324973e-12
in O 0 5.777751107410856e-12
15 O 0 1.542186170433446e-11
families O 0 1.7666250407000206e-11
, O 0 1.1271925233480307e-11
who O 0 1.129531024268715e-09
developed O 0 5.005576326766459e-07
leukemia B-Disease 1 0.6907680630683899
, O 0 3.795518921378971e-07
lymphoma B-Disease 1 1.0
, O 0 3.309034379839204e-09
preleukemic O 0 1.9446386431809515e-05
T O 0 0.00040275196079164743
- O 0 4.42477983142453e-07
cell O 0 1.6693417137503275e-07
proliferation O 0 1.232761945857419e-07
, O 0 4.649151341684643e-10
or O 0 3.348719417317625e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.931037330038521e-09
mostly O 0 2.89407942055675e-09
in O 0 4.654610030740969e-09
childhood O 0 3.260418679928989e-06
. O 0 2.0677013878867e-07

A O 0 3.9705703613890364e-08
wide O 0 6.195358004390528e-09
variety O 0 4.477225701293719e-09
of O 0 1.6605571084848947e-10
ATM O 0 2.3871746179793263e-07
mutation O 0 3.854329477803731e-08
types O 0 8.030779596879256e-09
, O 0 1.1682699252446582e-10
including O 0 4.0575529047792713e-10
missense O 0 8.173016681212175e-07
mutations O 0 1.7353657710827974e-07
and O 0 4.5978013063496803e-10
in O 0 2.500782636527532e-10
- O 0 1.633885204910257e-08
frame O 0 5.420340087880504e-08
deletions O 0 5.065174590868082e-08
, O 0 2.878481897283791e-10
were O 0 1.0286865109732091e-10
seen O 0 3.2263380855823698e-09
in O 0 1.2329884335748886e-10
these O 0 2.2467518956403865e-09
patients O 0 7.389306944105556e-08
. O 0 1.7598777546368183e-08

We O 0 3.240364065959511e-08
also O 0 1.581323405552837e-10
show O 0 4.800740360799693e-10
that O 0 2.2011177602809795e-11
25 O 0 2.177034767736341e-11
% O 0 7.460227748057324e-12
of O 0 3.088009882523668e-12
all O 0 3.265753178993691e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.0890853370001423e-07
carried O 0 1.53114088075057e-09
in O 0 2.9073396468071167e-10
- O 0 1.2545007699316102e-08
frame O 0 5.60530075688348e-08
deletions O 0 7.908449362048486e-08
or O 0 1.9082233571054985e-09
missense O 0 8.90027749278488e-08
mutations O 0 8.501695347717941e-09
, O 0 1.4899617997721215e-11
many O 0 2.7764815186542835e-12
of O 0 9.706628946795637e-13
which O 0 4.8486659132152e-10
were O 0 1.7895832593595173e-09
also O 0 4.5325404540719205e-10
associated O 0 3.5053229763271077e-10
with O 0 2.6880843037591085e-11
expression O 0 1.2499954404887603e-09
of O 0 1.3483172911499253e-10
mutant O 0 1.2719293351892702e-07
ATM O 0 4.4418692368708435e-07
protein O 0 4.300513012367446e-07
. O 0 5.7353595650511124e-08

The O 0 2.113711161655374e-08
DMPK O 0 1.4137705193206784e-06
gene O 0 1.685341288748532e-07
of O 0 3.235211654128989e-09
severely O 0 2.0538045646389946e-05
affected O 0 1.0968215065076947e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0006900967564433813
is O 0 1.2387335601715677e-09
hypermethylated O 0 1.522427908184909e-07
proximal O 0 4.804537212521609e-08
to O 0 1.1284349010765027e-09
the O 0 6.221820836316283e-10
largely O 0 9.954366930742253e-08
expanded O 0 4.3920752546000585e-07
CTG O 0 1.5626475942553952e-05
repeat O 0 4.456653641682351e-06
. O 0 2.0877796202967147e-07

Using O 0 1.40082988764334e-07
methylation O 0 8.366275778826093e-07
- O 0 9.463077503824024e-07
sensitive O 0 1.5709181866441213e-07
restriction O 0 9.29366539281773e-09
enzymes O 0 1.347316036515167e-08
, O 0 1.4818681004502565e-10
we O 0 6.188985435251482e-11
characterized O 0 1.549691069913095e-10
the O 0 3.1679173173593256e-11
methylation O 0 1.5946328701943457e-09
pattern O 0 7.754477948651584e-09
on O 0 3.6308178685828807e-10
the O 0 4.941692194337932e-11
5 O 0 2.445234015269193e-10
side O 0 2.902602047605285e-10
of O 0 5.783043315055192e-12
the O 0 9.65751645320978e-11
CTG O 0 1.8324428197047382e-07
repeat O 0 2.196549786503965e-08
in O 0 1.7362297363709978e-11
the O 0 7.20811821688927e-12
DMPK O 0 1.462670606855454e-08
gene O 0 3.9860231781929656e-10
of O 0 2.9795367562091e-12
normal O 0 1.0046749543413114e-10
individuals O 0 2.0660164551378202e-11
and O 0 2.1419180665227522e-11
of O 0 1.608186674106893e-11
patients O 0 4.527427766021219e-09
affected O 0 6.693731124940427e-10
with O 0 1.0152936269491875e-09
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
, O 0 7.535472801301069e-10
showing O 0 2.958181921641767e-09
expansions O 0 2.915422214755381e-08
of O 0 2.1005095232617954e-11
the O 0 3.337352894039469e-10
repetitive O 0 1.5966871558248386e-07
sequence O 0 2.457262269217608e-07
. O 0 1.245467728949734e-07

The O 0 6.154104426059348e-08
gene O 0 5.688208375431714e-07
segment O 0 3.7674800523745944e-07
analyzed O 0 3.513318347359018e-08
corresponds O 0 2.668979703912555e-09
to O 0 2.8802393803317727e-10
the O 0 6.695083931695933e-10
genomic O 0 1.0584526535240002e-06
SacI O 0 1.7515316358185373e-05
- O 0 9.508290759185911e-07
HindIII O 0 8.767606232140679e-07
fragment O 0 6.822622111712917e-08
carrying O 0 8.659295502866371e-09
exons O 0 3.1010134193820704e-07
11 O 0 2.085339367852157e-08
- O 0 2.984480431678094e-07
15 O 0 2.149865707679055e-08
. O 0 3.661001812815812e-08

There O 0 3.1472406902821604e-08
is O 0 1.0294761709772615e-09
constitutive O 0 1.0482845702597388e-08
methylation O 0 2.4912873541893532e-08
in O 0 3.0192076616586405e-10
intron O 0 3.267302020049101e-07
12 O 0 1.2246078595623544e-09
at O 0 4.443438325618665e-11
restriction O 0 6.814327574433676e-11
sites O 0 1.85561135901402e-10
of O 0 1.2409575103622394e-11
SacII O 0 3.852595398257108e-08
and O 0 4.786038787507607e-10
HhaI O 0 7.219510678169172e-08
, O 0 8.200293222238031e-11
localized O 0 3.993185782036335e-09
1 O 0 5.906858890902811e-10
, O 0 3.2696872986903713e-11
159 O 0 9.096538522435083e-10
- O 0 1.3078925498177796e-08
1 O 0 4.927040997415588e-10
, O 0 2.6550449339080018e-11
232 O 0 4.994036850725081e-10
bp O 0 9.126730482478251e-09
upstream O 0 2.2002710764468247e-10
of O 0 7.153524300695935e-12
the O 0 3.720493357839416e-11
CTG O 0 8.432643028299935e-08
repeat O 0 1.5903690808727333e-08
, O 0 7.244228654446072e-12
whereas O 0 3.1762908275778656e-11
most O 0 1.1370564212409562e-11
, O 0 1.2537811934498766e-11
if O 0 2.091846695861932e-10
not O 0 3.6898224059500606e-11
all O 0 2.369136570951058e-12
, O 0 1.8494155859527517e-12
of O 0 3.224289325115537e-13
the O 0 1.4951164221607693e-12
other O 0 6.4591470193275935e-12
sites O 0 3.6155592408881887e-10
of O 0 7.869267737437013e-12
SacII O 0 6.126555707197667e-09
, O 0 2.066355420105026e-11
HhaI O 0 6.275851394121901e-09
, O 0 1.6835179084129237e-11
and O 0 3.8300959626091924e-11
HpaII O 0 7.88231879766954e-09
in O 0 2.7052171266972458e-11
this O 0 1.932479870569992e-11
region O 0 6.664773732900642e-10
are O 0 5.1933801009651503e-11
unmethylated O 0 5.011465376014712e-08
, O 0 3.58521129451006e-11
in O 0 1.773451351050337e-11
normal O 0 1.3337837778681916e-10
individuals O 0 2.334820184413111e-11
and O 0 7.695176960920147e-12
most O 0 1.0237437633731084e-11
of O 0 7.154247680385417e-12
the O 0 6.661138862718019e-10
patients O 0 6.747046654709266e-08
. O 0 1.5164239641762833e-08

In O 0 3.2233855584706816e-09
a O 0 1.1685864775845545e-10
number O 0 6.947323272221695e-11
of O 0 1.4915426532757792e-11
young O 0 3.7023677457170834e-09
and O 0 1.3003846888182125e-09
severely O 0 9.260762681151391e-07
affected O 0 1.2229832702104204e-09
patients O 0 3.0750368917864535e-09
, O 0 1.4249946708733141e-11
however O 0 1.927819986979884e-10
, O 0 2.388461650681961e-11
complete O 0 3.923946584327709e-11
methylation O 0 1.250334058511271e-09
of O 0 5.042040569780415e-12
these O 0 1.342801304177188e-11
restriction O 0 6.373945815596471e-11
sites O 0 1.1315104408993193e-09
was O 0 1.731125104376119e-10
found O 0 5.295961585938258e-11
in O 0 4.907024786504621e-11
the O 0 4.4044826119638003e-10
mutated O 0 4.945816272083903e-07
allele O 0 2.005916030611843e-06
. O 0 1.4407034143459896e-07

In O 0 6.3706098174520776e-09
most O 0 2.0271548328842925e-10
of O 0 3.3925633569770186e-12
these O 0 4.247186283223847e-11
patients O 0 5.508927758413051e-10
, O 0 3.6208969850237693e-12
the O 0 1.93408379589588e-11
onset O 0 1.4891628374869015e-08
of O 0 5.399076324907881e-11
the O 0 6.62748256274881e-09
disease O 0 6.0226470850466285e-06
was O 0 4.062482616973284e-07
congenital O 1 0.9665706753730774
. O 0 2.382719088700469e-07

Preliminary O 0 2.582148226792924e-06
in O 0 1.0545075923573677e-07
vivo O 0 5.6453377510479186e-06
footprinting O 0 2.6011399313574657e-05
data O 0 2.2591978066088814e-08
gave O 0 7.323633921529904e-10
evidence O 0 5.180669782056668e-10
for O 0 5.280025722198545e-11
protein O 0 3.234977397070793e-09
- O 0 1.769288360264909e-08
DNA O 0 3.148855753920543e-08
contact O 0 6.29854035594235e-09
in O 0 2.7066893171223683e-10
normal O 0 1.528403958950264e-09
genes O 0 1.0279050499661935e-08
at O 0 3.3537412846840198e-09
an O 0 2.0037937975558862e-10
Sp1 O 0 7.098898180402102e-08
consensus O 0 2.8475849456199853e-10
binding O 0 1.261174498168316e-09
site O 0 5.600517827275553e-10
upstream O 0 7.326512174721245e-10
of O 0 4.400145178773407e-12
the O 0 2.5547590085106542e-11
CTG O 0 2.4610468329910873e-08
repeat O 0 4.0035117443437684e-09
and O 0 1.3627953800166015e-11
for O 0 1.4795761187416656e-12
a O 0 6.149727428683693e-12
significant O 0 1.8557282099873618e-10
reduction O 0 7.823495185022011e-10
of O 0 2.4397530436898185e-12
this O 0 7.343209373900095e-12
interaction O 0 6.976910021938565e-11
in O 0 6.121702450512245e-11
cells O 0 5.837629823979285e-10
with O 0 2.389737539798542e-11
a O 0 5.70425040535838e-10
hypermethylated O 0 4.144165188790794e-07
DMPK O 0 3.3716412417561514e-07
gene O 0 6.040369981974436e-08
. O 0 3.929133463032031e-09
. O 0 3.8392958146005185e-08

The O 0 5.122926722833654e-07
hemochromatosis B-Disease 1 0.9998703002929688
gene O 0 1.4787349300604546e-06
product O 0 3.154115191250639e-08
complexes O 0 1.4821380567298093e-08
with O 0 2.028249374008695e-10
the O 0 1.1023094659279309e-09
transferrin O 0 1.0336300420021871e-06
receptor O 0 1.275426342317587e-07
and O 0 5.3581494796617335e-09
lowers O 0 1.0131221728215678e-07
its O 0 7.087334191746564e-11
affinity O 0 1.99882110862859e-09
for O 0 1.1864094429103744e-10
ligand O 0 3.295802031288986e-08
binding O 0 2.472254152507958e-07
. O 0 2.822797284807166e-07

We O 0 1.3152101985269837e-07
recently O 0 2.8763444959167828e-08
reported O 0 1.7638994709301414e-09
the O 0 7.419261385810394e-12
positional O 0 8.957303787582305e-10
cloning O 0 1.0533970362658351e-09
of O 0 9.018082287870488e-12
a O 0 1.0556250318316529e-10
candidate O 0 3.273623860877706e-08
gene O 0 6.433302246477979e-07
for O 0 7.982584975252394e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.00011684712808346376
HFE O 1 0.7080899477005005
. O 0 1.358698796138924e-06

The O 0 3.207268894911408e-09
gene O 0 2.44759768008862e-08
product O 0 1.876666821942763e-08
, O 0 1.8030953119474447e-10
a O 0 1.1142777672779047e-10
member O 0 3.1573021974651283e-10
of O 0 1.472479430053575e-11
the O 0 1.0691323520939378e-10
major O 0 1.1888888984401547e-08
histocompatibility O 0 1.9542673612704675e-07
complex O 0 3.955226191010297e-08
class O 0 4.42748131490589e-08
I O 0 9.081374763297845e-09
- O 0 6.49517772899344e-10
like O 0 1.0907099529111619e-10
family O 0 7.534706886191955e-11
, O 0 2.7230198998418054e-11
was O 0 1.1968326329991896e-10
found O 0 3.53387839824304e-11
to O 0 2.0711219197999675e-11
have O 0 1.3619333438796843e-10
a O 0 1.262781823552217e-10
mutation O 0 2.2857326698044744e-08
, O 0 3.9465111734138247e-10
Cys O 0 4.946168337482959e-05
- O 0 1.918011633961214e-07
282 O 0 1.891685741384208e-07
- O 0 6.992046337472857e-07
- O 0 8.248547942457662e-07
> O 0 3.548987237422807e-08
Tyr O 0 1.5200006941995525e-07
( O 0 7.966437232109769e-11
C282Y O 0 2.5768867040198984e-09
) O 0 8.816238537823207e-12
, O 0 4.234533296926246e-12
in O 0 3.9779551180840755e-11
85 O 0 1.005156624600545e-09
% O 0 1.5770763861500114e-10
of O 0 8.128257095174618e-11
patient O 0 7.614147534695803e-08
chromosomes O 0 1.0913956884905929e-06
. O 0 2.5079341980926984e-07

This O 0 2.35123813752125e-08
mutation O 0 3.398244246000104e-07
eliminates O 0 1.9116055227641482e-07
the O 0 2.2494436868747414e-10
ability O 0 2.5803690295589377e-09
of O 0 5.111850526207107e-11
HFE O 0 6.35009826055466e-07
to O 0 2.5479571230668796e-10
associate O 0 2.9408546708964423e-09
with O 0 9.671027867419468e-11
beta2 O 0 3.216385039195302e-06
- O 0 9.870005897028022e-07
microglobulin O 0 4.1288803913630545e-06
( O 0 5.601329400306554e-10
beta2m O 0 2.0641532216814085e-07
) O 0 4.188621949285931e-10
and O 0 2.5134594405784583e-10
prevents O 0 7.217057174102592e-09
cell O 0 4.28528295515207e-07
- O 0 4.235295364196645e-06
surface O 0 3.9278845065382484e-07
expression O 0 1.757530441182098e-07
. O 0 9.063830930244876e-08

A O 0 4.065955039322944e-08
second O 0 5.6633395750793625e-09
mutation O 0 1.476182465154352e-08
that O 0 1.430900120613643e-10
has O 0 2.469814353034394e-10
no O 0 1.5874883352307023e-10
effect O 0 1.0230303271185903e-09
on O 0 1.1395365207000907e-10
beta2m O 0 8.231238979305999e-08
association O 0 1.5710598100238116e-10
, O 0 1.8203411000783376e-11
H63D O 0 1.2469196342124178e-08
, O 0 2.4158694142406567e-11
was O 0 6.18811252239837e-11
found O 0 2.4405455087417316e-11
in O 0 8.46719656194539e-12
eight O 0 4.767213707124185e-11
out O 0 5.3179977782535914e-11
of O 0 1.1548347347845045e-11
nine O 0 9.805004586027621e-10
patients O 0 1.200669785816899e-09
heterozygous O 0 2.6168678335380946e-09
for O 0 5.2638164660390174e-11
the O 0 6.946068165092356e-10
C282Y O 0 1.0663778766684118e-06
mutant O 0 1.2325133411650313e-06
. O 0 1.7754329917352152e-07

In O 0 9.66596669371711e-09
this O 0 2.9695318426448125e-10
report O 0 1.5192138658193244e-09
, O 0 4.8593472995461795e-11
we O 0 1.4370293843768422e-10
demonstrate O 0 8.969031628502933e-10
in O 0 3.2609945299633125e-10
cultured O 0 9.395672861955973e-08
293 O 0 2.380446950667192e-08
cells O 0 9.932022315695122e-09
overexpressing O 0 7.410916396111134e-07
wild O 0 9.742223028297303e-09
- O 0 2.6358048899055575e-07
type O 0 1.0177879516959365e-07
or O 0 3.1137541434134164e-09
mutant O 0 4.8215756720537684e-08
HFE O 0 2.569610160207958e-07
proteins O 0 6.183914491586506e-10
that O 0 1.002438843739073e-11
both O 0 6.418422651005562e-12
the O 0 1.3671978479901092e-11
wild O 0 9.971574677081207e-10
- O 0 5.992015417177754e-07
type O 0 1.2277703262952855e-06
and O 0 2.2812161049046153e-08
H63D O 0 9.108905032917392e-06
HFE O 0 1.072476152330637e-05
proteins O 0 5.14029991904863e-08
form O 0 1.1403333388670944e-08
stable O 0 9.098295450371552e-09
complexes O 0 1.856232678676406e-08
with O 0 2.814516952831525e-10
the O 0 5.10735231884496e-09
transferrin O 0 5.7350971474079415e-06
receptor O 0 3.9798285911274434e-07
( O 0 2.845973678944347e-09
TfR O 0 3.682794158521574e-06
) O 0 1.293538076652112e-08
. O 0 5.6057707809031854e-08

The O 0 3.628758449281122e-08
C282Y O 0 1.7583062117410009e-06
mutation O 0 3.1458549187846074e-07
nearly O 0 6.536953200964035e-09
completely O 0 2.158144241093396e-08
prevents O 0 1.3080397209819239e-08
the O 0 1.1364455904105952e-10
association O 0 2.0198295813678158e-10
of O 0 8.302936463366883e-12
the O 0 3.851298169266215e-10
mutant O 0 3.090482323386823e-07
HFE O 0 2.262769839944667e-06
protein O 0 1.1263604271505301e-08
with O 0 3.51072920734552e-10
the O 0 5.880781195344298e-09
TfR O 0 3.0898285331204534e-05
. O 0 1.229882684583572e-07

Studies O 0 6.152989726615488e-07
on O 0 1.6709950090287862e-09
cell O 0 1.6391861379361217e-07
- O 0 2.760635879894835e-07
associated O 0 1.3506557650089235e-08
transferrin O 0 6.617948145049013e-08
at O 0 7.185764205885903e-10
37 O 0 9.58558343810978e-10
degrees O 0 2.0106295295363452e-08
C O 0 1.1929798482412934e-08
suggest O 0 2.0924224575225026e-09
that O 0 8.534441209295807e-11
the O 0 1.8054183148485947e-10
overexpressed O 0 9.068878057405527e-07
wild O 0 2.708923396710361e-08
- O 0 1.2838654583902098e-06
type O 0 4.282758254703367e-07
HFE O 0 6.839990874141222e-06
protein O 0 4.8361560089915656e-08
decreases O 0 1.0539362271799746e-08
the O 0 6.545942260460791e-11
affinity O 0 2.22251306247756e-09
of O 0 8.427035458336007e-11
the O 0 1.1690707291123204e-09
TfR O 0 1.241790300809953e-06
for O 0 1.9657651062487957e-09
transferrin O 0 2.608667273307219e-06
. O 0 8.525017136662427e-08

The O 0 9.336612549759593e-08
overexpressed O 0 1.2430876267899293e-05
H63D O 0 7.115442031135899e-07
protein O 0 1.2892916068096838e-08
does O 0 2.4661346298415765e-09
not O 0 4.0706042703231304e-11
have O 0 1.565459567531846e-11
this O 0 3.72890303704243e-12
effect O 0 2.553396105664518e-10
, O 0 7.949478748880967e-12
providing O 0 1.8314402078223324e-11
the O 0 4.304483852690666e-12
first O 0 2.2531268517589353e-11
direct O 0 1.4583674545765035e-11
evidence O 0 6.08623096365335e-10
for O 0 4.3216631662179594e-11
a O 0 1.1420909357129361e-10
functional O 0 8.368580495243805e-09
consequence O 0 8.723948674571602e-09
of O 0 4.371162806715567e-11
the O 0 1.1103723496219686e-09
H63D O 0 1.2367931049084291e-05
mutation O 0 2.263559736093157e-06
. O 0 9.845059167901127e-08

Addition O 0 1.357158794235147e-07
of O 0 2.1454282794763913e-09
soluble O 0 2.781109742500121e-07
wild O 0 4.837004397018063e-08
- O 0 6.740178378095152e-06
type O 0 3.971319983975263e-06
HFE O 0 0.0011292030103504658
/ O 0 1.8713215013121953e-06
beta2m O 0 1.1281481420155615e-06
heterodimers O 0 1.5469026948267128e-07
to O 0 2.3360197110022796e-10
cultured O 0 1.503097024624367e-08
cells O 0 8.523029393359138e-09
also O 0 3.4715558205888897e-10
decreased O 0 4.741408377029188e-10
the O 0 3.321589531202207e-11
apparent O 0 2.548050881401309e-09
affinity O 0 3.275758331255929e-09
of O 0 1.7761934284488134e-11
the O 0 1.1232956231843616e-10
TfR O 0 7.303929550062094e-08
for O 0 1.4066319289907092e-11
its O 0 1.2013099716379205e-11
ligand O 0 5.638514100070324e-10
under O 0 8.645176935440091e-11
steady O 0 8.211038959871075e-09
- O 0 2.8295211507156637e-08
state O 0 1.476798461297335e-09
conditions O 0 2.728767878323879e-09
, O 0 1.1733967096583253e-11
both O 0 4.806234576992807e-11
in O 0 2.0172345738256325e-10
293 O 0 1.6856949169863356e-09
cells O 0 2.6960045307333758e-09
and O 0 5.389407808920055e-10
in O 0 2.374627827705922e-09
HeLa O 0 1.5431910469487775e-06
cells O 0 3.3968572665799e-07
. O 0 7.312041816476267e-08

Furthermore O 0 1.5995921387457201e-07
, O 0 8.696134923269483e-10
at O 0 2.7687582782043307e-10
4 O 0 2.2669435773003954e-10
degrees O 0 2.115328356921964e-08
C O 0 1.6531235758066032e-07
, O 0 2.8433244647629863e-10
the O 0 1.6369811062233453e-10
added O 0 2.6272102271462927e-09
soluble O 0 2.92984889682657e-08
complex O 0 4.4103103391535114e-09
of O 0 3.4977357121768193e-10
HFE O 0 1.5100693417480215e-05
/ O 0 1.8806197488174803e-07
beta2m O 0 4.3306641828166903e-07
inhibited O 0 3.913145008027641e-08
binding O 0 8.748293645055583e-09
of O 0 1.4237157286434154e-10
transferrin O 0 7.276106828157936e-08
to O 0 9.269885414830981e-10
HeLa O 0 2.5230789901797834e-07
cell O 0 1.6461119400901225e-07
TfR O 0 4.6949415377639525e-07
in O 0 1.7801149443386066e-10
a O 0 5.68524172184226e-10
concentration O 0 1.395269009663025e-06
- O 0 1.1262592352068168e-06
dependent O 0 2.3595589482283685e-07
manner O 0 2.850531188869354e-07
. O 0 1.7006424002374843e-07

Scatchard O 0 1.1243458175158594e-05
plots O 0 3.361258791301225e-07
of O 0 1.2789129477663863e-10
these O 0 3.683683566513274e-11
data O 0 6.698941401594993e-10
indicate O 0 1.02788100253548e-09
that O 0 6.457807205650923e-11
the O 0 1.552632050705327e-10
added O 0 4.1764263158938775e-09
heterodimer O 0 2.9973268311778156e-08
substantially O 0 1.1572907077095351e-08
reduced O 0 1.6853830553387183e-09
the O 0 9.876172102352143e-11
affinity O 0 1.032402519030029e-08
of O 0 2.4565188772029956e-10
TfR O 0 1.2399134448060067e-06
for O 0 2.822065470198254e-09
transferrin O 0 2.029278675763635e-06
. O 0 5.338982944635973e-08

These O 0 6.917107242543352e-08
results O 0 1.1548755196599814e-07
establish O 0 2.2804982791058137e-08
a O 0 1.0222793722647339e-09
molecular O 0 1.6846286143845646e-08
link O 0 7.66753061043346e-08
between O 0 2.137846788485831e-09
HFE O 0 1.456310292269336e-05
and O 0 3.483044963559223e-09
a O 0 2.381716213140095e-10
key O 0 2.489143779982328e-09
protein O 0 1.0302402264628086e-09
involved O 0 8.350048985583669e-10
in O 0 2.2231479157586165e-10
iron O 0 2.507414933461405e-07
transport O 0 1.0678815609566072e-09
, O 0 3.437613735335354e-11
the O 0 2.8267709353824166e-11
TfR O 0 7.01656759360958e-08
, O 0 5.189835020069644e-11
and O 0 4.3966406904072386e-11
raise O 0 9.519512955691312e-11
the O 0 8.29924670653348e-12
possibility O 0 2.0749424400889893e-10
that O 0 1.745403821473701e-11
alterations O 0 2.7068456365242355e-09
in O 0 3.947615845323327e-11
this O 0 2.039066485104435e-11
regulatory O 0 2.847939661876353e-09
mechanism O 0 4.0822539792984003e-10
may O 0 4.000563491590725e-10
play O 0 5.6894371158744406e-11
a O 0 8.664040838934906e-12
role O 0 5.223732557624317e-10
in O 0 4.970552441863063e-11
the O 0 1.7333122437346304e-10
pathogenesis O 0 5.982536777082714e-08
of O 0 1.1682309342120334e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.8338429299546988e-06
. O 0 2.4475562554471253e-07

Genomic O 0 1.9462193449726328e-05
organization O 0 1.9574494558582956e-07
of O 0 1.5106667028419452e-09
the O 0 5.819255743944041e-09
UBE3A O 0 3.3030108170351014e-05
/ O 0 1.3586185332314926e-06
E6 O 0 8.4671393096869e-07
- O 0 1.1961329846599256e-06
AP O 0 4.491804247663822e-06
gene O 0 2.7618725084721518e-08
and O 0 4.747054971332432e-10
related O 0 1.0300325037349012e-08
pseudogenes O 0 2.514465222702711e-06
. O 0 1.931416591105517e-07

The O 0 4.503675938849483e-07
UBE3A O 0 5.173631143406965e-05
gene O 0 1.4490747162199114e-06
encodes O 0 2.3424651374170935e-07
the O 0 5.842611727757685e-09
E6 O 0 1.048172521223023e-06
- O 0 1.892526029223518e-06
AP O 0 5.808281002828153e-06
ubiquitin O 0 8.915824167843311e-08
- O 0 1.58226942659212e-08
protein O 0 8.860144284916771e-10
ligase O 0 4.4808112775740483e-10
and O 0 2.5145323323538804e-11
has O 0 2.4562645320469478e-11
recently O 0 2.472298477051993e-10
been O 0 2.2927021392504798e-11
shown O 0 2.227403678167761e-11
to O 0 9.99878044943836e-12
be O 0 9.477409135261183e-11
mutated O 0 2.0279443901927152e-07
in O 0 2.8875919610982237e-07
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.4078724234423134e-05
who O 0 9.610594986497745e-09
lack O 0 9.815524393275155e-09
15q11 O 0 1.0897742868110072e-06
- O 0 5.02733428220381e-07
q13 O 0 7.474006338270556e-07
deletions O 0 3.6059660146747774e-07
or O 0 3.253406077874388e-08
chromosome O 0 1.132406760007143e-05
15 O 0 9.048871874028919e-08
paternal O 0 9.27705241338117e-06
uniparental B-Disease 0 0.009233365766704082
disomy I-Disease 0 0.0008617582498118281
. O 0 2.044636630671448e-06

Previous O 0 2.1722532892454183e-06
UBE3A O 0 1.2610829799086787e-05
cDNA O 0 4.769403290083574e-07
analysis O 0 5.13136590996055e-08
has O 0 1.3919090324776562e-09
shown O 0 1.2234474544570162e-09
a O 0 3.3787733721979407e-10
coding O 0 4.3225352897025004e-07
region O 0 1.6854190931780977e-08
of O 0 5.854162293816856e-11
approximately O 0 1.2764935775066988e-09
2 O 0 1.4238367818109054e-08
. O 0 4.415101528820742e-08

6 O 0 1.9386573058000067e-06
kb O 0 4.418591288413154e-06
and O 0 3.5013221211244172e-09
a O 0 2.1464763300116374e-09
3 O 0 4.066203018737724e-08
- O 0 1.1313618415442761e-05
untranslated O 0 0.07081160694360733
region O 0 4.2528228050287e-07
( O 0 7.371759869201355e-10
UTR O 0 1.2248962377725547e-07
) O 0 1.8587287264892893e-10
of O 0 1.3171582748106037e-11
< O 0 2.171306023868169e-09
50 O 0 3.612622700988055e-10
bp O 0 2.47434339684105e-08
, O 0 3.0342159340612795e-11
whereas O 0 5.77458469930292e-10
Northern O 0 1.5056786928369092e-09
analysis O 0 1.2963067952398433e-08
has O 0 2.2893789086708694e-09
indicated O 0 1.7805471541620932e-09
mRNA O 0 1.1105715236325864e-09
sizes O 0 6.347903980241654e-09
of O 0 6.783283656996986e-11
5 O 0 2.1124364479874203e-09
- O 0 3.9628918102607713e-07
8 O 0 4.409328369092691e-08
kb O 0 3.224265583412489e-06
. O 0 1.5099537620244519e-07

We O 0 1.077640447988415e-07
have O 0 7.742886332096077e-10
analyzed O 0 2.0485333429576258e-09
additional O 0 1.0200058853104821e-10
cDNA O 0 3.614843757659969e-09
clones O 0 4.251786478448594e-09
and O 0 6.04552519156698e-11
provide O 0 2.1139902328659588e-11
evidence O 0 5.162665087099505e-11
for O 0 9.799703583335262e-12
an O 0 8.166808375398293e-12
additional O 0 1.699058560511446e-09
0 O 0 1.5491666616185285e-08
. O 0 3.395120984350797e-08

5 O 0 3.517892253057653e-07
kb O 0 2.1631592517223908e-06
of O 0 1.0662004612527198e-09
5 O 0 1.7826515374963492e-08
- O 0 3.280518399151333e-07
UTR O 0 2.2654171516478527e-06
and O 0 2.9155264869018538e-09
> O 0 2.8165105803168444e-09
2 O 0 9.397779221487212e-10
kb O 0 5.1455966598723535e-08
of O 0 1.579132102857983e-10
3 O 0 2.6158112120810983e-08
- O 0 3.5107477742712945e-06
UTR O 0 5.4452433687401935e-05
. O 0 2.5244483481401403e-07

We O 0 5.506264528776228e-07
have O 0 9.171854387091116e-10
established O 0 5.549837256424439e-10
the O 0 5.055630566963565e-11
genomic O 0 2.0746197648691123e-08
organization O 0 7.018007286418992e-10
of O 0 4.408850715065249e-11
UBE3A O 0 1.785059424719293e-07
and O 0 2.2154816869957017e-10
the O 0 1.9567292230959765e-11
sequence O 0 1.1872249849886884e-09
of O 0 2.0959803337383676e-10
intron O 0 1.169161987490952e-05
- O 0 3.705927383634844e-06
exon O 0 4.828496003028704e-06
borders O 0 2.7433611649030354e-06
. O 0 1.789291133036386e-07

We O 0 3.089124334110238e-07
have O 0 7.853216410502739e-10
also O 0 1.457464288145971e-10
mapped O 0 7.797861023561836e-09
two O 0 1.402782473514108e-10
highly O 0 1.101746138765236e-09
homologous O 0 4.072379322650477e-09
processed O 0 2.6580471157444663e-09
pseudogenes O 0 4.1719300014619876e-08
, O 0 2.255617637114682e-10
UBE3AP1 O 0 7.843973293120143e-08
and O 0 3.540964743642405e-10
UBE3AP2 O 0 5.508513467589182e-08
, O 0 3.3432635132557564e-11
to O 0 1.324034631933202e-11
chromosomes O 0 5.457597707092532e-10
2 O 0 1.893058487745236e-10
and O 0 7.553584840946925e-11
21 O 0 6.434384969278284e-11
, O 0 8.329997282230384e-12
respectively O 0 5.501336053370665e-10
, O 0 4.26764977523586e-11
and O 0 6.179339817613538e-10
determined O 0 2.8705843035936596e-08
their O 0 1.7547352459956755e-09
genomic O 0 3.536676160820207e-07
organization O 0 7.760502285236726e-08
. O 0 5.821257431648519e-08

These O 0 1.6939466718213225e-08
results O 0 5.023217397592816e-08
will O 0 1.419404593860918e-10
form O 0 3.710239060428222e-11
the O 0 4.333712208537399e-12
basis O 0 7.802360840747369e-11
for O 0 1.9848610602335448e-11
studies O 0 1.2170656704668659e-09
of O 0 1.6031152100248747e-11
mutation O 0 8.826615882639999e-09
and O 0 1.5393839536415044e-09
imprinting O 0 6.738815159224032e-07
of O 0 6.749618641777033e-09
UBE3A O 0 0.00011559260747162625
. O 0 4.147169647694682e-07

Mutation O 0 1.1032481779693626e-05
spectrum O 0 3.5739520853894646e-07
and O 0 3.614762889014855e-08
genotype O 0 0.001083780312910676
- O 0 0.0003303945704828948
phenotype O 0 5.839456207468174e-06
analyses O 0 2.016823685835334e-07
in O 0 4.755086102647965e-09
Cowden B-Disease 0 1.3196167856222019e-05
disease I-Disease 0 8.267047633125912e-07
and O 0 8.688662234135336e-09
Bannayan B-Disease 1 0.9925798773765564
- I-Disease 1 0.9999667406082153
Zonana I-Disease 1 0.9999327659606934
syndrome I-Disease 1 0.9999327659606934
, O 0 3.6118457114042712e-09
two O 0 1.7564271814762833e-08
hamartoma B-Disease 0 0.054530128836631775
syndromes I-Disease 0 0.0016127978451550007
with O 0 1.0375276104923614e-07
germline O 0 0.0003870198270305991
PTEN O 0 0.0017397295450791717
mutation O 0 0.00012098835577489808
. O 0 1.8154291865357663e-06

The O 0 1.069033487510751e-06
tumour B-Disease 1 0.9999985694885254
suppressor O 0 2.6073563276440836e-05
gene O 0 4.473532499105204e-06
PTEN O 0 4.527253258856945e-05
, O 0 3.332844666914525e-09
which O 0 2.1339673084153077e-10
maps O 0 1.2984671116100799e-08
to O 0 7.511712141194948e-09
10q23 O 0 3.2815210033732e-06
. O 0 1.1333711569250227e-07

3 O 0 1.5449477075435425e-07
and O 0 2.5764836930619595e-09
encodes O 0 2.7647397260466278e-08
a O 0 6.3553060591914345e-09
403 O 0 5.844576023150694e-08
amino O 0 1.83889554250527e-07
acid O 0 3.08539085835946e-07
dual O 0 1.9454082575975917e-06
specificity O 0 2.3959355530678295e-06
phosphatase O 0 0.00027458975091576576
( O 0 8.109125815281004e-09
protein O 0 6.876735625382935e-08
tyrosine O 0 5.387839792092564e-07
phosphatase O 0 4.36266327596968e-06
; O 0 3.1556541824073747e-09
PTPase O 0 6.700609134213664e-08
) O 0 3.030111161983484e-10
, O 0 3.963640873849705e-11
was O 0 2.898021822517194e-10
shown O 0 4.823796917463596e-10
recently O 0 5.1009467760820826e-09
to O 0 4.907436609857818e-11
play O 0 3.639783197062485e-10
a O 0 5.671213845759304e-11
broad O 0 1.3122246622643274e-09
role O 0 1.2727842779725052e-08
in O 0 1.0648794068757184e-09
human O 0 2.4370974571752413e-08
malignancy B-Disease 0 4.305266702431254e-05
. O 0 1.3241356100479607e-07

Somatic O 0 0.00045278260949999094
PTEN O 0 0.0002772104344330728
deletions O 0 2.642794925122871e-06
and O 0 1.8983538296879487e-08
mutations O 0 8.520172656290015e-08
were O 0 4.856477442416463e-10
observed O 0 2.7748288111695274e-09
in O 0 7.245991029414256e-10
sporadic B-Disease 0 1.1374862879165448e-05
breast I-Disease 1 0.9980494976043701
, I-Disease 0 4.809066567190712e-08
brain I-Disease 0 3.1539544579572976e-05
, I-Disease 0 1.1501542829250866e-08
prostate I-Disease 0 0.0002165173937100917
and I-Disease 0 1.9060351519328833e-07
kidney I-Disease 0 6.6472161961428355e-06
cancer I-Disease 0 4.486216482746386e-07
cell O 0 1.0260327343303288e-07
lines O 0 2.1198243871367595e-07
and O 0 3.701638440212207e-10
in O 0 4.857957092152532e-11
several O 0 8.010795915502911e-10
primary O 0 8.997845725389197e-05
tumours B-Disease 1 1.0
such O 0 5.320516804907527e-10
as O 0 2.2356855922112118e-08
endometrial B-Disease 1 0.996112048625946
carcinomas I-Disease 1 1.0
, O 0 0.013468085788190365
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 0 0.08184774965047836
thyroid B-Disease 1 0.9999997615814209
tumours I-Disease 1 1.0
. O 0 1.231118858413538e-06

In O 0 1.7341804436910024e-08
addition O 0 6.307256050774868e-09
, O 0 4.1582298715425736e-10
PTEN O 0 8.186863169612479e-07
was O 0 5.895467447558644e-10
identified O 0 8.526472305980803e-10
as O 0 2.241968069527367e-11
the O 0 1.566764773475171e-11
susceptibility O 0 5.1208624007870185e-09
gene O 0 6.3443090780879174e-09
for O 0 5.925251400640263e-10
two O 0 8.302967557938246e-08
hamartoma B-Disease 1 0.9999492168426514
syndromes I-Disease 1 0.9999855756759644
Cowden B-Disease 1 0.9987708926200867
disease I-Disease 0 0.008606723509728909
( O 0 2.9784903432528154e-09
CD B-Disease 0 1.8130158707663213e-07
; O 0 9.62266444304305e-09
MIM O 0 7.861000995035283e-06
158350 O 0 1.9132488660034142e-07
) O 0 8.135815354748388e-10
and O 0 3.1104656628144767e-09
Bannayan B-Disease 0 0.00023887581482995301
- I-Disease 0 0.0029290548991411924
Zonana I-Disease 0 4.453681322047487e-05
( I-Disease 0 3.922476565776378e-09
BZS I-Disease 0 1.357840005766775e-06
) I-Disease 0 2.849660507564522e-10
or I-Disease 0 7.194019269185503e-10
Ruvalcaba I-Disease 0 7.730107427050825e-06
- I-Disease 0 5.643378244712949e-06
Riley I-Disease 0 0.00024344050325453281
- I-Disease 1 0.9987760186195374
Smith I-Disease 1 0.9883375763893127
syndrome I-Disease 1 0.9384526014328003
( O 0 7.907511090365915e-09
MIM O 0 7.248551810334902e-06
153480 O 0 9.023120242090954e-07
) O 0 1.0213931034286361e-08
. O 0 4.6226379168956555e-08

Constitutive O 0 3.160042751915171e-06
DNA O 0 6.108694492468203e-07
from O 0 1.3957053290880594e-09
37 O 0 3.932132397466148e-09
CD B-Disease 0 1.2794242110203413e-08
families O 0 6.525650575461839e-10
and O 0 4.3597495058556035e-10
seven O 0 2.7830391324812354e-09
BZS B-Disease 0 3.7299530504242284e-06
families O 0 1.3055788672389212e-09
was O 0 9.445058068990875e-10
screened O 0 7.734450946372817e-08
for O 0 5.189592755527883e-09
germline O 0 1.0856149856408592e-05
PTEN O 0 0.00016708952898625284
mutations O 0 2.445917561999522e-05
. O 0 5.597009362645622e-07

PTEN O 0 0.0005812860908918083
mutations O 0 6.100326572777703e-06
were O 0 8.33094748742269e-09
identified O 0 5.438812511471269e-09
in O 0 1.2610729127615627e-10
30 O 0 2.688977929210523e-10
of O 0 2.2360278559285796e-11
37 O 0 2.1661270555028977e-09
( O 0 1.411720601529609e-10
81 O 0 2.948245647615977e-09
% O 0 2.856108682891545e-10
) O 0 6.869712437795883e-11
CD B-Disease 0 7.3336878791963045e-09
families O 0 2.1647465764385032e-10
, O 0 1.2712345065502006e-11
including O 0 4.3965907303711305e-11
missense O 0 6.475330565081094e-07
and O 0 2.4315616187209343e-09
nonsense O 0 1.4189775754402945e-07
point O 0 1.1788631404385796e-08
mutations O 0 2.064873072527007e-08
, O 0 5.6428795663920894e-11
deletions O 0 5.594360530380982e-09
, O 0 1.1866742311017475e-10
insertions O 0 2.2541231103900827e-08
, O 0 3.841914286706327e-10
a O 0 6.126856244570433e-10
deletion O 0 8.155179216373654e-07
/ O 0 2.1528637716983212e-07
insertion O 0 1.2158881190771353e-07
and O 0 4.664502117890379e-09
splice O 0 6.473270786955254e-06
site O 0 7.582906391689903e-07
mutations O 0 1.2164800864411518e-05
. O 0 2.482983916252124e-07

These O 0 1.3136427057247602e-08
mutations O 0 5.474921138670652e-08
were O 0 3.336302623058174e-10
scattered O 0 6.600797131106617e-10
over O 0 3.292895678352892e-10
the O 0 9.70619487561386e-11
entire O 0 1.0049783227827902e-09
length O 0 4.227647565357984e-09
of O 0 4.482382173764954e-11
PTEN O 0 1.3671548515503673e-07
, O 0 2.9687773073217016e-11
with O 0 3.196820412554313e-12
the O 0 4.34167155352605e-12
exception O 0 4.013655519052861e-10
of O 0 2.545938503420442e-12
the O 0 1.8289163586371338e-11
first O 0 1.4760691557924588e-09
, O 0 1.1676840050434123e-10
fourth O 0 1.279706562939964e-09
and O 0 3.6174077622241896e-10
last O 0 3.669486936530575e-09
exons O 0 8.339915780197771e-07
. O 0 6.245522854442243e-08

A O 0 8.857887934254904e-08
hot O 0 4.272526723525516e-07
spot O 0 1.28331308246743e-07
for O 0 1.962068063576794e-09
PTEN O 0 4.8434294512844644e-06
mutation O 0 1.6320171880579437e-07
in O 0 5.13301512405917e-10
CD B-Disease 0 3.343963683732909e-08
was O 0 2.4298556500212953e-09
identified O 0 2.330075465906134e-09
in O 0 8.805319667848366e-11
exon O 0 1.4040152152006158e-08
5 O 0 4.859702085191486e-10
that O 0 1.2617314311402783e-11
contains O 0 2.1548257969628004e-11
the O 0 1.0641541120515186e-10
PTPase O 0 4.6129230213409755e-08
core O 0 4.853868418308593e-09
motif O 0 3.179464025393486e-09
, O 0 1.718658548810481e-11
with O 0 4.585194203488019e-12
13 O 0 4.364664532574558e-11
of O 0 3.7510237971272176e-12
30 O 0 1.105066593787285e-10
( O 0 2.786318745173766e-11
43 O 0 1.388186676720693e-09
% O 0 2.1391509397172825e-10
) O 0 3.583032481824233e-10
CD B-Disease 0 7.283465919272203e-08
mutations O 0 2.7967908877712944e-08
identified O 0 3.3846641045442993e-09
in O 0 4.3313845565773335e-11
this O 0 1.1303622621250398e-10
exon O 0 3.3132425869553117e-07
. O 0 7.141174052094357e-08

Seven O 0 1.18493383993723e-08
of O 0 8.794644873466595e-11
30 O 0 2.21477197692721e-10
( O 0 2.672145490989486e-11
23 O 0 2.5332841380176774e-10
% O 0 4.1612113060862654e-11
) O 0 5.420952228774034e-11
were O 0 1.0751896595273536e-10
within O 0 1.813164722530569e-11
the O 0 3.751461641332554e-11
core O 0 3.844093487970213e-09
motif O 0 2.906465068619468e-09
, O 0 3.1448958021096374e-11
the O 0 5.601356184437023e-12
majority O 0 2.1551145590326115e-10
( O 0 3.953023672287337e-12
five O 0 8.14658323439188e-12
of O 0 8.179665170020278e-13
seven O 0 1.3828259717851843e-11
) O 0 4.049098729919098e-12
of O 0 8.468533491644281e-13
which O 0 2.042305907723474e-10
were O 0 1.105737723605671e-09
missense O 0 1.8004412538630277e-07
mutations O 0 3.52774200962358e-08
, O 0 6.627665777303449e-11
possibly O 0 5.141804759745128e-10
pointing O 0 5.865098628987653e-09
to O 0 2.524794262548369e-10
the O 0 3.4168983614746296e-11
functional O 0 2.628583573027754e-09
significance O 0 5.812353931489156e-10
of O 0 1.6880677411457157e-11
this O 0 3.287724537059944e-10
region O 0 5.905580380272113e-08
. O 0 1.6848302664129733e-07

Germline O 0 0.0016126865521073341
PTEN O 0 0.00020379932539071888
mutations O 0 2.6204611458524596e-06
were O 0 1.544999350677756e-09
identified O 0 2.446191693650235e-09
in O 0 2.826797997068642e-11
four O 0 3.045975277560231e-11
of O 0 6.027193067553727e-12
seven O 0 2.679930721782853e-10
( O 0 6.943932234770855e-11
57 O 0 7.352497721768714e-09
% O 0 1.2959203710138922e-09
) O 0 3.479014631935229e-09
BZS B-Disease 0 1.173699911305448e-05
families O 0 8.419428709771637e-09
studied O 0 1.9692510022650822e-07
. O 0 1.297786695886316e-07

Interestingly O 0 1.3376546803556266e-06
, O 0 4.5307619878087735e-09
none O 0 2.424416001289842e-09
of O 0 1.3527781325683996e-11
these O 0 2.285874128871157e-10
mutations O 0 3.7605225600145786e-08
was O 0 2.3437729534947493e-09
observed O 0 1.904089774740214e-09
in O 0 3.7529668261981897e-10
the O 0 9.79610614848525e-10
PTPase O 0 9.590810350346146e-07
core O 0 3.6693074889626587e-07
motif O 0 2.0508625766524347e-06
. O 0 2.787681694371713e-07

It O 0 2.4357962757903806e-08
is O 0 4.377923579212961e-10
also O 0 9.903410730371931e-11
worthy O 0 2.8594770995482577e-10
of O 0 3.2488603821101414e-12
note O 0 1.529553039780751e-09
that O 0 2.8524814454922165e-11
a O 0 1.1148623690893089e-10
single O 0 6.262256491140761e-09
nonsense O 0 7.954590586223276e-08
point O 0 3.3682674427382153e-09
mutation O 0 1.621173417731825e-08
, O 0 9.610879453392229e-11
R233X O 0 2.1433477215282437e-08
, O 0 1.318471026801049e-10
was O 0 2.5558860583529963e-10
observed O 0 9.708569503885656e-10
in O 0 4.496305064383144e-11
the O 0 8.633659065448995e-11
germline O 0 3.919068447544305e-08
DNA O 0 1.9422454755613217e-08
from O 0 4.997140895524055e-11
two O 0 3.388504060675146e-11
unrelated O 0 4.670751785340599e-09
CD B-Disease 0 2.0761241614764003e-08
families O 0 1.0319433085825835e-09
and O 0 6.573558919420464e-10
one O 0 5.100090572085492e-09
BZS B-Disease 0 1.828571294026915e-05
family O 0 4.775958117875234e-08
. O 0 4.0518724375715465e-08

Genotype O 1 0.7931053638458252
- O 0 0.25128570199012756
phenotype O 0 4.100599653611425e-06
studies O 0 9.227591135640978e-08
were O 0 2.170865986972359e-10
not O 0 2.159277444346852e-11
performed O 0 2.0866743055680814e-10
on O 0 3.300603193534535e-11
this O 0 2.277921254401072e-11
small O 0 9.957814572914003e-10
group O 0 1.165835783467628e-08
of O 0 1.0434704211803592e-09
BZS B-Disease 0 3.5083161492366344e-05
families O 0 3.9682536367990906e-08
. O 0 4.212380844137442e-08

However O 0 2.028694865430225e-07
, O 0 8.308081334007511e-09
genotype O 0 1.2697063539235387e-05
- O 0 3.0207540930859977e-06
phenotype O 0 5.207870685808302e-07
analysis O 0 1.6873039854203853e-08
inthe O 0 3.3296760193479713e-07
group O 0 7.515925659618006e-09
of O 0 2.6636116923217656e-11
CD B-Disease 0 8.526802375286024e-09
families O 0 2.1451611320610908e-10
revealed O 0 1.5410467346654855e-09
two O 0 1.8599937562369107e-11
possible O 0 3.5101263562431484e-10
associations O 0 1.340092481427746e-10
worthy O 0 4.784925233813908e-10
of O 0 1.1322195785090639e-11
follow O 0 1.626509038565871e-09
- O 0 7.924847977847094e-08
up O 0 4.2014742795970506e-09
in O 0 8.460183664737997e-10
independent O 0 3.787639357710759e-08
analyses O 0 3.565284885098663e-07
. O 0 5.1409077883590726e-08

The O 0 4.1956043084212524e-09
first O 0 4.876575587786647e-09
was O 0 4.352298965670798e-09
an O 0 3.858928454558708e-11
association O 0 1.3829955236577263e-10
noted O 0 3.54149154446759e-10
in O 0 3.3687781730851185e-11
the O 0 4.732786038075254e-11
group O 0 1.2703510465783552e-09
of O 0 9.369223279154237e-12
CD B-Disease 0 4.087376836992007e-08
families O 0 2.6355366777863765e-09
with O 0 6.1894405156692756e-09
breast B-Disease 1 0.8402623534202576
disease I-Disease 0 4.6405280045291875e-06
. O 0 8.105078563858115e-08

A O 0 6.704546251512511e-08
correlation O 0 2.661189171249134e-07
was O 0 4.2003844846760785e-09
observed O 0 9.525420452405342e-10
between O 0 4.223162791694435e-11
the O 0 6.145696451742566e-11
presence O 0 6.664840679349027e-09
/ O 0 2.8562750387095548e-08
absence O 0 1.2950852612547692e-09
of O 0 2.304262856911432e-11
a O 0 4.561463984309455e-10
PTEN O 0 1.1444295751061873e-06
mutation O 0 2.4350439886688946e-08
and O 0 1.2237783009183545e-10
the O 0 3.9940804136273655e-11
type O 0 1.2072565169773952e-08
of O 0 5.99324423422587e-10
breast O 0 1.1874396477651317e-05
involvement O 0 3.194733437794639e-07
( O 0 3.0456877020412776e-09
unaffected O 0 4.267062649887521e-07
versus O 0 3.049094857487944e-06
benign O 0 0.0003716600767802447
versus O 0 8.73287717695348e-05
malignant O 0 0.349104642868042
) O 0 5.798473878826371e-08
. O 0 1.2959661432887515e-07

Specifically O 0 6.919641037939073e-08
and O 0 3.9167627474689937e-10
more O 0 1.3766048197194625e-11
directly O 0 3.291740213740013e-10
, O 0 3.49402839994184e-10
an O 0 5.1125034761234645e-11
association O 0 5.062841257341688e-10
was O 0 3.348584698414925e-08
also O 0 2.9521493583040126e-10
observed O 0 1.6038684269581438e-10
between O 0 1.2370346934298393e-11
the O 0 9.105469850334558e-12
presence O 0 2.2381708986163318e-10
of O 0 1.9747710411355257e-11
a O 0 2.331849602299485e-09
PTEN O 0 7.814403215888888e-05
mutation O 0 4.713874659501016e-06
and O 0 2.5973051265282265e-07
malignant B-Disease 1 0.9989966750144958
breast I-Disease 1 0.9997780919075012
disease I-Disease 0 0.00955435261130333
. O 0 9.685104487289209e-07

Secondly O 0 1.8027616533800028e-05
, O 0 2.8357598491624003e-09
there O 0 2.0004982392851645e-10
appeared O 0 2.149015854158165e-09
to O 0 8.404065637845903e-11
be O 0 2.978380597706831e-10
an O 0 5.221996793314254e-11
interdependent O 0 6.979740874157869e-08
association O 0 2.8626095938122376e-10
between O 0 1.4031437123307455e-10
mutations O 0 3.463594522301605e-09
upstream O 0 9.229413899802807e-10
and O 0 1.197467403013519e-10
within O 0 3.9424012665545405e-11
the O 0 8.604478241025504e-11
PTPase O 0 5.1833239922416396e-08
core O 0 4.677188414348166e-09
motif O 0 9.39608124639335e-09
, O 0 1.236860752706903e-10
the O 0 1.5350460486063255e-11
core O 0 1.8927921452416285e-09
motif O 0 6.54615750494969e-10
containing O 0 3.4261718462325064e-11
the O 0 2.5167010836435466e-11
majority O 0 6.444324518461997e-10
of O 0 2.002337184947578e-11
missense O 0 9.147263568820563e-08
mutations O 0 1.2123052783863386e-08
, O 0 2.6117391235813692e-11
and O 0 1.51351188526494e-11
the O 0 6.9956549234029275e-12
involvement O 0 2.500544216132994e-10
of O 0 1.862190089629845e-12
all O 0 1.7232671886691087e-11
major O 0 6.234841531949087e-10
organ O 0 5.7760964899955525e-09
systems O 0 9.904969289209475e-09
( O 0 4.959955016148321e-11
central O 0 1.1444597491916397e-09
nervous O 0 4.4883773853143794e-07
system O 0 3.4973439699825803e-09
, O 0 2.7075205966120564e-10
thyroid O 0 1.4925921277608722e-05
, O 0 5.166026495473375e-10
breast O 0 3.1546762329526246e-05
, O 0 2.5061284603111744e-08
skin O 1 0.9974894523620605
and O 0 0.0008601127192378044
gastrointestinal O 0 0.06689104437828064
tract O 0 0.0014840341173112392
) O 0 5.967288529973303e-08
. O 0 1.463082952568584e-07

However O 0 2.3077497246504208e-08
, O 0 1.505781471733414e-10
these O 0 8.454593795892418e-12
observations O 0 7.217136333004248e-10
would O 0 1.7037664334917935e-10
need O 0 2.962142683915481e-11
to O 0 6.850500635507961e-12
be O 0 3.676446647116194e-11
confirmed O 0 3.074646787171176e-11
by O 0 1.5876078663518145e-12
studying O 0 2.671545207277859e-10
a O 0 1.7182193168263638e-11
larger O 0 1.8167763127241443e-10
number O 0 3.9415914976359545e-10
of O 0 7.26044432908246e-11
CD B-Disease 0 1.3023705491832516e-07
families O 0 1.5954519483329932e-08
. O 0 4.439437972791893e-08

Molecular O 0 0.00016081961803138256
defects O 0 0.061835452914237976
leading O 0 2.358672013258456e-08
to O 0 8.300268250494014e-10
human O 0 3.781241986189343e-09
complement B-Disease 0 1.4199769111655769e-06
component I-Disease 1 0.8991116881370544
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.404396764494777e-10
an O 0 7.572309446146619e-11
African O 0 2.921203945405182e-09
- O 0 8.003443241477726e-08
American O 0 1.8762230880042807e-08
family O 0 2.0276827328302716e-08
. O 0 3.899153355746421e-08

Complement B-Disease 0 0.0006205928511917591
component I-Disease 1 0.993916928768158
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.1713948921965311e-08
C6D B-Disease 0 9.594314178684726e-07
) O 0 3.6294973693173915e-09
was O 0 7.416725011921699e-09
diagnosed O 0 2.202196753842145e-07
in O 0 1.0155255802946073e-10
a O 0 1.8233825560542982e-10
16 O 0 6.672774000016091e-10
- O 0 1.044845188147292e-08
year O 0 9.984503002158363e-09
- O 0 3.0335030487549375e-08
old O 0 2.0567843250773876e-07
African O 0 1.1980779701659117e-09
- O 0 5.2039652587154706e-09
American O 0 7.218874387149299e-09
male O 0 2.7274422720324765e-08
with O 0 1.8159051151656058e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999959468841553
. O 0 2.1108188263951888e-07

The O 0 2.6679837006327034e-08
patients O 0 1.3624210737361864e-07
father O 0 6.746825764736286e-09
and O 0 3.659867131577954e-10
two O 0 1.7253398709726753e-10
brothers O 0 5.5854282976497416e-08
also O 0 8.814599050666061e-10
had O 0 4.543273257606728e-10
C6D B-Disease 0 5.493488330898799e-08
, O 0 5.03093530376808e-12
but O 0 8.582527050160493e-12
gave O 0 3.032590151219594e-11
no O 0 2.5311914023107285e-11
history O 0 3.078433064018782e-10
of O 0 1.3332368542506856e-10
meningitis B-Disease 1 0.9999749660491943
or O 0 1.780088632052923e-09
other O 0 3.6097453914862854e-09
neisserial B-Disease 0 0.00024992425460368395
infection I-Disease 0 3.455454861978069e-05
. O 0 1.2991314690680156e-07

By O 0 5.70762681562087e-09
using O 0 1.7034334831578235e-08
exon O 0 6.516862640637555e-07
- O 0 1.9677098350712185e-07
specific O 0 1.0696576957514026e-08
polymerase O 0 3.205042276022141e-07
chain O 0 4.3927079218519793e-07
reaction O 0 1.4441335238757347e-08
( O 0 3.4825181627340385e-10
PCR O 0 6.139800490245761e-08
) O 0 2.1206222888814352e-10
/ O 0 3.299725159777722e-09
single O 0 6.547134834278268e-09
- O 0 1.0926500237928849e-07
strand O 0 4.782475571118994e-07
conformation O 0 2.457594305838029e-08
polymorphism O 0 3.095806633268694e-08
as O 0 1.0470026928777187e-10
a O 0 4.998961314339745e-11
screening O 0 1.3719981817317262e-09
step O 0 7.308897376212542e-10
and O 0 2.2852407466356084e-11
nucleotide O 0 1.7246037931073488e-09
sequencing O 0 5.312333906104527e-10
of O 0 1.4699708464349648e-11
target O 0 1.353362866218788e-09
exons O 0 1.963270612748147e-08
, O 0 2.5139054726786014e-10
we O 0 1.3203432791542014e-10
determined O 0 2.3036750285143626e-10
that O 0 1.064685405810506e-11
the O 0 1.7554600134639387e-11
proband O 0 6.992439693931374e-08
was O 0 3.76997016937608e-10
a O 0 5.8046064482786264e-11
compound O 0 4.43249792425604e-09
heterozygote O 0 1.2110518810004578e-07
for O 0 2.5135840631129724e-10
two O 0 2.813836719184337e-09
C6 O 0 4.519976300798589e-06
gene O 0 2.4556743483117316e-06
mutations O 0 7.158667813200736e-06
. O 0 3.65023339554682e-07

The O 0 6.398704233134822e-09
first O 0 1.655949710688276e-09
, O 0 8.639984561131797e-11
1195delC O 0 9.0360714466442e-09
located O 0 2.2244074637800537e-10
in O 0 9.73972430484693e-11
exon O 0 2.114545694098524e-08
7 O 0 3.1712876769063314e-09
, O 0 4.728671620934932e-11
is O 0 1.927304323079415e-11
a O 0 1.3240447800655364e-11
novel O 0 9.926790500713878e-10
mutation O 0 1.2622862755051756e-09
, O 0 1.286778843201386e-11
while O 0 2.180675258423026e-11
the O 0 7.956957141785903e-12
second O 0 2.3579588281918973e-10
, O 0 1.4106969065119657e-11
1936delG O 0 3.1524176602459875e-09
in O 0 1.5942540690372375e-11
exon O 0 2.793143050183744e-09
12 O 0 3.6365285782657963e-10
, O 0 1.5726239754876303e-11
has O 0 5.071285752444865e-11
been O 0 1.113251713036334e-10
described O 0 1.48692474999379e-10
before O 0 2.2290878864961172e-10
to O 0 4.388873986460595e-11
cause O 0 1.7994192247350327e-10
C6D B-Disease 0 5.15298275161058e-08
in O 0 5.027791377676394e-11
an O 0 1.3214033166286665e-11
unrelated O 0 5.040067030392947e-09
African O 0 4.265538144920811e-09
- O 0 2.579248459255723e-08
American O 0 6.3657878968115256e-09
individual O 0 4.927372732055346e-09
. O 0 1.6762918164658913e-08

Both O 0 1.7306192034993728e-07
mutations O 0 2.9960463052702835e-06
result O 0 6.163960364347076e-08
in O 0 7.804064949823442e-09
premature O 0 3.986255876498035e-07
termination O 0 6.618932388846588e-07
codons O 0 2.821652515194728e-06
and O 0 4.943906262155906e-08
C6 O 0 1.8949565856019035e-05
null O 0 1.3044519619143102e-05
alleles O 0 5.9870681070606224e-06
. O 0 4.63833686126236e-07

Allele O 0 0.0001306079066125676
- O 0 3.97047188016586e-06
specific O 0 1.0828570040644081e-08
PCR O 0 3.2239566394309804e-07
indicated O 0 2.8364577353556797e-09
that O 0 2.0715642742863416e-11
the O 0 1.4838161949137785e-11
probands O 0 2.2847999048281054e-08
two O 0 8.945347934607994e-11
brothers O 0 1.6009725101184813e-08
also O 0 4.3488451728634914e-10
inherited O 0 2.327647052879911e-08
the O 0 1.1319653547836594e-10
1195delC O 0 7.807329183151523e-08
mutation O 0 6.590698653496929e-09
from O 0 3.386371738578475e-11
their O 0 4.730565938970699e-11
heterozygous O 0 1.1152611278930635e-08
mother O 0 3.164037698510924e-09
and O 0 3.079018984220028e-11
the O 0 2.1870108155019885e-11
1936delG O 0 3.715591390118789e-08
mutation O 0 5.804867253544899e-09
from O 0 5.521369125793818e-11
their O 0 1.3885778638034196e-10
homozygous O 0 1.0475514500285499e-07
father O 0 2.224553874441426e-08
. O 0 4.3901757784681195e-09
. O 0 3.5629660999347834e-08

PAX6 O 0 0.004232439678162336
mutations O 0 0.00021537160500884056
reviewed O 0 1.7389225831720978e-05
. O 0 1.3722050198339275e-06

Mutations O 0 1.6555752154090442e-05
in O 0 7.024225201490708e-09
PAX6 O 0 7.777971973155218e-07
are O 0 2.772420348851057e-10
responsible O 0 8.85132744876671e-10
for O 0 2.716245284251073e-11
human O 0 1.089310794344378e-10
aniridia B-Disease 1 1.0
and O 0 4.5219969435628116e-10
have O 0 8.59619458948302e-11
also O 0 5.560695306994212e-11
been O 0 4.8404391606027275e-11
found O 0 2.571640296544775e-11
in O 0 2.916374433614699e-11
patients O 0 4.5631606826468385e-10
with O 0 1.1388325005246003e-10
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 4.954606169782494e-10
with O 0 3.9123375650262915e-09
congenital B-Disease 1 0.9999939203262329
cataracts I-Disease 1 0.9995911717414856
, O 0 2.4585262714538203e-09
with O 0 4.661077745993225e-09
autosomal B-Disease 1 0.9906741976737976
dominant I-Disease 0 0.48346441984176636
keratitis I-Disease 1 0.9969911575317383
, O 0 3.1132316724580278e-09
and O 0 5.33456001594601e-10
with O 0 2.912341701133414e-09
isolated B-Disease 0 0.0004979301011189818
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 6.121522801549872e-06

No O 0 7.158056547496017e-08
locus O 0 1.3136030929672415e-07
other O 0 7.045219407864067e-10
than O 0 8.114567906503112e-10
chromosome O 0 2.400182097517245e-07
11p13 O 0 9.167662256004405e-07
has O 0 4.983781387579711e-09
been O 0 1.255404891153944e-09
implicated O 0 2.3765501566685998e-08
in O 0 1.4155823180317384e-09
aniridia B-Disease 1 1.0
, O 0 1.2006011740339773e-09
and O 0 6.586033385325152e-10
PAX6 O 0 3.611727663610509e-07
is O 0 5.41225619876684e-10
clearly O 0 4.567131117738654e-10
the O 0 5.62006214135935e-12
major O 0 1.5680243214966083e-10
, O 0 3.1604760475367755e-11
if O 0 3.249297220175862e-10
not O 0 6.355869303087402e-11
only O 0 2.8069940469221955e-11
, O 0 3.692145894573784e-11
gene O 0 1.1476604555582526e-08
responsible O 0 7.486055864092123e-08
. O 0 8.026771780578201e-08

Twenty O 0 8.260112167590705e-07
- O 0 2.180010596930515e-06
eight O 0 1.871983457135684e-08
percent O 0 3.759934585900737e-08
of O 0 8.147379992884396e-11
identified O 0 6.010214548268777e-08
PAX6 O 0 3.496360250210273e-06
mutations O 0 2.3768748746988422e-07
are O 0 1.4847064688794376e-09
C O 0 3.2271648819914844e-07
- O 0 2.1108321561769117e-06
T O 0 7.45938052659767e-07
changes O 0 1.937028093479398e-09
at O 0 2.0940421618931282e-10
CpG O 0 3.576870000188137e-08
dinucleotides O 0 5.780783496334152e-08
, O 0 1.0810666944971459e-10
20 O 0 5.598923755179008e-11
% O 0 1.4842887335886346e-11
are O 0 2.0356418373862484e-12
splicing O 0 6.426566390160815e-09
errors O 0 4.185173985149504e-09
, O 0 7.754628536527086e-12
and O 0 2.2674644280240575e-12
more O 0 5.139306406658217e-13
than O 0 2.0505094150413683e-11
30 O 0 2.884566197014493e-10
% O 0 3.671877732425166e-11
are O 0 3.2978911268521927e-11
deletion O 0 1.841225483190101e-08
or O 0 6.383353290395632e-10
insertion O 0 1.5601351321947732e-08
events O 0 3.1781322462620665e-08
. O 0 7.150005387757119e-08

There O 0 5.234469924175755e-08
is O 0 1.2699610252298044e-09
a O 0 7.830287529486668e-10
noticeably O 0 3.5430087308441216e-08
elevated O 0 5.699677529946712e-08
level O 0 2.473096394339791e-09
of O 0 1.7071647914757015e-11
mutation O 0 2.813858257511015e-09
in O 0 4.9526095030616446e-11
the O 0 1.6405059602431216e-11
paired O 0 1.1636336338938236e-09
domain O 0 4.5172643403645907e-10
compared O 0 3.5425454236737153e-10
with O 0 6.8372382408532495e-12
the O 0 3.441215368216177e-11
rest O 0 4.5128722980791736e-10
of O 0 6.608576099548236e-12
the O 0 2.1356369450664658e-10
gene O 0 1.1503917107802408e-07
. O 0 8.749799462748342e-08

Increased O 0 6.426679988180695e-07
mutation O 0 4.6431964051407704e-07
in O 0 1.988667674979183e-09
the O 0 5.220585075349504e-10
homeodomain O 0 2.7809505809273105e-07
is O 0 1.073370073378932e-10
accounted O 0 6.778165251297708e-10
for O 0 8.46504897428213e-12
by O 0 4.097799530256019e-11
the O 0 5.791283563816307e-10
hypermutable O 0 4.961957984050969e-06
CpG O 0 3.8479356589959934e-06
dinucleotide O 0 2.7593589493335458e-06
in O 0 6.334213153991186e-09
codon O 0 5.562527576330467e-07
240 O 0 3.1160727331780436e-08
. O 0 3.6618818199940506e-08

Very O 0 2.2744861993828636e-08
nearly O 0 4.205338743901166e-09
all O 0 3.7912709083265383e-10
mutations O 0 1.4348124466323497e-08
appear O 0 3.6996921082277368e-09
to O 0 7.916033384347543e-10
cause O 0 2.842946322800799e-09
loss O 0 2.1065660327224123e-09
of O 0 3.266282426819811e-12
function O 0 1.4123399671994719e-10
of O 0 3.8842405854222495e-12
the O 0 1.1186660105189095e-11
mutant O 0 6.105243421927753e-09
allele O 0 6.703405386332406e-09
, O 0 1.451839603400229e-11
and O 0 2.547055665338971e-12
more O 0 3.270332680875565e-13
than O 0 6.128229434326782e-12
80 O 0 7.687405573220119e-11
% O 0 1.924824709342854e-11
of O 0 7.243717344701528e-12
exonic O 0 7.66912435778977e-08
substitutions O 0 1.404749117028814e-08
result O 0 6.39610497898957e-09
in O 0 4.363561956211015e-09
nonsense O 0 8.067728458627244e-07
codons O 0 3.913331511284923e-06
. O 0 1.580219191055221e-07

In O 0 9.62450030783657e-09
a O 0 2.2996406168207528e-10
gene O 0 1.587095455057863e-09
with O 0 1.8001563781289143e-11
such O 0 7.928858264394378e-11
extraordinarily O 0 1.0752830625904153e-08
high O 0 2.4199855452877728e-09
sequence O 0 8.561689690544938e-10
conservation O 0 1.5656873020297724e-10
throughout O 0 7.565249815488784e-11
evolution O 0 9.868018902015052e-11
, O 0 2.0605971789988686e-11
there O 0 1.988642930883522e-11
are O 0 1.951284966938971e-10
presumed O 0 7.909234511771501e-08
undiscovered O 0 5.866097012585669e-07
missense O 0 7.301902087419876e-07
mutations O 0 7.387362899180516e-08
, O 0 4.1135157780036735e-11
these O 0 1.8792429418157397e-11
are O 0 1.4407528989290874e-11
hypothesized O 0 9.727272320958491e-10
to O 0 2.447687365292328e-11
exist O 0 1.7914446592826039e-09
in O 0 6.169256078214502e-11
as O 0 8.180832677950889e-10
- O 0 3.814493538811803e-07
yet O 0 9.543160217617697e-08
unidentified O 0 3.272388084951672e-07
phenotypes O 0 1.9657029781683377e-07
. O 0 2.5266693182146582e-09
. O 0 1.9050460764447052e-08

Genetic O 0 3.3915934182005e-05
heterogeneity O 0 1.8940605514217168e-05
and O 0 5.0490854164308985e-08
penetrance O 0 2.1000716969865607e-06
analysis O 0 1.9122431638152193e-08
of O 0 7.731017215295566e-11
the O 0 7.628283560379145e-10
BRCA1 O 0 3.875120000884635e-06
and O 0 9.090351582585754e-09
BRCA2 O 0 2.822904207278043e-06
genes O 0 2.695142882203072e-07
in O 0 4.6427931721382265e-08
breast B-Disease 1 0.7198496460914612
cancer I-Disease 0 0.0017705735517665744
families O 0 1.3579783342265728e-07
. O 0 1.813078114309974e-07

The O 0 3.451328302617185e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.00012592895654961467
Consortium O 0 3.278842632425949e-05
. O 0 9.034779964167683e-07

The O 0 6.212124592508417e-09
contribution O 0 1.0148140106025494e-08
of O 0 1.6476535413811888e-10
BRCA1 O 0 5.444393309517181e-07
and O 0 9.112675947164917e-09
BRCA2 O 0 1.9747492842725478e-05
to O 0 1.1234359362788382e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 1.112283243287493e-07
assessed O 0 1.1176845227112153e-08
by O 0 1.1223789952996555e-10
linkage O 0 9.550698365501376e-08
and O 0 1.864798315764915e-09
mutation O 0 5.519648293983437e-09
analysis O 0 7.852048455880833e-10
in O 0 2.933568665763886e-11
237 O 0 2.0318463578306023e-10
families O 0 3.824664890350604e-11
, O 0 4.386921381716036e-12
each O 0 6.0267563509186495e-12
with O 0 8.920892670405411e-12
at O 0 9.533940303896316e-11
least O 0 8.949336931241003e-12
four O 0 4.018716956433188e-11
cases O 0 9.868269534862861e-10
of O 0 3.1043712045430993e-10
breast B-Disease 0 0.21206048130989075
cancer I-Disease 0 6.195602395564492e-07
, O 0 6.6019997628508076e-12
collected O 0 4.086778138123748e-11
by O 0 2.774102336733364e-10
the O 0 9.550431059324183e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 8.71547126735095e-06
Consortium O 0 2.713903995754663e-06
. O 0 1.3628421413613978e-07

Families O 0 9.778902665402711e-08
were O 0 3.8167380367326587e-10
included O 0 4.112700111025269e-11
without O 0 8.708479770636046e-11
regard O 0 1.3150552868879117e-10
to O 0 9.851389669301991e-12
the O 0 2.2656154730071876e-11
occurrence O 0 3.7514030992724656e-08
of O 0 1.1912421049586897e-09
ovarian B-Disease 0 0.00018644376541487873
or I-Disease 0 5.4672901761421144e-09
other I-Disease 0 1.75722458806149e-08
cancers I-Disease 0 0.03626495599746704
. O 0 1.5677409237468964e-07

Overall O 0 5.1220806199125946e-05
, O 0 1.2447480912669562e-07
disease O 0 2.422444254079892e-07
was O 0 1.2395017234823058e-09
linked O 0 2.256355458030157e-08
to O 0 3.051320585090167e-10
BRCA1 O 0 1.5577237277852873e-08
in O 0 2.543998171844475e-11
an O 0 2.5047661427607393e-12
estimated O 0 1.394906273821661e-10
52 O 0 1.1035906632983483e-09
% O 0 4.716241286395473e-11
of O 0 4.012205064712893e-12
families O 0 9.602413308940072e-11
, O 0 1.0284309862051977e-11
to O 0 5.236258995844345e-11
BRCA2 O 0 2.377112195972586e-08
in O 0 6.80126441277018e-11
32 O 0 5.473171915681974e-10
% O 0 3.306639684286239e-11
of O 0 1.5280461358041508e-12
families O 0 1.3448088476142317e-10
, O 0 1.3674013310538413e-11
and O 0 2.4499385159471032e-11
to O 0 2.469332724408524e-11
neither O 0 3.150901206616652e-10
gene O 0 1.118095505070471e-09
in O 0 9.565379044396138e-11
16 O 0 1.2403193749843666e-10
% O 0 3.219935082454661e-11
( O 0 9.592176011818943e-12
95 O 0 3.433578976697049e-10
% O 0 1.0284476603672488e-09
confidence O 0 6.830564558413244e-08
interval O 0 3.3911472741010584e-08
[ O 0 5.678060244207472e-09
CI O 0 8.638316728593054e-08
] O 0 2.996913828212655e-09
6 O 0 7.272880631070677e-10
% O 0 4.290545141394375e-10
- O 0 1.7009602970574633e-07
28 O 0 7.766052689817116e-09
% O 0 6.167844707194448e-11
) O 0 1.5721651411282345e-11
, O 0 1.2116121474170516e-11
suggesting O 0 1.871015342658211e-09
other O 0 1.3716370261818156e-09
predisposition O 0 2.4242791596407187e-07
genes O 0 5.537175411518547e-07
. O 0 1.1125082011176346e-07

The O 0 1.0343893741548982e-08
majority O 0 4.393965014060086e-08
( O 0 3.340416276920166e-10
81 O 0 1.1882670403196016e-09
% O 0 7.887739766898605e-11
) O 0 2.087963135721793e-11
of O 0 1.1037094849175588e-11
the O 0 1.0344076173396388e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.9934565109736013e-09
were O 0 9.91486406864972e-11
due O 0 1.2546334804408588e-10
to O 0 4.5949584415172495e-11
BRCA1 O 0 9.387571608954204e-09
, O 0 7.723703621120848e-12
with O 0 1.3860309384591818e-12
most O 0 3.000582768364346e-11
others O 0 3.5463584846517904e-10
( O 0 2.464937629009789e-11
14 O 0 2.845147450969421e-10
% O 0 7.203984631054539e-11
) O 0 1.6449340500823695e-10
due O 0 2.6410065245840997e-09
to O 0 1.0678413708831158e-08
BRCA2 O 0 1.1739372894226108e-05
. O 0 8.29994348805485e-08

Conversely O 0 9.768534710019594e-07
, O 0 1.108423575146844e-09
the O 0 3.869645229248597e-11
majority O 0 5.248500523080679e-10
of O 0 4.605678251973222e-12
families O 0 6.07349517900424e-11
with O 0 3.479356039393089e-11
male B-Disease 0 2.993356531533209e-07
and I-Disease 0 1.8961246794901854e-08
female I-Disease 0 3.523873965605162e-05
breast I-Disease 0 0.0006493614637292922
cancer I-Disease 0 3.106266149188741e-06
were O 0 6.104250438454528e-10
due O 0 1.3364532813753272e-09
to O 0 1.2635967827634431e-09
BRCA2 O 0 1.2140820899730898e-06
( O 0 8.923879968314452e-10
76 O 0 1.948378880456403e-08
% O 0 2.0763606389806455e-09
) O 0 5.724165585974106e-09
. O 0 6.871832169963454e-08

The O 0 6.020354881286494e-09
largest O 0 9.53789758284529e-09
proportion O 0 1.1583264125647474e-08
( O 0 1.931327459070431e-10
67 O 0 9.994234329013807e-10
% O 0 5.103287237240295e-11
) O 0 2.844494952081167e-11
of O 0 6.898753703715732e-12
families O 0 4.249530449751404e-10
due O 0 5.489764198784997e-10
to O 0 1.4796868591515633e-11
other O 0 1.4031108740153453e-11
genes O 0 3.480034871383708e-10
was O 0 5.188640073150452e-10
found O 0 6.311666467251342e-11
in O 0 1.1522956200327172e-11
families O 0 7.273428387355452e-12
with O 0 1.5115030537957153e-12
four O 0 2.011585516215053e-11
or O 0 5.566361954700838e-11
five O 0 2.994596584593445e-11
cases O 0 2.312559033157413e-10
of O 0 2.3821344896646224e-10
female O 0 0.0004042575310450047
breast B-Disease 0 0.16130675375461578
cancer I-Disease 0 8.025200258998666e-06
only O 0 4.249135265865789e-09
. O 0 3.6134942149601557e-08

These O 0 6.839309119044401e-09
estimates O 0 1.6332993624246228e-08
were O 0 4.781886553395509e-10
not O 0 1.1042743802702759e-10
substantially O 0 1.357799539469795e-09
affected O 0 1.0753967855103852e-10
either O 0 1.679611311145024e-11
by O 0 3.3953617695203775e-11
changing O 0 5.813609149640797e-09
the O 0 1.9774029635932777e-10
assumed O 0 2.8125450413085673e-08
penetrance O 0 9.264591227520214e-08
model O 0 7.749449970617661e-09
for O 0 7.805605467536836e-11
BRCA1 O 0 1.664560755898492e-08
or O 0 7.557274944725023e-11
by O 0 1.1715851379323627e-11
including O 0 8.647255134164311e-11
or O 0 4.364411054780248e-09
excluding O 0 1.5940944422254688e-06
BRCA1 O 0 1.8872413420467637e-05
mutation O 0 5.35686979219463e-07
data O 0 1.3872323734176462e-07
. O 0 8.62527755884912e-08

Among O 0 1.3639311902124973e-08
those O 0 1.3602050596972504e-09
families O 0 1.3720216074375458e-09
with O 0 2.7556870674239065e-10
disease O 0 1.640990454632174e-08
due O 0 6.24433837970173e-10
to O 0 1.5014593734985482e-10
BRCA1 O 0 2.2290942425229332e-08
that O 0 3.662023115302837e-11
were O 0 4.430076097627911e-11
tested O 0 7.403629792568367e-11
by O 0 8.3050699564019e-13
one O 0 8.956303580720526e-12
of O 0 3.9491408190470145e-13
the O 0 5.37720389048868e-12
standard O 0 8.222396097323781e-10
screening O 0 3.173640239495512e-10
methods O 0 1.9431189990370967e-09
, O 0 5.695321991794344e-11
mutations O 0 1.5461815161543768e-09
were O 0 8.941373336179836e-11
detected O 0 1.0455264431996625e-09
in O 0 2.5632858682844706e-11
the O 0 3.4450178820755184e-11
coding O 0 3.046154262165146e-08
sequence O 0 8.412233132304436e-10
or O 0 1.0458690163916984e-10
splice O 0 1.1870376681599737e-08
sites O 0 1.0059870714229646e-09
in O 0 9.954651686294724e-12
an O 0 3.899919016198128e-12
estimated O 0 3.1018440593832963e-10
63 O 0 4.701570244236564e-09
% O 0 1.397241489176082e-10
( O 0 4.644203077663889e-11
95 O 0 1.7886857550664104e-09
% O 0 1.5799433983332278e-09
CI O 0 4.7196951413752686e-07
51 O 0 2.32280399359297e-08
% O 0 4.1877932233092e-09
- O 0 1.493093168392079e-05
77 O 0 1.2782928138221905e-07
% O 0 3.4753402378129294e-09
) O 0 2.8416777819728622e-09
. O 0 3.9370423365880924e-08

The O 0 3.596646314107943e-09
estimated O 0 7.450949301990306e-10
sensitivity O 0 3.515796986874875e-09
was O 0 5.312333906104527e-10
identical O 0 1.5665026220634815e-10
for O 0 6.554384205520458e-12
direct O 0 2.4437875334459846e-11
sequencing O 0 4.075221271548912e-10
and O 0 4.664408442822676e-11
other O 0 5.951469178588908e-11
techniques O 0 1.0774411407510343e-07
. O 0 9.888739782581979e-08

The O 0 2.983466629302711e-08
penetrance O 0 6.80178754919325e-06
of O 0 1.1487746309768454e-09
BRCA2 O 0 9.295243899032357e-07
was O 0 2.257013020923182e-09
estimated O 0 8.304967824557252e-11
by O 0 2.960120690231882e-11
maximizing O 0 1.43641702976538e-08
the O 0 9.689016255975957e-10
LOD O 0 0.016106151044368744
score O 0 1.285032080744486e-08
in O 0 1.3984500224495378e-09
BRCA2 O 0 7.922806616988964e-06
- O 0 3.6533745628730685e-07
mutation O 0 4.466616942977453e-08
families O 0 3.352396693578896e-10
, O 0 8.84217265378906e-12
over O 0 4.482612891987259e-11
all O 0 1.05153163953986e-10
possible O 0 4.488109883737934e-09
penetrance O 0 5.35076821961411e-07
functions O 0 1.7664458340505007e-08
. O 0 8.674772544736697e-08

The O 0 8.572969001363617e-09
estimated O 0 1.613670796984934e-08
cumulative O 0 1.0208403011802147e-07
risk O 0 4.270530951089313e-07
of O 0 4.674831632911491e-10
breast B-Disease 0 0.0010779472067952156
cancer I-Disease 0 3.923022813978605e-05
reached O 0 1.1168406643946582e-08
28 O 0 3.5554152955086238e-09
% O 0 1.3837500589808371e-10
( O 0 4.023180746881572e-11
95 O 0 8.858420108559528e-10
% O 0 3.9573580523644125e-10
CI O 0 2.56013890975737e-07
9 O 0 1.7985830602640362e-09
% O 0 3.5753591753895364e-10
- O 0 5.994026963662691e-08
44 O 0 1.6637569100197425e-09
% O 0 5.695028823526904e-11
) O 0 6.011923164156441e-12
by O 0 1.0558501122026609e-11
age O 0 6.691062703900741e-10
50 O 0 4.2725201848670125e-11
years O 0 2.9703023374239024e-10
and O 0 1.039421673731944e-10
84 O 0 4.363268357732153e-10
% O 0 4.52315962462535e-11
( O 0 1.6069602246093773e-11
95 O 0 5.294530369681638e-10
% O 0 3.823543703873611e-10
CI O 0 1.2172687036127172e-07
43 O 0 3.1625111418520646e-09
% O 0 5.563073890435533e-10
- O 0 5.415627768456943e-08
95 O 0 3.56148310842741e-09
% O 0 2.000765386700465e-10
) O 0 4.3824246315216087e-11
by O 0 1.4163351047535855e-10
age O 0 9.989816973643428e-09
70 O 0 3.7754981363491424e-09
years O 0 1.87201933954384e-08
. O 0 4.035175038552552e-08

The O 0 2.773259382138349e-07
corresponding O 1 0.7659832835197449
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.07046137005090714
were O 0 1.1489483142668178e-08
0 O 0 6.049490508530653e-08
. O 0 8.789291428001889e-08

4 O 0 3.321598001093662e-07
% O 0 1.1791644993763839e-08
( O 0 9.574363524222917e-10
95 O 0 5.450433437914626e-09
% O 0 2.974442470105032e-09
CI O 0 8.850944936966698e-07
0 O 0 3.91977650338049e-09
% O 0 1.1544791789219744e-09
- O 0 9.245049881201339e-08
1 O 0 2.024930001454095e-09
% O 0 2.03520429675752e-11
) O 0 2.0397071618522e-12
by O 0 3.38730671116394e-12
age O 0 1.8898944909029325e-10
50 O 0 1.40510606622124e-11
years O 0 1.4788723023961836e-10
and O 0 1.7629467330415594e-10
27 O 0 4.931883235137491e-10
% O 0 3.3957631845327185e-11
( O 0 2.0010198359399212e-11
95 O 0 6.813798414384564e-10
% O 0 3.055286301734128e-10
CI O 0 7.161224147012035e-08
0 O 0 8.33343838380074e-10
% O 0 3.010122706648133e-10
- O 0 3.317928332080555e-08
47 O 0 5.836730654351641e-09
% O 0 6.271393820922455e-11
) O 0 9.650992678633674e-12
by O 0 4.3050032288993734e-11
age O 0 6.7839631689992075e-09
70 O 0 1.5449108659026933e-09
years O 0 1.539023664065553e-08
. O 0 4.847145262942831e-08

The O 0 2.6975698119713343e-08
lifetime O 0 5.30607110249548e-07
risk O 0 9.229094075635658e-07
of O 0 9.114635712847985e-10
breast B-Disease 0 0.012609978206455708
cancer I-Disease 0 5.579780463449424e-06
appears O 0 1.3043717217442463e-09
similar O 0 2.3856899789009844e-10
to O 0 3.508373036531509e-10
the O 0 2.0922417964808204e-10
risk O 0 1.6177571282582903e-08
in O 0 6.716158879038758e-11
BRCA1 O 0 2.0877273243513628e-08
carriers O 0 1.0798781868714968e-09
, O 0 2.4943073648198144e-11
but O 0 5.6140120330283594e-11
there O 0 1.0411712290936403e-11
was O 0 3.469071904738108e-11
some O 0 1.7310307917975387e-12
suggestion O 0 3.2400884752981085e-10
of O 0 6.724922702039393e-12
a O 0 6.050130951784638e-10
lower O 0 1.8198011275671888e-07
risk O 0 1.701164791256815e-07
in O 0 1.045404873778466e-09
BRCA2 O 0 7.184680157479306e-07
carriers O 0 9.46672340518262e-09
< O 0 3.774691670344055e-09
50 O 0 1.8952261982008167e-10
years O 0 7.597775186773958e-10
of O 0 9.489311419974555e-11
age O 0 2.9971499060366114e-08
. O 0 3.909921986178233e-08

Eye B-Disease 1 0.954142689704895
movement I-Disease 0 5.5112318477767985e-06
abnormalities I-Disease 0 0.00033824695856310427
correlate O 0 3.219516884200857e-07
with O 0 2.7316684469980146e-09
genotype O 0 2.7984722692053765e-05
in O 0 2.981106206334516e-08
autosomal O 1 0.7501751780509949
dominant O 0 0.04530720412731171
cerebellar B-Disease 0 0.013527221977710724
ataxia I-Disease 1 0.9610722661018372
type I-Disease 1 0.9999797344207764
I I-Disease 0 0.29397666454315186
. O 0 3.039810678728827e-07

We O 0 3.5185769320378313e-07
compared O 0 4.099736372609186e-08
horizontal O 0 2.3589520878886105e-06
eye O 0 0.36218151450157166
movements O 0 8.912948032957502e-06
( O 0 5.26287857738339e-09
visually O 0 3.144960203371738e-08
guided O 0 6.489177906132682e-08
saccades O 0 1.2963064364157617e-06
, O 0 5.213380838142712e-10
antisaccades O 0 8.034706411308434e-08
, O 0 1.5417839227538366e-10
and O 0 1.5339668424374509e-10
smooth O 0 3.6742351383622918e-09
pursuit O 0 7.573804694516184e-09
) O 0 2.7451949047296864e-10
in O 0 8.223725866951526e-11
control O 0 2.7581599226778053e-09
subjects O 0 1.3799667186731313e-08
( O 0 6.24259671733185e-11
n O 0 1.1249669640278626e-08
= O 0 9.259463418231917e-09
14 O 0 1.5914082551748976e-10
) O 0 1.8267269641381034e-11
and O 0 1.968213092506943e-11
patients O 0 3.8757243941978103e-11
with O 0 7.441535994183457e-13
three O 0 1.0491730748074524e-11
forms O 0 7.80147113577101e-10
of O 0 1.045169617519548e-09
autosomal O 0 0.24927787482738495
dominant O 0 0.002078909194096923
cerebellar B-Disease 0 9.544056229060516e-05
ataxias I-Disease 0 8.853046892909333e-05
type I-Disease 0 4.095268377568573e-05
I I-Disease 0 2.176312108304046e-07
spinocerebellar B-Disease 0 4.255644398654113e-06
ataxias I-Disease 0 3.75328977497702e-06
1 I-Disease 0 5.806306546674023e-09
and I-Disease 0 5.367935540512292e-10
2 I-Disease 0 6.41867448081257e-10
( O 0 1.5871795544519784e-10
SCA1 B-Disease 0 3.2477399258823425e-07
, O 0 3.384307556419941e-10
n O 0 7.836256799009789e-08
= O 0 2.2052308423781142e-08
11 O 0 6.377731120998931e-10
; O 0 1.6335502395214974e-10
SCA2 B-Disease 0 9.9895352434487e-08
, O 0 8.156258307634445e-11
n O 0 1.6687598858311503e-08
= O 0 1.9434905240700573e-08
10 O 0 2.902790507963715e-10
) O 0 9.165798675603298e-11
and O 0 1.7764696380595524e-09
SCA3 B-Disease 1 1.0
/ O 0 4.349036260009598e-07
Machado B-Disease 0 7.655992249055998e-07
- I-Disease 0 4.0829203840075934e-07
Joseph I-Disease 0 4.083826297573978e-06
disease I-Disease 0 9.588696912032901e-07
( O 0 1.535577554001577e-09
MJD B-Disease 1 1.0
) O 0 2.932307507919063e-09
( O 0 2.889169459230345e-10
n O 0 1.7049863743068272e-07
= O 0 3.379215627319354e-07
16 O 0 1.1112204489904798e-08
) O 0 3.4668130588499935e-09
. O 0 4.6567524947249694e-08

In O 0 5.837334526859195e-08
SCA1 B-Disease 0 2.0638985915866215e-06
, O 0 4.6513332074837876e-10
saccade O 0 1.9534697059953032e-07
amplitude O 0 1.701433127720975e-08
was O 0 4.372543216391023e-09
significantly O 0 9.207053786042252e-09
increased O 0 1.4854769636585274e-09
, O 0 1.7206273905667757e-10
resulting O 0 5.075616371641445e-09
in O 0 4.341810910801769e-09
hypermetria B-Disease 0 5.507748028321657e-06
. O 0 1.0182345988596353e-07

The O 0 5.8947176029278125e-09
smooth O 0 4.853407986615821e-08
pursuit O 0 1.0342931489049079e-07
gain O 0 1.4468597555605811e-06
was O 0 1.0304573550001805e-07
decreased O 0 7.994987640813633e-07
. O 0 1.1305385072546414e-07

In O 0 8.916232019373638e-08
SCA2 B-Disease 0 3.253119757573586e-06
, O 0 2.706592505674621e-09
saccade O 0 1.7977491779674892e-06
velocity O 0 1.7131341678577883e-07
was O 0 4.321669777596071e-08
markedly O 0 4.214125226553733e-07
decreased O 0 9.115823331740103e-07
. O 0 2.146674233927115e-07

The O 0 3.875455067969824e-09
percentage O 0 3.320485575386556e-08
of O 0 1.7873777111154787e-11
errors O 0 1.448256736757969e-09
in O 0 4.157752267475168e-11
antisaccades O 0 9.435613179675784e-08
was O 0 7.145636304883851e-10
greatly O 0 1.6591736318183337e-10
increased O 0 8.574072701827973e-11
and O 0 1.3879608573574842e-10
was O 0 2.468331095073495e-10
significantly O 0 5.710607542397383e-10
correlated O 0 9.35971300464189e-10
with O 0 1.2641482305397744e-10
age O 0 8.584324362459483e-09
at O 0 9.511065712786149e-09
disease O 0 1.3749753691172373e-07
onset O 0 1.7588730543138809e-06
. O 0 2.09694661634785e-07

In O 0 1.740658994719979e-08
addition O 0 5.279356507514876e-09
, O 0 1.4527377911743855e-10
a O 0 3.6176332762760666e-11
correlation O 0 4.652311424990785e-09
between O 0 2.0671447886755345e-10
smooth O 0 3.376481760852812e-09
pursuit O 0 1.3045242219789088e-08
gain O 0 1.309122126258444e-07
and O 0 1.5730927671597783e-10
the O 0 1.2386212715209677e-11
number O 0 1.0840751213381239e-10
of O 0 7.439996535518745e-11
trinucleotide O 0 1.3854121334588854e-06
repeats O 0 3.401872561425989e-07
was O 0 6.541991837138994e-09
found O 0 8.754819980083539e-09
. O 0 3.2367996283255707e-08

In O 0 1.5548629050954332e-07
SCA3 B-Disease 1 0.9999998807907104
, O 0 5.9183529188544526e-09
gaze B-Disease 0 6.337651029753033e-06
- I-Disease 0 9.02842259620229e-07
evoked I-Disease 0 1.7122245310474682e-07
nystagmus I-Disease 0 1.3145961474947399e-06
was O 0 1.6019430226776876e-09
often O 0 1.67651087457088e-10
present O 0 5.4909132796154836e-11
as O 0 6.291821924575558e-11
was O 0 6.218167092342242e-10
saccade O 0 1.7687627007489937e-07
hypometria O 0 5.512790934858458e-08
and O 0 2.2358924434140448e-10
smooth O 0 1.366018520521095e-09
pursuit O 0 1.0603400824038545e-08
gain O 0 1.7096202498123603e-07
was O 0 9.088877206409052e-09
markedly O 0 3.4598267006913375e-07
decreased O 0 6.298554922068433e-07
. O 0 8.58997921682203e-08

Three O 0 1.1634854857334176e-08
major O 0 1.4632091982491602e-08
criteria O 0 3.249288482720658e-08
, O 0 4.988933710592391e-10
saccade O 0 3.9104151028368506e-07
amplitude O 0 2.229145401599908e-08
, O 0 9.213337870406235e-10
saccade O 0 6.752550234523369e-07
velocity O 0 3.8007740954526525e-08
, O 0 6.809212083069838e-10
and O 0 4.153450083865806e-10
presence O 0 1.6808019420722076e-09
of O 0 7.406059099324125e-11
gaze B-Disease 0 1.7981941709876992e-05
- I-Disease 0 5.190753995520936e-07
evoked I-Disease 0 1.1781656183984524e-07
nystagmus I-Disease 0 1.434387399967818e-07
, O 0 3.535833778545161e-11
permitted O 0 1.736300131449653e-10
the O 0 1.798670240527045e-11
correct O 0 2.630449191798334e-09
assignment O 0 2.978592483771081e-09
of O 0 2.406330343318608e-12
90 O 0 3.8843536026567094e-11
% O 0 1.2039249805417818e-11
of O 0 1.7768363820211408e-12
the O 0 2.607210107530289e-11
SCA1 B-Disease 0 4.2533869759608933e-07
, O 0 4.421356336603566e-11
90 O 0 4.3397778426434996e-11
% O 0 1.5275223794186665e-11
of O 0 1.214172534215463e-12
the O 0 1.9367861481267568e-11
SCA2 B-Disease 0 2.1400066430032894e-07
, O 0 4.314242713077121e-11
and O 0 2.959572864558169e-11
93 O 0 8.029760883987436e-11
% O 0 1.198639017901959e-11
of O 0 1.167399944074221e-12
the O 0 1.3951750865714985e-10
patients O 0 3.0910907167225332e-09
with O 0 1.2676201754935335e-10
SCA3 B-Disease 1 1.0
to O 0 5.069324959805499e-10
their O 0 1.3511852747782882e-10
genetically O 0 3.6532781244602575e-09
confirmed O 0 5.902525579415396e-09
patient O 0 1.9221595426444082e-09
group O 0 2.9182845029396276e-10
and O 0 1.0007066009176668e-10
, O 0 2.631806751696164e-11
therefore O 0 2.5446983409338486e-10
, O 0 1.5570091049799117e-10
may O 0 1.7174084376847532e-09
help O 0 1.2253742465162532e-09
orient O 0 7.191336948153548e-08
diagnoses O 0 2.4037302637225366e-07
of O 0 5.959067961303077e-11
SCA1 B-Disease 0 1.8525443579164858e-07
, O 0 8.555857411440826e-11
SCA2 B-Disease 0 8.3552180285551e-08
, O 0 1.2531840842822106e-10
and O 0 3.262606018683556e-10
SCA3 B-Disease 1 1.0
at O 0 6.295750587526072e-10
early O 0 6.567117405431588e-10
clinical O 0 9.621636820611457e-09
stages O 0 2.616179051173617e-09
of O 0 6.046540351745122e-11
the O 0 1.4559452532481032e-09
diseases O 0 1.9421477759351546e-07
. O 0 1.3842048618428748e-09
. O 0 2.6308772049787876e-08

Genetic O 0 3.721400844369782e-06
basis O 0 2.8520233286144503e-08
and O 0 3.3184963665888745e-09
molecular O 0 2.0490703889208817e-07
mechanism O 0 1.1091347005276475e-06
for O 0 2.9739389901806135e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999977350234985
fibrillation I-Disease 1 1.0
. O 0 4.987699139746837e-05

Ventricular B-Disease 0 0.0021279945503920317
fibrillation I-Disease 0 0.00046091515105217695
causes O 0 4.2102442421310116e-08
more O 0 7.380000083268001e-11
than O 0 4.588118773796168e-11
300 O 0 2.9397034806422084e-10
, O 0 8.942141471734999e-11
000 O 0 6.151680831401052e-10
sudden O 0 1.2233658530647062e-09
deaths O 0 4.13860695713808e-10
each O 0 1.1105857899984528e-10
year O 0 8.68867366943249e-10
in O 0 6.539066510491409e-11
the O 0 3.5952177346310066e-10
USA O 0 3.6103364209338906e-07
alone O 0 2.113408825721308e-08
. O 0 1.1216717332729331e-08

In O 0 7.584675998373314e-09
approximately O 0 8.293605802123238e-10
5 O 0 2.016566247320384e-09
- O 0 5.799513758120156e-08
12 O 0 1.5807091191533118e-09
% O 0 3.498187850503598e-11
of O 0 2.7907675627901474e-13
these O 0 6.38807279643161e-12
cases O 0 9.588924793080267e-11
, O 0 7.725118288115507e-12
there O 0 1.0953877561947767e-11
are O 0 3.0404029988106984e-11
no O 0 2.3983187658060956e-10
demonstrable O 0 5.978967010378256e-07
cardiac O 0 1.4056958264063724e-07
or O 0 1.126633364378904e-08
non O 0 0.021079683676362038
- O 0 0.0038430984131991863
cardiac O 0 3.887097591359634e-06
causes O 0 5.904425837144345e-10
to O 0 1.1482148565278294e-11
account O 0 8.046933258620825e-11
for O 0 2.8050389701966827e-12
the O 0 1.5246108412206305e-12
episode O 0 1.2156596840284806e-09
, O 0 1.1965125071289329e-11
which O 0 3.977234513952155e-11
is O 0 3.420125641029337e-11
therefore O 0 1.3282137889536472e-10
classified O 0 3.100445411519104e-08
as O 0 4.89295246097754e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999492168426514
fibrillation I-Disease 1 1.0
( O 0 6.578594025086204e-07
IVF B-Disease 1 1.0
) O 0 2.623526711431623e-07
. O 0 1.8348193009387614e-07

A O 0 2.8211465163963112e-08
distinct O 0 1.8551354230567085e-08
group O 0 1.5583685453179896e-08
of O 0 1.1686286660594902e-10
IVF B-Disease 1 1.0
patients O 0 9.33441071993002e-07
has O 0 2.34788383179918e-10
been O 0 9.785045690380301e-11
found O 0 5.1663191086293025e-11
to O 0 1.2860133097314375e-11
present O 0 2.843366514460044e-11
with O 0 3.0504637010819735e-11
a O 0 6.101817939807574e-10
characteristic O 0 1.7495503357167763e-07
electrocardiographic O 0 1.6375801351387054e-05
pattern O 0 5.56538907403592e-06
. O 0 6.01129272581602e-07

Because O 0 1.190854703736477e-07
of O 0 6.169809801948034e-11
the O 0 1.7356503387300215e-11
small O 0 1.4489798250139074e-10
size O 0 2.9568716919392557e-10
of O 0 3.970986733881077e-12
most O 0 1.2742178839841856e-11
pedigrees O 0 1.076838795910362e-08
and O 0 2.369455187611891e-10
the O 0 9.02486627096799e-11
high O 0 1.9147980978573287e-08
incidence O 0 5.123346795699035e-07
of O 0 1.0784387965978581e-10
sudden B-Disease 0 7.869834561802236e-09
death I-Disease 0 1.774468350035363e-09
, O 0 4.315995824621943e-11
however O 0 1.3078163552115996e-10
, O 0 1.5690464552631234e-11
molecular O 0 1.6612010655947529e-09
genetic O 0 1.0470795785977316e-08
studies O 0 2.4943336285332407e-09
of O 0 1.1275280188682846e-11
IVF B-Disease 1 1.0
have O 0 1.506040625542937e-09
not O 0 9.734338335398718e-11
yet O 0 8.501772619240455e-10
been O 0 1.789962178477822e-09
done O 0 7.858869999211038e-09
. O 0 1.6194828589277677e-08

Because O 0 7.063375505822478e-06
IVF B-Disease 1 0.9999998807907104
causes O 0 7.42719930713065e-06
cardiac O 0 0.0003681171510834247
rhythm O 0 1.3905295190852485e-06
disturbance O 0 2.2458068826836097e-07
, O 0 6.510036398843511e-10
we O 0 3.552858007793702e-10
investigated O 0 5.97516791600583e-09
whether O 0 1.1584428971644911e-09
malfunction O 0 3.0369299963695084e-08
of O 0 1.1933080391879347e-11
ion O 0 1.723538534115221e-09
channels O 0 1.1347544415230004e-07
could O 0 1.7612923386423063e-07
cause O 0 3.2569931196491098e-09
the O 0 5.352467358221702e-10
disorder O 0 7.818400860060137e-08
by O 0 1.6833251806347427e-11
studying O 0 2.897349027364271e-09
mutations O 0 6.790076412244161e-08
in O 0 8.200704004757142e-10
the O 0 1.814809968969655e-09
cardiac O 0 3.1087893148651347e-07
sodium O 0 1.892963439331652e-07
channel O 0 3.9175296251414693e-07
gene O 0 2.319900886504911e-06
SCN5A O 0 5.0210379413329065e-05
. O 0 2.579419060566579e-07

We O 0 1.5648161877379607e-07
have O 0 5.143138692709215e-10
now O 0 1.0416072449004332e-09
identified O 0 3.5629710293250128e-09
a O 0 5.955866910767327e-10
missense O 0 7.569005333607493e-07
mutation O 0 6.969737142981103e-08
, O 0 1.3244243202148454e-10
a O 0 3.1919430987237263e-10
splice O 0 1.319351122219814e-05
- O 0 1.7135571397375315e-06
donor O 0 8.500855841475641e-08
mutation O 0 1.5385313645310816e-07
, O 0 2.2658627751859228e-10
and O 0 7.668385926251631e-10
a O 0 1.207281163928542e-09
frameshift O 0 3.2148088848771295e-06
mutation O 0 5.351696685806928e-08
in O 0 1.4810119797203924e-10
the O 0 1.0488634960559295e-10
coding O 0 6.089389330554695e-07
region O 0 1.4709799600609585e-08
of O 0 5.883131481976278e-11
SCN5A O 0 2.3326742848439608e-07
in O 0 4.678577525396577e-10
three O 0 4.510413376124234e-09
IVF B-Disease 1 0.9999994039535522
families O 0 4.70666918772622e-08
. O 0 3.525838110363111e-08

We O 0 1.3132924436831672e-07
show O 0 6.072620628572167e-09
that O 0 3.93247309715683e-11
sodium O 0 4.446068790908697e-10
channels O 0 5.904065014661342e-10
with O 0 1.697016312196542e-11
the O 0 1.271341781849955e-10
missense O 0 1.1766479701691424e-06
mutation O 0 1.5797279218077165e-07
recover O 0 6.653881001739137e-08
from O 0 9.626547475827252e-11
inactivation O 0 2.9178366389714938e-08
more O 0 1.248633575007263e-11
rapidly O 0 7.504963317472857e-10
than O 0 6.960905463149203e-11
normal O 0 6.492886228670613e-10
and O 0 1.3619722016855462e-10
that O 0 1.4293971561940566e-10
the O 0 9.77762537601734e-10
frameshift O 0 2.8640815799008124e-06
mutation O 0 6.619463022161653e-08
causes O 0 1.1138384659048484e-09
the O 0 3.8179737149590665e-11
sodium O 0 4.864507907598181e-09
channel O 0 5.8483649034712926e-09
to O 0 9.180040755341068e-11
be O 0 5.219828458358222e-10
non O 0 7.443058791523072e-08
- O 0 2.3488809119953658e-07
functional O 0 4.569366467421787e-07
. O 0 8.531311834758526e-08

Our O 0 2.3441234020538104e-07
results O 0 2.6853774315327428e-08
indicate O 0 3.6723575291830457e-09
that O 0 4.064524272706649e-10
mutations O 0 4.0443289606173494e-08
in O 0 5.873200814576762e-10
cardiac O 0 7.799038570510675e-08
ion O 0 1.6380970180307486e-07
- O 0 6.288075269367255e-07
channel O 0 7.43620489629393e-08
genes O 0 4.763418992581592e-09
contribute O 0 1.002202210109715e-10
to O 0 1.9194684036660803e-11
the O 0 3.20595668068524e-11
risk O 0 2.5089010868839523e-09
of O 0 1.9098309739229435e-11
developing O 0 1.8382918298698314e-08
IVF B-Disease 1 0.9999926090240479
. O 0 4.595698932519099e-09
. O 0 3.012446114780687e-08

Molecular O 0 3.4786298783728853e-06
heterogeneity O 0 3.0474438972305506e-06
in O 0 1.0870931710371678e-08
mucopolysaccharidosis B-Disease 0 4.198722763248952e-06
IVA I-Disease 0 3.7040758797957096e-06
in O 0 3.2088107726480075e-09
Australia O 0 4.9297415039006864e-09
and O 0 4.848313972516394e-10
Northern O 0 1.1125841581360874e-08
Ireland O 0 5.945555869857344e-08
: O 0 1.0531594346607775e-10
nine O 0 8.726037253881103e-11
novel O 0 3.5164118838970637e-10
mutations O 0 6.645821670758778e-10
including O 0 1.718055385457884e-11
T312S O 0 1.565025975480694e-08
, O 0 2.0375657758253674e-11
a O 0 3.447621008123569e-11
common O 0 1.5239647321863004e-09
allele O 0 4.654763685607577e-08
that O 0 3.8600347918027467e-10
confers O 0 4.4300659141072174e-08
a O 0 1.8786796118774873e-08
mild O 0 4.352112227934413e-06
phenotype O 0 2.6335681468481198e-05
. O 0 5.816440307171433e-07

Mucopolysaccharidosis B-Disease 0 0.015376253053545952
IVA I-Disease 0 0.007232735864818096
( O 0 8.91916442924412e-07
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
) O 0 3.744231591440439e-09
is O 0 2.069188154152357e-10
an O 0 1.1559664336857622e-09
autosomal B-Disease 1 0.9999151229858398
recessive I-Disease 1 0.9995889067649841
lysosomal I-Disease 1 0.9990691542625427
storage I-Disease 1 0.9900604486465454
disorder I-Disease 1 0.9999954700469971
caused O 0 1.2035496865792084e-07
by O 0 1.4682602911264553e-09
a O 0 1.0978914843917664e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 7.997732254239054e-09
N O 0 5.275874173094053e-06
- O 0 1.992455736399279e-06
acetylgalactosamine O 0 0.0006582465721294284
- O 0 4.3754757825809065e-06
6 O 0 1.8795186917941464e-07
- O 0 2.5069323328352766e-06
sulfate O 0 1.117343344958499e-05
sulfatase O 0 1.1033144801331218e-05
( O 0 1.7587259426576907e-09
GALNS O 0 3.733002529315854e-07
) O 0 2.8213442693214574e-09
. O 0 1.752772682550585e-08

Previous O 0 2.4139296783687314e-07
studies O 0 2.259313980346178e-08
of O 0 1.6784681283743552e-11
patients O 0 1.0966934027578645e-09
from O 0 1.9823337416013942e-11
a O 0 2.3451354747017206e-10
British O 0 1.7714141904434655e-06
- O 0 9.492163712820911e-07
Irish O 0 7.400802815027419e-08
population O 0 3.9341330193565227e-10
showed O 0 1.3883560967542508e-09
that O 0 1.2044187695792186e-11
the O 0 1.2444846368697693e-11
I113F O 0 1.14929692429655e-08
mutation O 0 1.5861815194639917e-09
is O 0 7.280395904196713e-12
the O 0 2.390232976823281e-12
most O 0 2.918823169273388e-11
common O 0 2.5917915036366423e-10
single O 0 6.212752534651145e-09
mutation O 0 1.54747965552815e-07
among O 0 5.693516769156304e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.2907351276680856e-07
and O 0 1.630658247320227e-10
produces O 0 2.3986994612812396e-09
a O 0 5.035522221419342e-09
severe O 0 3.5092848520434927e-06
clinical O 0 1.81933482963359e-05
phenotype O 0 3.778129757847637e-05
. O 0 4.0587650573797873e-07

We O 0 1.7699235854706785e-07
studied O 0 8.185085675904702e-08
mutations O 0 2.9342615448513243e-08
in O 0 1.0774889314113523e-10
the O 0 6.887463516180858e-11
GALNS O 0 8.250147232047311e-08
gene O 0 3.426358308189492e-09
from O 0 1.0239609854467702e-10
23 O 0 9.166765124746235e-10
additional O 0 5.587769802417597e-09
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 5.334779018539848e-08
( O 0 2.0399144179394924e-11
15 O 0 2.458392343862581e-11
from O 0 1.2101871588177104e-11
Australia O 0 1.8177745420011604e-10
, O 0 5.150348463683896e-12
8 O 0 1.5028683159057366e-11
from O 0 1.446361433399268e-11
Northern O 0 2.63294896996058e-09
Ireland O 0 1.481750899756662e-08
) O 0 1.163324037795066e-11
, O 0 4.917992011896355e-13
with O 0 5.081020782067569e-13
various O 0 1.0434798858316441e-10
clinical O 0 1.5429246502662863e-07
phenotypes O 0 1.559301239240085e-07
( O 0 7.99492194669682e-10
severe O 0 2.286016638208821e-07
, O 0 2.2107372876778442e-10
16 O 0 2.0066430461707085e-10
cases O 0 2.599380710677224e-10
; O 0 1.5341101999855056e-10
intermediate O 0 1.1153925560947187e-09
, O 0 1.9788165897538512e-11
4 O 0 7.763689691131503e-11
cases O 0 6.939513408354969e-10
; O 0 3.207476950706223e-09
mild O 0 5.258064916802141e-08
, O 0 2.1590025600648488e-10
3 O 0 1.202620336648863e-09
cases O 0 6.596521551216483e-09
) O 0 6.737592261885084e-09
. O 0 4.168827416606291e-08

We O 0 1.702454852647861e-07
found O 0 1.8020958059139502e-09
two O 0 6.722784828827599e-11
common O 0 1.930432480534705e-10
mutations O 0 1.3257949182943207e-09
that O 0 3.916489962202396e-12
together O 0 2.003536746231216e-11
accounted O 0 2.48947029657387e-10
for O 0 1.783607810057486e-11
32 O 0 1.7968401766488284e-10
% O 0 2.6257648833016844e-11
of O 0 6.288639747831226e-12
the O 0 2.3432844553639143e-10
44 O 0 1.3602465820383713e-09
unrelated O 0 6.3290319651798654e-09
alleles O 0 1.788587589146573e-08
in O 0 2.608842863960348e-10
these O 0 2.4207655879848744e-09
patients O 0 1.1024955171023976e-07
. O 0 3.229239453617083e-08

One O 0 3.8664346391215076e-08
is O 0 9.098291564590966e-10
the O 0 1.8617019037492355e-10
T312S O 0 2.629074629112438e-07
mutation O 0 4.809965403751448e-08
, O 0 1.2078010813709739e-10
a O 0 1.0395941746343951e-10
novel O 0 8.243882909653166e-09
mutation O 0 1.5143081455448737e-08
found O 0 3.3761130002751827e-10
exclusively O 0 1.0610495815299714e-09
in O 0 5.100262989721216e-10
milder O 0 6.216180281626293e-07
patients O 0 9.090352364182763e-07
. O 0 9.646778664773592e-08

The O 0 6.9012873193941e-10
other O 0 1.6647971889938162e-10
is O 0 3.0206923767872595e-11
the O 0 2.1486366505452104e-11
previously O 0 3.880558541169421e-09
described O 0 2.2302841795607264e-09
I113F O 0 4.052297697398899e-08
that O 0 1.4914211532435218e-10
produces O 0 6.200854940630052e-09
a O 0 7.161180537451628e-09
severe O 0 5.4850252126925625e-06
phenotype O 0 1.9916327801183797e-05
. O 0 4.4516994535115373e-07

The O 0 2.914427099653949e-08
I113F O 0 9.433828154215007e-07
and O 0 2.361195905464797e-09
T312S O 0 9.576947945788561e-08
mutations O 0 2.8896625536845022e-08
accounted O 0 2.1093080615486315e-09
for O 0 7.763156090190293e-11
8 O 0 2.4766308448498364e-10
( O 0 3.636714193677726e-11
18 O 0 1.679961447731415e-10
% O 0 2.4855310518101525e-11
) O 0 2.675664377560505e-11
and O 0 1.0230259001042796e-10
6 O 0 1.3841169876904758e-10
( O 0 1.1168432498265268e-11
14 O 0 4.264785399832327e-11
% O 0 1.7924339096309083e-11
) O 0 1.1377289735325924e-11
of O 0 8.63650383847725e-12
44 O 0 5.821551574136663e-10
unrelated O 0 1.256121695547563e-08
alleles O 0 5.079609266545049e-08
, O 0 1.5753695015163771e-09
respectively O 0 1.0982223841438099e-07
. O 0 1.1532191024343774e-07

The O 0 2.6292166666053163e-08
relatively O 0 9.31092980493986e-09
high O 0 2.7299456917262432e-08
residual O 0 5.320512173057068e-07
GALNS O 0 6.34649609310145e-07
activity O 0 8.44877057204485e-09
seen O 0 1.1992559834084204e-08
when O 0 1.3573567825275745e-09
the O 0 8.448666072302657e-11
T312S O 0 1.1342120131985212e-08
mutant O 0 4.888020654902903e-09
cDNA O 0 9.28581567194442e-09
is O 0 2.1727632193435653e-10
overexpressed O 0 1.214973508467665e-07
in O 0 9.939270934067324e-11
mutant O 0 5.579037232195105e-09
cells O 0 1.1681456912882027e-09
provides O 0 3.9002037710567095e-11
an O 0 8.858626722799134e-13
explanation O 0 7.507379440330197e-11
for O 0 1.766153195914555e-11
the O 0 2.531704290653636e-10
mild O 0 1.3598094028566265e-07
phenotype O 0 1.946804246699685e-07
in O 0 5.005833525473236e-10
patients O 0 5.776966460757649e-09
with O 0 9.578359633222178e-11
this O 0 1.7493116954980792e-09
mutation O 0 1.2729221907648025e-06
. O 0 1.571486194507088e-07

The O 0 3.736754905503403e-09
distribution O 0 1.992403575457047e-09
and O 0 3.02244562710996e-10
relative O 0 5.966201976903562e-10
frequencies O 0 5.410659031923615e-09
of O 0 3.979799476083734e-11
the O 0 2.1882845535614592e-10
I113F O 0 3.760823830134541e-08
and O 0 2.887869110512753e-10
T312S O 0 1.6290712778754823e-08
mutations O 0 4.5804022796858135e-09
in O 0 5.3519744191987684e-11
Australia O 0 3.1212372963995705e-11
corresponded O 0 5.272548370127694e-11
to O 0 3.748799014269277e-12
those O 0 1.0173803639823564e-11
observed O 0 6.995084372851679e-11
in O 0 6.807027164157375e-11
Northern O 0 8.629453596142866e-09
Ireland O 0 2.632366147281573e-07
and O 0 8.195493589324698e-11
are O 0 5.2189173121997e-12
unique O 0 2.5444252607642603e-11
to O 0 9.351833543669308e-12
these O 0 9.713153024948351e-12
two O 0 1.642992339401239e-11
populations O 0 2.5319360497100263e-10
, O 0 1.3727191258694482e-11
suggesting O 0 3.980271945369651e-10
that O 0 9.277800749885046e-12
both O 0 2.424575644421889e-11
mutations O 0 9.430638492347043e-10
were O 0 5.948598558180862e-11
probably O 0 9.636245967836743e-11
introduced O 0 1.7701910770551166e-10
to O 0 6.630661991691156e-11
Australia O 0 1.1500961294430567e-10
by O 0 3.0484281765552623e-11
Irish O 0 1.8484344055380575e-09
migrants O 0 1.2577081598408313e-09
during O 0 1.2326263620909828e-10
the O 0 6.366874388819e-11
19th O 0 1.4244615265113225e-08
century O 0 6.206560954069573e-08
. O 0 6.022746390499378e-08

Haplotype O 0 4.947933121002279e-05
analysis O 0 8.725284317279147e-08
using O 0 1.8219800779206707e-08
6 O 0 3.2185691889452528e-09
RFLPs O 0 3.334734799409489e-08
provides O 0 7.776983917961999e-11
additional O 0 4.595010830166224e-11
data O 0 4.33476643468822e-10
that O 0 1.8026302672780048e-11
the O 0 2.4990219962828242e-11
I113F O 0 4.600130054654983e-08
mutation O 0 5.356555643487582e-09
originated O 0 7.0150230069288e-10
from O 0 4.9314670402811345e-11
a O 0 1.0813430012523995e-10
common O 0 3.0016962249135304e-09
ancestor O 0 5.05111792392654e-08
. O 0 1.0454196797127224e-07

The O 0 4.671010245260732e-09
other O 0 1.2302311391820808e-09
9 O 0 1.1405024702426658e-09
novel O 0 2.470946336430302e-09
mutations O 0 1.4986371255076847e-08
identified O 0 5.095550204003985e-09
in O 0 6.901771515410715e-11
these O 0 6.955942072339738e-11
23 O 0 7.410612679059625e-10
patients O 0 3.448069607614457e-10
were O 0 1.6345685222018957e-11
each O 0 2.641134880243534e-11
limited O 0 3.4268007875759565e-10
to O 0 3.4626743139476446e-10
a O 0 8.194950273932022e-10
single O 0 5.1030024650344785e-08
family O 0 6.001691588153335e-08
. O 0 9.542595336142767e-08

These O 0 5.8197446861640856e-09
data O 0 3.8466234641987285e-09
provide O 0 2.26160978833434e-10
further O 0 3.085597749530322e-11
evidence O 0 2.193336484657138e-10
for O 0 6.142380354345889e-11
extensive O 0 7.725763140342679e-09
allelic O 0 3.9386199546243006e-07
heterogeneity O 0 6.802500251978927e-07
in O 0 7.822846015415053e-08
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 0.9999998807907104
in O 0 3.740357357173707e-08
British O 0 0.000337976380251348
- O 0 2.059826147160493e-05
Irish O 0 7.567700066601901e-08
patients O 0 1.0753337109647987e-09
and O 0 5.936466596079271e-12
provide O 0 4.2864106361562015e-12
evidence O 0 1.5130615510505763e-11
for O 0 2.6866323835778028e-12
their O 0 4.413745410825065e-12
transmission O 0 9.388194666115623e-10
to O 0 9.290094388214598e-11
Australia O 0 2.257601744437565e-10
by O 0 5.3886031053940187e-11
British O 0 5.613709390672739e-07
- O 0 1.0749306511570467e-07
Irish O 0 1.4377107504515152e-08
migrants O 0 5.6227298372846235e-09
. O 0 5.859437379740484e-10
. O 0 8.509596582939594e-09

Identification O 0 4.865986511504161e-07
of O 0 3.876637677535655e-09
constitutional O 0 7.21267028325201e-08
WT1 O 0 1.188164696941385e-05
mutations O 0 5.236287279331009e-07
, O 0 2.2335480687196707e-10
in O 0 2.0099336084378194e-10
patients O 0 4.781761653305239e-09
with O 0 3.9670386420276316e-10
isolated O 0 2.6257696390530327e-06
diffuse B-Disease 0 0.0834016427397728
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 5.6231268530382295e-09
and O 0 1.771238017367338e-10
analysis O 0 2.5318214191827337e-09
of O 0 5.006483005942641e-10
genotype O 0 7.119890506146476e-05
/ O 0 1.7024531189235859e-06
phenotype O 0 4.024783777367702e-07
correlations O 0 2.0621769181161653e-08
by O 0 2.1434628377781095e-11
use O 0 3.7012642950529084e-10
of O 0 3.108191135026139e-11
a O 0 4.999411995498804e-10
computerized O 0 8.309493750857655e-07
mutation O 0 1.2215568858664483e-06
database O 0 6.994106911406561e-07
. O 0 1.5223392324514862e-07

Constitutional O 0 1.848208057708689e-06
mutations O 0 1.6655442323099123e-06
of O 0 8.578378007939591e-10
the O 0 5.9542426544823e-10
WT1 O 0 1.2556663477880647e-06
gene O 0 2.5263140912556992e-08
, O 0 1.2418320538554184e-10
encoding O 0 3.2012428263783477e-09
a O 0 1.497744595013728e-09
zinc O 0 6.163896614452824e-05
- O 0 2.321612981859289e-07
finger O 0 3.611055774399574e-07
transcription O 0 3.723530284105436e-08
factor O 0 1.2138229976699222e-08
involved O 0 1.0614807921527358e-09
in O 0 1.0959322338521815e-09
renal O 0 3.890806510753464e-06
and O 0 3.16092529928369e-09
gonadal O 0 0.3192189335823059
development O 0 8.195794043430737e-10
, O 0 2.609597954394971e-11
are O 0 6.074117337578899e-12
found O 0 2.2183900549865854e-11
in O 0 4.695460166515009e-12
most O 0 3.899638598148236e-11
patients O 0 9.482441498676053e-10
with O 0 6.092943927171746e-10
Denys B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999998807907104
Drash I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999986886978149
( O 0 6.32238394970841e-09
DDS B-Disease 1 1.0
) O 0 1.9205763646112928e-09
, O 0 2.077865240979193e-10
or O 0 5.120298851579719e-08
diffuse B-Disease 1 0.8514253497123718
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 7.2438695042365e-08
DMS B-Disease 0 0.002140288706868887
) O 0 7.295554160791085e-10
associated O 0 8.533321826931228e-10
with O 0 4.927530050657936e-10
pseudohermaphroditism B-Disease 1 1.0
and O 0 4.8275847319700915e-08
/ O 0 5.878092110833677e-07
or O 0 1.5352480886576814e-07
Wilms B-Disease 0 0.1910489946603775
tumor I-Disease 0 0.0003633870219346136
( O 0 9.700951864033414e-08
WT B-Disease 1 1.0
) O 0 6.847235312079647e-08
. O 0 1.1668618071780656e-07

Most O 0 2.2338852545544796e-07
mutations O 0 7.381217073998414e-06
in O 0 8.1552592234857e-08
DDS B-Disease 1 1.0
patients O 0 8.831192826619372e-05
lie O 0 2.2559689227819035e-07
in O 0 1.023807261191223e-09
exon O 0 1.180270885470236e-07
8 O 0 3.774547785440063e-09
or O 0 1.3549306121518612e-09
exon O 0 1.1993103044005693e-07
9 O 0 5.964259752744283e-09
, O 0 2.430327050717551e-10
encoding O 0 5.96699223365249e-08
zinc O 0 2.099054108839482e-05
finger O 0 2.2049543986213394e-05
2 O 0 1.1837231639333368e-08
or O 0 8.336749068860172e-09
zinc O 0 2.2002072000759654e-05
finger O 0 1.8414824808132835e-05
3 O 0 1.6883077158524884e-09
, O 0 3.8442287547679754e-11
respectively O 0 8.288403297029845e-10
, O 0 1.9787676705518287e-11
with O 0 2.219011953352723e-11
a O 0 6.824112386283332e-10
hot O 0 1.3811047949729982e-07
spot O 0 7.01999454122415e-07
( O 0 3.3924762998793767e-10
R394W O 0 3.369875756220608e-08
) O 0 1.3312370650275795e-10
in O 0 3.130378734006456e-10
exon O 0 1.9947150065036112e-07
9 O 0 4.9960807047000344e-08
. O 0 3.0880865864446605e-08

We O 0 4.9146006375622164e-08
analyzed O 0 1.739504007503001e-08
a O 0 2.753459404924996e-10
series O 0 3.633173206729623e-10
of O 0 2.0143690535046055e-11
24 O 0 1.8650188060576056e-09
patients O 0 2.1900059543611405e-09
, O 0 2.746738426984141e-11
10 O 0 1.2089973466800075e-10
with O 0 3.07368103191763e-10
isolated B-Disease 0 9.794927791517694e-06
DMS I-Disease 1 0.8711363077163696
( O 0 1.3308670832046232e-09
IDMS B-Disease 0 2.5405504402442602e-06
) O 0 2.2694136847523083e-10
, O 0 3.457848243848538e-11
10 O 0 3.154604008570594e-11
with O 0 1.0289631646731578e-10
DDS B-Disease 1 1.0
, O 0 1.602963983771133e-09
and O 0 3.74365816124822e-10
4 O 0 6.706484811935809e-10
with O 0 4.0111683419219446e-10
urogenital B-Disease 0 6.494240369647741e-05
abnormalities I-Disease 1 0.9990587830543518
and O 0 4.767775507730221e-08
/ O 0 7.378852842521155e-06
or O 0 5.189998773857951e-06
WT B-Disease 1 1.0
. O 0 7.051859824969142e-07

We O 0 1.4865173625366879e-06
report O 0 3.168405839915067e-07
WT1 O 0 1.2934886399307288e-05
heterozygous O 0 4.0862474293135165e-07
mutations O 0 7.412004521256677e-08
in O 0 8.290079733797029e-10
16 O 0 1.1333031180171815e-09
patients O 0 3.058004960365679e-09
, O 0 3.0605049744503177e-11
4 O 0 1.195915311225093e-10
of O 0 3.687043725886241e-11
whom O 0 5.4506333668769e-08
presented O 0 1.8957775793637666e-08
with O 0 2.2298980439927618e-08
IDMS B-Disease 0 0.011692920699715614
. O 0 3.4951060001731094e-07

One O 0 8.757864122799219e-08
male O 0 1.0960941665416613e-07
and O 0 8.010276331127386e-10
two O 0 1.6787771173198962e-09
female O 0 6.653189075223054e-07
IDMS B-Disease 0 0.003190118120983243
patients O 0 2.3789046110778145e-07
with O 0 3.6693188487646466e-09
WT1 O 0 8.276711741928011e-05
mutations O 0 1.0463335456734058e-05
underwent O 0 3.5163568554708036e-06
normal O 0 1.6404230791522423e-06
puberty O 0 5.073607826489024e-05
. O 0 4.967735662830819e-07

Two O 0 2.6383327167422976e-07
mutations O 0 1.0458420547365677e-06
associated O 0 2.7489649667700178e-08
with O 0 6.46553754979351e-10
IDMS B-Disease 0 8.01442456577206e-06
are O 0 7.361695975038884e-11
different O 0 2.0913590303983653e-11
from O 0 2.1408236294817584e-11
those O 0 6.709794525550095e-11
described O 0 3.5107310392135105e-09
in O 0 3.169505546907203e-08
DDS B-Disease 1 1.0
patients O 0 7.737925443507265e-06
. O 0 1.5587586688070587e-07

No O 0 6.659765858785249e-07
WT1 O 0 1.313492248300463e-05
mutations O 0 2.645505787768343e-07
were O 0 3.524590896919477e-10
detected O 0 1.666799809285635e-09
in O 0 1.6008295383729276e-11
the O 0 1.3040296273358898e-11
six O 0 1.975909852403035e-10
other O 0 2.6048055379312984e-10
IDMS B-Disease 0 5.0465761887608096e-05
patients O 0 9.696304203998807e-09
, O 0 1.6476871950166228e-11
suggesting O 0 2.6549564768885148e-09
genetic O 0 1.6649257972289888e-08
heterogeneity O 0 6.369567984165769e-08
of O 0 2.1962837104538835e-10
this O 0 8.829630360196461e-09
disease O 0 8.10493759217934e-07
. O 0 9.859133598411063e-08

We O 0 6.153488811833085e-07
analyzed O 0 3.0664459700346924e-06
genotype O 0 2.113218215527013e-05
/ O 0 1.387895622428914e-06
phenotype O 0 2.318343064189321e-07
correlations O 0 1.0639323022587632e-07
, O 0 1.5705024780654497e-10
on O 0 3.0001362505416296e-11
the O 0 5.865179435876611e-12
basis O 0 7.141109231723064e-11
of O 0 5.17780002901036e-12
the O 0 1.0775978720456436e-10
constitution O 0 7.894622733317647e-10
of O 0 2.202730532696595e-11
a O 0 6.13499528956396e-10
WT1 O 0 1.6773973356976057e-06
mutation O 0 3.726649211444055e-08
database O 0 4.368158279532963e-09
of O 0 8.422343378278185e-11
84 O 0 4.5362442691043725e-09
germ O 0 5.545658950723009e-06
- O 0 3.2498887776455376e-06
line O 0 9.55288470549931e-08
mutations O 0 3.9137944440881256e-08
, O 0 2.6598194133309327e-11
to O 0 9.435522675682595e-12
compare O 0 5.359444554819959e-10
the O 0 7.272235331284849e-12
distribution O 0 2.411354449449732e-10
and O 0 2.7361929388902695e-10
type O 0 6.423245491049556e-09
of O 0 5.761104787671556e-11
mutations O 0 1.868758658929437e-08
, O 0 1.6410506634145783e-11
according O 0 1.267334327759162e-11
to O 0 1.4699007636065353e-11
the O 0 8.198010326143645e-11
different O 0 2.5164744954508933e-08
symptoms O 0 5.169403038962628e-07
. O 0 4.716914503433145e-08

This O 0 1.1148761913659655e-08
demonstrated O 0 1.4856760266468427e-08
( O 0 1.1135277422358314e-10
1 O 0 1.4793406777346974e-10
) O 0 8.305157950250219e-11
the O 0 3.800116124552666e-11
association O 0 3.4835745399419693e-10
between O 0 1.4787961133411187e-10
mutations O 0 1.058816234689175e-08
in O 0 1.3936722609297902e-10
exons O 0 3.819159744011813e-08
8 O 0 7.896022724551699e-10
and O 0 1.8568294124499118e-10
9 O 0 5.007982362137398e-10
and O 0 2.7485269615823427e-10
DMS B-Disease 0 1.4008448943059193e-06
; O 0 1.1460188353851208e-10
( O 0 8.083926757163074e-12
2 O 0 6.865272239586773e-11
) O 0 4.4647962410548914e-11
among O 0 1.4162973571707482e-10
patients O 0 6.380505013225957e-10
with O 0 2.529425106867489e-11
DMS B-Disease 0 1.4884152506056125e-06
, O 0 2.1796273119711884e-11
a O 0 2.0104846606971982e-11
higher O 0 2.728688386355316e-10
frequency O 0 1.1733753968456995e-09
of O 0 7.085387832006518e-11
exon O 0 3.0317618637809574e-08
8 O 0 1.8713401939152163e-09
mutations O 0 7.569038729116073e-09
among O 0 5.318335216664138e-10
46 O 0 4.4934460596834924e-09
, O 0 6.737345126239802e-10
XY O 0 8.152022132890124e-07
patients O 0 4.928538022141993e-09
with O 0 4.544830831121338e-11
female O 0 1.1854470294281327e-08
phenotype O 0 1.814956362977682e-08
than O 0 1.3733274240035342e-10
among O 0 9.205538553658243e-10
46 O 0 1.451113718076158e-08
, O 0 1.9393202599360393e-09
XY O 0 1.8238142729387619e-06
patients O 0 9.046452476013656e-09
with O 0 2.9585851130109475e-11
sexual O 0 3.6402849623584643e-09
ambiguity O 0 1.3845963486858182e-08
or O 0 6.823426268454114e-09
male O 0 1.0329210198278815e-07
phenotype O 0 4.637429995568709e-08
; O 0 2.0134482969780265e-10
and O 0 1.1357651624743781e-10
( O 0 2.961588613237254e-11
3 O 0 1.0890428142618092e-10
) O 0 3.50993054065718e-11
statistically O 0 1.2637967339301781e-09
significant O 0 4.687403243330834e-10
evidence O 0 4.219696592144828e-09
that O 0 1.8822032821219636e-10
mutations O 0 2.8134394813861263e-09
in O 0 7.435826260282496e-11
exons O 0 2.5689626426128598e-08
8 O 0 8.413035268439728e-10
and O 0 3.2549543615978394e-10
9 O 0 1.0632275060373786e-09
preferentially O 0 2.935061971243158e-08
affect O 0 1.2193758891498874e-08
amino O 0 8.019881647669536e-09
acids O 0 1.6810585146131984e-09
with O 0 7.738744541019305e-12
different O 0 2.813860776329502e-11
functions O 0 6.935530483254126e-10
. O 0 3.07128567023085e-09
. O 0 5.0347466640232597e-08

The O 0 2.1380809300808323e-07
185delAG O 0 1.0278705303790048e-05
BRCA1 O 0 4.785313649335876e-06
mutation O 0 7.907031829290645e-08
originated O 0 4.63733895728069e-09
before O 0 4.565876843276584e-10
the O 0 1.0926333622596207e-11
dispersion O 0 3.229601253096348e-09
of O 0 3.607482151543606e-12
Jews O 0 1.0610192724413992e-09
in O 0 1.6096598012826924e-11
the O 0 8.635219275743289e-12
diaspora O 0 3.2691045426247456e-09
and O 0 1.7990897660524752e-10
is O 0 4.386898830310848e-11
not O 0 1.4668151415708763e-10
limited O 0 6.811654573724013e-10
to O 0 1.1292832224896188e-09
Ashkenazim O 0 1.2056431160090142e-06
. O 0 6.013723208297961e-08

The O 0 3.517609670211641e-08
185delAG O 0 4.550711764750304e-06
mutation O 0 4.2445773829058453e-07
in O 0 1.5371043327050415e-09
BRCA1 O 0 3.7069489167151914e-07
is O 0 7.971365789671836e-10
detected O 0 2.065554660646285e-08
in O 0 4.375327322669875e-10
Ashkenazi O 0 1.5501322536692896e-07
Jews O 0 2.2489428097571817e-09
both O 0 2.822785338807421e-10
in O 0 1.1067927685459722e-09
familial B-Disease 1 0.666774332523346
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999994039535522
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.171974208437405e-10
in O 0 4.8609880010097584e-11
the O 0 1.4499253186972538e-10
general O 0 1.2885558176023437e-09
population O 0 1.5165396050065283e-08
. O 0 1.1429173696342332e-07

All O 0 1.691132496262071e-07
tested O 0 6.140234631857311e-07
Ashkenazi O 0 2.2612382508668816e-06
mutation O 0 6.8349827131442e-08
carriers O 0 1.689377882030385e-08
share O 0 5.476223918776668e-09
the O 0 1.1149239864671756e-10
same O 0 1.8528572010012567e-09
allelic O 0 1.441376866750943e-07
pattern O 0 3.9466888779315923e-07
at O 0 1.2191410547757187e-08
the O 0 5.206576503269389e-09
BRCA1 O 0 1.5808891475899145e-05
locus O 0 8.959462320490275e-06
. O 0 2.620603538616706e-07

Our O 0 7.902809784354758e-08
previous O 0 1.099458568631917e-08
study O 0 1.3585456093423431e-09
showed O 0 8.294492315208402e-10
that O 0 2.2622256498627813e-11
this O 0 9.051483174093988e-11
Ashkenazi O 0 1.1656488823064137e-06
mutation O 0 9.617343366130626e-09
also O 0 2.4406490717332474e-10
occurs O 0 1.3588766223371351e-10
in O 0 4.586657442740005e-11
Iraqi O 0 3.2403744132381007e-09
Jews O 0 2.3567685580871967e-09
with O 0 1.3187670573622245e-11
a O 0 1.1198344335161536e-10
similar O 0 9.080421747853507e-09
allelic O 0 1.6043846926550032e-06
pattern O 0 9.723207767819986e-06
. O 0 1.047461978487263e-06

We O 0 1.8562406012279098e-07
extended O 0 4.823339061488241e-09
our O 0 4.6409470710884193e-10
analysis O 0 3.5085936933576534e-10
to O 0 1.8605686435968494e-11
other O 0 6.000767244218608e-11
non O 0 7.234191201632711e-08
- O 0 7.896782960870041e-08
Ashkenazi O 0 2.9092129238961206e-07
subsets O 0 4.323069013878467e-09
354 O 0 2.039395319286541e-09
of O 0 2.8256012113425655e-11
Moroccan O 0 2.4134413578735803e-08
origin O 0 2.12170769842146e-09
, O 0 7.245075372974696e-11
200 O 0 1.8121597278319967e-10
Yemenites O 0 4.314603074817569e-08
and O 0 1.1622090789753514e-10
150 O 0 2.8535385165895377e-10
Iranian O 0 4.319246826867129e-08
Jews O 0 7.12255143753282e-08
. O 0 3.242737989239686e-08

Heteroduplex O 0 4.5060834963805974e-05
analysis O 0 2.2995996573627053e-07
complemented O 0 1.7454730993904377e-08
by O 0 2.5939922432272056e-10
direct O 0 1.283076977998121e-09
DNA O 0 1.0578674825012513e-08
sequencing O 0 5.247342116376785e-09
of O 0 1.211709899084923e-10
abnormally O 0 1.0645388570651448e-08
migrating O 0 8.460800948739688e-09
bands O 0 5.3994348547803384e-08
were O 0 5.672214697938216e-09
employed O 0 3.271676689564629e-07
. O 0 1.0711423215070681e-07

Four O 0 3.640682777472648e-08
of O 0 6.593122159337383e-10
Moroccan O 0 3.1170958436632645e-07
origin O 0 3.842348661464712e-09
( O 0 4.1330279476614606e-11
1 O 0 2.7625480028548033e-11
. O 0 2.4162149711570713e-11
1 O 0 1.101539692793807e-10
% O 0 1.631089707743172e-11
) O 0 1.3264208308105818e-11
and O 0 2.301552524952566e-11
none O 0 1.5704665345950275e-10
of O 0 1.327078095851586e-12
the O 0 7.68674186801821e-12
Yemenites O 0 1.6614109199508675e-08
or O 0 1.7584164679895764e-10
Iranians O 0 2.4981379187494213e-09
was O 0 1.2037670860109984e-10
a O 0 3.662434938656034e-11
carrier O 0 1.1018386203431874e-09
of O 0 1.0096324817854274e-11
the O 0 3.776526313892248e-10
185delAG O 0 1.095966240427515e-06
mutation O 0 7.908643624432443e-07
. O 0 8.946076945903769e-08

BRCA1 O 0 0.00012672627053689212
allelic O 0 2.8777001261914847e-06
patterns O 0 1.1256189225150592e-07
were O 0 9.602473260983402e-10
determined O 0 6.795407569981649e-10
for O 0 1.1337733703264963e-11
four O 0 1.0233805990134126e-11
of O 0 3.4944966299972624e-13
these O 0 1.9650949704269616e-12
individuals O 0 7.257325816689697e-12
and O 0 1.052582587063311e-11
for O 0 4.801550216454453e-12
12 O 0 6.28133031699285e-11
additional O 0 8.236916149151341e-10
non O 0 3.0137275643937755e-06
- O 0 4.880886535829632e-06
Ashkenazi O 0 6.57021337246988e-06
185delAG O 0 1.81264070420184e-07
mutation O 0 2.778929619751125e-08
carriers O 0 1.311344632881628e-08
who O 0 6.374317518265116e-09
had O 0 1.3097402984385553e-07
breast B-Disease 1 0.9999773502349854
/ I-Disease 1 0.999998927116394
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.846137014486885e-07

Six O 0 1.905009867186891e-06
non O 0 6.575299630640075e-05
- O 0 5.345298268366605e-05
Ashkenazi O 0 1.950180194398854e-05
individuals O 0 2.019468592351359e-09
shared O 0 9.415003221491247e-10
the O 0 1.5330571534466486e-10
common O 0 7.726042916544884e-09
Ashkenazi O 0 4.4718510139318823e-07
haplotype O 0 1.4105624757121404e-07
, O 0 2.0419087254364143e-10
four O 0 2.535270604564488e-10
had O 0 6.887335146643636e-10
a O 0 2.533301866891602e-11
closely O 0 1.5321780511001748e-09
related O 0 2.1730086618987343e-09
pattern O 0 1.5658775964766392e-07
, O 0 2.794964260033339e-10
and O 0 1.3746745408660388e-10
the O 0 8.420126401675887e-11
rest O 0 7.583891292739509e-10
( O 0 5.4639279212231884e-11
n O 0 4.422214772148436e-08
= O 0 7.522152856154207e-08
6 O 0 1.3387697617162075e-09
) O 0 6.851118283801583e-11
displayed O 0 1.7279756514554379e-09
a O 0 2.4059392256248202e-09
distinct O 0 4.585667454648501e-07
BRCA1 O 0 4.7337860451079905e-05
allelic O 0 1.319906186836306e-05
pattern O 0 8.12584039522335e-06
. O 0 1.4005602224642644e-06

We O 0 1.2158393758454622e-07
conclude O 0 2.740499738251856e-08
that O 0 2.7053062567894415e-10
the O 0 5.637847411144037e-10
185delAG O 0 6.780562671337975e-07
BRCA1 O 0 9.919301646732492e-07
mutation O 0 4.05162552397087e-08
occurs O 0 8.645115179284346e-10
in O 0 6.602922375531506e-11
some O 0 1.418744149939144e-10
non O 0 4.493775122682564e-06
- O 0 0.0002152894885512069
Ashkenazi O 0 0.0009349029278382659
populations O 0 1.7165874055535824e-08
at O 0 5.561694993438948e-10
rates O 0 8.931032025039087e-10
comparable O 0 5.377630007963319e-10
with O 0 2.637439745767356e-11
that O 0 1.3138869159323718e-10
of O 0 4.811970266693777e-10
Ashkenazim O 0 5.380259153753286e-06
. O 0 1.54987375822202e-07

The O 0 2.2428354284897978e-08
majority O 0 2.4190500269583026e-08
of O 0 2.8546054409162025e-10
Jewish O 0 7.402412194323915e-08
185delAG O 0 5.391735840021283e-07
mutation O 0 6.183967116157874e-08
carriers O 0 1.4431231321054838e-08
have O 0 4.284387566944048e-10
a O 0 1.0860184279648522e-10
common O 0 1.4276866355800166e-09
allelic O 0 3.7861223489699114e-08
pattern O 0 1.329439953678957e-07
, O 0 6.325203139034841e-10
supporting O 0 2.5651079038624403e-09
the O 0 6.590553797147791e-11
founder O 0 5.710250938761874e-09
effect O 0 1.400075388957589e-09
notion O 0 1.8866646023241174e-09
, O 0 5.878566383676898e-11
but O 0 6.027701948685404e-11
dating O 0 2.395229570240076e-09
the O 0 1.3757912344092293e-11
mutations O 0 3.624016919889783e-10
origin O 0 1.1013338158116781e-10
to O 0 1.0804147507204043e-11
an O 0 1.7200546542639472e-12
earlier O 0 1.6158126225906955e-10
date O 0 2.2447343983600376e-09
than O 0 2.375532548448689e-10
currently O 0 3.4129283843498115e-09
estimated O 0 3.73276520804211e-09
. O 0 3.9232041615377966e-08

However O 0 6.457471357634859e-08
, O 0 3.866526543383486e-10
the O 0 2.8490775710876548e-11
different O 0 2.793866249461985e-10
allelic O 0 4.8835872235031275e-08
pattern O 0 1.0105842562779799e-07
at O 0 2.400809773206447e-09
the O 0 2.6039659317689257e-10
BRCA1 O 0 2.8577144917107944e-07
locus O 0 2.608581972651791e-08
even O 0 1.209777611421714e-09
in O 0 2.7732333790497776e-11
some O 0 2.661575473905664e-11
Jewish O 0 2.4315720992262868e-08
mutation O 0 1.403519878095949e-08
carriers O 0 3.026970230024517e-09
, O 0 2.7604779573309202e-11
might O 0 1.9605256307286822e-10
suggest O 0 9.195010308715723e-10
that O 0 5.266950070526022e-11
the O 0 1.0635839431394345e-10
mutation O 0 2.8193124279596304e-08
arose O 0 4.4064596416149016e-09
independently O 0 9.322053351468185e-09
. O 0 4.169287137756328e-09
. O 0 4.6358028527038186e-08

Crystal O 0 1.6759560821810737e-05
structure O 0 1.6262299595837248e-07
of O 0 1.591135778689079e-09
the O 0 1.3085238670385024e-08
hemochromatosis B-Disease 1 0.9999995231628418
protein O 0 3.192087092429574e-07
HFE O 0 6.162360023154179e-06
and O 0 1.081747913467268e-09
characterization O 0 1.8736017182163778e-08
of O 0 3.8945690422620416e-11
its O 0 4.365932615435497e-10
interaction O 0 4.347246562730334e-09
with O 0 1.7157517628874075e-09
transferrin O 0 3.1063464120961726e-06
receptor O 0 9.092268555832561e-07
. O 0 1.59201164251499e-07

HFE O 0 0.003814907046034932
is O 0 1.5841889933199127e-07
an O 0 2.653984365608153e-09
MHC O 0 6.394463525793981e-06
- O 0 1.5962942256919632e-07
related O 0 3.6073639630984644e-09
protein O 0 1.2202291399532328e-09
that O 0 1.7427293982907877e-11
is O 0 1.3824672309703523e-11
mutated O 0 1.6644011724409324e-09
in O 0 1.0887166862483255e-10
the O 0 7.231604759461163e-10
iron B-Disease 1 0.995376467704773
- I-Disease 1 0.9999817609786987
overload I-Disease 1 0.7186151146888733
disease I-Disease 1 0.5384196639060974
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.2792365851055365e-05

HFE O 0 0.0009412531508132815
binds O 0 1.2818069990316872e-05
to O 0 6.606962443811426e-08
transferrin O 0 3.676183268908062e-06
receptor O 0 5.534018328035017e-07
( O 0 3.000139248143796e-09
TfR O 0 6.44074248157267e-07
) O 0 1.473427824194573e-09
and O 0 5.025962979132714e-10
reduces O 0 6.987770806432536e-09
its O 0 1.1973851077318187e-10
affinity O 0 5.174075390357302e-09
for O 0 3.6689110083365506e-10
iron O 0 5.904385488975095e-06
- O 0 6.622518640142516e-07
loaded O 0 2.7936559732211208e-08
transferrin O 0 7.324080115722609e-07
, O 0 1.2510831259859856e-09
implicating O 0 4.6385227392420347e-07
HFE O 0 2.2103484297986142e-05
in O 0 1.4706938777919731e-08
iron O 0 8.425289706792682e-06
metabolism O 0 2.9910104331065668e-06
. O 0 5.974622752091818e-08

The O 0 8.452916944179378e-08
2 O 0 1.504385380712847e-07
. O 0 1.0967947616791207e-07

6 O 0 1.812974119275168e-06
A O 0 2.3840412310960346e-08
crystal O 0 6.923614250808896e-07
structure O 0 1.0053511090291067e-07
of O 0 7.358933462597861e-10
HFE O 0 3.881777956848964e-06
reveals O 0 2.1984526199503307e-08
the O 0 4.3437361346709835e-11
locations O 0 7.261975021322087e-09
of O 0 7.898794951444188e-10
hemochromatosis B-Disease 1 1.0
mutations O 0 3.165688394801691e-05
and O 0 2.8528759354884414e-09
a O 0 8.18295486926246e-10
patch O 0 1.2495835335357697e-06
of O 0 4.563428107617895e-11
histidines O 0 2.7635491051114514e-07
that O 0 1.2492941403596802e-10
could O 0 6.649701345118331e-10
be O 0 2.9047831848205696e-11
involved O 0 4.6024950517420393e-10
in O 0 9.609893991679996e-10
pH O 0 2.7966822813141334e-07
- O 0 2.796530225168681e-07
dependent O 0 3.137483588488976e-07
interactions O 0 6.820904019377849e-08
. O 0 7.402651647225866e-08

We O 0 8.576309795671477e-08
also O 0 1.2121473824677764e-09
demonstrate O 0 2.7232303079216535e-09
that O 0 4.679238663207741e-10
soluble O 0 1.3804331899791578e-07
TfR O 0 8.616132163297152e-07
and O 0 1.0460691202140993e-09
HFE O 0 6.261745397750929e-07
bind O 0 7.598028872735085e-08
tightly O 0 6.82336391832905e-08
at O 0 1.4421207561454708e-09
the O 0 4.4348951594441743e-11
basic O 0 1.6358084886647362e-09
pH O 0 3.1715721160452404e-09
of O 0 3.1589073804655365e-12
the O 0 1.6916260059396393e-11
cell O 0 1.2865206677759033e-08
surface O 0 5.766511179672307e-08
, O 0 5.100622701981194e-10
but O 0 2.5060984398805886e-09
not O 0 2.9277288926543577e-10
at O 0 3.808956483553061e-10
the O 0 5.588353113594735e-10
acidic O 0 8.119251049265586e-08
pH O 0 4.441420031753296e-08
of O 0 6.304798905176767e-10
intracellular O 0 6.45308773528086e-07
vesicles O 0 2.7894047889276408e-06
. O 0 1.5331222869008343e-07

TfR O 0 0.31396469473838806
HFE O 0 0.002448665676638484
stoichiometry O 0 2.086433050862979e-05
( O 0 1.5358567750922703e-08
2 O 0 2.5127417924153406e-09
1 O 0 5.803557634465051e-10
) O 0 1.0755218937674726e-10
differs O 0 2.457771319797075e-09
from O 0 1.4654959468174411e-09
TfR O 0 1.2903342394565698e-06
transferrin O 0 2.8704371857202204e-07
stoichiometry O 0 3.39333396937036e-08
( O 0 1.2610391897371898e-10
2 O 0 1.3484562078058815e-10
2 O 0 1.1284967404989743e-10
) O 0 4.872749426176881e-11
, O 0 8.942886361995583e-12
implying O 0 7.241929278478665e-10
a O 0 6.285749698520249e-12
different O 0 3.052593941510473e-11
mode O 0 8.157398645458613e-10
of O 0 8.144144213184656e-12
binding O 0 3.8438661142947694e-09
for O 0 1.8323462191993656e-10
HFE O 0 6.865752766316291e-07
and O 0 7.609479157899557e-10
transferrin O 0 2.6220453364089735e-08
to O 0 1.7727352918939232e-10
TfR O 0 1.206514497198441e-07
, O 0 1.034800786725576e-10
consistent O 0 4.990456381470665e-10
with O 0 2.4248807822813134e-11
our O 0 2.245876817852377e-10
demonstration O 0 8.49387893353537e-10
that O 0 7.264890772296084e-11
HFE O 0 1.6868189334218187e-07
, O 0 1.4864795505609152e-10
transferrin O 0 1.98998897360525e-08
, O 0 1.4149176275068953e-10
and O 0 9.278429136116983e-10
TfR O 0 3.8662363976982306e-07
form O 0 1.3151613131867634e-09
a O 0 1.3485598193696546e-09
ternary O 0 2.946932511349587e-07
complex O 0 5.316991860127018e-07
. O 0 2.1905758273987885e-07

Identification O 0 1.8165050619245449e-07
of O 0 2.2993117132497076e-10
three O 0 1.6913301315035767e-10
novel O 0 2.9898339359846204e-09
mutations O 0 2.5507459255891263e-08
and O 0 2.685779376676578e-10
a O 0 7.756688347182461e-11
high O 0 3.1492669583244037e-10
frequency O 0 1.36690736507461e-09
of O 0 7.748684506536652e-12
the O 0 9.433008540948862e-11
Arg778Leu O 0 9.701874432721524e-07
mutation O 0 7.131794887982323e-08
in O 0 3.7596367685743814e-10
Korean O 0 1.2128070991934692e-08
patients O 0 2.082158889749053e-09
with O 0 1.0830480262624675e-10
Wilson B-Disease 0 3.0052271426939114e-07
disease I-Disease 0 2.6298167199456657e-07
. O 0 4.176309076342477e-08

Four O 0 1.3761598438577494e-07
mutations O 0 4.0923960114014335e-06
- O 0 9.844241503742523e-06
- O 0 4.689831712312298e-06
R778L O 0 1.1774540098485886e-06
, O 0 1.136897131992498e-09
A874V O 0 2.9554763969485975e-08
, O 0 1.2603033894276194e-10
L1083F O 0 1.693032736227451e-08
, O 0 5.235200814523999e-11
and O 0 6.17509515743464e-11
2304delC O 0 5.3548109946177647e-08
- O 0 4.302399503330889e-08
- O 0 2.0575646075826626e-08
in O 0 8.01238173031571e-11
the O 0 2.976675503307824e-11
copper O 0 1.3449583491365047e-07
- O 0 1.5294078892225116e-08
transporting O 0 4.1839611775174035e-09
enzyme O 0 8.14456058151336e-09
, O 0 8.484903751826423e-11
P O 0 3.9743406432535267e-07
- O 0 4.929029628897297e-08
type O 0 4.862497604563032e-08
ATPase O 0 1.0440422784085968e-06
( O 0 2.4804458487182046e-10
ATP7B O 0 4.9771248455954265e-08
) O 0 4.165046432746955e-11
, O 0 6.49619984541272e-12
were O 0 4.333086667251962e-11
identified O 0 3.3797935561352688e-09
in O 0 2.63059823923939e-10
Korean O 0 2.5864114405749206e-08
Patients O 0 2.3135264815010714e-09
with O 0 1.8170950855100898e-10
Wilson B-Disease 0 3.302983202502219e-07
disease I-Disease 0 3.750881489850144e-07
. O 0 4.911826678721809e-08

Arg778Leu O 0 1.579186755407136e-05
, O 0 3.7180565293226664e-09
the O 0 2.6122970106512433e-11
most O 0 4.53004925238254e-11
frequently O 0 7.921067357585798e-09
reported O 0 3.2408935535244154e-09
mutation O 0 1.3665032438936464e-09
of O 0 1.8608445947337904e-12
this O 0 5.157829458674046e-12
enzyme O 0 8.251052063812381e-10
, O 0 1.6328017063416134e-11
was O 0 7.480749353305782e-11
found O 0 2.9499187814696626e-11
in O 0 1.3674848579892096e-11
six O 0 3.8066595015040505e-11
of O 0 3.827129585465272e-12
eight O 0 1.7010810815509814e-10
unrelated O 0 7.275326119327019e-09
patients O 0 3.7068688119035187e-09
studied O 0 1.356557088882937e-09
, O 0 1.3389087581694437e-11
an O 0 1.946864024160444e-11
allele O 0 1.3074685334402147e-08
frequency O 0 3.878459153838776e-08
of O 0 9.40394762061203e-10
37 O 0 1.1510787345514473e-07
. O 0 9.865172501122288e-08

5 O 0 1.6507588895819936e-07
% O 0 4.540451126189282e-09
, O 0 1.0184313115058075e-10
which O 0 3.850650007186651e-11
is O 0 2.2480186115392264e-11
considerably O 0 4.4682912925253504e-10
higher O 0 1.2396335347109044e-10
than O 0 7.482315982076937e-12
those O 0 1.466126352267505e-11
in O 0 2.4352166116958784e-11
other O 0 2.3750523769905385e-10
Asian O 0 1.3368515183742602e-08
populations O 0 3.793922331851718e-08
. O 0 3.358434952360767e-08

The O 0 7.878155017237987e-09
novel O 0 3.691137351324869e-08
single O 0 6.9942114322429916e-09
nucleotide O 0 1.610372208915578e-07
deletion O 0 5.1917936616519e-08
, O 0 2.914729846370534e-10
2304delC O 0 4.6713864776393166e-08
, O 0 2.304281487841564e-10
was O 0 2.420981748407769e-10
found O 0 2.758763495425143e-10
in O 0 1.6247841960748133e-10
one O 0 6.028789023559966e-09
patient O 0 2.002839210035745e-07
. O 0 4.6100204542653955e-08

Since O 0 4.826488861908729e-07
a O 0 1.6654720269571044e-08
mutation O 0 3.028745254596288e-07
at O 0 5.293280924689725e-09
cDNA O 0 3.7130627106307657e-07
nucleotide O 0 5.1445208555378485e-06
2302 O 0 1.2031475307594519e-05
( O 0 6.80562883825786e-10
2302insC O 0 2.151625544399849e-08
) O 0 1.69105909830769e-10
had O 0 5.368581135201111e-10
been O 0 2.7864158202994815e-10
previously O 0 1.466793575488623e-09
described O 0 8.20898238274026e-10
, O 0 1.7762374904251033e-11
this O 0 6.114965304948594e-12
region O 0 2.025763445878681e-10
of O 0 6.58013791024481e-12
the O 0 1.1363329027735958e-10
ATP7B O 0 1.651891352594248e-07
gene O 0 8.575830712231891e-09
may O 0 1.6089646281969294e-09
be O 0 8.984539501266653e-11
susceptible O 0 4.190469748976966e-09
to O 0 2.1614086909149677e-10
gene O 0 1.5592848967571626e-07
rearrangements O 0 2.2613396595261293e-06
causing O 0 9.788789157028077e-07
Wilson B-Disease 0 3.243967967136996e-06
disease I-Disease 0 3.843490958388429e-06
. O 0 1.1796642951367176e-07

Disruption O 0 4.502710908127483e-06
of O 0 1.1143802547408654e-09
splicing O 0 2.867575119580579e-07
regulated O 0 7.258308443169881e-08
by O 0 3.706902007571955e-10
a O 0 1.5021246468904792e-09
CUG O 0 2.788630808936432e-06
- O 0 1.6226867671775835e-07
binding O 0 1.583826474416128e-07
protein O 0 1.6969387672816083e-07
in O 0 2.3905345258867783e-08
myotonic B-Disease 1 0.9999982118606567
dystrophy I-Disease 1 0.999995231628418
. O 0 2.7157864224136574e-06

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999998807907104
( O 0 2.0437677449081093e-05
DM B-Disease 1 1.0
) O 0 6.108997467890731e-07
is O 0 3.906126089248119e-09
caused O 0 1.9677119933447784e-09
by O 0 7.817421016076409e-11
a O 0 7.159674519918724e-10
CTG O 0 1.6075335906862165e-07
expansion O 0 3.820155747291665e-09
in O 0 3.4037603291459106e-10
the O 0 9.041354470662455e-11
3 O 0 1.0869453115347483e-09
untranslated O 0 5.022058644499339e-07
region O 0 1.6740010266858008e-08
of O 0 2.833974166449593e-10
the O 0 2.5655007007685526e-08
DM B-Disease 1 0.9999998807907104
gene O 0 2.7366559152142145e-06
. O 0 1.6347182452136622e-07

One O 0 9.590620919652793e-08
model O 0 1.6926314572174306e-07
of O 0 5.710163897276743e-09
DM B-Disease 1 0.9999995231628418
pathogenesis O 0 3.491620930162753e-07
suggests O 0 2.3904568990928965e-08
that O 0 1.3600851000994396e-10
RNAs O 0 1.2220675138507886e-08
from O 0 3.7867375901612377e-11
the O 0 1.5543616740942845e-11
expanded O 0 1.2817511496621137e-09
allele O 0 6.1884959379199245e-09
create O 0 2.003308491316247e-10
a O 0 4.994625199539193e-11
gain O 0 1.5512837236997257e-08
- O 0 8.75451977577768e-09
of O 0 1.1053195858590215e-10
- O 0 4.000811770765722e-08
function O 0 2.847972080388672e-09
mutation O 0 1.3817939015225988e-09
by O 0 1.2633399534833778e-11
the O 0 2.329922019206343e-11
inappropriate O 0 1.547798444967441e-09
binding O 0 1.3260906817080809e-09
of O 0 6.2366310032979655e-12
proteins O 0 8.98222676792848e-11
to O 0 3.791319688750683e-11
the O 0 3.5785863161663656e-10
CUG O 0 2.0507609406195115e-06
repeats O 0 1.2415653145581018e-06
. O 0 8.170361098791545e-08

Data O 0 1.2149746453360422e-07
presented O 0 6.087267134802232e-09
here O 0 2.1380822112782027e-10
indicate O 0 3.74791642165917e-10
that O 0 5.677599362874375e-11
the O 0 7.092215703607962e-11
conserved O 0 1.2521485182048764e-08
heterogeneous O 0 8.88570781398812e-08
nuclear O 0 1.4949361570870678e-07
ribonucleoprotein O 0 5.706916113012994e-07
, O 0 6.027682242226717e-10
CUG O 0 4.2851030457313755e-07
- O 0 5.1927049327105124e-08
binding O 0 1.4031665607205923e-08
protein O 0 1.1040859781985546e-08
( O 0 1.7938951712981321e-10
CUG O 0 3.410308693219122e-07
- O 0 1.4132419323686918e-07
BP O 0 5.955952246949892e-07
) O 0 1.3556304689910093e-10
, O 0 3.17877599242955e-11
may O 0 2.0864832084299678e-10
mediate O 0 3.2510845127120547e-09
the O 0 1.6742930653013133e-10
trans O 0 4.294799538229199e-08
- O 0 4.117792684610322e-08
dominant O 0 1.698512619441317e-07
effect O 0 1.009637884408221e-08
of O 0 2.064259527201351e-11
the O 0 3.3178487734986106e-10
RNA O 0 7.962484005474835e-08
. O 0 2.5573077877538708e-08

CUG O 0 0.0004820649337489158
- O 0 0.0028776447288691998
BP O 0 1.8310245650354773e-05
was O 0 1.563232099321965e-09
found O 0 3.0568412384690546e-11
to O 0 7.880157464057458e-12
bind O 0 9.490257468769414e-10
to O 0 4.0540387019616375e-11
the O 0 7.09842740143074e-11
human O 0 6.990943823836915e-09
cardiac O 0 3.4734870268948725e-07
troponin O 0 2.912659965659259e-06
T O 0 3.0444701337728475e-07
( O 0 3.269888804169341e-10
cTNT O 0 3.393275704866028e-08
) O 0 9.480993767851942e-10
pre O 0 9.64603032116429e-07
- O 0 1.6206206510105403e-07
messenger O 0 2.6267604980034776e-08
RNA O 0 7.1098029685856545e-09
and O 0 1.9429696740402846e-10
regulate O 0 3.427855110871292e-09
its O 0 4.5515302637966215e-10
alternative O 0 2.435777801679251e-08
splicing O 0 1.6587028994763386e-06
. O 0 9.492148222989272e-08

Splicing O 0 9.942316864908207e-06
of O 0 4.4703734047857324e-09
cTNT O 0 9.48306137615873e-07
was O 0 3.26336859757248e-08
disrupted O 0 7.690010761507438e-07
in O 0 2.2587926196138142e-08
DM B-Disease 1 1.0
striated O 0 2.3587728719576262e-05
muscle O 0 1.0839205060619861e-05
and O 0 5.430654592686324e-09
in O 0 7.791819967017943e-10
normal O 0 1.61813673571487e-08
cells O 0 1.7147025133112948e-08
expressing O 0 1.0482660295352275e-09
transcripts O 0 4.918686791199889e-09
that O 0 1.6033606387022559e-10
contain O 0 6.789244721971954e-09
CUG O 0 1.6104349924717098e-06
repeats O 0 1.1103878705398529e-06
. O 0 5.828979254829392e-08

Altered O 0 5.69243093195837e-06
expression O 0 7.76753665832075e-08
of O 0 3.6262570723977205e-10
genes O 0 2.299423584872784e-08
regulated O 0 5.1862507177702355e-08
posttranscriptionally O 0 1.441932226953213e-07
by O 0 4.6094356109804835e-10
CUG O 0 3.465860800133669e-06
- O 0 1.1804041832874645e-06
BP O 0 9.266937581742241e-07
therefore O 0 4.100889627878246e-10
may O 0 3.30717758734167e-10
contribute O 0 1.8253241973464895e-10
to O 0 1.3346903582345249e-09
DM B-Disease 1 0.9999978542327881
pathogenesis O 0 1.6881256215128815e-07
. O 0 2.9078790486636308e-09
. O 0 2.381119301730905e-08

Identification O 0 1.222524872446229e-07
of O 0 2.6643143247184753e-10
a O 0 6.905711558147232e-10
novel O 0 3.830408701332999e-08
nonsense O 0 6.04934143666469e-07
mutation O 0 7.260898371441726e-08
and O 0 5.721401130642789e-10
a O 0 3.291376060587936e-10
missense O 0 1.7384797956765397e-07
substitution O 0 2.4631965356292085e-09
in O 0 1.9298435072201414e-10
the O 0 2.3133134297026459e-10
vasopressin O 0 8.055450280153309e-07
- O 0 4.5087685407452227e-07
neurophysin O 0 9.095971904571343e-07
II O 0 4.979847645358859e-09
gene O 0 2.3214694611084497e-09
in O 0 7.512593325209593e-11
two O 0 3.423828442983279e-10
Spanish O 0 1.0585440435306737e-07
kindreds O 0 2.9770831133646425e-06
with O 0 1.8900225384754776e-08
familial B-Disease 1 0.8997546434402466
neurohypophyseal I-Disease 1 0.9995392560958862
diabetes I-Disease 1 0.9998701810836792
insipidus I-Disease 1 0.9848679900169373
. O 0 1.2397679711284582e-05

Familial B-Disease 1 0.9999898672103882
neurohypophyseal I-Disease 1 0.9999839067459106
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999333620071411
( O 0 7.562836117358529e-07
FNDI B-Disease 1 1.0
) O 0 5.665748759042799e-09
is O 0 2.8530158791006954e-10
an O 0 6.746011527170026e-10
autosomal B-Disease 1 0.9999470710754395
dominant I-Disease 1 0.9999949932098389
disease I-Disease 1 0.9555785059928894
caused O 0 5.667189029168185e-08
by O 0 3.514503132961977e-09
deficiency O 0 2.754630259005353e-05
in O 0 2.242307173272451e-10
the O 0 2.4340907067710305e-09
antidiuretic O 0 2.1941097656963393e-05
hormone O 0 1.2200015362395789e-06
arginine O 0 1.2338311705661908e-07
vasopressin O 0 1.4864731667785236e-07
( O 0 2.2534631105575187e-10
AVP O 0 2.1454090060046838e-08
) O 0 1.3530877807088615e-11
encoded O 0 3.281608318417284e-11
by O 0 1.466338855893312e-11
the O 0 1.8924520284180346e-10
AVP O 0 2.520729367461172e-06
- O 0 2.529728533318121e-07
neurophysin O 0 1.6409894669777714e-06
II O 0 7.739424034980402e-08
( O 0 9.306291293142976e-10
AVP O 0 1.4642291716882028e-06
- O 0 1.0948175344083211e-07
NPII O 0 6.079507102185744e-07
) O 0 3.5712835466661375e-10
gene O 0 5.6582538654481596e-09
on O 0 1.9401489304016195e-09
chromosome O 0 1.354253981844522e-06
20p13 O 0 4.609845291270176e-06
. O 0 1.1181882797473008e-07

In O 0 6.773929417391855e-09
this O 0 1.1392409238197843e-10
study O 0 3.5590638769456007e-10
, O 0 3.806151227525589e-11
we O 0 2.6925279714151706e-11
analyzed O 0 1.604296695489893e-10
two O 0 8.395266253014011e-12
families O 0 2.2986439141003956e-11
with O 0 1.4059533051669071e-11
FNDI B-Disease 1 0.9999806880950928
using O 0 3.6220335064562903e-10
direct O 0 5.141334025182687e-10
automated O 0 1.121909232182361e-08
fluorescent O 0 1.481386302515375e-08
, O 0 1.5155547650191892e-10
solid O 0 6.171875455152076e-09
phase O 0 6.114613260166379e-09
, O 0 1.0634986641333555e-10
single O 0 5.929776669688636e-09
- O 0 6.97355346801487e-08
stranded O 0 2.227847906155489e-09
DNA O 0 2.747569283201301e-09
sequencing O 0 6.925748863295667e-10
of O 0 4.562009450759241e-11
PCR O 0 4.019436516955466e-07
- O 0 1.2519173253622284e-07
amplified O 0 7.849253620406671e-07
AVP O 0 1.2966270332981367e-05
- O 0 1.096313326343079e-06
NPII O 0 3.519419578879024e-06
DNA O 0 1.03128070350067e-06
. O 0 8.276609975155225e-08

In O 0 5.226465926710944e-09
one O 0 2.670042797969785e-10
of O 0 9.51192163228809e-12
the O 0 4.9145087305246804e-11
families O 0 2.11972869812449e-10
, O 0 7.477753832807466e-11
affected O 0 2.6044080780884826e-10
individuals O 0 1.4088934185974011e-10
presented O 0 6.738565261343865e-10
a O 0 1.4019506389129077e-10
novel O 0 1.7779790084659908e-08
nonsense O 0 6.994160628437385e-08
mutation O 0 7.639061827546811e-09
in O 0 5.5757658906641083e-11
exon O 0 4.745934312211375e-09
3 O 0 3.1057215132967997e-10
of O 0 3.634431080742906e-12
the O 0 1.171898082047429e-11
gene O 0 9.396901035074734e-10
, O 0 1.9166074977094993e-11
consisting O 0 2.724079468940932e-11
in O 0 1.1797256227463748e-10
a O 0 3.855634700400401e-10
G O 0 7.566905679823321e-08
to O 0 7.793232170705267e-10
T O 0 1.1016378920203351e-07
transition O 0 4.385037666310154e-09
at O 0 5.406426972776046e-10
nucleotide O 0 1.9397909056806384e-08
2101 O 0 2.684153521670396e-08
, O 0 8.186572253432445e-11
which O 0 2.74710532099931e-11
produces O 0 1.3125368847344276e-10
a O 0 9.33371505085212e-11
stop O 0 4.051460944509699e-09
signal O 0 1.861739207242863e-08
in O 0 3.0299509568010308e-09
codon O 0 5.416442832029134e-07
82 O 0 2.9291170378087372e-08
( O 0 9.616825114022731e-10
Glu O 0 3.325664579278964e-07
) O 0 5.275800352144699e-10
of O 0 2.196639814489032e-10
NPII O 0 4.93280549562769e-06
. O 0 7.113793998314577e-08

The O 0 7.552846881253572e-08
premature O 0 3.3166946877827286e-07
termination O 0 7.367184906570401e-08
eliminates O 0 2.706485524583968e-08
part O 0 6.924282258680137e-10
of O 0 2.4049550545468534e-11
the O 0 1.813781486115218e-10
C O 0 4.8203435909499603e-08
- O 0 8.835745468616096e-09
terminal O 0 3.4357816591779056e-09
domain O 0 4.075151327498361e-10
of O 0 4.9680194853796156e-12
NPII O 0 1.3672234011607998e-08
, O 0 1.1244525276177253e-11
including O 0 6.33668031241319e-12
a O 0 2.1296155811034723e-11
cysteine O 0 5.55421098002995e-10
residue O 0 6.297615318118233e-09
in O 0 7.295857668010441e-11
position O 0 5.702240901683808e-09
85 O 0 1.953321948633402e-10
, O 0 1.2478883378019834e-11
which O 0 4.923647253796126e-11
could O 0 2.0521145893681592e-10
be O 0 2.279694662210563e-11
involved O 0 3.221612213111236e-11
in O 0 2.1964416396791364e-11
the O 0 1.2028124329876988e-10
correct O 0 4.453856305985937e-08
folding O 0 2.7335147478879662e-08
of O 0 9.663154998396095e-11
the O 0 1.922551673416706e-09
prohormone O 0 2.1485522665898316e-05
. O 0 1.1596078053344172e-07

In O 0 1.659004489340532e-08
the O 0 2.5125201918996254e-10
second O 0 7.743979346663821e-10
family O 0 6.004732266973178e-10
, O 0 1.7017292089360758e-11
a O 0 2.0968430117229708e-11
G279A O 0 4.041281531641516e-09
substitution O 0 1.2188608455865335e-10
at O 0 1.2820171313432382e-10
position O 0 1.0163443420196927e-08
- O 0 1.3017081634814076e-08
1 O 0 2.626687756190904e-10
of O 0 3.92913479529966e-12
the O 0 1.993724282889353e-11
signal O 0 1.6432635252527916e-09
peptide O 0 1.880481992344585e-09
was O 0 1.3996928616144544e-10
observed O 0 1.68218661222852e-10
in O 0 3.359711467365578e-11
all O 0 1.3657025510482868e-10
affected O 0 1.7704991917000257e-09
individuals O 0 1.360251800086587e-09
. O 0 1.9532530259880332e-08

This O 0 1.2597740806086222e-07
missense O 0 2.612072421470657e-05
mutation O 0 2.61378727373085e-06
, O 0 4.283605470334351e-09
which O 0 5.784078105364188e-09
replaces O 0 3.040657645669853e-07
Ala O 0 1.1858092818783916e-07
with O 0 1.973198271443266e-10
Thr O 0 1.2198711374367122e-06
, O 0 1.0538788591807347e-10
is O 0 4.488310764716452e-11
frequent O 0 8.48620729243521e-09
among O 0 1.3469383830511106e-08
FNDI B-Disease 1 1.0
patients O 0 7.0537231522394e-07
and O 0 1.8972731719024694e-10
is O 0 6.23167559221649e-11
thought O 0 1.0483620638268576e-09
to O 0 9.490071228857033e-11
reduce O 0 1.342474909016289e-09
the O 0 5.436110589451815e-11
efficiency O 0 1.0684377826919444e-09
of O 0 9.584988185096233e-12
cleavage O 0 2.1210372125324284e-08
by O 0 2.8706634291886246e-10
signal O 0 3.427196659799847e-08
peptidases O 0 5.211164193497098e-07
. O 0 3.971060813512395e-09
. O 0 2.5394641056664113e-08

Genetic O 0 2.570672040747013e-05
heterogeneity O 0 5.443580448627472e-06
of O 0 9.688262636586842e-09
Saethre B-Disease 1 0.9181222915649414
- I-Disease 1 0.9999524354934692
Chotzen I-Disease 1 0.999971866607666
syndrome I-Disease 1 0.999985933303833
, O 0 3.447372387554992e-10
due O 0 3.8234634902600817e-10
to O 0 2.2331049509549672e-10
TWIST O 0 2.067131163130398e-06
and O 0 2.550784827803909e-08
FGFR O 0 8.087702553893905e-06
mutations O 0 1.8781780681820237e-06
. O 0 9.171967008114734e-08

Thirty O 0 1.5456610071851173e-06
- O 0 8.371052899747156e-06
two O 0 1.0886279655508702e-09
unrelated O 0 1.224589851744895e-08
patients O 0 1.3171469470663055e-09
with O 0 2.2276872187199093e-12
features O 0 5.572525774155679e-10
of O 0 1.4101785017484048e-10
Saethre B-Disease 1 0.9993195533752441
- I-Disease 1 0.9997958540916443
Chotzen I-Disease 1 0.9999257326126099
syndrome I-Disease 1 0.9989991784095764
, O 0 3.239537110788504e-11
a O 0 1.7230444848692628e-10
common O 0 3.7565655475191306e-08
autosomal B-Disease 0 0.49199479818344116
dominant I-Disease 0 0.2505418062210083
condition I-Disease 0 4.795656877831789e-06
of O 0 3.823507066513798e-10
craniosynostosis B-Disease 0 0.028987359255552292
and O 0 1.8656317379850407e-08
limb B-Disease 0 1.7542095520184375e-05
anomalies I-Disease 0 0.00010564856347627938
, O 0 1.8988516314877302e-10
were O 0 2.0513554743750717e-10
screened O 0 1.7258749096527026e-08
for O 0 9.427685021545784e-11
mutations O 0 5.039442196874688e-09
in O 0 1.2382771197305686e-10
TWIST O 0 3.293465056231071e-07
, O 0 4.698430533522924e-10
FGFR2 O 0 2.648022245921311e-07
, O 0 2.4791121933098736e-10
and O 0 3.19673354454153e-09
FGFR3 O 0 1.0326435585739091e-05
. O 0 1.0983962539512504e-07

Nine O 0 5.360482191463234e-08
novel O 0 1.679841332702381e-08
and O 0 6.724621415266085e-10
three O 0 7.730078244172489e-10
recurrent O 0 7.608012424498156e-07
TWIST O 0 5.760130989074241e-06
mutations O 0 6.36381173535483e-07
were O 0 6.765404347852666e-10
found O 0 4.918506157913782e-10
in O 0 4.666706465705772e-10
12 O 0 2.675075272406957e-09
families O 0 5.999571950354721e-09
. O 0 4.2409112666064175e-08

Seven O 0 4.943642295529571e-08
families O 0 1.6800135727024212e-09
were O 0 9.437273879031594e-11
found O 0 7.501024107403609e-11
to O 0 2.558591880030825e-11
have O 0 1.5380186013658204e-10
the O 0 3.3669667748315035e-11
FGFR3 O 0 1.5419757914969523e-07
P250R O 0 1.8801600276674435e-08
mutation O 0 3.5222136318679986e-09
, O 0 2.2924790538114692e-11
and O 0 1.2889305942009877e-11
one O 0 2.9460614503484805e-11
individual O 0 1.0271161005048768e-10
was O 0 2.2905539687201326e-09
found O 0 9.173126841455215e-11
to O 0 2.861756318028874e-11
have O 0 8.425219549801355e-11
an O 0 6.398514357242036e-11
FGFR2 O 0 9.157508316093299e-07
VV269 O 0 6.557485221492243e-07
- O 0 2.4807047793729e-07
270 O 0 8.010498220301088e-08
deletion O 0 1.7853636791187455e-06
. O 0 1.254015558060928e-07

To O 0 8.710997256855535e-09
date O 0 3.1724511018182966e-08
, O 0 1.7311316269363886e-10
our O 0 6.91825971510518e-11
detection O 0 5.594293361887992e-10
rate O 0 3.2318053788671364e-10
for O 0 5.567973165865325e-12
TWIST O 0 2.0610210427207676e-08
or O 0 2.146811839409679e-09
FGFR O 0 2.4703143708393327e-07
mutations O 0 2.414067523659469e-08
is O 0 1.7307190403048622e-10
68 O 0 1.0964780194910873e-09
% O 0 8.101681131522653e-11
in O 0 1.1974811420234488e-10
our O 0 6.9783805400902565e-09
Saethre B-Disease 1 0.7538561820983887
- I-Disease 1 0.9940313696861267
Chotzen I-Disease 1 0.9992177486419678
syndrome I-Disease 1 0.9420444369316101
patients O 0 2.2129922783165057e-08
, O 0 7.014480576245097e-12
including O 0 1.85611682274045e-11
our O 0 2.8543659102986396e-10
five O 0 3.074970833516488e-10
patients O 0 1.317968734149133e-09
elsewhere O 0 5.438833383664132e-09
reported O 0 1.4395217462492838e-08
with O 0 1.6232115651604317e-09
TWIST O 0 6.802172720199451e-05
mutations O 0 1.538901233288925e-05
. O 0 3.13995286660429e-07

More O 0 1.4600163300571012e-09
than O 0 1.061551624381707e-09
35 O 0 6.891632264860448e-10
different O 0 1.393531401383541e-10
TWIST O 0 2.2349870221205492e-07
mutations O 0 9.008197565663068e-08
are O 0 1.0937765276830547e-10
now O 0 1.520601700111257e-10
known O 0 2.811158250626278e-10
in O 0 6.061320889649835e-11
the O 0 9.218906193986243e-11
literature O 0 1.7409245600674694e-08
. O 0 1.721561382339587e-08

The O 0 2.6399791241971116e-09
most O 0 3.830382955261058e-10
common O 0 4.3551035000533034e-10
phenotypic O 0 8.578251886603994e-09
features O 0 3.253565639127487e-09
, O 0 4.5206755006077515e-11
present O 0 2.3423001385691755e-11
in O 0 3.021255337923301e-12
more O 0 6.677907467451949e-13
than O 0 8.68210538185199e-12
a O 0 3.6647199164185906e-11
third O 0 3.248927127330603e-09
of O 0 3.072659487957097e-11
our O 0 1.3143538479809536e-09
patients O 0 9.00891139465898e-10
with O 0 1.3041340576891436e-11
TWIST O 0 4.2050038473462337e-07
mutations O 0 7.04374798488061e-08
, O 0 3.68256675153944e-11
are O 0 3.3453559367124797e-11
coronal B-Disease 0 9.436116954475438e-08
synostosis I-Disease 0 2.3851424657550524e-07
, O 0 2.096672002682709e-10
brachycephaly B-Disease 0 2.5465854491812934e-07
, O 0 3.0689197849653738e-09
low B-Disease 0 0.0004030826676171273
frontal I-Disease 1 0.9999959468841553
hairline I-Disease 1 0.9999998807907104
, O 0 7.327664519607424e-08
facial B-Disease 1 0.9464452266693115
asymmetry I-Disease 0 1.5280720617738552e-05
, O 0 2.9126431044801393e-08
ptosis B-Disease 0 0.2898285388946533
, O 0 9.591514249507327e-09
hypertelorism B-Disease 0 1.0301296242687386e-05
, O 0 2.4325452763207522e-09
broad B-Disease 0 2.8098961379896537e-08
great I-Disease 0 1.1184863701885206e-08
toes I-Disease 0 3.660412858152995e-06
, O 0 1.0681708850768246e-09
and O 0 3.0690543439959583e-09
clinodactyly B-Disease 0 3.378826932021184e-06
. O 0 8.17714251866164e-08

Significant O 0 2.9950069801998325e-07
intra O 0 9.760593457031064e-06
- O 0 7.703789378865622e-06
and O 0 1.07127071657942e-08
interfamilial O 0 8.272883178506163e-07
phenotypic O 0 3.725899944129196e-07
variability O 0 5.987422468933801e-08
is O 0 5.266708943962861e-11
present O 0 3.178951546445319e-11
for O 0 1.4411074764075771e-11
either O 0 8.120885075513229e-10
TWIST O 0 3.3266685477428837e-06
mutations O 0 2.3024488200462656e-06
or O 0 3.1020839230677666e-08
FGFR O 0 1.4326078598969616e-05
mutations O 0 5.748365310864756e-06
. O 0 1.1230058305500279e-07

The O 0 8.111786797826426e-09
overlap O 0 1.1412716816039392e-07
in O 0 8.287754926783464e-10
clinical O 0 1.0159062924230966e-08
features O 0 1.6756165344133933e-09
and O 0 5.929140511895525e-10
the O 0 3.08854192221375e-11
presence O 0 5.600753194556773e-10
, O 0 2.4766910744489223e-11
in O 0 7.678873162331179e-12
the O 0 6.011624358037704e-12
same O 0 5.947985159959757e-11
genes O 0 3.5109701257418635e-10
, O 0 1.384005410276501e-11
of O 0 5.968924356516969e-13
mutations O 0 1.584898462470008e-10
for O 0 9.687172938810384e-13
more O 0 4.596154728510327e-13
than O 0 1.3211336538643259e-11
one O 0 3.199232823103415e-10
craniosynostotic B-Disease 0 7.836232725821901e-06
condition I-Disease 0 6.749955616669467e-08
- O 0 2.2873798410927293e-09
such O 0 3.833348222181954e-11
as O 0 2.5967394901016405e-10
Saethre B-Disease 0 2.0267398781470547e-07
- I-Disease 0 3.368301193518164e-08
Chotzen I-Disease 0 5.979273964840104e-08
, I-Disease 0 8.28383125983656e-11
Crouzon I-Disease 0 2.1634772195966434e-08
, I-Disease 0 7.342833979739893e-11
and I-Disease 0 1.3936889420307352e-09
Pfeiffer I-Disease 0 1.0515494068386033e-05
syndromes I-Disease 0 1.960350346053019e-06
- O 0 6.20705762344187e-08
support O 0 7.209114971651331e-10
the O 0 3.574566337372076e-11
hypothesis O 0 1.1782556041950443e-09
that O 0 1.3963111049342114e-11
TWIST O 0 1.0093433644442484e-08
and O 0 6.501012228543601e-11
FGFRs O 0 2.8828788245505166e-09
are O 0 1.2615510198987767e-11
components O 0 5.342492004345445e-10
of O 0 2.4924847342316925e-12
the O 0 8.844179728850765e-12
same O 0 1.0942106248856831e-10
molecular O 0 2.2443704672525655e-09
pathway O 0 3.771552237186171e-10
involved O 0 9.607176859605104e-11
in O 0 2.0724179317088698e-11
the O 0 2.006121657682769e-11
modulation O 0 1.5303358580354143e-08
of O 0 1.6656992452013242e-10
craniofacial O 0 0.0052896467968821526
and O 0 2.4963151545875917e-08
limb O 0 2.33159653362236e-06
development O 0 1.1513981990063371e-09
in O 0 2.0931517630273788e-10
humans O 0 1.1555012502384443e-09
. O 0 1.6262982072134946e-09
. O 0 3.8704335736383655e-08

Mutation O 0 3.2602623832644895e-05
analysis O 0 6.377098884513543e-07
of O 0 1.2733767817962871e-08
UBE3A O 0 0.0017630886286497116
in O 0 6.548099918290973e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0004540617228485644
. O 0 4.815252623302513e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.8312668998987647e-06
AS B-Disease 1 1.0
) O 0 9.108783061151371e-09
is O 0 9.688554403197713e-10
caused O 0 5.346511233739193e-09
by O 0 3.7143971232111994e-10
chromosome O 0 2.7136709377373336e-06
15q11 O 0 5.332781711331336e-06
- O 0 4.5927572500659153e-07
q13 O 0 2.1499789681911352e-07
deletions O 0 5.25303249787612e-08
of O 0 8.820111307983325e-11
maternal O 0 6.3012675077800395e-09
origin O 0 2.3248283298471506e-09
, O 0 1.064501195524592e-10
by O 0 5.950325787651423e-10
paternal O 0 2.9054108381387778e-06
uniparental B-Disease 0 0.013813658617436886
disomy I-Disease 0 0.0007743439055047929
( O 0 2.0333372319214504e-08
UPD B-Disease 1 1.0
) O 0 5.697826654937899e-09
15 O 0 2.9204172413699325e-10
, O 0 8.846862478706363e-12
by O 0 9.37006791601469e-11
imprinting O 0 0.0064245471730828285
defects O 1 0.9995173215866089
, O 0 3.2788757819979253e-10
and O 0 1.2988744801933905e-10
by O 0 1.8883632157962182e-10
mutations O 0 8.674193452407053e-08
in O 0 9.313074200711924e-10
the O 0 2.4248230090506695e-09
UBE3A O 0 1.0369581104896497e-05
gene O 0 1.6117195400511264e-06
. O 0 2.712988305120234e-07

UBE3A O 0 0.0012777936644852161
encodes O 0 5.317313480190933e-06
a O 0 8.775923276971298e-08
ubiquitin O 0 9.154801432487147e-07
- O 0 1.7730710055730015e-07
protein O 0 8.674835072497444e-09
ligase O 0 1.3964304379499026e-08
and O 0 6.427973153755318e-10
shows O 0 4.683904109015202e-08
brain O 0 1.2472034995880676e-06
- O 0 5.114862346999871e-07
specific O 0 7.100076260257993e-08
imprinting O 0 1.2474600225687027e-05
. O 0 2.0567647140978806e-07

Here O 0 2.616694985135837e-07
we O 0 1.9130384387722188e-08
describe O 0 3.0408429552153393e-07
UBE3A O 0 6.375072553055361e-05
coding O 0 0.00028499876498244703
- O 0 4.3411546357674524e-05
region O 0 2.8825567710555333e-07
mutations O 0 5.280165282783855e-07
detected O 0 2.023270795348253e-08
by O 0 1.2988075892561568e-10
SSCP O 0 7.227032483569928e-08
analysis O 0 2.4145359045490977e-09
in O 0 1.7991720613341755e-10
13 O 0 9.631804243070974e-10
AS B-Disease 1 0.997205913066864
individuals O 0 8.911922866339239e-10
or O 0 3.5575655754627178e-09
families O 0 1.2266141879990755e-08
. O 0 4.4746496286052206e-08

Two O 0 1.3804451270971185e-07
identical O 0 6.097891400713706e-07
de O 0 9.840400707616936e-07
novo O 0 8.071398838183086e-07
5 O 0 5.410896175561675e-09
- O 0 3.7959345888793905e-08
bp O 0 9.922634802705943e-08
duplications O 0 4.635546346776209e-08
in O 0 2.314297642413976e-10
exon O 0 2.4084290117798446e-08
16 O 0 1.1551619660821189e-09
were O 0 2.9960778302751123e-10
found O 0 5.197120955813261e-09
. O 0 2.8909360239026682e-08

Among O 0 2.4096973305631764e-08
the O 0 2.1952072104536313e-10
other O 0 1.6558510118613867e-10
11 O 0 3.0824284791286516e-10
unique O 0 1.0041313336373037e-09
mutations O 0 2.3147503469544972e-08
, O 0 1.3390806519186782e-10
8 O 0 1.988188780277511e-10
were O 0 6.531637036788496e-11
small O 0 1.7268214635990375e-10
deletions O 0 1.5660171825970792e-08
or O 0 9.571077264070027e-10
insertions O 0 1.4659208602552098e-07
predicted O 0 3.9902868564922755e-08
to O 0 4.610226644885529e-10
cause O 0 6.132058749663827e-10
frameshifts O 0 1.1492940643620386e-07
, O 0 1.1751621897815312e-10
1 O 0 5.109658807178619e-10
was O 0 5.176205020163138e-10
a O 0 4.654889668165296e-11
mutation O 0 3.465543629843637e-09
to O 0 8.007278867738776e-11
a O 0 1.0618913387494544e-10
stop O 0 8.173022258972651e-09
codon O 0 4.8791832796268864e-08
, O 0 1.7974399746378822e-10
1 O 0 1.8516375932531304e-10
was O 0 2.2817880918069022e-10
a O 0 1.240399866153652e-10
missense O 0 2.0196780781134294e-07
mutation O 0 8.622427216664619e-09
, O 0 7.08350947342673e-11
and O 0 1.4005581416842716e-10
1 O 0 5.437585937073663e-10
was O 0 3.105024237726184e-09
predicted O 0 2.001735888157441e-09
to O 0 5.988967655135014e-11
cause O 0 8.373329807298546e-11
insertion O 0 7.981574845494777e-10
of O 0 1.998548375403697e-11
an O 0 7.39955041684226e-11
isoleucine O 0 3.4461747873137938e-06
in O 0 4.686195875791554e-10
the O 0 1.1666934085496905e-10
hect O 0 8.811834106836614e-08
domain O 0 3.328740394437091e-09
of O 0 1.8796087949968232e-11
the O 0 1.0161184393897571e-10
UBE3A O 0 1.3865896164588776e-07
protein O 0 2.4795956399259467e-09
, O 0 1.9141523435739494e-11
which O 0 6.656280561456729e-12
functions O 0 7.654075984131481e-11
in O 0 2.2673715682763884e-10
E2 O 0 1.4771879719432945e-08
binding O 0 5.5919917585356416e-09
and O 0 4.302912193221431e-10
ubiquitin O 0 1.632629853531853e-08
transfer O 0 3.15199848444081e-08
. O 0 7.679092561829748e-08

Eight O 0 1.1367198737843864e-08
of O 0 1.8769468618229368e-11
the O 0 1.7105121138949464e-11
cases O 0 3.4079764010819247e-10
were O 0 1.496005125334321e-10
familial O 0 4.793809083025735e-08
, O 0 2.693443801327078e-10
and O 0 2.807777066404782e-10
five O 0 6.976407229686288e-10
were O 0 3.556113847835718e-09
sporadic O 0 1.2930394177601556e-06
. O 0 3.02806654417509e-07

In O 0 1.2614614242068e-08
two O 0 1.3891003902699595e-09
familial O 0 3.495329110592138e-07
cases O 0 2.0414043788719027e-08
and O 0 6.229527449441719e-10
one O 0 2.5391569402621883e-10
sporadic O 0 2.2364533336372006e-08
case O 0 1.2242722391420102e-08
, O 0 3.79588721566293e-10
mosaicism O 0 5.201899284656974e-07
for O 0 1.0148677453969412e-09
UBE3A O 0 1.2782834346580785e-06
mutations O 0 1.39872469162583e-07
was O 0 7.783635957991919e-10
detected O 0 3.4090963385580153e-09
in O 0 5.8180075340752424e-11
the O 0 1.685345960011908e-11
mother O 0 9.128698685856307e-09
of O 0 5.088267480968245e-12
three O 0 8.463217349152785e-10
AS B-Disease 1 1.0
sons O 0 8.60404796299008e-08
, O 0 6.154048798334699e-11
in O 0 6.730662555076705e-11
the O 0 5.247136752872805e-11
maternal O 0 2.180145175501025e-09
grandfather O 0 2.0125123789682675e-09
of O 0 4.94406555626159e-12
two O 0 9.328412348130755e-11
AS B-Disease 1 0.9999996423721313
first O 0 9.000473283338195e-11
cousins O 0 1.6524040802323725e-08
, O 0 9.005229895109323e-11
and O 0 6.925626044873567e-11
in O 0 4.3445316788570665e-11
the O 0 1.76223396985975e-10
mother O 0 2.075061900086439e-07
of O 0 2.049907119050509e-11
an O 0 1.298956830986242e-09
AS B-Disease 1 1.0
daughter O 0 3.6146451748209074e-05
. O 0 2.075467619988558e-07

The O 0 1.2175207508846597e-09
frequencies O 0 7.957560832494437e-09
with O 0 1.5172207934455173e-10
which O 0 5.242257739013212e-10
we O 0 4.224469940528053e-10
detected O 0 1.3905027129723635e-09
mutations O 0 2.438049317987634e-09
were O 0 8.577834276213281e-11
5 O 0 3.177999877146398e-11
( O 0 8.466276291141384e-12
14 O 0 4.739886608207122e-11
% O 0 1.1252764345326405e-11
) O 0 8.92349735770459e-12
of O 0 2.982311446408925e-12
35 O 0 1.652736697499435e-10
in O 0 7.52896078815013e-11
sporadic O 0 1.3808355348032819e-08
cases O 0 2.748991079215557e-08
and O 0 1.4950504167998702e-09
8 O 0 1.9268790729665142e-10
( O 0 9.304258752340644e-12
80 O 0 2.4732497300172795e-11
% O 0 1.9712786958336892e-11
) O 0 2.4351888561202628e-11
of O 0 4.46073343193798e-12
10 O 0 2.1712591447009544e-10
in O 0 3.9533973317240623e-10
familial O 0 8.646902074360696e-07
cases O 0 5.524326951444891e-08
. O 0 6.495342042001084e-09
. O 0 4.61556339814706e-08

The O 0 4.152611552399321e-07
hemochromatosis B-Disease 1 0.9999830722808838
845 O 0 8.081511623458937e-06
G O 0 4.341753083281219e-06
- O 0 1.640116465750907e-06
- O 0 4.4572982460522326e-07
> O 0 6.181795075832497e-09
A O 0 2.664990172984716e-10
and O 0 1.4812662207930316e-10
187 O 0 1.320225595513591e-09
C O 0 1.926855119904758e-08
- O 0 5.152825721665977e-08
- O 0 1.3058601666671166e-07
> O 0 2.170214052910069e-08
G O 0 1.39508912866404e-07
mutations O 0 7.563168935575959e-08
: O 0 8.633136427960153e-10
prevalence O 0 2.7216014331088445e-08
in O 0 8.495256165197418e-10
non O 0 1.0233859484287677e-06
- O 0 2.4994317300297553e-06
Caucasian O 0 5.6956405387609266e-06
populations O 0 1.0178650882153306e-06
. O 0 1.26534530409117e-07

Hemochromatosis B-Disease 0 0.0005006948485970497
, O 0 1.6007579972665553e-07
the O 0 1.248513257223749e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 7.245742894568252e-10
iron I-Disease 0 2.760038842097856e-05
metabolism I-Disease 0 3.181019110343186e-07
, O 0 8.377674942661173e-11
leads O 0 7.187052064594468e-10
, O 0 4.167660661025252e-11
if O 0 1.2389178571936554e-09
untreated O 0 2.0676909073813476e-08
, O 0 2.1314118872628462e-11
to O 0 1.1544300237975591e-10
progressive O 0 3.627443589948598e-08
iron B-Disease 0 0.45007339119911194
overload I-Disease 0 1.2457505363272503e-05
and O 0 3.917655888585614e-08
premature B-Disease 0 1.9301772624658042e-07
death I-Disease 0 5.3465750937675693e-08
. O 0 6.873680291619166e-08

The O 0 3.331645359594404e-07
hemochromatosis B-Disease 1 0.9999035596847534
gene O 0 2.3142706595535856e-06
, O 0 5.2424899976699635e-09
HFE O 0 3.6450189782044617e-06
, O 0 2.8582134437016293e-09
recently O 0 6.273352681773758e-08
has O 0 1.1203862282371801e-09
been O 0 5.974867822722274e-10
identified O 0 1.5733756519864528e-09
, O 0 2.7123778917337305e-11
and O 0 1.597730454883095e-11
characterization O 0 2.014459488108855e-09
of O 0 4.204674802776864e-12
this O 0 1.1982755933337419e-11
gene O 0 2.776888496924812e-09
has O 0 1.251025838477915e-09
shown O 0 5.839299599408321e-10
that O 0 1.3500973776447989e-11
it O 0 6.179274973650006e-12
contains O 0 5.590799958404835e-12
two O 0 3.55486924619175e-11
mutations O 0 5.7974540723648715e-09
that O 0 1.2772137514271975e-10
result O 0 1.4588529273495965e-09
in O 0 2.2196904037041776e-10
amino O 0 1.4148920257639475e-08
acid O 0 4.333470915440785e-09
substitutions O 0 3.485423727411785e-09
- O 0 9.867538786068053e-09
cDNA O 0 7.825308756537197e-08
nucleotides O 0 6.788897621845535e-08
845 O 0 4.8613198799785096e-08
G O 0 1.010881192087254e-07
- O 0 1.3747445848366624e-07
- O 0 1.1028424751202692e-07
> O 0 4.3590615561583945e-09
A O 0 3.287574101840107e-10
( O 0 8.150021629793613e-11
C282Y O 0 4.4123718012656354e-09
) O 0 2.1168388222858603e-11
and O 0 2.446524927091076e-11
187 O 0 1.1236561681116086e-09
C O 0 2.117160846637489e-08
- O 0 7.689352088391388e-08
- O 0 2.393304043835087e-07
> O 0 1.576843366990488e-08
G O 0 1.3001529453049443e-07
( O 0 6.361960958045643e-10
H63D O 0 4.48599820401796e-07
) O 0 3.46248474336619e-09
. O 0 1.9933471762101362e-08

Although O 0 1.9574956695578294e-06
hemochromatosis B-Disease 1 0.9999998807907104
is O 0 6.0821720992976225e-09
common O 0 2.5759676614001137e-09
in O 0 4.751412041592573e-10
Caucasians O 0 1.656210173450745e-07
, O 0 9.175458726140562e-10
affecting O 0 4.2416696821589994e-09
> O 0 2.9348981023247234e-09
= O 0 8.922659056054272e-09
1 O 0 4.022354116450799e-10
/ O 0 6.390248330490067e-10
300 O 0 1.1280400225022191e-11
individuals O 0 9.209164680834547e-12
of O 0 3.1762470258100972e-12
northern O 0 5.4537636628992914e-08
European O 0 3.826640693205263e-08
origin O 0 1.8320674977090334e-09
, O 0 3.550959179476898e-11
it O 0 8.609715718144173e-11
has O 0 3.2570285357635953e-10
not O 0 6.376754679848773e-11
been O 0 5.194995128521285e-11
recognized O 0 1.2786006975407105e-10
in O 0 2.1458109594751917e-11
other O 0 1.1660504506405545e-10
populations O 0 1.3352257077769991e-08
. O 0 1.549952877155647e-08

The O 0 2.900002904482335e-09
present O 0 6.535266217078117e-10
study O 0 1.3353287919848356e-10
used O 0 1.682154554538684e-10
PCR O 0 5.135860448035601e-08
and O 0 1.2244531777394485e-10
restriction O 0 1.9447579102660484e-09
- O 0 5.580867767918107e-09
enzyme O 0 3.2037041908239416e-09
digestion O 0 8.71552940928666e-10
to O 0 7.89946493634508e-12
analyze O 0 3.1679067702405916e-10
the O 0 6.728836238201197e-12
frequency O 0 3.7647673867269305e-10
of O 0 7.005882853017287e-12
the O 0 3.3105903435304285e-11
845 O 0 4.399782760344806e-09
G O 0 2.858945791217593e-08
- O 0 2.0970579939216805e-08
- O 0 1.8765236475815072e-08
> O 0 6.502044458400746e-10
A O 0 4.3080670975026436e-11
and O 0 4.64796083565755e-11
187 O 0 9.940640532946077e-10
C O 0 4.407871845302225e-09
- O 0 2.0181909476946203e-08
- O 0 6.948910424853239e-08
> O 0 1.2300347407290246e-08
G O 0 6.870010338388965e-08
mutations O 0 2.0308913661892802e-08
in O 0 1.3682367738798717e-10
HLA O 0 2.1862176069475936e-08
- O 0 3.894090383482762e-09
typed O 0 8.720821398355838e-09
samples O 0 1.8430516002254649e-09
from O 0 6.741493474571314e-11
non O 0 2.5728462915708405e-08
- O 0 4.6679573983965383e-08
Caucasian O 0 1.0555137919254776e-07
populations O 0 2.83891488095378e-09
, O 0 5.2283552487430995e-11
comprising O 0 1.7448553712995363e-10
Australian O 0 1.3471149751254075e-09
Aboriginal O 0 9.103602871540772e-10
, O 0 1.66080656172074e-11
Chinese O 0 5.972503741569213e-12
, O 0 1.799768493959686e-11
and O 0 1.978779917699569e-10
Pacific O 0 2.0390917843116085e-09
Islanders O 0 4.296847677665028e-08
. O 0 2.6798156582685806e-08

Results O 0 2.3090940430847695e-06
showed O 0 3.3470392679646466e-08
that O 0 9.456174732136446e-11
the O 0 6.730058871307065e-11
845 O 0 1.530265869575942e-08
G O 0 9.509109588634601e-08
- O 0 1.0304770370339611e-07
- O 0 9.869971506759612e-08
> O 0 5.149167758844442e-09
A O 0 4.4327239101527027e-10
mutation O 0 6.2513252352403015e-09
was O 0 2.3848392705083654e-10
present O 0 2.9499468839899734e-11
in O 0 2.2452716769150172e-11
these O 0 5.283098264419195e-11
populations O 0 4.789052487907952e-10
( O 0 2.104925435342242e-11
allele O 0 1.2070118238227678e-09
frequency O 0 1.7655287232187789e-09
0 O 0 2.889913308656844e-10
. O 0 4.46320411184864e-11
32 O 0 1.2956974382305475e-10
% O 0 1.8575830110223457e-11
) O 0 1.2804377350073004e-11
, O 0 1.0316982511360262e-11
and O 0 1.4073839316175452e-10
, O 0 1.3833877619828794e-11
furthermore O 0 3.2992139575860335e-10
, O 0 1.2747210405283926e-11
it O 0 2.6022431431904636e-10
was O 0 2.1136910888230886e-08
always O 0 3.802904213756619e-09
seen O 0 1.8453309991173228e-09
in O 0 5.389219973062076e-11
conjunction O 0 1.1560128410081916e-09
with O 0 9.49902267954883e-10
HLA O 0 1.5358500604634173e-07
haplotypes O 0 7.259886558586004e-08
common O 0 1.2959154860325839e-09
in O 0 1.6448807593771875e-10
Caucasians O 0 2.561877288087544e-08
, O 0 8.591096584131819e-11
suggesting O 0 2.312313229779761e-09
that O 0 1.5832729571840787e-10
845 O 0 9.358235963929928e-09
G O 0 5.4541175131817e-08
- O 0 7.643816957170202e-08
- O 0 7.253935763174013e-08
> O 0 3.745510124275597e-09
A O 0 5.441040396014785e-10
may O 0 2.3883364175247834e-09
have O 0 2.6794844121269534e-11
been O 0 1.850831467253844e-11
introduced O 0 4.7021754545628625e-11
into O 0 1.1576045677585967e-11
these O 0 8.418135633014856e-11
populations O 0 2.630002882142435e-09
by O 0 1.4872686415756675e-09
Caucasian O 0 2.633222493386711e-06
admixture O 0 4.4715111471305136e-06
. O 0 2.236539415889638e-07

187 O 0 7.1976955950958654e-06
C O 0 4.636307949112961e-06
- O 0 1.9253013761044713e-06
- O 0 5.602114470093511e-07
> O 0 3.8779116806608727e-08
G O 0 6.17391435753234e-08
was O 0 2.085623895808908e-10
present O 0 3.4022396011579303e-11
at O 0 4.664461525361041e-11
an O 0 6.2316961486896805e-12
allele O 0 6.004162944606151e-09
frequency O 0 1.588598586010903e-08
of O 0 4.724643454245836e-10
2 O 0 1.701764240635839e-08
. O 0 4.84357762786658e-08

68 O 0 1.8487510260456474e-06
% O 0 1.0647093873217273e-08
in O 0 1.1412743666783243e-10
the O 0 2.269733012649766e-11
two O 0 6.848675099258017e-11
populations O 0 1.0969234409685669e-09
analyzed O 0 6.520963324874174e-09
( O 0 1.6507645250740666e-10
Australian O 0 2.729647619048592e-09
Aboriginal O 0 1.5984759071940857e-09
and O 0 1.780403463547131e-10
Chinese O 0 1.5641618555939374e-10
) O 0 5.644109624114435e-10
. O 0 6.897106441527967e-09

In O 0 5.175931239165266e-09
the O 0 5.6515425672643e-10
Australian O 0 4.006613263385361e-09
Aboriginal O 0 1.9936274853193936e-09
samples O 0 9.259918387627408e-10
, O 0 2.1532973321081172e-11
187 O 0 5.849633555321532e-10
C O 0 5.502912792110237e-09
- O 0 7.468681673117317e-09
- O 0 1.3693635558809092e-08
> O 0 1.521382797520232e-09
G O 0 1.0118819560034353e-08
was O 0 1.291537432557277e-10
found O 0 2.5294877303849717e-11
to O 0 1.7422275427891876e-11
be O 0 8.098142989521051e-11
associated O 0 6.349656911375234e-10
with O 0 4.60430388260491e-10
HLA O 0 1.522973889223067e-07
haplotypes O 0 1.5342118331318488e-07
common O 0 3.875174403589199e-09
in O 0 2.8573726718050807e-10
Caucasians O 0 4.6312777612911304e-08
, O 0 7.149340147671879e-11
suggesting O 0 1.5860303070880377e-09
that O 0 3.3049875336477186e-11
it O 0 5.3496675839204144e-11
was O 0 9.245777754518514e-11
introduced O 0 3.1579347470334085e-10
by O 0 1.3979478685754998e-10
recent O 0 3.9459806089325866e-08
admixture O 0 3.0752139537071344e-06
. O 0 2.674339896202582e-07

In O 0 2.3668333071213965e-08
the O 0 3.4374844637419244e-10
Chinese O 0 1.8246106014974117e-10
samples O 0 6.627833282202289e-10
analyzed O 0 1.8763508524699546e-09
, O 0 3.307932747165232e-11
187 O 0 1.0899701141653395e-09
C O 0 6.065790980613883e-09
- O 0 1.0127604532783607e-08
- O 0 1.303131558216819e-08
> O 0 2.3096113910270333e-09
G O 0 1.224954271350498e-08
was O 0 4.5066617104794204e-10
present O 0 3.548277990872428e-11
in O 0 4.737708489410686e-11
association O 0 1.7720854297853528e-11
with O 0 5.71078687811033e-12
a O 0 1.5563998007062096e-11
wide O 0 1.4300351180995818e-10
variety O 0 9.630297670426557e-10
of O 0 6.5286977213308e-11
HLA O 0 8.491080727424105e-09
haplotypes O 0 1.0077005896391711e-08
, O 0 2.7508332417491843e-11
showing O 0 4.0390216171637405e-10
this O 0 9.924679134076797e-12
mutation O 0 3.197689613099186e-10
to O 0 1.1774590850943678e-11
be O 0 1.2324305638522493e-11
widespread O 0 3.8665539520144065e-11
and O 0 2.207568572387686e-10
likely O 0 2.4725199665454056e-10
to O 0 1.803882390682965e-11
predate O 0 1.7353475323389489e-09
the O 0 7.296006680757028e-12
more O 0 1.5574005626795007e-11
genetically O 0 9.629086417106691e-10
restricted O 0 7.601529961043241e-10
845 O 0 8.681092289464232e-09
G O 0 4.9886342168292686e-08
- O 0 9.566706182795315e-08
- O 0 1.1083378836929114e-07
> O 0 1.08150093325321e-08
A O 0 4.2522163568037286e-09
mutation O 0 2.733922315201198e-07
. O 0 3.2005239347654424e-08

Genotype O 1 0.9852558374404907
- O 1 0.9624937176704407
phenotype O 0 0.0008992347866296768
correlations O 0 9.469277574680746e-05
in O 0 2.1299697436916176e-06
attenuated B-Disease 1 0.9992185831069946
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 1.0
. O 0 3.786035085795447e-05

Germ O 0 0.004444599617272615
- O 0 0.0021622581407427788
line O 0 4.1510909909447946e-07
mutations O 0 1.8228807618925202e-07
of O 0 1.0955847340454739e-10
the O 0 7.181680805601331e-10
tumor B-Disease 0 4.199621628231398e-07
suppressor O 0 9.902032616082579e-07
APC O 0 1.379863192596531e-07
are O 0 1.6790013823708705e-09
implicated O 0 5.514988288268796e-07
in O 0 1.4832049544111214e-07
attenuated B-Disease 1 0.9999334812164307
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 1.3884847476219875e-06
AAPC B-Disease 1 1.0
) O 0 6.274857966559466e-09
, O 0 1.0147143542083015e-10
a O 0 8.028662179526691e-10
variant O 0 2.762817166512832e-05
of O 0 1.8374964838585583e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.075383806892205e-05
FAP B-Disease 0 8.505603182129562e-05
) O 0 1.0610000344968284e-07
. O 0 1.5440345180195436e-07

AAPC B-Disease 1 0.9999998807907104
is O 0 9.158943470310987e-08
recognized O 0 5.866731989101481e-09
by O 0 1.2620834932697278e-10
the O 0 7.795011858213741e-11
occurrence O 0 1.2305885199737077e-08
of O 0 1.3946296895106514e-10
< O 0 2.8057939971404267e-08
100 O 0 1.2531202742138703e-09
colonic B-Disease 0 4.743855583910772e-07
adenomas I-Disease 0 1.7496716964160441e-06
and O 0 1.3855777636351263e-10
a O 0 1.4025469674550095e-10
later O 0 8.193735467898478e-09
onset O 0 1.5266441550920717e-06
of O 0 1.097810468309035e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.3337793092205175e-09
age O 0 2.4819000188358586e-09
> O 0 2.265306608961737e-09
40 O 0 9.731077055263881e-10
years O 0 5.66216229458405e-09
) O 0 3.0165845377183587e-09
. O 0 2.1261852722886943e-08

The O 0 7.500202237054054e-09
aim O 0 2.4399440690103802e-08
of O 0 7.663392490031562e-12
this O 0 6.25693333949906e-12
study O 0 7.559422532388282e-11
was O 0 5.596809474206488e-11
to O 0 1.6531938318298245e-10
assess O 0 2.1144333572920004e-07
genotype O 0 1.1173763596161734e-05
- O 0 2.8640815799008124e-06
phenotype O 0 3.4831443826988107e-06
correlations O 0 1.4226417306417716e-06
in O 0 6.005929265029408e-08
AAPC B-Disease 1 0.999997615814209
families O 0 4.434631364347297e-07
. O 0 1.4118410263108672e-07

By O 0 1.447710573643235e-08
protein O 0 3.283285252564383e-07
- O 0 1.0521777085159556e-06
truncation O 0 5.113509359944146e-06
test O 0 2.958534253139078e-07
( O 0 4.4964446055395513e-10
PTT O 0 3.708843365757275e-08
) O 0 7.188913353495252e-11
assay O 0 1.068960209238412e-08
, O 0 2.954671576849144e-11
the O 0 2.0541028947218543e-11
entire O 0 8.597740297489054e-10
coding O 0 5.818942554469686e-07
region O 0 4.484472793109262e-09
of O 0 1.9656694674741182e-11
the O 0 7.546083202747411e-11
APC B-Disease 0 2.424457745675568e-09
gene O 0 1.7264798479743604e-09
was O 0 4.08490991032906e-10
screened O 0 3.82914322472061e-09
in O 0 7.824729753025395e-11
affected O 0 6.052958689828358e-10
individuals O 0 3.0462904421213466e-10
from O 0 4.653880059102278e-10
11 O 0 2.6733117053368005e-08
AAPC B-Disease 1 0.9999992847442627
kindreds O 0 6.02389945925097e-06
, O 0 4.696764088762961e-10
and O 0 1.4940290671283663e-10
their O 0 2.2453415515766295e-10
phenotypic O 0 4.066948235958989e-07
differences O 0 1.0196508810622618e-06
were O 0 1.121177639618054e-08
examined O 0 7.396638466161676e-07
. O 0 1.3266966902847344e-07

Five O 0 1.6667615909682354e-07
novel O 0 2.3788886949205335e-07
germ O 0 3.029276012966875e-05
- O 0 1.5151283150771633e-05
line O 0 5.081276412965963e-07
APC B-Disease 0 9.256536515067637e-08
mutations O 0 4.286157562205517e-08
were O 0 3.26253135618515e-10
identified O 0 3.8533349844271925e-09
in O 0 1.1428478163821865e-09
seven O 0 1.998635212885347e-08
kindreds O 0 2.0280489479773678e-05
. O 0 1.26756276586093e-07

Mutations O 0 7.678003385080956e-06
were O 0 4.452240354169135e-09
located O 0 4.237656614503038e-10
in O 0 7.2080529045504e-11
three O 0 2.3437213975130433e-11
different O 0 1.248965236788635e-10
regions O 0 9.776488507640124e-10
of O 0 3.907456302965073e-11
the O 0 2.770527973705583e-10
APC B-Disease 0 5.124809909773376e-09
gene O 0 4.102894912705324e-09
( O 0 3.410276575022131e-11
1 O 0 8.481215035827105e-11
) O 0 2.8425151121780345e-11
at O 0 1.0942231148947101e-10
the O 0 5.775263947627174e-11
5 O 0 2.0208930362475286e-10
end O 0 3.15258458227774e-10
spanning O 0 2.560337053481021e-09
exons O 0 4.680626375375141e-08
4 O 0 3.716948415721788e-10
and O 0 1.4437025186442298e-10
5 O 0 7.825446540765668e-11
, O 0 2.2545023140030374e-11
( O 0 1.1047415586495912e-11
2 O 0 3.6507182693545914e-11
) O 0 2.4585236624297124e-11
within O 0 2.219456562979616e-11
exon O 0 3.43702710736693e-09
9 O 0 4.047767121484469e-10
, O 0 2.1652409032402176e-11
and O 0 6.113569372967476e-11
( O 0 1.033257941013277e-11
3 O 0 5.221617929707101e-11
) O 0 3.454729904928122e-11
at O 0 7.597960455241193e-11
the O 0 1.548136445428394e-11
3 O 0 1.6287372839318692e-10
distal O 0 7.194132845000922e-09
end O 0 4.824979527029427e-08
of O 0 6.439283828374442e-11
the O 0 9.181323479268144e-10
gene O 0 4.2435976865817793e-07
. O 0 1.2918766856273578e-07

Variability O 0 4.8211113607976586e-06
in O 0 1.986044440016599e-09
the O 0 7.272099589172853e-11
number O 0 1.0616002521501855e-09
of O 0 1.2517807235212786e-08
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 4.855120891988918e-07
most O 0 3.2779440273245086e-10
apparent O 0 4.7200257036195126e-09
in O 0 7.820089714671852e-11
individuals O 0 5.255028703854414e-11
with O 0 1.8974965695917057e-11
mutations O 0 2.9619094732424855e-08
in O 0 3.7434938482405755e-10
region O 0 4.15136147680073e-09
1 O 0 1.890385625813451e-09
, O 0 1.5185756818691942e-10
and O 0 4.510998241613606e-09
upper O 0 7.085339893819764e-05
- O 1 0.75497967004776
gastrointestinal O 0 1.1262475254625315e-06
manifestations O 0 1.861345211295884e-08
were O 0 1.639465230240944e-10
more O 0 1.8472624471743693e-11
severe O 0 1.130018478789907e-08
in O 0 1.4501963518931404e-10
them O 0 6.362555482475329e-10
. O 0 2.7590399298560442e-08

In O 0 1.2409595129270201e-08
individuals O 0 2.6135356101519847e-09
with O 0 1.671845578643527e-10
mutations O 0 1.1157590407151474e-08
in O 0 1.7024896770134745e-10
either O 0 2.1711030750992677e-09
region O 0 9.423648528184003e-09
2 O 0 7.820839531547108e-10
or O 0 9.221600705267008e-10
region O 0 1.5758413463018428e-09
3 O 0 2.542505372904458e-10
, O 0 1.3504889047333268e-11
the O 0 1.0704112075876626e-11
average O 0 1.9727466882279998e-10
number O 0 3.440723053693695e-11
of O 0 6.222313463088991e-12
adenomas B-Disease 0 4.893265170835548e-08
tended O 0 2.000148269232227e-09
to O 0 5.47492329250332e-11
be O 0 3.754267730027294e-11
lower O 0 4.948332368859276e-11
than O 0 4.575287631397584e-12
those O 0 1.2824786371767871e-11
in O 0 6.628471209413345e-12
individuals O 0 1.0413420126198503e-11
with O 0 1.0117819776445103e-11
mutations O 0 3.792473890484871e-09
in O 0 7.679213515077166e-11
region O 0 1.1913512398820103e-09
1 O 0 5.140980974260856e-10
, O 0 4.998017277824118e-11
although O 0 6.690437648337877e-10
age O 0 1.0513937498402015e-09
at O 0 4.5983009067107616e-10
diagnosis O 0 3.671560833140575e-08
was O 0 6.010530406719283e-10
similar O 0 7.374548527394609e-09
. O 0 9.95199442854755e-08

In O 0 3.6306767015048536e-07
all O 0 1.0456789567570013e-07
AAPC B-Disease 1 0.9999940395355225
kindreds O 0 1.3309168025443796e-05
, O 0 5.839956851438899e-10
a O 0 1.587985021256344e-10
predominance O 0 3.485578403683576e-08
of O 0 1.282638301125516e-10
right O 0 0.0011978523107245564
- O 1 0.9999922513961792
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 1.0012900020228699e-06
rectal B-Disease 1 0.9892529845237732
polyp I-Disease 0 0.0001443396758986637
sparing O 0 5.654954975398141e-07
was O 0 2.1905250946474553e-08
observed O 0 7.390223544234686e-08
. O 0 3.1602215955217616e-08

No O 0 3.952322913391981e-06
desmoid B-Disease 0 0.40429702401161194
tumors I-Disease 1 1.0
were O 0 1.3923823871664354e-08
found O 0 3.753684474361307e-09
in O 0 9.741215611924758e-10
these O 0 1.3595962577994669e-08
kindreds O 0 4.955917756888084e-05
. O 0 6.735063493579219e-07

Our O 0 3.3171815516652714e-08
data O 0 4.439969281122558e-09
suggest O 0 3.10518410984173e-09
that O 0 5.882323794725863e-11
, O 0 1.020410700380836e-10
in O 0 5.311239781313759e-10
AAPC B-Disease 1 1.0
families O 0 1.4002436987681222e-09
, O 0 1.0792902162271023e-11
the O 0 2.4241580964812215e-12
location O 0 1.2307217467366627e-09
of O 0 1.398163182453338e-11
the O 0 6.008787911682134e-10
APC B-Disease 0 2.0421042279394896e-07
mutation O 0 7.493727025575936e-07
may O 0 2.829866474485243e-08
partially O 0 1.1042590841725541e-07
predict O 0 2.6225553284575653e-08
specific O 0 1.1949588873960693e-08
phenotypic O 0 4.10650136473123e-06
expression O 0 1.1027684649889125e-06
. O 0 4.1047135823646386e-07

This O 0 5.707943007138283e-09
should O 0 8.879785795556927e-10
help O 0 2.808794863362607e-10
in O 0 1.0213993713314995e-11
the O 0 4.9624883195764635e-12
design O 0 4.5058645703477396e-09
of O 0 2.8097258894521637e-11
tailored O 0 4.848744694641027e-08
clinical O 0 7.133086796784482e-07
- O 0 1.0792922466862365e-07
management O 0 1.4626587718780115e-09
protocols O 0 7.084391406841917e-10
in O 0 3.533285122814256e-11
this O 0 2.601408151392537e-11
subset O 0 6.109146077903915e-09
of O 0 6.989273049207156e-10
FAP B-Disease 0 4.5420387095873593e-07
patients O 0 3.0936167405570814e-08
. O 0 1.6393378876600195e-09
. O 0 2.8202212121186676e-08

Wilms B-Disease 0 0.02978993020951748
' I-Disease 0 4.997152245778125e-06
tumor I-Disease 0 1.2925930832352606e-06
1 O 0 5.745045772442836e-09
and O 0 4.965561295477983e-10
Dax O 0 1.5132943190110382e-05
- O 0 1.7221927350874466e-07
1 O 0 3.820527449960309e-09
modulate O 0 3.415965110775687e-08
the O 0 8.56066051380111e-10
orphan O 0 1.735527916935098e-07
nuclear O 0 2.609627358651778e-07
receptor O 0 6.738275715179043e-08
SF O 0 7.965877557580825e-06
- O 0 7.903473431269958e-08
1 O 0 6.033248900472188e-10
in O 0 3.919787758266402e-11
sex O 0 6.7365384381901094e-09
- O 0 6.791355477986372e-09
specific O 0 1.5664914920776596e-09
gene O 0 6.831203336332692e-08
expression O 0 1.2650605185626773e-07
. O 0 1.4351961397096602e-07

Products O 0 4.1843341591629724e-07
of O 0 1.6630525845329203e-09
steroidogenic O 0 1.461196461605141e-06
factor O 0 5.022125293407953e-08
1 O 0 1.2354514078438683e-09
( O 0 2.7252605727667856e-10
SF O 0 0.00794801115989685
- O 0 8.640241730972775e-07
1 O 0 3.823756866694339e-09
) O 0 8.91214380072114e-10
and O 0 4.814341370007469e-09
Wilms B-Disease 0 4.553172857413301e-06
tumor I-Disease 0 3.0516008564518415e-07
1 O 0 3.3933063026125865e-09
( O 0 2.46129311376464e-10
WT1 O 0 1.953054322711978e-07
) O 0 1.1870252003554072e-10
genes O 0 4.074925674668606e-10
are O 0 1.913794643593203e-11
essential O 0 3.0903346548427635e-10
for O 0 2.99910651868629e-11
mammalian O 0 3.812250959356334e-09
gonadogenesis O 0 5.635950017790492e-08
prior O 0 2.101196994175325e-09
to O 0 3.992658426099638e-10
sexual O 0 3.4676546079026593e-08
differentiation O 0 1.7090398785057914e-07
. O 0 1.293269633606542e-07

In O 0 6.431314858446058e-08
males O 0 1.5084999915870867e-07
, O 0 2.1311374887034162e-09
SF O 0 0.010299698449671268
- O 0 1.3730716545978794e-06
1 O 0 1.5488526017293225e-09
participates O 0 1.0342448009126315e-09
in O 0 3.2691137991092134e-11
sexual O 0 4.693199717742402e-10
development O 0 2.7798426754932493e-11
by O 0 1.0577085214624748e-11
regulating O 0 8.541431451014603e-10
expression O 0 2.5364507716396645e-10
of O 0 2.30372214360397e-11
the O 0 6.29520990891308e-10
polypeptide O 0 2.0159036466793623e-06
hormone O 0 1.6877761481737252e-06
Mullerian O 0 3.354022965140757e-06
inhibiting O 0 1.8176694993599085e-07
substance O 0 1.0292002627920738e-07
( O 0 1.6032757343964477e-09
MIS O 0 3.575844857550692e-06
) O 0 9.323334104749392e-09
. O 0 2.983978930615194e-08

Here O 0 1.2391836889946717e-07
, O 0 2.4016020283568196e-09
we O 0 1.0250068571693305e-09
show O 0 1.1990501924685759e-08
that O 0 3.1075539919100947e-09
WT1 O 0 2.7406535082263872e-05
- O 0 1.3659366686624708e-06
KTS O 0 5.897576556890272e-06
isoforms O 0 1.5434014244419814e-07
associate O 0 3.550219673797983e-08
and O 0 5.167820060769657e-10
synergize O 0 3.9611458646504616e-07
with O 0 1.6793278989624127e-09
SF O 0 0.08086677640676498
- O 0 2.631987172208028e-06
1 O 0 4.26423651944674e-09
to O 0 9.334645278968878e-10
promote O 0 2.4767610184994737e-08
MIS O 0 5.5615105338802096e-06
expression O 0 1.1204085126337304e-07
. O 0 5.430460703337303e-08

In O 0 2.9436170834173936e-08
contrast O 0 1.9077991453286813e-07
, O 0 1.2047905784129398e-08
WT1 O 0 2.3932361727929674e-05
missense O 0 1.3017725905228872e-05
mutations O 0 7.983521186361031e-07
, O 0 4.679666654183734e-10
associated O 0 2.586922898117905e-09
with O 0 9.868513783928279e-10
male B-Disease 0 2.4422174647042993e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 4.8865313573287494e-08
Denys B-Disease 1 0.9999974966049194
- I-Disease 1 0.999998927116394
Drash I-Disease 1 0.999997615814209
syndrome I-Disease 1 0.999997615814209
, O 0 3.1827223079261557e-09
fail O 0 1.1765745711045383e-07
to O 0 1.8176914140521916e-10
synergize O 0 2.9255195954647206e-07
with O 0 1.9771098092036254e-09
SF O 1 0.737779974937439
- O 0 6.7230771492177155e-06
1 O 0 3.1129363975423985e-08
. O 0 4.5412679838818804e-08

Additionally O 0 1.008157255455444e-06
, O 0 1.7464313328829917e-09
the O 0 2.278743721495502e-10
X O 0 4.175889444013592e-06
- O 0 8.22225331376103e-07
linked O 0 3.899774128512945e-06
, O 0 1.8674027602028076e-10
candidate O 0 6.63432508929418e-09
dosage O 0 4.731286082915176e-07
- O 0 2.8096659221432674e-08
sensitive O 0 4.105519479935538e-08
sex O 0 1.841885755027306e-08
- O 0 7.0396222184854196e-09
reversal O 0 5.590968132906937e-09
gene O 0 2.9600557560627294e-09
, O 0 7.653259276318991e-11
Dax O 0 4.7648029521951685e-07
- O 0 4.878559778376257e-08
1 O 0 1.4071001031012997e-09
, O 0 1.2356535239455013e-10
antagonizes O 0 6.150794717996177e-08
synergy O 0 1.0864484423223075e-08
between O 0 7.186202188869117e-10
SF O 0 0.00021567118528764695
- O 0 1.2245494929175038e-07
1 O 0 7.798957035731746e-10
and O 0 4.920849491774071e-11
WT1 O 0 2.409476707043723e-08
, O 0 1.1731281744642441e-11
most O 0 4.648632173642753e-12
likely O 0 1.1735383498301388e-10
through O 0 6.942008166227476e-12
a O 0 1.952777176073006e-11
direct O 0 1.9665478967478833e-10
interaction O 0 8.946905438733666e-10
with O 0 1.130725180154002e-09
SF O 1 0.9333205819129944
- O 0 7.67439360060962e-06
1 O 0 6.78445744028977e-08
. O 0 5.006344849789457e-08

We O 0 2.4411596655227186e-07
propose O 0 1.0200189848319496e-07
that O 0 9.98954474695779e-10
WT1 O 0 5.530573616852053e-07
and O 0 9.695911851181904e-10
Dax O 0 8.611240446043666e-06
- O 0 1.537080862590301e-07
1 O 0 1.0561129748509757e-09
functionally O 0 3.3184899272953317e-09
oppose O 0 1.5828299781972532e-09
each O 0 7.74066782893712e-11
other O 0 1.1268083688342756e-10
in O 0 1.8837657822512455e-10
testis O 0 4.914525675303594e-08
development O 0 1.380086322999574e-10
by O 0 2.673910814987579e-10
modulating O 0 5.080873961560428e-07
SF O 1 0.6243337392807007
- O 0 1.6225334320552065e-06
1 O 0 4.22864196991668e-08
- O 0 3.785408182466199e-07
mediated O 0 9.221994332619943e-07
transactivation O 0 6.853585546195973e-06
. O 0 1.1196518379108511e-08
. O 0 5.449645712474194e-08

A O 0 6.075391922877316e-08
mouse O 0 4.104263382487261e-07
model O 0 4.787312946064048e-07
for O 0 2.3720039621366595e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.7068339586257935
- O 1 0.7691220641136169
centre O 0 3.1545268939225934e-06
mutations O 0 1.6707572285667993e-05
. O 0 4.644684281629452e-07

Imprinting O 0 1.0469273547641933e-05
in O 0 5.962985660801223e-09
the O 0 8.304354426336147e-10
15q11 O 0 1.021359821606893e-06
- O 0 2.6492119786780677e-07
q13 O 0 2.606975897379016e-07
region O 0 2.2547368416780955e-09
involves O 0 7.21925630386977e-10
an O 0 5.1715843413235874e-11
imprinting O 0 2.6842977263186185e-07
centre O 0 2.5126951186393853e-08
( O 0 1.9087721681021463e-10
IC O 0 1.5505916550750953e-08
) O 0 6.070715458106335e-11
, O 0 5.245873613973773e-12
mapping O 0 4.852792057086219e-10
in O 0 3.971761114440753e-11
part O 0 1.9029812448057015e-10
to O 0 4.589886803962884e-11
the O 0 1.795729190345874e-11
promoter O 0 6.4063119253887635e-09
and O 0 2.6751351134279844e-10
first O 0 5.918485146416685e-10
exon O 0 6.346937908574546e-08
of O 0 1.4147321092394805e-09
SNRPN O 0 7.123500381567283e-06
. O 0 1.5157623067807435e-07

Deletion O 0 8.798078852123581e-06
of O 0 4.120831231801958e-09
this O 0 7.351993236426324e-09
IC O 0 2.4080904950096738e-06
abolishes O 0 5.614828069155919e-07
local O 0 1.0687298157563418e-08
paternally O 0 4.198588499093603e-07
derived O 0 3.240776313973015e-09
gene O 0 7.881852503999198e-09
expression O 0 1.3070240445500758e-09
and O 0 2.380975971938426e-10
results O 0 1.0912063252987991e-08
in O 0 1.6006038094928954e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 6.586196263924649e-07
PWS B-Disease 1 0.9999998807907104
) O 0 1.8938445123239944e-07
. O 0 1.3955309441371355e-07

We O 0 1.0709952391607658e-07
have O 0 3.1588082149980323e-10
created O 0 2.6791383000990265e-10
two O 0 1.111015862642617e-10
deletion O 0 6.217580050815741e-08
mutations O 0 7.342691077383279e-08
in O 0 1.8079615582422548e-10
mice O 0 1.47623602231306e-08
to O 0 6.721851963931158e-10
understand O 0 4.4155729739259186e-08
PWS B-Disease 1 1.0
and O 0 1.5603210390402467e-10
the O 0 1.857395313942245e-11
mechanism O 0 2.698416212698618e-10
of O 0 2.5598464320486514e-11
this O 0 7.728883644197992e-10
IC O 0 3.5566424685384845e-06
. O 0 6.67272885834791e-08

Mice O 0 0.0001465542009100318
harbouring O 0 6.174250302137807e-05
an O 0 4.840250422688541e-09
intragenic O 0 1.4371042880156892e-06
deletion O 0 5.589477609646565e-07
in O 0 1.5680370335502403e-09
Snrpn O 0 4.2537720901236753e-07
are O 0 6.822134523964962e-10
phenotypically O 0 5.57206369933283e-08
normal O 0 2.9727975636717474e-09
, O 0 1.1507719083203582e-10
suggesting O 0 3.1471667494287203e-09
that O 0 2.0372327436124493e-10
mutations O 0 6.987037615147074e-09
of O 0 1.1466588095698782e-11
SNRPN O 0 3.271039616947746e-08
are O 0 4.61724686262599e-11
not O 0 1.3521649078196418e-10
sufficient O 0 9.689589131056664e-10
to O 0 3.122853975412454e-09
induce O 0 9.686046951173921e-07
PWS B-Disease 1 0.9999855756759644
. O 0 7.906758696663019e-07

Mice O 0 7.337023816944566e-06
with O 0 7.351316222425908e-10
a O 0 4.602548064891465e-10
larger O 0 3.326734887565408e-09
deletion O 0 5.3101206987093974e-08
involving O 0 3.6251590618263663e-09
both O 0 1.02762220954844e-09
Snrpn O 0 2.0525597221876524e-07
and O 0 9.041221660233134e-10
the O 0 1.8177062077739947e-09
putative O 0 2.3198115741251968e-05
PWS O 1 1.0
- O 0 0.08646102994680405
IC O 0 3.965064479416469e-06
lack O 0 6.520291417899671e-09
expression O 0 4.085137561560259e-09
of O 0 5.071634084918841e-11
the O 0 2.733595294568403e-10
imprinted O 0 5.830591476296831e-07
genes O 0 1.2879966959644662e-07
Zfp127 O 0 3.273115396495996e-07
( O 0 5.7427312905034e-10
mouse O 0 3.387242486496689e-08
homologue O 0 1.7293157839048945e-07
of O 0 4.543793119538009e-10
ZNF127 O 0 1.4378555306393537e-06
) O 0 2.3078805533316427e-09
, O 0 7.522892309097529e-10
Ndn O 0 4.460891886992613e-07
and O 0 1.0090464019896217e-09
Ipw O 0 2.2203050775715383e-07
, O 0 1.8851172012279704e-10
and O 0 1.6634069122112294e-10
manifest O 0 1.8643466770384975e-09
several O 0 6.363866655867412e-10
phenotypes O 0 1.3400278930930654e-07
common O 0 3.5079882110267135e-08
to O 0 2.398090828137356e-07
PWS B-Disease 1 1.0
infants O 0 0.0002827982243616134
. O 0 1.3356668659980642e-07

These O 0 3.8565484139496675e-09
data O 0 3.5348661775458368e-09
demonstrate O 0 1.1294878365930572e-09
that O 0 1.7803246724068522e-11
both O 0 4.111225596070689e-11
the O 0 3.22141549546906e-11
position O 0 6.934664043001249e-08
of O 0 1.765392172725644e-11
the O 0 1.5984659429424397e-10
IC O 0 6.855363210434007e-08
and O 0 1.6078073594716358e-10
its O 0 3.598797301829215e-11
role O 0 2.8265636498048252e-09
in O 0 5.073898245999686e-11
the O 0 3.604925385980451e-11
coordinate O 0 1.8400380108474224e-09
expression O 0 8.80181427742599e-10
of O 0 1.677060053328905e-11
genes O 0 1.4107844892308208e-09
is O 0 4.225023803039463e-11
conserved O 0 1.975043323332315e-10
between O 0 4.7585466816935096e-11
mouse O 0 3.937911330353927e-09
and O 0 2.842695523419536e-10
human O 0 4.594616700992482e-11
, O 0 3.4939801052402686e-11
and O 0 3.459470904187967e-11
indicate O 0 3.991927344237922e-10
that O 0 1.4402446249506262e-11
the O 0 7.065546064888295e-12
mouse O 0 4.328605474057667e-09
is O 0 1.4812322202129025e-10
a O 0 4.420639548863292e-11
suitable O 0 4.015204613239121e-09
model O 0 7.30384641656201e-08
system O 0 2.570126333978351e-10
in O 0 3.006827425933167e-11
which O 0 1.1614445516450189e-10
to O 0 3.099985546040074e-11
investigate O 0 6.231571925141566e-10
the O 0 1.843331043360763e-11
molecular O 0 9.509391052375804e-10
mechanisms O 0 1.941302812946688e-10
of O 0 6.193197864268196e-12
imprinting O 0 2.0886753659965507e-08
in O 0 2.8616323199948113e-10
this O 0 1.507330094074888e-10
region O 0 2.213160099628908e-09
of O 0 2.400024276538737e-11
the O 0 9.094643094176291e-11
genome O 0 4.428433175718283e-09
. O 0 2.3155084516446323e-09
. O 0 2.426420486756342e-08

Mutations O 0 5.354874701879453e-06
of O 0 5.037450456768511e-10
the O 0 2.0278122236927487e-10
ATM O 0 6.245129924309367e-08
gene O 0 6.585938905345756e-08
detected O 0 4.268934716833428e-08
in O 0 2.7230642185571696e-09
Japanese O 0 6.728728294547182e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.8604443669319153
: O 0 1.047562592226825e-09
possible O 0 7.599587070750147e-10
preponderance O 0 2.9754993136066332e-08
of O 0 2.0070172954134158e-11
the O 0 5.6631501571535736e-11
two O 0 4.18735185414576e-10
founder O 0 9.040211779165475e-08
mutations O 0 2.215651448977951e-07
4612del165 O 0 3.84314262191765e-07
and O 0 8.89165452377938e-09
7883del5 O 0 1.659971985645825e-06
. O 0 1.528466668787587e-07

The O 0 2.9641251231282695e-08
ATM O 0 2.378120143475826e-06
( O 0 2.7052161399865327e-08
A O 1 0.9999998807907104
- O 1 0.9999998807907104
T O 1 1.0
, O 0 7.631135723329407e-10
mutated O 0 1.8199967755094804e-08
) O 0 8.771677134644662e-11
gene O 0 2.7148754355721394e-09
on O 0 6.481984948791819e-10
human O 0 7.850974981238323e-09
chromosome O 0 3.1509730433754157e-06
11q22 O 0 8.516210073139518e-06
. O 0 2.8136349783380865e-07

3 O 0 3.268651767029951e-07
has O 0 8.336526136076827e-09
recently O 0 1.0806760819548344e-08
been O 0 3.7979150380174076e-10
identified O 0 4.2322445548137466e-10
as O 0 6.762043182340083e-12
the O 0 1.3052682849498676e-12
gene O 0 1.5176260248495055e-10
responsible O 0 4.7963626126357184e-11
for O 0 5.113027622821731e-12
the O 0 7.235505250502428e-11
human O 0 3.392331038298835e-08
recessive B-Disease 1 0.9999980926513672
disease I-Disease 1 0.9999485015869141
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.42507028579711914
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.2571048557674658e-07
. O 0 1.4967322670145222e-07

In O 0 7.069479224242059e-09
order O 0 2.543747157357501e-10
to O 0 4.153376947924059e-11
define O 0 1.3560034206605565e-09
the O 0 2.0008635373547357e-11
types O 0 2.227898754370017e-09
of O 0 1.1314214148905322e-10
disease O 0 1.8663119760731206e-07
- O 0 5.4562082141274e-07
causing O 0 4.801477615501426e-08
ATM O 0 2.2372773855749983e-07
mutations O 0 4.5632351231006396e-08
in O 0 2.4235041751197173e-10
Japanese O 0 4.668999622481351e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 4.88561795464193e-08
as O 0 1.5902452965566027e-11
well O 0 1.4249076744909939e-11
as O 0 6.851846780925319e-12
to O 0 1.222322069949211e-11
look O 0 5.363094968124926e-10
for O 0 2.4688522060056783e-11
possible O 0 5.609177011756117e-10
mutational O 0 1.983547548434217e-07
hotspots O 0 2.5848629903180154e-08
, O 0 2.4826563027602333e-10
reverse O 0 2.168253274703602e-07
- O 0 3.1284240975537614e-08
transcribed O 0 1.868391663606417e-08
RNA O 0 1.47342227307945e-09
derived O 0 1.0287120461027754e-10
from O 0 4.062117395925435e-12
ten O 0 5.180656945102946e-11
patients O 0 8.140902535425099e-11
belonging O 0 1.5880628409514763e-11
to O 0 9.033490101784114e-12
eight O 0 7.477911345699084e-11
unrelated O 0 7.185191996939011e-09
Japanese O 0 5.075447916169651e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
families O 0 3.5095526484951733e-09
was O 0 2.563981804648563e-10
analyzed O 0 1.7191127410498552e-09
for O 0 1.5972459466162547e-11
mutations O 0 6.678300135121162e-10
by O 0 5.23763497850549e-12
the O 0 3.456536099011309e-11
restriction O 0 2.216788974607198e-09
endonuclease O 0 1.4700367501063738e-07
fingerprinting O 0 1.542949661370585e-07
method O 0 9.846485937714533e-08
. O 0 6.110057171326844e-08

As O 0 2.936282683663194e-08
has O 0 3.772280710023779e-09
been O 0 4.3811901329071645e-10
reported O 0 2.277227295621742e-10
by O 0 4.447888238279241e-12
others O 0 1.2476986110954158e-10
, O 0 1.5888991511392447e-11
mutations O 0 1.8241661514650787e-09
that O 0 3.541921964056449e-11
lead O 0 1.7895961101910274e-10
to O 0 1.753970579887465e-11
exon O 0 8.828771491664611e-09
skipping O 0 3.833317663293201e-08
or O 0 7.828992565350745e-09
premature O 0 7.884755071074778e-09
protein O 0 1.5699311850525532e-09
truncation O 0 1.366816704262419e-08
were O 0 1.0612013490174377e-09
also O 0 1.3315526459223292e-09
predominant O 0 1.3472883608756092e-07
in O 0 2.3457720210728894e-09
our O 0 1.1821414958035348e-08
mutants O 0 3.989473498222651e-07
. O 0 5.928060531346091e-08

Six O 0 3.2694927654119965e-08
different O 0 1.5060779290365645e-09
mutations O 0 2.0415523493966248e-08
were O 0 2.1565618735230885e-10
identified O 0 8.953887631335533e-10
on O 0 2.1154070162232586e-10
12 O 0 1.6388869428229924e-10
of O 0 8.585506437730483e-12
the O 0 2.7808089164693683e-10
16 O 0 7.513976996165184e-09
alleles O 0 6.802066110367377e-08
examined O 0 5.97130792812095e-07
. O 0 1.3684385180567915e-07

Four O 0 1.882273359399278e-08
were O 0 4.423948152254553e-10
deletions O 0 4.703776923520309e-09
involving O 0 8.091863845649527e-10
a O 0 8.423889363839976e-10
loss O 0 4.515448903674724e-09
of O 0 8.184538984046252e-12
a O 0 1.6758586185439128e-10
single O 0 8.327150524678473e-09
exon O 0 1.9946408258419979e-07
exon O 0 2.128573726167815e-07
7 O 0 3.980562546246347e-09
, O 0 1.1025528406927165e-10
exon O 0 1.0580026632567296e-08
16 O 0 9.232442588213985e-10
, O 0 1.1287400181192453e-10
exon O 0 4.3607769839582033e-08
33 O 0 6.763188231673212e-09
or O 0 4.139406595271566e-09
exon O 0 5.695639515579387e-07
35 O 0 1.3942219823093183e-07
. O 0 1.5286912002920872e-07

The O 0 3.2047433595749908e-09
others O 0 1.90497595475847e-09
were O 0 6.397489482612428e-11
minute O 0 9.106624898613802e-10
deletions O 0 1.6700719029927313e-08
, O 0 1.7999444990035585e-10
4649delA O 0 1.8259354916949633e-08
in O 0 1.7500183246976775e-10
exon O 0 4.144251164461821e-08
33 O 0 8.404378526449818e-09
and O 0 4.3502801361228194e-10
7883del5 O 0 1.794609403305003e-07
in O 0 1.8276313795695387e-09
exon O 0 8.508608289048425e-07
55 O 0 3.777168160468136e-07
. O 0 1.7720651612762595e-07

The O 0 2.2796283971615594e-08
mutations O 0 2.9205938290033373e-07
4612del165 O 0 1.9660103589558275e-07
and O 0 5.165494143533067e-10
7883del5 O 0 2.4513026275485572e-08
were O 0 6.442994054944862e-11
found O 0 2.2551131101389288e-11
in O 0 1.832760289019464e-12
more O 0 6.896881611824501e-13
than O 0 5.271429993902732e-12
two O 0 1.3094355461040763e-11
unrelated O 0 1.2018681605496795e-09
families O 0 1.547106887045402e-10
; O 0 4.967964581381601e-11
44 O 0 6.820100734161727e-11
% O 0 1.7300317428636802e-11
( O 0 5.730230526190816e-12
7 O 0 6.043565647928517e-11
of O 0 2.7997419920627875e-12
16 O 0 6.000126784311277e-11
) O 0 6.953736631648555e-12
of O 0 4.936638120858761e-13
the O 0 7.232727871481215e-12
mutant O 0 9.518760002436011e-09
alleles O 0 2.866889392549865e-09
had O 0 1.3320861080856616e-09
one O 0 2.9735488377147234e-11
of O 0 4.8812581580903736e-12
the O 0 5.6950610893835574e-11
two O 0 3.736562170786328e-09
mutations O 0 1.1646800430753501e-06
. O 0 6.480075143144859e-08

The O 0 2.7600663088378496e-08
4612del165 O 0 3.3915682706719963e-07
mutations O 0 4.37994920332585e-08
in O 0 9.904204539834538e-11
three O 0 2.4046705598967932e-11
different O 0 6.437908539602688e-11
families O 0 1.1598794147360536e-10
were O 0 6.208469849333653e-11
all O 0 4.669016475528087e-12
ascribed O 0 6.978883027031202e-10
to O 0 5.571715658292398e-11
the O 0 2.6430194838278354e-11
same O 0 1.267062454957113e-09
T O 0 8.054021236603148e-07
- O 0 1.0940701855588486e-07
- O 0 3.378080748461798e-08
> O 0 1.1515191022937188e-09
A O 0 1.227277585114095e-10
substitution O 0 3.860145258993697e-10
at O 0 1.519033371311096e-10
the O 0 8.452469280051389e-11
splice O 0 2.2009034239545144e-07
donor O 0 1.0932645899686122e-08
site O 0 5.415005333020417e-09
in O 0 1.2710344998723144e-09
intron O 0 4.819920832233038e-06
33 O 0 2.638234661844763e-07
. O 0 9.642749887461832e-08

Microsatellite O 0 7.720490248175338e-05
genotyping O 0 7.761709639453329e-06
around O 0 5.2767288316601935e-09
the O 0 1.9991099053928707e-10
ATM O 0 4.4565922507899813e-08
locus O 0 7.235722421228274e-08
also O 0 2.2920136899529098e-09
indicated O 0 1.3585508273905589e-09
that O 0 1.3295819306646806e-11
a O 0 3.71849287472692e-11
common O 0 9.96784765838754e-10
haplotype O 0 1.4454266761276813e-07
was O 0 8.862476308379996e-10
shared O 0 1.0974755132453495e-10
by O 0 1.997389753594092e-11
the O 0 8.727269601438437e-11
mutant O 0 6.902702409661288e-08
alleles O 0 2.553389144566154e-08
in O 0 6.143906494671114e-10
both O 0 5.050960982799779e-09
mutations O 0 1.5405221347464249e-06
. O 0 9.836799819140651e-08

This O 0 4.718585522311969e-09
suggests O 0 6.0894849163162235e-09
that O 0 1.9301848314112746e-11
these O 0 4.6983202051098516e-11
two O 0 7.208163232963472e-11
founder O 0 1.062319832101366e-08
mutations O 0 5.693429727671173e-08
may O 0 1.8616282959627029e-09
be O 0 1.188733417256671e-10
predominant O 0 2.006178334568176e-08
among O 0 6.976101363243004e-10
Japanese O 0 1.052714626581519e-08
ATM O 0 5.253373842606379e-07
mutant O 0 1.0239619996355032e-06
alleles O 0 3.587776518543251e-06
. O 0 3.396915815301327e-07

W474C O 0 5.83998735237401e-05
amino O 0 2.5539698071952444e-06
acid O 0 3.1170424108495354e-07
substitution O 0 4.255461760749313e-09
affects O 0 2.8877162883134133e-09
early O 0 1.9276509555243848e-10
processing O 0 6.434044963476993e-10
of O 0 6.020747268797866e-12
the O 0 3.3226220386151084e-11
alpha O 0 7.256156231427724e-10
- O 0 1.058355292293811e-09
subunit O 0 1.6862801155426155e-09
of O 0 2.6579176359842194e-11
beta O 0 3.814906168742027e-09
- O 0 6.0346909691588735e-09
hexosaminidase O 0 4.896944005849946e-08
A O 0 1.2004265637077793e-10
and O 0 5.980953926565391e-11
is O 0 1.9059989697645108e-11
associated O 0 8.668214479534697e-10
with O 0 7.518531353056801e-10
subacute O 0 7.19695390216657e-06
G B-Disease 0 1.3576859601016622e-06
( I-Disease 0 1.2309447905423099e-09
M2 I-Disease 0 1.5927663525872049e-06
) I-Disease 0 2.5478479770413287e-08
gangliosidosis I-Disease 0 1.3007016605115496e-05
. O 0 3.5701708611668437e-07

Mutations O 0 6.170164851937443e-05
in O 0 3.0961075481172884e-08
the O 0 4.958039756530752e-09
HEXA O 0 6.151819889055332e-06
gene O 0 4.03828579464971e-08
, O 0 1.1355312523608774e-10
encoding O 0 7.78803133094641e-10
the O 0 7.687082914653587e-11
alpha O 0 3.1352620499802697e-09
- O 0 4.506956141625551e-09
subunit O 0 6.301508204131778e-09
of O 0 3.118446473271419e-11
beta O 0 1.3735855119989537e-08
- O 0 5.591653362557736e-08
hexosaminidase O 0 5.960071689514734e-07
A O 0 5.169377703673206e-10
( O 0 2.4939935533430102e-11
Hex O 0 5.0579886945456565e-09
A O 0 3.696465009084271e-11
) O 0 2.070047605551295e-11
, O 0 6.539062694099762e-12
that O 0 2.0002147507747203e-11
abolish O 0 1.0379250348080404e-08
Hex O 0 5.7293679134318154e-08
A O 0 2.1384737036722612e-10
enzyme O 0 2.393837839065327e-08
activity O 0 8.896153502746529e-08
cause O 0 4.888829153060215e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.0001285498437937349
( O 0 1.1505333352701541e-09
TSD B-Disease 0 1.2014251069558668e-06
) O 0 5.856242712987125e-10
, O 0 7.922388439718375e-11
the O 0 4.476147508203354e-10
fatal O 0 7.0764021984359715e-06
infantile B-Disease 0 4.584416615216469e-07
form I-Disease 0 8.376213500582708e-09
of I-Disease 0 1.975039576329607e-10
G I-Disease 0 2.1664428118128853e-07
( I-Disease 0 4.4081802097473144e-10
M2 I-Disease 0 3.153869272409793e-07
) I-Disease 0 1.4976246909270685e-09
gangliosidosis I-Disease 0 4.2643083020266204e-07
, I-Disease 0 9.41699607182045e-10
Type I-Disease 0 7.349107988829928e-08
1 I-Disease 0 3.587576813401938e-08
. O 0 5.095503752272634e-08

Less O 0 5.714028930015047e-07
severe O 0 7.957403795444407e-06
, O 0 5.4873385835207955e-09
subacute O 0 3.2063030630524736e-06
( O 0 2.3791568715125777e-09
juvenile O 0 9.161097295873333e-06
- O 0 0.3596002757549286
onset O 0 0.012170650996267796
) O 0 5.2373362535718115e-08
and O 0 1.15416753487807e-07
chronic O 0 0.001835828647017479
( O 0 4.5074699528413475e-10
adult O 0 3.8146174574649194e-07
- O 0 0.000962761347182095
onset O 0 1.072779582500516e-06
) O 0 1.6251995582639012e-10
variants O 0 1.12645870409267e-09
are O 0 2.4577267304648487e-11
characterized O 0 1.5883061532662168e-10
by O 0 1.759794567013362e-11
a O 0 6.08271141788741e-11
broad O 0 1.2259119275270791e-09
spectrum O 0 1.4725343167043548e-09
of O 0 3.143108689984686e-11
clinical O 0 1.4784507840204242e-08
manifestations O 0 4.287079580223008e-09
and O 0 1.3570998491641006e-10
are O 0 2.7690894716103642e-11
associated O 0 5.064425545597828e-10
with O 0 3.040665497167083e-10
residual O 0 0.00038833534927107394
levels O 0 1.1339214722738689e-07
of O 0 1.3486002592433266e-10
Hex O 0 4.1795405536504404e-07
A O 0 2.5351363230896595e-09
enzyme O 0 8.013646635163241e-08
activity O 0 8.428735043253255e-08
. O 0 1.0075298462197679e-07

We O 0 5.448699198495888e-07
identified O 0 5.525370738723723e-08
a O 0 3.104905665907154e-09
1422 O 0 1.351278910988185e-06
G O 0 1.1473955510155065e-06
- O 0 1.8650964648259105e-06
- O 0 1.3934298976892023e-06
> O 0 1.0261111071940832e-07
C O 0 4.7193797314548647e-08
( O 0 1.2092002399377577e-10
amino O 0 3.0363378478170944e-09
acid O 0 9.743649220794737e-10
W474C O 0 1.1690863832569676e-09
) O 0 3.6357692030641875e-12
substitution O 0 8.029236130135953e-12
in O 0 3.976496649321648e-12
the O 0 7.326281074859775e-12
first O 0 1.4485017352239282e-10
position O 0 1.7156471798784878e-09
of O 0 5.183076190462543e-12
exon O 0 7.3726211802238595e-09
13 O 0 2.143557970013532e-10
of O 0 1.154125666563699e-11
HEXA O 0 2.6339407099840173e-07
of O 0 2.1278454692685855e-11
a O 0 5.685296677881979e-10
non O 0 1.6000254277059867e-07
- O 0 7.836749915668406e-08
Jewish O 0 8.744610369149086e-08
proband O 0 3.7174561384745175e-07
who O 0 1.9722963262580606e-09
manifested O 0 1.1002263100579057e-08
a O 0 7.58718976534567e-10
subacute O 0 4.479521749090054e-07
variant O 0 3.2073657507680764e-07
of O 0 7.46658401773459e-10
G B-Disease 0 7.110198794180178e-07
( I-Disease 0 2.8599314028099343e-09
M2 I-Disease 0 4.08722826250596e-06
) I-Disease 0 4.155268484851149e-08
gangliosidosis I-Disease 0 1.3246299204183742e-05
. O 0 2.8328051371317997e-07

On O 0 9.671074607808805e-09
the O 0 8.649618243872226e-10
second O 0 1.24266010814722e-08
maternally O 0 1.759213546392857e-06
inherited O 0 3.9951464714249596e-07
allele O 0 2.1010201578519627e-07
, O 0 6.954181119844804e-10
we O 0 2.4343912996549477e-10
identified O 0 1.3431484813253292e-09
the O 0 1.6159883153843424e-10
common O 0 8.290735564742135e-08
infantile O 0 0.0001042371877701953
disease O 0 2.5338566047139466e-05
- O 0 2.683473439901718e-06
causing O 0 8.726882327891872e-08
4 O 0 7.623661701927631e-09
- O 0 3.4534710380285105e-07
bp O 0 7.985843240021495e-07
insertion O 0 8.681343643957007e-08
, O 0 1.6226574528488413e-09
+ O 0 4.7631854016572106e-08
TATC O 0 8.349171025656688e-07
1278 O 0 2.555358094014082e-07
, O 0 5.296874050486622e-10
in O 0 7.626276277150623e-10
exon O 0 5.018347906116105e-07
11 O 0 5.766291621966957e-08
. O 0 9.883459739512546e-08

Pulse O 0 0.0001573795307194814
- O 0 3.172815195284784e-05
chase O 0 1.5356448557213298e-06
analysis O 0 1.4963948302693098e-08
using O 0 1.1617403927743908e-08
proband O 0 8.615549518253829e-07
fibroblasts O 0 1.2272852245587274e-07
revealed O 0 5.7963287503071115e-08
that O 0 1.6933247859451939e-10
the O 0 1.4529594194456763e-10
W474C O 0 6.183802270243177e-08
- O 0 4.254723240393332e-09
containing O 0 1.1828783508249785e-09
alpha O 0 2.33266361782114e-09
- O 0 2.0334758321638446e-09
subunit O 0 4.149738774827938e-09
precursor O 0 5.352021048565803e-09
was O 0 2.73159384001076e-10
normally O 0 5.347372891706392e-11
synthesized O 0 4.873346726164129e-10
, O 0 1.004099754731147e-11
but O 0 2.0326981417517764e-11
not O 0 7.826517212095041e-12
phosphorylated O 0 4.439611456241721e-10
or O 0 2.5461438513119106e-11
secreted O 0 4.1206563161644283e-10
, O 0 3.4516740160528414e-11
and O 0 1.012701519864656e-10
the O 0 2.641508956013894e-10
mature O 0 1.986526676489575e-08
lysosomal O 0 1.7436951793570188e-07
alpha O 0 4.440333434274635e-09
- O 0 9.150086910381106e-09
subunit O 0 3.336929665920252e-08
was O 0 8.489429603741883e-09
not O 0 1.5733575553511514e-09
detected O 0 4.76409383054488e-08
. O 0 2.6807153830077368e-08

When O 0 2.2697804524796084e-07
the O 0 1.7468710922230457e-09
W474C O 0 2.1943979788829893e-07
- O 0 1.8122271683296276e-08
containing O 0 7.960562764530721e-10
alpha O 0 1.978988528605896e-09
- O 0 5.761736865395051e-09
subunit O 0 9.274629952926716e-09
was O 0 1.7373444904933422e-09
transiently O 0 1.1044907211044119e-07
co O 0 1.7749286485013727e-07
- O 0 1.1539997402110203e-08
expressed O 0 6.097067989374594e-11
with O 0 1.5799962033158366e-11
the O 0 5.156091179014943e-11
beta O 0 2.380468711038475e-09
- O 0 8.043545829394816e-10
subunit O 0 9.777663123600178e-10
to O 0 6.953222719818797e-11
produce O 0 5.56508006344103e-10
Hex O 0 9.346840101898124e-08
A O 0 4.679202580959441e-10
( O 0 5.868315555712655e-11
alphabeta O 0 3.297430595239348e-08
) O 0 2.921932695798546e-10
in O 0 3.1172286973912833e-10
COS O 0 1.0493574336578604e-05
- O 0 2.0922962562508474e-07
7 O 0 2.298795154231925e-09
cells O 0 3.29281579780627e-09
, O 0 7.001758894897847e-11
the O 0 4.0404367351865034e-11
mature O 0 1.6723981088873074e-09
alpha O 0 3.46259521055714e-10
- O 0 4.87096807333387e-10
subunit O 0 1.6251385792642736e-09
was O 0 1.7023989162812114e-10
present O 0 2.801666537655123e-11
, O 0 9.247712838555966e-12
but O 0 2.7224174303785986e-11
its O 0 4.9134307733567084e-11
level O 0 5.555376159094294e-10
was O 0 2.1136083161454877e-10
much O 0 1.9073081655718305e-11
lower O 0 1.91386129166915e-10
than O 0 3.7214582110367544e-11
that O 0 1.3224193441685461e-11
from O 0 2.7409973596403958e-11
normal O 0 3.176595375631308e-10
alpha O 0 3.327259856522602e-10
- O 0 6.898563387203183e-10
subunit O 0 1.5704643141489782e-09
transfections O 0 7.1651835575892164e-09
, O 0 9.810905560181382e-12
although O 0 1.6103628847075058e-11
higher O 0 2.7370689048566987e-11
than O 0 2.0629763522461708e-11
in O 0 1.17165069313252e-10
those O 0 1.0372120939905471e-09
cells O 0 4.3388470594152295e-09
transfected O 0 3.3460118231687375e-08
with O 0 3.8069790375683255e-11
an O 0 2.541670172939714e-11
alpha O 0 3.5348661775458368e-09
- O 0 1.4566653661063356e-08
subunit O 0 4.1682074680693404e-08
associated O 0 1.9327186961959342e-08
with O 0 1.9347103474842697e-08
infantile O 0 3.1213399779517204e-05
TSD B-Disease 0 0.0002947002067230642
. O 0 3.9290344489018025e-07

Furthermore O 0 3.982486589393375e-07
, O 0 1.0773374414796422e-09
the O 0 4.675997436476287e-11
precursor O 0 4.0448826510441904e-09
level O 0 7.420188352647017e-10
of O 0 7.222443997034755e-12
the O 0 6.848022149341659e-11
W474C O 0 1.2408459149071405e-08
alpha O 0 4.135151110418178e-10
- O 0 5.075003750576457e-10
subunit O 0 1.678367334001507e-09
was O 0 3.5671987586027853e-10
found O 0 5.6718411217682174e-11
to O 0 2.1811911651847815e-11
accumulate O 0 5.390487500811503e-10
in O 0 7.68369309150918e-12
comparison O 0 6.293169318993819e-10
to O 0 1.5450751789103379e-10
the O 0 1.858129622389626e-10
normal O 0 4.8857460299700506e-09
alpha O 0 3.7952090359283375e-09
- O 0 1.3428008038829375e-08
subunit O 0 5.2252726590040766e-08
precursor O 0 1.359398424938263e-07
levels O 0 6.47349054361257e-08
. O 0 1.479212308197475e-08

We O 0 2.990634584421059e-07
conclude O 0 5.703222427655419e-08
that O 0 2.489313755127398e-10
the O 0 2.285451272676653e-10
1422 O 0 1.4435778439292335e-07
G O 0 2.073582123784945e-07
- O 0 1.551444199776597e-07
- O 0 2.32696848456726e-07
> O 0 1.852900588517059e-08
C O 0 1.8630606390956927e-08
mutation O 0 2.1541621819665124e-09
is O 0 4.102030173869231e-11
the O 0 1.905860885775823e-11
cause O 0 2.773515028753337e-10
of O 0 3.955658023357955e-11
Hex B-Disease 0 5.706844603992067e-05
A I-Disease 0 2.769781133338256e-07
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.869296798051039e-10
the O 0 7.306444338439633e-10
proband O 0 4.3853092392964754e-06
. O 0 6.876631175600778e-08

The O 0 3.702249529169421e-08
resulting O 0 4.768748596006844e-08
W474C O 0 3.6897793620482844e-07
substitution O 0 1.8943532964499354e-08
clearly O 0 1.310524488928877e-08
interferes O 0 2.122101427914913e-08
with O 0 4.077053625262117e-11
alpha O 0 3.888098731863465e-10
- O 0 4.3304612673544796e-10
subunit O 0 3.846291618536668e-10
processing O 0 8.125828343530372e-10
, O 0 3.088058628253343e-11
but O 0 3.711831883523864e-11
because O 0 1.788257562862494e-11
the O 0 1.8293760603582676e-12
base O 0 6.661719786915654e-11
substitution O 0 1.8499254905712803e-10
falls O 0 1.1406553923620777e-08
at O 0 3.155073424743193e-11
the O 0 5.493707485454413e-12
first O 0 1.362733675902561e-10
position O 0 2.1099155755877064e-09
of O 0 1.4208395744674807e-11
exon O 0 8.337003087888206e-09
13 O 0 3.6532274427791833e-10
, O 0 1.352514975017094e-11
aberrant O 0 2.046939728828079e-09
splicing O 0 9.912571385939373e-08
may O 0 1.0962339480613537e-08
also O 0 1.7903813154251935e-10
contribute O 0 1.4765330624832984e-10
to O 0 4.924805008243993e-10
Hex B-Disease 0 6.746513463440351e-06
A I-Disease 0 2.7066713315093693e-08
deficiency I-Disease 0 5.631264343719522e-07
in O 0 4.957022986529225e-11
this O 0 1.323338522096762e-10
proband O 0 1.2084559841696318e-07
. O 0 1.8729326978217387e-09
. O 0 1.8806657564596208e-08

Two O 0 1.0027963526226813e-07
frequent O 0 2.934703616119805e-06
missense O 0 0.000590741983614862
mutations O 0 0.000957489013671875
in O 0 1.6085248716990463e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.5682558013359085e-06

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.7139853980552289e-06
an O 0 2.4673960069776513e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 2.433870349705103e-06
by O 0 3.6900160704789187e-09
early O 0 2.845087919922662e-06
childhood O 1 0.9995929598808289
deafness B-Disease 1 1.0
and O 0 0.0017796683823689818
goiter B-Disease 1 1.0
. O 0 2.9316433938220143e-06

A O 0 2.8717124678223627e-08
century O 0 6.608939173702311e-09
after O 0 8.900269410361261e-10
its O 0 1.9881877394434255e-11
recognition O 0 7.937244750344519e-10
as O 0 5.348446685538022e-10
a O 0 3.992066233138303e-09
syndrome O 0 5.512425104825525e-06
by O 0 1.993999271254765e-10
Vaughan O 0 4.198544445443986e-08
Pendred O 0 2.023825373953514e-07
, O 0 5.834790983705318e-10
the O 0 1.6531915836281996e-09
disease O 0 5.251619938917429e-08
gene O 0 4.0551274338440635e-08
( O 0 3.7419733978083514e-10
PDS O 0 9.040953585781608e-08
) O 0 3.440442652991038e-10
was O 0 5.522204360453031e-10
mapped O 0 6.142681741039269e-08
to O 0 4.190437774553857e-09
chromosome O 0 2.612894832054735e-06
7q22 O 0 1.1648304280242883e-05
- O 0 6.937785656191409e-06
q31 O 0 1.2040129149681889e-05
. O 0 1.9953849061948858e-07

1 O 0 2.1782099679512612e-07
and O 0 1.1910330499631527e-09
, O 0 1.2114002856389305e-10
recently O 0 6.110171035800249e-09
, O 0 3.2931827403936964e-11
found O 0 7.678056801463384e-11
to O 0 2.1327700022721885e-11
encode O 0 5.925796742189959e-09
a O 0 4.582927815022231e-09
putative O 0 4.702986188931391e-06
sulfate O 0 2.4605255021015182e-05
transporter O 0 1.5785240975674242e-05
. O 0 3.03195008655166e-07

We O 0 8.145666896552939e-08
performed O 0 8.58646931334306e-09
mutation O 0 5.016225657072937e-09
analysis O 0 7.598311424494852e-10
of O 0 1.0084739467119963e-11
the O 0 3.980376445111844e-11
PDS B-Disease 0 2.862579684403954e-08
gene O 0 8.204369628117547e-09
in O 0 2.3931276404987045e-10
patients O 0 1.8556512992873309e-09
from O 0 4.5467903747598015e-11
14 O 0 1.8998115580703967e-10
Pendred B-Disease 0 8.146082919324726e-09
families O 0 2.4846586593740838e-11
originating O 0 1.4053988528495154e-10
from O 0 2.126883738573504e-11
seven O 0 1.3946721555413433e-10
countries O 0 1.1643545849704395e-10
and O 0 1.6444071104793068e-10
identified O 0 6.119863726894437e-09
all O 0 7.797960610567145e-10
mutations O 0 1.95667681168743e-07
. O 0 2.810555699284123e-08

The O 0 6.282247166922161e-09
mutations O 0 2.5102425027512254e-08
include O 0 2.488254879917662e-10
three O 0 9.79591407990199e-11
single O 0 9.057256056266283e-10
base O 0 1.9316748200992606e-09
deletions O 0 2.4796914743774323e-08
, O 0 3.7817524112249146e-10
one O 0 4.5754663946517837e-10
splice O 0 7.965201120896381e-07
site O 0 1.160823828172397e-07
mutation O 0 5.873541795153869e-07
and O 0 2.1834337005088855e-08
10 O 0 2.1612089895484132e-08
missense O 0 1.8912411178462207e-05
mutations O 0 2.0010795196867548e-05
. O 0 6.981644560255518e-07

One O 0 4.508850111051288e-07
missense O 0 3.1715146178612486e-05
mutation O 0 1.7809441033023177e-06
( O 0 2.8015625375132913e-09
L236P O 0 7.360990395000044e-08
) O 0 6.182546141708656e-10
was O 0 4.6182707658104505e-10
found O 0 1.4518652946549082e-10
in O 0 2.6800008393057517e-11
a O 0 2.939494481157823e-11
homozygous O 0 4.131321507117036e-09
state O 0 1.6839458993889167e-10
in O 0 3.5581863844225126e-11
two O 0 4.1236652981169186e-11
consanguineous O 0 1.1639743036084838e-07
families O 0 3.439865059462477e-10
and O 0 6.493601489854228e-11
in O 0 2.3017457731477897e-11
a O 0 3.127536077340842e-11
heterozygous O 0 1.5191182756169042e-09
state O 0 3.423277980529882e-11
in O 0 1.7241581426463704e-11
five O 0 4.554784327481798e-11
additional O 0 1.1650639342164482e-09
non O 0 1.0802422139022383e-06
- O 0 2.058092377410503e-06
consanguineous O 0 5.019032323616557e-05
families O 0 1.1760001683569499e-07
. O 0 8.185428868046074e-08

Another O 0 6.531228677886247e-07
missense O 0 5.4152704251464456e-05
mutation O 0 1.4103528656050912e-06
( O 0 1.6151971982125701e-09
T416P O 0 7.698024973024076e-08
) O 0 7.363946674665556e-10
was O 0 3.6081465593085227e-10
found O 0 1.4494884459370638e-10
in O 0 1.6656157356131907e-11
a O 0 1.544355442140155e-11
homozygous O 0 4.13791445552647e-09
state O 0 1.526119369765766e-10
in O 0 6.779791311695149e-11
one O 0 6.649875095021685e-11
family O 0 8.824890124214946e-11
and O 0 8.31844315651864e-11
in O 0 3.144397936472032e-11
a O 0 9.608789458548372e-11
heterozygous O 0 6.517693051932838e-09
state O 0 3.4221178668580876e-10
in O 0 1.802754889812519e-10
four O 0 1.1449443615418886e-09
families O 0 4.573043721478598e-09
. O 0 1.8620696096149914e-08

Pendred B-Disease 0 5.605582919088192e-05
patients O 0 1.6456722278235247e-06
in O 0 3.876340082253904e-10
three O 0 8.501675474725801e-10
non O 0 2.755585342129052e-07
- O 0 1.5479828618936153e-07
consanguineous O 0 1.4070305951463524e-06
families O 0 6.520338158289007e-10
were O 0 3.572971432608263e-11
shown O 0 5.252503640362782e-11
to O 0 2.2868804072651017e-11
be O 0 4.0495950343055753e-11
compound O 0 1.0366345559731371e-09
heterozygotes O 0 2.0646407250524135e-08
for O 0 1.0284373352931198e-10
L236P O 0 7.099263399368283e-08
and O 0 2.5039483819710995e-09
T416P O 0 1.3359807553570135e-06
. O 0 8.436342824325038e-08

In O 0 8.846234855752755e-09
total O 0 2.138416665964371e-10
, O 0 2.6748070772186772e-11
one O 0 1.554228273858982e-11
or O 0 8.867984818694552e-11
both O 0 7.617752956212698e-11
of O 0 3.4730553936240804e-12
these O 0 4.983016083093261e-11
mutations O 0 1.479222855316209e-09
were O 0 6.788304640625853e-11
found O 0 4.806088166331435e-11
in O 0 3.351595737055568e-11
nine O 0 2.6042193401742963e-10
of O 0 8.446518658111746e-12
the O 0 1.774162761147835e-10
14 O 0 1.4517552715531679e-09
families O 0 1.0086230739503321e-09
analyzed O 0 5.781290823847485e-08
. O 0 3.0101372061608345e-08

The O 0 1.3525679465331564e-09
identification O 0 2.167974688660479e-09
of O 0 2.5480045157122433e-11
two O 0 2.699574452869058e-10
frequent O 0 5.358601384841677e-08
PDS B-Disease 0 1.730693043100473e-06
mutations O 0 2.787982396057487e-07
will O 0 1.8249482480747758e-10
facilitate O 0 3.0563707120734307e-10
the O 0 2.5264418335169125e-10
molecular O 0 2.3042053953759023e-07
diagnosis O 0 3.448005736572668e-05
of O 0 1.4205956233581674e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.910628253033792e-07

Insertional O 0 0.0001570242748130113
mutation O 0 1.4125428151601227e-06
by O 0 2.0559824953636507e-09
transposable O 0 3.208615908079082e-06
element O 0 2.690074154543254e-07
, O 0 2.304559432175779e-09
L1 O 0 2.7211194719711784e-07
, O 0 1.5383852525197028e-10
in O 0 1.497692525553873e-10
the O 0 1.0411762563222737e-09
DMD B-Disease 1 1.0
gene O 0 7.356280775638879e-07
results O 0 6.196329138674628e-08
in O 0 3.4486633548880263e-09
X B-Disease 1 0.9999971389770508
- I-Disease 1 0.9999992847442627
linked I-Disease 1 0.9999998807907104
dilated I-Disease 1 0.9999710321426392
cardiomyopathy I-Disease 1 1.0
. O 0 2.064839691229281e-06

X B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999998807907104
linked I-Disease 1 0.9999997615814209
dilated I-Disease 1 0.999991774559021
cardiomyopathy I-Disease 1 1.0
( O 0 1.9045156562924603e-08
XLDCM B-Disease 0 2.5557972094247816e-06
) O 0 9.965090974617397e-10
is O 0 7.35884617131255e-11
a O 0 1.5119053231593682e-10
clinical O 0 9.49077261225284e-08
phenotype O 0 6.103662286705003e-08
of O 0 3.9820771680076916e-11
dystrophinopathy B-Disease 0 1.686173732196039e-06
which O 0 3.1699737279566875e-10
is O 0 6.265189061993581e-11
characterized O 0 4.486592763974784e-10
by O 0 2.730875248158071e-10
preferential O 0 2.9776887799926044e-07
myocardial B-Disease 0 1.525450784356508e-06
involvement I-Disease 0 1.8554256797642665e-08
without O 0 7.932084433726061e-10
any O 0 9.693286173728666e-10
overt O 0 2.0455189542190055e-07
clinical O 0 3.9704573850940506e-07
signs O 0 1.2645912761399813e-07
of O 0 1.0637250191791736e-08
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 1.297755261475686e-05

To O 0 5.685732773486052e-09
date O 0 6.125247420385449e-09
, O 0 3.9461326567513666e-11
several O 0 1.0999776783870985e-10
mutations O 0 5.935842040116768e-09
in O 0 1.348011285928763e-10
the O 0 1.3527744480157367e-09
Duchenne B-Disease 0 1.7197458873852156e-05
muscular I-Disease 0 2.3366712866845774e-06
dystrophy I-Disease 0 1.6049922351157875e-06
gene O 0 3.950469817937119e-07
, O 0 3.1340723349870814e-09
DMD O 1 1.0
, O 0 7.558301762244923e-10
have O 0 2.3023748185746484e-10
been O 0 2.480791405634619e-10
identified O 0 3.2191893595268084e-09
in O 0 1.208646793759982e-10
patients O 0 6.777932104462536e-10
with O 0 1.1418268240637186e-11
XLDCM B-Disease 0 1.3890992249798728e-06
, O 0 4.111978466059263e-11
but O 0 1.616330541631683e-10
a O 0 7.718464062334007e-11
pathogenic O 0 5.684865467259215e-09
correlation O 0 1.4130869807615909e-09
of O 0 9.362703320969779e-12
these O 0 3.0842928211427534e-10
cardiospecific O 0 1.7967722953926568e-07
mutations O 0 6.645979055974749e-08
in O 0 5.981595774251502e-10
DMD O 1 0.9999997615814209
with O 0 2.817341915317684e-10
the O 0 4.132580666560415e-10
XLDCM B-Disease 0 0.0006896062404848635
phenotype O 0 3.9934043343237136e-06
has O 0 4.363337247070831e-09
remained O 0 2.868557613666667e-09
to O 0 1.4267795278577466e-10
be O 0 1.2043671615558083e-09
elucidated O 0 7.651809141862032e-07
. O 0 3.74239128575482e-08

We O 0 1.2302656386964372e-06
report O 0 7.557757975007462e-09
here O 0 3.8967905291453775e-11
the O 0 2.1074992879316357e-12
identification O 0 7.004807844879224e-10
of O 0 2.1117938994730245e-11
a O 0 4.5069370457895275e-10
unique O 0 2.9017970248901293e-08
de O 0 8.215097295760643e-07
novo O 0 9.7702309176384e-07
L1 O 0 1.577842851929745e-07
insertion O 0 9.583704496662904e-09
in O 0 2.2297129420589812e-10
the O 0 9.295837016809472e-11
muscle O 0 1.919720205023623e-08
exon O 0 3.192853625932912e-08
1 O 0 1.0241764103469109e-09
in O 0 5.563965399524307e-10
DMD O 1 1.0
in O 0 7.404537538668876e-10
three O 0 3.247382918125652e-10
XLDCM B-Disease 0 1.28517626762914e-06
patients O 0 2.9057498629470047e-09
from O 0 1.4919324456408312e-11
two O 0 3.4364205925285773e-11
unrelated O 0 1.2198667853624556e-08
Japanese O 0 2.4641703788574887e-08
families O 0 9.341240669868967e-09
. O 0 1.781227432218202e-08

The O 0 2.9764173348212353e-09
insertion O 0 5.768634281366758e-08
was O 0 4.676813603055052e-09
a O 0 3.592016684095256e-10
5 O 0 1.0314317178128363e-09
- O 0 8.391020323017528e-09
truncated O 0 4.7363691635382565e-08
form O 0 4.290964916719986e-09
of O 0 9.753853280614067e-11
human O 0 9.03153496434328e-10
L1 O 0 8.575703702717874e-08
inversely O 0 8.288107089526875e-09
integrated O 0 3.0368028092198074e-08
in O 0 1.1324663429235216e-10
the O 0 9.952113438904675e-11
5 O 0 1.17474374672355e-09
- O 0 2.723044900676541e-08
untranslated O 0 1.5699013147241203e-06
region O 0 3.948124494002059e-09
in O 0 1.3963277756268155e-10
the O 0 8.006011131822532e-11
muscle O 0 4.625740235297826e-09
exon O 0 9.638958076152448e-09
1 O 0 3.5997602121362604e-10
, O 0 1.4788264363074788e-11
which O 0 1.1102935237872202e-10
affected O 0 8.124412947951853e-11
the O 0 3.029819017202895e-12
transcription O 0 1.5512703621656243e-10
or O 0 3.7272357422679647e-10
the O 0 2.649591310244226e-11
stability O 0 9.483996921133553e-10
of O 0 4.97641251123726e-12
the O 0 1.0131690625359013e-10
muscle O 0 7.982415617391325e-09
form O 0 3.1878361061998817e-10
of O 0 1.7548974426406794e-11
dystrophin O 0 7.744928254282968e-09
transcripts O 0 2.3677848570713422e-09
but O 0 7.548357078279722e-11
not O 0 7.310173300023592e-12
that O 0 2.904831323397028e-12
of O 0 2.733514586558683e-12
the O 0 5.923418006092973e-11
brain O 0 1.3660921283076277e-08
or O 0 1.0961496155204031e-09
Purkinje O 0 5.716203190786473e-07
cell O 0 3.055261004192289e-07
form O 0 1.7179990763338537e-08
, O 0 1.081785105938593e-09
probably O 0 1.7215121772551356e-08
due O 0 6.633069093986421e-10
to O 0 3.3466004273341454e-11
its O 0 7.512163807676941e-11
unique O 0 7.118850509080232e-10
site O 0 3.944105486652916e-09
of O 0 1.1897678675598655e-10
integration O 0 3.533115489062766e-08
. O 0 2.8160396681187194e-08

We O 0 4.647134588253721e-08
speculate O 0 6.212859560150719e-09
that O 0 9.586451424348219e-12
this O 0 1.8559565776593567e-12
insertion O 0 1.8483417574266525e-10
of O 0 5.815375091200448e-12
an O 0 3.5579626050941116e-11
L1 O 0 7.347201602669884e-08
sequence O 0 5.915362422115322e-09
in O 0 2.4155490940813706e-09
DMD O 1 1.0
is O 0 3.9499453707847465e-10
responsible O 0 9.986301369169226e-11
for O 0 2.6222101746908866e-12
some O 0 1.3051488058704597e-12
of O 0 7.140393419764746e-13
the O 0 1.2870978588486182e-11
population O 0 1.3472864490715608e-10
of O 0 8.933612530293011e-12
Japanese O 0 1.0469877409491346e-08
patients O 0 1.6609540409717738e-09
with O 0 5.340920414265149e-11
XLDCM B-Disease 0 2.18045244082532e-07
. O 0 2.2191708470842286e-09
. O 0 2.6433562894112583e-08

Severe O 0 0.0002685568470042199
early O 0 2.9267906938912347e-05
- O 1 0.998254120349884
onset O 1 0.999264657497406
obesity B-Disease 1 1.0
, O 0 3.404826145469997e-07
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.107386798400057e-08
red O 0 3.8787260336903273e-07
hair O 1 0.999933123588562
pigmentation O 0 0.381369948387146
caused O 0 2.1810181749515323e-07
by O 0 5.903865396561514e-09
POMC O 0 5.376667104428634e-05
mutations O 0 1.001563191493915e-06
in O 0 2.875476301511526e-09
humans O 0 2.8087763226380957e-08
. O 0 5.6483582255850706e-08

Sequential O 0 1.775657892721938e-06
cleavage O 0 1.130634882429149e-05
of O 0 9.95052373831129e-10
the O 0 2.002452648142139e-10
precursor O 0 9.812679557796855e-09
protein O 0 1.3250472719050777e-08
pre O 0 8.910620294955152e-07
- O 0 3.4447148777871917e-07
pro O 0 6.591122314603126e-07
- O 0 8.796701536084583e-07
opiomelanocortin O 0 4.101436843484407e-06
( O 0 1.3591987535477301e-09
POMC O 0 7.858893695811275e-07
) O 0 5.686966453311015e-10
generates O 0 1.6291700211112925e-09
the O 0 6.438255484297883e-10
melanocortin O 0 1.3442712543110247e-06
peptides O 0 3.578781502255879e-07
adrenocorticotrophin O 0 1.4285039924288867e-06
( O 0 2.8160593856796368e-09
ACTH O 0 9.84567577688722e-07
) O 0 3.416476268558455e-10
, O 0 2.9252952837843793e-10
melanocyte O 0 4.175260073679965e-06
- O 0 2.2133399397716857e-06
stimulating O 0 8.364281711692456e-07
hormones O 0 2.1274432526752207e-07
( O 0 1.7506793237309637e-10
MSH O 0 1.2562492202050635e-07
) O 0 2.7967973423304038e-11
alpha O 0 6.416614461990378e-11
, O 0 3.52133491636486e-12
beta O 0 9.594376682020567e-11
and O 0 5.665805498378251e-12
gamma O 0 1.9694795794222841e-10
as O 0 1.788141683334299e-11
well O 0 2.6881559478386663e-11
as O 0 2.1974642591682247e-11
the O 0 5.8044628131748155e-11
opioid O 0 1.1774714181456147e-07
- O 0 5.57595498662522e-08
receptor O 0 8.363716830217527e-08
ligand O 0 1.1280184253337211e-07
beta O 0 3.0960964636506105e-07
- O 0 1.8549004607848474e-06
endorphin O 0 0.00012714436161331832
. O 0 1.1516255682408882e-07

While O 0 7.360036136105919e-08
a O 0 7.365112408841412e-10
few O 0 1.261689419607137e-09
cases O 0 3.73457398339383e-09
of O 0 7.094600462664857e-10
isolated O 0 4.506711047724821e-05
ACTH B-Disease 1 0.9999157190322876
deficiency I-Disease 0 0.01022686343640089
have O 0 6.059335255770293e-10
been O 0 2.2958945855577895e-09
reported O 0 1.1131550792242706e-08
( O 0 5.361990296215424e-10
OMIM O 0 3.0015346510481322e-06
201400 O 0 7.148383218691379e-08
) O 0 3.416991134486125e-10
, O 0 1.3165886436627972e-10
an O 0 2.718267833046184e-10
inherited O 0 0.00016686775779817253
POMC O 0 0.05756571888923645
defect O 0 0.018944932147860527
has O 0 5.443566042373504e-09
not O 0 3.2908739622250494e-10
been O 0 2.1028878638418291e-10
described O 0 8.175887189487696e-10
so O 0 1.1701594138102678e-09
far O 0 7.409259428214909e-09
. O 0 3.5852920632351015e-08

Recent O 0 7.431582389472169e-07
studies O 0 1.0743875122898316e-07
in O 0 2.3872101517774524e-10
animal O 0 6.151962828049307e-10
models O 0 9.37345578932991e-09
elucidated O 0 2.3157660677952663e-08
a O 0 1.1462133325812474e-10
central O 0 3.1435778979904683e-10
role O 0 2.9520046407327527e-09
of O 0 2.503501572714839e-11
alpha O 0 3.2286526785441083e-09
- O 0 1.590893816683092e-08
MSH O 0 7.369714012384065e-07
in O 0 2.316968492066529e-11
the O 0 8.667743606194378e-12
regulation O 0 1.1371480840294268e-10
of O 0 3.165904387605889e-12
food O 0 8.91594784113714e-11
intake O 0 2.05128483643513e-10
by O 0 4.217493975583464e-12
activation O 0 1.6353926546308628e-10
of O 0 1.6986420950382275e-11
the O 0 9.734362205193747e-10
brain O 0 3.11307928768656e-07
melanocortin O 0 2.8523609216790646e-06
- O 0 2.1975139929963916e-07
4 O 0 1.1842470115652759e-08
- O 0 1.9356059510755586e-07
receptor O 0 1.332582684199224e-07
( O 0 8.070238366464366e-10
MC4 O 0 2.8478161766543053e-06
- O 0 8.845597676554462e-08
R O 0 6.308160749313174e-08
; O 0 2.638467500037933e-10
refs O 0 1.0642891901113671e-08
3 O 0 2.395415532596701e-10
- O 0 1.3595150560874458e-09
5 O 0 5.0570100190716616e-11
) O 0 5.830179655025303e-12
and O 0 1.0351003040809381e-11
the O 0 1.470069031783705e-11
linkage O 0 1.700511909064062e-08
of O 0 1.167165114557278e-10
human O 0 3.4249270086661454e-09
obesity B-Disease 1 0.9999955892562866
to O 0 1.3838345747085867e-10
chromosome O 0 8.38660429991478e-09
2 O 0 2.2481139172469966e-10
in O 0 2.344767609241405e-11
close O 0 3.7721567536230793e-10
proximity O 0 1.3932345277467562e-09
to O 0 2.7279700720583833e-10
the O 0 1.5081497162228175e-10
POMC O 0 2.7341880581843725e-07
locus O 0 8.400596662738735e-09
, O 0 4.193424080201069e-11
led O 0 2.8941977286978116e-11
to O 0 6.665974196240487e-12
the O 0 7.1457648825878906e-12
proposal O 0 8.161538112005928e-10
of O 0 7.121898990686271e-12
an O 0 4.339380590967501e-11
association O 0 3.849234542219193e-10
of O 0 1.0829612206997297e-10
POMC O 0 1.95053735296824e-06
with O 0 1.9460046907227024e-09
human O 0 1.733703385298213e-07
obesity B-Disease 1 0.9999988079071045
. O 0 3.3751638284229557e-07

The O 0 2.3167864071638178e-08
dual O 0 1.1090215821241145e-06
role O 0 1.0643240244689878e-07
of O 0 3.0625915692361616e-10
alpha O 0 2.6906274541715902e-08
- O 0 2.3434438389813295e-07
MSH O 0 5.3677695177611895e-06
in O 0 2.998518933150507e-10
regulating O 0 4.444349777088519e-09
food O 0 1.3359230388587662e-09
intake O 0 2.1450068388162435e-09
and O 0 1.4846124329892518e-10
influencing O 0 6.779387007327387e-08
hair O 0 0.0038688250351697206
pigmentation O 0 3.3563587749085855e-06
predicts O 0 3.698861661405317e-08
that O 0 2.56500740786203e-11
the O 0 4.968391323356691e-11
phenotype O 0 1.7205110225404496e-08
associated O 0 6.085487669338363e-10
with O 0 6.345718395195377e-11
a O 0 1.254693904328974e-09
defect O 0 1.1898664524778724e-06
in O 0 1.0549391360470395e-09
POMC O 0 1.3694636891159462e-06
function O 0 5.236624023297054e-09
would O 0 4.275424458910493e-10
include O 0 1.213500633312492e-09
obesity B-Disease 1 0.9999934434890747
, O 0 1.451923303807945e-10
alteration O 0 2.970781309841186e-08
in O 0 6.128156648799177e-09
pigmentation O 0 0.010337636806070805
and O 0 2.992420741065871e-05
ACTH B-Disease 1 0.9986273050308228
deficiency I-Disease 0 0.005457120947539806
. O 0 1.0119422455545646e-07

The O 0 7.529987300358698e-09
observation O 0 1.917729441913707e-08
of O 0 6.365963312049416e-11
these O 0 4.3602149668586776e-10
symptoms O 0 1.0075006606768966e-08
in O 0 1.4403764639348005e-11
two O 0 6.840567695620692e-11
probands O 0 5.850242246197013e-08
prompted O 0 1.237630664618905e-09
us O 0 2.0624581209549575e-10
to O 0 6.866617083961524e-12
search O 0 1.8856097239172698e-10
for O 0 5.598720445587624e-11
mutations O 0 1.0945331752054699e-08
within O 0 4.565006428425278e-10
their O 0 6.8503021033450295e-09
POMC O 0 1.659824738453608e-05
genes O 0 8.241070190706523e-07
. O 0 1.4096130485086178e-07

Patient O 0 5.2529849199345335e-05
1 O 0 1.0593923605028976e-07
was O 0 1.5321341972907021e-09
found O 0 2.2360630014262028e-10
to O 0 5.5982937036125335e-11
be O 0 6.921373890689253e-11
a O 0 1.3903845956508842e-11
compound O 0 5.691958571141242e-10
heterozygote O 0 2.0720415605524067e-08
for O 0 4.191736541203639e-11
two O 0 5.474557959739279e-11
mutations O 0 8.932842021636134e-09
in O 0 1.7188037104709508e-10
exon O 0 1.1655245657493651e-08
3 O 0 6.123164753013555e-10
( O 0 6.723861745161486e-11
G7013T O 0 9.32674915077314e-09
, O 0 6.392415763389891e-11
C7133delta O 0 1.948304451104832e-08
) O 0 9.699199082779941e-11
which O 0 2.3335869694940392e-11
interfere O 0 2.8489757775140845e-10
with O 0 9.655522908991188e-12
appropriate O 0 5.424243831875231e-10
synthesis O 0 2.761202377854488e-09
of O 0 2.6547017362155145e-10
ACTH O 0 2.260425389977172e-06
and O 0 1.2301256679947414e-09
alpha O 0 3.635159373516217e-08
- O 0 1.35957770908135e-06
MSH O 0 0.0001010331543511711
. O 0 9.247430909908871e-08

Patient O 0 1.276516468351474e-05
2 O 0 1.5310307688309877e-08
was O 0 5.286306392626727e-10
homozygous O 0 1.0601560518352926e-08
for O 0 8.498962644765129e-11
a O 0 2.637451368414645e-10
mutation O 0 3.027549055900636e-08
in O 0 4.71836736348763e-10
exon O 0 5.199880348527586e-08
2 O 0 6.019367226883787e-09
( O 0 2.904429752259574e-10
C3804A O 0 1.8267651569203736e-07
) O 0 1.4632950406934242e-09
which O 0 5.408822278951675e-09
abolishes O 0 2.078881834677304e-06
POMC O 0 3.1886371289147064e-05
translation O 0 3.2866032029232883e-07
. O 0 2.0292270619393094e-07

These O 0 2.2207713445965283e-09
findings O 0 1.214359723888947e-09
represent O 0 3.4348350552715345e-11
the O 0 2.2817251560391938e-12
first O 0 6.412194560045936e-12
examples O 0 1.3964876477423616e-10
of O 0 1.186146406789712e-11
a O 0 7.2836567888145964e-09
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 3.6287148841296357e-09
the O 0 6.722928880265044e-10
POMC O 0 5.46382068478124e-07
gene O 0 5.147812398575979e-09
and O 0 6.972705746122188e-11
define O 0 6.0759108855279464e-09
a O 0 6.075513425685131e-10
new O 0 3.245497737225378e-08
monogenic B-Disease 0 0.06637469679117203
endocrine I-Disease 0 0.482132226228714
disorder I-Disease 0 0.014910271391272545
resulting O 0 5.399020341911864e-09
in O 0 3.6304645401052937e-10
early O 0 1.1022575563401915e-06
- O 1 0.997989296913147
onset O 1 0.9996281862258911
obesity B-Disease 1 1.0
, O 0 4.2797449850695557e-07
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.6333623281971086e-08
red O 0 2.1561780272350006e-07
hair O 1 0.9790633320808411
pigmentation O 0 7.322620513150468e-05
. O 0 1.8190457140576655e-08
. O 0 6.189206658291369e-08

A O 0 2.598903279249498e-07
European O 0 3.3696707646413415e-07
multicenter O 0 1.048878129950026e-05
study O 0 1.1883769701626079e-07
of O 0 3.854646024592512e-08
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.4813095456675e-09
classification O 0 6.620685333302845e-09
of O 0 1.0744244036131612e-11
105 O 0 5.168726557869263e-10
mutations O 0 2.2376267949653084e-08
and O 0 3.5858835345514706e-10
a O 0 6.537544811058282e-11
general O 0 3.635542214497356e-11
system O 0 3.15708542641957e-10
for O 0 5.240135755868458e-11
genotype O 0 1.771139324091564e-07
- O 0 3.154560701545961e-08
based O 0 9.277248302907992e-09
prediction O 0 4.3658619830466705e-08
of O 0 1.05102082592623e-09
metabolic O 0 5.822234470542753e-06
phenotype O 0 1.7462829418946058e-05
. O 0 5.740436677115213e-07

Phenylketonuria B-Disease 0 0.002972239162772894
( O 0 2.132399714582789e-07
PKU B-Disease 0 3.3103476653195685e-06
) O 0 4.698755606824534e-09
and O 0 2.6020061660858573e-09
mild B-Disease 0 2.019421117438469e-06
hyperphenylalaninemia I-Disease 1 1.0
( O 0 6.232207283574098e-08
MHP B-Disease 1 1.0
) O 0 1.729321574828191e-08
are O 0 5.966455329797782e-09
allelic B-Disease 0 0.00038358953315764666
disorders I-Disease 1 0.9321855306625366
caused O 0 7.684451297507167e-09
by O 0 2.354332007126203e-10
mutations O 0 7.326211459712795e-08
in O 0 3.509015578107011e-10
the O 0 4.574236267540499e-10
gene O 0 3.259282266299124e-07
encoding O 0 1.8656727434063214e-06
phenylalanine O 0 0.0006535544525831938
hydroxylase O 0 0.08054442703723907
( O 0 4.429237776548689e-08
PAH O 0 2.233919258287642e-05
) O 0 1.873097943416724e-08
. O 0 7.334222118515754e-08

Previous O 0 1.425119648956752e-07
studies O 0 1.9947620444327185e-08
have O 0 8.734613032856942e-11
suggested O 0 1.803790172782982e-10
that O 0 5.158095305046739e-12
the O 0 1.502739252479124e-11
highly O 0 6.0899498777189365e-09
variable O 0 4.35284135846814e-07
metabolic O 0 3.000993820023723e-05
phenotypes O 0 1.229456302098697e-05
of O 0 6.918083528262287e-08
PAH B-Disease 1 0.9895226359367371
deficiency I-Disease 1 0.6659411787986755
correlate O 0 1.0191181445406983e-06
with O 0 7.588239014921783e-08
PAH O 0 0.0008097527897916734
genotypes O 0 4.715992690762505e-05
. O 0 1.87177334964872e-07

We O 0 1.1897116536374597e-07
identified O 0 1.9065145906438374e-08
both O 0 1.3501012530170442e-09
causative O 0 7.915517130641092e-07
mutations O 0 1.796239530449384e-07
in O 0 4.701021238950887e-10
686 O 0 2.4256106456732596e-08
patients O 0 1.3040017954324412e-08
from O 0 9.191902100580407e-11
seven O 0 1.2415175554281177e-09
European O 0 1.7305458399619056e-08
centers O 0 3.2688380002809936e-08
. O 0 2.207781335528125e-08

On O 0 6.148165088148971e-09
the O 0 4.080663584815625e-11
basis O 0 2.000357102183159e-10
of O 0 7.989700047394965e-12
the O 0 3.806151227525589e-11
phenotypic O 0 4.0945941748304904e-08
characteristics O 0 4.937928288484272e-09
of O 0 9.419524188425399e-11
297 O 0 1.104701041754197e-08
functionally O 0 5.738182551340287e-08
hemizygous O 0 4.1625318658589094e-07
patients O 0 2.2598872106982526e-08
, O 0 1.0595540937685666e-11
105 O 0 2.1354727014477604e-11
of O 0 2.488893206115117e-12
the O 0 2.7011387918052243e-11
mutations O 0 5.378474110528941e-09
were O 0 5.6357158523256956e-11
assigned O 0 1.39520964226314e-10
to O 0 5.333587738132195e-12
one O 0 9.008128444565333e-12
of O 0 2.5917542851444653e-12
four O 0 1.1529228266526914e-10
arbitrary O 0 3.5961264188699715e-08
phenotype O 0 5.408368451753631e-06
categories O 0 1.0959599876514403e-06
. O 0 1.7028835941346188e-07

We O 0 4.166458822396635e-08
proposed O 0 1.9289059238758455e-09
and O 0 4.5629777734035315e-10
tested O 0 1.4807980397435472e-09
a O 0 9.747934230641686e-12
simple O 0 6.897060006449962e-11
model O 0 9.391203370512358e-10
for O 0 3.1792974503064286e-11
correlation O 0 4.411101262036254e-09
between O 0 1.6437118333101353e-09
genotype O 0 4.1307887954644684e-07
and O 0 3.3444722546960293e-09
phenotypic O 0 2.4149162527464796e-06
outcome O 0 2.037415242739371e-06
. O 0 3.501291132579354e-07

The O 0 9.556088365059168e-09
observed O 0 7.155107795142612e-08
phenotype O 0 1.9033485898489744e-07
matched O 0 4.0007808621567165e-08
the O 0 3.549011085013376e-10
predicted O 0 1.6614109199508675e-08
phenotype O 0 3.6704896899664163e-08
in O 0 2.1948599882026798e-10
79 O 0 2.0091717178871704e-09
% O 0 4.8774172201060395e-11
of O 0 1.1161654283123323e-12
the O 0 1.1742407393655618e-11
cases O 0 1.1098642005435977e-09
, O 0 4.497402797398742e-11
and O 0 4.516349100258665e-11
in O 0 1.79415093892743e-11
only O 0 2.7481378284122115e-11
5 O 0 1.2432793509986606e-11
of O 0 2.3852870633528367e-12
184 O 0 1.7100856841700818e-10
patients O 0 1.8357506625932274e-09
was O 0 1.6716637796232447e-10
the O 0 2.1667364083488572e-11
observed O 0 1.2786720571256183e-09
phenotype O 0 8.166427534206377e-10
more O 0 2.0399446021279743e-12
than O 0 5.277566578199e-12
one O 0 1.4923506874708892e-11
category O 0 1.2656976577929413e-09
away O 0 6.910217953404185e-10
from O 0 5.5767127027372965e-11
that O 0 1.8461961126536863e-10
expected O 0 8.480156132861794e-09
. O 0 3.165524375958739e-08

Among O 0 3.031235706885127e-08
the O 0 2.7512228606418887e-10
seven O 0 1.0944903316989496e-10
contributing O 0 2.638799734278052e-10
centers O 0 3.0865290878701046e-10
, O 0 2.0680587450860877e-11
the O 0 1.85589009438214e-11
proportion O 0 1.957317197209818e-09
of O 0 6.866145672856927e-12
patients O 0 3.0636779224657573e-10
for O 0 6.013356479428467e-12
whom O 0 8.379500426869413e-10
the O 0 2.8944298346988973e-11
observed O 0 1.2513695635263389e-09
phenotype O 0 7.665567736125922e-09
did O 0 6.253504380993036e-10
not O 0 1.0637421499204436e-10
match O 0 1.2960860162891663e-09
the O 0 5.479781212125445e-11
predicted O 0 9.96522953045087e-09
phenotype O 0 2.500670603922117e-08
was O 0 9.397796985055606e-10
4 O 0 4.079747650820309e-10
% O 0 3.5909961115798694e-10
- O 0 3.434736299823271e-07
23 O 0 9.994504779342606e-09
% O 0 6.687184139764213e-10
( O 0 1.5014994803053128e-10
P O 0 7.378377517852641e-07
< O 0 5.931835023176291e-09
. O 0 4.816845811106418e-10
0001 O 0 2.8773376570256914e-08
) O 0 3.869239650899914e-11
, O 0 1.2295308868259802e-11
suggesting O 0 1.0145349005341586e-09
that O 0 2.1592484744648033e-11
differences O 0 4.76368944291039e-10
in O 0 5.345238574677724e-12
methods O 0 1.536751836894723e-10
used O 0 1.0002410011367147e-10
for O 0 1.413692166801761e-11
mutation O 0 2.5468360753677644e-09
detection O 0 3.4824072514538784e-09
or O 0 3.442183649227104e-09
phenotype O 0 3.246126709655073e-07
classification O 0 2.60927848216852e-08
may O 0 3.809094706319627e-10
account O 0 5.997963931081429e-11
for O 0 5.076596261421873e-12
a O 0 2.174013920275275e-11
considerable O 0 1.4850066731852962e-09
proportion O 0 7.259610157461793e-08
of O 0 1.719657083398829e-09
genotype O 0 0.0702974870800972
- O 0 0.021147042512893677
phenotype O 0 2.1303179892129265e-05
inconsistencies O 0 3.6365365758683765e-06
. O 0 1.7578439326371154e-07

Our O 0 1.3293232825617451e-07
data O 0 1.900070856208913e-08
indicate O 0 6.1006923957052095e-09
that O 0 7.288152026330152e-11
the O 0 1.549779887755065e-10
PAH O 0 2.8385213681758614e-06
- O 0 1.3716748981096316e-07
mutation O 0 7.838947624350112e-08
genotype O 0 9.328922345730462e-08
is O 0 3.815680410523825e-11
the O 0 6.269130180258653e-12
main O 0 5.74916447781959e-10
determinant O 0 2.3770034829340148e-08
of O 0 1.2249880276815617e-10
metabolic O 0 8.068905117397662e-07
phenotype O 0 2.3520213687788782e-07
in O 0 4.333138292622607e-10
most O 0 3.5873766179861377e-09
patients O 0 2.9614813001899165e-07
with O 0 8.521635663782945e-08
PAH B-Disease 1 0.7634958028793335
deficiency I-Disease 1 0.8128608465194702
. O 0 7.895005893487905e-08

In O 0 2.0194615757418433e-08
the O 0 2.103521662411012e-10
present O 0 2.1981444442431552e-10
study O 0 3.0010594009866054e-10
, O 0 3.628296274538201e-11
the O 0 2.704448297252693e-11
classification O 0 5.609308129095325e-09
of O 0 5.82238146584757e-11
105 O 0 1.0413792495000962e-08
PAH O 0 1.5186576547421282e-06
mutations O 0 7.615483355039032e-08
may O 0 5.923149748454648e-10
allow O 0 4.2880646949905454e-11
the O 0 9.206899131974922e-12
prediction O 0 1.2459346887538914e-09
of O 0 4.397376560105748e-12
the O 0 1.615886591199711e-10
biochemical O 0 4.882106168224709e-07
phenotype O 0 4.8661068063893254e-08
in O 0 1.5808769571190595e-10
> O 0 1.4198683340183038e-09
10 O 0 1.3940711085513868e-10
, O 0 4.9883795011362864e-11
000 O 0 1.0206369083221034e-09
genotypes O 0 2.8815501096346452e-08
, O 0 6.246980016610948e-11
which O 0 9.365958703044797e-11
may O 0 1.5054080204635056e-10
be O 0 2.511133011598443e-12
useful O 0 2.3626350875716184e-11
for O 0 3.3062155443963626e-12
the O 0 1.3742307639064144e-11
management O 0 1.017445461215516e-09
of O 0 8.792816474922915e-11
hyperphenylalaninemia B-Disease 1 1.0
in O 0 6.721217005178914e-08
newborns O 0 8.432765753241256e-06
. O 0 3.855741326219686e-08

Somatic O 0 7.61127084842883e-05
instability O 0 5.575551767833531e-06
of O 0 4.083982874103498e-10
the O 0 4.2798792287968013e-10
CTG O 0 5.832604870192881e-07
repeat O 0 6.880711111989513e-08
in O 0 1.0866151728405882e-10
mice O 0 2.6260378316322885e-09
transgenic O 0 2.206475224753035e-09
for O 0 3.525597522258117e-11
the O 0 2.0175115744702765e-10
myotonic B-Disease 1 0.9999984502792358
dystrophy I-Disease 1 0.9999995231628418
region O 0 1.3341531257538009e-07
is O 0 1.9057537770095223e-09
age O 0 3.015433902575637e-09
dependent O 0 2.7875866059901e-09
but O 0 4.631643957253573e-10
not O 0 4.029800451665899e-11
correlated O 0 4.0033951154150316e-10
to O 0 3.268951775936557e-11
the O 0 4.5807298926225926e-11
relative O 0 7.902023035910588e-09
intertissue O 0 2.4249567331935395e-07
transcription O 0 6.188025736264535e-08
levels O 0 7.391464151851324e-08
and O 0 1.3795666831128983e-08
proliferative O 0 5.0811224355129525e-05
capacities O 0 2.736473106779158e-06
. O 0 2.181411389301502e-07

A O 0 2.0878432849258388e-07
( O 0 6.456951862077176e-09
CTG O 0 1.0922797173407162e-06
) O 0 2.108764940444985e-09
nexpansion O 0 1.3653163932758616e-07
in O 0 4.268058684253617e-10
the O 0 4.4571318857933306e-10
3 O 0 4.2269164168828866e-08
- O 0 1.9263285139459185e-05
untranslated O 0 0.0087949363514781
region O 0 1.3902361217787984e-07
( O 0 6.862670431928564e-10
UTR O 0 1.1257014875809546e-07
) O 0 1.8637093257556359e-10
of O 0 1.9121381561459927e-11
the O 0 3.3864786530557467e-09
DM O 1 1.0
protein O 0 1.0922894944087602e-07
kinase O 0 1.4092286448885716e-07
gene O 0 2.0525394717196832e-08
( O 0 2.158693779286125e-10
DMPK O 0 4.260710539938373e-08
) O 0 5.395885127601474e-11
is O 0 2.5010627249799633e-11
responsible O 0 1.5662106056524294e-09
for O 0 2.2520891818089694e-09
causing O 0 2.2354292923409957e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.163730869142455e-06
DM B-Disease 1 1.0
) O 0 1.7467959878558759e-07
. O 0 1.400602798184991e-07

Major O 0 1.4667209597973851e-06
instability O 0 6.450553087233857e-07
, O 0 3.8851336037204476e-10
with O 0 1.6918712958391424e-11
very O 0 6.281078435144138e-11
large O 0 5.802304470226005e-11
expansions O 0 1.622627365804874e-08
between O 0 6.516853723326221e-11
generations O 0 2.7625191023616935e-09
and O 0 5.071278952328839e-10
high O 0 1.1898024787626582e-09
levels O 0 6.254290974005983e-10
of O 0 8.648603534722188e-12
somatic O 0 1.0596687971542451e-08
mosaicism O 0 3.843348110876832e-07
, O 0 7.644315735966245e-11
is O 0 7.494502934912717e-11
observed O 0 2.5314255136521524e-09
in O 0 2.140980726039743e-09
patients O 0 7.39260599402769e-08
. O 0 2.5943165837816196e-08

There O 0 3.600230513711722e-08
is O 0 6.9021033333172e-10
a O 0 2.973918888926619e-10
good O 0 1.0932870164737096e-09
correlation O 0 2.093727857754857e-09
between O 0 3.2785318904160476e-10
repeat O 0 4.3311757735864376e-08
size O 0 1.4772660872353072e-09
( O 0 5.041081094225852e-11
at O 0 5.256131294095745e-11
least O 0 6.576135469504862e-12
in O 0 2.620261473074148e-11
leucocytes O 0 4.533245245852413e-08
) O 0 4.173890053027485e-11
, O 0 1.3966226612704968e-11
clinical O 0 2.443780733329959e-09
severity O 0 7.682107394657578e-09
and O 0 7.278320168779828e-10
age O 0 2.864276815728317e-09
of O 0 5.707112560315863e-10
onset O 0 1.2084403806511546e-06
. O 0 1.6550796999581507e-07

The O 0 3.5004231335733493e-07
trinucleotide O 0 0.0005785828689113259
repeat O 0 3.842223668470979e-05
instability O 0 3.4192544262623414e-07
mechanisms O 0 5.992870200088873e-09
involved O 0 2.290689193884532e-09
in O 0 1.461771925725941e-09
DM B-Disease 1 1.0
and O 0 2.747657101842549e-10
other O 0 1.2272306781913045e-10
human O 0 6.404857977315714e-09
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.1415558498484302e-09
unknown O 0 6.030677468515933e-08
. O 0 5.577231476650013e-08

We O 0 3.022971100108407e-07
studied O 0 1.5975903977505368e-07
somatic O 0 3.3697511980790296e-07
instability O 0 9.830741731775561e-08
by O 0 3.005825588431321e-10
measuring O 0 3.348329258301419e-08
the O 0 6.773951954919255e-10
CTG O 0 3.966211181705148e-07
repeat O 0 7.18856654202682e-08
length O 0 1.6248007383978802e-09
at O 0 1.0155759566643496e-10
several O 0 2.3433414930718044e-11
ages O 0 7.06109393178167e-10
in O 0 1.171567357016734e-11
various O 0 7.177417687964649e-11
tissues O 0 2.1869253075124107e-09
of O 0 3.4185605735093105e-11
transgenic O 0 2.914921992669406e-08
mice O 0 2.718996583439548e-08
carrying O 0 7.854804584539465e-10
a O 0 2.824923628352849e-10
( O 0 1.585793579783612e-10
CTG O 0 1.599526484596936e-07
) O 0 4.1933059802268247e-10
55expansion O 0 3.213957455727723e-08
surrounded O 0 1.5713542689255178e-09
by O 0 2.202395626982323e-10
45 O 0 7.150722236559659e-10
kb O 0 3.5498334938210974e-08
of O 0 2.5464935715646675e-11
the O 0 2.7524404977441463e-10
human O 0 3.1706242964446574e-08
DM B-Disease 1 1.0
region O 0 2.8362752146904313e-08
, O 0 4.37969209510225e-11
using O 0 5.449182771677386e-10
small O 0 1.0995780286293666e-08
- O 0 4.958140380040277e-06
pool O 0 5.09082155986107e-07
PCR O 0 2.8375632155075436e-06
. O 0 4.239463535782306e-08

These O 0 7.563612847150125e-09
mice O 0 6.275866581972878e-08
have O 0 5.1774295961593e-10
been O 0 8.053781253014591e-11
shown O 0 1.6123338775209106e-10
to O 0 1.7297017984585494e-11
reproduce O 0 4.7407411329913884e-09
the O 0 3.770974851824427e-11
intergenerational O 0 1.1768636731801507e-08
and O 0 1.3665989173627935e-10
somatic O 0 1.0201353539684987e-08
instability O 0 1.0321170584859374e-08
of O 0 1.7741721286546053e-11
the O 0 1.3335267612379909e-10
55 O 0 2.1886530365833323e-09
CTG O 0 1.318159803531671e-07
repeat O 0 2.7476126263081824e-08
suggesting O 0 2.2429669233048344e-09
that O 0 9.371456735629557e-12
surrounding O 0 2.71039718446886e-11
sequences O 0 8.176261334646995e-10
and O 0 1.1915528286277066e-10
the O 0 1.862422022158583e-11
chromatin O 0 4.693506472364106e-09
environment O 0 4.845392975738605e-10
are O 0 1.5552007598396145e-11
involved O 0 2.0853532789466556e-10
in O 0 7.874485508096996e-10
instability O 0 2.295449803568772e-07
mechanisms O 0 1.3881376048630045e-07
. O 0 9.779257226227855e-08

As O 0 6.377272487867458e-09
observed O 0 2.2386417164454997e-09
in O 0 3.1948225315270307e-11
some O 0 5.7697562005909475e-12
of O 0 2.1661485539309355e-12
the O 0 4.8164392613125884e-11
tissues O 0 1.2734496124267025e-08
of O 0 3.7703440369796226e-10
DM B-Disease 1 1.0
patients O 0 1.2299290119699435e-06
, O 0 2.3007977467681684e-11
there O 0 2.065015693164529e-11
is O 0 2.8644760174945105e-11
a O 0 4.6198017633614086e-11
tendency O 0 3.8752849818024515e-09
for O 0 6.504113220229257e-11
repeat O 0 1.6946835046383057e-08
length O 0 1.2801069093626438e-09
and O 0 1.3179177194011515e-10
somatic O 0 4.5783585811420835e-09
mosaicism O 0 4.064218117605378e-08
to O 0 6.666359131379807e-11
increase O 0 5.531161292871012e-11
with O 0 6.307775916175595e-12
the O 0 5.6436220280398075e-11
age O 0 9.397277400680082e-10
of O 0 5.801648224335043e-12
the O 0 1.77861489425446e-10
mouse O 0 1.8106727850408788e-07
. O 0 1.4822278160409041e-07

Furthermore O 0 7.26697976460855e-07
, O 0 2.7364661647766297e-09
we O 0 3.5317307411908416e-10
observed O 0 4.216798021872137e-10
no O 0 6.78045050661602e-11
correlation O 0 3.4870181742086004e-10
between O 0 1.8861807948855613e-11
the O 0 6.997886992099467e-11
somatic O 0 7.059780671170302e-08
mutation O 0 9.41115132491177e-08
rate O 0 7.690232450840995e-08
and O 0 5.282911885728936e-09
tissue O 0 5.640148970087466e-07
proliferation O 0 3.3581741263333242e-06
capacity O 0 8.993947631097399e-08
. O 0 5.7543594778053375e-08

The O 0 2.1851628062563577e-08
somatic O 0 8.873291221789259e-07
mutation O 0 3.0978978315943095e-07
rates O 0 2.7322011320052297e-08
in O 0 2.863656534124459e-11
different O 0 4.449060911349001e-11
tissues O 0 1.1949354838947102e-09
were O 0 1.500546076282916e-10
also O 0 1.608457533830432e-10
not O 0 1.0423083229849084e-10
correlated O 0 1.3520340402806141e-09
to O 0 7.320125061660576e-11
the O 0 6.476754549344932e-11
relative O 0 1.5672304343183896e-08
inter O 0 2.969255490370415e-07
- O 0 1.979116603934017e-07
tissue O 0 5.9433450161350265e-08
difference O 0 5.805055547369875e-09
in O 0 2.2591383624925854e-11
transcriptional O 0 6.998935209168167e-09
levels O 0 1.320578202346212e-09
of O 0 1.7391952678372236e-12
the O 0 1.4285569255312325e-11
three O 0 7.933911166935204e-11
genes O 0 1.8019996606000177e-09
( O 0 6.517425488183903e-11
DMAHP O 0 3.801368819722484e-08
, O 0 1.2448365949158102e-10
DMPK O 0 1.3821126287894003e-07
and O 0 6.615998859871297e-10
59 O 0 1.1033023383788532e-09
) O 0 4.5991582070525894e-11
surrounding O 0 5.14080444879994e-10
the O 0 3.282686622529951e-10
repeat O 0 7.776548045512754e-07
. O 0 3.92999544018835e-09
. O 0 2.2329709636892403e-08

A O 0 4.359109766483016e-07
novel O 0 8.518854315298086e-07
missense O 0 2.8497441235231236e-05
mutation O 0 1.2740832744384534e-06
in O 0 3.0261044781099145e-09
patients O 0 3.472903742363087e-08
from O 0 1.0421234014623693e-10
a O 0 3.552640959192388e-10
retinoblastoma B-Disease 0 6.298885182332015e-07
pedigree O 0 4.88443038193509e-06
showing O 0 3.768615499666339e-07
only O 0 3.655341362929221e-09
mild O 0 2.371496776731874e-08
expression O 0 2.042786162448351e-09
of O 0 8.459566380736305e-11
the O 0 1.7549061093191654e-09
tumor B-Disease 0 3.7584616165986517e-06
phenotype O 0 1.3308089364727493e-05
. O 0 3.0851114729557594e-07

We O 0 5.750037246343709e-08
have O 0 4.52926501859352e-10
used O 0 5.858163953931239e-10
single O 0 2.3335535725976797e-09
strand O 0 1.6164561600362504e-07
conformation O 0 3.351447475097302e-08
polymorphism O 0 3.400188575142238e-08
analysis O 0 3.3536708965442585e-09
to O 0 5.364156341336468e-11
study O 0 1.224161189083972e-10
the O 0 1.3639500119622117e-11
27 O 0 1.879401634319322e-10
exons O 0 9.333778194786646e-09
of O 0 2.1881082015728914e-11
the O 0 2.403562071595644e-10
RB1 O 0 2.9336300144677807e-07
gene O 0 6.4845484537556786e-09
in O 0 5.845972317342074e-11
individuals O 0 7.99810495610842e-11
from O 0 1.5854298776596387e-11
a O 0 9.197356071188878e-11
family O 0 4.089823146813387e-09
showing O 0 3.991372352629696e-07
mild O 0 9.168608983145532e-08
expression O 0 6.545449515726887e-09
of O 0 1.657320114478722e-10
the O 0 4.7622199517149966e-09
retinoblastoma B-Disease 0 2.5844103220151737e-05
phenotype O 0 2.6969944883603603e-05
. O 0 4.950435936734721e-07

In O 0 6.4979568392686815e-09
this O 0 2.2253199283284175e-10
family O 0 9.732969985520867e-10
affected O 0 4.2258638255354697e-10
individuals O 0 1.0835604635772711e-10
developed O 0 6.8300405331456204e-09
unilateral B-Disease 0 0.19628101587295532
tumors I-Disease 1 1.0
and O 0 3.228505018881833e-09
, O 0 1.9213438132159588e-11
as O 0 2.962769612979699e-11
a O 0 4.886132470849347e-11
result O 0 5.520350288001907e-10
of O 0 6.543541750114734e-12
linkage O 0 1.6897903520884938e-08
analysis O 0 5.7098374917075034e-09
, O 0 2.402022192260489e-10
unaffected O 0 2.180262725914872e-08
mutation O 0 3.615900467934807e-08
carriers O 0 2.0703033953850536e-08
were O 0 8.840714271762806e-10
also O 0 5.441590511523486e-10
identified O 0 1.9326400479968697e-09
within O 0 1.7690503228973142e-10
the O 0 9.56002166319081e-10
pedigree O 0 2.843400807250873e-06
. O 0 1.668397970888691e-07

A O 0 1.1321655790652585e-07
single O 0 2.119383069043579e-08
band O 0 2.176759750227575e-08
shift O 0 1.585021180972035e-08
using O 0 5.660801605245069e-09
SSCP O 0 4.839237703890831e-07
was O 0 1.3640709672912976e-09
identified O 0 9.76342451330936e-10
in O 0 6.923381312695653e-11
exon O 0 9.33080546161591e-09
21 O 0 9.413637647170958e-10
which O 0 1.6599777108439184e-10
resulted O 0 5.478561493355016e-10
in O 0 3.144753069062034e-10
a O 0 2.0686603541264503e-09
missense O 0 2.33910168390139e-06
mutation O 0 8.302223619693905e-08
converting O 0 2.963175482761926e-08
a O 0 5.066747021942319e-09
cys O 0 0.00014830511645413935
- O 0 1.4490028661384713e-06
- O 0 5.19897298545402e-07
> O 0 6.668504681783816e-08
arg O 0 2.53284270002041e-07
at O 0 3.7980019129690845e-10
nucleotide O 0 2.681257349479438e-08
position O 0 2.903657403408033e-08
28 O 0 1.126224447034474e-09
in O 0 9.208098172841517e-11
the O 0 7.390991707545425e-10
exon O 0 9.183045222016517e-07
. O 0 1.2091327050711698e-07

The O 0 9.656093169496671e-08
mutation O 0 6.355981554406753e-07
destroyed O 0 2.7953436187999614e-07
an O 0 6.99506119694604e-10
NdeI O 0 8.762857532929047e-07
restriction O 0 3.944724014104395e-08
enzyme O 0 1.7606558344596124e-07
site O 0 7.50378177372113e-08
. O 0 6.840460287094174e-08

Analysis O 0 2.3402144222472998e-07
of O 0 2.3204856092196025e-10
all O 0 9.593260907880818e-11
family O 0 1.639036961709195e-10
members O 0 1.7989070302815158e-11
demonstrated O 0 1.809562222288008e-10
that O 0 8.261185138747074e-12
the O 0 5.652703305436546e-11
missense O 0 5.468612016557017e-07
mutation O 0 1.5898375238521112e-07
co O 0 1.3872921726942877e-06
- O 0 9.827085989400075e-08
segregated O 0 3.044191032586241e-08
with O 0 2.049658082148298e-10
patients O 0 6.269714081241773e-09
with O 0 1.9452464639080347e-10
tumors B-Disease 1 1.0
or O 0 2.148926903089432e-08
who O 0 1.2075582311865674e-08
, O 0 1.1385408241193495e-11
as O 0 2.862662711045072e-11
a O 0 4.364398425993343e-11
result O 0 6.453598766498203e-10
of O 0 5.994610190185323e-12
linkage O 0 6.945342967412671e-09
analysis O 0 9.302072001560191e-09
had O 0 2.6340942760327835e-09
been O 0 5.553045800965606e-10
predicted O 0 5.211730491616606e-10
to O 0 3.287829730691527e-11
carry O 0 1.0740014433352485e-09
the O 0 8.926059336111791e-10
predisposing O 0 1.1335760063957423e-06
mutation O 0 6.102184784140263e-07
. O 0 6.712684808007907e-08

These O 0 3.2984353026677127e-09
observations O 0 4.183737356555639e-09
point O 0 1.4591952091080884e-09
to O 0 1.1281330730694705e-10
another O 0 2.743069937860554e-10
region O 0 3.5637188755544003e-09
of O 0 6.961875520516969e-11
the O 0 7.395025147793888e-10
RB1 O 0 8.195401619559561e-07
gene O 0 2.099523399579084e-08
where O 0 9.714756776801892e-10
mutations O 0 4.47328218911025e-09
only O 0 1.976983333984439e-11
modify O 0 1.1383314291180113e-09
the O 0 1.399996611695098e-11
function O 0 7.853152850234579e-11
of O 0 1.9862687883343e-12
the O 0 7.624261465222215e-12
gene O 0 8.953613961359963e-10
and O 0 8.682308344498679e-11
raise O 0 4.7027135657851105e-11
important O 0 3.2740685163012984e-11
questions O 0 1.3187803626912853e-10
for O 0 6.441860499889485e-12
genetic O 0 1.7514416583708226e-09
counseling O 0 2.7448820993924983e-09
in O 0 3.8571111582452744e-11
families O 0 9.44191946850026e-11
with O 0 3.692180935987999e-11
these O 0 1.2316798692069142e-09
distinctive O 0 2.6260548224854574e-07
phenotypes O 0 6.353727144414734e-07
. O 0 1.2496218282365135e-08
. O 0 8.104397863917256e-08

Maternal B-Disease 0 0.0007102143717929721
disomy I-Disease 0 0.006933724973350763
and O 0 0.0003845154424197972
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
consistent O 0 1.7528805074107368e-07
with O 0 1.9587997890369024e-09
gamete O 0 8.762523293626145e-07
complementation O 0 7.237999852804933e-07
in O 0 2.1477815359549624e-10
a O 0 7.319272965489176e-11
case O 0 1.0762961633048462e-09
of O 0 5.417551476871729e-11
familial O 0 6.100502787376172e-07
translocation O 0 9.239673204319843e-08
( O 0 5.119424328903222e-10
3 O 0 4.1114786575313644e-10
; O 0 5.125335156286326e-10
15 O 0 3.0402944051211023e-10
) O 0 1.3872543391801884e-10
( O 0 4.326867683590585e-11
p25 O 0 6.160842946911771e-09
; O 0 1.455500164837531e-10
q11 O 0 2.023016243413167e-08
. O 0 1.83782739027194e-10
2 O 0 7.507210963986211e-10
) O 0 1.7900612103716185e-09
. O 0 1.6071037833853552e-08

Maternal B-Disease 0 0.00954355113208294
uniparental I-Disease 0 0.260390967130661
disomy I-Disease 0 0.004514646250754595
( I-Disease 0 2.875456743822724e-07
UPD I-Disease 1 0.9999997615814209
) I-Disease 0 6.7761525279763646e-09
for I-Disease 0 4.925807678413108e-11
chromosome I-Disease 0 5.4181175102030465e-08
15 I-Disease 0 1.412523875643501e-09
is O 0 1.5811961115441697e-11
responsible O 0 5.069699868243127e-11
for O 0 6.892598471142097e-12
an O 0 2.6330203208718705e-12
estimated O 0 7.082536640501402e-11
30 O 0 1.3898868167494527e-10
% O 0 1.0851690206148401e-11
of O 0 3.0377581960311373e-12
cases O 0 1.6219157572550102e-08
of O 0 2.683435127437406e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.562748803342402e-07
PWS B-Disease 1 0.9999998807907104
) O 0 9.865134842357293e-08
. O 0 1.2468046861613402e-07

We O 0 1.4977432272189617e-07
report O 0 1.6668315616641394e-09
on O 0 1.528204299217073e-11
an O 0 2.4703724309238506e-12
unusual O 0 1.8018268821418104e-10
case O 0 6.533982799261651e-10
of O 0 2.7531532609259557e-11
maternal B-Disease 0 9.503467346405614e-09
disomy I-Disease 0 4.0648001231602393e-07
15 I-Disease 0 1.6200134567156965e-09
in O 0 8.54258774829475e-10
PWS B-Disease 1 1.0
that O 0 4.2198877725496686e-10
is O 0 5.084981741232397e-11
most O 0 2.9100622953026622e-11
consistent O 0 2.5063456865481726e-10
with O 0 1.1799928222033795e-11
adjacent O 0 4.640807738098829e-09
- O 0 1.1294097248537582e-06
1 O 0 2.8964706189071876e-09
segregation O 0 7.79059128319659e-09
of O 0 1.516178675664559e-11
a O 0 1.7784858308278473e-10
paternal O 0 6.516539485801331e-08
t O 0 5.444004713694994e-08
( O 0 6.433661242644106e-11
3 O 0 1.0825296214989066e-10
; O 0 1.7490439652156908e-10
15 O 0 1.0421314505792978e-10
) O 0 5.021322593834476e-11
( O 0 1.1987647853539674e-11
p25 O 0 3.1633378139162005e-09
; O 0 1.0948306150559972e-10
q11 O 0 8.647576876796848e-09
. O 0 6.695514975785244e-11
2 O 0 4.028917130471932e-11
) O 0 2.312575651808313e-11
with O 0 2.4225369973929212e-11
simultaneous O 0 3.057014907881239e-08
maternal O 0 2.5941540116036776e-07
meiotic O 0 2.333676320631639e-06
nondisjunction O 0 1.1888784001712338e-06
for O 0 1.9030876874381875e-09
chromosome O 0 2.0387271888466785e-06
15 O 0 6.417419484705533e-08
. O 0 6.454860823623676e-08

The O 0 4.5549391813892726e-08
patient O 0 1.7928269357980753e-07
( O 0 1.0791204596571902e-09
J O 0 2.575707185314968e-07
. O 0 1.0897145408250708e-09
B O 0 9.137216316901231e-09
. O 0 2.8281460506818235e-11
) O 0 1.4427851274811943e-11
, O 0 1.0035062190938415e-11
a O 0 3.8959807602267915e-11
17 O 0 7.191330309019861e-10
- O 0 8.918847882455339e-09
year O 0 1.700982288355135e-08
- O 0 2.0378766407702642e-07
old O 0 3.2374593956774333e-06
white O 0 2.3606748555948798e-08
male O 0 7.163844184532309e-09
with O 0 1.30147337351616e-10
PWS B-Disease 1 1.0
, O 0 7.808612784154789e-11
was O 0 1.4234577405680682e-10
found O 0 5.5014909294826e-11
to O 0 4.191177266354984e-11
have O 0 2.268816523542938e-10
47 O 0 3.5377242801892805e-10
chromosomes O 0 2.0879293849418445e-09
with O 0 1.9348854463085985e-10
a O 0 1.227783985591202e-09
supernumerary O 0 3.256826175856986e-06
, O 0 1.0514258352856132e-09
paternal O 0 1.0896178537223022e-07
der O 0 3.2846585327206412e-06
( O 0 2.2538672317384822e-10
15 O 0 1.3569420587167258e-10
) O 0 1.6169957733902507e-11
consisting O 0 1.3016639849317002e-11
of O 0 6.504531722267837e-12
the O 0 1.0505793457404877e-10
short O 0 6.26167945938505e-07
arm O 0 0.004562851041555405
and O 0 7.175998129049788e-10
the O 0 8.354170827340468e-11
proximal O 0 6.673110419797013e-08
long O 0 1.8926200482383138e-06
arm O 0 1.4400098734768108e-05
of O 0 7.06012054374483e-11
chromosome O 0 1.571992811477685e-07
15 O 0 2.4643571627791516e-09
, O 0 1.5661531793664807e-10
and O 0 1.0471908895581805e-09
distal O 0 2.6960783543472644e-06
chromosome O 1 0.6503229141235352
arm O 1 0.9277089834213257
3p O 0 0.00029766399529762566
. O 0 7.802771619935811e-07

The O 0 4.2539788580597815e-08
t O 0 3.778209531901666e-07
( O 0 1.3221099215421361e-10
3 O 0 8.694903130823661e-11
; O 0 4.805868203394681e-11
15 O 0 5.992749352312643e-11
) O 0 3.6398856151365067e-11
was O 0 3.826987338140242e-10
present O 0 2.4822477406871712e-11
in O 0 2.069842387764087e-11
the O 0 1.6850503631316016e-11
balanced O 0 4.666154684862533e-10
state O 0 1.6602721975012003e-10
in O 0 8.219037256340656e-11
the O 0 1.9167291365196348e-10
patients O 0 5.914121636863001e-09
father O 0 2.560044176647125e-09
and O 0 6.26801333059035e-10
a O 0 2.069291848982857e-09
sister O 0 4.8029755816969555e-06
. O 0 2.531384382109536e-07

Fluorescent O 0 2.695325065360521e-06
in O 0 5.828609150881903e-09
situ O 0 7.810992741497103e-08
hybridization O 0 2.239505292322974e-08
analysis O 0 3.1895468488585266e-09
demonstrated O 0 3.456255948108833e-09
that O 0 1.651299791349814e-10
the O 0 1.9169750231640137e-09
PWS B-Disease 1 0.9999997615814209
critical O 0 1.1136609856521318e-07
region O 0 9.681502710634504e-09
resided O 0 5.156443450005099e-08
on O 0 6.262814711277542e-10
the O 0 1.2852734154744638e-10
derivative O 0 2.575664659332233e-08
chromosome O 0 2.760097927989591e-08
3 O 0 6.910758076905665e-10
and O 0 1.1975130609354068e-10
that O 0 1.959425677267035e-11
there O 0 5.606157899018527e-11
was O 0 5.675036551799906e-10
no O 0 8.011678126473853e-11
deletion O 0 5.539539049692621e-09
of O 0 5.467514288537423e-11
the O 0 1.5573070610841455e-09
PWS B-Disease 1 1.0
region O 0 1.3803194143235942e-08
on O 0 2.7708765837353155e-10
the O 0 7.426088910467143e-11
normal O 0 1.0431282504441697e-09
pair O 0 5.407264414003521e-09
of O 0 9.70397373567522e-11
15s O 0 1.6265037316998132e-08
present O 0 1.278467220977575e-09
in O 0 3.2614937417463352e-09
J O 0 1.261202123714611e-05
. O 0 8.59240429917918e-08

B O 0 0.003159505547955632
. O 0 3.594276222429471e-06

Methylation O 0 2.8274844225961715e-06
analysis O 0 8.603391421502238e-08
at O 0 1.716501274451332e-09
exon O 0 1.4870482623052794e-08
alpha O 0 1.1344862826945246e-09
of O 0 1.1024323814945447e-11
the O 0 9.99785115807228e-11
small O 0 1.1400289601226632e-08
nuclear O 0 2.5401800485269632e-06
ribonucleoprotein O 0 3.684768671519123e-06
- O 0 2.5945251991288387e-07
associated O 0 3.778007240384795e-08
polypeptide O 0 1.797821141735767e-06
N O 0 3.1006291578705714e-07
( O 0 3.604548881597225e-10
SNRPN O 0 4.4996063763846905e-08
) O 0 1.6079637621402298e-10
gene O 0 6.341514424690331e-09
showed O 0 1.4419041960422874e-08
a O 0 4.5266998482951237e-10
pattern O 0 1.9434979847687828e-08
characteristic O 0 2.389157671700559e-08
of O 0 9.76632594240634e-11
only O 0 4.469663805739543e-10
the O 0 1.1034664293418928e-09
maternal O 0 9.88508119803555e-08
chromosome O 0 3.7001077544118743e-06
15 O 0 2.7913015898661797e-08
in O 0 1.031211915858421e-08
J O 0 6.24342865194194e-05
. O 0 2.6678367248678114e-07

B O 0 0.0018134068232029676
. O 0 2.960362053272547e-06

Maternal B-Disease 0 0.0004542496462818235
disomy I-Disease 0 0.003659469075500965
was O 0 1.0044502829487101e-07
confirmed O 0 4.205201964424532e-09
by O 0 1.3192306969056489e-10
polymerase O 0 3.808328585819254e-08
chain O 0 1.819979900119506e-07
reaction O 0 1.0368169434116226e-08
analysis O 0 3.0249964755313385e-09
of O 0 1.2571535479288798e-10
microsatellite O 0 4.2912458297905687e-07
repeats O 0 1.0757367618907665e-07
at O 0 5.513563494652374e-10
the O 0 1.2472274601993405e-10
gamma O 0 9.831322955733413e-08
- O 0 1.4389954685611883e-06
aminobutyric O 0 1.6627889635856263e-05
acid O 0 8.890248750503815e-07
receptor O 0 2.3167251583799953e-07
beta3 O 0 4.586305806242308e-07
subunit O 0 3.318071151170443e-07
( O 0 3.608203291705081e-09
GABRB3 O 0 1.64614948516828e-06
) O 0 9.715002136090334e-09
locus O 0 2.4380240120081e-06
. O 0 1.7869415103177744e-07

A O 0 1.7515452555016964e-07
niece O 0 1.7658783235674491e-06
( O 0 3.511742230344339e-09
B O 0 6.27628509164424e-08
. O 0 6.236589578101359e-10
B O 0 4.471269132722e-09
. O 0 2.2121448770007213e-11
) O 0 1.7921124653708098e-11
with O 0 1.0531389128820567e-11
45 O 0 3.57757434787942e-11
chromosomes O 0 1.3773101548153477e-09
and O 0 8.969711084994003e-11
the O 0 1.0127087536615509e-11
derivative O 0 1.1879142114423757e-08
3 O 0 1.5410166198659425e-10
but O 0 2.131648607628378e-10
without O 0 1.7164711318962134e-10
the O 0 7.00045021950757e-11
der O 0 2.1153550733288284e-07
( O 0 2.3081600866725616e-11
15 O 0 3.3478327748914793e-11
) O 0 2.0735170525032487e-11
demonstrated O 0 5.525175317266928e-10
a O 0 1.7700256538244474e-10
phenotype O 0 2.047729807941323e-08
consistent O 0 9.343444906662057e-10
with O 0 4.744155415736806e-11
that O 0 6.517114625737008e-11
reported O 0 3.9851491551168294e-10
for O 0 2.4812490603820514e-11
haploinsufficiency O 0 4.6117531127265465e-08
of O 0 1.1510682684789941e-10
distal O 0 2.369851586081495e-07
3 O 0 3.7002837416366674e-07
p O 0 0.0005869788001291454
. O 0 1.3359880313146277e-07

Uniparental B-Disease 1 0.9999988079071045
disomy I-Disease 1 0.9999996423721313
associated O 0 6.920373607499641e-07
with O 0 2.5799704594930972e-09
unbalanced O 0 6.441921982514032e-07
segregation O 0 1.2296365525799047e-07
of O 0 1.2890591372105575e-10
non O 0 9.652594457065788e-08
- O 0 4.970076616928054e-08
Robertsonian O 0 9.36514936711319e-08
translocations O 0 2.075182550242971e-07
has O 0 1.004420657757521e-09
been O 0 3.80326492521732e-10
reported O 0 2.7892765874781844e-10
previously O 0 2.9778028931559675e-09
but O 0 1.8329482376344686e-09
has O 0 6.416507325468501e-10
not O 0 3.2439223529578953e-10
, O 0 9.492438085567656e-12
to O 0 1.602699396807683e-11
our O 0 2.806426445400856e-11
knowledge O 0 3.6482122878211953e-11
, O 0 5.015337537633835e-12
been O 0 1.7924885534204016e-11
observed O 0 1.1386282888770083e-10
in O 0 2.329762077701858e-11
a O 0 1.2963771722773743e-10
case O 0 1.3184321190351511e-08
of O 0 8.152564845431698e-09
PWS B-Disease 1 0.9999997615814209
. O 0 3.5329208003531676e-07

Furthermore O 0 1.5085992117747082e-06
, O 0 6.360605375732575e-09
our O 0 9.355196617377715e-10
findings O 0 4.951205556658067e-10
are O 0 1.3329819019414213e-11
best O 0 1.1818922229789308e-10
interpreted O 0 3.6466554775849147e-10
as O 0 2.1817662954060069e-10
true O 0 8.957444563861827e-09
gamete O 0 1.3017300943829468e-06
complementation O 0 3.2046830256149406e-06
resulting O 0 7.615643227154578e-08
in O 0 3.3861056181194726e-08
maternal B-Disease 0 0.0001315553527092561
UPD I-Disease 1 1.0
15 I-Disease 0 3.0664107271149987e-06
and O 0 2.1163025394344004e-06
PWS B-Disease 1 0.9999992847442627

Schwartz B-Disease 1 0.9998700618743896
- I-Disease 1 0.9999942779541016
Jampel I-Disease 1 0.999948263168335
syndrome I-Disease 1 0.9999514818191528
type I-Disease 0 7.705280609116016e-07
2 I-Disease 0 9.477743923014259e-09
and O 0 1.2539170590741833e-08
Stuve B-Disease 1 0.9999865293502808
- I-Disease 1 0.9999994039535522
Wiedemann I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9997555613517761
: O 0 1.6229567689762803e-10
a O 0 4.3375681518798004e-11
case O 0 5.666697111550434e-10
for O 0 4.4292482875851746e-11
" O 0 9.707421533278193e-10
lumping O 0 1.4665627645626955e-07
" O 0 2.5838472694772463e-08
. O 0 3.058508113440439e-08

Recent O 0 1.767093493754146e-07
studies O 0 3.261035175228244e-08
demonstrated O 0 8.348344793240869e-10
the O 0 1.1434068102056383e-11
existence O 0 3.3856245584829026e-10
of O 0 5.546371521780724e-12
a O 0 3.331900380598718e-11
genetically O 0 5.72606295712319e-10
distinct O 0 1.1524374787796887e-09
, O 0 3.715585825125878e-11
usually O 0 5.5955819838748866e-11
lethal O 0 3.534507131419673e-10
form O 0 4.4248067015972836e-11
of O 0 6.534175544387066e-12
the O 0 5.55826995540798e-10
Schwartz B-Disease 1 0.999964714050293
- I-Disease 1 0.9998927116394043
Jampel I-Disease 1 0.9999728202819824
syndrome I-Disease 1 0.9996548891067505
( O 0 8.989930577740779e-09
SJS B-Disease 0 0.4160003364086151
) O 0 1.132819060778445e-09
of O 0 4.2082573536994516e-10
myotonia B-Disease 0 0.49021100997924805
and O 0 3.63769103728373e-08
skeletal B-Disease 0 0.0008891654433682561
dysplasia I-Disease 1 0.9991893172264099
, O 0 7.364862941727779e-09
which O 0 5.89567328290741e-09
we O 0 5.351878051840231e-09
called O 0 1.5980194945086623e-08
SJS B-Disease 1 0.6826192736625671
type I-Disease 0 1.993859370941209e-07
2 I-Disease 0 1.8068670115667373e-08
. O 0 6.517210238143889e-08

This O 0 7.727254569545039e-08
disorder O 0 1.2335738574620336e-05
is O 0 1.6528942103910538e-10
reminiscent O 0 2.9362923203990476e-09
of O 0 1.1005247928241868e-11
another O 0 9.161883751662714e-11
rare O 0 1.7995814838300817e-09
condition O 0 1.7457692180755657e-08
, O 0 7.528774131904115e-11
the O 0 7.83726583630795e-10
Stuve B-Disease 1 0.9999284744262695
- I-Disease 1 0.9999983310699463
Wiedemann I-Disease 1 0.9999924898147583
syndrome I-Disease 1 0.9996849298477173
( O 0 2.074872273993833e-09
SWS B-Disease 0 3.0987837362772552e-06
) O 0 4.640150486068251e-10
, O 0 3.051272776111169e-11
which O 0 7.253399270101824e-11
comprises O 0 2.402480436813903e-10
campomelia B-Disease 0 1.7810430108511355e-07
at O 0 4.743380133120922e-10
birth O 0 3.9263916562504164e-09
with O 0 7.836025162077931e-10
skeletal B-Disease 0 0.001486111432313919
dysplasia I-Disease 1 0.9502549171447754
, O 0 4.443756473904159e-09
contractures B-Disease 0 1.971524216060061e-05
, O 0 1.2949148420204892e-09
and O 0 9.993432747990028e-10
early B-Disease 0 2.7681220871045298e-08
death I-Disease 0 3.469249065801705e-08
. O 0 9.339230189198133e-08

To O 0 1.4706040829537415e-08
test O 0 5.6083560018294065e-09
for O 0 2.6275934553177116e-11
possible O 0 6.072698455206194e-10
nosologic O 0 9.969263459197464e-08
identity O 0 1.4044865714879506e-08
between O 0 3.082152311151276e-10
these O 0 1.1089903440009152e-09
disorders O 0 2.1633788094277406e-07
, O 0 3.6627145760803614e-11
we O 0 4.27645002742949e-11
reviewed O 0 1.8413712221665435e-10
the O 0 2.2891703723576518e-12
literature O 0 7.222269310380725e-11
and O 0 1.0846599660108147e-11
obtained O 0 2.2289603496261634e-10
a O 0 6.7211527142452265e-12
follow O 0 2.9678556834333847e-10
- O 0 2.6036444111809942e-09
up O 0 1.7725527989842504e-10
of O 0 1.4547910402382125e-12
the O 0 7.132992113634273e-12
only O 0 3.784694432851232e-11
two O 0 8.231979681250223e-11
surviving O 0 5.288631044209069e-08
patients O 0 2.0284476320853173e-09
, O 0 5.573009501796955e-12
one O 0 4.293547808953413e-11
with O 0 2.741532001415692e-10
SJS B-Disease 0 0.0040507507510483265
type I-Disease 0 1.4743506859815625e-08
2 I-Disease 0 3.8353101250443444e-10
at O 0 2.433546419933208e-10
age O 0 2.6464511138080127e-10
10 O 0 9.758835232964724e-12
years O 0 5.607719150146906e-11
and O 0 8.558480313336503e-12
another O 0 3.675114726431339e-11
with O 0 1.5881364279213273e-10
SWS B-Disease 0 9.13840085559059e-06
at O 0 1.207044020290482e-09
age O 0 1.9453292310345205e-09
7 O 0 1.3817463839771449e-09
years O 0 1.0331470789992636e-08
. O 0 1.4198285214206408e-08

Patients O 0 7.40407922421582e-05
reported O 0 1.4689491933950194e-07
as O 0 1.6243173472929584e-09
having O 0 3.005123261345943e-08
either O 0 3.582516967526317e-07
neonatal O 1 0.9995988011360168
SJS B-Disease 1 0.9999996423721313
or O 0 1.331077754684884e-07
SWS B-Disease 0 8.112120667647105e-06
presented O 0 6.501486571330872e-10
a O 0 2.124216080812147e-11
combination O 0 2.0580803727909824e-10
of O 0 2.864775040453682e-12
a O 0 1.165050000917489e-10
severe O 0 4.272722264886397e-08
, O 0 2.653699482380034e-10
prenatal O 1 0.9175129532814026
- O 1 0.642193615436554
onset O 0 0.09748955070972443
neuromuscular B-Disease 1 0.9998658895492554
disorder I-Disease 1 0.999680757522583
( O 0 1.9508581416971538e-09
with O 0 1.9337575984934574e-09
congenital B-Disease 1 0.9999204874038696
joint I-Disease 0 3.863604069920257e-05
contractures I-Disease 1 0.9986096620559692
, O 0 1.918322034555331e-08
respiratory O 0 1.990518285310827e-06
and O 0 1.0843446140995638e-09
feeding O 0 1.6393386204072158e-08
difficulties O 0 3.0096524028522254e-07
, O 0 1.3553254352149935e-10
tendency O 0 6.021652065868466e-09
to O 0 2.691112332975365e-10
hyperthermia B-Disease 0 2.2941169675050332e-07
, O 0 9.957163565887939e-11
and O 0 4.7318472057300554e-11
frequent O 0 3.6051903684608533e-09
death O 0 4.614451931672647e-09
in O 0 7.157968107129875e-10
infancy O 0 3.869467377626279e-07
) O 0 5.1658663458020726e-11
with O 0 1.205804813636524e-11
a O 0 4.930660324475866e-10
distinct O 0 1.9327525535572931e-07
campomelic B-Disease 0 0.10826870054006577
- I-Disease 0 0.0039484938606619835
metaphyseal I-Disease 0 0.00043288845336064696
skeletal I-Disease 0 0.0014461054233834147
dysplasia I-Disease 0 0.028038088232278824
. O 0 7.737829150755715e-07

The O 0 2.329764603459239e-09
similarity O 0 9.687560975635279e-09
of O 0 3.638802800742802e-11
the O 0 7.013747915785018e-11
clinical O 0 1.7184644818257766e-08
and O 0 1.5305298695089675e-10
radiographic O 0 1.4255711903388146e-05
findings O 0 5.128388824715557e-09
is O 0 5.140331216235694e-11
so O 0 4.238171966153281e-11
extensive O 0 2.387579023377384e-10
that O 0 1.4239004419991375e-10
these O 0 4.2223916030259545e-10
disorders O 0 1.2976055785429708e-08
appear O 0 2.2696909629527084e-10
to O 0 5.188142623846481e-11
be O 0 1.365804275232918e-10
a O 0 4.347368853796496e-10
single O 0 5.101104960658631e-08
entity O 0 4.8194333430728875e-06
. O 0 3.9199136381284916e-07

The O 0 2.398461651509365e-09
follow O 0 2.9456546091211067e-09
- O 0 1.7549906417002603e-08
up O 0 4.774969308840582e-10
observation O 0 4.960071242621211e-10
of O 0 1.5374802125878162e-12
an O 0 3.8417563401338395e-12
identical O 0 2.341806748518138e-09
and O 0 1.101228760957973e-10
unique O 0 3.9024530829046e-10
pattern O 0 7.212821628854726e-08
of O 0 4.1849324006193456e-10
progressive O 0 4.008304870239954e-07
bone B-Disease 1 0.6254639029502869
dysplasia I-Disease 1 0.9958394765853882
in O 0 1.4986190066679228e-09
the O 0 1.6012090264805323e-10
two O 0 8.443788446221845e-10
patients O 0 4.65472549393553e-09
( O 0 1.759167117532101e-11
one O 0 1.1333804728064223e-10
with O 0 1.1120764309424658e-09
SJS B-Disease 1 0.9970877766609192
type I-Disease 0 5.39749898109676e-08
2 I-Disease 0 7.685180825056648e-10
, O 0 3.7164930855038136e-11
one O 0 1.219007256247906e-10
with O 0 8.851445132407321e-10
SWS B-Disease 0 1.4791645298828371e-05
) O 0 1.0243736969783868e-09
surviving O 0 3.7476482361853414e-08
beyond O 0 1.2185132902686746e-08
infancy O 0 2.722528904541832e-07
adds O 0 8.607639045976612e-09
to O 0 1.3478151754398038e-11
the O 0 3.6333150030265493e-12
evidence O 0 2.8267399532211357e-10
in O 0 5.323163437820355e-11
favor O 0 7.199097984411651e-10
of O 0 7.102490817700868e-11
identity O 0 2.99527556535395e-07
. O 0 6.688044607017218e-08

The O 0 1.865219090291248e-08
hypothesis O 0 2.1869749389225035e-07
that O 0 5.161636007500192e-09
SWS B-Disease 0 1.4690680472995155e-05
and O 0 6.785916717433338e-09
SJS B-Disease 0 0.1397855579853058
type I-Disease 0 2.0260745969835625e-08
2 I-Disease 0 1.2748747890700685e-10
are O 0 1.1494332395611817e-11
the O 0 2.0272696715784022e-11
same O 0 2.0109863996253807e-08
disorder O 0 5.3493567975237966e-06
should O 0 2.117009484381427e-10
be O 0 1.3314141456000073e-11
testable O 0 1.5962638988398226e-09
by O 0 1.1938908195396891e-11
molecular O 0 1.3654897212944661e-09
methods O 0 2.166917312251826e-08
. O 0 2.3246242708552245e-09
. O 0 6.086840187435882e-08

A O 0 2.1796180860178538e-08
mouse O 0 1.0050769105873769e-07
model O 0 1.1363951557541441e-07
of O 0 5.4377959912699225e-09
severe O 1 0.9988879561424255
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0029460631776601076
defects O 1 0.9999330043792725
in O 0 6.12557613521858e-08
hemostasis O 1 0.7700033187866211
and O 0 8.908878044167068e-07
thrombosis B-Disease 0 0.0009507040958851576
. O 0 2.3535807258667774e-07

von B-Disease 1 0.9606612324714661
Willebrand I-Disease 0 0.18819887936115265
factor I-Disease 0 4.647577225114219e-05
( I-Disease 0 1.969388279121631e-07
vWf I-Disease 0 0.00788850523531437
) I-Disease 0 3.659299181890674e-05
deficiency I-Disease 1 0.9995641112327576
causes O 0 8.201171294786036e-05
severe O 1 0.9999984502792358
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 1.457441385355196e-07
humans O 0 6.116815143286658e-07
. O 0 2.7024756832361163e-07

We O 0 5.17008302836075e-08
generated O 0 7.793365952579734e-10
a O 0 1.0760861646197384e-10
mouse O 0 7.593361495139561e-09
model O 0 1.1431033897224552e-08
for O 0 7.301871607356958e-11
this O 0 1.7089803183711894e-10
disease O 0 9.928778910150982e-10
by O 0 6.319661807752119e-12
using O 0 2.239615382038096e-09
gene O 0 2.0865616079390747e-07
targeting O 0 2.0651666545745684e-06
. O 0 2.8534060447782394e-07

vWf B-Disease 1 0.9728773832321167
- I-Disease 1 0.9996986389160156
deficient I-Disease 0 0.03843618929386139
mice O 0 5.643518306897022e-06
appeared O 0 2.9961952918711177e-08
normal O 0 5.141640446737483e-09
at O 0 3.250661129161614e-10
birth O 0 3.219439437263105e-10
; O 0 6.559890824986425e-11
they O 0 3.7365815996892593e-10
were O 0 7.658753631289983e-10
viable O 0 2.7234014510213456e-07
and O 0 4.9687089997974e-09
fertile O 0 2.2953271638925798e-07
. O 0 1.3177688629184559e-07

Neither O 0 5.294899892760441e-05
vWf O 0 0.0010951498989015818
nor O 0 2.8054304493707605e-05
vWf O 0 0.0011119069531559944
propolypeptide O 0 0.00023946756846271455
( O 0 3.932772187908995e-07
von B-Disease 0 0.002747718710452318
Willebrand I-Disease 0 0.004372655879706144
antigen O 0 0.0002661632897797972
II O 0 4.152609562879661e-06
) O 0 4.5501264978042855e-09
were O 0 6.247959927208058e-10
detectable O 0 9.750964125032624e-08
in O 0 3.627536881989357e-10
plasma O 0 4.026134803325476e-08
, O 0 4.095535299786235e-10
platelets O 0 5.318340612348038e-08
, O 0 4.19854012667642e-10
or O 0 1.6025909488348589e-09
endothelial O 0 3.7036178568428113e-09
cells O 0 2.9567941428609856e-09
of O 0 1.5891052362881908e-11
the O 0 4.967967703883858e-10
homozygous O 0 3.662538858861808e-07
mutant O 0 7.373495805040875e-07
mice O 0 1.2477092923290911e-06
. O 0 6.468491875466498e-08

The O 0 4.051864976872821e-08
mutant O 0 3.5880193536286242e-06
mice O 0 2.881965201595449e-06
exhibited O 0 7.24277072094992e-07
defects O 0 0.00022861563775222749
in O 0 1.2504676183411334e-09
hemostasis O 0 1.472913709221757e-06
with O 0 2.4539806298129463e-10
a O 0 1.2243672742329181e-09
highly O 0 8.659167605173934e-08
prolonged O 0 1.708434137981385e-05
bleeding O 0 0.003792051924392581
time O 0 6.550557429818582e-09
and O 0 7.321259709591743e-10
spontaneous O 0 4.526961028261667e-09
bleeding O 0 2.9148199587325507e-07
events O 0 1.1262480947848985e-09
in O 0 1.043048147852943e-10
approximately O 0 4.363826244802027e-10
10 O 0 7.506323340678023e-10
% O 0 2.759758255255207e-10
of O 0 4.947004472732885e-10
neonates O 0 2.1817950255353935e-06
. O 0 5.026610239156071e-08

As O 0 9.092137709387771e-09
in O 0 3.6731964692116037e-10
the O 0 1.108456798570856e-10
human O 0 1.287487227941142e-09
disease O 0 7.396015355709551e-09
, O 0 1.7362064910764197e-11
the O 0 4.408598486271842e-11
factor O 0 1.153227380257249e-08
VIII O 0 6.829665721852507e-08
level O 0 2.250822417337872e-09
in O 0 2.3297311996239856e-11
these O 0 1.0081378787329953e-10
mice O 0 7.299302939856034e-09
was O 0 2.198292214927733e-09
reduced O 0 2.4523616470872867e-10
strongly O 0 1.3637035944924492e-10
as O 0 1.493584561584882e-10
a O 0 8.896582082140725e-11
result O 0 7.099230092677544e-10
of O 0 5.734363504872331e-12
the O 0 8.639193527226752e-11
lack O 0 3.0673150130944293e-10
of O 0 1.4544448978526248e-11
protection O 0 2.8088806280912593e-10
provided O 0 8.429675846244322e-10
by O 0 1.990238418514423e-09
vWf O 0 8.11841255199397e-06
. O 0 2.1161400809432962e-07

Defective O 0 0.0016522792866453528
thrombosis B-Disease 0 0.0009742591646499932
in O 0 1.9833199971230897e-08
mutant O 0 6.535883585456759e-07
mice O 0 3.5876328183803707e-06
was O 0 3.915639013030159e-08
also O 0 1.0929679383764324e-09
evident O 0 1.3414536148559364e-09
in O 0 4.6229485517468305e-11
an O 0 1.1222670362465159e-11
in O 0 1.913073033321666e-10
vivo O 0 3.182964292136603e-07
model O 0 1.9504796000546776e-08
of O 0 8.664842732208911e-10
vascular B-Disease 0 8.663973130751401e-05
injury I-Disease 0 0.0018505078041926026
. O 0 2.776138501303649e-07

In O 0 7.238259769337674e-09
this O 0 1.9932880346296145e-10
model O 0 8.212479585267829e-09
, O 0 1.1474098754460371e-10
the O 0 1.575825581134893e-10
exteriorized O 0 3.2052287224360043e-07
mesentery O 0 2.441684273435385e-06
was O 0 4.052867819126504e-09
superfused O 0 7.546928770807426e-08
with O 0 1.5678985887390695e-10
ferric O 0 3.5206234372253675e-08
chloride O 0 2.9220917241445932e-08
and O 0 3.001969506311042e-10
the O 0 4.096509936823978e-11
accumulation O 0 2.309694879798485e-09
of O 0 9.951258567175714e-11
fluorescently O 0 1.6345077256119112e-06
labeled O 0 4.679225185100222e-07
platelets O 0 5.403900331657496e-07
was O 0 2.2138186839271157e-09
observed O 0 2.868240311926229e-09
by O 0 7.975320404085551e-10
intravital O 0 6.702711630168778e-07
microscopy O 0 5.799270184070338e-07
. O 0 1.8316829653031164e-07

We O 0 8.589782396484225e-08
conclude O 0 6.861953671943866e-09
that O 0 2.624708263232467e-11
these O 0 2.4806148454792343e-11
mice O 0 1.0659056970396819e-09
very O 0 4.583246976386235e-11
closely O 0 9.566811343120207e-09
mimic O 0 8.312663339893334e-07
severe O 0 2.3638456241315e-06
human O 0 3.313369063562277e-07
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0005154194659553468
will O 0 3.938662729296993e-09
be O 0 5.413079012805966e-11
very O 0 7.15785113472589e-12
useful O 0 5.263374805442034e-11
for O 0 3.9726455632049795e-12
investigating O 0 1.272918853656435e-10
the O 0 9.595214379987116e-12
role O 0 1.1113152620367828e-09
of O 0 1.3384619801382058e-11
vWf O 0 7.030138249319862e-08
in O 0 2.622487782488747e-10
normal O 0 2.9062654505196406e-09
physiology O 0 6.307966149421418e-09
and O 0 5.749964948620345e-10
in O 0 2.2480550754266915e-09
disease O 0 2.8861428802429145e-08
models O 0 4.4769546292400264e-08
. O 0 2.511419294748407e-09
. O 0 2.1805288241694143e-08

Oral O 0 1.1041017842217116e-06
contraceptives O 0 1.0970382390951272e-05
and O 0 3.280660187954254e-09
the O 0 7.367655374679316e-10
risk O 0 3.533325241278362e-07
of O 0 1.567365082166816e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.352388931598398e-07

Hereditary B-Disease 1 0.9999998807907104
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9996634721755981
Clinical O 0 0.0001242235885001719
Study O 0 4.4689224409921735e-07
Group O 0 4.860680178353505e-07
. O 0 1.9990436328498618e-07

BACKGROUND O 0 0.00012916898413095623
Women O 0 7.67226993048098e-08
with O 0 3.132552828244428e-10
mutations O 0 6.241697825259962e-09
in O 0 9.28233670483003e-11
either O 0 3.778032331425152e-10
the O 0 1.7142495756239384e-10
BRCA1 O 0 1.9695085029525217e-07
or O 0 9.352003615958893e-10
the O 0 5.6454847741083114e-11
BRCA2 O 0 5.03907031657036e-08
gene O 0 1.8622428044068329e-09
have O 0 6.332950136522797e-11
a O 0 5.677761732991726e-11
high O 0 7.161398585253664e-09
lifetime O 0 3.2837988328537904e-07
risk O 0 3.498763544484973e-05
of O 0 7.040382570266956e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.874569867752143e-07

Oral O 0 1.0420684702694416e-05
contraceptives O 0 0.00047736469423398376
protect O 0 9.860364116320852e-06
against O 0 0.03217725455760956
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.2481741468460825e-10
general O 0 7.941571705805117e-11
, O 0 1.5849530021760927e-10
but O 0 1.870141153048621e-09
it O 0 2.0582453796880174e-10
is O 0 1.6125668508837343e-11
not O 0 8.017040156738098e-12
known O 0 1.2422316647553444e-11
whether O 0 4.776615908363979e-11
they O 0 6.87833887069722e-11
also O 0 5.4162289236936445e-11
protect O 0 2.421189360113374e-10
against O 0 7.944030433471028e-10
hereditary B-Disease 0 6.130637757451041e-07
forms I-Disease 0 3.889642243848357e-07
of I-Disease 0 1.1021756108675618e-05
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0433294878330344e-07

METHODS O 0 8.22750109819026e-07
We O 0 1.4771852185901935e-08
enrolled O 0 3.37356063084826e-08
207 O 0 1.7513290373472046e-08
women O 0 2.6856131540853312e-08
with O 0 1.996330212250541e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.699241410032755e-10
161 O 0 4.075026982519603e-10
of O 0 6.690226064115512e-12
their O 0 1.8074684804414431e-10
sisters O 0 4.134429332225409e-08
as O 0 3.1827268598405567e-10
controls O 0 2.0086057261892165e-08
in O 0 2.5998866948206967e-10
a O 0 3.239489232420567e-10
case O 0 5.764950117281842e-08
- O 0 6.692345095871133e-07
control O 0 1.40933750003569e-07
study O 0 1.9729180067429297e-08
. O 0 2.2976392344276064e-08

All O 0 5.823741933141946e-09
the O 0 4.247123763789773e-10
patients O 0 3.86590137679832e-09
carried O 0 7.895074038977157e-10
a O 0 2.0492749164269242e-10
pathogenic O 0 1.8334281648435535e-08
mutation O 0 1.887882561391052e-08
in O 0 1.5332209113427808e-10
either O 0 2.1321702181609226e-09
BRCA1 O 0 6.820304747634509e-07
( O 0 5.846019779376377e-10
179 O 0 3.662836922657675e-09
women O 0 2.1597739152667828e-09
) O 0 3.676715043532397e-10
or O 0 1.3748430172100257e-09
BRCA2 O 0 1.5082755453477148e-06
( O 0 1.8276383739745938e-09
28 O 0 1.3403800736000449e-08
women O 0 2.839972346180275e-08
) O 0 2.6114179707548146e-09
. O 0 1.6420518278437157e-08

The O 0 1.3005020171874548e-08
control O 0 6.718986611531363e-08
women O 0 1.0783905324274201e-08
were O 0 8.498120263045195e-11
enrolled O 0 6.335272861868191e-10
regardless O 0 2.9451643901445834e-10
of O 0 7.003581200225317e-13
whether O 0 3.8220173553815684e-11
or O 0 1.2895362555553902e-10
not O 0 1.2562881290811845e-10
they O 0 1.824422835028372e-10
had O 0 1.1660710175220856e-09
either O 0 3.840099349616821e-09
mutation O 0 2.7958955683971e-07
. O 0 6.536905772236423e-08

Lifetime O 0 2.3414941097144037e-06
histories O 0 4.1171099951498036e-07
of O 0 1.8616877484056715e-10
oral O 0 3.005455795346279e-08
- O 0 4.467809944230794e-08
contraceptive O 0 2.21372744135806e-07
use O 0 5.94047144808485e-10
were O 0 2.428564987999593e-11
obtained O 0 1.6131275482056395e-10
by O 0 3.1727728083685847e-11
interview O 0 7.339523211413734e-09
or O 0 3.883790511416407e-11
by O 0 3.015532702016488e-12
written O 0 5.005172318273132e-11
questionnaire O 0 5.361203148090965e-10
and O 0 1.4652709601215008e-11
were O 0 1.4227811637179677e-11
compared O 0 6.067427810174664e-11
between O 0 4.715719481573899e-11
patients O 0 1.3351665328897866e-09
and O 0 2.0341303641480124e-10
control O 0 6.0805134260988325e-09
women O 0 1.3699663625743597e-09
, O 0 9.481707953507001e-12
after O 0 3.0598457795294465e-11
adjustment O 0 8.641818372012722e-10
for O 0 1.3820744028392173e-11
year O 0 6.979251898631134e-11
of O 0 6.0462719900233886e-12
birth O 0 5.927696111740488e-09
and O 0 2.0487445073769095e-09
parity O 0 9.945447487780257e-08
. O 0 3.425588701588822e-08

RESULTS O 0 5.024837150813255e-07
The O 0 1.1054149817724124e-09
adjusted O 0 5.276319257063733e-07
odds O 0 4.161836113780737e-05
ratio O 0 0.00019911001436412334
for O 0 0.00922136940062046
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.779951380205148e-09
with O 0 1.0525886585954769e-11
any O 0 5.927396073968083e-11
past O 0 1.4681082738388085e-10
use O 0 1.8421897340914484e-10
of O 0 7.934875846660194e-12
oral O 0 5.07533570726082e-09
contraceptives O 0 9.964650416804943e-06
was O 0 1.2671210747328132e-08
0 O 0 9.961162561467063e-09
. O 0 2.6372728001433643e-08

5 O 0 4.926961594264867e-08
( O 0 1.0882459378080966e-09
95 O 0 3.508762835835455e-09
percent O 0 2.1447957010423124e-07
confidence O 0 2.7414301939643337e-08
interval O 0 7.193172280040017e-09
, O 0 5.224347690568898e-11
0 O 0 9.644796766794528e-11
. O 0 1.8207232596600953e-11
3 O 0 4.000897182998564e-11
to O 0 4.8223959547843975e-11
0 O 0 2.334438198303701e-10
. O 0 1.1362722568408756e-10
8 O 0 9.444806048364285e-10
) O 0 1.2679617356070594e-09
. O 0 1.445690678281153e-08

The O 0 7.46098223203262e-08
risk O 0 2.0531901157028187e-07
decreased O 0 4.943818243674514e-09
with O 0 1.833561774633452e-11
increasing O 0 1.4299807171713752e-10
duration O 0 2.20360263369912e-09
of O 0 5.153689541098627e-12
use O 0 3.5032907130805313e-10
( O 0 4.43011009820804e-11
P O 0 5.188447715909206e-08
for O 0 3.9606859458807264e-11
trend O 0 1.8058747386362484e-08
, O 0 2.747845562200979e-10
< O 0 2.446467028960342e-09
0 O 0 3.508975054966612e-10
. O 0 7.586809652737614e-11
001 O 0 1.6046738382513581e-09
) O 0 2.5461520912484215e-12
; O 0 5.299786759623004e-13
use O 0 6.3648309713004725e-12
for O 0 1.7588307112820223e-12
six O 0 9.149374834149793e-12
or O 0 1.5080827212021752e-11
more O 0 4.8041427606893006e-12
years O 0 6.019619913644192e-09
was O 0 1.12291909104556e-09
associated O 0 6.559990745058641e-11
with O 0 4.229811379624637e-12
a O 0 6.094382637433782e-11
60 O 0 9.171399750762532e-10
percent O 0 1.8218791808521928e-08
reduction O 0 1.4646751367308752e-08
in O 0 8.218560054729096e-09
risk O 0 7.819144798304478e-07
. O 0 4.8013308884264916e-08

Oral O 0 8.717733180674259e-06
- O 0 3.3591254577913787e-06
contraceptive O 0 2.0346637938928325e-06
use O 0 1.5141809583951726e-08
protected O 0 1.3660901743151044e-07
against O 0 0.0009433792438358068
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
both O 0 2.5200924680390813e-11
for O 0 9.283571307527883e-12
carriers O 0 4.1279485385459225e-10
of O 0 8.407813507915751e-12
the O 0 3.4925093372883964e-10
BRCA1 O 0 1.2013940704491688e-06
mutation O 0 4.8142975828113777e-08
( O 0 2.896054784873314e-10
odds O 0 2.4950827537395526e-07
ratio O 0 1.57759547647629e-08
, O 0 1.0576121922678539e-10
0 O 0 9.930156003035151e-11
. O 0 1.7763662069070207e-11
5 O 0 1.8364669160386704e-11
; O 0 1.9131959905216434e-11
95 O 0 2.1638631164666577e-10
percent O 0 4.213610438341675e-08
confidence O 0 4.119660168555583e-09
interval O 0 7.804656365628659e-10
, O 0 6.0118654846008646e-12
0 O 0 1.622946742274589e-11
. O 0 6.231054734684438e-12
3 O 0 1.8610300800414592e-11
to O 0 7.039382531742744e-12
0 O 0 2.4802080528241177e-11
. O 0 4.7049629817164096e-12
9 O 0 8.285976939303996e-12
) O 0 1.951644141434672e-12
and O 0 3.475865645655163e-12
for O 0 4.156750464667791e-12
carriers O 0 2.8497093573776056e-10
of O 0 5.202994719094578e-12
the O 0 7.073562846571235e-10
BRCA2 O 0 3.122366706520552e-06
mutation O 0 6.051532608353227e-08
( O 0 1.5608747627737785e-10
odds O 0 2.325040782125143e-07
ratio O 0 2.010660260509667e-08
, O 0 9.343333745581717e-11
0 O 0 5.7893814742193683e-11
. O 0 1.2854002584550273e-11
4 O 0 1.6819870149453742e-11
; O 0 2.0770281328186257e-11
95 O 0 2.541850896431441e-10
percent O 0 9.042040005624585e-08
confidence O 0 7.065947826845331e-09
interval O 0 2.340337701411954e-09
, O 0 3.268789405819206e-11
0 O 0 3.9624088732370666e-11
. O 0 1.768988601436039e-11
2 O 0 3.909364498788648e-11
to O 0 3.796566186431427e-11
1 O 0 1.8204462937099208e-10
. O 0 1.0317263016146327e-10
1 O 0 6.195602364478248e-10
) O 0 7.805028290341909e-10
. O 0 1.249629022481713e-08

CONCLUSIONS O 0 1.0273599855281645e-06
Oral O 0 4.509873861024971e-07
- O 0 4.260243429143884e-07
contraceptive O 0 1.0813790822794545e-06
use O 0 4.494217442641002e-09
may O 0 2.896945794361727e-09
reduce O 0 1.0031743213900768e-09
the O 0 1.6704143623869072e-10
risk O 0 2.3785688085808943e-07
of O 0 5.032267491600351e-09
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.77015271832326e-10
women O 0 1.565681917448103e-09
with O 0 8.443123977741607e-11
pathogenic O 0 1.7402573604385907e-08
mutations O 0 1.90058919713465e-08
in O 0 1.3650801322651063e-10
the O 0 1.3817939015225988e-09
BRCA1 O 0 7.962064046296291e-06
or O 0 3.744587218079687e-07
BRCA2 O 0 0.00016340968431904912
gene O 0 0.00014318789180833846

A O 0 5.640445266408278e-08
Japanese O 0 1.729229381908226e-08
family O 0 1.3928306286103975e-09
with O 0 2.2872087557246346e-10
adrenoleukodystrophy B-Disease 1 0.9999994039535522
with O 0 3.689423211383769e-10
a O 0 2.5120614477458503e-09
codon O 0 1.1510604736031382e-06
291 O 0 1.790489001507467e-08
deletion O 0 3.8739194963000045e-08
: O 0 1.4371938361623648e-10
a O 0 4.9354471898244157e-11
clinical O 0 1.2651071301661432e-08
, O 0 1.0367210562245432e-10
biochemical O 0 5.490471366442762e-08
, O 0 2.4786772634399767e-10
pathological O 0 2.116886221870118e-08
, O 0 1.1603644711755123e-09
and O 0 3.4597251730161815e-09
genetic O 0 1.7458296497352421e-06
report O 0 4.4332233528621146e-07
. O 0 8.842898324701309e-08

We O 0 2.927581874700991e-07
report O 0 4.046148305292263e-09
a O 0 1.4278821180990775e-10
Japanese O 0 2.0819681534334222e-09
family O 0 1.9136288109677935e-09
with O 0 1.769233315407348e-09
adrenoleukodystrophy B-Disease 1 1.0
( O 0 1.495724255562436e-08
ALD B-Disease 1 1.0
) O 0 1.237862035097237e-09
with O 0 2.5293959635130925e-11
a O 0 6.341024233469383e-11
three O 0 2.6880447867583257e-10
base O 0 2.6150765997101644e-09
pair O 0 2.995178149944877e-08
deletion O 0 2.7342926500750764e-07
( O 0 5.606310415906535e-10
delGAG O 0 6.549510800368807e-08
291 O 0 5.083881315925964e-09
) O 0 3.778212465110897e-10
in O 0 9.692102675984415e-10
the O 0 2.1002243499879114e-08
ALD B-Disease 1 0.9999998807907104
gene O 0 5.363179752748692e-06
. O 0 2.499915296994004e-07

A O 0 2.5395756608759257e-08
variety O 0 7.708027105479687e-09
of O 0 1.2286313633147472e-10
phenotypes O 0 4.606258485750914e-08
were O 0 1.1488403561799032e-09
observed O 0 3.1277660461626056e-09
within O 0 3.4132846549184137e-10
this O 0 9.248798393812763e-10
family O 0 6.733817770054884e-08
. O 0 1.0447639198218894e-07

While O 0 1.492211367803975e-07
the O 0 1.589567588666796e-09
proband O 0 4.3142333083778794e-07
( O 0 4.3333364674325026e-10
patient O 0 4.730687841458803e-09
1 O 0 1.8298489112833494e-10
) O 0 3.88300537557118e-11
was O 0 3.7198261831905555e-11
classified O 0 2.8710631094774897e-10
as O 0 4.894116709119878e-11
having O 0 3.7562536414625924e-10
a O 0 3.9153791320245546e-11
rare O 0 4.0232903120163144e-10
intermediate O 0 2.34559305312132e-09
type O 0 7.679558322593039e-09
of O 0 1.5988042834091942e-10
adult O 0 5.626766323985066e-07
cerebral O 0 5.983877144899452e-06
and O 0 4.860344127166627e-09
cerebello O 0 0.03585129603743553
- O 0 0.000618383230175823
brain O 0 1.6242208857875085e-06
stem O 0 1.5965875732604218e-08
forms O 0 2.2351174244761296e-09
, O 0 1.1209028150105382e-10
his O 0 1.4641876600052228e-10
younger O 0 7.484025843496056e-09
brother O 0 4.406652820421186e-09
( O 0 7.420496161980594e-11
patient O 0 1.4454639707395245e-09
2 O 0 1.6277186543067756e-10
) O 0 6.46135506210399e-11
and O 0 1.5331683145269892e-10
nephew O 0 1.3373922413961736e-08
( O 0 1.3779452578965845e-10
patient O 0 3.916742485898794e-09
3 O 0 2.879069482819574e-10
) O 0 3.7445149758674745e-10
had O 0 6.781698758118182e-09
a O 0 9.963594393980202e-09
childhood O 0 0.0008796598413027823
ALD B-Disease 1 1.0
type O 0 0.00022338911367114633
. O 0 4.4232274376554415e-07

Another O 0 1.618884368781437e-07
nephew O 0 4.650672451589344e-07
( O 0 1.644044234083708e-09
patient O 0 2.1792731175196423e-08
4 O 0 5.508518086116965e-10
) O 0 3.2192798427033154e-10
of O 0 5.10812711573827e-11
patient O 0 6.205365110645289e-08
1 O 0 4.678401666069476e-09
was O 0 5.600560570862001e-10
classified O 0 1.6578490802388046e-09
as O 0 3.0503022330208296e-10
having O 0 5.9642824012939855e-09
an O 0 2.0295302938233561e-10
adolescent O 0 1.5044658141505352e-07
form O 0 3.214877253299164e-08
. O 0 8.861335487608812e-08

The O 0 1.7545723096645816e-08
tau O 0 4.038578538256843e-08
level O 0 1.1340475225551927e-08
in O 0 5.762876842396736e-10
the O 0 4.869344483182658e-09
cerebrospinal O 0 2.074443955280003e-06
fluid O 0 6.90016150883821e-08
( O 0 1.1763603424697067e-09
CSF O 0 9.863250625130604e-07
) O 0 8.563988407317424e-11
in O 0 3.2502629060404686e-11
patient O 0 2.2292505619248004e-09
1 O 0 3.8421121839604666e-10
was O 0 9.355732855098609e-10
as O 0 4.1580378029593135e-11
high O 0 8.039507948254254e-11
as O 0 1.3066638049341606e-11
that O 0 7.1813032950784894e-12
of O 0 1.3890062711130469e-11
patients O 0 3.9834864296039996e-09
with O 0 3.862231423568119e-09
Alzheimers B-Disease 1 0.9563223123550415
disease I-Disease 0 3.654598231150885e-06
( O 0 1.103959035297919e-09
AD B-Disease 0 1.418945316800091e-06
) O 0 1.9766090986195195e-08
. O 0 4.4052008263406606e-08

His O 0 1.4508528067835869e-07
brain O 0 1.1828517472167732e-06
magnetic O 0 3.686282923354156e-08
resonance O 0 4.244213300808042e-07
image O 0 7.195603757281788e-07
( O 0 1.079344835730467e-09
MRI O 0 5.0816737484638e-07
) O 0 1.7592929335563667e-09
showed O 0 2.9074591623157175e-08
abnormalities B-Disease 0 1.7922764072864084e-06
in I-Disease 0 9.48697648217589e-11
the I-Disease 0 2.468514559428314e-10
bilateral I-Disease 0 1.6909993405533896e-08
cerebellar I-Disease 0 5.407771936916106e-07
hemispheres I-Disease 0 6.197279617481399e-06
and O 0 9.701317971178014e-09
brain O 0 6.192890822376285e-08
stem O 0 6.15367889977847e-09
, O 0 6.839145222370391e-11
but O 0 8.665284462194833e-11
not O 0 4.515323878684363e-11
in O 0 3.9795566147970973e-11
the O 0 1.5826993882139817e-10
cerebral O 0 5.425284399507291e-08
white O 0 3.8712362204762485e-09
matter O 0 1.4079880317208193e-10
, O 0 1.2511726030228765e-11
where O 0 3.174861762378356e-11
marked O 0 2.1029880614698016e-10
reductions O 0 7.249119082786137e-09
of O 0 9.72449811648124e-12
the O 0 4.052231883377999e-10
cerebral O 0 1.054039131531681e-07
blood O 0 1.4238584533643461e-08
flow O 0 1.1472293337533301e-08
and O 0 2.502515972224728e-09
oxygen O 0 5.19854603808767e-10
metabolism O 0 3.352543798129659e-10
were O 0 1.7947601738121932e-11
clearly O 0 9.195461753153111e-11
demonstrated O 0 8.290249042808284e-11
by O 0 2.8500448528978595e-11
positron O 0 4.151640453642358e-08
emission O 0 2.9009559199266732e-08
tomography O 0 3.153833176838816e-07
( O 0 4.977929179972307e-09
PET O 0 2.271660122232788e-07
) O 0 1.2102352009435435e-08
. O 0 4.489165306154064e-08

In O 0 1.925803019275918e-07
patients O 0 1.7370811633554695e-07
2 O 0 1.164164209477292e-09
and O 0 3.4980626728575714e-10
3 O 0 3.9352812675197413e-10
, O 0 2.2874910299286455e-11
the O 0 2.6222512009010934e-11
autopsy O 0 4.548202170440163e-08
findings O 0 8.632548009757102e-09
showed O 0 6.755027648353007e-09
massive O 0 7.03203983931644e-09
demyelination B-Disease 1 0.9999998807907104
of I-Disease 0 2.813008714852572e-10
the I-Disease 0 9.211615914495042e-10
cerebral I-Disease 0 4.775907882503816e-07
white I-Disease 0 4.152889587771824e-09
matter I-Disease 0 5.039148959218309e-11
with O 0 6.598663455925635e-12
sparing O 0 4.488861227169849e-10
of O 0 1.0991276465366351e-11
the O 0 8.05756086852405e-11
U O 0 2.5372864911332726e-06
- O 0 6.2386698118643835e-06
fibers O 0 1.0406920409877785e-05
, O 0 2.022357281639131e-11
compatible O 0 9.705046488672764e-11
with O 0 8.725201117165682e-12
the O 0 4.9140025382143904e-11
findings O 0 6.228010551723173e-09
of O 0 1.497750368173456e-09
childhood O 0 1.1936832379433326e-05
ALD B-Disease 1 0.9999997615814209
. O 0 7.883522243901098e-07

Oleic O 0 0.04065841808915138
and O 0 8.071006050158758e-07
erucic O 0 0.00017321333871223032
acids O 0 1.0370858944952488e-06
( O 0 7.568660143064676e-10
Lorenzos O 0 4.644236994977291e-08
Oil O 0 1.0237472203300513e-08
) O 0 6.025357296435274e-11
were O 0 2.7578099526248678e-11
administered O 0 2.5974727924094054e-10
to O 0 4.8695623922068165e-11
patients O 0 8.192684308738762e-10
1 O 0 5.7686477122897983e-11
and O 0 8.637315168646964e-11
4 O 0 9.766139286160325e-11
, O 0 3.188522015862283e-11
but O 0 1.9605968237801363e-10
sufficient O 0 1.789739328961204e-10
effectiveness O 0 2.8944604490988013e-09
was O 0 7.138920565807894e-10
not O 0 1.7386596329327375e-10
obtained O 0 1.0739711342466762e-08
. O 0 3.550029958887535e-08

The O 0 8.37445668366854e-09
findings O 0 4.853923485370615e-09
in O 0 6.470703833860725e-11
this O 0 1.5292656030396756e-11
family O 0 1.9227083813966317e-10
suggest O 0 7.554612491134094e-10
that O 0 1.2759714292098767e-11
delGAG291 O 0 3.298001427509689e-09
is O 0 8.73925844885326e-12
part O 0 1.7016383094259346e-11
of O 0 2.137134219593051e-12
the O 0 6.218366099819406e-11
cause O 0 4.602433989475685e-10
of O 0 4.9867047990925784e-11
Japanese O 0 2.2742807459508185e-07
ALD B-Disease 1 0.9999997615814209
with O 0 2.2359234463920075e-09
phenotypic O 0 7.076861265886691e-07
variations O 0 1.36892958835233e-06
. O 0 2.735831685640733e-07

Moreover O 0 2.7317904027768236e-07
, O 0 5.362706390066307e-10
although O 0 1.2179358910291427e-10
the O 0 1.0748732633125702e-11
scale O 0 2.4351030081248837e-09
of O 0 8.839070100852275e-12
the O 0 1.1554031169314083e-11
study O 0 1.374422797795205e-10
is O 0 1.4835160877524345e-11
limited O 0 6.327564860963975e-11
, O 0 1.3117828871755943e-11
there O 0 1.4462897025835364e-11
is O 0 9.343151252672044e-12
a O 0 1.0043315137875375e-11
possibility O 0 2.420011968595759e-10
that O 0 3.4875283216884156e-11
PET O 0 1.9023327357814424e-09
can O 0 6.182641065777261e-10
detect O 0 1.0095882174709914e-07
an O 0 3.067069098694475e-10
insidious B-Disease 0 1.1830684343294706e-06
lesion I-Disease 0 0.2881825268268585
which O 0 1.0142295892023867e-08
is O 0 5.289291782339944e-10
undetectable O 0 1.163250384905723e-08
by O 0 2.3011268238115612e-11
computed O 0 8.292376563190373e-09
tomogram O 0 1.132502518430556e-07
( O 0 8.938901008281874e-11
CT O 0 9.224156201526057e-06
) O 0 1.2738127219691364e-10
or O 0 2.692380485225243e-10
MRI O 0 4.1900324987409476e-08
analysis O 0 8.519076000190751e-10
, O 0 2.6068520606048473e-11
and O 0 2.96043640990451e-11
that O 0 1.1718287798445637e-11
the O 0 5.891630933119174e-11
higher O 0 1.148580253129694e-08
level O 0 1.0701591834916258e-09
of O 0 8.817601163113586e-12
tau O 0 1.4725308472574028e-10
reflects O 0 2.2298746182869422e-10
the O 0 1.702066786124501e-11
process O 0 8.735400736092913e-10
of O 0 1.0229205676948183e-10
neuronal B-Disease 0 2.3074312593962532e-07
degeneration I-Disease 0 4.175371486780932e-06
in O 0 1.0794940408231923e-07
ALD B-Disease 1 0.9999998807907104
. O 0 1.05347783119214e-06

Lorenzos O 0 1.766644709277898e-05
Oil O 0 2.3349944058281835e-06
should O 0 2.7951148062754783e-09
be O 0 2.6074436013101554e-11
given O 0 2.029745989340359e-11
in O 0 7.466392087929208e-12
the O 0 3.995040409598971e-11
early O 0 2.6455959201143742e-08
stage O 0 1.5810481102107588e-07
. O 0 4.069040659970824e-09
. O 0 4.214928850387878e-08

Nonsense O 0 6.090218448662199e-05
mutation O 0 3.1506754112342605e-06
in O 0 3.957503658114092e-09
exon O 0 1.657425343637442e-07
4 O 0 2.8841493637798976e-09
of O 0 3.297230544152541e-11
human O 0 8.336458745539232e-10
complement O 0 1.1464484472867298e-08
C9 O 0 1.9951126262185426e-07
gene O 0 1.8638676380078323e-08
is O 0 1.266853982828664e-10
the O 0 3.63037308548364e-11
major O 0 2.971992651978894e-09
cause O 0 2.3543691440863768e-09
of O 0 2.4352411753802983e-10
Japanese O 0 5.833350087414146e-07
complement B-Disease 0 6.744293841620674e-06
C9 I-Disease 0 0.00237918714992702
deficiency I-Disease 0 0.0006464779726229608
. O 0 8.385759997509012e-08

Deficiency B-Disease 1 0.9950718283653259
of I-Disease 0 3.825877947782885e-10
the I-Disease 0 1.76080275360313e-10
ninth I-Disease 0 2.1613233425199496e-09
component I-Disease 0 4.493223126900148e-09
of I-Disease 0 2.429056088215642e-11
human I-Disease 0 2.073565624760576e-10
complement I-Disease 0 1.6030373695130606e-09
( O 0 6.510914724033867e-11
C9 O 0 1.3857060388033915e-08
) O 0 2.899397215372357e-11
is O 0 1.8913458039310216e-12
the O 0 2.583063537370256e-12
most O 0 1.6945719827354822e-10
common O 0 4.483543136757362e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.0231000074911734e-10
Japan O 0 3.72629010980674e-10
but O 0 1.5081497162228175e-10
is O 0 4.151663821755358e-12
rare O 0 2.139615221108393e-11
in O 0 8.121774953961935e-12
other O 0 8.101032344942638e-11
countries O 0 1.3522093444962024e-09
. O 0 1.306277042090187e-08

We O 0 1.2263420501312794e-07
studied O 0 9.290634928049712e-09
the O 0 3.3211270539235116e-11
molecular O 0 2.3826172146357294e-09
basis O 0 2.28422347703372e-09
of O 0 8.280613417177562e-10
C9 B-Disease 0 0.0016762599116191268
deficiency I-Disease 0 3.3889911719597876e-05
in O 0 6.278563086103972e-11
four O 0 7.352521924630651e-10
Japanese O 0 1.9621587910023663e-08
C9 B-Disease 0 3.7863097531953827e-05
- I-Disease 0 8.539986993127968e-07
deficient I-Disease 0 2.3046008834626264e-07
patients O 0 9.361467157020797e-09
who O 0 1.2481371491901427e-09
had O 0 1.08903552842321e-08
suffered O 0 7.240227205329575e-06
from O 0 1.3132172682617238e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.103627027987386e-06

Direct O 0 2.065366118131351e-07
sequencing O 0 3.3915424069164146e-07
of O 0 4.531073294344878e-09
amplified O 0 9.068055533134611e-07
C9 O 0 2.9538052785937907e-06
cDNA O 0 1.699915941344443e-07
and O 0 3.1415172685456128e-09
DNA O 0 4.973794176521551e-08
revealed O 0 1.3909888352259259e-08
a O 0 5.042805062416278e-10
nonsense O 0 3.246797675160451e-08
substitution O 0 4.360084293608679e-09
( O 0 2.627278949951517e-10
CGA O 0 7.609007468545315e-08
- O 0 4.2865499949584773e-07
- O 0 1.5291868749045534e-07
> O 0 1.1598408455881781e-08
TGA O 0 2.3541825555639662e-07
) O 0 1.9835789955013894e-10
at O 0 1.284932715783782e-10
codon O 0 6.274666564110021e-09
95 O 0 1.7146256636735302e-10
in O 0 1.8963967549079364e-11
exon O 0 2.94115753973756e-09
4 O 0 2.2332498350596808e-10
in O 0 2.370823849739967e-11
the O 0 1.4643664059121875e-10
four O 0 7.945337721082524e-09
C9 B-Disease 0 6.425983156077564e-05
- I-Disease 0 5.850961770192953e-06
deficient I-Disease 0 2.3193169909063727e-06
individuals O 0 8.55815063260934e-09
. O 0 2.5601675446296213e-08

An O 0 4.779047202418951e-08
allele O 0 3.047795416932786e-06
- O 0 3.1247628839992103e-07
specific O 0 1.3516350705344848e-08
polymerase O 0 1.9236536275002436e-07
chain O 0 2.771337506146665e-07
reaction O 0 1.1557840906561978e-08
system O 0 6.999839596844026e-10
designed O 0 8.724926892078599e-10
to O 0 3.161277836727372e-11
detect O 0 8.544396856713377e-10
exclusively O 0 7.3853798077117e-11
only O 0 5.346023970731473e-12
one O 0 6.193883080041207e-12
of O 0 9.75730455633761e-13
the O 0 1.7697614207445866e-11
normal O 0 6.004205466147994e-10
and O 0 6.978200656204692e-11
mutant O 0 2.2369044394565663e-09
alleles O 0 2.7879905051264586e-09
indicated O 0 7.739430762931931e-10
that O 0 4.4317470700161454e-12
all O 0 1.832602862864019e-12
the O 0 3.2848066714580293e-12
four O 0 3.2069534527945365e-11
patients O 0 7.828835496548336e-11
were O 0 5.331838703187541e-12
homozygous O 0 5.353018583953428e-10
for O 0 9.22016716448093e-12
the O 0 2.5373010983931188e-11
mutation O 0 4.513511786541358e-09
in O 0 5.671797753681318e-11
exon O 0 7.0067756041680695e-09
4 O 0 4.4369025120616357e-10
and O 0 8.168759418891725e-11
that O 0 2.0490786151183826e-11
the O 0 4.5436522599917595e-11
parents O 0 9.422493896238393e-10
of O 0 1.5140373330058132e-11
patient O 0 3.157635042327911e-09
2 O 0 4.5216433375294685e-10
were O 0 1.5689614052405432e-09
heterozygous O 0 3.5650572272061254e-07
. O 0 6.014514752905598e-08

The O 0 1.2069709676154616e-08
common O 0 1.4583974028425928e-08
mutation O 0 4.559476352028469e-08
at O 0 7.142557101325053e-10
codon O 0 1.5003472242369753e-08
95 O 0 3.838427908853248e-10
in O 0 3.372037718496479e-11
exon O 0 3.3721438974509965e-09
4 O 0 2.529696452313601e-10
might O 0 2.934801290876976e-10
be O 0 7.633720044974979e-12
responsible O 0 2.892840134105512e-11
for O 0 7.052606762480984e-12
most O 0 3.089609401651927e-10
Japanese O 0 3.5386631225264864e-07
C9 B-Disease 0 0.00018396499217487872
deficiency I-Disease 0 4.9611253416514955e-06
. O 0 2.2328079385403043e-09
. O 0 2.2942234778611237e-08

BRCA1 O 0 2.4387250959989615e-05
required O 0 3.731663866801682e-08
for O 0 2.920851616128317e-10
transcription O 0 9.355847652159355e-08
- O 0 7.344423920585541e-06
coupled O 0 1.2813958392143832e-06
repair O 0 3.723939016708755e-06
of O 0 5.838631800259009e-10
oxidative O 0 5.461091063807544e-07
DNA O 0 2.2363183234119788e-06
damage O 0 4.092833023605635e-06
. O 0 1.6249958889602567e-07

The O 0 7.036469469312578e-07
breast B-Disease 1 0.9999701976776123
and I-Disease 1 0.9997908473014832
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 5.93778895563446e-05
gene O 0 9.897389645630028e-06
BRCA1 O 0 2.648513691383414e-05
encodes O 0 5.838526249135612e-07
a O 0 6.055412171690477e-08
zinc O 0 3.555615330697037e-05
finger O 0 3.971990736317821e-06
protein O 0 1.817603703102577e-07
of O 0 6.609162106485655e-10
unknown O 0 1.2200115406812984e-07
function O 0 2.0059550820406002e-07
. O 0 1.5216353688174422e-07

Association O 0 1.8533006596044288e-07
of O 0 6.99439395290824e-10
the O 0 1.1371747987709568e-09
BRCA1 O 0 2.1123112503573793e-07
protein O 0 5.7118629825936296e-09
with O 0 1.456480630546153e-10
the O 0 4.110678741842122e-10
DNA O 0 2.1925612259110494e-07
repair O 0 2.664721705514239e-07
protein O 0 6.685963338526335e-09
Rad51 O 0 3.250785880481999e-07
and O 0 3.6489516963555957e-10
changes O 0 3.4873171017579807e-10
in O 0 3.688317012917608e-11
the O 0 1.2111939055869936e-11
phosphorylation O 0 1.3271433951800304e-09
and O 0 4.1108980108894855e-10
cellular O 0 8.245770288795029e-09
localization O 0 3.3548737121691374e-09
of O 0 1.2155680108316691e-11
the O 0 3.1316192694585965e-11
protein O 0 1.8993886463647414e-09
after O 0 1.6312967643372644e-09
exposure O 0 1.6191153306976958e-08
to O 0 7.26315951826706e-11
DNA O 0 1.2258007586751773e-07
- O 0 7.913217814348172e-08
damaging O 0 1.4252877100773276e-08
agents O 0 2.3094131051948352e-09
are O 0 1.2234906664188028e-11
consistent O 0 1.022319798260618e-10
with O 0 1.1840623100056735e-11
a O 0 8.563073167211499e-11
role O 0 7.589827433207574e-09
for O 0 5.019639703895962e-10
BRCA1 O 0 1.8564776382845594e-07
in O 0 1.114935144208573e-09
DNA O 0 6.362834596984612e-07
repair O 0 7.275617917912314e-06
. O 0 1.2639088708965573e-07

Here O 0 4.266769337846199e-08
, O 0 6.1662003281171e-10
it O 0 6.468162117023724e-11
is O 0 1.2528346415852099e-11
shown O 0 1.8307320936994387e-10
that O 0 6.244025435586664e-11
mouse O 0 4.057247338096204e-08
embryonic O 0 1.2825776707359182e-07
stem O 0 6.460588224399544e-07
cells O 0 3.2855095355444064e-07
deficient B-Disease 0 3.2214393286267295e-07
in I-Disease 0 1.9482912505530692e-10
BRCA1 I-Disease 0 6.290714793522056e-08
are O 0 6.768330340634066e-11
defective O 0 3.210133048270336e-09
in O 0 5.3795457671812486e-11
the O 0 1.117508082598695e-11
ability O 0 2.3623566991481937e-10
to O 0 2.1472519942666857e-11
carry O 0 1.9321048927434248e-10
out O 0 2.978936194941717e-11
transcription O 0 5.274907621810598e-09
- O 0 9.899684982883628e-08
coupled O 0 1.3467820281221066e-07
repair O 0 3.6275412185204914e-07
of O 0 6.543408176407084e-11
oxidative O 0 3.094147871252062e-08
DNA O 0 1.5935928843191505e-07
damage O 0 2.0826988134103885e-07
, O 0 4.870667758005709e-11
and O 0 2.8071493046732954e-11
are O 0 2.6709835732052767e-11
hypersensitive O 0 1.8084531205886378e-08
to O 0 3.337543852399705e-10
ionizing O 0 2.1978327424676536e-07
radiation O 0 3.279273812495376e-07
and O 0 2.152987566006459e-09
hydrogen O 0 6.352908599183138e-08
peroxide O 0 8.968592737801373e-06
. O 0 8.103965143391179e-08

These O 0 2.999757597876851e-08
results O 0 2.3995289311073975e-08
suggest O 0 1.2492000323049979e-08
that O 0 3.8623323983522084e-10
BRCA1 O 0 1.0022839092016511e-07
participates O 0 3.901777567705267e-09
, O 0 5.930777396967457e-11
directly O 0 1.45250783623041e-10
or O 0 3.197677400645915e-10
indirectly O 0 7.163174942093065e-09
, O 0 9.522455046706568e-11
in O 0 8.623849551137042e-11
transcription O 0 3.992083819071013e-08
- O 0 9.859086276264861e-06
coupled O 0 8.201507739613589e-07
repair O 0 1.046735064846871e-06
of O 0 2.5227192557153444e-10
oxidative O 0 1.382008605332885e-07
DNA O 0 6.878223643980164e-07
damage O 0 5.578900754699134e-07
. O 0 6.15086337418802e-09
. O 0 5.668345792742002e-08

Truncation O 0 1.689990131126251e-05
mutations O 0 4.692193670052802e-06
in O 0 4.437167078208404e-09
the O 0 1.6591744644856021e-09
transactivation O 0 3.991359790234128e-06
region O 0 4.666978270506661e-08
of O 0 3.15633880143551e-10
PAX6 O 0 1.7435519339414896e-06
result O 0 1.042404740303482e-08
in O 0 7.193964313145784e-10
dominant O 0 1.0864652722375467e-05
- O 0 4.731664739665575e-05
negative O 0 1.0174545650443179e-06
mutants O 0 1.0820548368428717e-06
. O 0 3.764074918422011e-08

PAX6 O 0 0.00017602462321519852
is O 0 3.419674499127723e-08
a O 0 8.601643841643636e-10
transcription O 0 1.1595930438090818e-08
factor O 0 7.783595101784613e-09
with O 0 6.920238687646574e-11
two O 0 2.6471982939035854e-10
DNA O 0 4.809924689652689e-07
- O 0 7.94639959167398e-07
binding O 0 6.910646277447086e-08
domains O 0 3.013929017470218e-08
( O 0 2.237590390752331e-10
paired O 0 1.7012839137464653e-08
box O 0 1.686383832577576e-08
and O 0 5.383243295575824e-10
homeobox O 0 1.2549357109037373e-07
) O 0 1.619589323764714e-10
and O 0 6.202623137330221e-11
a O 0 3.1029920299907587e-10
proline O 0 6.204311944202345e-07
- O 0 2.5730113861754944e-07
serine O 0 9.085134479391854e-06
- O 0 4.922382572658535e-07
threonine O 0 8.709835128684063e-07
( O 0 5.565791161288303e-10
PST O 0 1.302776695411012e-07
) O 0 2.055119852073517e-09
- O 0 8.766187420405913e-08
rich O 0 7.26030293662916e-08
transactivation O 0 6.197586571943248e-06
domain O 0 3.6960622651349695e-07
. O 0 1.4571884321412654e-07

PAX6 O 0 0.0005307707469910383
regulates O 0 1.0487061445019208e-05
eye O 0 0.0006639999919570982
development O 0 2.6596396196509886e-09
in O 0 9.911441806176313e-11
animals O 0 6.781821632051432e-11
ranging O 0 1.0687653539953601e-10
from O 0 5.268195601981773e-11
jellyfish O 0 1.908689428731236e-09
to O 0 4.8018915232983517e-11
Drosophila O 0 3.4190969500080826e-10
to O 0 9.77049899320015e-11
humans O 0 2.437217094808375e-09
. O 0 1.4004580606297168e-08

Heterozygous O 0 0.00010857464076252654
mutations O 0 5.529056579689495e-06
in O 0 2.6624209503722795e-09
the O 0 3.4356359424059235e-10
human O 0 1.3149857869265702e-09
PAX6 O 0 7.94382287949702e-07
gene O 0 5.052370610769685e-08
result O 0 1.3711819457640217e-09
in O 0 1.4178453550117709e-11
various O 0 5.150645882023852e-11
phenotypes O 0 2.1893221457958134e-08
, O 0 5.538054390075153e-11
including O 0 3.8117761724798527e-10
aniridia B-Disease 1 1.0
, O 0 3.6489417709617555e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 3.707492979287963e-08
autosomal B-Disease 0 0.014904724434018135
dominant I-Disease 0 0.001254019676707685
keratitis I-Disease 1 0.9986233711242676
, O 0 4.280014564983503e-08
and O 0 1.3276597599087836e-07
familial B-Disease 1 0.8506507277488708
foveal I-Disease 1 0.9287540912628174
dysplasia I-Disease 1 0.9956392049789429
. O 0 4.7773933147254866e-06

It O 0 1.954710349139077e-08
is O 0 4.189213143046544e-10
believed O 0 9.22497855881943e-10
that O 0 1.1918817495459866e-11
the O 0 4.638342834817344e-11
mutated O 0 3.907416967763311e-08
allele O 0 8.078870905592339e-08
of O 0 1.7095606874573122e-10
PAX6 O 0 5.686158033313404e-07
produces O 0 3.4788354419390544e-09
an O 0 2.6866182889495605e-11
inactive O 0 4.016177168608692e-09
protein O 0 1.2219013578729232e-09
and O 0 4.600388681108569e-10
aniridia B-Disease 1 1.0
is O 0 1.032485297258745e-08
caused O 0 4.095099814804826e-09
due O 0 1.5190979585355535e-09
to O 0 9.91252524507047e-10
genetic O 0 4.6059776082074677e-07
haploinsufficiency O 0 5.214179509493988e-06
. O 0 1.0948551931733164e-07

However O 0 4.539518272395071e-08
, O 0 3.175771590147036e-10
several O 0 2.3604471155458384e-10
truncation O 0 6.256313156427495e-08
mutations O 0 1.1810826094915683e-07
have O 0 1.211038047621571e-09
been O 0 2.3879706545493207e-10
found O 0 7.267925844489653e-11
to O 0 2.996510678476838e-11
occur O 0 1.0510925463336207e-10
in O 0 2.364294003631695e-11
the O 0 9.857353128195356e-11
C O 0 1.0234683855969706e-07
- O 0 1.1263561638941155e-08
terminal O 0 9.989760130224568e-09
half O 0 3.5213787441534805e-10
of O 0 1.5899843941458158e-11
PAX6 O 0 1.2358425749425805e-07
in O 0 1.3146890520676635e-10
patients O 0 1.8617704045098549e-09
with O 0 1.533004417852979e-10
Aniridia B-Disease 1 1.0
resulting O 0 1.5137363362782708e-08
in O 0 2.0081900031776456e-10
mutant O 0 8.142323260074136e-09
proteins O 0 9.718240656653165e-10
that O 0 1.1008088190989085e-10
retain O 0 5.867638819267995e-09
the O 0 4.926399566063111e-11
DNA O 0 3.2422679652199804e-08
- O 0 1.723815579168786e-08
binding O 0 3.25212035079403e-09
domains O 0 1.2181966546620515e-09
but O 0 2.5168944706166485e-10
have O 0 1.308964325819062e-10
lost O 0 1.1190278703665513e-09
most O 0 1.7669248009166694e-11
of O 0 2.1472438410663486e-11
the O 0 5.223533272591396e-10
transactivation O 0 3.6623748655983945e-06
domain O 0 5.053054792369949e-07
. O 0 1.0837852215672683e-07

It O 0 1.671716454154648e-08
is O 0 2.2725887838248582e-10
not O 0 4.73816021140383e-11
clear O 0 5.7830684685455935e-11
whether O 0 3.239611356953276e-11
such O 0 2.056957035256879e-11
mutants O 0 6.076655267861497e-08
really O 0 4.394364871984635e-09
behave O 0 3.8044983829976786e-10
as O 0 2.795367930186199e-11
loss O 0 5.2465493061149e-10
- O 0 4.420467103471992e-09
of O 0 9.657571964361011e-11
- O 0 9.279021639940765e-08
function O 0 3.505324697172796e-09
mutants O 0 3.352879218709859e-08
as O 0 2.8783883609939664e-10
predicted O 0 2.19588680572258e-09
by O 0 3.745357912698921e-10
haploinsufficiency O 0 1.5502862424909836e-06
. O 0 8.664520123602415e-08

Contrary O 0 1.5228592076255154e-07
to O 0 9.678192691708887e-10
this O 0 3.3812858762916065e-11
theory O 0 1.7775363125860366e-10
, O 0 2.7039634420411574e-11
our O 0 2.0924402835409417e-11
data O 0 2.2001450661335298e-10
showed O 0 3.396859737936353e-10
that O 0 3.414349098590508e-12
these O 0 7.934134252374214e-12
mutants O 0 1.6457822882287587e-09
are O 0 3.9530104883889194e-11
dominant O 0 4.9571440285944846e-08
- O 0 2.2619168760229513e-07
negative O 0 6.293895182807319e-08
in O 0 1.7665079121709226e-10
transient O 0 6.878503544527348e-09
transfection O 0 1.753542591131918e-07
assays O 0 1.8501519605251815e-07
when O 0 1.0906835434809636e-09
they O 0 8.730132589063189e-11
are O 0 1.0108830439392591e-11
coexpressed O 0 4.42651648668857e-09
with O 0 4.2499091051917404e-11
wild O 0 4.914645135301043e-09
- O 0 1.6597218746028375e-06
type O 0 2.301834001627867e-06
PAX6 O 0 8.98960352060385e-05
. O 0 3.0480319423986657e-07

We O 0 5.249387058370303e-08
found O 0 7.299981175101777e-10
that O 0 1.980602661044717e-11
the O 0 2.7881049899369792e-11
dominant O 0 1.2987871400582662e-07
- O 0 5.292092737363419e-07
negative O 0 5.332535693014506e-07
effects O 0 1.2403269522565097e-07
result O 0 7.021113135330381e-10
from O 0 1.9133420542383206e-11
the O 0 2.223591970273997e-11
enhanced O 0 9.425351610303778e-10
DNA O 0 4.7059485197564754e-09
binding O 0 1.4277302673448844e-09
ability O 0 5.258199431423805e-10
of O 0 6.3278878664752014e-12
these O 0 2.421545186592766e-10
mutants O 0 2.1475834444117936e-07
. O 0 2.4860563385686874e-08

Kinetic O 0 7.938074872981815e-07
studies O 0 1.6039503236697783e-07
of O 0 1.1075481504141393e-10
binding O 0 1.686493256158883e-08
and O 0 6.595738399894913e-10
dissociation O 0 1.1301478863856573e-08
revealed O 0 2.677397858974473e-09
that O 0 7.519858000182289e-12
various O 0 6.088062692866103e-11
truncation O 0 2.2862122861511125e-08
mutants O 0 4.342127724044076e-08
have O 0 3.50059231601918e-10
3 O 0 3.313093410728385e-10
- O 0 1.3965422596129429e-08
5 O 0 2.470371462948151e-09
- O 0 2.9221528308198685e-08
fold O 0 6.318577305819417e-08
higher O 0 4.886628879319233e-10
affinity O 0 2.914474217519114e-10
to O 0 9.84828971845042e-12
various O 0 1.59173230152021e-11
DNA O 0 2.7230018240231857e-09
- O 0 8.838556553314447e-10
binding O 0 1.6291908100374286e-10
sites O 0 2.478143246165132e-10
when O 0 6.332080693116637e-11
compared O 0 1.7050593575929085e-11
with O 0 1.5047117198074833e-12
the O 0 3.678663276773797e-11
wild O 0 6.330975743651379e-09
- O 0 1.8352461665926967e-06
type O 0 1.6419004396084347e-06
PAX6 O 0 8.665179484523833e-05
. O 0 2.9948012070235563e-07

These O 0 3.137399318120515e-08
results O 0 8.028330000797723e-09
provide O 0 2.3067484034022812e-10
a O 0 3.00511872330933e-11
new O 0 2.542243360270646e-10
insight O 0 2.101251950215044e-10
into O 0 1.2610168985405235e-11
the O 0 1.7328518828185757e-11
role O 0 1.2801704141196524e-09
of O 0 3.3634043467012376e-11
mutant O 0 6.212174241682078e-08
PAX6 O 0 1.3806402421323583e-06
in O 0 3.4175013929882425e-09
causing O 0 8.029068254700178e-08
aniridia B-Disease 1 0.9999998807907104
. O 0 3.381768109989025e-08
. O 0 8.495004522046656e-08

Reversal O 0 9.060026059160009e-06
of O 0 2.0770508868395154e-08
severe O 0 5.09668534505181e-05
hypertrophic B-Disease 1 0.6987780928611755
cardiomyopathy I-Disease 1 1.0
and O 0 1.1962922030761547e-07
excellent O 0 6.260861340479096e-08
neuropsychologic O 0 2.0530269466689788e-06
outcome O 0 4.645167450689769e-08
in O 0 1.0368282898909342e-09
very B-Disease 0 6.5825198625191206e-09
- I-Disease 0 1.8622881725605112e-06
long I-Disease 0 7.040080163278617e-07
- I-Disease 0 4.776859441335546e-07
chain I-Disease 0 2.334558075745008e-06
acyl I-Disease 0 3.0477808650175575e-06
- I-Disease 0 7.86091732152272e-07
coenzyme I-Disease 0 1.1209615422558272e-06
A I-Disease 0 1.197212213810417e-07
dehydrogenase I-Disease 0 0.00013691448839381337
deficiency I-Disease 0 8.166886254912242e-05
. O 0 1.0992220467187508e-07

Very B-Disease 0 6.726461947437201e-07
- I-Disease 0 3.057177673326805e-05
long I-Disease 0 9.148412232207193e-07
- I-Disease 0 2.6264108328177826e-06
chain I-Disease 0 6.316423423413653e-06
acyl I-Disease 0 2.31682242883835e-05
- I-Disease 0 2.129807398887351e-06
coenzyme I-Disease 0 1.6276713665774878e-07
A I-Disease 0 2.821747946413211e-09
dehydrogenase I-Disease 0 4.738890595490375e-07
( I-Disease 0 4.970981404284203e-10
VLCAD I-Disease 0 4.901738179796666e-07
) I-Disease 0 3.067491816111101e-09
deficiency I-Disease 0 1.18877480304036e-07
is O 0 1.50368620333019e-10
a O 0 1.2530700921331572e-09
disorder O 0 3.076703069382347e-05
of O 0 1.4392922964567845e-10
fatty O 0 4.1221548485737003e-07
acid O 0 6.155489273851344e-08
beta O 0 1.761431778213307e-09
oxidation O 0 1.1243507236358141e-09
that O 0 5.953092879762423e-11
reportedly O 0 4.574581069505257e-08
has O 0 2.429406231740927e-09
high O 0 3.937047576840769e-09
rates O 0 4.424779476153162e-08
of O 0 3.1454910898176536e-10
morbidity O 0 4.197197540634079e-06
and O 0 1.932829185591345e-08
mortality O 0 8.294537678921188e-07
. O 0 6.284982134729944e-08

We O 0 4.368644113128539e-08
describe O 0 7.522924505565243e-09
the O 0 3.7104867789405915e-11
outcome O 0 5.575204742314099e-10
of O 0 2.838986207578942e-12
a O 0 2.110038359315336e-11
5 O 0 1.644071684347992e-10
- O 0 8.077911672899063e-09
year O 0 4.289549604408194e-09
- O 0 1.281345305415016e-07
old O 0 4.1122702896245755e-06
girl O 0 1.2745229582833417e-07
with O 0 1.3020500233551502e-09
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.735115328140637e-09
was O 0 1.1943673827730095e-10
first O 0 2.3904668175478427e-11
seen O 0 6.335526547829318e-10
at O 0 4.869581127220357e-11
5 O 0 7.219937321611969e-12
months O 0 5.923090490300709e-11
of O 0 2.4646166184305596e-12
age O 0 1.2897237722242494e-09
with O 0 1.2125821458042196e-09
severe O 0 0.0024282524827867746
hypertrophic B-Disease 1 0.9970501661300659
cardiomyopathy I-Disease 1 1.0
, O 0 1.7619106529309647e-07
hepatomegaly B-Disease 1 1.0
, O 0 3.38832819579693e-08
encephalopathy B-Disease 0 1.2023835552099627e-05
, O 0 1.6961314575070219e-09
and O 0 7.672676716197202e-09
hypotonia B-Disease 0 1.83486317837378e-05
. O 0 2.24388230662953e-07

Biochemical O 0 0.00016190248425118625
studies O 0 3.8143462006701156e-05
indicated O 0 0.0020680695306509733
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.0386521864802489e-07
by O 0 1.6738843644503731e-10
a O 0 2.9227311681978563e-09
stable O 0 2.4855307856341824e-07
yet O 0 1.303527312757069e-07
inactive O 0 5.592196998804866e-07
enzyme O 0 9.398465863341698e-07
. O 0 3.55222447012693e-08

Molecular O 0 4.732594788947608e-06
genetic O 0 1.062540604834794e-06
analysis O 0 3.5315792956680525e-08
of O 0 2.1764214042097052e-10
her O 0 2.571399093653781e-08
VLCAD O 0 3.364607891853666e-06
gene O 0 2.6604939762364666e-07
revealed O 0 1.1355501783327782e-07
a O 0 2.0119943489049774e-09
T1372C O 0 4.2260984400854795e-07
( O 0 1.1630256757655388e-09
F458L O 0 1.754112872731639e-07
) O 0 3.749355492743689e-09
missense O 0 2.891432586693554e-06
mutation O 0 2.1828959688718896e-06
and O 0 1.6602642816110347e-08
a O 0 1.0812166095774955e-07
1668 O 0 0.05835261195898056
ACAG O 0 0.0006867152987979352
1669 O 0 9.239756764145568e-06
splice O 0 1.5140593859541696e-05
site O 0 1.1425844377299654e-06
mutation O 0 1.3469993064063601e-05
. O 0 5.418148134594958e-07

After O 0 4.782867790709133e-08
initial O 0 1.2437271657006477e-08
treatment O 0 8.501500836644027e-09
with O 0 8.550050251132646e-11
intravenous O 0 1.4357870448122867e-08
glucose O 0 4.304041567593231e-07
and O 0 7.73611064097679e-10
carnitine O 0 9.961489411125513e-08
, O 0 1.227535156855808e-10
the O 0 4.639696613017996e-11
patient O 0 2.717678304620108e-09
has O 0 1.7685070075046383e-10
thrived O 0 1.0954375184724086e-08
on O 0 2.9680824464861644e-10
a O 0 3.1988484083811386e-10
low O 0 6.133632268756628e-08
- O 0 3.2672300420699685e-08
fat O 0 2.9079249230790083e-08
diet O 0 3.728190201002235e-09
supplemented O 0 3.882054233628196e-09
with O 0 2.2870950966424886e-10
medium O 0 7.623650049026764e-07
- O 0 1.1222265072774462e-07
chain O 0 2.4793325792416e-07
triglyceride O 0 3.424965768772381e-07
oil O 0 5.083844456521547e-08
and O 0 3.613208343633545e-10
carnitine O 0 2.2656188036762615e-08
and O 0 1.1563274643355825e-10
avoidance O 0 2.3387134451269276e-09
of O 0 1.3060265369180257e-10
fasting O 0 4.0646219190421107e-07
. O 0 3.575894780283306e-08

Her O 0 2.596054764580913e-05
ventricular O 0 3.396902320673689e-05
hypertrophy O 0 1.0527604899834841e-05
resolved O 0 1.7585348643933685e-07
significantly O 0 2.0841744330368783e-08
over O 0 3.0012367591147893e-10
1 O 0 3.6561831340264916e-10
year O 0 4.296146494109365e-10
, O 0 1.3910955720675133e-11
and O 0 2.966513146240857e-11
cognitively O 0 4.254276930737433e-09
, O 0 3.129851933181271e-11
she O 0 4.169670830833638e-08
is O 0 1.8370412829815663e-11
in O 0 1.8766425913252505e-11
the O 0 3.6626028598885085e-11
superior O 0 3.8212344399823905e-09
range O 0 2.8238047455886317e-09
for O 0 4.965712840920844e-10
age O 0 2.2895417117752004e-08
. O 0 3.534382742031994e-08

Clinical O 0 9.976499313779641e-06
recognition O 0 2.7330150942361797e-07
of O 0 5.7415107335145876e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.6779536093913805e-10
important O 0 5.0872320245254343e-11
because O 0 9.242692028399446e-11
it O 0 1.2455010113543441e-11
is O 0 2.6285946076037847e-12
one O 0 3.6163346622819503e-12
of O 0 5.287095088991889e-13
the O 0 1.004743510613082e-11
few O 0 1.7053310985559733e-09
directly O 0 2.3892077649634302e-08
treatable O 0 0.00030051605426706374
causes O 0 2.69470401548233e-09
of O 0 4.157738320298421e-10
cardiomyopathy B-Disease 1 1.0
in O 0 6.736101454407617e-09
children O 0 1.0980649278735655e-08
. O 0 4.107781226281304e-09
. O 0 4.820481436240698e-08

Cloning O 0 2.9986622962496767e-07
of O 0 2.884291139260142e-10
a O 0 1.8063965601111676e-10
novel O 0 2.9440312410144998e-09
member O 0 3.358207323334028e-10
of O 0 1.1306119235277023e-11
the O 0 6.573608879456572e-10
low O 0 0.00011199076834600419
- O 0 0.007029139902442694
density O 0 7.616804396093357e-07
lipoprotein O 0 6.14794043940492e-05
receptor O 0 5.997863354423316e-06
family O 0 4.2406608713463356e-07
. O 0 2.0356660002107674e-07

A O 0 1.2137262217493117e-07
gene O 0 3.9856627154222224e-07
encoding O 0 1.5854209323151736e-07
a O 0 9.059575312164725e-09
novel O 0 1.7115796424604923e-07
transmembrane O 0 8.856188173922419e-07
protein O 0 1.5186415680545906e-07
was O 0 2.581289404446352e-09
identified O 0 2.266058451994013e-09
by O 0 4.115901716672532e-11
DNA O 0 8.516464866659135e-09
sequence O 0 1.43179357259271e-09
analysis O 0 8.971187681616755e-10
within O 0 7.180841338216837e-11
the O 0 8.143764551604704e-10
insulin B-Disease 1 0.9997993111610413
- I-Disease 1 0.9999884366989136
dependent I-Disease 1 0.9999974966049194
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 5.128528357545292e-08
IDDM B-Disease 0 7.198533239716198e-06
) O 0 4.9690123127277275e-09
locus O 0 5.887416136829415e-07
IDDM4 O 0 7.3362193688808475e-06
on O 0 2.4897671480061945e-08
chromosome O 0 1.6281108401017264e-05
11q13 O 0 2.575977850938216e-05
. O 0 4.619121227733558e-07

Based O 0 1.1038842728794407e-07
on O 0 1.1994566451178912e-09
its O 0 2.8239055538392677e-10
chromosomal O 0 1.7140151612693444e-05
position O 0 9.355271686217748e-06
, O 0 4.729212854659437e-11
this O 0 5.491612373176302e-12
gene O 0 4.3273568062218715e-10
is O 0 1.6676630562595385e-11
a O 0 2.5842623180283297e-11
candidate O 0 2.5894357769118415e-09
for O 0 5.516432449725883e-11
conferring O 0 1.6281580528243467e-08
susceptibility O 0 7.599129503432778e-07
to O 0 2.0198186234665627e-07
diabetes B-Disease 0 0.006905264221131802
. O 0 3.458589503679832e-07

The O 0 9.915686938199997e-09
gene O 0 5.482183595972856e-08
, O 0 1.7063657153926215e-09
termed O 0 1.1323998450052386e-07
low O 0 2.8107701837143395e-06
- O 0 2.4955663320724852e-05
density O 0 4.412597434111376e-07
lipoprotein O 0 2.5315839593531564e-05
receptor O 0 9.491674859418708e-07
related O 0 2.4235159656882388e-08
protein O 0 3.795406300355353e-08
5 O 0 6.364716531592762e-10
( O 0 8.068618689849316e-11
LRP5 O 0 7.539260593603103e-08
) O 0 1.1211765543750474e-10
, O 0 1.5393648161721174e-11
encodes O 0 1.0508865999625527e-09
a O 0 3.035346141100348e-10
protein O 0 4.246493823245601e-09
of O 0 1.7758318426874808e-10
1615 O 0 1.2016950279303273e-07
amino O 0 2.0307869164071235e-08
acids O 0 4.131416098118734e-09
that O 0 4.4837306610590044e-12
contains O 0 8.055098255077553e-12
conserved O 0 1.0912781095440138e-10
modules O 0 2.5542096215858123e-10
which O 0 1.272947459246554e-11
are O 0 2.40176325008723e-12
characteristic O 0 1.550785194703863e-10
of O 0 6.7079232793365584e-12
the O 0 4.83458273414783e-10
low O 0 0.0021474119275808334
- O 0 0.07404536008834839
density O 0 2.4511959964002017e-06
lipoprotein O 0 0.012139121070504189
( O 0 3.959755190408032e-08
LDL O 0 1.202725343318889e-05
) O 0 1.5701328237582857e-08
receptor O 0 2.419899658434588e-07
family O 0 6.809166563925828e-08
. O 0 8.179544863651245e-08

These O 0 7.153194925280104e-09
modules O 0 1.2402117555154746e-08
include O 0 9.180745053072314e-10
a O 0 4.161292421756002e-10
putative O 0 2.7759947229810678e-08
signal O 0 3.923082747547824e-09
peptide O 0 6.4770202534703e-09
for O 0 2.124722620067132e-11
protein O 0 2.0081593332665904e-10
export O 0 8.95573282200246e-10
, O 0 9.68420760250055e-11
four O 0 3.7938391317382525e-10
epidermal O 0 1.7442989985738677e-07
growth O 0 5.068817898745692e-08
factor O 0 3.1674812106530226e-08
( O 0 5.87232651394487e-10
EGF O 0 5.495352866091707e-07
) O 0 2.8997027001764764e-10
repeats O 0 1.260999571428556e-08
with O 0 7.916708955058027e-11
associated O 0 2.6559796584280093e-09
spacer O 0 7.313059313673875e-07
domains O 0 1.46851505178347e-07
, O 0 1.024530016380254e-09
three O 0 3.479532217909309e-09
LDL O 0 1.8343489500693977e-05
- O 0 1.831857275647053e-06
receptor O 0 3.85630073651555e-07
( O 0 6.777208794161993e-10
LDLR O 0 1.0105959091788463e-07
) O 0 2.2897707341318352e-10
repeats O 0 1.0098824887450064e-08
, O 0 1.479397021553197e-10
a O 0 1.5851282786361054e-10
single O 0 5.926655610721809e-09
transmembrane O 0 6.253330298022775e-08
spanning O 0 7.2537660322780084e-09
domain O 0 3.1915082132627504e-08
, O 0 6.504277116903268e-10
and O 0 1.112965608562888e-09
a O 0 2.394329623456315e-09
cytoplasmic O 0 1.4389255511559895e-06
domain O 0 1.3039204986853292e-06
. O 0 2.1252613180422486e-07

The O 0 2.178524027840467e-09
encoded O 0 5.214586984436664e-09
protein O 0 6.493855675415716e-09
has O 0 2.5765364841667804e-10
a O 0 4.3916037473223923e-11
unique O 0 6.389029860720541e-10
organization O 0 1.111603586956278e-09
of O 0 1.2274462002359599e-10
EGF O 0 1.107264097299776e-06
and O 0 7.580738814461085e-10
LDLR O 0 1.5922181262340018e-07
repeats O 0 2.0927986454921665e-08
; O 0 1.822485495850401e-10
therefore O 0 1.8091619868876307e-10
, O 0 5.080047493777329e-11
LRP5 O 0 1.6996143870073865e-07
likely O 0 1.0919136705922483e-09
represents O 0 2.7948083083928488e-11
a O 0 2.037612439886871e-11
new O 0 2.0382820431485982e-10
category O 0 2.6565214472640264e-09
of O 0 1.3385845383517836e-11
the O 0 9.108118703693435e-10
LDLR O 0 1.4976180864323396e-05
family O 0 4.601841396834061e-08
. O 0 7.066139318112619e-08

Both O 0 2.8455572120833494e-08
human O 0 6.268637608997096e-09
and O 0 1.5018983834380606e-09
mouse O 0 5.8094112631579264e-08
LRP5 O 0 8.704944320925279e-07
cDNAs O 0 1.7099138460707763e-07
have O 0 1.1531213761628578e-09
been O 0 5.317868922993796e-10
isolated O 0 1.239712776879287e-08
and O 0 4.0204900519924536e-10
the O 0 2.1340070335829076e-11
encoded O 0 6.355436177329921e-10
mature O 0 8.161631370739997e-10
proteins O 0 1.2737397248052673e-10
are O 0 1.2476171137865144e-11
95 O 0 7.044007044321177e-11
% O 0 2.0073579951040976e-11
identical O 0 8.688210151319709e-10
, O 0 1.257784293384745e-10
indicating O 0 2.0041388548719397e-09
a O 0 5.793802659859182e-10
high O 0 8.936846818130562e-09
degree O 0 8.389788419549404e-09
of O 0 2.643846599981181e-11
evolutionary O 0 3.876364118582387e-09
conservation O 0 1.9578809684617227e-09
. O 0 1.7129724305675609e-09
. O 0 2.282665434449882e-08

The O 0 3.766480460853927e-08
APC B-Disease 0 2.737603495006624e-07
variants O 0 3.0543574780494964e-08
I1307K O 0 6.197948465569425e-08
and O 0 1.7284823572438768e-10
E1317Q O 0 1.2087634004842585e-08
are O 0 7.285261283129785e-11
associated O 0 5.289223725668535e-09
with O 0 0.00020661030430346727
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.576558474880585e-06
but O 0 1.9499440284675984e-08
not O 0 5.013592319080828e-10
always O 0 1.0980371056845684e-09
with O 0 1.8238860075014962e-11
a O 0 2.426121803456027e-10
family O 0 2.6022395349656335e-09
history O 0 3.125745706711314e-08
. O 0 4.407983311693897e-08

Classical O 1 0.823084831237793
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.4263595150841866e-06
FAP B-Disease 0 5.339285507943714e-06
) O 0 2.631166839961452e-09
is O 0 1.0989081172807502e-10
a O 0 7.918283251306946e-10
high O 0 2.3546261218143627e-05
- O 1 0.9998941421508789
penetrance O 1 0.9999735355377197
autosomal B-Disease 1 0.9999898672103882
dominant I-Disease 1 0.9782916307449341
disease I-Disease 0 6.211171239556279e-06
that O 0 6.796596618841022e-11
predisposes O 0 1.2444153263402313e-08
to O 0 1.5933360533737506e-11
hundreds O 0 1.8750003286105432e-11
or O 0 5.82264791937348e-11
thousands O 0 4.3038972386000296e-10
of O 0 1.516140457624715e-08
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.003019776428118348
carcinoma I-Disease 1 1.0
and O 0 3.622354682875084e-08
that O 0 1.1904352503755433e-10
results O 0 1.121996384689794e-09
from O 0 6.201936880723125e-11
truncating O 0 6.274454023014187e-08
mutations O 0 6.239700667265424e-08
in O 0 4.671782960485871e-10
the O 0 1.2488277079114596e-09
APC B-Disease 0 7.613958530328091e-08
gene O 0 3.8617511677330185e-07
. O 0 1.1030761015717871e-07

A O 0 6.164795252061595e-08
variant O 0 6.148250122350873e-07
of O 0 3.3742282301574278e-09
FAP B-Disease 0 1.3155029591871426e-05
is O 0 2.916513324180414e-07
attenuated B-Disease 1 0.7988642454147339
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 1.0
, O 0 2.2487038009444404e-08
which O 0 1.7133645613398585e-09
results O 0 1.0379205273025605e-09
from O 0 8.352465941108278e-11
germ O 0 7.606902272527805e-07
- O 0 2.1432335017834703e-07
line O 0 5.069223973919179e-08
mutations O 0 1.8326520745404196e-08
in O 0 4.242984089075641e-11
the O 0 3.392073427699316e-11
5 O 0 1.0952692919286022e-10
and O 0 1.1721804082931442e-10
3 O 0 1.1344963857240487e-10
regions O 0 3.088437006137923e-10
of O 0 2.4489668973282086e-11
the O 0 6.554941034409012e-10
APC B-Disease 0 8.666636119869509e-08
gene O 0 2.8478223157435423e-07
. O 0 9.109168530585521e-08

Attenuated B-Disease 1 0.9999598264694214
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9990004897117615
have O 0 1.2672274785074933e-08
" O 0 2.3423205597339347e-09
multiple O 0 2.3012627536900254e-07
" O 0 0.22020801901817322
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 4.769453165742732e-10
typically O 0 3.1512858988946846e-10
fewer O 0 1.2966640261513618e-10
than O 0 3.779688020899563e-11
100 O 0 4.170603098985204e-11
) O 0 4.914696427604781e-11
without O 0 1.8999021800247817e-10
the O 0 1.6786674827962145e-10
florid O 0 1.4063060689295526e-06
phenotype O 0 2.7277863523522683e-07
of O 0 3.762125888595591e-10
classical O 0 1.1373991526397731e-07
FAP B-Disease 0 3.406743417144753e-06
. O 0 8.591700151328041e-08

Another O 0 3.522544744782863e-08
group O 0 1.7198448887256745e-08
of O 0 2.811296508087313e-11
patients O 0 1.440943919739368e-09
with O 0 9.166336092936156e-12
multiple O 0 1.4649993218540658e-08
adenomas B-Disease 1 0.8390235900878906
has O 0 2.1628156332553772e-07
no O 0 1.6532325508578083e-09
mutations O 0 1.7729975709812607e-08
in O 0 6.017914638833943e-11
the O 0 2.1207022249392082e-11
APC B-Disease 0 7.840495475086584e-10
gene O 0 1.2462293419446269e-09
, O 0 7.157335835117351e-11
and O 0 7.019864550761312e-11
their O 0 3.5084396499129866e-10
phenotype O 0 6.976546984560628e-08
probably O 0 5.44242384492577e-09
results O 0 8.400929396579215e-10
from O 0 1.750117585574973e-11
variation O 0 9.527146849208634e-10
at O 0 5.985270057351499e-10
a O 0 1.210120892380928e-10
locus O 0 5.701700089844053e-08
, O 0 2.2849282188541764e-10
or O 0 3.9487021985529225e-10
loci O 0 5.22452259232864e-09
, O 0 7.181526207045152e-11
elsewhere O 0 3.77660036576799e-09
in O 0 1.7127266271899089e-10
the O 0 3.237499990316195e-10
genome O 0 7.289970227475351e-08
. O 0 1.2607860355728917e-07

Recently O 0 1.7566032965987688e-06
, O 0 8.171101573140049e-10
however O 0 3.349494848148282e-10
, O 0 4.2415196355172213e-11
a O 0 2.4451082825116544e-10
missense O 0 5.682553023689252e-07
variant O 0 3.374600510142045e-07
of O 0 4.1211592471945835e-10
APC B-Disease 0 4.641420758844106e-08
( O 0 2.6153595955591413e-10
I1307K O 0 3.937410397725216e-08
) O 0 3.619823329970018e-10
was O 0 1.9595612632539172e-10
described O 0 8.181327143530481e-11
that O 0 7.137074785334985e-12
confers O 0 3.3703481672198166e-10
an O 0 1.7372202634757805e-11
increased O 0 2.946165755801644e-09
risk O 0 3.5275579648441635e-06
of O 0 3.895276677212678e-06
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.1929474075245139e-09
including O 0 1.3538448140337778e-10
multiple O 0 1.3508026697195419e-08
adenomas B-Disease 0 7.683664443902671e-05
, O 0 1.0151174345551794e-09
in O 0 4.933014441377281e-09
Ashkenazim O 0 4.0181155782192945e-05
. O 0 3.1971137559594354e-07

We O 0 1.0192410826448395e-07
have O 0 2.48728232454809e-10
studied O 0 5.313285922348143e-10
a O 0 1.276653002063588e-11
set O 0 4.145525589471788e-11
of O 0 5.57502958728473e-12
164 O 0 1.2807614968579628e-09
patients O 0 2.5902853195702846e-09
with O 0 4.940564068967035e-10
multiple O 1 0.9998373985290527
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 5.343936663848581e-06
/ I-Disease 0 2.051377305178903e-05
or I-Disease 0 2.8695608307316434e-06
carcinoma I-Disease 1 1.0
and O 0 8.042663779406212e-08
analyzed O 0 9.085082979254366e-07
codons O 0 3.0194121336535318e-06
1263 O 0 3.731703600351466e-06
- O 0 9.147732384917617e-07
1377 O 0 8.120704819702951e-07
( O 0 5.846466089032276e-10
exon O 0 4.562164690469217e-08
15G O 0 3.144034224078496e-07
) O 0 1.9086920932664952e-10
of O 0 4.4849280539382974e-12
the O 0 1.7445085306877495e-11
APC B-Disease 0 1.3027282586008937e-09
gene O 0 1.7219020653769235e-09
for O 0 1.0050468790545608e-10
germ O 0 9.065713015843357e-07
- O 0 3.464399469521595e-07
line O 0 2.1526277294015017e-07
variants O 0 3.00121740792747e-07
. O 0 6.605224456279757e-08

Three O 0 2.38589716872184e-08
patients O 0 5.442364425789492e-08
with O 0 6.657667472875772e-11
the O 0 5.099084002258003e-11
I1307K O 0 4.20951380419865e-08
allele O 0 1.9015029550928375e-08
were O 0 1.7147171182951837e-10
detected O 0 1.3723723268910248e-09
, O 0 2.1358597182552508e-11
each O 0 1.5437083555891462e-10
of O 0 7.166656157409079e-10
Ashkenazi O 0 0.00045860701357014477
descent O 0 2.9217294468253385e-06
. O 0 3.5648227481033246e-07

Four O 0 1.2949519145877275e-07
patients O 0 4.1850165644063964e-07
had O 0 2.460336823162379e-09
a O 0 1.0161035346456515e-09
germ O 0 1.2964971574547235e-05
- O 0 2.1160039977985434e-06
line O 0 2.498397009276232e-07
E1317Q O 0 6.435008117477992e-07
missense O 0 6.686998403893085e-07
variant O 0 6.901846916207433e-08
of O 0 6.545055469819872e-11
APC O 0 2.130987164505882e-09
that O 0 1.0491096186227011e-10
was O 0 4.92408169794345e-10
not O 0 3.922615010587549e-11
present O 0 1.8754832756262552e-11
in O 0 1.8437319379560613e-11
controls O 0 2.4961945843671174e-09
; O 0 8.46515080255017e-11
one O 0 2.2657103623813235e-11
of O 0 4.603760948851399e-13
these O 0 1.0082508612729857e-11
individuals O 0 1.0379180154229672e-10
had O 0 1.2409209215746841e-09
an O 0 1.2445036320918312e-11
unusually O 0 3.7636330163515197e-10
large O 0 3.461730069265201e-10
number O 0 1.1078931105856782e-09
of O 0 1.2395341697502005e-10
metaplastic B-Disease 0 6.925602065166458e-07
polyps I-Disease 0 7.019311851763632e-07
of I-Disease 0 1.0879009498809822e-10
the I-Disease 0 1.3126001396912557e-09
colorectum I-Disease 0 4.5198557927506045e-06
. O 0 6.570154909013581e-08

There O 0 1.9487764291170606e-08
is O 0 6.08943562241393e-10
increasing O 0 3.060092179651974e-10
evidence O 0 1.5815745380010071e-09
that O 0 1.3444960422770436e-10
there O 0 7.03117425393529e-11
exist O 0 2.7006263891848903e-09
germ O 0 3.2202416377913323e-07
- O 0 1.3410781818379292e-08
line O 0 2.249534780673912e-09
variants O 0 9.480993767851942e-10
of O 0 4.73941415626844e-12
the O 0 3.464073125569733e-11
APC B-Disease 0 1.0941694217336817e-09
gene O 0 1.0161577135292532e-09
that O 0 1.435053725157287e-11
predispose O 0 5.046336681857611e-10
to O 0 3.990789036040221e-12
the O 0 2.7472297440406246e-12
development O 0 3.753093669178753e-11
of O 0 1.2735551502274234e-10
multiple O 1 0.9998356103897095
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.0291435569524765
carcinoma I-Disease 1 1.0
, O 0 2.369103802024597e-09
but O 0 4.149594001745527e-10
without O 0 2.0894941332727512e-10
the O 0 1.0798240079878951e-10
florid O 0 4.1726306676537206e-07
phenotype O 0 1.1546982392474092e-07
of O 0 3.1680501971775854e-11
classical O 0 8.992365962967597e-09
FAP B-Disease 0 2.3637655388597523e-08
, O 0 2.273181642920008e-11
and O 0 6.44799404841967e-12
possibly O 0 4.108552734138904e-11
with O 0 3.713911990443908e-12
importance O 0 1.674594130030016e-09
for O 0 6.373291398631409e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.00016442388005089015
in O 0 1.496367474373983e-10
the O 0 7.101095406136793e-11
general O 0 5.20732901243548e-10
population O 0 1.918185610350065e-09
. O 0 3.5237455175973764e-09
. O 0 4.619817417506056e-08

Genomic O 0 7.847159395169001e-06
structure O 0 6.604405200505425e-08
of O 0 1.530369303504031e-10
the O 0 6.199988300537029e-10
human O 0 8.575197085747277e-08
congenital B-Disease 1 0.9999889135360718
chloride I-Disease 1 0.9999796152114868
diarrhea I-Disease 1 1.0
( O 0 5.031200203120534e-07
CLD B-Disease 0 0.003522141370922327
) O 0 6.71084094960861e-08
gene O 0 2.244409870399977e-06
. O 0 3.1399019917444093e-07

Congenital B-Disease 1 0.9999992847442627
chloride I-Disease 1 0.9999963045120239
diarrhea I-Disease 1 1.0
( O 0 1.096035248338012e-06
CLD B-Disease 1 0.987537682056427
) O 0 6.918413930634415e-08
is O 0 2.208512928092432e-09
caused O 0 1.5812157139194483e-09
by O 0 1.1392757570671819e-10
mutations O 0 1.2693288908849354e-07
in O 0 2.323896214351251e-10
a O 0 1.6953802250974093e-10
gene O 0 1.6030810456868494e-08
which O 0 1.981307562459733e-09
encodes O 0 5.67569138354429e-08
an O 0 3.815611826496479e-09
intestinal O 0 1.869011794042308e-05
anion O 0 6.9313588028308e-05
transporter O 0 4.381426697364077e-05
. O 0 5.881562969989318e-07

We O 0 1.7095987914217403e-06
report O 0 2.116829733722625e-08
here O 0 1.0683577633674446e-10
the O 0 1.1374077894810153e-11
complete O 0 1.01992227163894e-10
genomic O 0 7.794277223638346e-09
organization O 0 6.48893661026051e-10
of O 0 1.5295632815881532e-11
the O 0 1.0271631462055453e-10
human O 0 2.1699810837105815e-09
CLD B-Disease 0 2.7494479581946507e-06
gene O 0 2.0576390369342334e-08
which O 0 4.440864898036523e-10
spans O 0 7.45007255886776e-09
approximately O 0 1.8766230791555927e-09
39kb O 0 8.0376770483781e-07
, O 0 7.843082849845473e-10
and O 0 1.2825998041421371e-09
comprises O 0 8.062950307419214e-09
21 O 0 1.1225535168080114e-08
exons O 0 1.9318140402901918e-06
. O 0 1.5239139372624777e-07

All O 0 1.1843017233559294e-07
exon O 0 5.118798071634956e-06
/ O 0 1.0356704933656147e-06
intron O 0 5.585083272308111e-06
boundaries O 0 3.857212504954077e-08
conform O 0 1.2044004904510075e-07
to O 0 3.941741655300035e-10
the O 0 4.864970093443333e-10
GT O 0 2.201243347599302e-07
/ O 0 2.9123884814907797e-07
AG O 1 0.9837227463722229
rule O 0 2.3230437307120155e-07
. O 0 2.1279709017107962e-07

An O 0 2.8069968571742265e-09
analysis O 0 4.7622199517149966e-09
of O 0 2.3225079845423657e-11
the O 0 8.444911436811253e-11
putative O 0 2.5692957095202473e-08
promoter O 0 6.106259320404206e-08
region O 0 1.0790201621091455e-08
sequence O 0 1.3685593103218707e-08
shows O 0 3.840035489588445e-08
a O 0 2.630609730047695e-09
putative O 0 7.047509598123725e-07
TATA O 0 1.2261461961315945e-06
box O 0 2.856552860919237e-08
and O 0 1.9279606799926796e-09
predicts O 0 1.9909380810645416e-08
multiple O 0 4.951396181951395e-09
transcription O 0 7.932681711508849e-08
factor O 0 7.163983894997727e-08
binding O 0 1.2123680903641798e-07
sites O 0 2.2826704082490323e-07
. O 0 1.6706255223652988e-07

The O 0 3.0815851204124556e-08
genomic O 0 7.054624120428343e-07
structure O 0 1.087711609670805e-07
was O 0 3.0121398708615743e-09
determined O 0 6.423768739161062e-10
using O 0 5.922381474121607e-10
DNA O 0 8.999091249961566e-09
from O 0 2.115748895525904e-11
several O 0 1.9767682282734178e-11
sources O 0 1.0068734734858253e-10
including O 0 2.6281596690602704e-11
multiple O 0 2.4956614552706924e-09
large O 0 2.2574489833004918e-08
- O 0 1.3686092643183656e-05
insert O 0 6.031356747371319e-07
libaries O 0 3.8267654645096627e-07
and O 0 3.693619576861096e-10
genomic O 0 4.2256669274820524e-08
DNA O 0 7.805616775158342e-08
from O 0 2.483415251219867e-09
Finnish O 0 9.298240684074699e-07
CLD B-Disease 0 0.00011445565905887634
patients O 0 3.757275521820702e-07
and O 0 5.055645235785278e-09
controls O 0 1.266522644982615e-06
. O 0 3.844187403956312e-07

Exon O 0 1.8186236047768034e-05
- O 0 2.5124229523498798e-06
specific O 0 1.3857086145208086e-08
primers O 0 4.153526447225886e-07
developed O 0 3.4245155600132193e-09
in O 0 5.211171077990073e-11
this O 0 1.3569955922831944e-11
study O 0 1.6815321357555035e-10
will O 0 2.4949688148812044e-11
facilitate O 0 2.1198498512120523e-10
mutation O 0 3.398112236041584e-09
screening O 0 2.7205826480525275e-09
studies O 0 1.0517267057252866e-09
of O 0 5.910166019779117e-12
patients O 0 7.079731245696053e-10
with O 0 5.144607656548672e-11
the O 0 2.911053398335639e-09
disease O 0 4.7069116249076615e-07
. O 0 6.46009539195802e-08

Genomic O 0 6.811778348492226e-06
sequencing O 0 1.4741755194336292e-07
of O 0 2.6383883966474286e-09
a O 0 3.4205225318828525e-08
BAC O 0 8.32587102195248e-06
clone O 0 3.914585704478668e-06
H O 1 0.9999996423721313
_ O 0 2.7650456146943725e-08
RG364P16 O 0 7.77462219048175e-08
revealed O 0 2.665917042676824e-09
the O 0 1.7163130291986128e-11
presence O 0 2.7935304069970357e-10
of O 0 4.202958727578254e-12
another O 0 1.1237712843614744e-10
, O 0 4.496442107537746e-11
highly O 0 1.870161664419001e-10
homologous O 0 1.1388852083626944e-09
gene O 0 4.899968431004709e-09
3 O 0 2.5059920805148295e-10
of O 0 1.1451485593116928e-11
the O 0 2.6070720582360707e-10
CLD B-Disease 0 8.74545946771832e-07
gene O 0 5.0640220905506794e-09
, O 0 4.770833728073853e-11
with O 0 1.2871077467724312e-11
a O 0 4.961383734403135e-11
similar O 0 1.1679963662913906e-09
genomic O 0 7.81813227490602e-08
structure O 0 3.156673145099376e-08
, O 0 8.61967233700689e-11
recently O 0 2.7186581874616422e-09
identified O 0 4.4444599112125616e-09
as O 0 1.1140594002867488e-09
the O 0 1.9467485401492013e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.0509902494959533e-06
( O 0 1.8445498461971965e-09
PDS B-Disease 0 1.522480204130261e-07
) O 0 1.0030479780098744e-09
. O 0 1.8611704399873474e-09
. O 0 5.866108665486536e-08

The O 0 4.2982577497241437e-08
APCI1307K O 0 1.3124629731464665e-05
allele O 0 8.669388989801519e-06
and O 0 3.3586758263481897e-07
cancer B-Disease 0 0.00012197810428915545
risk O 0 6.502720566459175e-07
in O 0 2.8118932182685796e-10
a O 0 3.233926737511439e-10
community O 0 2.7048998596512774e-09
- O 0 4.857575319761054e-08
based O 0 9.916348631122673e-09
study O 0 3.1186755400369748e-09
of O 0 2.7015215064984943e-10
Ashkenazi O 0 1.8596828113004449e-06
Jews O 0 1.373076514710192e-07
. O 0 7.478192998178201e-08

Mutations O 0 1.5128743143577594e-05
in O 0 5.020551974155296e-09
APC O 0 5.767138233636615e-08
are O 0 1.612586952859374e-09
classically O 0 6.5715039454516955e-06
associated O 0 4.278790015632694e-07
with O 0 4.300219188735355e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.0298359711669036e-06
FAP B-Disease 0 2.583880132078775e-06
) O 0 1.010375338950098e-09
, O 0 5.343467682217273e-11
a O 0 9.032671832720496e-10
highly O 0 6.517796919069951e-06
penetrant O 1 0.9999991655349731
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 5.5383054586855e-07
by O 0 1.7201687851908787e-09
multiple O 0 1.6916486345053272e-07
intestinal O 0 1.807778244256042e-05
polyps B-Disease 0 2.910125294874888e-05
and O 0 2.8253008266254653e-10
, O 0 1.59167453522846e-11
without O 0 5.964185395557209e-11
surgical O 0 1.146726269496412e-08
intervention O 0 9.033430115046315e-10
, O 0 1.0854215963529423e-11
the O 0 3.052558900096258e-11
development O 0 2.964688938789095e-09
of O 0 4.090101811016211e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 5.498066002473934e-09
CRC B-Disease 0 2.791137490021356e-07
) O 0 8.25403123627666e-09
. O 0 2.821372646621967e-08

APC B-Disease 0 1.256381074199453e-05
is O 0 6.801495544550562e-08
a O 0 4.28171276212197e-08
tumour O 1 1.0
- O 0 1.302373220823938e-06
suppressor O 0 3.3147406952593883e-07
gene O 0 7.501778753749022e-08
, O 0 3.2837951802200394e-10
and O 0 3.217186794746141e-10
somatic O 0 1.4595305231068778e-07
loss O 0 5.987262596818255e-08
occurs O 0 2.35682371396706e-08
in O 0 4.8259554574769936e-08
tumours B-Disease 1 1.0
. O 0 1.191520937027235e-06

The O 0 7.934891499417063e-08
germline O 0 1.8400360204395838e-05
T O 0 3.579195208658348e-06
- O 0 1.1498433138967812e-07
to O 0 1.2304517404970738e-09
- O 0 1.8889126707222204e-08
A O 0 3.8536054902671424e-10
transversion O 0 1.125531490231424e-08
responsible O 0 2.1658697058057896e-10
for O 0 2.2756239601018358e-11
the O 0 6.883234260346427e-11
APC O 0 8.228848713542902e-09
I1307K O 0 1.894360579512977e-08
allele O 0 5.569999572685447e-09
converts O 0 2.4858937131000403e-09
the O 0 2.0176681506112182e-11
wild O 0 3.741102982957045e-10
- O 0 9.056224214987196e-09
type O 0 9.943522671918004e-10
sequence O 0 7.652036781991001e-10
to O 0 9.793167665694824e-11
a O 0 2.297032147824396e-10
homopolymer O 0 1.5890567510723486e-06
tract O 0 5.134156140229607e-07
( O 0 3.7932817997798907e-10
A8 O 0 1.603174979436517e-07
) O 0 1.318911091452435e-10
that O 0 3.10877816545041e-11
is O 0 1.378736569357386e-10
genetically O 0 2.1091603130685144e-08
unstable O 0 6.4604000726831146e-06
and O 0 8.978278565052733e-09
prone O 0 1.6777623557118204e-07
to O 0 2.9229372255912267e-09
somatic O 0 2.754203478616546e-06
mutation O 0 6.096906872699037e-06
. O 0 1.5891099280906928e-07

The O 0 3.4796997283592646e-08
I1307K O 0 1.5976862641764455e-06
allele O 0 7.361425105045782e-07
was O 0 1.7859356660210324e-08
found O 0 2.7715016948093307e-09
in O 0 1.6032207783567287e-09
6 O 0 1.9655074012803198e-08
. O 0 6.54424141544041e-08

1 O 0 3.1099989428184927e-07
% O 0 5.078928388968507e-09
of O 0 2.9766031306444063e-10
unselected O 0 3.772793570533395e-05
Ashkenazi O 0 2.276282430102583e-05
Jews O 0 7.835434701064514e-08
and O 0 5.742950559550764e-10
higher O 0 1.2538997617994596e-09
proportions O 0 1.9765714398545242e-08
of O 0 4.4589498759961543e-11
Ashkenazim O 0 1.7688047648789507e-07
with O 0 1.2589963793718795e-10
family O 0 1.0536421735096724e-09
or O 0 1.684145822800076e-09
personal O 0 6.130226104517078e-09
histories O 0 1.8688892566842696e-07
of O 0 6.489592752068063e-10
CRC B-Disease 0 2.542687980167102e-07
( O 0 5.810579795095805e-10
ref O 0 3.385389675258921e-07
. O 0 7.092219589388549e-10
2 O 0 1.89327598043576e-09
) O 0 2.4300039758173853e-09
. O 0 1.673330629614611e-08

To O 0 8.89502960177424e-09
evaluate O 0 3.0727459687796e-08
the O 0 5.934907426619063e-11
role O 0 1.4665725300844201e-09
of O 0 1.882180869494654e-11
I1307K O 0 3.51412907662052e-08
in O 0 3.321838359937601e-10
cancer B-Disease 0 2.5014196936012922e-08
, O 0 7.691922793151562e-11
we O 0 6.116441242376425e-10
genotyped O 0 7.719064853972668e-08
5 O 0 9.195957328955728e-10
, O 0 1.3498052675586791e-09
081 O 0 1.95233519661997e-06
Ashkenazi O 0 1.6342863773388672e-06
volunteers O 0 7.700531767795837e-09
in O 0 1.3097534168338143e-10
a O 0 7.961049042215507e-10
community O 0 1.5065815262005344e-08
survey O 0 3.000599235747359e-07
. O 0 1.0368331970767031e-07

Risk O 0 0.0001381975453114137
of O 0 1.7825519948999613e-09
developing O 0 9.724095662022592e-07
colorectal B-Disease 1 1.0
, I-Disease 0 1.0624333413034037e-08
breast I-Disease 0 2.8899916287628002e-05
and I-Disease 0 2.8281705866106677e-09
other I-Disease 0 1.3115990515899512e-09
cancers I-Disease 0 4.2134237446589395e-05
were O 0 2.2853814674039796e-10
compared O 0 6.997623036575362e-10
between O 0 1.35151514979448e-10
genotyped O 0 3.731208551016607e-07
I1307K O 0 7.665775569876132e-08
carriers O 0 6.6373879725745155e-09
and O 0 1.3322276615213013e-10
non O 0 1.158321971672649e-08
- O 0 2.0504264952592166e-08
carriers O 0 2.3498023526968836e-09
and O 0 2.008480187720707e-11
their O 0 2.383005598405319e-11
first O 0 7.924387257496335e-10
- O 0 5.6810307569321594e-08
degree O 0 3.502967160784465e-08
relatives O 0 3.353186528443075e-08
. O 0 2.847202296152318e-08

Sperm O 0 5.9036251514044125e-06
DNA O 0 3.8738389207537693e-07
analysis O 0 5.094775090697112e-08
in O 0 1.428089757560258e-09
a O 0 6.326907886489153e-09
Friedreich B-Disease 0 3.571413617464714e-05
ataxia I-Disease 0 0.00011017410724889487
premutation O 0 0.00045611540554091334
carrier O 0 1.7930951798916794e-06
suggests O 0 4.017566013203577e-08
both O 0 1.0793942406550627e-09
meiotic O 0 2.9451513228195836e-07
and O 0 7.680637792439882e-10
mitotic O 0 3.2259336535389593e-08
expansion O 0 7.361029563668353e-09
in O 0 3.7408315334275244e-10
the O 0 8.82580397654209e-10
FRDA B-Disease 0 3.2172010833164677e-06
gene O 0 7.90534102179663e-07
. O 0 1.1077926842517627e-07

Friedreich B-Disease 0 0.018269972875714302
ataxia I-Disease 0 0.4202084541320801
is O 0 3.7378690649347845e-06
usually O 0 1.437788057501166e-07
caused O 0 1.8407014801269383e-09
by O 0 1.846304532870935e-11
an O 0 1.2998626480742459e-11
expansion O 0 1.5211942816506507e-09
of O 0 9.546204798871472e-11
a O 0 4.449523860472482e-09
GAA O 0 7.959573622429161e-07
trinucleotide O 0 8.884807357389946e-06
repeat O 0 3.5524897157301893e-07
in O 0 5.350241916168841e-10
intron O 0 4.979185632691951e-07
1 O 0 4.005482612257083e-09
of O 0 5.298053315505591e-11
the O 0 1.4540469939205991e-09
FRDA B-Disease 0 3.675489097076934e-06
gene O 0 1.2539262570498977e-06
. O 0 1.2234545465616975e-07

Occasionally O 0 2.8360750548017677e-06
, O 0 2.1675612416061085e-09
a O 0 4.38503566790871e-10
fully O 0 3.779655699531759e-09
expanded O 0 1.844729258237976e-09
allele O 0 2.1066474786834988e-08
has O 0 5.689266280306526e-10
been O 0 1.1129205196303005e-10
found O 0 2.6701838656828514e-11
to O 0 1.1325673905659972e-11
arise O 0 1.1066570576589996e-10
from O 0 2.3754169204553977e-12
a O 0 1.2995825769690494e-11
premutation O 0 6.2081921825551944e-09
of O 0 8.278346758094912e-12
100 O 0 9.580478771420431e-11
or O 0 6.441829847325664e-10
less O 0 2.114996622282206e-09
triplet O 0 8.88667182152858e-06
repeats O 0 5.4103697948448826e-06
. O 0 3.176029679252679e-07

We O 0 4.0831150727171917e-07
have O 0 1.3786900510126543e-09
examined O 0 8.11731126759696e-09
the O 0 5.477827219602105e-11
sperm O 0 4.6009964727034e-09
DNA O 0 8.97964813617591e-09
of O 0 4.9546408642520134e-11
a O 0 2.0139101497562706e-09
premutation O 0 4.101077138329856e-06
carrier O 0 2.315626261406578e-06
. O 0 7.217955300120593e-08

This O 0 2.525446873846704e-08
mans O 0 3.124887939520704e-07
leucocyte O 0 1.1876807093358366e-06
DNA O 0 1.3068282100903161e-07
showed O 0 1.3029699985622756e-08
one O 0 2.669609810990181e-10
normal O 0 2.077834349023533e-09
allele O 0 2.7055564899569617e-08
and O 0 3.021183303530961e-10
one O 0 1.6967939553413913e-10
allele O 0 1.0828384411354364e-08
of O 0 4.619167201513896e-11
approximately O 0 1.1213524553355114e-09
100 O 0 4.161548439185481e-09
repeats O 0 1.5327684650401352e-06
. O 0 1.293786624501081e-07

His O 0 2.020898826060602e-08
sperm O 0 1.7158484411083919e-07
showed O 0 1.0611817202743623e-08
an O 0 3.201709730671354e-11
expanded O 0 2.862479808740659e-09
allele O 0 2.6005489317526553e-08
in O 0 8.22068690897737e-10
a O 0 6.951687558931496e-10
tight O 0 1.1354197582136294e-08
range O 0 7.4560391194467e-10
centering O 0 1.209777611421714e-09
on O 0 2.0741471040697235e-10
a O 0 1.203317168130269e-10
size O 0 2.330226678282088e-09
of O 0 2.393835407676903e-10
approximately O 0 9.041380977237168e-09
320 O 0 1.9827645303394092e-07
trinucleotide O 0 5.497104211826809e-05
repeats O 0 1.1164304851263296e-05
. O 0 3.939119608276087e-07

His O 0 1.0784321347045989e-07
affected O 0 1.3478383209530875e-07
son O 0 1.5329526092955348e-07
has O 0 5.9817928388383734e-09
repeat O 0 6.785207773418733e-08
sizes O 0 5.517998502568844e-08
of O 0 1.7156069620494208e-10
1040 O 0 7.077739638816638e-08
and O 0 2.516943542474337e-09
540 O 0 8.421343977715878e-08
. O 0 6.537977981224685e-08

These O 0 6.0329758966304325e-09
data O 0 4.1505696657395674e-09
suggest O 0 4.7504262745690085e-09
that O 0 1.9057335570726863e-11
expansion O 0 2.781901931037112e-10
occurs O 0 1.0625113289197685e-10
in O 0 1.0567022951102345e-11
two O 0 1.3568662686480604e-11
stages O 0 9.761023100907096e-10
, O 0 1.2837488017058973e-11
the O 0 5.674424471968642e-12
first O 0 6.199725455235949e-11
during O 0 8.197135331622363e-11
meiosis O 0 1.1409942990425748e-09
followed O 0 1.0522218513164816e-10
by O 0 2.218009109711261e-11
a O 0 2.647122521182155e-10
second O 0 3.904777834407014e-09
mitotic O 0 3.45051461181356e-07
expansion O 0 3.444790195317182e-07
. O 0 1.8849020477773593e-07

We O 0 2.62611507650945e-07
also O 0 9.419744984029421e-10
show O 0 2.2028840973575825e-09
that O 0 2.14732173015042e-11
in O 0 6.671061706514658e-12
all O 0 5.140171708412078e-12
informative O 0 1.0711046494193965e-09
carrier O 0 2.2982078462518984e-09
father O 0 2.3784160751993966e-10
to O 0 5.038437722593159e-11
affected O 0 1.7668078111654495e-10
child O 0 4.898134675634935e-10
transmissions O 0 6.900132909493095e-09
, O 0 2.4410156188037213e-11
with O 0 2.3801108653409564e-12
the O 0 3.7691247692372976e-12
notable O 0 2.872257154340474e-10
exception O 0 5.121162383048272e-10
of O 0 2.153505672397582e-12
the O 0 2.7183182788048654e-11
premutation O 0 1.0456390242552516e-07
carrier O 0 5.100080802122875e-09
, O 0 1.2381489063184592e-11
the O 0 9.791015220805832e-12
expansion O 0 1.590383491567593e-09
size O 0 5.57209300922068e-09
decreases O 0 4.594623348452842e-08
. O 0 4.150941812497422e-09
. O 0 3.0974604214861756e-08

The O 0 2.3363650569763195e-08
R496H O 0 9.870975645753788e-07
mutation O 0 1.3627173700569983e-07
of O 0 1.857268505656151e-10
arylsulfatase O 0 3.444366711846669e-07
A O 0 3.0997635569463e-09
does O 0 6.067957514233058e-08
not O 0 3.9627096271033224e-08
cause O 0 5.662520834448515e-07
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999992847442627
. O 0 3.3227208859898383e-06

Deficiency B-Disease 1 0.9994505047798157
of I-Disease 0 7.085300346432177e-09
arylsulfatase I-Disease 0 1.3067877262074035e-05
A I-Disease 0 2.3086213829515145e-08
( O 0 5.303832040226553e-09
ARSA O 0 4.322461973060854e-05
) O 0 6.149713183134509e-09
enzyme O 0 1.8385186706382228e-07
activity O 0 6.079762329136429e-07
causes O 0 3.245035486543202e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 9.067788369065966e-07
MLD B-Disease 1 0.9999986886978149
) O 0 8.705104193040825e-08
. O 0 9.277074752844783e-08

A O 0 3.656647251659706e-08
number O 0 6.914598671414751e-09
of O 0 8.417144758965378e-10
ARSA O 0 2.50821904046461e-05
gene O 0 1.6175108896732127e-07
mutations O 0 2.886226297960093e-07
responsible O 0 1.4398842118623634e-08
for O 0 5.0395865258678896e-09
MLD B-Disease 1 1.0
have O 0 1.4196335662575166e-08
been O 0 5.387663204459159e-09
identified O 0 6.39635118204751e-08
. O 0 5.314082329732628e-08

Recently O 0 1.4575862223864533e-06
, O 0 9.249927490628806e-10
the O 0 1.2205962629519007e-10
R496H O 0 7.777009614073904e-08
mutation O 0 1.5561440136480087e-08
of O 0 2.4598463890801447e-11
ARSA O 0 1.462271256968961e-06
was O 0 2.294199413777065e-10
proposed O 0 6.018856246736703e-11
to O 0 1.8688413663814352e-11
be O 0 6.054561019208649e-11
a O 0 7.696046577798654e-11
cause O 0 1.8427424031131068e-09
of O 0 1.507236002673551e-09
MLD B-Disease 1 1.0
( O 0 1.9794756944691017e-09
Draghia O 0 1.960801228051423e-07
et O 0 1.353826206695885e-07
al O 0 3.397888576728292e-06
. O 0 4.825409849473772e-09
, O 0 7.107264221595244e-10
1997 O 0 1.538389859945255e-08
) O 0 2.241546948056339e-09
. O 0 1.9112295746026575e-08

We O 0 1.4160994510348246e-07
have O 0 7.635562182528588e-10
investigated O 0 3.436843698523262e-09
the O 0 5.437365488414336e-11
R496H O 0 4.9129980084217095e-08
mutation O 0 4.5655221825313674e-09
and O 0 6.784681150229233e-11
found O 0 7.957659531321326e-11
this O 0 1.630399287799733e-11
mutation O 0 1.5380779982976378e-09
at O 0 1.33286826020651e-10
a O 0 3.651129051873703e-11
relatively O 0 2.435789347998707e-10
high O 0 9.549578905421185e-10
frequency O 0 7.982248639848422e-09
in O 0 4.5904405276964155e-10
an O 0 9.994800820312122e-11
African O 0 5.647749490300669e-10
American O 0 1.7482844061333935e-09
population O 0 2.7687740988824316e-10
( O 0 3.8358056314580224e-11
f O 0 6.641946992402836e-09
= O 0 1.2301097918054893e-08
0 O 0 1.2824040718228957e-09
. O 0 5.463492436241779e-10
09 O 0 9.144050849840824e-09
, O 0 2.262162124289091e-10
n O 0 5.603194708214687e-08
= O 0 9.021024283129009e-08
61 O 0 9.280327617489093e-09
subjects O 0 3.3938778898345845e-08
) O 0 4.619171711794934e-09
. O 0 2.1892470059015068e-08

The O 0 1.3355051464714052e-07
ARSA O 0 4.792681647813879e-05
enzyme O 0 2.0492190344612027e-07
activity O 0 1.0762165381095201e-08
in O 0 7.072682717268464e-11
subjects O 0 8.52027837172642e-10
with O 0 2.0298812977714853e-11
and O 0 1.4636682144075763e-10
without O 0 8.918907279387156e-11
the O 0 1.3052140965252867e-11
R496H O 0 2.4260225828243165e-08
mutation O 0 6.255929108078817e-09
was O 0 6.089690973709594e-10
determined O 0 1.3169585422190266e-09
and O 0 1.476175293113613e-10
found O 0 1.9785875715605528e-10
to O 0 1.2983641939356971e-10
be O 0 9.476889273329903e-10
normal O 0 2.3522519043694956e-08
. O 0 6.915920636174633e-08

It O 0 4.112094487140894e-08
is O 0 7.542115820768913e-10
therefore O 0 2.0022082602988434e-10
concluded O 0 5.413123282949073e-10
that O 0 1.6093558777297012e-11
the O 0 5.257174209849502e-11
R496H O 0 4.1520682003692855e-08
mutation O 0 1.3840629975447882e-08
of O 0 5.871831493253765e-11
ARSA O 0 2.470293793521705e-06
does O 0 3.4862417397363288e-09
not O 0 1.0064088451500197e-10
negatively O 0 2.830478906812317e-10
influence O 0 3.473880627602455e-10
the O 0 3.29340270333045e-11
activity O 0 2.3354638223338497e-09
of O 0 6.469247360030295e-11
ARSA O 0 7.720021130808163e-06
and O 0 6.790186191096836e-10
is O 0 1.7057628920458257e-10
not O 0 5.598734253986493e-10
a O 0 9.30971744139697e-10
cause O 0 2.9051308914063156e-08
of O 0 9.962344904579368e-08
MLD B-Disease 1 0.9999992847442627

Down O 0 3.797155159190879e-06
- O 0 1.5977260545696481e-06
regulation O 0 7.59275593509301e-08
of O 0 1.6355027332437544e-09
transmembrane O 0 1.423784624421387e-06
carbonic O 0 1.0432826456963085e-05
anhydrases O 0 1.371317557641305e-05
in O 0 8.143290841644557e-08
renal B-Disease 0 0.05275924503803253
cell I-Disease 1 0.9953727126121521
carcinoma I-Disease 1 1.0
cell O 0 0.030284808948636055
lines O 0 1.9753245794618124e-07
by O 0 6.630767046544861e-10
wild O 0 5.921890533500118e-08
- O 0 0.33336031436920166
type O 1 0.9484722018241882
von B-Disease 1 0.9999247789382935
Hippel I-Disease 1 0.9987161159515381
- I-Disease 1 0.829832136631012
Lindau I-Disease 1 0.8179259896278381
transgenes O 0 0.0009035501279868186
. O 0 3.2625960102450335e-06

To O 0 7.965294201994766e-08
discover O 0 3.691081360557291e-07
genes O 0 9.121930588662508e-08
involved O 0 4.194846425775722e-08
in O 0 4.5483933064360826e-08
von B-Disease 1 0.999976634979248
Hippel I-Disease 1 0.9999951124191284
- I-Disease 1 0.9999943971633911
Lindau I-Disease 1 0.9999899864196777
( O 0 9.711633452980095e-08
VHL B-Disease 0 2.4865861632861197e-05
) O 0 1.423920892307251e-08
- O 0 3.101457082266279e-07
mediated O 0 5.036389438828337e-07
carcinogenesis O 0 1.5178322883002693e-06
, O 0 1.0480941670110155e-09
we O 0 1.44027900716992e-09
used O 0 4.907762374273261e-08
renal B-Disease 0 7.984429248608649e-05
cell I-Disease 1 0.977287769317627
carcinoma I-Disease 1 1.0
cell O 1 0.9671430587768555
lines O 0 1.638364301470574e-05
stably O 0 2.7876255899172975e-06
transfected O 0 7.83217558364413e-07
with O 0 6.670686780729795e-10
wild O 0 4.041252310571508e-08
- O 0 2.1404735889518633e-05
type O 0 4.4685886678053066e-05
VHL O 0 0.0007302789017558098
- O 0 7.373886091954773e-06
expressing O 0 4.652939651350607e-07
transgenes O 0 2.625122942845337e-05
. O 0 4.15890525573559e-07

Large O 0 7.080682280502515e-07
- O 0 5.366034656617558e-06
scale O 0 1.569907368548229e-07
RNA O 0 3.031120243690566e-08
differential O 0 7.133465818043305e-09
display O 0 1.6189755092099745e-09
technology O 0 4.463106328955746e-09
applied O 0 1.802700877462371e-09
to O 0 3.371420156939031e-11
these O 0 5.254297344436942e-11
cell O 0 8.070351498190576e-09
lines O 0 1.6199432906205402e-08
identified O 0 3.4494924694428164e-09
several O 0 2.6250851492548577e-10
differentially O 0 3.263436809675113e-08
expressed O 0 2.747426453009183e-10
genes O 0 2.206054450226702e-09
, O 0 6.129261681531162e-11
including O 0 1.02446502669995e-10
an O 0 3.2125815896399956e-10
alpha O 0 1.5009175058366964e-07
carbonic O 0 5.15879310114542e-06
anhydrase O 0 3.270109573350055e-06
gene O 0 4.5817154159522033e-07
, O 0 1.0445383225032856e-08
termed O 0 6.339110427688865e-07
CA12 O 0 5.6172910262830555e-05
. O 0 4.3772689650722896e-07

The O 0 2.0282667989590664e-08
deduced O 0 5.2246747372919344e-08
protein O 0 3.957050687120045e-09
sequence O 0 3.5694602829039468e-09
was O 0 3.4095759549046534e-10
classified O 0 1.0502914093990512e-09
as O 0 6.985657885483221e-11
a O 0 6.612916464421303e-11
one O 0 2.519547015467083e-09
- O 0 9.873508588498225e-07
pass O 0 2.9696256120814724e-08
transmembrane O 0 3.916072728316067e-07
CA O 0 5.6415103699691826e-08
possessing O 0 2.72676481394285e-09
an O 0 1.790890075126228e-10
apparently O 0 2.277829125318931e-08
intact O 0 1.4592293595683259e-08
catalytic O 0 1.0638588676670224e-08
domain O 0 4.647664031409704e-09
in O 0 5.432154170925685e-10
the O 0 8.687314756450348e-10
extracellular O 0 4.6162855937836866e-07
CA O 0 1.1276842997176573e-05
module O 0 1.3905304285799502e-07
. O 0 3.7336146618827115e-08

Reintroduced O 0 3.0731384867976885e-06
wild O 0 9.033349215314956e-07
- O 0 1.353238712908933e-05
type O 0 1.8267998029841692e-06
VHL B-Disease 0 1.119469106924953e-05
strongly O 0 2.1772374125816896e-08
inhibited O 0 3.18178337010977e-08
the O 0 1.0472823303020462e-10
overexpression O 0 4.411866871834036e-09
of O 0 1.1675742837835568e-11
the O 0 4.9403165586214826e-11
CA12 O 0 7.594174888936323e-08
gene O 0 7.86209319869613e-09
in O 0 3.1287372692645476e-10
the O 0 1.4428416239553599e-09
parental O 0 3.692774043884128e-05
renal B-Disease 1 0.6036455035209656
cell I-Disease 1 0.9995063543319702
carcinoma I-Disease 1 1.0
cell O 1 0.9620890021324158
lines O 0 0.003245278727263212
. O 0 1.1465444913483225e-06

Similar O 0 4.979716905495479e-08
results O 0 4.4878124327851765e-08
were O 0 2.0489700214287865e-10
obtained O 0 1.952160877394249e-09
with O 0 4.08233197246588e-10
CA9 O 0 1.3100944670441095e-05
, O 0 2.0138900269639493e-10
encoding O 0 6.0703277959817115e-09
another O 0 6.64122490334762e-09
transmembrane O 0 4.422849542606855e-06
CA O 0 1.940222500707023e-05
with O 0 1.0803699601602545e-10
an O 0 5.712187389761425e-10
intact O 0 3.379647637302696e-07
catalytic O 0 5.595381367129448e-07
domain O 0 8.126266948238481e-07
. O 0 1.7561315246439335e-07

Although O 0 5.595547847292437e-08
both O 0 1.1437396585378679e-09
domains O 0 3.934210290879037e-09
of O 0 4.483972221303034e-11
the O 0 2.9922972433205075e-10
VHL B-Disease 0 3.2902096336329123e-07
protein O 0 1.8720720529330492e-09
contribute O 0 1.0612615647387358e-10
to O 0 3.0678282830765014e-11
regulation O 0 2.7878349628807086e-10
of O 0 1.488081706468858e-11
CA12 O 0 6.674969199593761e-08
expression O 0 8.78254635683362e-10
, O 0 3.5338246218152847e-11
the O 0 5.4133166699221746e-11
elongin O 0 5.467877173259694e-08
binding O 0 6.9764110044445715e-09
domain O 0 2.0044380377726156e-08
alone O 0 1.8036233839779925e-08
could O 0 7.400079216068889e-09
effectively O 0 7.792198886136248e-08
regulate O 0 9.262511184715549e-07
CA9 O 0 6.850186036899686e-05
expression O 0 3.1873170769358694e-07
. O 0 2.4679573584762693e-07

We O 0 8.972937735052255e-07
mapped O 0 4.839998837269377e-06
CA12 O 0 2.72399811365176e-05
and O 0 5.6948415760871285e-08
CA9 O 0 4.9289166781818494e-05
loci O 0 3.078477845974703e-07
to O 0 3.185582908571405e-09
chromosome O 0 3.9123921169448295e-07
bands O 0 3.8143190295159e-07
15q22 O 0 1.8255615259477054e-06
and O 0 2.212325433958995e-08
17q21 O 0 5.189345756662078e-06
. O 0 1.0766768809844507e-07

2 O 0 8.659778671926688e-08
respectively O 0 7.194764339857329e-09
, O 0 1.2564391194125335e-10
regions O 0 2.9015743141513894e-09
prone O 0 4.069461922995288e-08
to O 0 1.0012163320638479e-10
amplification O 0 9.327354000276955e-09
in O 0 7.515259248247474e-11
some O 0 1.9786516869402249e-10
human O 0 1.9523517025277215e-08
cancers B-Disease 0 0.000547282921615988
. O 0 6.058878199155515e-08

Additional O 0 8.24499934992673e-09
experiments O 0 9.500404019036068e-09
are O 0 1.46486087149178e-10
needed O 0 1.328259446875535e-10
to O 0 1.0133617903140824e-11
define O 0 9.883829310552983e-10
the O 0 2.663769378685732e-11
role O 0 5.365451194450088e-09
of O 0 1.8529024148339346e-10
CA O 0 1.9293929653940722e-06
IX O 0 5.635315858398826e-08
and O 0 7.392602530131853e-09
CA O 0 4.7636032007858375e-08
XII O 0 3.426371186776578e-09
enzymes O 0 6.229349258646266e-10
in O 0 1.107684863971281e-11
the O 0 1.8483549760195395e-11
regulation O 0 2.15394341251951e-10
of O 0 1.4224230300563523e-11
pH O 0 1.273317895567061e-09
in O 0 2.961125789013863e-11
the O 0 2.8063195864347357e-11
extracellular O 0 3.6258369640052024e-09
microenvironment O 0 6.671024266324821e-08
and O 0 2.2390589382581538e-10
its O 0 2.8952704123064166e-10
potential O 0 9.240533671572848e-09
impact O 0 1.2756472322905665e-08
on O 0 5.734908103960379e-09
cancer B-Disease 0 2.7582331085795886e-07
cell O 0 2.8123420747760974e-07
growth O 0 2.3921245428937254e-07
. O 0 6.059455870399688e-08

A O 0 2.8972621635148244e-08
gene O 0 1.225402144200416e-07
encoding O 0 8.278883001366921e-08
a O 0 5.64794566670912e-09
transmembrane O 0 8.461498879341889e-08
protein O 0 8.137619467163404e-09
is O 0 9.782023108195759e-11
mutated O 0 1.6132521096778873e-08
in O 0 9.264936040587202e-10
patients O 0 8.807582929648561e-08
with O 0 1.6462877283629496e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 3.1803929232410155e-06
optic B-Disease 1 0.9999970197677612
atrophy I-Disease 1 0.999862551689148
( O 0 5.0171562179457396e-05
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 2.5049484975170344e-07
. O 0 1.1169539249067384e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.413234364619711e-06
WFS B-Disease 0 0.00582386227324605
; O 0 7.30827736106221e-08
OMIM O 0 3.78631339117419e-05
222300 O 0 2.748249983142159e-07
) O 0 3.2089317314465404e-10
is O 0 1.6209490694141238e-10
an O 0 1.4411802862213108e-09
autosomal B-Disease 1 0.9999943971633911
recessive I-Disease 1 0.9999960660934448
neurodegenerative I-Disease 1 0.9998811483383179
disorder I-Disease 1 0.9999212026596069
defined O 0 4.242820494937405e-08
by O 0 1.0310501341592726e-09
young O 0 2.721913574532664e-07
- O 0 1.674571103649214e-05
onset O 0 0.0022631739266216755
non O 0 0.05206558480858803
- O 0 0.0013371749082580209
immune O 0 0.0003036413691006601
insulin B-Disease 1 0.9999217987060547
- I-Disease 1 0.9961270689964294
dependent I-Disease 1 0.9783745408058167
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 1.2307779684306297e-07
progressive O 0 8.949556331572239e-07
optic B-Disease 1 0.9920326471328735
atrophy I-Disease 0 0.0012097774306312203
. O 0 1.3997711221236386e-06

Linkage O 0 5.538122877624119e-06
to O 0 1.0190657206976539e-08
markers O 0 1.90873279848347e-07
on O 0 7.3639223607813165e-09
chromosome O 0 4.009389158454724e-06
4p O 0 0.00922543928027153
was O 0 6.859954737592489e-08
confirmed O 0 1.0185372545379323e-08
in O 0 6.271146379965842e-10
five O 0 3.73611319659517e-09
families O 0 1.2532141546728326e-08
. O 0 4.8576680455880705e-08

On O 0 7.034870908029234e-09
the O 0 6.870917723666992e-11
basis O 0 4.533284025942663e-10
of O 0 7.068366725260233e-11
meiotic O 0 5.616547582576459e-07
recombinants O 0 3.0274997698143125e-05
and O 0 5.6740788068054826e-08
disease O 0 4.711114911515324e-07
- O 0 3.541056798894715e-07
associated O 0 7.443541250040653e-08
haplotypes O 0 9.201112334267236e-07
, O 0 8.958755959298514e-10
the O 0 4.737313319402858e-10
WFS B-Disease 0 2.3834513740439434e-06
gene O 0 3.441765628053872e-08
was O 0 8.577462629055788e-10
localized O 0 1.2634938428845999e-08
to O 0 9.7062180515195e-10
a O 0 3.734467401983466e-09
BAC O 0 1.7790038100429229e-06
/ O 0 7.646383437531767e-08
P1 O 0 1.8623542530349368e-07
contig O 0 4.236432360471554e-08
of O 0 1.452119414296904e-11
less O 0 7.42038236412057e-11
than O 0 1.2059710174927574e-10
250 O 0 3.2519467119129786e-09
kb O 0 2.491183749953052e-06
. O 0 1.0770548186656015e-07

Mutations O 0 5.4647873184876516e-05
in O 0 7.870164964174364e-09
a O 0 4.747942039529107e-10
novel O 0 8.861230860190972e-09
gene O 0 1.127818336499331e-07
( O 0 1.4034630124726277e-09
WFS1 O 0 2.65975330648871e-07
) O 0 2.2862446658056257e-10
encoding O 0 2.286913325377782e-09
a O 0 6.322175560846688e-10
putative O 0 1.1061943183676703e-07
transmembrane O 0 3.134085702072298e-08
protein O 0 1.452804987422951e-09
were O 0 2.2743308972228427e-11
found O 0 3.7036141514734666e-11
in O 0 9.463856781577462e-12
all O 0 1.3273293922311247e-11
affected O 0 5.3260375276753535e-11
individuals O 0 3.959129898922775e-11
in O 0 7.119023426316318e-11
six O 0 1.1562774071549597e-09
WFS B-Disease 0 5.42560428584693e-07
families O 0 7.271767216154856e-11
, O 0 6.572862479986563e-12
and O 0 1.3997696231282664e-11
these O 0 2.912044563818661e-11
mutations O 0 2.9801778822502456e-09
were O 0 6.762845838892417e-11
associated O 0 2.4260016218136116e-10
with O 0 1.0509321191065624e-10
the O 0 7.284365111104307e-09
disease O 0 2.182061507483013e-06
phenotype O 0 5.002816578780767e-06
. O 0 1.8891671516030328e-07

WFS1 O 0 4.7946974518708885e-05
appears O 0 1.5567175637443142e-07
to O 0 7.520424283313787e-10
function O 0 3.3880227512383954e-09
in O 0 1.5382304319189188e-09
survival O 0 1.6922440693178942e-07
of O 0 2.0873032469115316e-10
islet O 0 6.952370313229039e-06
beta O 0 1.4930013776393025e-06
- O 0 5.391926265474467e-07
cells O 0 4.714971524322209e-08
and O 0 5.92526250287051e-10
neurons O 0 7.214387309772974e-09
. O 0 1.1695613366669022e-09
. O 0 1.6172295502769884e-08

Stable O 0 3.507070005071e-06
interaction O 0 1.8843856253170088e-08
between O 0 6.815371045298946e-10
the O 0 5.5851427649411534e-11
products O 0 1.6292756033209344e-09
of O 0 1.9706321643941926e-11
the O 0 6.343591762991707e-10
BRCA1 O 0 3.3891346902237274e-06
and O 0 2.634758899944245e-08
BRCA2 O 0 7.42842530598864e-06
tumor B-Disease 0 6.282093636400532e-07
suppressor O 0 5.280265895635239e-07
genes O 0 2.864224200038734e-07
in O 0 6.887746373251957e-09
mitotic O 0 1.694210709501931e-06
and O 0 7.406097779494303e-08
meiotic O 0 2.5745119273778982e-05
cells O 0 5.3566268434224185e-06
. O 0 3.662608776267007e-07

BRCA1 O 0 0.00012844701996073127
and O 0 2.8890951853099978e-08
BRCA2 O 0 5.04157469549682e-07
account O 0 2.109436847419488e-09
for O 0 1.4036488985014195e-11
most O 0 1.6647107303757736e-11
cases O 0 1.908379010373551e-10
of O 0 1.232395348965687e-11
familial O 0 2.4733176928748435e-07
, O 0 3.5102068474124337e-10
early O 0 2.5029562422673735e-08
onset O 0 4.527876171778189e-06
breast B-Disease 0 0.3114502429962158
and I-Disease 0 1.1838595810331753e-06
/ I-Disease 0 0.10857398808002472
or I-Disease 1 0.9998346567153931
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.2525697413188226e-11
encode O 0 4.2248970988367773e-10
products O 0 3.134526638248758e-09
that O 0 1.8484502123383706e-11
each O 0 2.9371071547101835e-11
interact O 0 3.7571135091951646e-10
with O 0 2.360298623216295e-10
hRAD51 O 0 1.8100148508892744e-06
. O 0 7.717312655586284e-08

Results O 0 2.0169927950064448e-07
presented O 0 6.477279601568853e-09
here O 0 3.0677010931512427e-10
show O 0 4.355280580625731e-09
that O 0 8.819639463197859e-11
BRCA1 O 0 1.4492155742118484e-07
and O 0 7.140349977952098e-10
BRCA2 O 0 3.3722488979037735e-07
coexist O 0 3.764685274632029e-08
in O 0 2.1292186069832297e-10
a O 0 1.1937867361311305e-10
biochemical O 0 2.151678835105031e-08
complex O 0 1.7625139125954092e-09
and O 0 5.916939160854895e-10
colocalize O 0 1.8077275854011532e-07
in O 0 1.0872044375886958e-09
subnuclear O 0 3.883322960973601e-07
foci O 0 2.3731806209070783e-07
in O 0 2.9757687980414005e-10
somatic O 0 2.6998911550890625e-08
cells O 0 6.9824146464725345e-09
and O 0 1.0692302598869219e-10
on O 0 4.8599402280302684e-11
the O 0 1.7385527045776783e-11
axial O 0 4.48693704413472e-09
elements O 0 8.35991720293805e-09
of O 0 4.830591482374302e-10
developing O 0 6.116610506978759e-08
synaptonemal O 0 1.5720557939857827e-06
complexes O 0 6.391059059751569e-07
. O 0 1.0205307887645176e-07

Like O 0 4.932302090310259e-06
BRCA1 O 0 8.446293941233307e-05
and O 0 8.945787044467579e-08
RAD51 O 0 6.432714872062206e-05
, O 0 4.353172755600099e-08
BRCA2 O 0 9.176407729682978e-06
relocates O 0 1.34549998165312e-06
to O 0 1.5682141807360495e-08
PCNA O 0 1.125073049479397e-05
+ O 0 5.980734130162091e-08
replication O 0 6.102577554401023e-09
sites O 0 4.4338510640784534e-09
following O 0 9.535419120965116e-10
exposure O 0 6.458629542294148e-08
of O 0 1.7380363814822886e-10
S O 0 3.439534737026406e-07
phase O 0 9.136937428877445e-09
cells O 0 6.31571905884698e-09
to O 0 3.105218027155132e-10
hydroxyurea O 0 2.1496897772976808e-07
or O 0 2.8510211969035026e-09
UV O 0 6.584029392797675e-07
irradiation O 0 8.767170811552205e-07
. O 0 6.731352186761796e-08

Thus O 0 3.605948961649119e-07
, O 0 6.2080145468712544e-09
BRCA1 O 0 6.04375884449837e-07
and O 0 2.7753526143925455e-09
BRCA2 O 0 1.0901624136749888e-07
participate O 0 4.5187809050162286e-10
, O 0 2.2735849661281726e-11
together O 0 6.47980627488387e-11
, O 0 3.5879542392702746e-11
in O 0 6.519762507650739e-11
a O 0 1.1832862467642258e-10
pathway O 0 2.6909903194649587e-09
( O 0 1.5791351559713007e-10
s O 0 1.9729066380591576e-08
) O 0 1.54331381008177e-10
associated O 0 2.6895524696257667e-10
with O 0 2.2728346982248127e-11
the O 0 4.609837858660093e-11
activation O 0 3.8433214943900396e-10
of O 0 1.492194215413356e-11
double O 0 1.6246720235812973e-07
- O 0 7.075173925841227e-06
strand O 0 0.008861500769853592
break O 0 3.2415034638688667e-06
repair O 0 6.370806886479841e-07
and O 0 8.359052339201867e-10
/ O 0 9.303864345611146e-09
or O 0 2.980911295580313e-09
homologous O 0 2.8249974093341734e-07
recombination O 0 7.047805752335989e-07
. O 0 1.6043404116317106e-07

Dysfunction O 0 0.00023856238112784922
of O 0 2.2709476521498573e-09
this O 0 3.1420133161930153e-10
pathway O 0 7.2860051325562836e-09
may O 0 5.86424864224e-09
be O 0 4.697585723190123e-11
a O 0 9.837963776959668e-12
general O 0 1.7388247092187115e-11
phenomenon O 0 1.1817801182090193e-09
in O 0 4.2359331320351856e-11
the O 0 2.2147794015436872e-11
majority O 0 2.5250013191424614e-10
of O 0 3.3277957212779485e-12
cases O 0 3.652899926986919e-10
of O 0 1.6250507883786014e-10
hereditary B-Disease 1 0.9982902407646179
breast I-Disease 1 0.9999059438705444
and I-Disease 0 0.0011911471374332905
/ I-Disease 1 0.8021342754364014
or I-Disease 1 0.9996834993362427
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5992268842524027e-08
. O 0 9.36797164285963e-08

A O 0 1.2980973451703903e-07
novel O 0 1.5994532986951526e-07
Arg362Ser O 0 1.6518171150892158e-06
mutation O 0 1.9039332244119578e-07
in O 0 9.125176725355288e-10
the O 0 7.422509273879996e-10
sterol O 0 1.255945062439423e-05
27 O 0 1.0033378572416041e-07
- O 0 2.984639593250904e-07
hydroxylase O 0 8.094925760815386e-06
gene O 0 1.559582472054899e-07
( O 0 6.400910357307055e-10
CYP27 O 0 1.5889992255324614e-07
) O 0 2.794985631826563e-10
: O 0 2.922287758999609e-11
its O 0 7.524021683469329e-11
effects O 0 1.523959802796071e-08
on O 0 6.890081838406559e-10
pre O 0 4.106961171146395e-07
- O 0 1.2857650943942645e-08
mRNA O 0 4.585673618606734e-09
splicing O 0 2.5765046984815854e-08
and O 0 4.5049086683235373e-10
enzyme O 0 7.155268377800894e-09
activity O 0 2.3355140044145628e-08
. O 0 1.3886851668587497e-08

A O 0 4.7299955951984884e-08
novel O 0 7.817684632982491e-08
C O 0 6.420957276986883e-08
to O 0 2.2239154962022667e-10
A O 0 5.787771928389418e-10
mutation O 0 1.3827252232090359e-08
in O 0 2.8727339951295505e-10
the O 0 1.8841115334566894e-09
sterol O 0 5.215189958107658e-05
27 O 0 1.558580322580383e-07
- O 0 3.323160058243957e-07
hydroxylase O 0 9.369002327730414e-06
gene O 0 1.0447220688547532e-07
( O 0 3.0924868221759994e-10
CYP27 O 0 1.3875857973744132e-07
) O 0 2.2484442085968226e-10
was O 0 1.5755489968238834e-10
identified O 0 2.792587550093373e-10
by O 0 2.332955009731741e-11
sequencing O 0 4.148780874402291e-09
amplified O 0 1.4373213730323187e-08
CYP27 O 0 3.231956924309998e-08
gene O 0 3.5403517895105097e-09
products O 0 7.966471371467776e-10
from O 0 1.3836860476845736e-11
a O 0 7.511417876582271e-11
patient O 0 8.316071387071133e-09
with O 0 3.1219846707841725e-09
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 4.3424751794418626e-08
CTX B-Disease 0 9.718089859234169e-05
) O 0 2.692449996288815e-08
. O 0 8.49119814461119e-08

The O 0 3.270365667162878e-08
mutation O 0 3.5861611991094833e-07
changed O 0 2.0416536017364706e-08
the O 0 4.6189138624974646e-10
adrenodoxin O 0 3.973605373630562e-07
cofactor O 0 1.3061827530691517e-07
binding O 0 5.925359403136099e-08
residue O 0 2.401741312496597e-07
362Arg O 0 2.622361137127882e-07
to O 0 1.1574291525207059e-09
362Ser O 0 2.926923059476394e-07
( O 0 6.427678944653792e-10
CGT O 0 1.6465280339161836e-07
362Arg O 0 1.8918554189895076e-07
to O 0 1.2194194543013737e-09
AGT O 0 3.3849053693302267e-07
362Ser O 0 4.9362927967422365e-08
) O 0 9.741898260307025e-11
, O 0 1.132420459487582e-11
and O 0 9.147983759394407e-11
was O 0 1.7475875191408363e-09
responsible O 0 2.7978297456598966e-09
for O 0 4.050781043929419e-09
deficiency O 0 2.7115629563922994e-07
in O 0 1.9178078569659363e-10
the O 0 3.5688593746918684e-10
sterol O 0 3.656735134427436e-05
27 O 0 1.5538541120463378e-08
- O 0 1.8881310737128842e-08
hydroxylase O 0 3.542894546626485e-07
activity O 0 2.7034401384185003e-09
, O 0 4.992567817496685e-11
as O 0 7.584465694376874e-11
confirmed O 0 3.7872166513963634e-10
by O 0 1.4915683271832236e-11
expression O 0 5.94433613443357e-10
of O 0 1.962530138399643e-11
mutant O 0 7.560626791303093e-09
cDNA O 0 2.434737389478414e-08
into O 0 5.269387148842952e-09
COS O 0 1.3837080587109085e-05
- O 0 4.164012921137328e-07
1 O 0 1.1262915933230033e-08
cells O 0 9.212924112489418e-08
. O 0 4.847302292887434e-08

Quantitative O 0 3.4822410270862747e-06
analysis O 0 1.6016834081256093e-07
showed O 0 2.602469173496047e-08
that O 0 1.0010483414424343e-10
the O 0 7.302484311688673e-11
expression O 0 1.8245908117719978e-09
of O 0 3.788146532568426e-11
CYP27 O 0 6.390717288695669e-08
gene O 0 6.703175792210914e-09
mRNA O 0 2.5144870630100513e-09
in O 0 9.74332906023001e-11
the O 0 7.31215712979072e-11
patient O 0 7.260271939202312e-09
represented O 0 1.999869825297651e-09
52 O 0 6.719474043848095e-08
. O 0 1.1348129191901535e-07

5 O 0 1.828185531849158e-07
% O 0 3.6991769647443107e-09
of O 0 3.5155853922441693e-11
the O 0 8.845639776211556e-10
normal O 0 1.0812063777621006e-07
level O 0 1.9174865428794874e-07
. O 0 8.602948753377859e-08

As O 0 3.5678556997709165e-08
the O 0 1.1196704674532043e-09
mutation O 0 1.7499900195616647e-08
occurred O 0 7.709967775326731e-09
at O 0 2.777501284523254e-10
the O 0 4.494435726365431e-11
penultimate O 0 8.040589527524844e-09
nucleotide O 0 2.2106508623664922e-08
of O 0 6.755974252259378e-11
exon O 0 1.498579749181772e-08
6 O 0 7.456991690801829e-10
( O 0 7.629574749756785e-11
- O 0 9.061165151535988e-09
2 O 0 6.221643200632343e-10
position O 0 4.197229230840094e-09
of O 0 2.945488644656713e-11
exon O 0 5.3267566357817486e-08
6 O 0 9.118066301994077e-09
- O 0 3.66489345537957e-08
intron O 0 1.1601557616813807e-06
6 O 0 1.332218224625592e-09
splice O 0 4.562608424407699e-08
site O 0 1.9993700028919648e-09
) O 0 4.507932221953226e-11
of O 0 1.2414446640823806e-12
the O 0 6.9302740629551e-12
gene O 0 1.7491115222867393e-09
, O 0 1.1717533887622977e-10
we O 0 3.956374811098229e-11
hypothesized O 0 1.7533728635665824e-10
that O 0 1.4356205460530624e-11
the O 0 4.1318927446187814e-11
mutation O 0 7.344567620748421e-08
may O 0 1.0051437016045384e-08
partially O 0 3.7469337854645346e-08
affect O 0 1.926402148910711e-09
the O 0 3.830110881231086e-11
normal O 0 4.011841969742136e-10
splicing O 0 1.1110043551809667e-08
efficiency O 0 7.450750572068898e-10
in O 0 3.133818204936745e-11
exon O 0 6.826107679103188e-09
6 O 0 7.044735905736843e-10
and O 0 1.2469705823470179e-10
cause O 0 9.480121548888221e-11
alternative O 0 4.3316014664007696e-10
splicing O 0 1.13050147021454e-08
elsewhere O 0 7.2218493407660844e-09
, O 0 2.892840134105512e-11
which O 0 9.6259590576242e-11
resulted O 0 4.236702932924885e-10
in O 0 2.3098567503154754e-10
decreased O 0 2.4135919929335614e-09
transcript O 0 1.2259429027494662e-08
in O 0 4.4768819207341437e-10
the O 0 1.7247880901294366e-09
patient O 0 1.6543269509838865e-07
. O 0 8.197380907404295e-08

Transfection O 0 8.350599091500044e-05
of O 0 1.0462206656569606e-09
constructed O 0 2.510687835410863e-08
minigenes O 0 2.047771374691365e-07
, O 0 5.931342916820626e-11
with O 0 6.80079473638906e-12
or O 0 2.9748947749652643e-10
without O 0 5.264371161217696e-10
the O 0 5.667601804537625e-11
mutation O 0 6.324591073081365e-09
, O 0 6.415550035665518e-11
into O 0 4.468913572530653e-10
COS O 0 2.4081540686893277e-05
- O 0 1.2843023000641551e-07
1 O 0 1.1395413501702478e-09
cells O 0 1.8089213460470432e-09
confirmed O 0 4.247415474889493e-10
that O 0 6.572474335608813e-12
the O 0 9.887890853321757e-12
mutant O 0 5.830054661259965e-09
minigene O 0 4.0988762606275486e-08
was O 0 3.053620412085678e-10
responsible O 0 2.654721997785714e-10
for O 0 3.303361750806033e-11
a O 0 1.1739210992178783e-10
mRNA O 0 1.7040435729143155e-09
species O 0 1.0748123224768591e-10
alternatively O 0 1.5053139845733199e-09
spliced O 0 1.4311942209133122e-07
at O 0 1.310681341237796e-09
an O 0 1.7032367183311692e-10
activated O 0 9.996640848441984e-09
cryptic O 0 2.5457639551973443e-08
5 O 0 1.0464122901510109e-09
splice O 0 1.2501634216732782e-07
site O 0 1.503558699766927e-08
88 O 0 2.859227743456927e-09
bp O 0 1.5909940032088343e-08
upstream O 0 2.8486116243620074e-10
from O 0 1.4865128225571844e-11
the O 0 1.7054432518981422e-11
3 O 0 1.3168273416130916e-10
end O 0 5.8758670151704e-10
of O 0 7.303905397160193e-11
exon O 0 1.7017440256950067e-07
6 O 0 3.090608657885241e-08
. O 0 5.120513790757286e-08

Our O 0 4.4955402955793033e-08
data O 0 6.218952908199071e-09
suggest O 0 2.4551523036819844e-09
that O 0 1.5041041329100224e-11
the O 0 2.1427760607539703e-11
C O 0 1.3271813648074726e-09
to O 0 1.8698181891707577e-11
A O 0 1.1266235860896145e-10
mutation O 0 2.1409767292368542e-09
at O 0 5.3827175355847245e-11
the O 0 1.2832469462042972e-11
penultimate O 0 4.093171135366447e-09
nucleotide O 0 7.068130969400954e-09
of O 0 1.1116533041310994e-11
exon O 0 2.7342956787634876e-09
6 O 0 1.4881532117705376e-10
of O 0 1.0070605373918573e-12
the O 0 8.686444792627146e-12
CYP27 O 0 2.71820859154559e-08
gene O 0 2.1904862368415934e-09
not O 0 1.3588404013109567e-10
only O 0 4.454172447543314e-11
causes O 0 7.28904547830922e-10
the O 0 8.293511433166145e-10
deficiency B-Disease 0 1.2149577059972216e-06
in I-Disease 0 1.151373510421827e-10
the I-Disease 0 2.8069094271110373e-10
sterol I-Disease 0 2.482259787939256e-06
27 I-Disease 0 6.029456045553161e-09
- I-Disease 0 9.300014092161746e-09
hydroxylase I-Disease 0 1.687221100610259e-07
activity I-Disease 0 1.982498387675946e-09
, O 0 6.310908046147645e-11
but O 0 2.192654807720018e-10
also O 0 6.25735796511151e-10
partially O 0 1.4863591246694341e-08
leads O 0 4.224953442655277e-10
to O 0 6.059656249002288e-11
alternative O 0 4.49475745512018e-09
pre O 0 1.8226843678803561e-07
- O 0 5.971635630430683e-09
mRNA O 0 2.72244116139575e-09
splicing O 0 7.563959236733808e-09
of O 0 3.1923980819970055e-11
the O 0 3.194324527111547e-10
gene O 0 1.747715856481591e-07
. O 0 6.48911608891467e-08

To O 0 1.769291735342904e-08
our O 0 7.366868226554857e-10
knowledge O 0 4.327059544007028e-10
, O 0 1.107349021506332e-11
this O 0 3.383219485814104e-12
is O 0 1.499031974938614e-11
the O 0 7.479747723970753e-12
first O 0 4.097418238035999e-10
report O 0 1.056824294742853e-09
regarding O 0 3.602589893070274e-10
effects O 0 3.4148361915953274e-09
on O 0 2.1965308738547407e-10
pre O 0 7.444563721037412e-08
- O 0 2.328964798792299e-09
mRNA O 0 7.316066641394059e-10
splicing O 0 5.025687421778002e-09
of O 0 5.828956674974739e-12
a O 0 3.441563353745458e-11
mutation O 0 7.212140884504947e-10
at O 0 5.841257338934369e-11
the O 0 2.0829471827910062e-11
- O 0 1.259799233821468e-07
2 O 0 1.814616235051858e-09
position O 0 1.153446760326915e-07
of O 0 1.806864380338169e-11
a O 0 8.063300027671971e-10
5 O 0 1.333797183811214e-09
splice O 0 5.029252747590363e-07
site O 0 3.480417376522382e-07
. O 0 7.643262733836309e-08

ATM O 0 0.00029238994466140866
germline O 0 0.00024857893004082143
mutations O 0 1.1487025403766893e-05
in O 0 2.3616564703843324e-08
classical O 0 0.00018652093422133476
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9994722008705139
in O 0 3.3503717578042824e-09
the O 0 1.609302247018718e-09
Dutch O 0 8.488876119372435e-06
population O 0 3.6689989713067916e-08
. O 0 5.22825338578059e-08

Germline O 0 0.0002731762651819736
mutations O 0 4.655168140743626e-06
in O 0 1.7643939642653095e-09
the O 0 1.0877972134171188e-10
ATM O 0 8.231140213865729e-09
gene O 0 1.3819256849956219e-09
are O 0 5.405565318278294e-12
responsible O 0 7.099497378870723e-11
for O 0 1.35635974674031e-10
the O 0 2.6432664981257403e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.5143001079559326
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.0787942272827422e-07
. O 0 7.53726183688741e-08

In O 0 5.639681432967336e-08
our O 0 3.4166018902936912e-09
study O 0 7.093924336842861e-10
, O 0 5.895273158529335e-11
we O 0 1.0124852345416713e-10
have O 0 2.188450289042354e-11
determined O 0 3.3853594927357733e-10
the O 0 3.4547500277204435e-11
ATM O 0 1.3065935000611262e-08
mutation O 0 2.021985245903579e-09
spectrum O 0 5.975255290557868e-10
in O 0 1.3602459436601322e-10
19 O 0 5.403570924045198e-10
classical O 0 4.080514770521404e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.5146854315826204e-08
, O 0 2.4706410962221925e-12
including O 0 1.339206957134964e-12
some O 0 4.366527538851583e-12
immigrant O 0 1.0170055020353175e-08
populations O 0 7.527973244769726e-10
, O 0 1.1610275241213941e-11
as O 0 1.0046860045298533e-11
well O 0 6.35256083847402e-11
as O 0 1.0769013458755694e-10
12 O 0 1.2561515716491556e-10
of O 0 3.0557396890618094e-11
Dutch O 0 1.7643430965108564e-06
ethnic O 0 6.54868586025259e-08
origin O 0 1.957802311380874e-07
. O 0 8.669032780517227e-08

Both O 0 5.140456593721865e-08
the O 0 2.071084415078417e-09
protein O 0 3.558734817943332e-08
truncation O 0 5.07618096889928e-07
test O 0 1.3786728914055857e-07
( O 0 3.9558112341353535e-10
PTT O 0 4.9408892976998686e-08
) O 0 4.4999771270370914e-11
and O 0 1.7184061465447265e-11
the O 0 1.2893781528577897e-11
restriction O 0 1.0607946743235175e-09
endonuclease O 0 6.043596556537523e-08
fingerprinting O 0 6.990266143702684e-08
( O 0 1.1622490470042379e-10
REF O 0 1.540433203217617e-08
) O 0 1.4352153146490743e-11
method O 0 7.100919158231633e-11
were O 0 1.2535660010026817e-11
used O 0 1.84894127785995e-10
and O 0 3.464958528431872e-11
compared O 0 4.9292098180941935e-11
for O 0 5.736430861574826e-12
their O 0 1.8983835337049726e-11
detection O 0 1.2229411927577871e-09
efficiency O 0 2.788329567238179e-10
, O 0 5.489266593355913e-12
identifying O 0 9.761562669297064e-10
76 O 0 7.560406745099613e-10
% O 0 2.797240043761473e-11
and O 0 8.189336708763761e-11
60 O 0 3.0902991277059755e-10
% O 0 1.1187882564822615e-10
of O 0 5.8653468366920425e-12
the O 0 2.241575813854979e-10
mutations O 0 1.7169008970085997e-07
, O 0 5.777801570516772e-10
respectively O 0 2.085108796734403e-08
. O 0 4.544577691945051e-08

Most O 0 3.021336425490517e-08
patients O 0 1.7888783077069093e-07
were O 0 1.7618945191699709e-10
found O 0 1.2109450941988342e-10
to O 0 1.0180254556013679e-10
be O 0 4.118322627366666e-10
compound O 0 2.3272164639820403e-08
heterozygote O 0 1.6752977899159305e-05
. O 0 1.5563642818960943e-07

Seventeen O 0 4.360620550869498e-06
mutations O 0 1.947225428011734e-06
were O 0 4.4064005777499915e-09
distinct O 0 3.735514564340292e-09
, O 0 2.222092232440076e-10
of O 0 6.463904064779591e-12
which O 0 1.7919869754745577e-10
10 O 0 1.5649527507211047e-10
were O 0 4.709124756807626e-10
not O 0 1.5137645581475567e-09
reported O 0 2.2571388313963325e-08
previously O 0 1.7196096280258644e-07
. O 0 6.518590112136735e-08

Mutations O 0 4.5701319322688505e-05
are O 0 5.468155706012112e-09
small O 0 3.2789586601467136e-09
deletions O 0 2.146772430933197e-07
or O 0 5.184925555568043e-08
point O 0 1.0992136623144688e-07
mutations O 0 2.7052162749896524e-06
frequently O 0 5.643877898364735e-07
affecting O 0 1.6257460799806722e-07
splice O 0 1.0119118087459356e-05
sites O 0 1.8439336599840317e-06
. O 0 4.226686769470689e-07

Moreover O 0 5.771116320829606e-06
, O 0 2.01268246513564e-08
a O 0 8.153855368675522e-09
16 O 0 3.6971545824826535e-08
. O 0 5.144713455251804e-08

7 O 0 2.9779459964629496e-06
- O 0 3.384247747817426e-06
kb O 0 1.4579879916709615e-06
genomic O 0 2.39162034176843e-07
deletion O 0 8.680366647695337e-08
of O 0 3.556279923322414e-11
the O 0 3.2729322724245336e-11
3 O 0 3.243353363657775e-10
end O 0 3.9002429064183275e-10
of O 0 2.4382412321805047e-12
the O 0 3.721811487472637e-12
gene O 0 5.401757374734473e-10
, O 0 3.004362383873804e-11
most O 0 5.896162030838425e-11
likely O 0 7.667903534347431e-10
a O 0 8.270175516633671e-11
result O 0 7.546691049853393e-10
of O 0 3.715321886949008e-12
recombination O 0 3.4706884588509013e-10
between O 0 4.7918821688419655e-11
two O 0 1.865380766519209e-10
LINE O 0 3.486323052470652e-08
elements O 0 1.0157823027157065e-08
, O 0 7.405497881585177e-10
was O 0 4.756401050798331e-09
identified O 0 4.012075294212991e-08
. O 0 4.1519967908243416e-08

The O 0 1.6803533009479565e-09
most O 0 3.0790028859861707e-10
frequently O 0 1.0205595479817475e-08
found O 0 1.1434059254966655e-09
mutation O 0 6.003165964330037e-09
, O 0 3.288996158756774e-11
identified O 0 6.957245890504282e-10
in O 0 3.304212459198652e-11
three O 0 7.148671932188932e-11
unrelated O 0 2.8838208265824505e-08
Turkish O 0 0.014204900711774826
A B-Disease 1 1.0
- I-Disease 1 0.9999747276306152
T I-Disease 1 1.0
individuals O 0 3.7735956026629935e-10
, O 0 1.968611038072332e-11
was O 0 2.0806809053475206e-10
previously O 0 7.446715466485898e-10
described O 0 1.2955343742238057e-10
to O 0 1.9963501338149392e-11
be O 0 7.229931930918809e-11
a O 0 1.5647229345550073e-10
Turkish O 0 5.0084225222235546e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999961853027344
T I-Disease 1 1.0
founder O 0 8.298912916870904e-07
mutation O 0 7.867299700592412e-07
. O 0 6.473898395142896e-08

The O 0 4.521990781825025e-09
presence O 0 2.7233135746485004e-09
of O 0 1.6307163952511416e-11
a O 0 9.745001333660852e-11
founder O 0 9.66098934185311e-09
mutation O 0 1.0215625678711149e-08
among O 0 1.1681004774555248e-10
relatively O 0 9.945110707176852e-11
small O 0 9.786189636429299e-10
ethnic O 0 1.3790247166411973e-08
population O 0 8.500848358572455e-10
groups O 0 5.764108079731045e-10
in O 0 1.0200759681389115e-10
Western O 0 1.7937421548097632e-09
Europe O 0 3.133368764451916e-08
could O 0 3.572005746743656e-10
indicate O 0 2.123876907678124e-10
a O 0 4.52595565192393e-11
high O 0 4.1546863172037263e-10
carrier O 0 1.128346638346045e-09
frequency O 0 7.771026599989739e-10
in O 0 7.199890683651233e-11
such O 0 8.352820102253133e-10
communities O 0 5.002106817642016e-08
. O 0 8.961225006487439e-08

In O 0 6.574041577778189e-08
patients O 0 1.962222881957132e-07
of O 0 3.798654168996052e-10
Dutch O 0 5.3642488637706265e-06
ethnic O 0 7.636410614964007e-09
origin O 0 2.104230034660759e-08
, O 0 1.937551924457992e-10
however O 0 2.886228200882357e-10
, O 0 2.530882448059657e-11
no O 0 5.104065781136313e-11
significant O 0 3.794598801842852e-10
founder O 0 8.732123468746522e-09
effect O 0 2.0346639928447985e-08
could O 0 3.975266782418885e-09
be O 0 5.476858411235241e-10
identified O 0 2.6660201157824304e-08
. O 0 2.882116056923678e-08

The O 0 1.605332933252157e-08
observed O 0 6.491010395848207e-08
genetic O 0 6.910487826417011e-08
heterogeneity O 0 6.084773929160292e-08
including O 0 4.863531799514931e-10
the O 0 2.2547444467058142e-10
relative O 0 3.69134838251739e-08
high O 0 2.405637644642411e-08
percentage O 0 2.5608349574213207e-07
of O 0 7.334058360619622e-11
splice O 0 1.5499726941925474e-05
- O 0 3.882563817114715e-07
site O 0 1.7934146612219592e-08
mutations O 0 7.63126024594385e-08
had O 0 3.0492335323373254e-09
no O 0 2.0785391463551406e-10
reflection O 0 8.453925337548185e-10
on O 0 4.201127501435309e-10
the O 0 2.7735853613819472e-09
phenotype O 0 2.198056108682067e-06
. O 0 1.3870590009901207e-07

All O 0 5.06511632636375e-08
patients O 0 6.411730169020302e-08
manifested O 0 2.7328734830689427e-08
classical O 0 2.335588220603313e-07
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999948740005493
T I-Disease 1 1.0
and O 0 1.2116394998429314e-08
increased O 0 4.4551877742549095e-09
cellular O 0 1.1403034250179189e-07
radioresistant O 0 4.6226469407883997e-07
DNA O 0 2.686321067812969e-07
synthesis O 0 2.1614361855881725e-07
. O 0 8.183727118193929e-08

Determination O 0 5.430014198282151e-07
of O 0 1.4506168488637172e-10
the O 0 6.983406908300793e-11
genomic O 0 6.423098497521096e-09
structure O 0 2.2096717788855358e-09
of O 0 6.6533866090179306e-12
the O 0 2.095579612615417e-11
COL4A4 O 0 1.6946318126542792e-08
gene O 0 2.034375778947606e-09
and O 0 4.720768220778382e-11
of O 0 2.794029937969178e-11
novel O 0 4.442199497134425e-07
mutations O 0 0.0057231467217206955
causing O 0 2.1595256839646026e-05
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 6.378475973178865e-06

Autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.5820407384126156e-07
a O 0 5.919326895309496e-08
progressive O 0 1.0121453669853508e-05
hematuric B-Disease 1 0.9970631003379822
glomerulonephritis I-Disease 1 1.0
characterized O 0 5.830752797919558e-06
by O 0 7.69965495805991e-08
glomerular B-Disease 0 0.19620299339294434
basement I-Disease 1 0.9921669960021973
membrane I-Disease 0 0.13838441669940948
abnormalities I-Disease 1 0.9999964237213135
and O 0 4.8338106850565055e-09
associated O 0 4.741030679156211e-09
with O 0 1.7775160510158372e-10
mutations O 0 4.3829661677818876e-08
in O 0 1.9485328628388032e-10
either O 0 9.088803598622519e-10
the O 0 2.7550406400678185e-10
COL4A3 O 0 3.759354285648442e-07
or O 0 5.317382090197498e-10
the O 0 6.782519684778165e-11
COL4A4 O 0 7.63571463835433e-08
gene O 0 2.7644113664848646e-09
, O 0 1.823531256550659e-11
which O 0 6.098309357494003e-12
encode O 0 2.1922449966460533e-10
the O 0 8.743163831814726e-11
alpha3 O 0 1.809086711546115e-07
and O 0 9.77747660613204e-10
alpha4 O 0 1.2198316881040228e-06
type O 0 9.053357530319772e-07
IV O 0 2.6612147507876216e-07
collagen O 0 2.456503125358722e-07
chains O 0 1.3922995094617363e-06
, O 0 2.79570144812169e-09
respectively O 0 9.891832775110743e-08
. O 0 1.2254945147560647e-07

To O 0 1.16048699538851e-08
date O 0 2.9277989810339022e-08
, O 0 1.9566331888043464e-10
mutation O 0 1.2226589740649274e-09
screening O 0 2.2337791616422464e-09
in O 0 2.5057947036777328e-11
the O 0 4.631285806244723e-12
two O 0 1.80572050367811e-11
genes O 0 1.0314730181093523e-09
has O 0 3.220890665289744e-09
been O 0 5.3874065208958655e-09
hampered O 0 5.918940448879084e-09
by O 0 3.388142197358057e-11
the O 0 9.065582312617337e-11
lack O 0 9.14973319332546e-10
of O 0 4.051441473973405e-11
genomic O 0 3.8281736891576656e-08
structure O 0 2.3256545134131557e-08
information O 0 9.068322981420351e-09
. O 0 4.5360216915923957e-08

We O 0 5.92683932154614e-07
report O 0 6.641060146250766e-09
here O 0 3.3897839396557217e-11
the O 0 3.5515668097424458e-12
complete O 0 1.493156639997828e-11
characterization O 0 1.5558077048893892e-09
of O 0 5.1491796937419565e-12
the O 0 4.087144511721874e-11
48 O 0 3.538486725851442e-10
exons O 0 6.087092607742761e-09
of O 0 8.666486799036033e-12
the O 0 5.3200169963796284e-11
COL4A4 O 0 7.722142214561245e-08
gene O 0 4.81756545767098e-09
, O 0 1.0988285281676724e-10
a O 0 4.035938944157991e-11
comprehensive O 0 7.062427309634245e-10
gene O 0 2.305702739846538e-09
screen O 0 2.566734735864884e-07
, O 0 8.669649026460391e-11
and O 0 3.5867503411779467e-11
the O 0 5.184381136197347e-12
subsequent O 0 2.5269283887574545e-10
detection O 0 1.0732621458231506e-09
of O 0 3.25013085021586e-12
10 O 0 2.098287342489069e-11
novel O 0 4.673262332666184e-10
mutations O 0 6.545461950224762e-09
in O 0 1.1574771002775819e-10
eight O 0 2.2214661221653387e-09
patients O 0 1.1100028274313445e-07
diagnosed O 0 9.443709132028744e-06
with O 0 6.057352663901838e-08
autosomal B-Disease 1 0.9999995231628418
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.0477215255377814e-05

Furthermore O 0 1.67611324286554e-06
, O 0 1.077925837478233e-08
we O 0 1.0984413378878344e-09
identified O 0 2.2160999701981154e-09
a O 0 7.338368107623339e-11
glycine O 0 1.035785146541457e-08
to O 0 1.0595585520078998e-10
alanine O 0 2.0154983459974574e-08
substitution O 0 8.768586412521984e-10
in O 0 5.500735283936464e-11
the O 0 7.651974193167987e-11
collagenous O 0 1.4815027782333345e-07
domain O 0 3.0532607553368507e-09
that O 0 5.7766964822736355e-11
is O 0 3.7616649378735545e-11
apparently O 0 1.383141268185284e-09
silent O 0 1.3341456828186438e-09
in O 0 3.246631782860554e-11
the O 0 3.3272769955905446e-11
heterozygous O 0 1.0992383892016733e-08
carriers O 0 3.010715676765585e-09
, O 0 7.876554269925506e-11
in O 0 3.805717685434473e-10
11 O 0 7.128134527079055e-09
. O 0 3.4506260959688007e-08

5 O 0 1.2698701823410374e-07
% O 0 2.1577479802914468e-09
of O 0 1.4495485541055064e-11
all O 0 7.34749969200088e-11
control O 0 1.935266613628528e-09
individuals O 0 1.603327054455761e-10
, O 0 2.904417331639486e-11
and O 0 3.118910338328895e-11
in O 0 1.8243035554421638e-11
one O 0 1.347736228174412e-10
control O 0 1.34295374820681e-09
individual O 0 1.6382743772691555e-10
homozygous O 0 4.151939236862745e-09
for O 0 1.6202065730719362e-11
this O 0 1.3761408679258125e-10
glycine O 0 1.2871690557858528e-07
substitution O 0 5.497051702718636e-08
. O 0 8.582658495015494e-08

There O 0 4.301464073819261e-08
has O 0 2.6103523786957794e-09
been O 0 6.613828373858155e-10
no O 0 1.0065200756192993e-10
previous O 0 3.3563696266725174e-10
finding O 0 2.1226984059374843e-10
of O 0 1.8938945463981005e-12
a O 0 1.0650937597167509e-11
glycine O 0 2.6486894899591107e-09
substitution O 0 2.2597039517346929e-10
that O 0 3.762152742114999e-11
is O 0 3.3298801216385954e-11
not O 0 1.877086507062753e-11
associated O 0 6.04096078715699e-11
with O 0 6.160316614461925e-12
any O 0 6.937621033209496e-10
obvious O 0 2.874057614121739e-08
phenotype O 0 6.804855701147972e-08
in O 0 6.009475694845889e-10
homozygous O 0 3.523963130191987e-07
individuals O 0 1.803183202753189e-08
. O 0 1.0700151165110583e-07

Founder O 0 1.5044406609376892e-05
BRCA1 O 0 5.923062053625472e-05
and O 0 4.433294975569879e-08
BRCA2 O 0 7.291377642104635e-06
mutations O 0 4.0199196860157826e-07
in O 0 6.6279755017717434e-09
French O 0 2.318794940947555e-06
Canadian O 0 4.8930874072539154e-06
breast B-Disease 1 0.999997615814209
and I-Disease 1 0.9999971389770508
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.218030534910213e-07
. O 0 1.4846568774373736e-07

We O 0 1.6309141415149497e-07
have O 0 8.904276205257133e-10
identified O 0 1.0907645897617613e-09
four O 0 5.2481977097507126e-11
mutations O 0 7.052466388657308e-10
in O 0 5.9610883937355474e-12
each O 0 2.7951547326710013e-11
of O 0 1.74507751998787e-11
the O 0 5.697381233460419e-09
breast B-Disease 1 0.9999092817306519
cancer I-Disease 1 0.9584199786186218
- O 0 2.915433697125991e-06
susceptibility O 0 9.824075277720112e-07
genes O 0 8.345551094635084e-08
, O 0 5.718771567408965e-10
BRCA1 O 0 2.474693303611275e-07
and O 0 1.1221119589066575e-09
BRCA2 O 0 1.8088330477894488e-07
, O 0 1.688519324360982e-10
in O 0 4.3002620908616507e-10
French O 0 4.564275286611519e-07
Canadian O 0 4.750623645577434e-07
breast B-Disease 0 0.061739228665828705
cancer I-Disease 0 0.0011634117690846324
and O 0 5.109658104629489e-06
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.856591052591284e-08
from O 0 3.89137255751848e-09
Quebec O 0 6.397803531399404e-07
. O 0 2.8757364134435193e-07

To O 0 2.927156650400775e-08
identify O 0 1.3053123382178455e-07
founder O 0 4.982738488479299e-08
effects O 0 3.4174905749750906e-07
, O 0 6.899734672494162e-10
we O 0 7.658213507788503e-10
examined O 0 1.0359550550731456e-08
independently O 0 9.602808326292234e-09
ascertained O 0 1.7166586019357055e-07
French O 0 1.131463989167969e-07
Canadian O 0 1.7099960558653038e-08
cancer B-Disease 0 2.3945775140532533e-08
families O 0 9.688697066856378e-11
for O 0 3.940099548710441e-12
the O 0 3.2986883623936647e-12
distribution O 0 1.435377511294078e-10
of O 0 1.799964170767776e-11
these O 0 7.595761797318801e-10
eight O 0 1.1303849412058753e-08
mutations O 0 7.55028224830312e-07
. O 0 4.926811314476254e-08

Mutations O 0 2.5690221718832618e-06
were O 0 3.1567439773283468e-09
found O 0 6.743811065135219e-10
in O 0 1.7677313779440595e-10
41 O 0 1.5139810516373586e-09
of O 0 1.35140176826809e-10
97 O 0 4.1391636784737784e-08
families O 0 2.1444106934609408e-08
. O 0 7.872390739294133e-08

Six O 0 6.485095127573004e-08
of O 0 2.0643195486336197e-10
eight O 0 1.575381491925043e-09
mutations O 0 2.044045999127775e-08
were O 0 2.3367904833371256e-10
observed O 0 1.9954231600394223e-09
at O 0 7.068141072430478e-10
least O 0 6.543011688009415e-10
twice O 0 7.869388696235546e-08
. O 0 1.3601751902569958e-07

The O 0 7.269670021514685e-08
BRCA1 O 0 9.314658200310078e-06
C4446T O 0 1.3643236798088765e-06
mutation O 0 3.1973272029972577e-07
was O 0 2.8113156247400184e-09
the O 0 1.751533466876065e-11
most O 0 9.906149511795803e-11
common O 0 1.350315081971587e-09
mutation O 0 5.612079689853999e-09
found O 0 2.9188132466551053e-10
, O 0 1.2417768202599433e-11
followed O 0 7.094258513973273e-11
by O 0 8.096166098647828e-11
the O 0 4.107154172316996e-09
BRCA2 O 0 2.6295476345694624e-05
8765delAG O 0 4.732274192065233e-06
mutation O 0 5.46505816600984e-06
. O 0 2.0402393374752137e-07

Together O 0 4.079720383742824e-08
, O 0 6.120934314957083e-10
these O 0 5.0092787556854645e-11
mutations O 0 2.0625376961902475e-09
were O 0 1.0850019493968688e-10
found O 0 1.0096561781081093e-10
in O 0 1.1726679349788327e-10
28 O 0 5.813462489179244e-10
of O 0 1.1621486759039179e-11
41 O 0 1.1479357464594386e-09
families O 0 5.506119865605896e-11
identified O 0 9.446012860792052e-10
to O 0 1.1656656195846438e-10
have O 0 4.757569338487144e-10
a O 0 1.475734090483627e-09
mutation O 0 6.416556175281585e-07
. O 0 6.709446154218313e-08

The O 0 1.1270825162057463e-08
odds O 0 4.970622171640571e-07
of O 0 3.2129722493667856e-11
detection O 0 1.5285497312333973e-09
of O 0 8.849798498189454e-12
any O 0 1.2940351568069275e-10
of O 0 9.627753455587751e-12
the O 0 1.3536563536753476e-10
four O 0 3.0095155256759654e-09
BRCA1 O 0 1.078679474630917e-06
mutations O 0 3.007056079695758e-07
was O 0 2.0076022622106393e-08
18 O 0 9.741127016127393e-09
. O 0 4.233742600945334e-08

7x O 0 5.247337685432285e-05
greater O 0 2.348633998394689e-08
if O 0 1.8938828283410203e-09
one O 0 5.983689238542311e-12
or O 0 6.581631507157626e-12
more O 0 1.773917384512158e-12
cases O 0 3.3805285237775706e-09
of O 0 1.492235668365538e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 3.289714722853887e-09
also O 0 2.3181322139631533e-10
present O 0 7.547968500221103e-11
in O 0 2.670047793973396e-10
the O 0 3.6072383968743793e-10
family O 0 3.8259912571447785e-08
. O 0 1.0896427937723274e-07

The O 0 1.0554992435629629e-08
odds O 0 3.859719299725839e-07
of O 0 1.8185609268472902e-11
detection O 0 9.259123467941777e-10
of O 0 3.609932665293858e-12
any O 0 9.196127886967886e-11
of O 0 6.8557815674497036e-12
the O 0 2.3041189789463346e-10
four O 0 6.795670248749275e-09
BRCA2 O 0 3.044469167434727e-06
mutations O 0 4.6831357281007513e-07
was O 0 1.7876566005270433e-08
5 O 0 5.717389672810214e-09
. O 0 4.8029981769559527e-08

3x O 0 1.3748059245699551e-05
greater O 0 1.2888293099422299e-08
if O 0 3.5550018484542534e-09
there O 0 3.795349798330072e-11
were O 0 2.1788126858268697e-11
at O 0 1.1482674186491515e-11
least O 0 4.587372148812108e-12
five O 0 3.6794702701348214e-11
cases O 0 5.251765133884589e-10
of O 0 3.5911401630173145e-10
breast B-Disease 0 0.2142389863729477
cancer I-Disease 0 7.087390258675441e-06
in O 0 3.5132410869387343e-10
the O 0 1.0776600722905982e-09
family O 0 6.67605206672306e-08
. O 0 1.5534503461367422e-07

Interestingly O 0 3.933679977308202e-07
, O 0 1.2327115994636983e-09
the O 0 3.479309548803933e-11
presence O 0 7.385439482199274e-10
of O 0 4.330657360496204e-11
a O 0 1.924349346538179e-09
breast B-Disease 0 2.1213636500760913e-05
cancer I-Disease 0 3.3657204312476097e-07
case O 0 1.765649737528463e-09
< O 0 1.95962202020894e-09
36 O 0 2.3563806461623926e-10
years O 0 2.633916973415751e-10
of O 0 5.165509079502195e-12
age O 0 1.30911481655005e-09
was O 0 2.876610338820029e-10
strongly O 0 1.1296553970030487e-10
predictive O 0 6.295693744107211e-09
of O 0 4.665758664840203e-12
the O 0 1.2491029044436885e-11
presence O 0 2.2720036962908807e-10
of O 0 1.3441612189621366e-12
any O 0 4.1107083015301527e-11
of O 0 6.595542688392353e-12
the O 0 1.2276193950278014e-10
eight O 0 3.811320592461698e-09
mutations O 0 2.970164416637999e-07
screened O 0 4.899606551589386e-07
. O 0 6.647424299899285e-08

Carriers O 0 7.309517400244658e-07
of O 0 1.0972075331627806e-10
the O 0 1.6134529476352633e-11
same O 0 4.9814003616477365e-11
mutation O 0 1.527150961244672e-09
, O 0 5.3591328423585605e-12
from O 0 2.4470605663323708e-12
different O 0 3.24912839688718e-11
families O 0 1.1059247961853202e-10
, O 0 7.345801050773204e-12
shared O 0 8.206160750923175e-11
similar O 0 1.5226363225817607e-10
haplotypes O 0 1.5574265432860557e-08
, O 0 2.919569100368058e-11
indicating O 0 2.4544299925821633e-10
that O 0 1.3677065556494394e-11
the O 0 4.986169897108761e-12
mutant O 0 2.1222135160314792e-09
alleles O 0 2.055613901319475e-09
were O 0 2.0948293100175874e-10
likely O 0 3.479178611875966e-10
to O 0 1.890628972822661e-11
be O 0 2.0147649174018234e-11
identical O 0 1.576501984512646e-10
by O 0 3.024866468415155e-11
descent O 0 7.393928136423256e-09
for O 0 1.1381636605412027e-10
a O 0 3.3240818431146124e-10
mutation O 0 2.462901704802789e-08
in O 0 4.147703014378834e-10
the O 0 5.02243580058348e-10
founder O 0 1.1121559850835183e-07
population O 0 1.7020887810303975e-08
. O 0 5.15712201831775e-08

The O 0 4.650909879444498e-09
identification O 0 6.458589663083103e-09
of O 0 2.0529326849594298e-10
common O 0 2.479043637038103e-08
BRCA1 O 0 3.5814146031043492e-06
and O 0 8.46417425037771e-09
BRCA2 O 0 1.8677289972401923e-06
mutations O 0 9.500226383352128e-08
will O 0 1.3295546608116382e-10
facilitate O 0 5.284582216269484e-10
carrier O 0 3.9031471388284444e-09
detection O 0 2.8759696846236693e-09
in O 0 3.7994438151223164e-10
French O 0 3.5288599065097515e-07
Canadian O 0 2.3795216463895486e-07
breast B-Disease 0 0.08397199958562851
cancer I-Disease 0 0.00022079235350247473
and O 0 1.3792846402793657e-06
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.471094262546103e-07
. O 0 1.348712714843714e-07

Are O 0 7.805914492564625e-08
Dp71 O 0 8.88823160494212e-06
and O 0 3.207723153764164e-08
Dp140 O 0 3.4984382182301488e-06
brain O 0 1.2433059737304575e-06
dystrophin O 0 1.0443230848977691e-06
isoforms O 0 6.62513457427849e-08
related O 0 8.18878209685181e-09
to O 0 2.1153716556199242e-09
cognitive B-Disease 0 7.278118800968514e-07
impairment I-Disease 0 3.136550219551282e-07
in O 0 9.460514149850496e-09
Duchenne B-Disease 0 0.00027374853380024433
muscular I-Disease 0 0.0003672261373139918
dystrophy I-Disease 0 0.005222012754529715
? O 0 8.570755016990006e-05

Molecular O 0 3.5360658330318984e-06
study O 0 1.34654584371674e-07
and O 0 4.1631840197453585e-09
neuropsychological O 0 6.828519616419726e-08
analysis O 0 1.809542515829321e-09
were O 0 3.928942240993827e-11
performed O 0 1.2187469089486314e-10
concurrently O 0 3.206643284237032e-10
on O 0 3.040920848462747e-10
49 O 0 1.6679898351412703e-08
patients O 0 8.491291225709574e-09
with O 0 1.1807347322090322e-09
Duchenne B-Disease 0 7.512123556807637e-05
muscular I-Disease 0 1.0479173397470731e-05
dystrophy I-Disease 0 4.3073199776699767e-05
( O 0 2.3169411278445295e-08
DMD B-Disease 1 1.0
) O 0 1.0991209720145889e-08
in O 0 9.181301552363408e-11
order O 0 2.186632402922939e-10
to O 0 7.600772095051056e-11
find O 0 3.5311850665742384e-10
a O 0 5.952396995440035e-12
molecular O 0 1.8296639203718712e-10
explanation O 0 8.511097382424282e-11
for O 0 7.454239482618252e-12
the O 0 8.83947845475852e-11
cognitive B-Disease 0 1.8111529698217055e-07
impairment I-Disease 0 1.255271531164226e-08
observed O 0 1.3005657661935288e-09
in O 0 7.409354796372725e-10
most O 0 3.771282663933562e-08
DMD B-Disease 1 1.0
patients O 0 9.63849470281275e-06
. O 0 8.787480965111172e-08

Complete O 0 6.365134197494626e-08
analysis O 0 1.55803583368197e-08
of O 0 6.320954870631112e-11
the O 0 7.934743834203672e-11
dystrophin O 0 4.3637971458565517e-08
gene O 0 1.659833692713164e-08
was O 0 7.762182563375575e-10
performed O 0 5.75772429733945e-10
to O 0 3.4655403546857144e-11
define O 0 5.526253232801537e-09
the O 0 5.395638102978495e-11
localization O 0 8.559876696345725e-10
of O 0 2.5527702781497075e-12
deletions O 0 3.8276972702533385e-09
and O 0 1.0841474940015416e-10
duplications O 0 1.536026594806117e-08
in O 0 5.7883763754373874e-11
relation O 0 2.3396001802566957e-10
to O 0 4.915708812225361e-11
the O 0 1.6349528675352332e-10
different O 0 1.4303258133452346e-08
DMD B-Disease 1 0.9999995231628418
promoters O 0 3.210718659829581e-06
. O 0 1.8047683170152595e-07

Qualitative O 0 2.1851767542102607e-06
analysis O 0 6.284491149699534e-08
of O 0 1.8717352667785292e-10
the O 0 1.5289018662212328e-10
Dp71 O 0 3.9681474106600945e-08
transcript O 0 5.998373353577335e-08
and O 0 2.9685973124138343e-10
testing O 0 6.263113361271166e-10
for O 0 3.104610752507897e-12
the O 0 9.894450710146163e-13
specific O 0 2.8396864720781068e-11
first O 0 3.5468433745577954e-11
exon O 0 1.3312784208352468e-09
of O 0 1.1031959200324959e-11
Dp140 O 0 2.3889844769087176e-08
were O 0 3.3639319108047516e-10
also O 0 1.4529014102926396e-10
carried O 0 3.298882056412822e-09
out O 0 8.149532604306842e-09
. O 0 4.3571603214331844e-08

Neuropsychological O 0 9.553536074236035e-05
analysis O 0 1.8780119148686936e-07
assessed O 0 1.1406937971969455e-07
verbal O 0 2.506568819171662e-07
and O 0 2.2881785355366446e-09
visuospatial O 0 1.3109728342897142e-06
intelligence O 0 2.168786892298158e-07
, O 0 4.716603219101501e-10
verbal O 0 4.756412508299945e-08
memory O 0 4.39653007333618e-08
, O 0 6.858221213157378e-10
and O 0 2.458648173941924e-09
reading O 0 5.686180415409581e-08
skills O 0 6.454066578953643e-07
. O 0 1.6714778894311166e-07

Comparison O 0 3.2701919394639845e-07
of O 0 4.259162467157296e-10
molecular O 0 5.7888382087867285e-08
and O 0 2.3699944229349512e-09
psychometric O 0 1.570611175338854e-06
findings O 0 1.4914281365463466e-08
demonstrated O 0 2.4413626675823252e-09
that O 0 1.933818209731708e-11
deletions O 0 2.74375144826422e-09
and O 0 8.185916527958526e-11
duplications O 0 9.612649343182511e-09
that O 0 4.846462467456014e-11
were O 0 3.011373095329617e-11
localized O 0 9.191205574410333e-10
in O 0 1.0395605209989611e-10
the O 0 1.2269258525821058e-11
distal O 0 2.855952141445073e-09
part O 0 1.3418732791592447e-09
of O 0 9.59810616402157e-12
the O 0 1.6489257875784702e-11
gene O 0 1.0828212770874757e-09
seemed O 0 4.671462106031754e-10
to O 0 6.4748484351895286e-12
be O 0 1.9823942834507058e-11
preferentially O 0 8.779246774004434e-10
associated O 0 1.6932740765085441e-09
with O 0 1.7664110174564485e-09
cognitive B-Disease 0 1.064021034835605e-06
impairment I-Disease 0 9.312830684393703e-07
. O 0 7.237571963969458e-08

Two O 0 5.730690588734433e-08
altered O 0 2.847477276191057e-07
Dp71 O 0 3.5203456150156853e-07
transcripts O 0 7.349135699996623e-08
and O 0 3.0668642625464315e-10
two O 0 7.292546427839497e-11
deleted O 0 1.2779949543073599e-08
Dp140 O 0 8.67437233154078e-09
DNA O 0 1.037014252247559e-09
sequences O 0 2.378420516091495e-10
were O 0 1.0939262516662662e-11
found O 0 5.7478431736424085e-12
in O 0 8.402715155619855e-12
four O 0 2.5209687115612667e-10
patients O 0 5.005444503325407e-09
with O 0 1.5409439280134052e-09
severe O 0 0.09841898083686829
cerebral B-Disease 1 0.965128481388092
dysfunction I-Disease 0 0.012052705511450768
. O 0 8.693710924490006e-07

These O 0 1.6442175621023125e-08
findings O 0 9.167975711932286e-09
suggest O 0 1.2842106267285658e-09
that O 0 7.759156164799386e-12
some O 0 1.596864459239844e-12
sequences O 0 1.8170258353489288e-10
located O 0 2.619568173489739e-10
in O 0 5.7479885434696953e-11
the O 0 1.882845268585953e-11
distal O 0 2.0874475481491572e-09
part O 0 1.31340149867043e-09
of O 0 5.178846500947243e-12
the O 0 1.0051516910469793e-11
gene O 0 5.983147310928416e-10
and O 0 1.544400440867122e-10
, O 0 7.94193183439873e-12
in O 0 5.508743634863311e-12
particular O 0 1.4874211584636754e-10
, O 0 8.754076630257401e-11
some O 0 2.934762433071114e-10
DMD B-Disease 1 0.9999760389328003
isoforms O 0 1.2763993417763686e-08
expressed O 0 2.747546912207355e-10
in O 0 1.3252986208467377e-10
the O 0 1.9721899113811503e-10
brain O 0 2.3225055656439508e-07
may O 0 7.420726255702448e-10
be O 0 2.095350585748501e-12
related O 0 2.1843301473145615e-11
to O 0 3.855154737109068e-11
the O 0 4.2069731032157165e-10
cognitive B-Disease 0 4.162559719134151e-07
impairment I-Disease 0 4.3077534428448416e-08
associated O 0 3.4217213507048427e-09
with O 0 5.254252588571262e-09
DMD B-Disease 1 1.0
. O 0 7.509509458714092e-08
. O 0 1.323618050719233e-07

I1307K O 0 5.2976472943555564e-05
APC O 0 1.3962194316263776e-06
and O 0 9.016633661929063e-09
hMLH1 O 0 2.1022367491241312e-07
mutations O 0 1.3697872702778113e-07
in O 0 3.339893639431324e-10
a O 0 8.206305635027888e-10
non O 0 2.282052946611657e-06
- O 0 3.170162017340772e-07
Jewish O 0 6.015719833385447e-08
family O 0 2.669305665392585e-09
with O 0 2.1841031205838135e-09
hereditary B-Disease 1 0.9991397857666016
non I-Disease 1 0.9999933242797852
- I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.2401774205936817e-06

We O 0 6.59452368267921e-08
describe O 0 7.563573234392607e-08
a O 0 1.0169493691591924e-08
French O 0 5.819458692712942e-07
Canadian O 0 4.5273654336597247e-07
hereditary B-Disease 1 0.994721531867981
non I-Disease 1 0.9999978542327881
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.9243050764525833e-07
HNPCC B-Disease 0 0.054487455636262894
) O 0 2.337684357200942e-08
kindred O 0 5.52523317765008e-07
which O 0 9.787664012606001e-10
carries O 0 2.3190620535018525e-09
a O 0 5.003304437423139e-10
novel O 0 1.883235967170549e-08
truncating O 0 1.6969402167887893e-06
mutation O 0 5.187320084587554e-07
in O 0 1.0663963045942637e-08
hMLH1 O 0 7.259060112119187e-06
. O 0 2.1594335919417063e-07

Interestingly O 0 7.734670930403809e-07
, O 0 3.113077351457605e-09
the O 0 4.988591206789295e-10
I1307K O 0 2.6320572033000644e-07
APC O 0 1.664922599786678e-08
polymorphism O 0 2.7208903574660326e-08
, O 0 2.1053710858032204e-11
associated O 0 5.2346314782791836e-11
with O 0 4.5134187186268715e-12
an O 0 4.754999519129832e-11
increased O 0 1.891609358040114e-08
risk O 0 5.828403664054349e-05
of O 0 3.4837316320590617e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.324438140912434e-09
is O 0 4.2415540524309847e-10
also O 0 4.499129679924607e-10
present O 0 1.2078080202648778e-10
in O 0 1.228907947625757e-10
this O 0 1.6059285845582139e-10
family O 0 2.425319323151598e-08
. O 0 3.283823346578174e-08

The O 0 4.084989679853379e-09
I1307K O 0 2.031068220276211e-07
polymorphism O 0 8.05917110824339e-08
has O 0 8.68817684462897e-10
previously O 0 8.413870156154246e-10
only O 0 2.5215924834287584e-11
been O 0 1.1899743690424458e-10
identified O 0 4.6324216684823227e-10
in O 0 1.0657419391435496e-11
individuals O 0 5.260785557181791e-11
of O 0 6.837684585203618e-11
self O 0 0.01270828116685152
- O 0 0.18496708571910858
reported O 0 0.00023258104920387268
Ashkenazi O 0 2.522200156818144e-05
Jewish O 0 2.204562861152226e-07
origins O 0 1.1476624877104769e-06
. O 0 1.529042492620647e-07

In O 0 3.9684109331972195e-09
addition O 0 2.738450133321635e-09
, O 0 1.3411868837742702e-10
in O 0 2.924808312210203e-11
this O 0 1.299609898863796e-11
family O 0 1.8247917066283037e-10
, O 0 3.159125738783075e-11
there O 0 2.0777612269595735e-11
appears O 0 5.281428627768037e-10
to O 0 1.0019479690370758e-10
be O 0 4.727879754362618e-10
no O 0 6.757237130949889e-11
relationship O 0 4.718969659478489e-10
between O 0 2.5575722095716458e-11
the O 0 2.3190244863302567e-11
I1307K O 0 3.809633941642687e-09
polymorphism O 0 4.0931245059994126e-09
and O 0 2.726428978416795e-11
the O 0 3.4827405716308935e-12
presence O 0 2.811946786529518e-10
or O 0 4.945240328346756e-10
absence O 0 1.2132321813851377e-09
of O 0 1.365246804496678e-10
cancer B-Disease 0 1.1494990559413054e-07
. O 0 1.9151222829805192e-09
. O 0 6.220996340289275e-08

Identification O 0 1.2217614653309283e-07
of O 0 1.3550437161224949e-10
a O 0 1.468197924348047e-10
novel O 0 5.464715346903404e-09
mutation O 0 1.7829030696248083e-08
of O 0 2.6984713075162148e-11
the O 0 1.0890635615545818e-10
CPO O 0 1.843900463427417e-07
gene O 0 1.0026085739411883e-08
in O 0 6.162696464251383e-10
a O 0 2.247266150945393e-09
Japanese O 0 3.6523854873848904e-07
hereditary B-Disease 0 8.721143240109086e-05
coproporphyria I-Disease 0 2.4467784896842204e-05
family O 0 3.6076966125619947e-07
. O 0 2.281547466509437e-07

Hereditary B-Disease 1 0.9895361661911011
coproporphyria I-Disease 0 0.0004969481378793716
( O 0 1.8526355560766206e-08
HCP B-Disease 0 2.5050921976799145e-06
) O 0 1.4107576218336249e-09
is O 0 3.3924246745087316e-10
an O 0 3.117712088496205e-09
autosomal B-Disease 1 0.9999911785125732
dominant I-Disease 1 0.9999927282333374
disease I-Disease 0 0.0018419938860461116
characterized O 0 7.874489504899884e-09
by O 0 4.130689401637966e-10
a O 0 1.7696391907406905e-08
deficiency B-Disease 0 2.889090683311224e-05
of I-Disease 0 1.5972406730568878e-10
coproporphyrinogen I-Disease 0 2.6091151994478423e-06
oxidase I-Disease 0 3.797372585268022e-07
( O 0 7.578685456977041e-10
CPO O 0 1.7213191938481032e-07
) O 0 6.876716418524609e-10
caused O 0 1.0890033319554959e-10
by O 0 1.6231821442502792e-11
a O 0 2.550047673022249e-10
mutation O 0 2.142407673488833e-08
in O 0 7.850790573193933e-10
the O 0 1.6787579104615702e-09
CPO O 0 3.4084787330357358e-06
gene O 0 1.0656988251867006e-06
. O 0 1.5926175933600462e-07

Only O 0 8.073294566202094e-08
11 O 0 8.731873002432167e-09
mutations O 0 8.126219697146553e-09
of O 0 8.193504902331838e-12
the O 0 1.0471299174974469e-11
gene O 0 4.529362662708536e-09
have O 0 1.0772921443802375e-09
been O 0 1.3385654806796765e-09
reported O 0 8.853931809937876e-09
in O 0 3.687813832087272e-09
HCP B-Disease 0 3.934453707188368e-05
patients O 0 8.831265745357086e-07
. O 0 6.557259979445007e-08

We O 0 3.9468432078137994e-07
report O 0 1.2003819271910743e-08
another O 0 4.2046627291014715e-10
mutation O 0 8.385677041644612e-09
in O 0 1.4985668261857654e-10
a O 0 1.1253762366436604e-09
Japanese O 0 4.3918284120536555e-08
family O 0 6.738545721418632e-08
. O 0 1.2000539584278158e-07

Polymerase O 0 2.515690357540734e-05
chain O 0 9.282175597036257e-06
reaction O 0 1.468441155338951e-06
- O 0 2.0849474822171032e-06
single O 0 4.3732960364195606e-08
strand O 0 7.4848918529824e-07
conformational O 0 7.235708920916295e-08
polymorphism O 0 8.254853867128986e-08
and O 0 3.8799052859417316e-10
direct O 0 7.750702857300951e-10
sequence O 0 4.020323629561062e-09
analyses O 0 2.7128011836907717e-08
demonstrated O 0 4.778205831001969e-09
a O 0 2.4636367945696236e-10
C O 0 2.3614663557935955e-09
to O 0 5.4740878496772893e-11
T O 0 4.3886356770883594e-09
substitution O 0 2.0877968798238555e-10
in O 0 2.4933798081772096e-11
exon O 0 4.022693733674032e-09
1 O 0 1.9564463937804533e-10
of O 0 4.804179623563165e-12
the O 0 6.658886636534689e-11
CPO O 0 2.090297357426607e-08
gene O 0 2.439109803020756e-09
at O 0 8.273409735082282e-11
nucleotide O 0 1.1072999406280815e-08
position O 0 2.2114058140232373e-08
85 O 0 5.711925932239126e-10
, O 0 3.3416314854095575e-11
which O 0 1.6553425297161084e-10
lies O 0 9.015649338195431e-10
in O 0 5.1788000970942605e-11
the O 0 4.28682957187565e-11
putative O 0 1.8274963764497443e-08
presequence O 0 4.6356969818361904e-08
for O 0 8.684626628951975e-11
targeting O 0 2.0008513956781826e-08
to O 0 1.7254329076621389e-09
mitochondria O 0 2.581535341050767e-07
. O 0 5.818082726705143e-08

This O 0 1.2051812880997659e-08
mutation O 0 6.687611175948405e-08
changes O 0 2.6274507014534265e-09
the O 0 9.831103292556875e-11
codon O 0 1.112813396986212e-08
for O 0 1.3860738945492557e-11
glutamine O 0 5.487108101220883e-09
to O 0 8.774554693946612e-11
a O 0 2.9780966581682833e-10
termination O 0 6.288603771054113e-08
codon O 0 2.973667676542391e-07
at O 0 2.7775715061295614e-09
amino O 0 5.930978730361858e-08
acid O 0 9.190284089299894e-08
position O 0 9.109933785111934e-08
29 O 0 9.006495815810922e-08
. O 0 4.6457167002245114e-08

MaeI O 0 1.3600026250060182e-05
restriction O 0 3.182632823950371e-08
analysis O 0 1.0686319384944909e-08
showed O 0 8.321589528570428e-10
two O 0 7.744385861763181e-12
other O 0 1.8887872169082165e-11
carriers O 0 9.206135853645492e-10
in O 0 4.668146424968711e-11
the O 0 2.882014349392392e-10
family O 0 3.904496992390705e-08
. O 0 6.96496655905321e-08

The O 0 2.1455772980516485e-07
C O 0 3.94871094613336e-05
- O 0 4.514935426414013e-05
T O 0 1.5953011825331487e-05
mutation O 0 5.2083073853737005e-08
is O 0 9.103285486533608e-11
located O 0 7.44639974681327e-11
within O 0 6.709219291245461e-11
a O 0 3.5445865687044886e-10
recently O 0 7.722771755425129e-09
proposed O 0 2.4126713960015422e-09
putative O 0 4.708105549866559e-08
alternative O 0 7.06784808457428e-09
translation O 0 2.5913278189904076e-09
initiation O 0 1.379771941145691e-08
codon O 0 3.7169991173868766e-07
( O 0 4.869499803383803e-10
TIC O 0 1.3222403083545942e-07
- O 0 1.7876736535527016e-08
1 O 0 4.54356774426401e-10
) O 0 3.506109985673689e-11
, O 0 8.239767375350926e-12
supporting O 0 5.351027954070275e-10
that O 0 6.738819224860748e-11
TIC O 0 4.818486587510051e-08
- O 0 1.6724117202215893e-08
1 O 0 3.92248206138035e-10
is O 0 2.8691018311155503e-11
the O 0 3.479780699700008e-11
real O 0 6.621001080731048e-09
TIC O 0 1.256838277896577e-08
rather O 0 1.803181354231853e-10
than O 0 2.0338743189629582e-10
TIC O 0 1.2407316773987986e-07
- O 0 2.300270196542442e-08
2 O 0 1.0567456909527095e-09
. O 0 1.117185233212581e-09
. O 0 1.875858046673784e-08

Human B-Disease 0 2.2256791964991862e-07
complement I-Disease 0 1.6254001593551948e-06
factor I-Disease 0 0.00010990842565661296
H I-Disease 1 1.0
deficiency I-Disease 1 0.9815969467163086
associated O 0 1.440672008357069e-06
with O 0 3.6479018490354065e-06
hemolytic B-Disease 1 0.9999996423721313
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.280146898352541e-05

This O 0 4.253432717149508e-09
study O 0 1.5677379394674062e-09
reports O 0 1.5114152984718743e-10
on O 0 2.604238005798898e-11
six O 0 8.654531952201339e-11
cases O 0 4.693432864577574e-10
of O 0 1.1845734115834006e-10
deficiency B-Disease 0 6.656101732005482e-07
in I-Disease 0 2.4826455127802127e-11
the I-Disease 0 2.045302642528224e-11
human I-Disease 0 2.7196056517908573e-10
complement I-Disease 0 2.8373559057826014e-09
regulatory I-Disease 0 1.0342097844784348e-08
protein I-Disease 0 9.27257737259879e-09
Factor I-Disease 0 1.49523931014528e-08
H I-Disease 1 0.9999988079071045
( O 0 4.757333416094411e-10
FH O 0 1.7706439621179015e-06
) O 0 3.4322152758781144e-11
in O 0 3.827012491630644e-12
the O 0 3.4828203689107884e-12
context O 0 2.6471577707631866e-10
of O 0 4.039350798290542e-11
an O 0 1.7362555837507898e-08
acute B-Disease 1 0.7493833899497986
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.6166162595254718e-06

Five O 0 7.280990033109447e-09
of O 0 8.274384649675781e-12
the O 0 3.266544153224249e-12
cases O 0 3.949943150338697e-11
were O 0 3.413940657948089e-11
observed O 0 1.7026066667646944e-10
in O 0 5.097139030296738e-11
children O 0 5.524817270341487e-10
presenting O 0 2.3012356464846562e-08
with O 0 1.9954343599692947e-07
idiopathic O 1 0.9999582767486572
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.2851915016653948e-05
HUS B-Disease 1 0.9998970031738281
) O 0 9.156137821264565e-07
. O 0 4.977400749339722e-07

Two O 0 2.430940337916354e-09
of O 0 2.5005809922706845e-11
the O 0 5.170755837391461e-11
children O 0 3.365722978099228e-10
exhibited O 0 5.644994693909666e-09
a O 0 4.390017238620203e-09
homozygous O 0 0.000162926284247078
deficiency O 0 8.355874342669267e-06
characterized O 0 1.118929615628872e-09
by O 0 8.126350981019215e-11
the O 0 7.801125717632473e-11
absence O 0 6.101038008132775e-10
of O 0 2.4925749398524433e-12
the O 0 1.1095965292418075e-11
150 O 0 1.0680847872812649e-10
- O 0 2.345722727170596e-09
kD O 0 3.607379639447572e-08
form O 0 2.837186596771346e-10
of O 0 3.115610547332892e-11
Factor O 0 1.184963327460764e-08
H O 1 1.0
and O 0 5.407633230092301e-10
the O 0 2.7898816937210746e-11
presence O 0 8.019021002780846e-10
, O 0 1.5319807922242745e-11
upon O 0 2.0234298611643275e-11
immunoblotting O 0 7.51268647292136e-09
, O 0 2.0438518932852645e-11
of O 0 3.3065308303881213e-12
the O 0 6.209061736983656e-11
42 O 0 2.2551067679899006e-09
- O 0 2.226829387552698e-08
kD O 0 1.0350109960199916e-06
Factor O 0 7.216770825380081e-08
H O 1 0.9999995231628418
- O 0 4.135628373092004e-08
like O 0 2.731350701168367e-09
protein O 0 2.91333068780375e-09
1 O 0 3.3253502729202467e-10
( O 0 4.838999340117667e-11
FHL O 0 2.5706640371936373e-07
- O 0 1.0258444760324892e-08
1 O 0 1.301073832005173e-10
) O 0 8.878084031826994e-12
and O 0 1.9256802749612056e-11
other O 0 3.1675925771246227e-10
FH O 0 0.013008060865104198
- O 0 3.690039207526752e-08
related O 0 1.1392986110081438e-08
protein O 0 9.796765176872668e-09
( O 0 2.792284181651894e-10
FHR O 0 1.585047471053258e-07
) O 0 1.121476467247362e-09
bands O 0 1.3778658569663094e-07
. O 0 1.1649249387346572e-07

Southern O 0 4.678418463299749e-06
blot O 0 2.0436604245333e-05
and O 0 4.630754002477033e-09
PCR O 0 6.562552812283684e-08
analysis O 0 1.1584252446183996e-09
of O 0 5.897418404315902e-12
DNA O 0 1.7110164396427763e-09
of O 0 5.994975349477016e-12
one O 0 2.2256042842005996e-10
patient O 0 4.14605949572433e-09
with O 0 3.414906413201635e-10
homozygous O 0 9.5761924967519e-06
deficiency O 0 3.734314304892905e-05
ruled O 0 1.93738749487693e-08
out O 0 1.787579945178308e-10
the O 0 1.7588047337979695e-11
presence O 0 2.867609760759393e-10
of O 0 1.994529758367336e-12
a O 0 1.4440129647574906e-11
large O 0 1.8730603179584193e-10
deletion O 0 2.162388135218407e-08
of O 0 2.772291944619365e-11
the O 0 1.2396335347109044e-10
FH O 0 5.260883995106269e-07
gene O 0 1.1373243458123738e-09
as O 0 6.668648272478706e-11
the O 0 5.3980878794712694e-11
underlying O 0 1.0885288226347711e-08
defect O 0 6.773970540052687e-08
for O 0 3.011053073542769e-10
the O 0 1.3968460166324803e-08
deficiency O 0 6.983553612371907e-05
. O 0 4.141832832260661e-08

The O 0 6.237219629667834e-10
other O 0 1.784793146608621e-10
four O 0 7.059824252975133e-11
children O 0 1.0231040320496376e-10
presented O 0 1.8942034052393808e-10
with O 0 4.1839109954366904e-10
heterozygous O 0 2.3339100607699947e-06
deficiency O 0 9.07178446141188e-07
and O 0 1.210104655369193e-10
exhibited O 0 6.566193810897403e-09
a O 0 4.971759115512953e-10
normal O 0 6.1278879748272175e-09
immunoblotting O 0 1.8723251571373112e-07
pattern O 0 3.7835452104673095e-08
of O 0 2.251331066016604e-11
proteins O 0 3.1192390337331233e-10
of O 0 3.907478507425566e-11
the O 0 2.171202551082274e-09
FH O 0 0.07643178105354309
family O 0 6.113787520689584e-08
. O 0 4.8761503279592944e-08

Factor B-Disease 1 0.9979561567306519
H I-Disease 1 1.0
deficiency I-Disease 1 0.9846345782279968
is O 0 3.788639957313933e-10
the O 0 1.2154527384566904e-10
only O 0 2.189305270405839e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 4.221292826400713e-08
with O 0 1.1918950271194717e-08
HUS B-Disease 1 0.9863830804824829
. O 0 5.507819196282071e-07

These O 0 6.479553338323285e-09
observations O 0 9.36228872205902e-09
suggest O 0 4.776538276018982e-09
a O 0 1.7007663333235001e-10
role O 0 4.375955597879511e-09
for O 0 7.761102316372614e-10
FH O 0 1.5239722415572032e-05
and O 0 1.8351835606722489e-09
/ O 0 4.33006093203403e-08
or O 0 7.783254041271448e-09
FH O 0 2.1927544366917573e-05
receptors O 0 1.867543630851287e-08
in O 0 7.375385024932513e-11
the O 0 1.0492056529143312e-10
pathogenesis O 0 2.707084512110214e-08
of O 0 8.561003017604207e-10
idiopathic O 0 4.233161962474696e-05
HUS B-Disease 1 0.988934338092804
. O 0 7.183906802765705e-08
. O 0 2.2807815014402877e-07

Further O 0 4.115183749320295e-09
evidence O 0 1.0171544717607617e-09
for O 0 2.5322343180644857e-11
a O 0 4.313386800514074e-11
major O 0 6.427556265009571e-10
ancient O 0 2.515725761043086e-08
mutation O 0 5.6188587223005015e-06
underlying O 0 3.2466359698446468e-06
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.999994158744812
from O 0 7.093373444178042e-09
linkage O 0 6.902945415276918e-07
disequilibrium O 0 1.8744276530924253e-06
studies O 0 3.6643971412786414e-08
in O 0 8.833631048865698e-11
the O 0 8.926684391674655e-11
Japanese O 0 9.097480102582267e-09
population O 0 4.903296879632535e-09
. O 0 1.639657654095572e-08

The O 0 1.7896169310915866e-06
myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999998807907104
( O 0 3.015239599335473e-06
DM B-Disease 1 1.0
) O 0 1.7168549959478696e-07
mutation O 0 6.081543233449338e-07
is O 0 2.66832844708631e-09
an O 0 9.229836339663677e-10
unstable O 0 3.59362161361787e-06
( O 0 2.325369230504748e-09
CTG O 0 4.84742201933841e-07
) O 0 8.624166381032694e-10
n O 0 4.630271277505926e-08
repeat O 0 6.026078835930093e-07
, O 0 8.76144365391518e-11
present O 0 4.446957038717336e-11
at O 0 6.433538424222007e-11
a O 0 6.519162813745094e-12
copy O 0 1.68592639848697e-09
number O 0 2.2558370449399234e-10
of O 0 1.665628572566913e-11
5 O 0 8.917210858605529e-10
- O 0 3.561029870979837e-08
37 O 0 1.3459617864697293e-09
repeats O 0 8.563506348480132e-09
on O 0 2.734508175450401e-10
normal O 0 6.032282451329252e-10
chromosomes O 0 2.299470613920107e-09
but O 0 1.8625082032208695e-10
amplified O 0 8.757204961185039e-10
to O 0 5.5167901497066296e-11
50 O 0 2.375704910573262e-10
- O 0 2.7317725859177244e-09
3000 O 0 3.5721980928826724e-09
copies O 0 1.5567881206379752e-08
on O 0 5.6919638780073e-08
DM B-Disease 1 0.9999953508377075
chromosomes O 0 3.913697128155036e-06
. O 0 2.703272059534356e-07

Previous O 0 1.9593190359046275e-07
findings O 0 4.0123968148009226e-08
in O 0 1.3176193469632835e-09
Caucasian O 0 2.8413276709216007e-07
populations O 0 1.555562256783105e-08
of O 0 2.412361976844579e-10
a O 0 2.669423970758089e-08
DM B-Disease 1 1.0
founder O 0 8.858226152597126e-08
chromosome O 0 3.4168650131505274e-07
raise O 0 5.667564639821876e-09
a O 0 1.0380189763292691e-10
question O 0 6.844029787345107e-10
about O 0 9.342723643335216e-12
the O 0 5.775470813401684e-12
molecular O 0 2.9643085208697073e-10
events O 0 1.499942253735398e-10
involved O 0 4.0544739787762296e-10
in O 0 7.924912115431226e-11
the O 0 2.7065397145698e-10
expansion O 0 1.849642075058e-07
mutation O 0 1.1911550927834469e-06
. O 0 1.2716854769223573e-07

To O 0 8.353716829390123e-09
investigate O 0 1.6220177201375918e-08
whether O 0 3.8965124460332845e-09
a O 0 2.1956637896725084e-10
founder O 0 5.239830791481381e-09
chromosome O 0 4.852435964153301e-08
for O 0 5.686195958531925e-10
the O 0 7.0275882890769026e-09
DM B-Disease 1 1.0
mutation O 0 1.3138060239725746e-07
exists O 0 2.023582412746805e-09
in O 0 3.468919596016917e-11
the O 0 1.0618543370977118e-11
Japanese O 0 8.588987299162909e-10
population O 0 7.055247358556116e-11
, O 0 2.7834609617194417e-11
we O 0 1.0198872302247253e-10
genotyped O 0 1.0495970315105296e-08
families O 0 3.281295374302218e-11
using O 0 1.3113533869901772e-10
polymorphic O 0 1.1237768049454644e-08
markers O 0 1.9103476134318953e-08
near O 0 4.573043721478598e-09
the O 0 5.335221153757175e-10
( O 0 6.833607568701439e-10
CTG O 0 4.206544019780267e-07
) O 0 1.1997084436998762e-09
n O 0 2.779484304937796e-07
repeat O 0 2.7222271455684677e-05
region O 0 4.9342407493213614e-08
and O 0 4.159009137083558e-09
constructed O 0 4.955367103320896e-07
haplotypes O 0 1.0748568456619978e-05
. O 0 3.9116011407713813e-07

Six O 0 2.2824128365073193e-08
different O 0 1.0416688622783e-09
haplotypes O 0 1.1099542263082185e-07
were O 0 6.016138698328177e-10
found O 0 1.705493746229081e-09
and O 0 1.3671478171772833e-08
DM B-Disease 1 1.0
alleles O 0 3.9933635775923904e-07
were O 0 7.061394136087529e-09
always O 0 3.393573422272311e-08
haplotype O 0 1.6850581232574768e-06
A O 0 3.2995380649936124e-08
. O 0 1.889509491093122e-07

To O 0 1.155552542542182e-08
find O 0 8.628991743364622e-09
an O 0 2.4001340845347663e-11
origin O 0 9.496559094657187e-10
of O 0 3.049864527593371e-11
the O 0 3.5125241604205826e-10
( O 0 6.174768474309644e-10
CTG O 0 3.0253704608185217e-07
) O 0 6.850768841104582e-10
n O 0 4.746009452105682e-08
repeat O 0 2.293786707241452e-07
mutation O 0 1.6319013695920148e-08
and O 0 1.725705411903533e-10
to O 0 2.743037220975797e-11
investigate O 0 3.2702254793015584e-10
the O 0 1.2097879122097144e-11
mechanism O 0 2.1934358843123114e-11
of O 0 7.213024665400636e-13
the O 0 2.9553013682070972e-12
expansion O 0 5.607626030190715e-10
mutation O 0 6.297287691303666e-10
in O 0 8.716684492260374e-12
the O 0 6.759205608414254e-12
Japanese O 0 5.858834528638113e-10
population O 0 4.399325001513965e-11
we O 0 3.388917618751819e-11
have O 0 1.3753083741296912e-11
studied O 0 5.545657821848238e-10
90 O 0 2.64961774743e-10
Japanese O 0 2.316693681336801e-08
DM B-Disease 1 0.9999995231628418
families O 0 1.898468715566537e-09
comprising O 0 2.5991478413978086e-10
190 O 0 1.2393361892293342e-09
affected O 0 9.548577484252974e-10
and O 0 4.92344331970429e-10
130 O 0 3.558325856189981e-09
unaffected O 0 1.4158281658183114e-07
members O 0 1.0990182985892716e-08
. O 0 6.585636924683058e-08

The O 0 1.388470671770392e-08
results O 0 8.63109939075457e-09
suggest O 0 1.7958065035017512e-09
that O 0 1.3625458400445822e-11
a O 0 3.095506836969797e-11
few O 0 2.9144073265818804e-10
common O 0 9.928924349367207e-11
ancestral O 0 1.0277084738774533e-09
mutations O 0 2.186776271173585e-08
in O 0 1.087739065486204e-10
both O 0 6.565000765235141e-10
Caucasian O 0 3.664394228053425e-07
and O 0 6.500990301638865e-10
Japanese O 0 8.950711283262081e-10
populations O 0 5.493052679383936e-10
have O 0 1.7539773453090213e-11
originated O 0 4.5647076396537756e-11
by O 0 2.2639036912491806e-12
expansion O 0 1.1207830497017568e-10
of O 0 2.179077664837825e-12
an O 0 1.1304479921592225e-11
ancestral O 0 9.033452208484505e-09
n O 0 2.0209110118685203e-07
= O 0 3.208371524010545e-08
5 O 0 5.375322964518148e-10
repeat O 0 2.4708441515031154e-08
to O 0 2.433797052781017e-10
n O 0 3.756665734044873e-08
= O 0 4.051138446925506e-08
19 O 0 7.262626056103727e-09
- O 0 5.031828465007493e-08
37 O 0 8.280237828728332e-09
copies O 0 5.1379668519757615e-08
. O 0 1.0140713868622697e-07

These O 0 2.3978030672111572e-09
data O 0 2.5153072957806444e-09
support O 0 1.971798696542848e-10
multistep O 0 6.095297777619635e-08
models O 0 1.1231360730334927e-08
of O 0 2.9477927043775054e-11
triplet O 0 8.585703881180962e-08
repeat O 0 2.8560027232060747e-08
expansion O 0 5.264562119577931e-10
that O 0 1.477512556746774e-11
have O 0 1.0167460623433655e-11
been O 0 8.56045616337564e-12
proposed O 0 3.9344614372049946e-11
for O 0 2.0295756394950182e-11
both O 0 8.698179065902423e-09
DM B-Disease 1 1.0
and O 0 3.508101897864435e-08
Friedreichs B-Disease 0 2.773285814328119e-06
ataxia I-Disease 0 3.4331678762100637e-06
. O 0 4.515855778208788e-08
. O 0 2.1998228305619705e-07

The O 0 9.58493018288209e-09
molecular O 0 1.0848109610606116e-07
basis O 0 4.015796406520167e-08
of O 0 3.266905679311094e-08
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.1119478388342827e-10
the O 0 5.5173476898318086e-11
western O 0 9.500729980516098e-09
Cape O 0 1.143805672398912e-08
, O 0 7.681180136387411e-10
South O 0 2.5611675003034406e-09
Africa O 0 1.010221595265648e-08
. O 0 1.4111242840897376e-08

Deficiency B-Disease 1 0.9814334511756897
of I-Disease 0 5.097520738850392e-10
the I-Disease 0 2.4375321205916123e-10
sixth I-Disease 0 4.214476323483041e-09
component I-Disease 0 6.416902564865268e-09
of I-Disease 0 2.755711804580674e-11
human I-Disease 0 4.058327007783191e-10
complement I-Disease 0 4.718576640527772e-09
( O 0 9.230218672717783e-11
C6 O 0 1.5236023997999837e-08
) O 0 9.208976636809751e-11
has O 0 8.827095304697608e-11
been O 0 2.459359660367255e-10
reported O 0 2.5778049139724146e-10
in O 0 4.7330993291350154e-12
a O 0 7.639079473154009e-12
number O 0 2.4404337925498787e-11
of O 0 4.635280440729028e-12
families O 0 6.172905242518567e-11
from O 0 5.056148642129665e-12
the O 0 1.765661575281463e-11
western O 0 2.7102966537739803e-09
Cape O 0 2.388341080461487e-09
, O 0 1.1607203392882681e-10
South O 0 2.769863449714194e-09
Africa O 0 2.714808156056847e-09
. O 0 1.0588808940781291e-08

Meningococcal B-Disease 1 0.9021405577659607
disease I-Disease 0 0.001810767687857151
is O 0 3.355372646396404e-09
endemic O 0 2.4676871657192123e-09
in O 0 2.2610405214784635e-10
the O 0 4.5674422577413054e-11
Cape O 0 6.177030553722318e-10
and O 0 1.728811191425983e-11
almost O 0 4.70195757329428e-12
all O 0 7.405674164184806e-12
pedigrees O 0 6.922490136673787e-09
of O 0 2.82293632913877e-10
total O 0 3.3828634968813276e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.780644603461724e-10
C6Q0 O 0 5.12218392145769e-08
) O 0 3.640732854082174e-11
have O 0 2.6460661786686934e-11
been O 0 8.918855931572267e-11
ascertained O 0 4.624055360835655e-09
because O 0 6.947751263197688e-10
of O 0 2.904662343983233e-10
recurrent O 0 0.012183649465441704
disease O 0 1.1118988368252758e-05
. O 0 8.565340436916813e-08

We O 0 2.7971944405180693e-07
have O 0 1.427986284774363e-09
sequenced O 0 3.4767060341778233e-09
the O 0 8.064002937624437e-11
expressed O 0 2.277235899850183e-10
exons O 0 2.856754477420509e-08
of O 0 4.887306878642583e-11
the O 0 1.020165479870272e-10
C6 O 0 1.837920216019029e-08
gene O 0 4.678327725216036e-10
from O 0 4.636200277852165e-12
selected O 0 1.4228029344975912e-11
cases O 0 4.377779388997638e-11
and O 0 3.956933045112798e-11
have O 0 6.800396357142802e-11
found O 0 9.148367480227293e-11
three O 0 6.1468927170516e-11
molecular O 0 8.345996604930406e-08
defects O 0 7.50429680920206e-05
leading O 0 5.605618191850681e-09
to O 0 6.192530932480622e-10
total O 0 2.699086509849735e-09
deficiency O 0 1.6191204394999659e-06
879delG O 0 8.693704955931025e-08
, O 0 3.061001452309142e-11
which O 0 4.6004391268672506e-11
is O 0 1.5556904722768827e-11
the O 0 7.860252379532362e-12
common O 0 3.8006833791293104e-10
defect O 0 2.318391167932532e-08
in O 0 6.86120119053335e-11
the O 0 5.492735780099345e-11
Cape O 0 2.3953345973382056e-09
and O 0 1.8278849267527875e-10
hitherto O 0 1.5096881966769615e-08
unreported O 0 2.152282263523375e-08
, O 0 4.6492018568322635e-11
and O 0 5.595208324438161e-11
1195delC O 0 5.749989817616097e-09
and O 0 6.32871186012629e-11
1936delG O 0 7.80531550503838e-09
, O 0 1.4608338844146473e-11
which O 0 3.373002571693817e-11
have O 0 9.014063107048997e-11
been O 0 3.323397113064175e-10
previously O 0 5.8314562068062514e-09
reported O 0 3.2891060985917875e-09
in O 0 3.23255755496632e-10
African O 0 4.086431637517762e-09
- O 0 2.384403501309862e-07
Americans O 0 8.828725128751103e-08
. O 0 2.84070384992674e-08

We O 0 1.6352281306808436e-07
also O 0 7.354808428949866e-10
show O 0 1.000048821531152e-09
that O 0 1.3523499160783548e-11
the O 0 2.1806586050776566e-11
879delG O 0 8.253877581410052e-08
and O 0 1.2307476149331364e-09
1195delC O 0 1.8581191625344218e-06
defects O 0 3.2289059163304046e-05
are O 0 1.6947465653061045e-10
associated O 0 3.995044739468767e-09
with O 0 1.755532053060449e-09
characteristic O 0 0.00012598407920449972
C6 O 1 0.5592365264892578
/ O 0 2.572590165073052e-05
C7 O 0 4.895351139566628e-06
region O 0 5.188259422084229e-08
DNA O 0 8.955602481819369e-08
marker O 0 4.359080207905208e-08
haplotypes O 0 1.4100298528774147e-07
, O 0 2.4044882751539376e-10
although O 0 6.671297958504852e-10
small O 0 1.0364309410704209e-09
variations O 0 3.619633659468491e-08
were O 0 5.222798638016002e-09
observed O 0 1.1159169588381701e-07
. O 0 9.738659656477466e-08

The O 0 2.4231830764165352e-08
1936delG O 0 1.935631416927208e-06
defect O 0 2.137400088031427e-07
was O 0 4.506885142863126e-10
observed O 0 3.2358887791517077e-10
only O 0 1.793665042881809e-11
once O 0 5.446689210764077e-10
in O 0 2.2252040488002223e-11
the O 0 4.8486263615199476e-11
Cape O 0 1.7069680113834806e-09
, O 0 6.387735479451706e-11
but O 0 7.507565402686822e-11
its O 0 5.4248723568850465e-11
associated O 0 3.3190594717069644e-09
haplotype O 0 6.570481048129295e-08
could O 0 5.542224013055375e-09
be O 0 6.239243011130213e-10
deduced O 0 1.0028690411445496e-07
. O 0 4.229609729122785e-08

The O 0 3.169588591589445e-09
data O 0 4.363204020307876e-09
from O 0 6.317302930769486e-11
the O 0 5.5746494226349697e-11
haplotypes O 0 2.1821474405214758e-08
indicate O 0 4.802958919469802e-09
that O 0 1.6817526538037697e-11
these O 0 1.3995480989403841e-11
three O 0 2.9818352648147695e-11
molecular O 0 3.668061410166956e-08
defects O 0 1.2454432862796239e-06
account O 0 6.76493971951686e-10
for O 0 3.6902730871091194e-11
the O 0 7.603077889495324e-11
defects O 0 4.872194494964788e-06
in O 0 1.2959537956658274e-11
all O 0 1.0610586194392813e-11
the O 0 2.4208324581054264e-11
38 O 0 2.254099268350629e-10
unrelated O 0 3.2997363175191197e-10
C6Q0 O 0 2.3642661162170953e-08
individuals O 0 4.5371397611182473e-11
we O 0 5.0207955848424746e-11
have O 0 8.909347218311048e-12
studied O 0 5.355286214481225e-10
from O 0 3.249258501147878e-11
the O 0 3.298024631170904e-10
Cape O 0 2.884073779796381e-08
. O 0 2.501734464033234e-08

We O 0 3.9441380295102135e-07
have O 0 1.128480087153605e-09
also O 0 1.0765727198602804e-10
observed O 0 3.3851463299150453e-10
the O 0 8.307185495048941e-11
879delG O 0 1.3665905385096266e-07
defect O 0 8.074680835079562e-08
in O 0 3.969619633004129e-10
two O 0 1.9516404492492256e-08
Dutch O 1 0.9999908208847046
C6 B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
deficient I-Disease 1 1.0
kindreds O 0 1.0196255971095525e-05
, O 0 5.227440702526565e-10
but O 0 1.6963894178267935e-10
the O 0 5.4915523517440334e-11
879delG O 0 6.905902694143151e-08
defect O 0 1.3343957938616313e-08
in O 0 1.867465904137333e-11
the O 0 2.440215043919558e-11
Cape O 0 5.047703366400924e-10
probably O 0 3.9620784431093625e-10
did O 0 2.4050939018138706e-10
not O 0 2.7779185202136958e-11
come O 0 4.632649125424493e-11
from O 0 7.480789425418077e-12
The O 0 2.943826085677337e-11
Netherlands O 0 5.0539899376644826e-08
. O 0 1.0393309546330443e-09
. O 0 1.3361428408131815e-08

Complement B-Disease 1 0.9547452926635742
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.121278181415164e-08
seven O 0 1.0318882415205621e-09
further O 0 5.702825434106273e-10
molecular O 0 1.529792257315421e-06
defects O 1 0.9974848031997681
and O 0 5.397619684543997e-09
their O 0 2.3809225702109416e-09
associated O 0 1.0015137519303607e-07
marker O 0 3.387797050891095e-06
haplotypes O 0 2.302222310390789e-05
. O 0 5.692348850061535e-07

Seven O 0 3.729991604473071e-08
further O 0 1.096390089827537e-09
molecular O 0 2.529303522180726e-08
bases O 0 1.126397393136358e-07
of O 0 1.7875620983431872e-07
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.7894533349837047e-09
described O 0 1.6286115567254456e-08
. O 0 3.8416619219105996e-08

All O 0 1.6539484226640866e-09
these O 0 3.8760145093519327e-10
new O 0 2.3980684105140426e-09
molecular O 0 8.152863983923453e-08
defects O 0 1.3590021126219654e-06
involve O 0 4.195532365969257e-09
single O 0 1.1022175172570314e-08
- O 0 5.0029463238843164e-08
nucleotide O 0 9.772693232434904e-08
events O 0 7.832812176644666e-10
, O 0 1.7702577251310636e-11
deletions O 0 1.2903266233266208e-09
and O 0 2.7472574562481533e-11
substitutions O 0 2.852434122235792e-10
, O 0 1.2949630083525232e-11
some O 0 4.427767614362255e-12
of O 0 6.380620424378813e-12
which O 0 5.83225412409405e-10
alter O 0 8.498749082264112e-08
splice O 0 1.0022169760759425e-07
sites O 0 9.819962620838396e-09
, O 0 1.9025567232766605e-10
and O 0 6.700577315221778e-10
others O 0 6.1034972631546225e-09
codons O 0 1.3800162150801043e-06
. O 0 7.919952338397707e-08

They O 0 2.9483203434210736e-08
are O 0 1.1233234481489163e-10
distributed O 0 2.1263453497954998e-10
along O 0 2.9072344531755334e-10
the O 0 3.380301039079825e-10
C7 O 0 5.830180072052826e-08
gene O 0 4.354466121014866e-09
, O 0 1.3350512362286793e-10
but O 0 1.1663350840684927e-10
predominantly O 0 1.0374613390595755e-09
towards O 0 3.555108152308861e-10
the O 0 3.332283615709031e-10
3 O 0 2.480456506859241e-09
end O 0 4.0639235976414056e-08
. O 0 6.535060492751654e-08

All O 0 7.642763755200122e-09
were O 0 7.516179900690645e-10
found O 0 4.3171508035122486e-10
in O 0 9.380778792644762e-11
compound O 0 1.7195072032905045e-08
heterozygous O 0 3.440564739776164e-07
individuals O 0 6.979285593899931e-09
. O 0 4.6933838149243456e-08

The O 0 1.8177888705395162e-06
C6 O 0 0.0010639536194503307
/ O 0 4.951308073941618e-05
C7 O 0 1.9038863683817908e-05
marker O 0 1.3778161473965156e-06
haplotypes O 0 1.8783196082949871e-06
associated O 0 1.4250429281048582e-08
with O 0 5.341330711061687e-10
most O 0 1.4091070532629146e-08
C7 B-Disease 0 0.008933263830840588
defects I-Disease 1 0.5492154955863953
are O 0 1.2560708029241141e-09
tabulated O 0 1.2879857536063355e-07
. O 0 3.6470610975669615e-09
. O 0 4.139574372175048e-08

A O 0 6.02273431127287e-08
genome O 0 7.884983688200009e-08
- O 0 9.329669836688481e-08
wide O 0 3.1441249603858523e-09
search O 0 4.223472682696183e-09
for O 0 1.9647933280353413e-10
chromosomal O 0 1.6072867765615229e-06
loci O 0 9.646687004760679e-08
linked O 0 1.7429800891477498e-06
to O 0 1.7938456053911978e-08
mental O 0 2.003972804232035e-05
health O 0 9.338140927184213e-09
wellness O 0 2.347204208774656e-09
in O 0 1.7141146141375074e-11
relatives O 0 3.0453842225774963e-10
at O 0 2.3013782546321693e-10
high O 0 3.339194698526171e-09
risk O 0 8.146708552203563e-08
for O 0 1.4500450840060353e-09
bipolar B-Disease 0 0.07303642481565475
affective I-Disease 0 0.13326187431812286
disorder I-Disease 0 0.0924028754234314
among O 0 3.4992191366711722e-09
the O 0 1.0499209279757338e-09
Old O 0 1.4101161696089548e-06
Order O 0 2.0316081261739782e-08
Amish O 0 3.5007076348847477e-06
. O 0 1.6283233605918213e-07

Bipolar B-Disease 1 0.999996542930603
affective I-Disease 1 0.9999696016311646
disorder I-Disease 1 0.9999842643737793
( O 0 8.810764597910747e-07
BPAD B-Disease 1 1.0
; O 0 2.0381290596560575e-05
manic B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9989523887634277
) O 0 6.594018220340558e-09
is O 0 1.917661585082442e-10
characterized O 0 7.027987081187348e-10
by O 0 5.402970432166754e-11
episodes O 0 1.1532252486290417e-08
of O 0 9.327023875460583e-11
mania B-Disease 0 4.959489388056681e-07
and O 0 2.0146899704087673e-09
/ O 0 2.0989148197259055e-08
or O 0 1.36048006194045e-09
hypomania B-Disease 0 4.567288272028236e-07
interspersed O 0 1.724733067476336e-08
with O 0 2.361352224866664e-10
periods O 0 3.5402660358840876e-08
of O 0 9.184423221952898e-10
depression B-Disease 0 1.8037029576589703e-06
. O 0 6.68002542170143e-08

Compelling O 0 8.726855185159366e-07
evidence O 0 3.114890390065739e-08
supports O 0 8.070736079446306e-09
a O 0 3.269901294178368e-10
significant O 0 1.973711194480643e-09
genetic O 0 2.9309164872870497e-08
component O 0 9.487945540342935e-09
in O 0 1.0980785031255991e-10
the O 0 2.2468665816788302e-10
susceptibility O 0 1.669752549560144e-07
to O 0 1.5719935575475574e-08
develop O 0 1.6601144352534902e-06
BPAD B-Disease 1 0.9999996423721313
. O 0 3.376316612957453e-07

To O 0 2.880949478978323e-09
date O 0 9.21896781136411e-09
, O 0 3.7635453781215134e-11
however O 0 8.508208027002695e-11
, O 0 1.0731730608337653e-11
linkage O 0 1.1725834747622343e-09
studies O 0 1.1010906630914974e-09
have O 0 2.365922562030942e-11
attempted O 0 5.707134209664844e-10
only O 0 1.5641521064480024e-11
to O 0 5.575202452479111e-11
identify O 0 1.2928942361156714e-08
chromosomal O 0 3.085623347942601e-07
loci O 0 1.3221213457370595e-08
that O 0 1.2348383426896703e-10
cause O 0 2.689675426825744e-10
or O 0 5.549996018316961e-10
increase O 0 1.5704374467517823e-09
the O 0 1.0649363613168816e-09
risk O 0 1.2176495545190846e-07
of O 0 2.86820067696425e-10
developing O 0 4.605959986747621e-07
BPAD B-Disease 1 1.0
. O 0 3.828013745987846e-07

To O 0 4.891573812670913e-09
determine O 0 1.5339177705797624e-09
whether O 0 3.699408002155735e-10
there O 0 2.5973724906980244e-11
could O 0 2.261376919054925e-10
be O 0 2.8134581470107278e-11
protective O 0 4.698448297091318e-10
alleles O 0 9.829683733642014e-10
that O 0 2.6826549662239962e-11
prevent O 0 4.953188414980048e-10
or O 0 5.499563027200338e-10
reduce O 0 2.2473263250333275e-09
the O 0 8.596325734577803e-11
risk O 0 2.516502117799746e-09
of O 0 3.066270544763161e-12
developing O 0 3.6026401861732893e-09
BPAD B-Disease 1 1.0
, O 0 9.810531727272309e-12
similar O 0 5.634434325357818e-12
to O 0 2.7019053227411716e-12
what O 0 5.657382548540646e-12
is O 0 1.4223137641614092e-12
observed O 0 1.839411609139141e-11
in O 0 9.082175116137403e-12
other O 0 9.461411654143603e-10
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 6.470938368474677e-11
we O 0 9.83292267053848e-11
used O 0 8.107286397773805e-09
mental O 0 9.425636449122976e-07
health O 0 2.4365431894324274e-09
wellness O 0 1.444942943074068e-09
( O 0 1.0924250219701559e-11
absence O 0 1.2778206270880332e-10
of O 0 1.8134240636902277e-11
any O 0 1.906343705115887e-08
psychiatric B-Disease 1 0.5299186706542969
disorder I-Disease 0 9.643735211284366e-06
) O 0 1.986524555963598e-10
as O 0 1.7211328195987363e-10
the O 0 6.006289909876728e-10
phenotype O 0 2.7406233016336046e-07
in O 0 8.792468975116208e-10
our O 0 5.002759873029561e-10
genome O 0 1.1386680487390777e-09
- O 0 7.275035240894567e-09
wide O 0 1.4418513050173942e-09
linkage O 0 1.7956805820062982e-08
scan O 0 4.953514576300222e-08
of O 0 6.677376533648083e-12
several O 0 2.8568479179535977e-11
large O 0 4.004808151769623e-10
multigeneration O 0 4.104230356460903e-06
Old O 0 1.0036229980414646e-07
Order O 0 1.2881873345804706e-09
Amish O 0 4.2909508835009547e-08
pedigrees O 0 3.117904157079465e-08
exhibiting O 0 3.8732381746342526e-09
an O 0 1.673067379082127e-10
extremely O 0 1.6426062288132925e-08
high O 0 5.8624845422627914e-08
incidence O 0 5.105142463435186e-06
of O 0 2.1830548035950414e-08
BPAD B-Disease 1 1.0
. O 0 3.2787013992674474e-07

We O 0 2.3898033418845444e-07
have O 0 2.98473301629798e-10
found O 0 1.264731791517093e-10
strong O 0 4.822212421040639e-11
evidence O 0 1.2656681258604863e-10
for O 0 1.9004811613321237e-11
a O 0 1.3490170092111953e-10
locus O 0 7.815210523176574e-08
on O 0 1.4742550291657608e-08
chromosome O 0 5.406650871009333e-06
4p O 0 5.3984822443453595e-05
at O 0 5.319332530007159e-09
D4S2949 O 0 9.342990381355776e-08
( O 0 2.53950055428831e-10
maximum O 0 1.2051462050521877e-09
GENEHUNTER O 0 1.5046651924421894e-06
- O 0 2.1401208982751996e-07
PLUS O 0 8.33087128171428e-08
nonparametric O 0 5.805921432511241e-07
linkage O 0 7.182098471503195e-08
score O 0 9.735369843610897e-09
= O 0 1.2876327559752099e-08
4 O 0 4.6163953215661024e-10
. O 0 3.4460181930207057e-10
05 O 0 8.972084941660796e-08
, O 0 2.514600749847773e-10
P O 0 1.2011817318580142e-07
= O 0 5.093023780489148e-09
5 O 0 1.8558131420487456e-10
. O 0 7.036943250326999e-11
22 O 0 1.2792081283130585e-10
x O 0 2.4385005126248416e-09
10 O 0 1.5134922481951918e-10
( O 0 4.662193547888549e-11
- O 0 1.654712811216541e-08
4 O 0 6.632727700406349e-10
) O 0 1.0379971882024108e-10
; O 0 3.1677857559309075e-10
SIBPAL O 0 1.7777017546904972e-07
Pempirical O 0 3.599241793494912e-08
value O 0 8.727507050387828e-10
< O 0 1.3542561516644014e-09
3 O 0 5.604565075922885e-11
x O 0 2.4054620517688363e-09
10 O 0 1.01862754342541e-10
( O 0 3.0752626140051476e-11
- O 0 6.25633456152741e-09
5 O 0 2.1963925123102968e-10
) O 0 3.182658650513481e-11
) O 0 1.1731415318350091e-11
and O 0 1.2692308141992736e-11
suggestive O 0 1.1816043699042211e-09
evidence O 0 1.5614970427790809e-10
for O 0 2.056047172793729e-11
a O 0 1.16603920963243e-10
locus O 0 1.230903592386312e-07
on O 0 2.29427605802357e-08
chromosome O 0 2.181774289056193e-05
4q O 1 0.661135196685791
at O 0 7.895875953067844e-09
D4S397 O 0 7.967557991150898e-08
( O 0 1.6451788542592993e-10
maximum O 0 9.547229673501079e-10
GENEHUNTER O 0 7.871442448958987e-07
- O 0 9.012837409727581e-08
PLUS O 0 3.203785325922581e-08
nonparametric O 0 2.7317904027768236e-07
linkage O 0 8.771974080445943e-08
score O 0 8.667259798755822e-09
= O 0 8.462592404612224e-09
3 O 0 2.5470922593306966e-10
. O 0 9.69694255448239e-11
29 O 0 8.333120304904185e-10
, O 0 6.655991729997979e-11
P O 0 8.603014123309549e-08
= O 0 3.999138797894375e-09
2 O 0 3.5407216048000123e-10
. O 0 1.0513491466301872e-10
57 O 0 4.1930178773519344e-10
x O 0 1.479807743010042e-08
10 O 0 3.0388741523168505e-10
( O 0 8.572976356591155e-11
- O 0 5.817394566065559e-08
3 O 0 6.79460376851182e-10
) O 0 7.874541990693373e-11
; O 0 1.7632258153543745e-10
SIBPAL O 0 1.0027103058973807e-07
Pempirical O 0 4.882003779016486e-08
value O 0 6.75466349520093e-10
< O 0 9.497247432932454e-10
1 O 0 7.0612925229252e-11
x O 0 2.4923505481666552e-09
10 O 0 1.3767735562719707e-10
( O 0 3.633448403261852e-11
- O 0 5.930738122827961e-09
3 O 0 1.6849451001110793e-10
) O 0 1.3525769046451863e-11
) O 0 4.2602301894567596e-12
that O 0 2.501233161561478e-12
are O 0 2.6404850528294332e-11
linked O 0 4.010820831013007e-08
to O 0 6.53765086511271e-09
mental O 0 2.1981943518767366e-06
health O 0 7.081736441705289e-08
wellness O 0 5.552590209845221e-07
. O 0 4.7515161583078225e-08

These O 0 1.2600305687726632e-08
findings O 0 1.120617465488749e-08
are O 0 7.621444447769576e-11
consistent O 0 2.0741590389672382e-10
with O 0 7.13214860434408e-12
the O 0 7.30791469005787e-12
hypothesis O 0 3.5930652897420146e-10
that O 0 4.180636305889385e-12
certain O 0 7.901502369067614e-11
alleles O 0 3.1995883720270513e-09
could O 0 1.348809286483288e-09
prevent O 0 6.544085273674227e-10
or O 0 1.344203776065811e-10
modify O 0 2.6564153099428722e-09
the O 0 6.452906264886593e-11
clinical O 0 7.812792190975415e-09
manifestations O 0 2.124311393458811e-09
of O 0 2.7291448614907843e-11
BPAD B-Disease 1 1.0
and O 0 1.345958622334109e-10
perhaps O 0 1.6069548469666017e-10
other O 0 1.817441752649529e-10
related O 0 1.0614858325652676e-07
affective B-Disease 0 0.0002827429852914065
disorders I-Disease 0 0.00020887887512799352
. O 0 2.3274034788300924e-07

Segregation O 0 0.0001496698969276622
distortion O 0 4.939399877912365e-05
in O 0 7.571683795504214e-07
myotonic B-Disease 1 0.9999970197677612
dystrophy I-Disease 1 0.9999972581863403
. O 0 3.6280985113990027e-06

Myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999998807907104
( O 0 1.017641079670284e-05
DM B-Disease 1 1.0
) O 0 7.026639536888979e-08
is O 0 1.395945026239076e-09
an O 0 6.52872589324005e-10
autosomal B-Disease 1 0.7137447595596313
dominant I-Disease 1 0.9997740387916565
disease I-Disease 0 0.001434587175026536
which O 0 6.849070199876905e-10
, O 0 2.2125669352224264e-11
in O 0 2.2842734648254037e-11
the O 0 2.6131692296149645e-11
typical O 0 4.530986696948958e-09
pedigree O 0 5.779978096143168e-07
, O 0 6.826478271548808e-11
shows O 0 1.2965361007033493e-09
a O 0 1.799759091758446e-10
three O 0 1.3752599059557724e-09
generation O 0 3.3589731884831053e-08
anticipation O 0 4.52345041423996e-08
cascade O 0 5.289822411214118e-07
. O 0 1.075662936500521e-07

This O 0 7.521289369094575e-09
results O 0 4.118931684615745e-08
in O 0 3.707469664604446e-09
infertility B-Disease 0 0.007632221095263958
and O 0 1.5283895038464834e-07
congenital B-Disease 1 0.9999692440032959
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.397163629235365e-07
CDM B-Disease 0 6.768196953998995e-07
) O 0 2.647233543484617e-10
with O 0 1.1349308645658418e-11
the O 0 5.19806732379724e-11
disappearance O 0 2.4405585108411287e-08
of O 0 1.2791111503318575e-09
DM B-Disease 1 1.0
in O 0 2.2654447207060002e-09
that O 0 4.5512460467023175e-09
pedigree O 0 3.419861513975775e-06
. O 0 1.0106266756793048e-07

The O 0 2.471318705232761e-09
concept O 0 2.519369157738538e-09
of O 0 4.654117022329096e-11
segregation O 0 1.0863303145924874e-08
distortion O 0 1.1702157465265373e-08
, O 0 2.276991616090296e-11
where O 0 2.6202514116779874e-11
there O 0 4.632735167708901e-12
is O 0 4.283313287389845e-12
preferential O 0 5.026010718722773e-10
transmission O 0 8.17977185985086e-10
of O 0 3.674489098409728e-12
the O 0 1.6009639794423158e-11
larger O 0 1.0573847353256838e-09
allele O 0 2.4607230031392646e-08
at O 0 7.301109161694797e-10
the O 0 4.3887840583956006e-10
DM B-Disease 1 0.9999997615814209
locus O 0 1.0230234437358376e-07
, O 0 4.5651107893895926e-10
has O 0 3.1341781947524794e-10
been O 0 3.315432373085514e-10
put O 0 2.1198702515601298e-10
forward O 0 1.238244090595586e-10
to O 0 8.077903623782134e-11
explain O 0 1.6039242156651312e-09
partially O 0 1.7325769263720758e-08
the O 0 3.696147554688167e-11
maintenance O 0 3.0587050670050075e-09
of O 0 7.731990742110284e-11
DM B-Disease 1 1.0
in O 0 5.907129230209307e-10
the O 0 1.008269245872384e-09
population O 0 2.6415369447363446e-08
. O 0 7.482145036874499e-08

In O 0 2.342446769887374e-08
a O 0 5.010106107761203e-09
survey O 0 3.780385782192752e-08
of O 0 4.944004650120348e-10
DM B-Disease 1 1.0
in O 0 1.0377171122399886e-08
Northern O 0 3.642475121523603e-07
Ireland O 0 3.8004409361747093e-06
, O 0 8.58562942962493e-10
59 O 0 6.61821086822556e-09
pedigrees O 0 1.423954074653011e-07
were O 0 1.025382889707771e-08
ascertained O 0 3.834224742149672e-07
. O 0 8.680731156118782e-08

Sibships O 0 1.0166351785301231e-05
where O 0 1.3807644805297059e-08
the O 0 2.7026899815374428e-11
status O 0 8.60774895805605e-10
of O 0 2.6498122272788915e-12
all O 0 5.0702675565006405e-12
the O 0 1.5807248088597903e-12
members O 0 1.8065679160961245e-11
had O 0 1.4584347618473714e-10
been O 0 7.710989485820718e-11
identified O 0 6.005900221595084e-10
were O 0 1.4872048037517516e-11
examined O 0 2.0525059429843395e-10
to O 0 9.037746245832423e-12
determine O 0 2.1915426418050998e-10
the O 0 4.445987848711308e-12
transmission O 0 6.255663209664419e-10
of O 0 5.6200838254028e-12
the O 0 2.4969934453444864e-10
DM B-Disease 1 1.0
expansion O 0 3.0322286903583517e-09
from O 0 1.8217140296261647e-10
affected O 0 1.0365613922758143e-09
parents O 0 1.3683367772188149e-09
to O 0 9.645220039322666e-11
their O 0 1.3935347320526148e-09
offspring O 0 1.3076596871997026e-07
. O 0 3.257379788124126e-08

Where O 0 7.416628733381003e-08
the O 0 1.4901336831130152e-09
transmitting O 0 1.3305856327860965e-06
parent O 0 8.85205906797637e-07
was O 0 1.5740697634214484e-08
male O 0 6.58430607813898e-08
, O 0 2.379769492577566e-09
58 O 0 6.622923365284805e-08
. O 0 5.935290658953818e-08

3 O 0 6.271127972468094e-08
% O 0 1.353192446984508e-09
of O 0 8.72129105045083e-12
the O 0 1.348699884412552e-11
offspring O 0 4.281318410903623e-09
were O 0 3.840038842461979e-10
affected O 0 9.061191380554945e-11
, O 0 1.460187699919846e-11
and O 0 3.4747666549650447e-11
in O 0 8.606755932949461e-12
the O 0 8.088846432940944e-12
case O 0 5.185266660490129e-10
of O 0 6.092449895273022e-12
a O 0 1.8133523849162003e-10
female O 0 2.6351257176315812e-08
transmitting O 0 4.004049003469845e-07
parent O 0 4.2076555928360904e-07
, O 0 3.4676066462679955e-09
68 O 0 1.2256838033408712e-07
. O 0 6.447256595265571e-08

7 O 0 1.0597223081276752e-06
% O 0 2.90241697342708e-08
were O 0 7.411789848532635e-09
affected O 0 4.562817323972013e-08
. O 0 6.528831164587245e-08

Studies O 0 6.747470706613967e-07
on O 0 4.942828368825758e-09
meiotic O 0 7.269364346029761e-07
drive O 0 7.239560062544115e-08
in O 0 3.3311284841630595e-09
DM B-Disease 1 1.0
have O 0 6.937634355885791e-10
shown O 0 2.0168267056419609e-10
increased O 0 6.315725026295738e-11
transmission O 0 3.685154126298329e-10
of O 0 1.930916797981963e-12
the O 0 4.132198055950553e-12
larger O 0 4.043091139660504e-10
allele O 0 9.01756269655607e-09
at O 0 4.769089012590655e-10
the O 0 3.4253697100972147e-10
DM B-Disease 1 0.9999998807907104
locus O 0 3.980925953328551e-07
in O 0 6.1456679745219844e-09
non O 0 3.395256862859242e-05
- O 0 0.00036893010837957263
DM O 1 0.9999994039535522
heterozygotes O 0 9.594624543751706e-07
for O 0 1.7066065227666627e-09
CTGn O 0 1.6199267065530876e-06
. O 0 7.413390079591409e-08

This O 0 3.633092049426523e-09
study O 0 8.557607955594904e-10
provides O 0 6.215875036907903e-11
further O 0 9.092626825080163e-12
evidence O 0 2.610351101939301e-10
that O 0 1.0023627761146514e-10
the O 0 5.217001275426014e-10
DM B-Disease 1 0.9999998807907104
expansion O 0 7.3390191701605545e-09
tends O 0 1.2433477358797518e-08
to O 0 1.3703341239512667e-10
be O 0 1.5874429548645708e-10
transmitted O 0 5.605960584631475e-09
preferentially O 0 1.0706500574997335e-07
. O 0 3.3793504883306014e-08

Diagnosis O 0 0.30334097146987915
of O 0 7.284340313162829e-07
hemochromatosis B-Disease 1 0.9999998807907104
. O 0 5.7389984249311965e-06

If O 0 5.274125669529894e-07
untreated O 0 4.391063612274593e-06
, O 0 5.814906778311979e-09
hemochromatosis B-Disease 1 1.0
can O 0 1.714855216050637e-06
cause O 0 6.379367079034637e-08
serious O 0 5.907438662688946e-07
illness O 0 1.0908046306212782e-06
and O 0 5.6432671036166226e-11
early B-Disease 0 7.38189065430106e-10
death I-Disease 0 8.238770221602465e-10
, O 0 5.7491508081986e-11
but O 0 9.522133082029427e-10
the O 0 3.6336167408279607e-10
disease O 0 1.5095988459279397e-08
is O 0 2.2424909151830263e-10
still O 0 2.4925692621025064e-09
substantially O 0 2.585844072200416e-08
under O 0 1.6224355192662188e-08
- O 0 0.07172861695289612
diagnosed O 0 8.441004320047796e-05
. O 0 3.6583283957725143e-08

The O 0 5.046146167586585e-09
cornerstone O 0 5.698144889265677e-08
of O 0 4.698132161085056e-11
screening O 0 5.265146985067304e-09
and O 0 7.163440673974009e-11
case O 0 1.2553683093052825e-10
detection O 0 1.3582813762624824e-09
is O 0 2.752686099893875e-11
the O 0 1.953499861873098e-11
measurement O 0 1.7535418450620455e-08
of O 0 1.7016067721531414e-10
serum O 0 6.429254284512353e-08
transferrin O 0 1.8091590447966155e-07
saturation O 0 5.389803803268478e-08
and O 0 1.2792062964450679e-09
the O 0 8.464234868554854e-10
serum O 0 3.558772903033969e-07
ferritin O 0 5.381470145948697e-06
level O 0 1.7575153776761e-07
. O 0 7.194945794708474e-08

Once O 0 4.7330550501101243e-07
the O 0 1.7534940166541446e-09
diagnosis O 0 8.572969818487763e-07
is O 0 4.591272362297616e-10
suspected O 0 1.232488102687057e-07
, O 0 3.291231731594735e-10
physicians O 0 5.682729842249046e-09
must O 0 1.2382304070968075e-09
use O 0 6.943635000311588e-09
serum O 0 3.295548083315225e-07
ferritin O 0 2.9909704153396888e-06
levels O 0 8.344897395318185e-08
and O 0 3.264394088375866e-09
hepatic O 0 7.14698501269595e-07
iron O 0 8.62204217355611e-07
stores O 0 1.405098117857051e-07
on O 0 1.4122167879548897e-09
liver O 0 4.308057199864379e-08
biopsy O 0 2.5433575956412824e-07
specimens O 0 4.3626631196502785e-09
to O 0 2.796990694609036e-10
assess O 0 1.835443441677853e-08
patients O 0 1.7288656062319774e-09
for O 0 8.435940314355239e-12
the O 0 6.998928520074443e-11
presence O 0 6.99362390221836e-09
of O 0 7.401290136321848e-10
iron B-Disease 0 0.0011010675225406885
overload I-Disease 0 4.8271754167217296e-06
. O 0 5.4619352596319004e-08

Liver O 0 0.00022181721578817815
biopsy O 1 0.9937426447868347
is O 0 3.996965425301369e-09
also O 0 7.403220397828036e-11
used O 0 1.8583104499647618e-10
to O 0 1.281652128176658e-11
establish O 0 1.4317655394613382e-10
the O 0 8.704058307440476e-12
presence O 0 2.5056190455785554e-10
or O 0 3.796626069085818e-10
absence O 0 7.790988409972499e-10
of O 0 2.7025970003591304e-11
cirrhosis B-Disease 0 7.144129909875119e-08
, O 0 2.019420047849607e-11
which O 0 2.422552158876101e-10
can O 0 2.8613174052338763e-09
affect O 0 1.5241429451862132e-08
prognosis O 0 1.5736651448605699e-07
and O 0 1.6445899087003113e-09
management O 0 2.5050768570622495e-08
. O 0 3.844637674887963e-08

A O 0 3.418220018147622e-08
DNA O 0 1.3386980413088168e-07
- O 0 1.330271857113985e-07
based O 0 7.22364035254941e-09
test O 0 2.028223144989738e-09
for O 0 8.869265565036866e-12
the O 0 1.884569583721074e-11
HFE O 0 6.509086603045944e-08
gene O 0 1.5436237843502454e-09
is O 0 2.5738387116058803e-11
commercially O 0 1.3669594345344649e-09
available O 0 8.455118272188145e-10
, O 0 1.770159713254671e-11
but O 0 1.5649578855025936e-11
its O 0 5.394708985084762e-12
place O 0 1.9923455940595858e-10
in O 0 9.889173681332242e-12
the O 0 5.079272072383567e-11
diagnosis O 0 2.0324671368143754e-07
of O 0 1.324732545882057e-10
hemochromatosis B-Disease 1 1.0
is O 0 5.266111102741888e-09
still O 0 1.8480546870591752e-08
being O 0 3.507110379885603e-09
evaluated O 0 4.4232947971067915e-08
. O 0 2.983967561931422e-08

Currently O 0 3.5336620385351125e-07
, O 0 3.5097516559723374e-10
the O 0 1.0772171349371362e-11
most O 0 1.0855333125447952e-11
useful O 0 4.9311849742439406e-11
role O 0 2.0238942466388465e-10
for O 0 9.416878735124534e-12
this O 0 2.6546346718059333e-11
test O 0 6.514955241954112e-10
is O 0 1.4408153489742226e-12
in O 0 1.5316936087528266e-12
the O 0 2.3687388855941904e-12
detection O 0 2.5783211676788653e-10
of O 0 1.300284272615082e-11
hemochromatosis B-Disease 1 1.0
in O 0 4.3664905025053713e-10
the O 0 5.502613989460947e-11
family O 0 4.2643727438118617e-10
members O 0 3.790596656005896e-11
of O 0 5.267108364043205e-12
patients O 0 6.379993755523117e-10
with O 0 4.999101826941299e-12
a O 0 9.10781866592103e-11
proven O 0 6.720906498003387e-09
case O 0 3.331603604106448e-10
of O 0 2.7345847808391e-11
the O 0 4.717685797572813e-09
disease O 0 3.7040510392216675e-07
. O 0 4.0277626567331026e-08

It O 0 7.545183144941348e-09
is O 0 5.094711319486578e-10
crucial O 0 9.178561022338272e-09
to O 0 5.771657818343101e-09
diagnose O 0 0.0012520940508693457
hemochromatosis B-Disease 1 1.0
before O 0 1.278844956686953e-05
hepatic B-Disease 1 0.9931517839431763
cirrhosis I-Disease 0 0.2528526782989502
develops O 0 1.0953873470498365e-06
because O 0 1.8698282033824398e-08
phlebotomy O 0 6.000867415423272e-06
therapy O 0 7.401070547530253e-07
can O 0 1.2588295739135447e-08
avert O 0 4.124995939491782e-06
serious O 0 0.00099798827432096
chronic O 1 0.9996410608291626
disease O 0 1.646355121920351e-05
and O 0 1.7862404610990978e-10
can O 0 1.8131414425415215e-10
even O 0 5.02273334035408e-10
lead O 0 1.1640755026576244e-09
to O 0 1.4922177382636903e-10
normal O 0 2.6903388405941087e-09
life O 0 2.5774669065725675e-09
expectancy O 0 1.3204125792753985e-08
. O 0 5.20021192773612e-10
. O 0 2.5405688219848344e-08

Prevalence O 0 0.013679095543920994
of O 0 4.54715021191987e-09
the O 0 2.4183983704517686e-09
I1307K O 0 6.748668397449364e-07
APC B-Disease 0 6.127504548203433e-08
gene O 0 2.0692098701147188e-08
variant O 0 4.040597190169137e-08
in O 0 1.908597307975768e-10
Israeli O 0 3.649275726047563e-08
Jews O 0 2.9065649886916844e-09
of O 0 2.9027156112776398e-12
differing O 0 5.705544925405093e-10
ethnic O 0 3.041507934398169e-09
origin O 0 1.0842230224739069e-08
and O 0 3.770065148955837e-09
risk O 0 7.379693442999269e-07
for O 0 3.1138631584326504e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.78637206874555e-07

BACKGROUND O 0 0.0001226927270181477
& O 0 5.832142960571218e-06
AIMS O 0 7.062312192829268e-07
Israeli O 0 6.099589882069267e-07
Jews O 0 7.482302066819102e-08
of O 0 8.323188666059522e-11
European O 0 1.3660713449326067e-08
birth O 0 5.291181270905554e-09
, O 0 8.08918973471684e-11
i O 0 5.924279400382204e-10
. O 0 1.8038891561045212e-11
e O 0 3.8731032270256094e-10
. O 0 1.1023966461909396e-11
, O 0 5.311538101709923e-12
Ashkenazim O 0 3.7488474546876205e-09
, O 0 1.3802515554106609e-11
have O 0 7.991288880626612e-11
the O 0 8.572555443286944e-10
highest O 1 0.9999322891235352
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 5.7360762184544e-06
of O 0 5.967826233188589e-11
any O 0 8.114463767583402e-09
Israeli O 0 0.010442727245390415
ethnic O 0 1.171499661722919e-06
group O 0 1.4954581502024666e-06
. O 0 1.1033369418100847e-07

The O 0 1.2601813637047599e-07
I1307K O 0 7.5238485806039535e-06
APC B-Disease 0 2.6968089628098824e-07
gene O 0 9.770121067731452e-08
variant O 0 6.354908350658661e-07
was O 0 1.1856867487836098e-08
found O 0 3.163114659088251e-09
in O 0 3.0662168359896214e-09
6 O 0 3.520052871408552e-08
. O 0 6.135843477750313e-08

1 O 0 9.730490546644432e-08
% O 0 7.382031652625187e-10
of O 0 2.7000608780053392e-12
American O 0 1.7021131726302485e-10
Jews O 0 1.0495524449538607e-09
, O 0 2.5960599989161004e-11
28 O 0 1.3719476943396813e-10
% O 0 1.6615162370947623e-11
of O 0 6.287595877979557e-12
their O 0 1.516175842652956e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 2.599161064154032e-07
, O 0 2.3588045405809055e-10
but O 0 5.811311432069033e-10
not O 0 2.615678784678721e-10
in O 0 5.127691604656093e-10
non O 0 3.405492066121951e-07
- O 0 1.973274237343503e-07
Jews O 0 2.6080851966980845e-07
. O 0 3.6192261632095324e-08

We O 0 1.5887400195424561e-07
assessed O 0 4.636766703924877e-08
the O 0 5.938715630371405e-10
I1307K O 0 1.2131256710290472e-07
prevalence O 0 1.2760662571054127e-07
in O 0 8.312352889339181e-11
Israeli O 0 1.97853289307659e-08
Jews O 0 3.0878319901006535e-09
of O 0 1.7251572349483157e-12
differing O 0 3.611541066206314e-10
ethnic O 0 1.616682787641821e-09
origin O 0 4.436371714433562e-09
and O 0 2.911575203157213e-09
risk O 0 2.042324211970481e-07
for O 0 1.1172907221634887e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.042364131848444e-07

METHODS O 0 4.382937106583995e-07
DNA O 0 5.791632062823737e-08
samples O 0 2.7039457339839146e-09
from O 0 1.9039351692451412e-11
500 O 0 2.6502584848930866e-11
unrelated O 0 1.265330201727366e-10
Jews O 0 3.9204941515436076e-09
of O 0 1.3851701036182718e-11
European O 0 4.214251170253647e-09
or O 0 1.829539297837357e-09
non O 0 1.3929130773249199e-06
- O 0 2.99319680152621e-07
European O 0 1.559720796961983e-09
origin O 0 1.6354706477983427e-10
, O 0 2.5283672724918382e-12
with O 0 9.741200901469682e-13
or O 0 1.9692053543352017e-10
without O 0 1.458888426730809e-10
a O 0 2.1563509658428792e-11
personal O 0 1.2943073279814143e-09
and O 0 7.660564960154659e-10
/ O 0 5.603993713521049e-09
or O 0 8.480475210959071e-10
family O 0 7.119461686855288e-10
history O 0 1.3819863031727664e-09
of O 0 2.7847512490408732e-11
neoplasia B-Disease 0 3.1114765874917794e-07
, O 0 3.18965305556862e-11
were O 0 4.5784674662652236e-11
examined O 0 1.2836032237117934e-09
for O 0 1.955803748121543e-11
the O 0 3.2137199151849316e-11
I1307K O 0 1.3053455205636055e-08
variant O 0 4.126328612130692e-09
by O 0 3.537574053136261e-11
the O 0 1.249522846302753e-10
allele O 0 1.002639535840899e-07
- O 0 8.665545436770117e-08
specific O 0 2.0807465972438877e-08
oligonucleotide O 0 5.829262590850703e-06
( O 0 4.189279145805358e-09
ASO O 0 1.352611747051924e-07
) O 0 6.669733099151642e-10
method O 0 2.1911853664846603e-08
. O 0 5.005275482972138e-08

RESULTS O 0 6.424277216865448e-07
In O 0 2.3635196577664885e-10
persons O 0 3.779423163319251e-10
at O 0 3.829878914007878e-10
average O 0 1.8679960689382824e-08
risk O 0 1.5279289300451637e-06
for O 0 1.6880829207366332e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.9341632739866554e-09
I1307K O 0 2.210813789815802e-07
was O 0 3.734403009048037e-09
found O 0 6.821145315250021e-10
in O 0 4.89434326400584e-10
5 O 0 6.384842876627772e-09
. O 0 3.0865557221204654e-08

0 O 0 6.809958108533465e-07
% O 0 6.364671012448753e-09
of O 0 4.395148134328508e-11
120 O 0 1.2876246735515906e-09
European O 0 2.7177627259789006e-08
and O 0 3.368807233172788e-09
1 O 0 6.613516401188235e-09
. O 0 1.7013098485563205e-08

6 O 0 1.4092998412706947e-07
% O 0 2.66203503684892e-09
of O 0 4.4193156079064266e-11
188 O 0 5.471149755464921e-09
non O 0 6.127212941464677e-07
- O 0 1.63359914040484e-06
European O 0 2.138137489282599e-08
Jews O 0 1.5681752785212666e-08
( O 0 3.4291025574617606e-10
P O 0 1.9333663203724427e-07
= O 0 1.7195793233781842e-08
0 O 0 1.5764185512523454e-09
. O 0 6.742756908373337e-10
08 O 0 3.0585546539896313e-08
) O 0 2.2326291926333397e-09
. O 0 2.2413514599861628e-08

It O 0 5.608016806490923e-08
occurred O 0 5.178205242373224e-08
in O 0 4.051731394838498e-09
15 O 0 2.533141696403618e-08
. O 0 5.281413706370586e-08

4 O 0 1.2368754198632814e-07
% O 0 3.3880938055119714e-09
of O 0 2.344652805241765e-10
52 O 0 1.24095166142979e-07
Ashkenazi O 0 0.003617173293605447
Israelis O 0 0.00015368939784821123
with O 0 1.1195343319059248e-08
familial O 0 0.034427255392074585
cancer B-Disease 0 0.00018164864741265774
( O 0 6.726780465982074e-09
P O 0 4.3277661461615935e-05
= O 0 2.628986806030298e-07
0 O 0 8.953652930188127e-09
. O 0 1.2012517647264076e-09
02 O 0 5.441437966879903e-09
) O 0 2.5304962986139046e-11
and O 0 3.2893538587375204e-11
was O 0 4.789225682699794e-10
not O 0 9.152033297876727e-11
detected O 0 1.523604353792507e-09
in O 0 1.284675421597825e-10
51 O 0 3.545954418981978e-09
non O 0 1.3434724621674832e-07
- O 0 1.1695065893491119e-07
European O 0 2.9192210870832014e-09
Jews O 0 2.376893348809972e-09
at O 0 4.327554703476011e-10
increased O 0 5.364919175576688e-09
cancer B-Disease 0 5.884228357899701e-07
risk O 0 2.5648506607467425e-07
. O 0 4.4918202490862313e-08

Colorectal B-Disease 1 0.9862030744552612
neoplasia I-Disease 0 0.0003942915645893663
occurred O 0 2.7802505542240397e-07
personally O 0 2.0001644784883865e-08
or O 0 6.9479366704428e-10
in O 0 3.29462811199388e-11
the O 0 1.320828776213423e-11
families O 0 1.0590797683285302e-10
of O 0 9.713931915789065e-12
13 O 0 1.4046297458492063e-10
of O 0 1.0416380431810257e-11
20 O 0 7.776082555643882e-10
Ashkenazi O 0 1.3340985560716945e-07
I1307K O 0 1.312150299526138e-08
carriers O 0 7.071606633601846e-10
, O 0 8.130299385122886e-12
8 O 0 1.692620002491374e-11
of O 0 1.0790694509807408e-12
whom O 0 1.7089005766024457e-08
also O 0 5.256610791093408e-08
had O 0 1.2984275876704032e-08
a O 0 2.6142211659307968e-11
personal O 0 1.1949992106963236e-09
or O 0 1.2967140694541968e-09
family O 0 8.169621090736712e-10
history O 0 7.983739891415098e-09
of O 0 1.1584893044869204e-09
noncolonic O 0 9.53569688135758e-05
neoplasia B-Disease 0 0.0003222634841222316
. O 0 2.1203115352363966e-07

CONCLUSIONS O 0 1.6219624967561685e-06
The O 0 7.316321326555908e-09
I1307K O 0 1.6152494026755448e-06
APC O 0 1.0542582629113895e-07
variant O 0 1.2663291215631034e-07
may O 0 1.6284802395460929e-09
represent O 0 1.2249062875113736e-10
a O 0 1.4024988115313164e-10
susceptibility O 0 8.802927276008177e-09
gene O 0 3.196869613475428e-08
for O 0 3.6443004169939286e-09
colorectal B-Disease 1 1.0
, I-Disease 0 2.9578531290930243e-10
or I-Disease 0 5.554401383278673e-10
other I-Disease 0 7.721767114610145e-10
, I-Disease 0 5.617091680676367e-09
cancers I-Disease 0 0.13131572306156158
in O 0 1.4645737955731875e-09
Ashkenazi O 0 9.249260074284393e-06
Jews O 0 4.556320831738958e-08
, O 0 3.1074398609831633e-10
and O 0 3.0774235937336414e-10
partially O 0 4.2810672340465317e-08
explains O 0 7.362447540515404e-09
the O 0 1.1504053959443539e-10
higher O 0 1.030142549041102e-08
incidence O 0 1.0516737347643357e-05
of O 0 6.161219971545506e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.5461670105642042e-08
European O 0 3.897666545071843e-07
Israelis O 0 5.3499898058362305e-06
. O 0 1.1462871185585755e-07

Systematic O 0 6.950818374207302e-07
analysis O 0 6.969045784899208e-08
of O 0 9.413494428400782e-10
coproporphyrinogen O 0 5.548314675252186e-06
oxidase O 0 3.6215926684235455e-06
gene O 0 6.438761374738533e-06
defects O 0 0.21325001120567322
in O 0 4.186227808844478e-09
hereditary B-Disease 0 0.0006495993584394455
coproporphyria I-Disease 0 0.0027462898287922144
and O 0 2.0900420949487852e-08
mutation O 0 1.7497316093795234e-06
update O 0 2.7154264898854308e-06
. O 0 1.0514548876017216e-07

Hereditary B-Disease 1 0.8547906875610352
coproporphyria I-Disease 0 0.0005011062021367252
( O 0 1.919610248535264e-08
HC B-Disease 0 1.0988463827743544e-06
) O 0 1.417776451795305e-09
is O 0 9.293377734032049e-10
an O 0 8.548394880847354e-09
acute O 0 5.192581011215225e-05
hepatic B-Disease 1 0.9868430495262146
porphyria I-Disease 1 0.9999403953552246
with O 0 1.1016735612656703e-07
autosomal O 1 0.999762237071991
dominant O 1 0.8823242783546448
inheritance O 0 0.03244011104106903
caused O 0 2.8015273301207344e-07
by O 0 8.862070521864496e-10
deficient B-Disease 0 4.720343440567376e-07
activity I-Disease 0 1.1519852627372984e-08
of I-Disease 0 3.3742780791712335e-10
coproporphyrinogen I-Disease 0 5.9926833273493685e-06
III I-Disease 0 2.3673442228755448e-07
oxidase I-Disease 0 3.713477099154261e-07
( O 0 1.5262133779003761e-09
CPO O 0 8.535045594726398e-07
) O 0 1.1030145685708703e-08
. O 0 4.925439611724869e-08

Clinical O 0 6.6180377871205565e-06
manifestations O 0 1.5269559128228138e-07
of O 0 1.183121517422947e-10
the O 0 8.109864446659287e-10
disease O 0 1.6552116122170446e-08
are O 0 1.2651364331150994e-11
characterized O 0 6.794396711917727e-10
by O 0 7.95581212020835e-10
acute O 0 3.549617701992247e-07
attacks O 0 0.0126832015812397
of O 0 7.596721474101287e-09
neurological B-Disease 1 0.9977205395698547
dysfunction I-Disease 0 5.2204140956746414e-06
often O 0 7.269791435504658e-09
precipitated O 0 4.7791175461497915e-09
by O 0 1.4791593297425187e-11
drugs O 0 1.7102497196219701e-09
, O 0 7.997521915548145e-12
fasting O 0 2.064135751211893e-09
, O 0 6.078362119188441e-11
cyclical O 0 4.005622429303912e-07
hormonal O 0 6.346610916807549e-07
changes O 0 2.9526012745861863e-09
, O 0 2.560238410165283e-10
or O 0 1.0635241132206374e-08
infectious B-Disease 0 3.7339282243920024e-07
diseases I-Disease 0 1.2916318610223243e-06
. O 0 5.880559683646425e-08

Skin O 1 0.9991211295127869
photosensitivity O 1 0.9980564713478088
may O 0 0.0005840433877892792
also O 0 2.9874911433580564e-09
be O 0 5.808274972096683e-10
present O 0 4.461361502450245e-09
. O 0 6.136662733524645e-08

The O 0 8.23161183660659e-09
seven O 0 2.3406858673524766e-09
exons O 0 4.7949065162811166e-08
, O 0 9.123310440450894e-11
the O 0 6.635533095211699e-11
exon O 0 5.08423276812664e-08
/ O 0 1.8876448848459404e-08
intron O 0 3.353155193508428e-07
boundaries O 0 9.918959875676592e-09
and O 0 6.474262237432526e-10
part O 0 3.4928490655339317e-10
of O 0 2.481726976699683e-11
3 O 0 2.2774009067472178e-10
noncoding O 0 4.076204618286283e-08
sequence O 0 1.3791686681585702e-09
of O 0 1.689088625911328e-11
the O 0 5.386383700178854e-11
CPO O 0 5.768843536202439e-08
gene O 0 5.212946074806268e-09
were O 0 2.4952603872030465e-10
systematically O 0 4.836051559209409e-09
analyzed O 0 1.3755616645738655e-09
by O 0 8.743225761442819e-12
an O 0 1.4328056102685949e-11
exon O 0 1.8362174003527798e-08
- O 0 1.4026420913637594e-08
by O 0 1.1982356218354084e-09
- O 0 2.0280120338611596e-07
exon O 0 2.6010854980995646e-06
denaturing O 0 2.864878115360625e-05
gradient O 0 3.6903531963616842e-06
gel O 0 4.685849853558466e-05
electrophoresis O 0 1.5301219491448137e-06
( O 0 1.1380340003697142e-09
DGGE O 0 1.8333133766645915e-07
) O 0 2.3331298004691803e-10
strategy O 0 1.2827368056633759e-09
followed O 0 5.192587679281324e-11
by O 0 3.2501371385884603e-12
direct O 0 5.2678743311940224e-11
sequencing O 0 5.534003255647235e-10
in O 0 9.72370517438037e-11
seven O 0 8.287723285427262e-10
unrelated O 0 5.559547489042416e-08
heterozygous O 0 4.818808179152256e-07
HC B-Disease 0 5.03785429373238e-07
patients O 0 3.958079020094374e-08
from O 0 5.051392082400241e-10
France O 0 5.86646024203219e-07
, O 0 1.7416336428599521e-10
Holland O 0 7.444904781550576e-08
, O 0 2.713124447328852e-10
and O 0 3.364139189443449e-09
Czech O 0 1.7961518778975005e-06
Republic O 0 6.559511689374631e-08
. O 0 3.7897059712577175e-08

Seven O 0 1.0968888375373353e-07
novel O 0 6.536381391697432e-08
mutations O 0 2.2023142776106397e-07
and O 0 5.618053244837995e-10
two O 0 2.0235313424876722e-10
new O 0 2.190030823356892e-09
polymorphisms O 0 1.295933088840684e-06
were O 0 1.6089224175175332e-08
detected O 0 3.257635228237632e-07
. O 0 5.975739725272433e-08

Among O 0 2.2885158657004467e-08
these O 0 8.837426901386891e-10
mutations O 0 2.6095820615523735e-08
two O 0 2.4308974277964523e-10
are O 0 5.612601494675573e-10
missense O 0 5.674895078300324e-07
( O 0 6.286271503341823e-10
G197W O 0 8.296714781863557e-08
, O 0 1.6346286824120426e-10
W427R O 0 1.871080357318533e-08
) O 0 6.494567383885652e-11
, O 0 7.816789750203501e-12
two O 0 3.318834790322356e-11
are O 0 2.9747246332867405e-10
nonsense O 0 7.037463234382813e-08
( O 0 1.168564134346184e-10
Q306X O 0 3.1059379068665294e-08
, O 0 1.094198065487717e-10
Q385X O 0 1.5391410812526374e-08
) O 0 8.439936249882152e-11
, O 0 6.490452706536809e-12
two O 0 7.77546603492052e-12
are O 0 4.53459630955777e-11
small O 0 6.592241752478856e-10
deletions O 0 1.1238287100923117e-07
( O 0 4.917680707094974e-10
662de14bp O 0 3.163786033155702e-08
; O 0 5.467057917485363e-10
1168del3bp O 0 6.261422669240346e-08
removing O 0 8.579069898928537e-09
a O 0 1.34833283427227e-10
glycine O 0 1.9486723346062718e-08
at O 0 4.832121369702236e-10
position O 0 9.483128726728296e-10
390 O 0 3.057595010513836e-10
) O 0 2.5526499317085616e-11
, O 0 1.5444380149776116e-11
and O 0 4.0618560598337794e-11
one O 0 1.283925743500447e-10
is O 0 7.47793979516409e-11
a O 0 2.6005858577704544e-10
splicing O 0 1.1121449006168405e-06
mutation O 0 3.4879903410001134e-07
( O 0 1.2556755635273475e-09
IVS1 O 0 1.2781737268596771e-06
- O 0 2.6045356094073213e-07
15c O 0 4.802260718861362e-06
- O 0 1.620529559431816e-07
- O 0 5.917622658557775e-08
> O 0 8.313628896416958e-09
g O 0 1.3590542913277659e-08
) O 0 7.083685027442499e-11
which O 0 6.875244124016078e-11
creates O 0 5.320811014009053e-10
a O 0 1.3129926312860363e-10
new O 0 2.1151214113501737e-09
acceptor O 0 4.4029498269537726e-08
splice O 0 1.6204705843847478e-06
site O 0 2.8430082466002204e-07
. O 0 1.2692913742284873e-07

The O 0 7.19855286490656e-09
pathological O 0 2.2648194430985313e-08
significance O 0 3.2740219424454153e-09
of O 0 4.555592361676908e-11
the O 0 9.56610901603483e-11
point O 0 3.9723411227043925e-09
mutations O 0 3.582065843943383e-08
G197W O 0 5.443028783247428e-08
, O 0 4.847424198151096e-11
W427R O 0 5.769302369174056e-09
, O 0 3.181487365222502e-11
and O 0 2.4257689607010136e-11
the O 0 1.1861282789293881e-11
in O 0 4.127161390421463e-10
- O 0 4.326618352479272e-08
frame O 0 6.077310672480962e-07
deletion O 0 1.4492998445803096e-07
390delGly O 0 6.197736013291433e-08
were O 0 5.8074305780975166e-11
assessed O 0 2.055444286996888e-10
by O 0 8.164503795260458e-12
their O 0 3.8706048782755076e-11
respective O 0 1.010036165816075e-09
expression O 0 1.1079036577044121e-09
in O 0 1.3961413969365566e-10
a O 0 7.250051947682579e-11
prokaryotic O 0 7.432511273108844e-10
system O 0 1.3838319379289032e-10
using O 0 2.725140946235882e-10
site O 0 5.002619207772341e-09
- O 0 8.574052401399967e-08
directed O 0 8.473401180708606e-08
mutagenesis O 0 1.8567729966889601e-06
. O 0 1.4678303728032915e-07

These O 0 2.2977751257258205e-08
mutations O 0 2.0504349151906354e-07
resulted O 0 4.605105186072933e-09
in O 0 1.1244274261690279e-10
the O 0 6.757946285906868e-11
absence O 0 9.669908207499134e-10
or O 0 2.8939842189323883e-10
a O 0 2.668164023056363e-10
dramatic O 0 7.751020092428007e-08
decrease O 0 1.9381401727969205e-07
of O 0 7.246226396695477e-10
CPO O 0 8.05905983725097e-06
activity O 0 6.925991442585655e-07
. O 0 7.751508235287474e-08

The O 0 6.725189738432391e-09
two O 0 1.0521400417573545e-09
polymorphisms O 0 2.675926964457176e-07
were O 0 1.7224343062949288e-09
localized O 0 1.7684110176219292e-08
in O 0 1.1582949044353086e-09
noncoding O 0 4.877927040070063e-07
part O 0 1.3497485351621208e-09
of O 0 1.5522966592684817e-11
the O 0 4.041963291845363e-11
gene O 0 2.637824847440129e-09
1 O 0 3.2013633410876707e-10
) O 0 5.902913574606927e-11
a O 0 2.6546612130751157e-10
C O 0 2.5106782430839303e-08
/ O 0 9.192244299072172e-09
G O 0 2.3611880450857825e-08
polymorphism O 0 3.925075375832421e-08
in O 0 2.6206625758362634e-10
the O 0 2.844870727880533e-10
promotor O 0 3.160553490033635e-07
region O 0 1.0036321995698927e-08
, O 0 1.6623509513369328e-10
142 O 0 1.12055709156067e-09
bp O 0 2.87998407344503e-08
upstream O 0 5.070650010985389e-10
from O 0 2.3738736670830818e-11
the O 0 3.259711944814114e-11
transcriptional O 0 6.1316760557872385e-09
initiation O 0 5.149489168410071e-10
site O 0 1.4274035287087372e-09
( O 0 2.4913227036904573e-10
- O 0 1.0131198102669714e-08
142C O 0 1.3254533826057013e-07
/ O 0 8.843517917966892e-09
G O 0 4.631814043420945e-09
) O 0 1.7733566351485486e-11
, O 0 8.361053169259058e-12
and O 0 2.7002013472388064e-11
2 O 0 5.400373898067912e-11
) O 0 3.523022845675072e-11
a O 0 9.071013384875926e-11
6 O 0 9.400648037782844e-10
bp O 0 4.622435412215964e-08
deletion O 0 1.4881321064308395e-08
polymorphism O 0 3.8338878738386484e-08
in O 0 1.826261086801395e-10
the O 0 9.117830795934978e-11
3 O 0 2.6547120057784923e-10
noncoding O 0 4.509529460960948e-08
part O 0 6.205205793641255e-10
of O 0 2.3387333736302196e-11
the O 0 1.6924918411209688e-10
CPO O 0 6.036673028120276e-08
gene O 0 8.40410674385339e-09
, O 0 2.2996361759286543e-10
574 O 0 3.926810876464515e-09
bp O 0 1.2224801615445813e-08
downstream O 0 3.980575868922642e-10
of O 0 1.3780648714170618e-12
the O 0 7.90424236479792e-12
last O 0 2.0611523599001202e-10
base O 0 1.551983680458946e-10
of O 0 7.0954323146132925e-12
the O 0 1.6575574246502356e-10
normal O 0 2.5666068381724472e-08
termination O 0 4.6358780991795356e-07
codon O 0 6.0923929368073e-07
( O 0 1.4431498218669958e-09
+ O 0 5.6717958329954854e-08
574 O 0 8.019120656399537e-08
delATTCTT O 0 2.0250358545581548e-07
) O 0 5.766167543441725e-09
. O 0 1.655574699555018e-08

Five O 0 5.636068323155996e-08
intragenic O 0 6.996721708674158e-07
dimorphisms O 0 5.676367891283007e-07
are O 0 3.026172090692114e-10
now O 0 4.399562381074418e-10
well O 0 4.0335838835670046e-11
characterized O 0 2.2012827671780144e-10
and O 0 1.1668402355446972e-10
the O 0 3.617557642332514e-11
high O 0 9.093086839051523e-10
degree O 0 2.2206485539300047e-09
of O 0 2.7555697307279914e-11
allelic O 0 1.996970055984093e-08
heterogeneity O 0 4.049500645919579e-08
in O 0 5.768419630847177e-10
HC B-Disease 0 1.283832062881629e-07
is O 0 1.8195402129439486e-10
demonstrated O 0 8.14857695208282e-11
with O 0 3.947877615095852e-12
seven O 0 1.1515244487114717e-11
new O 0 1.1716321489385617e-11
different O 0 1.1442140637751841e-11
mutations O 0 3.609729737341638e-10
making O 0 5.342275233299887e-11
a O 0 3.517852328882576e-11
total O 0 4.896768407425256e-11
of O 0 4.809572531905282e-11
nineteen O 0 1.2748888877922582e-07
CPO O 0 0.0001563091791467741
gene B-Disease 0 8.415950105700176e-06
defects I-Disease 0 0.14353753626346588
reported O 0 4.896175465063379e-09
so O 0 2.0006737933009333e-10
far O 0 8.134837803375206e-10
. O 0 1.6678778358425461e-09
. O 0 4.024360933385651e-08

Coincidence O 0 2.7424562176747713e-07
of O 0 1.2388487458103725e-10
two O 0 1.4240741919024913e-10
novel O 0 5.563172589262422e-09
arylsulfatase O 0 4.310400072427001e-07
A O 0 2.323835124329321e-09
alleles O 0 1.3584096336671792e-07
and O 0 1.624327161664496e-08
mutation O 0 1.0237569085802534e-06
459 O 0 2.712442324082076e-07
+ O 0 2.1645881531640043e-07
1G O 0 1.707627234281972e-06
> O 0 3.452574404150255e-08
A O 0 7.568270454783033e-10
within O 0 1.5812148812521798e-10
a O 0 3.169067230857081e-10
family O 0 5.9223959070209276e-09
with O 0 2.382023112090792e-08
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 6.450033840366132e-09
molecular O 0 1.413187433740859e-08
basis O 0 5.605479191927998e-09
of O 0 7.819705993838966e-10
phenotypic O 0 1.0472659596416634e-05
heterogeneity O 0 6.300414679571986e-05
. O 0 1.2833440905524185e-06

In O 0 2.2422236511943083e-08
a O 0 5.122403057278291e-10
family O 0 6.646632688678267e-10
with O 0 2.5040221632299797e-11
three O 0 1.3850598445941387e-10
siblings O 0 1.5504317829595493e-08
, O 0 2.7752439235584347e-11
one O 0 5.1337076950597194e-11
developed O 0 1.273427141512684e-09
classical O 0 9.298155134729313e-08
late O 0 1.4529493910231395e-06
infantile O 1 0.8278802037239075
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.820000766234898e-08
MLD B-Disease 1 0.9999979734420776
) O 0 1.3271534982095545e-09
, O 0 1.1771744690136643e-10
fatal O 0 4.2531109301080505e-08
at O 0 1.3336953763598558e-09
age O 0 1.5351558912968244e-09
5 O 0 1.6220315368631333e-10
years O 0 1.2471995658458468e-09
, O 0 4.664158989586831e-11
with O 0 4.107089390803509e-10
deficient O 0 1.2348369864412234e-06
arylsulfatase O 0 6.789252893213416e-07
A O 0 2.30107666254753e-09
( O 0 2.850024938272355e-10
ARSA O 0 9.56161329668248e-07
) O 0 1.6393808532910725e-10
activity O 0 1.2469664190106755e-09
and O 0 2.9643990040462143e-10
increased O 0 2.373015783874166e-09
galactosylsulfatide O 0 7.457680339939543e-07
( O 0 4.405921405492563e-09
GS O 1 0.9999995231628418
) O 0 8.97307383951329e-09
excretion O 0 1.7073180913484975e-07
. O 0 6.28751166686925e-08

The O 0 1.867425103441178e-09
two O 0 1.4082834898232477e-10
other O 0 1.1730616478189404e-10
siblings O 0 1.723006981535491e-08
, O 0 2.1097376623480102e-10
apparently O 0 1.4252768743006072e-08
healthy O 0 1.48646894793103e-09
at O 0 3.038624629692066e-10
12 O 0 9.10160141698313e-11
( O 0 1.5243790604801966e-11
1 O 0 6.178040717896849e-11
/ O 0 3.756970012869232e-10
2 O 0 2.4290238223589888e-11
) O 0 1.4812484572246376e-11
and O 0 3.807167775482512e-11
15 O 0 3.335054107878044e-11
years O 0 1.0842033520974681e-10
, O 0 6.373663315878408e-12
respectively O 0 4.0181136196082434e-10
, O 0 6.258023266259016e-11
and O 0 2.0052963456418382e-10
their O 0 9.905261333376103e-11
father O 0 5.612850628722299e-09
, O 0 1.4211248844375746e-10
apparently O 0 6.69732269642509e-09
healthy O 0 3.895031519540737e-10
as O 0 5.7105067202689597e-11
well O 0 2.234319257388151e-10
, O 0 6.579475853030203e-11
presented O 0 5.9286571207906036e-09
ARSA O 0 6.573140581167536e-06
and O 0 1.4258586311655108e-08
GS O 1 0.9999992847442627
values O 0 7.300120508091368e-10
within O 0 1.6222998638903974e-11
the O 0 2.3504274915264745e-11
range O 0 1.4405152626295603e-09
of O 0 2.1981874098742082e-09
MLD B-Disease 1 0.9999988079071045
patients O 0 6.724217200826388e-07
. O 0 3.4937986725935843e-08

Mutation O 0 1.2566853911266662e-05
screening O 0 1.3847385389453848e-06
and O 0 1.3133764076300736e-09
sequence O 0 3.1880447171062087e-09
analysis O 0 4.503484696272153e-09
disclosed O 0 7.108054589366475e-09
the O 0 2.7288640097600236e-11
involvement O 0 1.2596167442424644e-09
of O 0 1.026878582166546e-11
three O 0 1.0078072404384741e-10
different O 0 2.086456341032772e-09
ARSA O 0 4.3082894990220666e-05
mutations O 0 1.1358274321082718e-07
being O 0 9.794237643134807e-10
the O 0 3.203322329614622e-11
molecular O 0 1.5848147238983756e-09
basis O 0 7.393670675703845e-10
of O 0 6.031419808039118e-10
intrafamilial O 0 9.949724699254148e-06
phenotypic O 0 1.81122959475033e-05
heterogeneity O 0 5.4564290621783584e-05
. O 0 1.2286956234675017e-06

The O 0 5.636756128524212e-08
late O 0 5.370951612349018e-07
infantile O 0 2.0417999621713534e-05
patient O 0 1.5936080899336957e-06
inherited O 0 1.0768509355330025e-06
from O 0 8.257900474539781e-10
his O 0 5.588470797235345e-10
mother O 0 1.0405280193026556e-07
the O 0 2.0436229097864356e-10
frequent O 0 6.951296427359921e-08
0 O 0 5.9499914328853265e-08
- O 0 2.4697615117474925e-06
type O 0 2.8295964966673637e-06
mutation O 0 1.653208755669766e-06
459 O 0 1.0692051688465654e-07
+ O 0 2.7633216603817345e-08
1G O 0 1.1273731814753774e-07
> O 0 2.2602224536427684e-09
A O 0 2.2537038901759843e-10
, O 0 4.648678664231909e-11
and O 0 5.999909596932085e-11
from O 0 3.169525059076861e-11
his O 0 2.3733404130865665e-10
father O 0 9.03017927100791e-09
a O 0 7.93363916229417e-11
novel O 0 2.105577712185891e-09
, O 0 7.506119337197248e-11
single O 0 1.5476242509748772e-09
basepair O 0 1.1226331508851217e-07
microdeletion O 0 3.4367797496770436e-08
of O 0 2.2693995987976834e-11
guanine O 0 1.6947611314321875e-08
at O 0 3.065893372511397e-10
nucleotide O 0 2.2330773674639204e-08
7 O 0 9.005062806544117e-10
in O 0 1.1243502656688165e-10
exon O 0 3.8162323079404814e-08
1 O 0 3.4314462382667443e-09
( O 0 5.010934445159876e-10
7delG O 0 1.7783257533210417e-07
) O 0 6.238579874917605e-09
. O 0 3.125054348629419e-08

The O 0 2.4925800090613848e-08
two O 0 1.1508454633712972e-08
clinically O 0 5.839116283823387e-07
unaffected O 0 4.137664575409872e-07
siblings O 0 2.310465561095043e-07
carried O 0 9.594588235017909e-09
the O 0 1.6085994758441302e-09
maternal O 0 4.921509457744833e-07
mutation O 0 7.026779371699376e-07
459 O 0 7.666010048978933e-08
+ O 0 5.5355183548044806e-08
1G O 0 2.7295871518617787e-07
> O 0 8.624681413493818e-09
A O 0 8.552076269374709e-10
and O 0 3.1148811308057134e-10
, O 0 3.6980023210286816e-11
on O 0 8.366369402823537e-11
their O 0 2.2487101070112203e-10
paternal O 0 2.4895486561149482e-08
allele O 0 6.059202206643022e-08
, O 0 1.0524846966175616e-10
a O 0 5.616186335433149e-11
novel O 0 3.101531920179923e-09
cytosine O 0 2.8923148320814107e-08
to O 0 1.1203150213079383e-10
thymidine O 0 1.455116489523789e-07
transition O 0 1.0739610090126916e-08
at O 0 1.2336313082172978e-09
nucleotide O 0 1.3959382272332732e-07
2435 O 0 6.246405064302962e-07
in O 0 2.890756800599803e-10
exon O 0 2.537498566823615e-08
8 O 0 1.0417106066640258e-09
, O 0 3.2414716744089134e-11
resulting O 0 9.540088857784568e-11
in O 0 2.6928259969083435e-11
substitution O 0 5.03082520086906e-10
of O 0 8.03674765625928e-11
alanine O 0 5.305200829752721e-07
464 O 0 1.3853915348249757e-08
by O 0 1.3941197085642898e-09
valine O 0 2.9361253837123513e-05
( O 0 4.866123060054406e-09
A464V O 0 4.3202030042266415e-07
) O 0 6.869994351177411e-09
. O 0 1.945389449531376e-08

The O 0 7.181961336755194e-08
fathers O 0 7.298337436623115e-07
genotype O 0 2.901570269386866e-06
thus O 0 2.8666340412542013e-08
was O 0 2.2859243387074457e-08
7delG O 0 3.4416389098623767e-06
/ O 0 1.2827750879296218e-06
A464V O 0 8.857076863932889e-06
. O 0 3.424746921609767e-07

Mutation O 0 8.110449925879948e-06
A464V O 0 2.8560953069245443e-06
was O 0 4.3337022859191165e-09
not O 0 9.314579663133316e-11
found O 0 1.936458216000858e-10
in O 0 3.618642885339085e-10
18 O 0 3.3610607630407685e-09
unrelated O 0 1.4293445360635815e-07
MLD B-Disease 1 0.9999998807907104
patients O 0 3.7840581512682547e-07
and O 0 7.654898381836972e-10
50 O 0 3.4950835559044435e-09
controls O 0 6.126044809207087e-07
. O 0 2.4343711402252666e-07

A464V O 0 1.040820097841788e-05
, O 0 7.2662289518632406e-09
although O 0 3.7728202784137466e-09
clearly O 0 1.2703952556591958e-08
modifying O 0 1.1593523652209115e-07
ARSA O 0 2.3189335479401052e-05
and O 0 5.1433008962931126e-08
GS O 1 1.0
levels O 0 2.7726134277372694e-08
, O 0 9.432469388892528e-11
apparently O 0 1.32310196132579e-09
bears O 0 7.6358241951624e-10
little O 0 1.5635534533764428e-10
significance O 0 6.874749103324973e-10
for O 0 1.2152627515416015e-10
clinical O 0 1.9322284217082597e-08
manifestation O 0 1.3695933276380856e-08
of O 0 1.3052003922098265e-09
MLD B-Disease 1 0.9999947547912598
, O 0 7.937078216890825e-10
mimicking O 0 1.1518451970005117e-07
the O 0 8.482259339359643e-09
frequent O 0 4.435199571162229e-06
ARSA O 0 0.00415662070736289
pseudodeficiency O 0 0.00011227787763345987
allele O 0 7.97170796431601e-05
. O 0 1.6096519175334834e-06

Our O 0 1.8161897230584145e-07
results O 0 1.0243546455512842e-08
demonstrate O 0 9.280340385053876e-10
that O 0 9.79473273321485e-12
in O 0 1.4755608193639524e-11
certain O 0 3.487549971037396e-10
genetic O 0 1.8216294961348467e-07
conditions O 0 1.9292203035092825e-07
MLD B-Disease 1 0.9999963045120239
- O 0 3.776854669013119e-07
like O 0 2.2909876662424722e-08
ARSA O 0 1.5842806533328258e-05
and O 0 7.524646683521041e-09
GS O 1 0.9999974966049194
values O 0 8.194419032214739e-10
need O 0 5.1039294318711015e-11
not O 0 4.747122400033943e-12
be O 0 1.1844637683861015e-12
paralleled O 0 2.481089500516731e-10
by O 0 1.4485378174722285e-10
clinical O 0 2.586964740203257e-07
disease O 0 8.402872175850007e-09
, O 0 1.0369796167586376e-11
a O 0 4.379575174739969e-11
finding O 0 1.0196173905185901e-09
with O 0 2.419564271161079e-10
serious O 0 3.4885317745647626e-08
diagnostic O 0 2.081537218145968e-07
and O 0 5.76416647746214e-09
prognostic O 0 9.100552233576309e-06
implications O 0 5.888898613193305e-07
. O 0 1.6304305461289914e-07

Moreover O 0 3.6357464523462113e-06
, O 0 2.3662375170374617e-08
further O 0 3.973631379494691e-08
ARSA O 0 0.00014745694352313876
alleles O 0 4.775147317559458e-07
functionally O 0 5.9145417452555193e-08
similar O 0 1.4189073249681883e-09
to O 0 2.373268248589966e-10
A464V O 0 3.193596853634517e-08
might O 0 1.688694073465058e-09
exist O 0 7.018515768564271e-10
which O 0 7.180033650966422e-11
, O 0 3.3855433647506095e-12
together O 0 7.896828156661595e-12
with O 0 1.7758140444246173e-11
0 O 0 4.872958481172418e-09
- O 0 2.259556168837662e-07
type O 0 1.8709810944983474e-07
mutations O 0 2.2859032355881936e-07
, O 0 2.694481582299346e-10
may O 0 4.5129260328735654e-09
cause O 0 1.330463517135172e-09
pathological O 0 1.0882553169722087e-07
ARSA O 0 0.000496425258461386
and O 0 2.1312609987944597e-07
GS O 1 1.0
levels O 0 1.4106130485913582e-08
, O 0 1.1027835762622562e-11
but O 0 6.681329101088096e-11
not O 0 1.826623297063179e-10
clinical O 0 9.096560837917878e-09
outbreak O 0 1.2866500087582722e-09
of O 0 8.149193993223225e-12
the O 0 8.710244747689444e-10
disease O 0 7.221769493526153e-08
. O 0 2.685201838659168e-09
. O 0 6.558398268907695e-08

Human O 0 3.405809184187092e-05
MLH1 O 0 0.3785277307033539
deficiency O 0 0.00539264315739274
predisposes O 0 1.8404325601295568e-05
to O 0 1.2163984308699582e-07
hematological B-Disease 1 0.6948127746582031
malignancy I-Disease 1 0.9985141158103943
and O 0 3.152931071781495e-07
neurofibromatosis B-Disease 0 0.0020406991243362427
type I-Disease 0 4.0695977077120915e-05
1 I-Disease 0 4.855731958741671e-07
. O 0 2.8234595106368943e-07

Heterozygous O 0 4.210688348393887e-05
germ O 0 0.0006727210129611194
- O 0 0.00027686444809660316
line O 0 2.641915273216e-07
mutations O 0 9.452833893419665e-08
in O 0 1.8313119076740492e-10
the O 0 1.4875629894550713e-10
DNA O 0 3.378558233180229e-07
mismatch O 0 3.919744813174475e-06
repair O 0 8.548738605895778e-07
genes O 0 1.3615689908874629e-07
lead O 0 9.793237865096671e-08
to O 0 4.541016451753421e-08
hereditary B-Disease 1 0.9997015595436096
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.4893229136941954e-06

The O 0 4.0896146913382836e-08
disease O 0 2.3658679992877296e-07
susceptibility O 0 2.3690553518918023e-08
of O 0 4.231185193881437e-11
individuals O 0 1.7650235717425744e-09
who O 0 2.0813894607840666e-08
constitutionally O 0 2.9012989344323614e-08
lack O 0 5.368877564748686e-10
both O 0 1.9212932633738689e-10
wild O 0 4.12817113826236e-09
- O 0 1.7619571508475929e-06
type O 0 4.913218276669795e-07
alleles O 0 2.2416536182845448e-07
is O 0 3.275658189139108e-09
unknown O 0 1.722922178259978e-07
. O 0 8.134643536550357e-08

We O 0 1.6097119726055098e-07
have O 0 3.408262561066522e-10
identified O 0 6.432879229301136e-10
three O 0 5.041638981295726e-11
offspring O 0 1.0100497105369755e-09
in O 0 9.450314836234597e-11
a O 0 6.667612240107701e-09
hereditary B-Disease 1 0.9999833106994629
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 6.305803026407375e-07
who O 0 3.615190280470415e-08
developed O 0 3.387365410389975e-08
hematological B-Disease 0 0.0009183930815197527
malignancy I-Disease 0 0.31081968545913696
at O 0 8.94775864512809e-10
a O 0 3.656446326272267e-11
very O 0 4.730476080294643e-11
early O 0 2.0674493228511892e-09
age O 0 2.2308583869090626e-09
, O 0 1.1744758811327305e-11
and O 0 3.480511018283394e-11
at O 0 2.705397711411095e-11
least O 0 2.201351731109802e-12
two O 0 1.7059662059740188e-12
of O 0 3.465853905953997e-13
them O 0 4.600728825687739e-11
displayed O 0 3.952856708622221e-09
signs O 0 2.818806876803137e-08
of O 0 4.4780604224747833e-10
neurofibromatosis B-Disease 0 2.2828780856798403e-05
type I-Disease 0 1.103466956919874e-06
1 I-Disease 0 3.2588090448371076e-08
( O 0 3.758843014622926e-09
NF1 B-Disease 0 1.5440298739122227e-05
) O 0 1.3694366529648505e-08
. O 0 5.411208903183251e-08

DNA O 0 1.8155366205974133e-06
sequence O 0 3.1550058565699146e-08
analysis O 0 1.4156829486466904e-08
and O 0 5.59796542454194e-10
allele O 0 4.443080570126767e-08
- O 0 1.0276266060316175e-08
specific O 0 6.667049690101123e-10
amplification O 0 1.1359613694139625e-08
in O 0 9.908739107000741e-11
two O 0 2.0474698325667617e-10
siblings O 0 3.692693439916184e-08
revealed O 0 4.439437972791893e-08
a O 0 3.2696907403817477e-09
homozygous O 0 6.275163286773022e-06
MLH1 O 0 4.455295857042074e-05
mutation O 0 4.834827223021421e-07
( O 0 2.1977304420772725e-09
C676T O 0 5.414738666331687e-07
- O 0 2.4418682187388185e-06
- O 0 2.6662191885407083e-06
> O 0 2.1649474035712046e-07
Arg226Stop O 0 2.624813078000443e-06
) O 0 9.707056491947696e-09
. O 0 4.773426454107721e-08

Thus O 0 1.6865293162027228e-07
, O 0 7.87086673614823e-10
a O 0 1.2300647167506895e-09
homozygous O 0 7.267610158123716e-07
germ O 0 9.872148075373843e-05
- O 0 2.5563003873685375e-05
line O 0 9.971495273930486e-07
MLH1 O 0 9.600560588296503e-05
mutation O 0 1.2923046597279608e-06
and O 0 5.128427904566024e-09
consequent O 0 4.047531092510326e-06
mismatch O 1 0.7350925803184509
repair O 1 0.6973207592964172
deficiency O 0 0.015084800310432911
results O 0 4.552695997972478e-09
in O 0 1.6190272733584976e-10
a O 0 2.814711574927742e-09
mutator O 0 4.153502231929451e-05
phenotype O 0 1.228618316417851e-06
characterized O 0 1.7661628604059842e-08
by O 0 4.3711754216246845e-09
leukemia B-Disease 0 0.00804158952087164
and O 0 1.703219076887308e-08
/ O 0 0.07736605405807495
or O 1 0.9925153851509094
lymphoma B-Disease 1 1.0
associated O 0 5.958468136668671e-06
with O 0 5.959892579454618e-09
neurofibromatosis B-Disease 0 0.078705795109272
type I-Disease 0 7.454215665347874e-05
1 I-Disease 0 2.7095021337686376e-08
. O 0 6.745538350116931e-09
. O 0 8.04600901460617e-08

Missense O 0 0.00023680293816141784
mutations O 0 9.022758604260162e-06
in O 0 2.5250361801454346e-09
the O 0 2.242241808891876e-11
most O 0 1.5409130568744267e-11
ancient O 0 2.3202909038566588e-10
residues O 0 3.5468064041310754e-09
of O 0 7.933181021824165e-12
the O 0 1.2132200799541693e-10
PAX6 O 0 8.806866844679462e-07
paired O 0 1.87201933954384e-08
domain O 0 5.466518349095395e-09
underlie O 0 1.414848949110592e-08
a O 0 1.006842664796892e-10
spectrum O 0 3.1694920021863027e-09
of O 0 5.885423259854861e-10
human O 0 1.2902846435736137e-07
congenital B-Disease 1 0.999950647354126
eye I-Disease 1 0.9998416900634766
malformations I-Disease 1 0.9970273375511169
. O 0 3.7188290207268437e-06

Mutations O 0 9.57894189923536e-06
of O 0 7.116176536925423e-10
the O 0 8.269817053374595e-10
human O 0 6.606519331597838e-09
PAX6 O 0 1.5086687199072912e-05
gene O 0 1.979223270609509e-06
underlie O 0 5.633265755022876e-05
aniridia B-Disease 1 1.0
( O 0 7.781594746347764e-08
congenital B-Disease 1 0.9993979930877686
absence I-Disease 0 4.3931017046361376e-08
of I-Disease 0 4.095728964315093e-11
the I-Disease 0 9.279309959309145e-11
iris I-Disease 0 3.6786272517019825e-07
) O 0 1.502637569927856e-09
, O 0 9.523199590022458e-11
a O 0 3.427899075703067e-10
rare O 0 2.486777184174116e-08
dominant O 0 0.08990176022052765
malformation B-Disease 0 0.3613220751285553
of I-Disease 0 5.473579367532011e-10
the I-Disease 0 1.1695507673437078e-08
eye I-Disease 0 0.05740799009799957
. O 0 7.663537644475582e-07

The O 0 1.2872914290085191e-08
spectrum O 0 7.287217584917016e-08
of O 0 1.470701449513001e-09
PAX6 O 0 1.0532787200645544e-05
mutations O 0 1.1062392104577157e-06
in O 0 7.917109634547614e-09
aniridia B-Disease 1 1.0
patients O 0 1.254918061022181e-06
is O 0 8.53261836186725e-11
highly O 0 3.5555150490473864e-10
biased O 0 1.6136368685693014e-08
, O 0 4.7711432027419676e-11
with O 0 2.427768576451772e-11
92 O 0 7.873914853462338e-10
% O 0 3.3325106563175666e-11
of O 0 2.9282229852684027e-12
all O 0 2.2829939327895232e-10
reported O 0 3.4240475343949583e-08
mutations O 0 3.367999212855466e-08
leading O 0 2.7363094012855527e-09
to O 0 6.456012391353738e-10
premature O 0 8.147948094006097e-09
truncation O 0 2.891967376683624e-08
of O 0 2.8554752312670573e-11
the O 0 1.1505261326982819e-10
protein O 0 7.71595498605393e-09
( O 0 1.8574811133653668e-10
nonsense O 0 9.985302362736093e-09
, O 0 3.178466517761436e-11
splicing O 0 8.242074578390657e-09
, O 0 3.5854711560867614e-11
insertions O 0 4.177238999147903e-09
and O 0 6.052782580701077e-11
deletions O 0 2.3548407668272375e-09
) O 0 7.547566044374676e-11
and O 0 3.93610526117083e-11
just O 0 1.2877909849606795e-10
2 O 0 5.229761068648031e-11
% O 0 5.896260476395687e-12
leading O 0 3.375744128675251e-11
to O 0 4.769830364015348e-12
substitution O 0 6.246384659513993e-11
of O 0 6.242700367059539e-12
one O 0 2.912412533362385e-10
amino O 0 6.082763626125143e-09
acid O 0 1.2236972546375569e-09
by O 0 1.0099387472151111e-11
another O 0 4.1767189706831687e-10
( O 0 5.408850034527291e-10
missense O 0 8.575619858675054e-07
) O 0 7.834056958699875e-09
. O 0 4.6036412015837413e-08

The O 0 6.179472933354191e-09
extraordinary O 0 5.918793011261414e-09
conservation O 0 1.9417036867253046e-09
of O 0 4.8231595800585225e-11
the O 0 1.3549686372904546e-10
PAX6 O 0 8.248495220186669e-08
protein O 0 2.782317265470624e-09
at O 0 1.054401635447455e-10
the O 0 4.666775646477994e-11
amino O 0 1.7807280983106466e-08
acid O 0 2.3369130630612744e-08
level O 0 4.860239988246917e-10
amongst O 0 3.520747582363981e-10
vertebrates O 0 3.471292364665146e-09
predicts O 0 1.6445843797896487e-08
that O 0 1.5069420711277814e-10
pathological O 0 1.938100879783633e-08
missense O 0 3.381291833193245e-07
mutations O 0 1.9254046890182508e-07
should O 0 5.037085748504921e-10
in O 0 9.642087475669747e-12
fact O 0 8.064341555646948e-11
be O 0 1.6102124841821386e-11
common O 0 1.671943659908859e-11
even O 0 3.213780977451286e-11
though O 0 7.753552661027285e-11
they O 0 1.6621185330856214e-11
are O 0 1.048137097947599e-11
hardly O 0 1.0006803163875588e-09
ever O 0 4.955288623875731e-09
seen O 0 7.8152666560527e-09
in O 0 3.769238698936306e-09
aniridia B-Disease 1 1.0
patients O 0 1.0037576885224553e-06
. O 0 4.3426823026493366e-08

This O 0 9.328954497789255e-09
indicates O 0 1.80277748285107e-08
that O 0 4.9137773711072086e-11
there O 0 3.239703991186893e-11
is O 0 5.188756369012282e-11
a O 0 2.0395110600368582e-10
heavy O 0 7.818788816393862e-08
ascertainment O 0 3.0430178412643727e-06
bias O 0 6.003403996146517e-07
in O 0 8.736995849023543e-11
the O 0 1.2176193213420117e-11
selection O 0 7.597134032977237e-11
of O 0 1.2490361175898634e-11
patients O 0 9.532218347985122e-10
for O 0 2.5931352551356035e-11
PAX6 O 0 2.3267332949217234e-07
mutation O 0 7.215928743420363e-09
analysis O 0 8.137258644680401e-10
and O 0 7.93077895022698e-11
that O 0 4.68920666185646e-11
the O 0 6.077437997298318e-10
missing O 0 1.3139313637111627e-07
PAX6 O 0 2.913779826485552e-05
missense O 0 1.6534797396161593e-05
mutations O 0 1.4656317262051743e-06
frequently O 0 3.4270274795744626e-07
may O 0 8.22351822193923e-08
underlie O 0 1.0138070365428575e-06
phenotypes O 0 4.5709006712968403e-07
distinct O 0 4.853843194041474e-08
from O 0 8.478036939152389e-09
textbook O 0 3.5896369809051976e-05
aniridia B-Disease 1 0.9999995231628418
. O 0 8.571678904445434e-07

Here O 0 1.5540059905561066e-07
we O 0 5.347898124341555e-09
present O 0 5.963574079004275e-10
four O 0 4.014582000166911e-10
novel O 0 2.7735760355085404e-08
PAX6 O 0 1.2618746040971018e-05
missense O 0 5.41664758202387e-06
mutations O 0 3.8285469372567604e-07
, O 0 1.8172822968676172e-10
two O 0 4.533610292734025e-11
in O 0 7.649624683692124e-11
association O 0 3.6549838156041403e-10
with O 0 2.712684521455344e-10
atypical O 0 5.044811359766754e-07
phenotypes O 0 3.7269592212396674e-06
ectopia B-Disease 0 6.744924121449003e-06
pupillae I-Disease 0 4.945344244333683e-06
( O 0 2.745845772977873e-09
displaced B-Disease 0 4.236028061654906e-08
pupils I-Disease 0 3.2443625741507276e-07
) O 0 8.535034901058225e-09
and O 0 2.428633649742551e-08
congenital B-Disease 1 0.9303276538848877
nystagmus I-Disease 0 2.989635731864837e-06
( O 0 7.360857479099536e-10
searching B-Disease 0 1.711813979454746e-08
gaze I-Disease 0 1.2687758044194197e-07
) O 0 2.744535154697303e-10
, O 0 2.2170702773660622e-11
and O 0 3.373156962083179e-11
two O 0 6.388697210146788e-11
in O 0 2.2492077644820085e-10
association O 0 5.493374852227895e-11
with O 0 1.1940184084513472e-11
more O 0 1.6805415392617817e-10
recognizable O 0 8.937055099522695e-05
aniridia B-Disease 1 1.0
phenotypes O 0 1.4283596101449803e-05
. O 0 2.0151587420969008e-07

Strikingly O 0 9.055879104380438e-07
, O 0 5.024901383876568e-09
all O 0 2.3641147373076876e-10
four O 0 2.818648092706155e-10
mutations O 0 1.094633361731212e-08
are O 0 2.5761911701116524e-11
located O 0 1.537364541226438e-10
within O 0 1.7468768098716225e-10
the O 0 5.451251672283774e-10
PAX6 O 0 7.26266307538026e-07
paired O 0 3.539685167197604e-08
domain O 0 7.368671006702243e-09
and O 0 6.771097016411431e-10
affect O 0 1.297117413479043e-09
amino O 0 2.128582199389939e-09
acids O 0 1.6178920425602428e-09
which O 0 2.7557749485151994e-11
are O 0 8.955108356245578e-12
highly O 0 4.342029860660013e-11
conserved O 0 1.7663696894043568e-10
in O 0 6.843999672545564e-11
all O 0 1.8301341345172695e-11
known O 0 1.1678539246773312e-09
paired O 0 1.9375095305917966e-08
domain O 0 4.0255507371966814e-08
proteins O 0 5.422356608164591e-08
. O 0 4.6868976255609596e-08

Our O 0 2.7567682536755456e-07
results O 0 1.2022471018724445e-08
support O 0 3.9386455208401117e-10
the O 0 1.6604993421931447e-11
hypothesis O 0 4.776444795240309e-10
that O 0 3.882077818928575e-12
the O 0 2.9548165129955617e-12
under O 0 4.076245244122312e-11
- O 0 1.1049997583612026e-09
representation O 0 1.7278272146370455e-09
of O 0 1.7144817510139632e-10
missense O 0 1.928975279952283e-06
mutations O 0 4.0714812143960444e-07
is O 0 7.969921389516799e-10
caused O 0 6.972269983585022e-10
by O 0 1.5310641643395684e-10
ascertainment O 0 5.8309473160989e-07
bias O 0 3.185624564139289e-07
and O 0 2.3412652372378773e-10
suggest O 0 3.829426220569587e-10
that O 0 1.0252737894789199e-11
a O 0 4.9095432580470444e-11
substantial O 0 7.55112949946124e-09
burden O 0 1.1697241575348016e-07
of O 0 1.5196188751787076e-10
PAX6 B-Disease 0 0.0003259376098867506
- I-Disease 0 0.012527920305728912
related I-Disease 0 1.2205124221509323e-05
disease I-Disease 0 8.615171509518404e-07
remains O 0 1.6188180795850826e-09
to O 0 1.6171754213534228e-10
be O 0 2.1755747203755504e-10
uncovered O 0 6.843749389418008e-08
. O 0 2.1470740740880956e-09
. O 0 1.8270050361479662e-08

The O 0 2.4105567320020782e-08
chromosomal O 0 4.582031124300556e-06
order O 0 1.0494789037807095e-08
of O 0 2.3424889805667704e-10
genes O 0 2.8005487706650456e-08
controlling O 0 1.4847333318357414e-07
the O 0 9.522950206175551e-10
major O 0 1.2174377950202597e-08
histocompatibility O 0 1.773854023667809e-07
complex O 0 5.952519810392687e-09
, O 0 2.7474578168096286e-10
properdin O 0 1.2624825274087925e-07
factor O 0 6.286911968800268e-08
B O 0 3.586663694932213e-07
, O 0 2.3467464083104517e-10
and O 0 3.891543531864272e-09
deficiency B-Disease 0 5.938427349860831e-08
of I-Disease 0 1.251515601222164e-12
the I-Disease 0 1.487624606832938e-11
second I-Disease 0 6.831379351091016e-10
component I-Disease 0 1.0673323558307857e-08
of I-Disease 0 2.1689082474463106e-10
complement I-Disease 0 7.807820168181934e-08
. O 0 5.116393708703981e-08

The O 0 5.860122609391283e-09
relationship O 0 1.4227291345036974e-08
of O 0 2.7094925261761382e-11
the O 0 2.8667004534077556e-11
genes O 0 1.6258949742109507e-09
coding O 0 2.721674086103576e-08
for O 0 2.914167171463866e-11
HLA O 0 1.730010246170366e-09
to O 0 1.4386576999148026e-11
those O 0 4.404732134588585e-11
coding O 0 1.23093126802587e-08
for O 0 1.176840014327496e-10
properdin O 0 9.423202840252998e-08
Factor O 0 2.0327826533161897e-08
B O 0 9.191051475454515e-09
allotypes O 0 2.17640696575927e-08
and O 0 2.088442196956919e-10
for O 0 8.828206915501013e-11
deficiency B-Disease 0 1.1972333346932373e-08
of I-Disease 0 9.319029922738586e-13
the I-Disease 0 6.3403679008422476e-12
second I-Disease 0 1.3618241256896368e-10
component I-Disease 0 2.0152435276088454e-09
of I-Disease 0 9.05344722801349e-12
complement I-Disease 0 1.2445617869616399e-09
( O 0 7.200824658770699e-11
C2 O 0 7.592274364753848e-09
) O 0 1.7411943414868958e-11
was O 0 3.114885779864629e-11
studied O 0 3.8996550433267885e-10
in O 0 1.97983990313233e-11
families O 0 3.725392910824965e-11
of O 0 7.782885447227272e-12
patients O 0 3.765975975511537e-09
with O 0 1.1826821744165272e-09
connective O 0 0.002905063098296523
tissue O 1 0.9948061108589172
disorders O 1 0.9696655869483948
. O 0 3.3910311003637617e-07

Patients O 0 2.4040793960011797e-06
were O 0 2.067223614510283e-10
selected O 0 6.199844110321706e-11
because O 0 4.860515115390207e-11
they O 0 1.5020172605684223e-11
were O 0 1.374705210777094e-11
heterozygous O 0 4.213817295095623e-09
or O 0 6.277249275932206e-10
homozygous O 0 2.3742632038192824e-06
for O 0 7.335733016589074e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.8754900565909338e-07

12 O 0 1.3929940223533777e-07
families O 0 2.960812262031709e-09
with O 0 2.2367284413515875e-10
15 O 0 1.7213636072099803e-09
matings O 0 1.0662904514902038e-06
informative O 0 6.277122679421154e-07
for O 0 8.221412826969754e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.8821145470203646e-09
found O 0 4.682097376473848e-09
. O 0 4.2303764047346704e-08

Of O 0 6.186159584586903e-09
57 O 0 2.561252010480075e-08
informative O 0 1.2810210670011202e-08
meioses O 0 2.4111366769830056e-07
, O 0 1.0950289980327099e-10
two O 0 3.384989857857512e-11
crossovers O 0 1.0475250888930532e-08
were O 0 7.490305597990243e-10
noted O 0 1.9568506814948705e-09
between O 0 3.0683815488430355e-09
the O 0 2.329749349883059e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.256252251697788e-08
and O 0 1.762956725048781e-10
the O 0 7.036084215261695e-11
HLA O 0 1.1063736593541762e-07
- O 0 1.0885044332553662e-07
B O 0 1.4536817971588789e-08
gene O 0 7.603792040455915e-10
, O 0 5.820068819245572e-12
with O 0 1.0673178920533877e-12
a O 0 7.750088765190455e-12
recombinant O 0 1.0004493899984368e-09
fraction O 0 2.4953090704826764e-09
of O 0 3.14823389579999e-10
0 O 0 2.056748371614958e-08
. O 0 5.7568296796262075e-08

035 O 0 0.03605807572603226
. O 0 2.2278281903709285e-05

A O 0 1.9445924692718108e-07
lod O 0 1.839607830333989e-05
score O 0 2.776423713157783e-08
of O 0 3.866871059465815e-11
13 O 0 1.434602991956524e-10
was O 0 3.4653023506248104e-11
calculated O 0 4.5092243827760115e-10
for O 0 1.0944569556192718e-10
linkage O 0 2.3561685793538345e-06
between O 0 0.0013677079696208239
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 6.862644341687485e-10
HLA O 0 4.708411083242936e-08
- O 0 1.0075126510855625e-07
B O 0 2.4698074696516414e-08
at O 0 2.5086974164700848e-11
a O 0 4.479132342805059e-12
maximum O 0 3.306564050342686e-11
likelihood O 0 1.2654291503544357e-10
value O 0 3.6096042821398555e-11
of O 0 8.838070791709896e-13
the O 0 2.578884154835759e-12
recombinant O 0 9.178272031284962e-11
fraction O 0 7.168337590179874e-10
of O 0 9.626840991039387e-11
0 O 0 8.940171269955499e-09
. O 0 3.440531415321857e-08

04 O 0 0.0013349810615181923
. O 0 5.633033197227633e-06

18 O 0 2.4220608452196757e-07
families O 0 3.432297335237422e-09
with O 0 7.713784472285212e-11
21 O 0 2.5511129320143766e-10
informative O 0 4.14375700419356e-10
matings O 0 2.2865522808501737e-08
for O 0 7.425719761311456e-11
both O 0 3.9505329563205294e-10
properdin O 0 9.021881055559788e-07
Factor O 0 6.936449636896214e-08
B O 0 6.792614470896297e-08
allotype O 0 1.2532169080259337e-07
and O 0 1.5922501095388952e-09
HLA O 0 3.5278165455565613e-07
- O 0 3.912253305315971e-06
B O 0 7.524677698711457e-07
were O 0 1.1925401777190814e-09
found O 0 6.5189738052140456e-09
. O 0 2.7122009527147384e-08

Of O 0 6.457419488015148e-09
72 O 0 2.2266000598847313e-08
informative O 0 1.0263475402894073e-08
meioses O 0 1.9639153947537125e-07
, O 0 9.59574919523476e-11
three O 0 6.286975801073069e-11
recombinants O 0 2.9159561876213047e-08
were O 0 1.4523554581202802e-10
found O 0 5.995779567280479e-11
, O 0 4.596875397694378e-12
giving O 0 1.9052866923052747e-11
a O 0 1.1763501631123496e-11
recombinant O 0 7.090055209602042e-10
fraction O 0 2.973092438907088e-09
of O 0 2.2800522581079008e-10
0 O 0 4.4376772478926796e-08
. O 0 9.919417465198421e-08

042 O 0 0.001588114770129323
. O 0 1.5132481166801881e-05

A O 0 1.4450944263444399e-07
lod O 0 1.1321637430228293e-05
score O 0 8.517732297264047e-09
of O 0 7.762549630863091e-11
16 O 0 2.2701671098523946e-10
between O 0 2.350186711908009e-10
HLA O 0 9.525374622398886e-08
- O 0 3.955151441914495e-07
B O 0 9.133194822652513e-08
and O 0 6.090109527789878e-10
Factor O 0 1.5255789964641053e-09
B O 0 3.05418090817966e-09
allotypes O 0 4.078224424830523e-09
was O 0 3.930568717724903e-11
calculated O 0 1.6348343512273544e-10
at O 0 3.247065463729548e-11
a O 0 7.058150938710206e-12
maximum O 0 4.9633148285765927e-11
likelihood O 0 3.2618593936994955e-10
value O 0 2.8249871192320697e-11
of O 0 4.0978106866963737e-13
the O 0 1.5681542436113416e-12
recombinant O 0 1.316503295267779e-10
fraction O 0 7.123944212317213e-10
of O 0 1.104105903926289e-10
0 O 0 9.91016602114314e-09
. O 0 2.4928558772785436e-08

04 O 0 0.0015823142603039742
. O 0 3.7180450362939155e-06

A O 0 1.9707291798454207e-08
crossover O 0 3.671028991902858e-08
was O 0 1.142566596890049e-09
shown O 0 2.2087015549843159e-10
to O 0 2.469464563392698e-11
have O 0 2.670637148927124e-11
occurred O 0 5.144528900102863e-11
between O 0 1.380570137377024e-11
genes O 0 5.89673865292184e-10
for O 0 5.3799152632816316e-11
Factor O 0 1.6574918104694802e-09
B O 0 5.762891053251451e-09
and O 0 1.8169911408794093e-10
HLA O 0 1.8415907021562816e-08
- O 0 8.699245768184483e-08
D O 0 1.749847342580324e-07
, O 0 2.142114263747885e-11
in O 0 8.968406746412416e-12
which O 0 3.8790617939987726e-10
HLA O 0 9.92125279708489e-08
- O 0 2.500299274288409e-07
D O 0 2.3467136145427503e-07
segregared O 0 4.4682789024363956e-08
with O 0 8.79206152326617e-11
HLA O 0 4.075349480103796e-08
- O 0 1.1181796821801981e-07
A O 0 3.1896565388933595e-09
and O 0 7.433195836625828e-09
B O 0 3.8334462715283735e-07
. O 0 2.7062791119192298e-08

These O 0 5.019537230310789e-09
studies O 0 8.316800581553707e-09
suggest O 0 7.946515112600139e-10
that O 0 5.746933311179259e-12
the O 0 3.266195256965143e-12
genes O 0 5.962311755425276e-10
for O 0 3.3312158587150975e-10
Factor O 0 9.540453902445734e-07
B O 1 0.6841936111450195
and O 0 0.31832355260849
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 7.349125474842566e-11
located O 0 2.649854294323184e-11
outside O 0 3.662938008464067e-11
those O 0 1.3399894041588034e-11
for O 0 4.134918102360885e-12
HLA O 0 3.9421776953929566e-10
, O 0 4.975928089706594e-12
that O 0 3.2336522782366872e-12
the O 0 3.7855803561304135e-12
order O 0 6.143457964569166e-11
of O 0 4.349496023764443e-12
genese O 0 5.994438367906696e-08
is O 0 2.0840251746534477e-10
HLA O 0 1.07898925350014e-08
- O 0 1.659602588688358e-08
A O 0 4.310272139207427e-10
, O 0 1.8141377289282445e-10
- O 0 1.1064111404834875e-08
B O 0 9.708241321959576e-09
, O 0 3.4154189892943165e-11
- O 0 6.609077729535784e-09
D O 0 2.9626894715306662e-08
, O 0 5.625288082566904e-11
Factor O 0 9.585368943021422e-09
B O 0 7.665951073931865e-08
allotype O 0 2.5099179765675217e-06
, O 0 2.859126482235297e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 6.4883857835151826e-12
that O 0 2.1854042013547126e-12
the O 0 1.7338172564329568e-11
genes O 0 6.624740311877986e-09
coding O 0 1.4192754633768345e-06
for O 0 1.866151677631933e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.4837611967143403e-09
Factor O 0 2.344431315748352e-08
B O 0 2.3938058646422178e-08
allotypes O 0 3.010722693375101e-08
are O 0 3.7404801478402305e-11
approximately O 0 3.407129786636709e-11
3 O 0 2.7672639180131853e-10
- O 0 3.7544094055874666e-08
- O 0 3.084684152554473e-08
5 O 0 1.7298081023131573e-10
centimorgans O 0 3.851755359107756e-09
from O 0 9.886966245709061e-12
the O 0 3.297721123951547e-11
HLA O 0 1.2613026179053577e-08
- O 0 5.824164261980513e-09
A O 0 3.17986276199278e-10
and O 0 8.57433790635298e-10
HLA O 0 5.824777815632842e-08
- O 0 5.685648929443232e-08
B O 0 3.939315984524683e-09
loci O 0 4.843868084414282e-10
, O 0 1.185816115439886e-11
and O 0 1.4721031685316355e-11
that O 0 5.158144744665805e-12
the O 0 1.7823529110949643e-11
apparent O 0 1.9868782175080923e-09
lack O 0 3.230751777216767e-10
of O 0 5.661959182751142e-12
recombinants O 0 8.714136967569175e-09
between O 0 5.7090037558493734e-11
the O 0 8.736095874484207e-11
Factor O 0 4.912229556452985e-08
B O 0 7.174868699166836e-08
gene O 0 2.1127583238467196e-07
and O 0 0.00034682033583521843
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 2.699391821181507e-08
suggests O 0 3.9176688559905415e-09
that O 0 5.494336322714455e-12
these O 0 1.841911172195676e-11
two O 0 3.565102033031842e-11
genes O 0 3.234150725006657e-09
lie O 0 2.885928296336715e-08
in O 0 1.5366198591326707e-10
close O 0 1.2588530218238247e-09
proximity O 0 4.5828754124954685e-09
to O 0 1.7096299931296244e-09
one O 0 1.863045495653637e-09
another O 0 1.0017598306433229e-08
. O 0 1.27394073956566e-07

Distribution O 0 8.220821001714285e-08
of O 0 4.749345916543746e-10
emerin O 0 3.8769434240748524e-07
and O 0 1.2419154593601434e-09
lamins O 0 9.506205174147908e-07
in O 0 4.5099296519524046e-10
the O 0 2.3023571937841325e-10
heart O 0 1.0351610235659336e-08
and O 0 1.31211139176024e-10
implications O 0 6.058760604332747e-09
for O 0 4.596749092478092e-10
Emery B-Disease 0 4.96060965815559e-06
- I-Disease 0 2.526531352486927e-05
Dreifuss I-Disease 0 0.0013354032998904586
muscular I-Disease 0 5.548744957195595e-05
dystrophy I-Disease 0 0.00017330370610579848
. O 0 8.73719784522109e-07

Emerin O 0 0.00016685390437487513
is O 0 6.791564999275579e-08
a O 0 6.962427079315603e-09
nuclear O 0 2.255637525649945e-07
membrane O 0 5.851969131498436e-09
protein O 0 2.965299561452639e-09
which O 0 1.1681228206938954e-10
is O 0 8.49450648710004e-11
missing O 0 1.9593304756426733e-09
or O 0 4.446450430073412e-10
defective O 0 3.183586017030393e-08
in O 0 9.676088819077222e-10
Emery B-Disease 0 0.001389414188452065
- I-Disease 0 0.0028460961766541004
Dreifuss I-Disease 0 0.11722740530967712
muscular I-Disease 0 3.527599619701505e-05
dystrophy I-Disease 0 4.765882113133557e-05
( O 0 4.357650595920859e-08
EDMD B-Disease 1 1.0
) O 0 6.343065450664653e-08
. O 0 1.3123334952069854e-07

It O 0 9.874076312144098e-08
is O 0 1.2597224374744087e-09
one O 0 3.4587405162156415e-10
member O 0 2.3144476613001785e-10
of O 0 1.5320217316983076e-11
a O 0 3.5285321886568966e-10
family O 0 3.51212414706481e-09
of O 0 2.239819302252144e-10
lamina O 0 0.0022642468102276325
- O 0 5.292910645948723e-05
associated O 0 1.532836435558238e-08
proteins O 0 1.1048058023988006e-09
which O 0 1.0593060456587367e-10
includes O 0 2.5175089790607785e-10
LAP1 O 0 2.13742438859299e-07
, O 0 4.3838063734646937e-10
LAP2 O 0 5.32002559339162e-07
and O 0 1.084868461731503e-08
lamin O 0 1.8459588318364695e-05
B O 0 4.58830163552193e-06
receptor O 0 6.040664857209777e-07
( O 0 8.531780615328444e-09
LBR O 0 3.4880125895142555e-05
) O 0 2.8185866085550515e-08
. O 0 6.50293188186879e-08

A O 0 9.047922588933943e-08
panel O 0 1.0496395219661281e-07
of O 0 6.156352649888674e-10
16 O 0 2.8317224121110485e-09
monoclonal O 0 7.675505031556895e-08
antibodies O 0 5.137859204751294e-08
( O 0 2.5541171955190123e-10
mAbs O 0 5.2885408052816274e-08
) O 0 3.331762365998969e-10
has O 0 9.48974579473294e-11
been O 0 6.497553883821894e-11
mapped O 0 2.801690657250333e-09
to O 0 8.17072312586653e-11
six O 0 2.812691052289651e-11
specific O 0 7.173777544222659e-11
sites O 0 7.203548313405861e-10
throughout O 0 4.5805134685217297e-10
the O 0 1.0475179751390229e-10
emerin O 0 2.77515308511056e-08
molecule O 0 1.6288965731803273e-09
using O 0 1.103224511744827e-09
phage O 0 1.4502980150155054e-07
- O 0 4.051105673141819e-09
displayed O 0 3.018816030486704e-10
peptide O 0 1.3042099622495584e-09
libraries O 0 3.9354614012054867e-10
and O 0 3.521168773223948e-11
has O 0 2.5266476411101024e-11
been O 0 3.607029952501506e-11
used O 0 1.6036266758945317e-10
to O 0 7.275707120113495e-11
localize O 0 7.599420115411704e-08
emerin O 0 1.7209482905400364e-07
in O 0 2.167895030158462e-10
human O 0 4.1105532866403394e-10
and O 0 2.623364636633596e-09
rabbit O 0 3.330836761961109e-06
heart O 0 5.764185516454745e-06
. O 0 1.0588993859528273e-07

Several O 0 4.612703108364258e-08
mAbs O 0 1.8701476847127196e-06
against O 0 2.0237793663113735e-09
different O 0 1.2090763945593608e-09
emerin O 0 1.6566208671520144e-07
epitopes O 0 2.460287191752286e-07
did O 0 6.1208327295503295e-09
not O 0 1.701632723616342e-10
recognize O 0 2.0630532837628834e-09
intercalated O 0 4.868285774506376e-09
discs O 0 1.35349775831628e-08
in O 0 1.2050513364947335e-10
the O 0 5.861916507754472e-11
heart O 0 5.046223439109099e-09
, O 0 2.8590119854898788e-11
though O 0 2.998129799980376e-10
they O 0 1.2163851870194975e-10
recognized O 0 9.791024657701541e-10
cardiomyocyte O 0 1.546253081130544e-08
nuclei O 0 8.047612576334018e-10
strongly O 0 4.502915817994335e-10
, O 0 1.214784609709918e-11
both O 0 4.06202640967912e-11
at O 0 1.6143400505264083e-10
the O 0 3.945477972111533e-11
rim O 0 6.819470321772769e-09
and O 0 5.633375987912359e-10
in O 0 4.179460111330968e-10
intranuclear O 0 1.675472702800107e-07
spots O 0 1.1973641278473224e-07
or O 0 6.7279994908631124e-09
channels O 0 4.416015713104571e-07
. O 0 1.0438735387197084e-07

A O 0 7.24261155937711e-07
polyclonal O 0 3.102223126916215e-05
rabbit O 0 4.180535597697599e-06
antiserum O 0 7.4855934144579805e-06
against O 0 8.903448645014578e-09
emerin O 0 3.341895364883385e-07
did O 0 3.278489701941112e-09
recognize O 0 3.2889930778878806e-09
both O 0 3.0577232412731803e-10
nuclear O 0 2.6593770741101252e-08
membrane O 0 8.59609994297017e-10
and O 0 4.0495565234444086e-11
intercalated O 0 5.373928524399219e-10
discs O 0 1.440347618952842e-09
but O 0 8.323759737027814e-11
, O 0 3.0375727974596423e-12
after O 0 6.4550331226043145e-12
affinity O 0 7.020399539481303e-11
purification O 0 1.4299915418458653e-10
against O 0 9.979142512328565e-11
a O 0 5.6305689277724724e-11
pure O 0 2.1606432198950642e-09
- O 0 1.555514828055493e-08
emerin O 0 1.1205708716488516e-07
band O 0 1.3450609515075485e-09
on O 0 6.377995354078791e-11
a O 0 4.0981041476984004e-11
western O 0 2.524318754026922e-09
blot O 0 2.099570701830089e-05
, O 0 3.918601276797773e-10
it O 0 3.623263633567575e-10
stained O 0 4.2838064473471604e-06
only O 0 7.284319814004903e-10
the O 0 6.618447456752108e-10
nuclear O 0 2.2219086304176017e-07
membrane O 0 1.3759617445430194e-07
. O 0 4.1395189498416585e-08

These O 0 8.684635233180416e-09
results O 0 8.989656130609092e-09
would O 0 8.712699312019012e-11
not O 0 4.280220275432178e-11
be O 0 2.1231386440612177e-11
expected O 0 4.438076989243811e-11
if O 0 1.3698324419220143e-10
immunostaining O 0 6.0993774475548435e-09
at O 0 3.566530057397266e-11
intercalated O 0 5.36278854657013e-10
discs O 0 7.434174165155127e-09
were O 0 2.2600660232185987e-10
due O 0 1.6865171759139486e-10
to O 0 3.2318040604772946e-11
a O 0 2.5222081367903826e-11
product O 0 6.216697157057638e-10
of O 0 3.605789928792791e-12
the O 0 3.3032861168624805e-11
emerin O 0 3.263573944423115e-08
gene O 0 3.1725220228651096e-09
and O 0 4.0765893438710066e-10
, O 0 4.218517549170464e-11
therefore O 0 1.3228791673203233e-10
, O 0 1.8280306088303e-11
cast O 0 2.1592796439762196e-09
some O 0 5.366571423359723e-11
doubt O 0 6.216021031235641e-10
upon O 0 1.2281902057875715e-11
the O 0 1.502733527891653e-11
hypothesis O 0 3.187327290987696e-09
that O 0 6.13937345406157e-10
cardiac B-Disease 0 2.1292295571129216e-07
defects I-Disease 0 0.00016978979692794383
in O 0 1.8212945596118857e-09
EDMD B-Disease 1 1.0
are O 0 4.274138376558767e-09
caused O 0 8.76823502693469e-10
by O 0 6.950186259846447e-11
absence O 0 1.8862582606971046e-09
of O 0 2.999449646989838e-11
emerin O 0 1.8425241421482497e-07
from O 0 8.575793408738264e-10
intercalated O 0 2.3996395270842186e-07
discs O 0 7.386572633549804e-07
. O 0 1.3502931039965915e-07

Although O 0 1.6819132042655838e-07
emerin O 0 1.686561290625832e-06
was O 0 2.118133224371377e-09
abundant O 0 6.691918130741215e-10
in O 0 1.4657021429886896e-10
the O 0 1.22816035119655e-10
membranes O 0 1.5140798836910108e-08
of O 0 3.0104769371819273e-11
cardiomyocyte O 0 2.912765495466374e-08
nuclei O 0 1.623332357425511e-09
, O 0 4.693412325451618e-11
it O 0 1.3019525735291637e-10
was O 0 6.079246550605433e-10
absent O 0 5.886658382969756e-10
from O 0 1.5436723080353154e-11
many O 0 1.1652455389477012e-10
non O 0 9.542667811501815e-08
- O 0 8.611041835138167e-08
myocyte O 0 1.0883316008403199e-06
cells O 0 9.580306326029131e-09
in O 0 2.9429123027391313e-10
the O 0 2.2065174132279708e-09
heart O 0 5.544076202568249e-07
. O 0 5.9534539076366855e-08

This O 0 1.5723405910605948e-09
distribution O 0 1.4544131454741205e-09
of O 0 2.673960358690053e-11
emerin O 0 7.69109789189315e-08
was O 0 1.9201466805451872e-10
similar O 0 4.0242243565247193e-11
to O 0 3.08684570959894e-11
that O 0 9.776720232002045e-12
of O 0 3.71590301931346e-12
lamin O 0 5.049210471952392e-08
A O 0 1.1399538951684107e-10
, O 0 1.3074415682046148e-11
a O 0 5.782514224395019e-12
candidate O 0 5.33799004998059e-10
gene O 0 2.817778899100176e-09
for O 0 1.372989499870414e-10
an O 0 9.771580072870378e-11
autosomal O 0 2.073437372018816e-06
form O 0 6.823441367487248e-08
of O 0 1.2537329396877794e-08
EDMD B-Disease 1 1.0
. O 0 9.82271672000934e-07

In O 0 4.1738402956070786e-08
contrast O 0 1.972358063540014e-07
, O 0 1.756256295948333e-08
lamin O 0 4.115804040338844e-05
B1 O 0 5.919098111917265e-05
was O 0 4.424912436462591e-09
absent O 0 8.89189166741744e-09
from O 0 1.4829228123236504e-10
cardiomyocyte O 0 1.9848489074547615e-08
nuclei O 0 3.1402713762673784e-09
, O 0 1.4131078251988782e-10
showing O 0 1.1715266978740146e-08
that O 0 1.6836254612684343e-09
lamin O 0 5.19100876772427e-06
B1 O 0 1.4035005051482585e-06
is O 0 4.730836555832951e-11
not O 0 1.0656179064150173e-11
essential O 0 5.812616707401297e-11
for O 0 4.225094232812587e-12
localization O 0 1.462005377872444e-10
of O 0 2.9726967415433236e-12
emerin O 0 1.8028735837560816e-08
to O 0 2.09952930041446e-10
the O 0 7.120317113695762e-10
nuclear O 0 7.0066244006739e-07
lamina O 0 4.6814661800453905e-06
. O 0 9.578445769875543e-08

Lamin O 0 0.17106497287750244
B1 O 0 0.4754141867160797
is O 0 3.790593172681156e-09
also O 0 9.595150229912974e-10
almost O 0 5.816335191255462e-10
completely O 0 5.838537120439469e-08
absent O 0 5.6950700155766754e-08
from O 0 1.34798883166809e-09
skeletal O 0 2.0546467567328364e-06
muscle O 0 2.775460870907409e-06
nuclei O 0 1.0219541763945017e-06
. O 0 2.7093736321148754e-07

In O 0 8.744577684183241e-08
EDMD B-Disease 1 0.9999994039535522
, O 0 1.8730673956302013e-10
the O 0 1.508879653167039e-11
additional O 0 1.3649734120768642e-10
absence O 0 1.877632715974187e-09
of O 0 2.204837423747108e-10
lamin O 0 1.1926876140933018e-05
B1 O 0 9.475301339989528e-06
from O 0 9.679262946704625e-10
heart O 0 9.863045846714158e-08
and O 0 1.6010602843508082e-09
skeletal O 0 7.50021854400984e-07
muscle O 0 1.4686257543417014e-07
nuclei O 0 1.579772401782975e-08
which O 0 4.005826337305507e-09
already O 0 8.711412036177535e-09
lack O 0 3.056172537263535e-10
emerin O 0 4.845185586077605e-08
may O 0 1.5730808322622636e-10
offer O 0 2.8265174922825764e-11
an O 0 6.371180167642765e-13
alternative O 0 2.887770023107805e-10
explanation O 0 5.948495862551084e-11
of O 0 4.212493201483092e-12
why O 0 3.139120074990842e-10
these O 0 3.197126591247823e-11
tissues O 0 8.588758038108324e-10
are O 0 9.774413223251344e-11
particularly O 0 1.6480031783672189e-09
affected O 0 2.282111388751673e-09
. O 0 2.128448306493169e-09
. O 0 3.489622812935522e-08

Genetic O 0 8.22858237370383e-06
mapping O 0 6.08057462159195e-07
of O 0 1.298411933525756e-09
the O 0 3.0664975003702466e-09
copper B-Disease 0 1.6371535593862063e-06
toxicosis I-Disease 0 0.00011296043521724641
locus O 0 7.901692811174144e-07
in O 0 6.514697670212399e-09
Bedlington O 0 1.4249214927986031e-06
terriers O 0 4.955792292093975e-07
to O 0 1.1915783915128486e-09
dog O 0 9.594807615087575e-09
chromosome O 0 7.734007567705703e-08
10 O 0 5.928099677809939e-10
, O 0 3.4754626260236066e-11
in O 0 4.084635060741526e-11
a O 0 2.947299626576694e-10
region O 0 6.925606310659305e-09
syntenic O 0 4.3581167119555175e-07
to O 0 7.357601194968311e-10
human O 0 3.4038594165508584e-09
chromosome O 0 1.9085796338913497e-06
region O 0 2.89945489839738e-07
2p13 O 0 9.719212357595097e-06
- O 0 3.8681905607518274e-06
p16 O 0 1.0187042789766565e-05
. O 0 2.2034151925254264e-07

Abnormal O 0 0.0008043150301091373
hepatic B-Disease 0 0.003219838719815016
copper I-Disease 0 8.18046919448534e-06
accumulation I-Disease 0 8.728580525030338e-08
is O 0 4.560193889169284e-10
recognized O 0 3.747639532036828e-09
as O 0 3.190733677271851e-09
an O 0 2.082469663378106e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 4.395085628772222e-09
man O 0 5.145115622440244e-08
, O 0 1.3623438488430395e-10
mouse O 0 2.350834549247338e-08
, O 0 6.443562905467104e-10
rat O 0 2.7139768121742236e-07
and O 0 5.3642743580439856e-09
dog O 0 4.849188144362415e-07
. O 0 2.797493152684183e-07

The O 0 1.5422296328893026e-08
major O 0 3.39990329223383e-08
cause O 0 1.8846911586933857e-08
of O 0 3.4208777477395813e-10
hepatic B-Disease 0 3.65064806828741e-06
copper I-Disease 0 1.563658543091151e-06
accumulation I-Disease 0 1.827635998097321e-08
in O 0 1.2657918047054295e-09
man O 0 1.2041247998695326e-07
is O 0 7.337280227837084e-10
a O 0 2.1781625392236492e-09
dysfunctional O 0 1.399541474711441e-06
ATP7B O 0 1.769116465766274e-06
gene O 0 4.4902571971761063e-07
, O 0 4.937146691474936e-09
causing O 0 1.0190660759690218e-07
Wilson B-Disease 0 7.125633601390291e-06
disease I-Disease 0 1.865384547272697e-06
( O 0 1.932571258578264e-08
WD B-Disease 1 0.9999926090240479
) O 0 1.1405078481629971e-07
. O 0 1.5172447831446334e-07

Mutations O 0 3.538131568348035e-05
in O 0 1.034760277462965e-08
the O 0 3.791820468723728e-10
ATP7B O 0 1.6300153049542132e-07
genes O 0 1.1389292176033905e-08
have O 0 6.638118943413929e-10
also O 0 1.9272024254224362e-10
been O 0 2.154584288760475e-10
demonstrated O 0 9.039997084236973e-10
in O 0 1.3714245017393267e-10
mouse O 0 4.095062777764724e-08
and O 0 1.5762811500508178e-08
rat O 0 2.3457250790670514e-06
. O 0 9.94757201056018e-08

The O 0 2.5100558076474044e-08
ATP7B O 0 6.413002324734407e-07
gene O 0 4.0593064909444365e-08
has O 0 1.04002506606804e-09
been O 0 2.0644574938444293e-10
excluded O 0 1.3353982364350259e-09
in O 0 9.25969804305149e-12
the O 0 6.541857333619561e-12
much O 0 1.0582235782097271e-10
rarer O 0 5.8907641431460434e-08
human O 0 2.108370811271243e-09
copper B-Disease 0 1.940958782142843e-06
overload I-Disease 0 1.0550020306254737e-06
disease O 0 3.606217262586142e-07
non B-Disease 0 2.9398913738987176e-06
- I-Disease 0 4.512103259912692e-05
Indian I-Disease 0 4.5506146761908894e-07
childhood I-Disease 0 1.4611317965318449e-05
cirrhosis I-Disease 0 4.6325731091201305e-06
, O 0 8.304781862200628e-10
indicating O 0 3.2584985376615805e-08
genetic O 0 1.0092953743878752e-06
heterogeneity O 0 6.2954773056844715e-06
. O 0 5.229131261330622e-07

By O 0 3.2007603234518456e-09
investigating O 0 9.993194538537864e-08
the O 0 5.10601827485857e-09
common O 0 2.7885778308700537e-07
autosomal O 0 0.024225255474448204
recessive O 0 0.010719561018049717
copper B-Disease 0 0.00015868947957642376
toxicosis I-Disease 0 0.007224892266094685
( O 0 7.039957505838856e-09
CT B-Disease 0 0.0002537031832616776
) O 0 2.291082656924459e-09
in O 0 1.9483954727395059e-10
Bedlington O 0 1.7957633247078775e-07
terriers O 0 5.591620606537617e-07
, O 0 7.468777818431249e-10
we O 0 2.460542047888481e-10
have O 0 3.120302627390714e-11
identified O 0 1.544279704113194e-10
a O 0 1.5194760380476957e-11
new O 0 1.275371058762076e-10
locus O 0 3.212504751104461e-08
involved O 0 5.8236309108394835e-09
in O 0 2.890213934847452e-08
progressive O 1 0.809982419013977
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 9.74839508671721e-07

We O 0 1.4258128544497595e-07
examined O 0 6.781740324868224e-08
whether O 0 2.8619449032873945e-09
the O 0 1.0438327979755968e-09
WD B-Disease 0 0.003414750099182129
gene O 0 7.914032806866089e-08
ATP7B O 0 1.302487589782686e-06
was O 0 1.6116766810014838e-09
also O 0 1.4523804381383343e-10
causative O 0 1.8579825677988993e-08
for O 0 5.107951561722501e-11
CT B-Disease 0 2.86515000880172e-06
by O 0 2.521180209047458e-10
investigating O 0 1.7947355601677373e-08
the O 0 8.492161973627788e-10
chromosomal O 0 0.0025105245877057314
co O 0 0.0027119594160467386
- O 0 2.173545112782449e-07
localization O 0 3.6091822863681955e-08
of O 0 1.2768509860539012e-10
ATP7B O 0 4.2703109670583217e-07
and O 0 1.5686105192536104e-10
C04107 O 0 3.9192831202683465e-09
, O 0 4.826819933329007e-12
using O 0 8.160770670340156e-11
fluorescence O 0 2.345539540371533e-09
in O 0 1.3486722849620492e-10
situ O 0 1.6113363088265942e-08
hybridization O 0 2.752180883192068e-08
( O 0 3.975446360993118e-10
FISH O 0 1.009170080834565e-08
) O 0 5.0141211183074574e-09
. O 0 2.1071377531711732e-08

C04107 O 0 6.995417061261833e-05
is O 0 4.380375528967306e-08
an O 0 7.707288141034496e-10
anonymous O 0 8.369525517082366e-08
microsatellite O 0 4.9317986849928275e-06
marker O 0 1.8021694359049434e-07
closely O 0 9.274350531995879e-08
linked O 0 9.770378710527439e-07
to O 0 2.2454935688642763e-08
CT B-Disease 1 0.5240353941917419
. O 0 2.32597002991497e-07

However O 0 1.9749761293041956e-07
, O 0 1.2151851080943743e-08
BAC O 0 4.241494195866835e-07
clones O 0 1.6538294289603073e-08
containing O 0 3.522079072837414e-09
ATP7B O 0 7.027114747870655e-07
and O 0 2.818621169797808e-10
C04107 O 0 1.5943234288329222e-08
mapped O 0 1.0557187124504708e-08
to O 0 1.8955369218698337e-10
the O 0 2.2653486031476433e-10
canine O 0 1.704084127140959e-07
chromosome O 0 3.5409149745646573e-07
regions O 0 1.861735654529184e-08
CFA22q11 O 0 4.63548019524751e-07
and O 0 6.732026602840335e-10
CFA10q26 O 0 5.03848376354199e-08
, O 0 4.327445346508085e-11
respectively O 0 3.4674196847106487e-10
, O 0 2.3208209659619783e-11
demonstrating O 0 1.1916057029992544e-09
that O 0 9.143626966690022e-10
WD B-Disease 1 0.9994606375694275
cannot O 0 2.7174309025213006e-08
be O 0 1.274007149776324e-10
homologous O 0 3.307192075752141e-09
to O 0 7.112743172221769e-10
CT B-Disease 0 6.807447789469734e-05
. O 0 8.587095834400316e-08

The O 0 2.316596336982002e-08
copper O 0 4.216026638914627e-07
transport O 0 1.0301897113151881e-08
genes O 0 2.6679632725290503e-08
CTR1 O 0 4.2179047454737884e-07
and O 0 4.955494348202194e-10
CTR2 O 0 1.2332100141065894e-07
were O 0 3.038537754740389e-10
also O 0 2.621432515503841e-10
excluded O 0 2.4063706582921895e-09
as O 0 4.499444913874662e-11
candidate O 0 9.238396159183537e-10
genes O 0 7.823585113087006e-10
for O 0 4.2569187758134674e-11
CT B-Disease 0 7.028972322586924e-05
since O 0 5.700065752733963e-09
they O 0 1.2225091772233299e-10
both O 0 8.558714154061065e-11
mapped O 0 6.435609378740992e-08
to O 0 3.856195363027837e-09
canine O 0 1.276523107662797e-06
chromosome O 0 1.0426819244457874e-05
region O 0 1.5197643961073481e-06
CFA11q22 O 0 2.237748594779987e-05
. O 0 3.4526772196841193e-07

2 O 0 7.983520845300518e-06
- O 0 0.00012597627937793732
22 O 0 7.101145342858217e-07
. O 0 2.379099584004507e-07

5 O 0 1.1744409675884526e-05
. O 0 1.3817914350511273e-06

A O 0 4.44448780001494e-08
transcribed O 0 1.2138663407768036e-07
sequence O 0 2.37856365714606e-08
identified O 0 1.7829675513780785e-08
from O 0 1.958589679329492e-10
the O 0 1.601966753694839e-10
C04107 O 0 2.1471451816523768e-07
- O 0 1.1763789053986784e-08
containing O 0 2.2075992145431655e-09
BAC O 0 1.253728640904228e-07
was O 0 3.084792699059591e-10
found O 0 3.882442631275573e-11
to O 0 1.512441213935567e-11
be O 0 6.4734289977053106e-12
homologous O 0 2.4581028879033795e-10
to O 0 1.9441512635887115e-11
a O 0 3.2035239044825303e-11
gene O 0 4.7797099611557314e-09
expressed O 0 1.5537962583245246e-10
from O 0 1.0998894850455798e-10
human O 0 1.5822836374468352e-09
chromosome O 0 1.38503267521628e-07
2p13 O 0 5.545260819417308e-07
- O 0 6.239081784542577e-08
p16 O 0 6.145342013041954e-08
, O 0 3.597090403317793e-10
a O 0 3.3226682516485084e-10
region O 0 5.426937121910669e-09
devoid O 0 1.2471573995753715e-08
of O 0 7.833704518400708e-11
any O 0 1.3788530317526693e-09
positional O 0 1.593412122247173e-07
candidate O 0 3.177253802277846e-07
genes O 0 9.80913341663836e-07
. O 0 3.161503059345705e-07

Molecular O 0 1.4279700053521083e-06
analysis O 0 6.774965299882751e-08
of O 0 1.1594481624799258e-10
the O 0 1.67173705434287e-10
APC B-Disease 0 6.737001179146773e-09
gene O 0 8.281833885348533e-09
in O 0 2.039160923450467e-10
205 O 0 5.596726415646458e-10
families O 0 3.349168997690555e-10
: O 0 1.3579257163165437e-10
extended O 0 6.311913658407775e-09
genotype O 0 7.022231875453144e-05
- O 0 1.815059658838436e-05
phenotype O 0 9.424845188732434e-07
correlations O 0 1.205211503929604e-07
in O 0 2.5488611221646806e-10
FAP B-Disease 0 7.164036031070964e-09
and O 0 2.5367785996821546e-11
evidence O 0 5.8205044950465634e-11
for O 0 5.485320964809803e-12
the O 0 4.949878180948719e-12
role O 0 7.971578397381052e-10
of O 0 2.8618328193341647e-11
APC B-Disease 0 5.727769814001249e-09
amino O 0 3.5924778707396854e-09
acid O 0 8.027732256721265e-09
changes O 0 6.77018352490677e-09
in O 0 7.782126658639754e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.0001053504747687839
. O 0 4.6934195552239544e-07

BACKGROUND O 0 8.167108717316296e-06
/ O 0 5.120287369209109e-06
AIMS O 0 8.904573434165286e-08
The O 0 9.045632992643604e-11
development O 0 6.02657868054024e-10
of O 0 6.666454943626832e-09
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.561671513274689e-10
a O 0 3.713233540092453e-11
variable O 0 3.5381984009319467e-09
range O 0 2.747459149077258e-09
of O 0 3.7798339458383623e-10
extracolonic O 0 5.565802894125227e-06
manifestations O 0 6.594525984837674e-06
in O 0 1.8822357787939836e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.165920764378825e-07
FAP B-Disease 0 3.525304350660008e-07
) O 0 8.5390688964182e-10
is O 0 5.849296047522046e-11
the O 0 1.2121414115495721e-11
result O 0 2.484769057176095e-10
of O 0 5.125750518475414e-12
the O 0 1.6570990413189435e-10
dominant O 0 6.831776317994809e-06
inheritance O 0 0.01173712033778429
of O 0 9.032186198965064e-07
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 8.4780744202817e-08
APC B-Disease 0 3.2689038675925985e-07
) O 0 6.924074646974532e-09
gene O 0 6.716103371218196e-07
mutations O 0 7.968681529746391e-06
. O 0 3.097076728408865e-07

In O 0 1.5098780892230934e-08
this O 0 1.5273016185091137e-10
study O 0 4.780263407333507e-10
, O 0 2.7251605486111607e-11
direct O 0 3.542896809261009e-10
mutation O 0 5.8605471586758995e-09
analysis O 0 2.1492660984279155e-09
of O 0 1.4198858235003886e-11
the O 0 4.227506539278281e-11
APC B-Disease 0 1.4803998027446141e-09
gene O 0 1.598448373663075e-09
was O 0 1.8509771493313565e-10
performed O 0 2.9012128810457227e-10
to O 0 6.602191710003424e-11
determine O 0 1.6288103310557744e-08
genotype O 0 4.69262340629939e-06
- O 0 2.513213530619396e-07
phenotype O 0 5.280698545107043e-08
correlations O 0 1.374203950632591e-08
for O 0 4.174853518446042e-11
nine O 0 2.703108847867952e-10
extracolonic O 0 2.5503958056560805e-08
manifestations O 0 5.857094365069315e-09
and O 0 3.51074724846967e-11
to O 0 1.4440129647574906e-11
investigate O 0 4.755537075240568e-10
the O 0 6.186259837726027e-11
incidence O 0 8.864699907462636e-08
of O 0 1.2154620365745217e-10
APC B-Disease 0 2.4748059601620298e-08
mutations O 0 5.6174162210709255e-08
in O 0 3.0924469651694153e-09
non O 0 0.001084121991880238
- O 1 0.9993612170219421
FAP O 1 0.9997081160545349
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.200419875312946e-07

METHODS O 0 1.3190240224503214e-06
The O 0 2.5471371678520427e-09
APC B-Disease 0 2.70253437406609e-08
gene O 0 1.5647842133148515e-08
was O 0 1.0344737289003092e-09
analysed O 0 4.199615322164618e-09
in O 0 6.386249168377489e-11
190 O 0 7.558604853130646e-10
unrelated O 0 6.688641640550941e-09
FAP B-Disease 0 5.501740574231917e-08
and O 0 8.54020909546449e-10
15 O 0 4.803197395375491e-09
non O 0 0.000326356734149158
- O 1 0.9998307228088379
FAP O 1 0.9998974800109863
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.8081931330016232e-07
using O 0 1.0074277412286392e-08
denaturing O 0 2.3350354240392335e-05
gradient O 0 4.759589501190931e-06
gel O 0 5.3026407840661705e-05
electrophoresis O 0 1.8013118960880092e-06
, O 0 7.576806404507863e-10
the O 0 4.851308937903198e-11
protein O 0 1.1953709133649681e-09
truncation O 0 5.513684797620044e-08
test O 0 9.600463535264225e-09
, O 0 1.1134104055399163e-11
and O 0 3.832778192047748e-11
direct O 0 1.4683386728719938e-09
sequencing O 0 2.5026133698702324e-07
. O 0 2.1849820086572436e-07

RESULTS O 0 1.9434296518738847e-06
Chain O 0 1.8062628726056573e-07
terminating O 0 5.541983583157162e-08
signals O 0 1.5791458807257186e-08
were O 0 4.190603419829131e-10
only O 0 4.0318148125662034e-11
identified O 0 1.3789082098369931e-09
in O 0 6.768317850625039e-11
patients O 0 4.79303652323182e-10
belonging O 0 1.8171712745651547e-10
to O 0 7.702875143289489e-11
the O 0 1.8749904406867302e-10
FAP B-Disease 0 6.447957900945767e-08
group O 0 1.97720018135783e-09
( O 0 7.434450277621352e-11
105 O 0 2.191819614694168e-09
patients O 0 1.520443859703846e-08
) O 0 1.2653645908855538e-09
. O 0 2.0719111759603948e-08

Amino O 0 2.426189348625485e-05
acid O 0 1.9402627913223114e-06
changes O 0 4.178984269742614e-09
were O 0 1.2601254761879233e-10
identified O 0 2.0108192888557141e-10
in O 0 1.1943007346970624e-11
four O 0 4.653992816128216e-11
patients O 0 1.7931255091863108e-10
, O 0 1.232389949638868e-12
three O 0 2.385455548370441e-12
of O 0 1.9820377977763926e-12
whom O 0 1.3836531920219386e-09
belonged O 0 7.157425319093136e-09
to O 0 1.195938070797098e-10
the O 0 1.5241094497575602e-10
non O 0 2.013179482673877e-06
- O 0 2.863304189304472e-07
FAP O 0 1.876467052852604e-07
group O 0 1.7946396368984097e-08
of O 0 3.2128237847928176e-08
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.9399058146518655e-06
. O 0 3.87574523585954e-08

Genotype O 1 0.9991820454597473
- O 1 0.994851291179657
phenotype O 0 6.719930388499051e-05
correlations O 0 1.6609681097179418e-06
identified O 0 6.981179012655048e-08
significant O 0 3.959194749825201e-09
differences O 0 5.878888487131917e-08
in O 0 2.691199763038554e-10
the O 0 2.3796898479533368e-11
nature O 0 3.0991059718488145e-10
of O 0 6.5960206047099845e-12
certain O 0 6.904803395713088e-10
extracolonic O 0 1.9865461808876717e-07
manifestations O 0 4.225949012948149e-08
in O 0 1.336532218232378e-09
FAP B-Disease 0 1.8306508309251512e-07
patients O 0 4.608725845400841e-09
belonging O 0 6.004777786117188e-10
to O 0 1.8020743230984237e-10
three O 0 9.340594964157845e-10
mutation O 0 4.216577167426294e-07
subgroups O 0 3.585381307402713e-07
. O 0 1.283151505049318e-07

CONCLUSIONS O 0 4.25981897933525e-06
Extended O 0 3.0737285783288826e-07
genotype O 0 3.4443248296156526e-05
- O 0 2.0592292457877193e-06
phenotype O 0 1.5870334379997075e-07
correlations O 0 4.1129336381118264e-08
made O 0 2.0941541556407373e-10
in O 0 2.789200641284406e-11
this O 0 9.23762975835185e-12
study O 0 1.7193675649895823e-10
may O 0 1.9615992163934948e-10
have O 0 7.462092575794e-12
the O 0 1.5524053396942517e-12
potential O 0 7.786126604569787e-11
to O 0 9.308501018601145e-12
determine O 0 7.309452348946976e-11
the O 0 1.0600972140048515e-12
most O 0 1.0740899272429494e-12
appropriate O 0 8.373245673209961e-12
surveillance O 0 2.825214784341057e-10
and O 0 1.4802740630481814e-11
prophylactic O 0 9.243124488023113e-09
treatment O 0 8.604039702930777e-10
regimens O 0 2.1153434559550988e-09
for O 0 3.6196334558119547e-12
those O 0 5.641394296151958e-11
patients O 0 5.136266412186785e-10
with O 0 3.4926943281998746e-11
mutations O 0 3.032450024420541e-08
associated O 0 1.3412746469043668e-09
with O 0 3.4809841120697627e-10
life O 0 6.068755453725316e-08
threatening O 0 8.57860050018644e-06
conditions O 0 1.019206479213608e-06
. O 0 3.5329881598045176e-07

This O 0 4.282167953562066e-09
study O 0 1.8273351720665687e-09
also O 0 4.79553931287402e-11
provided O 0 1.073431014214643e-11
evidence O 0 2.7140753186549738e-11
for O 0 4.956339592215864e-12
the O 0 1.148412094587048e-11
pathological O 0 5.838356020859692e-09
nature O 0 8.591216071884844e-10
of O 0 2.6715235926233483e-11
amino O 0 9.327815853055199e-09
acid O 0 8.256613170942728e-09
changes O 0 8.041076138276537e-10
in O 0 1.0137257699938118e-10
APC O 0 1.0951444195939075e-09
associated O 0 1.805624955109053e-10
with O 0 1.0389217264261674e-11
both O 0 4.3138581595769665e-10
FAP B-Disease 0 7.320289086010234e-08
and O 0 6.282366626919611e-09
non O 0 0.00204673083499074
- O 1 0.9998780488967896
FAP O 1 0.9999706745147705
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.675586519122589e-07
. O 0 2.0242116871571625e-09
. O 0 2.2468817917342676e-08

Inherited B-Disease 1 0.9999876022338867
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999996423721313
and O 0 0.03373337537050247
cancer B-Disease 1 0.9912945628166199
risk O 0 5.9970971051370725e-06
of O 0 2.5317237195565667e-10
the O 0 3.7074978642692713e-09
APC O 0 6.519287012451969e-07
I1307K O 0 2.668047955012298e-06
polymorphism O 0 6.915497579029761e-06
. O 0 1.7454371459280082e-07

Germ O 0 0.0030349567532539368
- O 0 0.00041287700878456235
line O 0 1.8739311258286762e-07
and O 0 1.3412284616265424e-09
somatic O 0 1.0978098430314276e-07
truncating O 0 3.5102246442875185e-07
mutations O 0 1.5706156375472347e-07
of O 0 4.5957557204268085e-11
the O 0 5.048201787150042e-11
APC B-Disease 0 1.4166546824512238e-09
gene O 0 1.2890303269230685e-09
are O 0 2.252576770944703e-11
thought O 0 4.1419870311365514e-10
to O 0 5.166223560060246e-10
initiate O 0 3.8003506119821395e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 1.7136344467871822e-05
formation O 0 1.0242549706163118e-06
in O 0 9.415311069460586e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 3.3693024761305423e-06
sporadic O 1 0.9811902046203613
colorectal O 1 1.0
carcinogenesis O 1 0.9629302024841309
, O 0 1.0892375001958499e-07
respectively O 0 1.0578493174762116e-06
. O 0 2.3619116973350174e-07

Recently O 0 2.8528857001219876e-06
, O 0 3.0102504933182672e-09
an O 0 5.359966359641533e-10
isoleucine O 0 2.1969364752294496e-05
- O 0 7.2445573096047156e-06
- O 0 1.885548840618867e-06
> O 0 1.3009106680783589e-07
lysine O 0 4.942043574374111e-07
polymorphism O 0 3.1048219284457446e-07
at O 0 3.848267482453593e-09
codon O 0 1.5506957140587474e-07
1307 O 0 1.1390708465341959e-07
( O 0 1.8336537843666179e-10
I1307K O 0 1.0494709989927742e-08
) O 0 5.572693001498763e-11
of O 0 6.4890666624795035e-12
the O 0 6.419038217631012e-11
APC B-Disease 0 2.5572917117244742e-09
gene O 0 5.263320002057981e-09
has O 0 9.092704922331052e-10
been O 0 3.879335741530099e-10
identified O 0 7.826957415524305e-10
in O 0 6.941707625385263e-11
6 O 0 2.793759668051621e-10
% O 0 1.2767485679798796e-10
- O 0 1.331248533631424e-08
7 O 0 1.5237264783252158e-09
% O 0 5.6295922784554975e-11
of O 0 9.099184947181094e-12
the O 0 2.2957500345199833e-09
Ashkenazi O 0 3.891110736731207e-06
Jewish O 0 2.3799664461421344e-07
population O 0 2.6770468508630074e-08
. O 0 7.342971031221168e-08

To O 0 2.714778624124392e-08
assess O 0 2.53813340123088e-07
the O 0 3.15201337253157e-10
risk O 0 2.8731352852418013e-09
of O 0 3.714110182601038e-12
this O 0 3.2806698330167805e-11
common O 0 1.4999058661757658e-09
APC B-Disease 0 3.98180972638329e-08
allelic O 0 1.0100948344415883e-07
variant O 0 3.73453360680287e-07
in O 0 3.1624406204855404e-08
colorectal O 1 1.0
carcinogenesis O 0 0.0028029894456267357
, O 0 5.7264148978219964e-09
we O 0 5.510598644065112e-10
have O 0 3.2609803746197485e-11
analyzed O 0 3.6848588069737787e-10
a O 0 1.4890895808084004e-11
large O 0 5.832154204021833e-10
cohort O 0 1.199676376018033e-07
of O 0 2.0220188023944985e-10
unselected O 0 4.716851617558859e-05
Ashkenazi O 0 9.819785918807611e-05
Jewish O 0 2.4406313059444074e-07
subjects O 0 6.528469498334744e-08
with O 0 1.640704794247938e-09
adenomatous B-Disease 0 1.1047326552215964e-05
polyps I-Disease 0 2.904208486143034e-06
and O 0 1.1696238422231886e-09
. O 0 4.637126682638382e-09
or O 0 0.0920272022485733
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 5.316306839198148e-10
for O 0 6.994070600452318e-11
the O 0 6.477708369700963e-10
APC O 0 3.060116284814285e-07
I1307K O 0 1.03128070350067e-06
polymorphism O 0 3.1306619803217473e-06
. O 0 1.610622746284207e-07

The O 0 9.789987842623304e-08
APC O 0 6.488027111117844e-07
I1307K O 0 6.748423970748263e-07
allele O 0 2.994464409766806e-07
was O 0 4.030804134913524e-09
identified O 0 2.798859810582144e-09
in O 0 1.6332168950583537e-10
48 O 0 7.298059379046151e-10
( O 0 2.0166179490188618e-11
10 O 0 1.419338951924587e-11
. O 0 6.34046773417829e-11
1 O 0 3.215560873126577e-10
% O 0 4.4151793332503075e-11
) O 0 1.4984803328732532e-11
of O 0 2.5979867562808678e-11
476 O 0 8.8792020846995e-08
patients O 0 1.5614158144217072e-07
. O 0 3.5322127445169826e-08

Compared O 0 6.199769586601178e-08
with O 0 2.0174116543980603e-10
the O 0 5.88510629118133e-11
frequency O 0 8.543863394550044e-09
in O 0 1.4546398807713246e-10
two O 0 2.2323119047706896e-11
separate O 0 4.524654262372252e-10
population O 0 4.3684564299262263e-10
control O 0 1.067635202467443e-09
groups O 0 2.1737993349812967e-10
, O 0 2.6868693034365343e-11
the O 0 4.039989870419092e-11
APC O 0 8.044408694729555e-09
I1307K O 0 2.645969310322016e-08
allele O 0 8.384141381156951e-09
is O 0 4.145367729635474e-11
associated O 0 1.1309747582899377e-10
with O 0 9.133421449702972e-12
an O 0 1.689211097388732e-11
estimated O 0 7.292660919588911e-10
relative O 0 3.1126489830057835e-07
risk O 0 6.569772494913195e-07
of O 0 2.5194976660536383e-10
1 O 0 3.9024271814014355e-08
. O 0 8.564964559809596e-08

5 O 0 1.2463819984986912e-06
- O 0 1.6722635336918756e-05
1 O 0 1.8565042125828768e-07
. O 0 1.1806051958274111e-07

7 O 0 3.22440723721229e-06
for O 0 1.2725493547804945e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.010580591857433319
( O 0 4.3824628370714436e-09
both O 0 1.0097187974622557e-08
P O 0 0.19600364565849304
= O 0 2.639492777234409e-06
. O 0 3.54944091895959e-08
01 O 0 7.560629455838352e-07
) O 0 4.947318110737342e-09
. O 0 3.395677694584265e-08

Furthermore O 0 1.3883943950077082e-07
, O 0 1.0615536227831512e-09
compared O 0 1.1323006976482475e-09
with O 0 8.047347510586889e-11
noncarriers O 0 3.737861504760076e-07
, O 0 3.1717761750371665e-10
APC O 0 5.6498423717243895e-09
I1307K O 0 2.3288594164228016e-08
carriers O 0 2.2237085506304766e-09
had O 0 1.6305742867039896e-10
increased O 0 5.237977412919648e-11
numbers O 0 3.763977740600666e-10
of O 0 7.669567064771954e-11
adenomas B-Disease 0 0.0017515351064503193
and O 0 7.504592758778017e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.999380350112915
per O 0 1.2919797676147482e-08
patient O 0 3.5087847294335006e-08
( O 0 4.333038927661903e-10
P O 0 1.5251921468006913e-05
= O 0 1.0010210615973847e-07
. O 0 2.2327568682811716e-09
03 O 0 3.295054185059598e-08
) O 0 5.114180606780039e-11
, O 0 4.857306397376693e-12
as O 0 1.215438253515666e-11
well O 0 3.9279152846960486e-11
as O 0 6.667681684557891e-11
a O 0 1.973540775246363e-10
younger O 0 1.386528136748666e-08
age O 0 3.5601042114308257e-09
at O 0 2.600458293144925e-09
diagnosis O 0 6.592926524717768e-07
. O 0 5.981566886248402e-08

We O 0 2.885411447550723e-07
conclude O 0 4.0755285368732075e-08
that O 0 3.224202016482991e-10
the O 0 3.2796576565630176e-10
APC O 0 1.6975013394926464e-08
I1307K O 0 7.666799461958362e-08
variant O 0 4.022419375360187e-08
leads O 0 3.916249546875861e-09
to O 0 7.216227615458592e-10
increased O 0 1.3139383803206783e-08
adenoma B-Disease 1 1.0
formation O 0 5.22327692209501e-09
and O 0 2.3688814798639157e-10
directly O 0 2.530280429624554e-10
contributes O 0 2.9798125078528415e-10
to O 0 4.746101428532157e-11
3 O 0 1.0264189498343512e-10
% O 0 7.874301211074908e-11
- O 0 2.134147747412385e-09
4 O 0 2.06007572112199e-10
% O 0 3.5066050757537326e-11
of O 0 8.951897383091545e-12
all O 0 7.57384732708033e-09
Ashkenazi O 0 0.09970799088478088
Jewish O 1 0.9968287348747253
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.608700348602724e-07

The O 0 7.452473305136209e-09
estimated O 0 3.5945888487987077e-09
relative O 0 3.131301440362222e-08
risk O 0 1.034312901992962e-07
for O 0 1.8043580518600777e-10
carriers O 0 8.501793047344108e-09
may O 0 7.21556703275894e-10
justify O 0 1.6740832053940835e-09
specific O 0 3.641491552741627e-10
clinical O 0 1.577769137561802e-09
screening O 0 5.068773734073773e-10
for O 0 2.1466407210818383e-12
the O 0 2.7611296495727577e-12
360 O 0 8.441030513450798e-11
, O 0 1.2799323233225746e-11
000 O 0 9.953195212464294e-11
Americans O 0 2.7718174977486854e-10
expected O 0 3.3919894670830786e-11
to O 0 8.72187305017702e-12
harbor O 0 7.425384196402263e-10
this O 0 3.8337484228878616e-12
allele O 0 1.5827363863962773e-09
, O 0 2.807882919231286e-11
and O 0 4.917406412618952e-11
genetic O 0 2.009267641156498e-09
testing O 0 1.5764516358984793e-09
in O 0 4.271809034978036e-12
the O 0 2.2707883750444635e-12
setting O 0 1.0977601466732878e-10
of O 0 4.915631270085985e-12
long O 0 3.784625945968401e-09
- O 0 7.622240616456111e-08
term O 0 2.3458744635718176e-07
- O 0 3.177410690113902e-08
outcome O 0 1.8055570372155216e-09
studies O 0 1.6694595705857296e-09
may O 0 2.347292638038567e-10
impact O 0 6.740377700431566e-10
significantly O 0 1.0376794534749934e-08
on O 0 0.0003789421170949936
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 3.4413762950435967e-09
in O 0 4.184355986702748e-11
this O 0 1.0782454790136953e-10
population O 0 6.938193575223295e-09
. O 0 5.963943294773344e-08

Localization O 0 1.193500793306157e-06
of O 0 5.520782719869999e-10
human O 0 8.726241396139756e-10
BRCA1 O 0 1.0035234510041846e-07
and O 0 6.603680935413081e-10
its O 0 2.5652044377544314e-10
loss O 0 5.991533047478015e-09
in O 0 1.613961464475011e-10
high O 0 2.0039416881445504e-07
- O 0 0.00019894454453606158
grade O 0 2.913802018156275e-05
, O 0 1.4753456234473106e-09
non B-Disease 0 4.372080638859188e-06
- I-Disease 0 0.0022385641932487488
inherited I-Disease 1 0.9758541584014893
breast I-Disease 1 0.9994537234306335
carcinomas I-Disease 1 1.0
. O 0 1.8508504808778525e-06

Although O 0 2.7681114289634934e-08
the O 0 1.1033859242948196e-10
link O 0 1.1042228464930304e-08
between O 0 4.302862788296835e-10
the O 0 1.9499282188917277e-09
BRCA1 O 0 0.00012379372492432594
tumour B-Disease 1 1.0
- O 0 2.534485759042582e-07
suppressor O 0 4.169401108811144e-07
gene O 0 5.346034868125571e-07
and O 0 7.044957328616874e-08
hereditary B-Disease 1 0.9998534917831421
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.232081658919526e-09
established O 0 2.3945109783873875e-10
, O 0 1.7449444666972624e-11
the O 0 3.327694239954604e-12
role O 0 9.569580683432832e-10
, O 0 2.6885918838481793e-11
if O 0 7.303765925392725e-11
any O 0 3.225559402908473e-11
, O 0 9.557058269771268e-12
of O 0 8.391327563361806e-12
BRCA1 O 0 1.3934389642145106e-07
in O 0 4.019549137979084e-09
non B-Disease 0 0.2792660892009735
- I-Disease 1 0.9643142223358154
familial I-Disease 1 0.9996312856674194
cancers I-Disease 1 0.9999614953994751
is O 0 1.3591165526349869e-08
unclear O 0 2.2412879729927226e-07
. O 0 1.708560830593342e-07

BRCA1 O 0 0.00014435563934966922
mutations O 0 2.1807716166222235e-06
are O 0 1.160900375829499e-09
rare O 0 1.7902763715937908e-09
in O 0 1.112668401859196e-09
sporadic B-Disease 0 1.8417073079035617e-05
cancers I-Disease 1 0.9999825954437256
, O 0 3.264157610871621e-09
but O 0 9.676407231040685e-09
loss O 0 9.316578619689153e-09
of O 0 5.383826370830569e-11
BRCA1 O 0 2.5023675220836594e-07
resulting O 0 2.9135307499927876e-09
from O 0 2.581563851578039e-10
reduced O 0 1.6786714240879519e-09
expression O 0 2.2012041078767197e-09
or O 0 1.1060562465914359e-09
incorrect O 0 1.7539232288754647e-08
subcellular O 0 9.374227971647997e-08
localization O 0 1.215310341251552e-08
is O 0 2.0486329646574042e-11
postulated O 0 3.3654468101218526e-10
to O 0 8.53788827831492e-12
be O 0 4.4702644363958655e-12
important O 0 2.4901671002997006e-11
in O 0 1.6407446234989465e-10
non B-Disease 0 2.284110678374418e-06
- I-Disease 0 7.830142567399889e-05
familial I-Disease 1 0.9872819781303406
breast I-Disease 1 0.9999990463256836
and I-Disease 1 0.9999572038650513
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.5125017398531782e-06

Epigenetic O 0 9.825258530327119e-06
loss O 0 2.237491571577266e-06
, O 0 8.273619567233936e-10
however O 0 3.62054164426695e-10
, O 0 3.6336839787098896e-11
has O 0 6.317218970153249e-11
not O 0 2.059021876610334e-11
received O 0 3.089372507814048e-11
general O 0 1.4307383403022733e-11
acceptance O 0 1.0064745703530775e-09
due O 0 3.6426375804587963e-10
to O 0 6.137591129773412e-11
controversy O 0 5.549360970746875e-10
regarding O 0 3.9353262315522386e-10
the O 0 7.288013248452074e-11
subcellular O 0 1.1405415989429457e-07
localization O 0 1.900770385532269e-08
of O 0 7.211532065953818e-11
BRCA1 O 0 2.574657642639977e-08
proteins O 0 3.0078614599027276e-10
, O 0 2.242015080533566e-11
reports O 0 1.2351210332273155e-10
of O 0 1.20246943912522e-12
which O 0 6.605643115831228e-11
have O 0 5.5436984863765915e-11
ranged O 0 8.824520281169868e-11
from O 0 1.125512530397721e-11
exclusively O 0 9.059640260211665e-10
nuclear O 0 2.872161708467047e-08
, O 0 7.841773237704519e-12
to O 0 5.200960755818995e-12
conditionally O 0 3.890237465498103e-09
nuclear O 0 6.151543274768301e-09
, O 0 5.314456340277385e-12
to O 0 1.0390207791366457e-11
the O 0 1.0409255402077378e-10
ER O 0 1.300641514490053e-07
/ O 0 3.297145889646913e-09
golgi O 0 4.231764449968978e-08
, O 0 4.3955592637923147e-11
to O 0 9.218466268112735e-11
cytoplasmic O 0 6.428052046203447e-08
invaginations O 0 1.3333303172657907e-07
into O 0 1.0318803589370873e-09
the O 0 9.097198550023222e-10
nucleus O 0 4.458037849985885e-08
. O 0 5.651849832588596e-08

In O 0 1.068933741521505e-08
an O 0 1.0230688518575448e-10
attempt O 0 5.922237811262221e-09
to O 0 1.8110815624972076e-10
resolve O 0 3.330175690763326e-09
this O 0 1.1129474945803519e-11
issue O 0 1.5450161983121546e-10
, O 0 2.2745780953181693e-11
we O 0 1.1383503167872178e-10
have O 0 1.3639687990174565e-10
comprehensively O 0 1.7827670006909102e-08
characterized O 0 4.145189969051444e-09
19 O 0 2.5874213882559616e-09
anti O 0 1.072626645282071e-07
- O 0 5.450191338240984e-07
BRCA1 O 0 7.933360393508337e-06
antibodies O 0 7.171666425165313e-07
. O 0 7.780985811223218e-08

These O 0 1.7119933914955254e-08
reagents O 0 1.2431051743533317e-07
detect O 0 3.1378186804431607e-07
a O 0 1.6261462176814234e-09
220 O 0 6.5860743525547605e-09
- O 0 1.458570579870866e-07
kD O 0 1.4072761587158311e-06
protein O 0 1.7868112323071728e-08
localized O 0 9.572232784194057e-09
in O 0 8.204924933918889e-11
discrete O 0 1.575436492373683e-08
nuclear O 0 1.1723117410156192e-07
foci O 0 4.62174725157638e-08
in O 0 3.000143744547046e-10
all O 0 6.539714603182034e-11
epithelial O 0 4.796659958117289e-09
cell O 0 5.093045629678272e-08
lines O 0 1.151752471173495e-08
, O 0 1.0979920098130869e-11
including O 0 8.91995765445186e-12
those O 0 5.085767570967015e-11
derived O 0 4.180769952455421e-09
from O 0 5.105395217697151e-09
breast B-Disease 0 0.0028229081071913242
malignancies I-Disease 0 0.02777588553726673
. O 0 6.931146003807953e-07

Immunohistochemical O 0 0.002063875552266836
staining O 0 0.0005738851032219827
of O 0 4.018890109591666e-09
human O 0 7.410220881354235e-09
breast O 0 1.7906173752635368e-06
specimens O 0 4.772415351794734e-08
also O 0 3.4275737803568518e-09
revealed O 0 6.959269427397885e-08
BRCA1 O 0 1.9432259250606876e-06
nuclear O 0 1.3507670360013435e-07
foci O 0 1.918051850680058e-07
in O 0 2.335887039350837e-09
benign O 0 4.432497462403262e-06
breast O 0 5.310221604304388e-05
, O 0 1.6947158343327828e-08
invasive B-Disease 0 0.00029442721279338
lobular I-Disease 1 0.9999603033065796
cancers I-Disease 1 0.9999985694885254
and O 0 4.0629166164762864e-07
low B-Disease 0 0.004697547294199467
- I-Disease 1 0.9470959901809692
grade I-Disease 0 0.16869346797466278
ductal I-Disease 1 0.9179570078849792
carcinomas I-Disease 1 1.0
. O 0 5.08274752064608e-06

Conversely O 0 1.7880229279398918e-05
, O 0 2.622245176553406e-08
BRCA1 O 0 1.0195662980549969e-06
expression O 0 4.273741183169477e-08
was O 0 8.063810952307904e-09
reduced O 0 2.46886422416992e-09
or O 0 1.1287319967578924e-09
undetectable O 0 4.4916745878254005e-08
in O 0 2.7265642868479212e-11
the O 0 1.654060395595014e-11
majority O 0 5.721008111692072e-10
of O 0 5.192706334367081e-11
high O 0 9.250003358829417e-07
- O 0 9.501414751866832e-06
grade O 0 9.485394798502966e-07
, O 0 2.1643542513771763e-10
ductal B-Disease 0 1.3127806823831634e-06
carcinomas I-Disease 1 1.0
, O 0 4.669965525394559e-10
suggesting O 0 4.6163974865010005e-09
that O 0 9.763718306077251e-11
absence O 0 4.481880144791006e-10
of O 0 1.517665854100514e-11
BRCA1 O 0 9.632143616045141e-08
may O 0 8.397804673876408e-10
contribute O 0 3.275255414103562e-11
to O 0 8.954220177825878e-12
the O 0 3.36401219380722e-12
pathogenesis O 0 2.0868891337233464e-10
of O 0 4.561274318318209e-13
a O 0 4.838738350970706e-12
significant O 0 2.9322219652350157e-10
percentage O 0 3.620213462340871e-08
of O 0 4.143915210974569e-10
sporadic B-Disease 0 0.02193230204284191
breast I-Disease 1 0.9999874830245972
cancers I-Disease 1 0.9999586343765259
. O 0 5.090831223242276e-08
. O 0 1.3903475348797656e-07

